data_2dgo_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2dgo _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.93 0.395 . . . . 0.0 110.883 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 69.6 m-70 -86.62 144.45 27.16 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.861 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 23.7 t -118.86 146.71 23.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.114 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -99.26 135.59 40.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.935 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 6.0 t -134.56 131.07 54.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.152 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.459 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -137.07 -175.8 14.01 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.459 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 60.74 26.4 16.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.897 0.379 . . . . 0.0 110.899 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.9 mt -84.53 128.22 34.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.907 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.41 153.93 6.73 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.685 0.755 . . . . 0.0 110.841 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 -9.87 27.19 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.711 2.274 . . . . 0.0 112.325 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -97.44 -5.04 37.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.901 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.459 HG23 ' CB ' ' A' ' 93' ' ' ASP . 40.5 mm -77.23 139.4 18.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.131 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.6 t -116.8 163.7 15.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.131 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.3 m -43.8 -38.56 3.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.079 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -63.09 -56.56 15.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.896 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.459 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.4 m-20 -37.75 -52.88 1.28 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.842 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 5.1 mt -52.11 -58.7 2.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.127 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.464 ' O ' ' N ' ' A' ' 99' ' ' ALA . 24.2 mtmt -49.45 -39.2 32.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.889 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.87 -35.0 75.49 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.112 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -68.67 -55.53 11.12 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.091 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 35.6 m-85 -85.05 1.63 46.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.874 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.485 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -52.75 -60.11 7.3 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.605 0.717 . . . . 0.0 111.147 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.485 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.7 -1.03 7.72 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.689 2.26 . . . . 0.0 112.357 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -99.96 9.55 42.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.26 143.48 5.78 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.497 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 45.8 mtt85 -52.17 121.87 7.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.739 0.304 . . . . 0.0 110.857 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.435 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 13.1 mt -95.04 136.79 25.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.102 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.432 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 2.4 p -103.28 -64.53 1.07 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.86 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -100.59 109.17 21.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.822 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . 0.462 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -138.94 125.03 20.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.116 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.47 ' HB2' ' CZ ' ' A' ' 108' ' ' ARG . 2.6 ptm85 -157.39 165.08 36.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.867 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 87.3 t -112.93 112.73 41.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.168 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.503 HG13 ' CZ ' ' A' ' 121' ' ' TYR . 97.1 t -45.98 137.9 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.154 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . 0.464 ' N ' HG11 ' A' ' 110' ' ' VAL . 84.7 mttt -137.86 161.22 37.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.924 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.423 ' O ' ' N ' ' A' ' 116' ' ' GLY . 9.3 t0 -75.15 125.94 29.99 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.868 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 14.3 ptp -75.77 -1.74 26.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.929 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -96.58 -39.59 9.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 30.6 p -119.51 -33.91 3.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.16 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 93.62 24.22 21.55 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.468 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 41.2 mmtt -93.55 151.17 19.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.82 0.343 . . . . 0.0 110.874 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 1.8 m -52.53 113.18 0.98 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.855 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 26.2 mmtt -63.14 -38.54 91.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.926 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 129.81 -40.06 1.73 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.505 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.503 ' CZ ' HG13 ' A' ' 110' ' ' VAL . 3.0 p90 -100.02 155.09 17.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.943 0.402 . . . . 0.0 110.924 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.04 168.28 24.37 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.479 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 81.9 m-85 -117.47 141.54 48.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.914 0.388 . . . . 0.0 110.911 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.571 HG12 ' CZ ' ' A' ' 126' ' ' PHE . 88.9 t -141.94 114.04 3.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.132 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 45.7 t -106.06 142.99 34.84 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.816 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.571 ' CZ ' HG12 ' A' ' 124' ' ' VAL . 1.5 m-85 -119.24 158.46 25.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.898 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.432 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 20.7 m-85 -66.91 -42.3 85.67 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.883 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 25.3 m-80 -110.13 166.95 10.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.911 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 58.7 tttt -76.15 -44.2 39.39 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.898 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.429 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -54.71 -59.32 4.88 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.929 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 130' ' ' TRP . 88.8 m-20 -35.8 -56.17 0.7 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.896 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . 0.515 ' HB1' ' CD1' ' A' ' 126' ' ' PHE . . . -63.39 -65.11 0.73 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.084 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.415 ' C ' ' O ' ' A' ' 132' ' ' ALA . 4.6 mm-40 -37.31 -59.01 0.79 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -42.65 -48.58 5.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.907 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.47 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -64.64 -56.45 13.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.094 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 94.8 mt -38.6 -34.45 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.139 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 -86.09 -60.39 2.02 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.883 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 25.8 mt-30 -63.73 -58.14 7.8 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.47 ' N ' ' O ' ' A' ' 135' ' ' ALA . 50.3 mmm -54.86 -34.91 63.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.878 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.45 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -60.89 117.45 11.66 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.47 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 92.56 12.48 58.22 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.524 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 13.6 mm-40 -94.43 170.83 9.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.759 0.314 . . . . 0.0 110.901 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . . . . . . . . . 16.2 m95 -106.1 109.08 20.91 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.87 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 64.6 tp -102.51 128.88 48.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.86 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 69.03 -75.69 0.33 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.458 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.37 15.54 0.32 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.478 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . 0.422 ' HB3' ' NH1' ' A' ' 147' ' ' ARG . 8.0 mtp-105 -156.11 159.33 38.96 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.796 0.331 . . . . 0.0 110.859 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 30.2 mt-30 -64.27 167.83 6.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.909 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 32.4 pt -140.89 145.97 24.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.136 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.459 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 6.5 ptt180 -107.25 109.76 21.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.45 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 43.8 p -103.84 137.01 42.45 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.112 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . 0.423 ' CG ' ' O ' ' A' ' 151' ' ' THR . 19.6 m120 -166.89 176.29 7.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.923 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 10.4 m95 . . . . . 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 179.98 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.555 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 93.2 m-85 . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.839 0.352 . . . . 0.0 110.905 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.48 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.5 OUTLIER -88.54 149.08 23.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.887 179.988 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 42.0 t -124.7 147.53 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.161 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -98.22 138.63 35.21 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.846 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 15.2 t -136.07 129.56 47.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.12 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.453 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -139.75 177.49 20.45 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.439 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 18.8 t0 64.08 41.91 6.03 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.848 0.356 . . . . 0.0 110.909 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.5 mt -102.41 137.02 41.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.929 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -54.93 153.86 10.78 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.691 0.758 . . . . 0.0 110.875 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 -12.0 31.91 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.676 2.251 . . . . 0.0 112.317 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -93.26 -9.57 38.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.915 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.447 ' CD1' ' HA3' ' A' ' 145' ' ' GLY . 42.3 mm -74.65 137.1 23.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.077 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.446 ' N ' HG23 ' A' ' 89' ' ' ILE . 11.3 t -120.46 162.48 19.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.116 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.421 ' C ' ' O ' ' A' ' 90' ' ' THR . 53.2 m -36.03 -49.27 0.64 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.14 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 93' ' ' ASP . 20.2 mt-10 -52.8 -60.33 3.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.899 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.441 ' C ' ' O ' ' A' ' 92' ' ' GLU . 1.0 OUTLIER -34.78 -57.47 0.53 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.909 179.972 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.458 HG21 ' CG2' ' A' ' 124' ' ' VAL . 12.6 mt -48.61 -60.0 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.093 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.415 ' HG3' ' CB ' ' A' ' 107' ' ' ALA . 24.5 mtmt -47.66 -39.85 18.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.931 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.49 -28.91 70.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.087 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.7 -50.68 13.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.095 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 -91.16 12.16 20.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.493 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -66.6 -59.68 7.73 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.578 0.704 . . . . 0.0 111.09 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.493 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.73 -0.6 7.12 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.637 2.225 . . . . 0.0 112.35 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.505 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 74.9 m-85 -99.61 -11.96 20.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.888 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 152.26 137.53 2.59 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.496 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.403 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 10.1 mtm-85 -48.76 122.64 5.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.81 0.338 . . . . 0.0 110.848 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.471 HG21 ' CG1' ' A' ' 124' ' ' VAL . 10.2 mt -99.99 141.75 16.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.125 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.401 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 3.5 t -109.68 -63.73 1.33 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.858 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -100.44 104.85 16.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.881 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . 0.415 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -134.67 128.91 33.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.109 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 11.5 ptm180 -161.79 163.6 29.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.841 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 89.9 t -110.85 120.47 61.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.098 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.483 HG12 ' CZ ' ' A' ' 121' ' ' TYR . 57.4 t -50.7 135.85 10.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.115 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 46.3 mttm -136.21 146.08 46.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.45 ' O ' ' N ' ' A' ' 116' ' ' GLY . 32.1 t0 -55.02 123.42 13.51 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.891 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 9.1 tpt -71.07 -2.52 15.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.873 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -103.08 -48.72 3.96 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.062 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 34.0 p -102.25 -29.37 11.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.138 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 80.51 28.45 47.75 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.47 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 14.5 mtpp -99.86 148.82 24.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.781 0.324 . . . . 0.0 110.891 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 5.4 t -51.8 105.64 0.12 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.842 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 36.6 mttt -58.47 -46.81 85.88 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.9 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 142.13 -41.94 1.17 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.484 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.483 ' CZ ' HG12 ' A' ' 110' ' ' VAL . 9.5 p90 -99.86 149.15 23.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.888 0.375 . . . . 0.0 110.947 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -130.58 179.64 16.77 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.479 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -126.62 142.04 51.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.876 0.37 . . . . 0.0 110.921 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.566 HG11 ' CZ ' ' A' ' 126' ' ' PHE . 60.2 t -138.94 123.9 21.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.096 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 33.0 m -112.19 144.77 41.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.877 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.566 ' CZ ' HG11 ' A' ' 124' ' ' VAL . 1.2 m-85 -125.32 150.55 47.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.403 ' CE2' ' HB3' ' A' ' 103' ' ' ARG . 21.9 m-85 -57.65 -46.48 84.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.92 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 25.7 m-20 -112.05 163.45 14.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.91 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.555 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 69.9 tttt -72.11 -61.64 1.72 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.897 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.434 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.9 OUTLIER -34.78 -56.76 0.55 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.906 179.99 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -42.08 -52.02 4.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.851 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -63.37 -60.64 3.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.115 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -39.44 -60.21 0.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 32.6 t-20 -40.29 -44.77 1.98 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.903 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.424 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -69.63 -54.39 14.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.091 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 91.7 mt -41.58 -34.83 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.14 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -87.29 -60.55 1.95 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.911 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 29.3 mm-40 -60.29 -60.17 4.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.901 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.505 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 75.7 mmm -56.84 -41.8 78.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.873 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.441 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -53.09 103.07 0.11 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.478 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 107.41 6.65 33.28 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.51 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 -90.11 173.87 7.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.799 0.333 . . . . 0.0 110.932 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . 0.459 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 17.8 m95 -109.02 121.22 44.68 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.952 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.468 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 34.2 tp -122.85 127.27 48.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.888 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . 0.447 ' HA3' ' CD1' ' A' ' 89' ' ' ILE . . . 72.12 -7.08 8.37 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.474 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 124.16 -9.71 8.36 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.507 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 17.9 mtt180 -127.63 148.9 50.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.722 0.296 . . . . 0.0 110.91 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . 0.459 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 28.1 mt-30 -60.19 152.96 23.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.923 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.468 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 24.6 pt -123.07 153.55 28.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.099 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.474 ' CG ' ' O ' ' A' ' 150' ' ' ARG . 10.1 ptm180 -114.93 114.05 24.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.441 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 73.4 p -107.86 130.4 55.0 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.159 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -157.39 172.38 18.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 24.2 m95 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.896 179.968 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.493 ' CD2' ' HA ' ' A' ' 129' ' ' LYS . 37.3 m-85 . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.881 0.372 . . . . 0.0 110.855 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 58.4 m-70 -86.08 155.87 20.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.866 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 45.4 t -129.07 141.55 46.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.098 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.0 t80 -90.7 133.33 35.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.414 ' CG1' HD22 ' A' ' 85' ' ' LEU . 5.6 t -129.74 110.0 19.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.123 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.463 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -118.18 168.21 13.07 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.473 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.9 t70 68.76 52.73 0.54 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.813 0.34 . . . . 0.0 110.877 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.414 HD22 ' CG1' ' A' ' 82' ' ' VAL . 16.2 mt -109.68 131.49 55.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.919 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.1 t -53.98 154.71 7.16 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.624 0.726 . . . . 0.0 110.885 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -14.51 36.15 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.693 2.262 . . . . 0.0 112.36 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -93.07 -5.24 50.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.911 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.427 HG21 ' CB ' ' A' ' 93' ' ' ASP . 40.5 mm -78.37 138.11 20.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.127 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.3 t -120.84 170.5 9.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.181 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.441 HG21 ' CE ' ' A' ' 95' ' ' LYS . 88.3 m -43.64 -49.85 7.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.168 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.437 ' O ' ' C ' ' A' ' 93' ' ' ASP . 57.7 mt-10 -52.05 -60.16 3.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.91 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.437 ' C ' ' O ' ' A' ' 92' ' ' GLU . 5.9 m-20 -34.51 -57.99 0.5 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.891 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.409 HG21 ' CG2' ' A' ' 124' ' ' VAL . 7.6 mt -49.52 -62.26 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.117 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.459 ' HA ' ' CD1' ' A' ' 104' ' ' ILE . 27.8 mtmt -46.12 -40.1 10.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.943 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.52 -31.61 71.63 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.154 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -72.97 -53.86 10.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.121 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -88.14 7.07 33.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.853 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.486 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -60.73 -59.93 12.27 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.609 0.719 . . . . 0.0 111.097 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.486 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.1 Cg_endo -69.77 -0.75 7.38 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.685 2.257 . . . . 0.0 112.314 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.593 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 73.8 m-85 -99.78 -5.04 29.3 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.914 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 144.25 136.2 3.04 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.507 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 29.5 mtt180 -46.78 124.41 6.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.795 0.331 . . . . 0.0 110.869 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.459 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 13.2 mt -100.09 138.26 24.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.151 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.483 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 47.1 p -107.33 -61.83 1.5 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.848 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -100.2 104.56 16.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.871 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -134.94 127.32 30.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.051 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 1.9 ptt-85 -160.94 157.94 27.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.886 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 86.8 t -110.26 115.42 49.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.135 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.557 HG13 ' CE2' ' A' ' 121' ' ' TYR . 48.7 t -46.97 136.82 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.147 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 54.0 mttt -137.46 148.69 46.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.945 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -58.54 130.18 45.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.879 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 28.4 ptm -78.88 1.63 22.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.866 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -102.82 -41.18 6.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.087 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 45.1 p -114.43 -29.07 6.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.167 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 84.52 21.43 56.4 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.497 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 48.4 mmtt -92.93 145.25 24.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.769 0.318 . . . . 0.0 110.902 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 4.9 t -46.69 111.86 0.44 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.853 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -62.7 -51.46 67.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 147.46 -41.56 0.93 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.486 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.557 ' CE2' HG13 ' A' ' 110' ' ' VAL . 4.9 p90 -100.06 153.13 19.47 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.928 0.394 . . . . 0.0 110.915 -179.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.42 173.7 22.14 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.468 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -122.54 140.45 52.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.897 0.379 . . . . 0.0 110.92 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.57 HG13 ' CZ ' ' A' ' 126' ' ' PHE . 59.2 t -137.62 116.38 14.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.12 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 15.5 t -104.87 147.16 28.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.852 -179.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.57 ' CZ ' HG13 ' A' ' 124' ' ' VAL . 1.2 m-85 -126.84 150.2 49.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.875 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.483 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 23.1 m-85 -56.7 -44.42 81.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 24.4 m-20 -112.86 166.47 11.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.905 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.568 ' HE3' ' CH2' ' A' ' 153' ' ' TRP . 39.2 tptt -70.99 -59.99 2.48 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.944 179.854 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.426 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.8 OUTLIER -40.93 -59.92 1.32 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.922 179.941 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.426 ' C ' ' O ' ' A' ' 130' ' ' TRP . 6.9 m-20 -35.8 -39.11 0.14 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.863 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -80.43 -58.51 3.09 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.063 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.4 mt-10 -44.38 -55.68 4.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.948 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 54.7 t30 -42.8 -42.07 3.46 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.909 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.49 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -71.81 -55.78 6.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.055 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 76.1 mt -38.76 -36.4 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.104 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.1 mt-30 -83.6 -57.19 3.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 16.8 mm-40 -68.54 -61.16 1.95 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.897 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.593 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 41.3 mmm -52.97 -31.38 40.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.905 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.447 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -63.04 107.78 1.84 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.491 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 99.94 13.73 36.12 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.487 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 66.5 mm-40 -93.1 166.88 12.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.802 0.334 . . . . 0.0 110.89 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . 0.422 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 14.5 m95 -102.89 107.06 17.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.89 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 63.6 tp -100.02 126.46 46.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.873 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 70.25 -76.95 0.46 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.493 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -155.96 14.5 0.41 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.497 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 36.7 mtp180 -153.04 157.01 39.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.783 0.325 . . . . 0.0 110.866 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . 0.422 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 30.8 mt-30 -62.16 167.2 4.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.927 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 25.7 pt -138.96 153.21 24.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.488 ' CG ' ' O ' ' A' ' 150' ' ' ARG . 7.0 ptm180 -118.82 116.47 26.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.9 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.447 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 53.5 p -107.53 135.53 48.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.134 -179.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 28.4 t30 -160.15 171.09 19.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . 0.568 ' CH2' ' HE3' ' A' ' 129' ' ' LYS . 15.3 m95 . . . . . 0 C--N 1.328 -0.344 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.937 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.56 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 84.3 m-85 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.85 0.357 . . . . 0.0 110.906 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 10.2 m-70 -89.65 147.84 23.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.89 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 41.4 t -119.21 143.47 30.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.157 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.1 t80 -93.56 135.3 34.96 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.4 ' O ' ' CB ' ' A' ' 121' ' ' TYR . 4.0 t -131.25 131.04 63.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.157 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.416 ' N ' ' HG2' ' A' ' 150' ' ' ARG . . . -135.8 179.41 17.82 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.524 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 52.37 47.61 24.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.86 0.362 . . . . 0.0 110.852 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 30.0 mt -99.65 132.91 44.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.938 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -53.01 156.33 3.61 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.651 0.738 . . . . 0.0 110.868 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -39.53 6.28 Favored 'Trans proline' 0 C--O 1.231 0.125 0 C-N-CA 122.675 2.25 . . . . 0.0 112.337 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -71.46 1.2 6.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.887 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.466 HG21 ' CB ' ' A' ' 93' ' ' ASP . 37.3 mm -83.01 132.37 31.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.169 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.1 t -114.74 175.34 5.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.104 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 16.2 m -52.99 -41.66 64.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.147 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -62.36 -47.03 85.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.894 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.466 ' CB ' HG21 ' A' ' 89' ' ' ILE . 17.1 m-20 -47.87 -50.08 27.54 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.911 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 8.1 mt -54.7 -54.97 17.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.132 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.418 ' O ' ' N ' ' A' ' 99' ' ' ALA . 22.0 mtmt -50.93 -42.47 59.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.866 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -58.42 -30.98 67.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.107 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -72.46 -57.16 4.39 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.101 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.418 ' C ' HD13 ' A' ' 104' ' ' ILE . 22.0 m-85 -87.37 12.22 12.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.935 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.482 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -61.79 -60.19 11.05 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.613 0.72 . . . . 0.0 111.119 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.482 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.5 Cg_endo -69.8 -0.8 7.47 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.678 2.252 . . . . 0.0 112.306 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -99.9 9.57 42.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.883 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.26 136.02 4.24 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.525 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 38.9 mtt85 -46.73 125.04 6.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.766 0.317 . . . . 0.0 110.882 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.451 HG22 ' CG1' ' A' ' 124' ' ' VAL . 10.9 mt -98.21 138.83 21.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.153 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.455 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.9 t -106.73 -62.91 1.34 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.848 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -100.25 105.2 16.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.861 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -136.46 127.01 26.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.138 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.2 ptm180 -161.91 155.85 21.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.892 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 58.4 t -102.07 119.14 49.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.557 HG13 ' CE2' ' A' ' 121' ' ' TYR . 59.8 t -53.86 136.99 15.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.141 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . 0.4 ' C ' ' HG3' ' A' ' 119' ' ' LYS . 57.5 mttt -136.59 153.89 50.83 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.501 ' O ' ' N ' ' A' ' 116' ' ' GLY . 23.2 t70 -64.99 120.21 12.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 179.871 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 16.4 ptp -67.14 -10.93 55.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.841 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -83.62 -54.81 4.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.107 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 13.5 p -104.85 -34.4 8.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.171 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.501 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 95.89 25.71 12.7 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.477 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 44.4 mtmt -95.33 154.68 17.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.781 0.324 . . . . 0.0 110.867 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 8.0 t -54.89 112.49 1.05 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.91 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.456 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 16.6 mttp -63.36 -54.23 40.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.895 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 150.2 -41.76 0.79 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.469 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.557 ' CE2' HG13 ' A' ' 110' ' ' VAL . 5.4 p90 -100.01 155.25 17.8 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.96 0.41 . . . . 0.0 110.938 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -134.46 169.88 22.9 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.464 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -118.77 138.44 52.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.873 0.368 . . . . 0.0 110.914 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.553 HG13 ' CZ ' ' A' ' 126' ' ' PHE . 61.2 t -138.77 115.08 10.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.143 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 8.2 t -107.23 140.02 40.77 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.877 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.553 ' CZ ' HG13 ' A' ' 124' ' ' VAL . 1.2 m-85 -119.51 163.45 17.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.894 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.455 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 22.9 m-85 -72.32 -42.91 64.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.902 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 68.0 m-20 -114.18 161.44 17.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.864 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.56 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 44.3 tptt -69.74 -61.63 1.71 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.464 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.9 OUTLIER -33.27 -60.7 0.33 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.883 179.972 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 -39.67 -54.07 2.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.875 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -65.02 -59.49 4.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.08 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -43.5 -60.7 1.63 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.894 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -43.57 -44.11 5.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.836 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.462 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -66.63 -56.48 10.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.132 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 82.8 mt -40.91 -37.84 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.14 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 15.7 mt-30 -76.47 -63.81 1.25 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.947 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 27.0 mt-30 -63.85 -61.24 2.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.931 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.462 ' N ' ' O ' ' A' ' 135' ' ' ALA . 65.6 mmm -51.43 -34.0 33.07 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.858 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.443 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -58.69 93.47 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.483 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 113.52 4.55 23.3 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.426 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 16.2 mm100 -80.66 171.13 15.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.797 0.332 . . . . 0.0 110.875 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . 0.4 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 15.4 m95 -106.7 111.29 23.76 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.92 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.437 ' CB ' HG23 ' A' ' 149' ' ' ILE . 66.3 tp -104.91 129.22 53.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.932 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . 0.411 ' HA3' ' CD1' ' A' ' 89' ' ' ILE . . . 70.31 -78.04 0.45 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.492 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -155.29 14.03 0.46 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.499 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 23.9 mtt85 -153.73 161.46 42.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.771 0.32 . . . . 0.0 110.893 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . 0.4 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 23.0 mt-30 -62.95 171.0 2.38 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.437 HG23 ' CB ' ' A' ' 144' ' ' LEU . 14.0 pt -142.07 158.43 20.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.124 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.487 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 7.7 ptm180 -120.82 118.6 30.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.867 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.443 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 61.0 p -111.15 132.44 54.29 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.159 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 41.2 t30 -157.66 174.07 15.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.942 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . 0.551 ' CH2' ' HE3' ' A' ' 129' ' ' LYS . 9.8 m95 . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.914 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.897 0.379 . . . . 0.0 110.911 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.434 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.5 OUTLIER -82.21 141.75 32.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.892 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 41.6 t -119.2 144.11 28.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.164 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.0 t80 -97.51 131.68 43.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.866 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.516 HG22 ' CZ ' ' A' ' 98' ' ' PHE . 3.6 t -133.42 109.98 14.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.148 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -116.61 -178.12 17.99 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.519 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 63.98 34.99 11.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.894 0.378 . . . . 0.0 110.923 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.411 HD23 ' CG1' ' A' ' 82' ' ' VAL . 9.9 mt -92.76 128.96 38.8 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.918 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.05 154.27 5.48 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.657 0.741 . . . . 0.0 110.874 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -13.79 35.18 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.681 2.254 . . . . 0.0 112.358 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -92.94 -7.78 45.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.87 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.463 HG22 ' N ' ' A' ' 90' ' ' THR . 30.5 mm -78.38 138.54 20.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.17 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.463 ' N ' HG22 ' A' ' 89' ' ' ILE . 11.0 t -119.27 167.26 12.04 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.11 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 21.2 m -42.4 -47.0 4.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.143 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -54.1 -57.71 10.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.885 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -38.45 -57.11 1.18 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.862 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 6.4 mt -48.16 -58.33 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.101 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 23.6 mtmt -49.93 -44.37 50.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.928 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -58.56 -30.12 66.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.095 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -74.85 -58.19 3.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.157 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.516 ' CZ ' HG22 ' A' ' 82' ' ' VAL . 42.9 m-85 -82.42 8.04 12.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.483 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -60.02 -60.21 11.35 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.591 0.71 . . . . 0.0 111.051 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.483 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.7 -0.99 7.66 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.661 2.241 . . . . 0.0 112.378 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.501 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 81.2 m-85 -99.91 3.63 44.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.903 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 136.55 156.61 7.47 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.458 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.44 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 34.0 mtt85 -64.44 125.18 23.84 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.796 0.331 . . . . 0.0 110.882 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.468 HG22 ' CG1' ' A' ' 124' ' ' VAL . 11.6 mt -100.3 137.21 28.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.115 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.534 ' OG ' ' CZ ' ' A' ' 127' ' ' PHE . 2.5 m -110.14 -60.41 1.8 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.895 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.0 t0 -101.22 102.24 13.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.878 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -131.99 125.62 31.97 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.117 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 11.9 ptp180 -159.73 157.58 29.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.841 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 99.2 t -109.36 116.0 51.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.147 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.54 HG21 ' CE2' ' A' ' 121' ' ' TYR . 94.5 t -49.16 138.32 4.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.134 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . 0.435 ' N ' HG11 ' A' ' 110' ' ' VAL . 28.7 mttm -138.39 155.95 48.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.892 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.499 ' O ' ' N ' ' A' ' 116' ' ' GLY . 36.5 t0 -65.49 121.01 13.91 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.889 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 7.0 tpt -69.6 -9.29 53.5 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.898 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.93 -47.8 5.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.105 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 21.9 p -98.35 -34.23 10.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.099 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.499 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 86.33 23.6 43.36 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.474 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 14.8 mtpp -98.93 158.13 15.85 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.797 0.332 . . . . 0.0 110.91 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 47.4 t -56.67 112.91 1.42 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.868 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 25.3 mmtt -63.09 -38.83 92.76 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.918 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 130.49 -42.77 1.37 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.444 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.54 ' CE2' HG21 ' A' ' 110' ' ' VAL . 12.0 p90 -99.91 151.42 21.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.957 0.408 . . . . 0.0 110.892 -179.813 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -136.75 172.4 22.57 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.473 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -120.07 139.06 53.12 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.889 0.376 . . . . 0.0 110.914 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.512 HG12 ' CZ ' ' A' ' 126' ' ' PHE . 53.1 t -136.84 111.0 9.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.111 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.8 t -99.38 151.58 20.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.893 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.512 ' CZ ' HG12 ' A' ' 124' ' ' VAL . 1.5 m-85 -130.83 152.37 50.24 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.875 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.534 ' CZ ' ' OG ' ' A' ' 105' ' ' SER . 76.2 m-85 -66.01 -34.95 79.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.842 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -120.74 149.96 41.73 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.87 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.463 ' O ' ' C ' ' A' ' 130' ' ' TRP . 45.0 tttt -59.05 -65.82 0.6 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.866 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.463 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -33.47 -60.83 0.34 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.923 179.951 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 130' ' ' TRP . 68.8 m-20 -35.81 -46.63 0.46 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.87 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -74.78 -59.8 2.57 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.085 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -39.07 -53.31 1.82 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.846 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 50.5 t30 -49.22 -50.04 40.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.888 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -61.91 -53.15 59.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.085 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 96.6 mt -42.28 -37.11 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.142 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 6.1 mt-30 -86.87 -62.29 1.54 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.908 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 26.3 mt-30 -54.4 -61.52 2.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.885 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.501 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 92.6 mmm -58.45 -41.07 84.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.878 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.443 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -46.88 99.48 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.462 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 101.55 17.78 20.64 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.518 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 57.0 mm-40 -96.51 172.42 7.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.782 0.325 . . . . 0.0 110.898 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . 0.499 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 16.0 m95 -107.54 110.71 22.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.873 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 57.3 tp -103.56 127.47 50.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.934 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 69.89 -75.66 0.44 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.463 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.83 15.51 0.3 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.475 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 42.3 mtt-85 -154.62 156.77 37.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.726 0.298 . . . . 0.0 110.874 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . 0.499 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 33.4 mt-30 -63.12 168.95 3.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.921 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 26.5 pt -149.23 144.73 18.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.112 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 14.0 ptt180 -105.63 124.06 48.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.863 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.443 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 69.0 p -115.28 141.12 48.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.185 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . 0.442 ' CG ' ' O ' ' A' ' 151' ' ' THR . 73.9 m-20 -165.11 177.13 7.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.885 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 11.9 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.942 179.969 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.547 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 54.5 m-85 . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.87 0.366 . . . . 0.0 110.856 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 40.2 m-70 -87.32 148.25 25.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.83 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 34.9 t -123.64 139.64 49.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.122 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -91.94 134.48 34.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.903 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.441 ' CG1' HD22 ' A' ' 85' ' ' LEU . 3.8 t -132.51 109.93 15.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.14 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.4 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -117.36 170.72 13.59 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.478 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.8 t70 68.83 51.67 0.57 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.847 0.356 . . . . 0.0 110.905 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.441 HD22 ' CG1' ' A' ' 82' ' ' VAL . 16.5 mt -108.91 131.92 54.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.893 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 t -54.92 153.71 11.01 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.676 0.75 . . . . 0.0 110.85 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -11.29 30.5 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.682 2.254 . . . . 0.0 112.313 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -94.0 -9.83 35.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.911 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 46.9 mm -74.42 137.99 22.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.131 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.2 t -117.84 166.52 12.37 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.162 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.442 ' CG2' ' HA ' ' A' ' 108' ' ' ARG . 86.1 m -43.37 -46.34 6.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.137 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 93' ' ' ASP . 35.2 mt-10 -55.55 -57.94 9.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.891 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 92' ' ' GLU . 3.0 m-20 -35.18 -58.59 0.54 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.879 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 10.9 mt -48.5 -58.91 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.138 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.46 ' HA ' ' CD1' ' A' ' 104' ' ' ILE . 23.9 mtmt -49.41 -39.41 32.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.929 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.03 -27.66 69.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.085 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.65 -52.2 9.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.121 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -89.33 13.49 13.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.481 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -67.61 -60.26 5.83 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.554 0.692 . . . . 0.0 111.082 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.481 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.5 Cg_endo -69.76 -0.84 7.49 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.689 2.259 . . . . 0.0 112.323 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -99.95 -5.14 28.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.876 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 144.2 142.0 3.84 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.494 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.423 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 57.4 mtt180 -50.81 125.91 14.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.81 0.338 . . . . 0.0 110.882 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.46 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 17.4 mt -99.32 145.72 9.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.127 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.451 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.0 OUTLIER -119.3 -60.09 1.77 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.823 -179.892 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -100.53 92.47 5.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.829 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -129.5 124.64 34.47 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.103 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.442 ' HA ' ' CG2' ' A' ' 91' ' ' THR . 10.5 ptm180 -158.13 161.84 37.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.905 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 79.5 t -113.44 116.82 53.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.562 HG22 ' CE2' ' A' ' 121' ' ' TYR . 77.1 t -52.58 137.46 12.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.131 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . 0.441 ' N ' HG12 ' A' ' 110' ' ' VAL . 1.7 mtmp? -130.19 156.97 43.72 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.906 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.515 ' O ' ' N ' ' A' ' 116' ' ' GLY . 27.5 t0 -64.47 118.85 9.37 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.855 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' MET . . . . . 0.467 ' C ' ' SD ' ' A' ' 113' ' ' MET . 2.6 tmm? -65.85 -9.79 32.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.893 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -92.92 -53.41 4.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.07 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 20.7 p -100.71 -35.41 9.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.108 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 92.76 28.05 13.14 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.483 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -100.24 156.26 17.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.738 0.304 . . . . 0.0 110.917 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 36.7 t -51.77 109.03 0.32 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.876 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 18.9 mmtt -61.14 -51.74 67.81 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.89 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 144.95 -40.59 1.12 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.533 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.562 ' CE2' HG22 ' A' ' 110' ' ' VAL . 6.2 p90 -100.09 151.99 20.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.939 0.4 . . . . 0.0 110.944 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -141.0 172.96 23.46 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.495 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -121.19 141.2 51.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.874 0.369 . . . . 0.0 110.862 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.529 HG13 ' CZ ' ' A' ' 126' ' ' PHE . 58.6 t -139.18 113.52 7.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.132 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 4.3 t -104.35 147.68 27.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.823 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.529 ' CZ ' HG13 ' A' ' 124' ' ' VAL . 1.3 m-85 -126.47 153.86 44.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.876 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.451 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 20.9 m-85 -62.02 -43.43 98.86 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.896 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -114.65 161.72 17.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.877 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.547 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 39.9 tptt -69.04 -62.07 1.53 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.917 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.459 ' C ' ' O ' ' A' ' 129' ' ' LYS . 1.0 OUTLIER -33.53 -61.83 0.31 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.937 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.408 ' C ' ' O ' ' A' ' 130' ' ' TRP . 75.2 m-20 -37.09 -57.46 0.85 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.835 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -58.88 -62.16 2.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.103 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -39.7 -59.52 1.13 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.876 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 53.3 t30 -41.07 -46.45 2.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.879 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.484 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -67.32 -51.84 47.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.107 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 97.6 mt -43.42 -35.11 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.151 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -88.33 -55.23 3.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.9 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 5.0 mm100 -67.31 -61.01 2.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.93 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.484 ' N ' ' O ' ' A' ' 135' ' ' ALA . 57.4 mmm -59.2 -26.46 64.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.434 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -65.1 113.54 5.94 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.45 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 89.36 18.25 53.27 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.494 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 89.8 mm-40 -97.47 171.2 8.54 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.788 0.328 . . . . 0.0 110.898 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . 0.414 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 15.4 m95 -104.14 110.68 22.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.949 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 59.2 tp -103.27 129.22 50.19 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.906 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 67.28 -74.74 0.19 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.493 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.81 18.05 0.28 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.511 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 72.2 mtt180 -156.69 155.41 31.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.756 0.312 . . . . 0.0 110.906 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . 0.414 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 31.1 mt-30 -60.18 170.38 1.29 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.915 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 19.2 pt -146.39 150.18 15.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.106 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.424 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 13.1 ptp180 -113.99 121.96 45.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.87 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.434 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 73.4 p -112.56 128.11 56.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.168 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -151.33 170.77 18.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.898 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . 0.528 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 9.8 m95 . . . . . 0 C--N 1.328 -0.362 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.921 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.573 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 97.3 m-85 . . . . . 0 C--O 1.232 0.154 0 CA-C-O 120.911 0.386 . . . . 0.0 110.916 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.467 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.9 OUTLIER -95.51 139.92 31.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 -180.0 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 57.4 t -113.96 152.02 15.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.06 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -102.09 132.89 47.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.915 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.1 t -129.57 129.78 66.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.142 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.45 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -136.69 -173.54 12.96 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.494 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 27.0 m-20 55.3 36.33 26.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.831 0.348 . . . . 0.0 110.851 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.3 mt -96.18 131.02 43.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.886 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 t -53.1 153.71 6.15 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.652 0.739 . . . . 0.0 110.818 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -13.84 35.25 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.7 2.267 . . . . 0.0 112.338 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -91.04 -8.75 48.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.888 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.456 HG21 ' CB ' ' A' ' 93' ' ' ASP . 39.1 mm -76.37 136.67 24.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.176 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.444 ' OG1' ' N ' ' A' ' 91' ' ' THR . 2.3 t -114.55 177.54 4.61 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.163 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.444 ' N ' ' OG1' ' A' ' 90' ' ' THR . 69.9 m -52.6 -47.67 66.78 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.177 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 93' ' ' ASP . 32.0 mt-10 -56.42 -58.26 8.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.879 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.456 ' CB ' HG21 ' A' ' 89' ' ' ILE . 2.9 m-20 -35.49 -54.63 0.68 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.911 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 6.2 mt -51.18 -60.17 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.117 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.423 ' O ' ' N ' ' A' ' 99' ' ' ALA . 21.7 mtmt -47.14 -43.13 20.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.904 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -57.43 -31.57 66.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.134 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -74.42 -52.65 11.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.12 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -88.77 12.4 15.11 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.868 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.484 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -65.72 -60.1 7.98 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.597 0.713 . . . . 0.0 111.096 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.484 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.4 Cg_endo -69.8 -0.87 7.58 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.694 2.263 . . . . 0.0 112.321 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.506 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 78.3 m-85 -99.75 4.61 45.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.887 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.06 159.63 8.74 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.475 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.494 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 39.8 mtp85 -65.72 125.71 26.16 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.804 0.335 . . . . 0.0 110.866 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.404 HG23 ' CG1' ' A' ' 124' ' ' VAL . 14.4 mt -100.46 138.14 25.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.186 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -109.86 -60.76 1.74 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.849 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -100.75 103.96 15.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.904 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -133.84 124.86 27.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.124 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.414 ' HA ' ' CG2' ' A' ' 91' ' ' THR . 17.6 ptt180 -161.94 160.16 27.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.9 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 99.4 t -110.12 116.31 51.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.148 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.568 HG11 ' CE2' ' A' ' 121' ' ' TYR . 51.5 t -50.99 132.73 12.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.101 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 69.1 mttt -133.45 148.76 51.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.867 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.44 ' O ' ' N ' ' A' ' 116' ' ' GLY . 29.6 t0 -58.28 123.66 16.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.88 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 36.3 ttp -71.77 -2.83 18.97 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.865 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -99.87 -49.91 4.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.094 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 18.7 p -102.15 -28.2 12.45 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.127 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 82.68 25.31 50.65 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.504 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 48.1 mtmt -99.99 147.08 25.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.757 0.313 . . . . 0.0 110.923 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 5.0 t -50.18 113.46 0.87 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.813 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 41.5 mttt -63.6 -51.52 64.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.898 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 148.65 -40.02 0.93 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.476 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.568 ' CE2' HG11 ' A' ' 110' ' ' VAL . 10.1 p90 -100.03 149.43 23.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.934 0.397 . . . . 0.0 110.898 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -130.88 176.94 18.75 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.505 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -123.78 139.25 54.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.884 0.373 . . . . 0.0 110.867 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.517 HG11 ' CZ ' ' A' ' 126' ' ' PHE . 42.9 t -139.67 113.31 6.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.124 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 24.4 t -102.83 149.6 24.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.843 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.517 ' CZ ' HG11 ' A' ' 124' ' ' VAL . 1.6 m-85 -129.29 141.56 51.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.874 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.494 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 82.7 m-85 -56.12 -41.16 74.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.882 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 12.7 m120 -109.21 155.28 21.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.905 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.573 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 26.8 tttt -68.51 -40.16 80.94 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.891 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.422 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.9 OUTLIER -60.87 -58.92 6.41 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.911 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.422 ' C ' ' O ' ' A' ' 130' ' ' TRP . 78.5 m-20 -36.07 -41.57 0.25 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.871 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . 0.467 ' HB3' ' CD1' ' A' ' 126' ' ' PHE . . . -80.51 -54.71 5.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.1 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -42.29 -54.28 3.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.898 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -45.42 -51.87 10.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.913 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.461 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -60.95 -56.64 18.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.114 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 85.8 mt -37.76 -35.32 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.147 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -90.07 -59.22 2.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.937 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 25.2 mm-40 -63.64 -59.49 4.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.919 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.506 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 78.3 mmm -57.08 -40.09 76.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.897 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.436 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -52.15 118.65 7.7 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.519 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.83 -24.89 29.75 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.556 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . 0.409 ' NE2' ' HA ' ' A' ' 142' ' ' GLN . 8.7 mm-40 -56.64 -177.26 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.823 0.344 . . . . 0.0 110.901 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . 0.469 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 13.6 m95 -120.42 131.32 54.73 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.914 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 41.6 tp -128.97 129.17 45.08 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.942 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 71.66 -6.07 9.84 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.467 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 123.05 -10.54 8.81 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.504 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 17.1 mtt85 -125.84 147.76 49.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.741 0.305 . . . . 0.0 110.857 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . 0.469 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 22.6 mt-30 -51.61 169.46 0.06 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.927 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.5 pt -140.62 151.19 20.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.14 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.45 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 16.9 ptp180 -113.74 118.79 35.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.862 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.436 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 72.2 p -112.08 125.28 53.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.153 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 11.2 m120 -152.76 179.13 8.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.868 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 15.0 m95 . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.929 179.98 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.567 ' CE1' ' HB2' ' A' ' 129' ' ' LYS . 46.9 m-85 . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.83 0.348 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.474 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.4 OUTLIER -87.21 144.24 26.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.84 179.984 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 69.4 t -120.22 144.16 29.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.141 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 19.7 t80 -95.63 134.66 38.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.877 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.439 ' CG1' HD21 ' A' ' 85' ' ' LEU . 2.7 t -132.62 129.1 58.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.11 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.464 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -134.9 179.89 17.19 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.479 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 6.6 t0 57.75 45.05 19.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.82 0.343 . . . . 0.0 110.845 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.439 HD21 ' CG1' ' A' ' 82' ' ' VAL . 18.5 mt -100.2 131.72 45.98 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.902 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -52.92 154.1 5.39 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.671 0.748 . . . . 0.0 110.842 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.76 -16.0 37.37 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.654 2.236 . . . . 0.0 112.356 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -90.54 -6.53 54.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.853 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.466 ' CD1' ' HA3' ' A' ' 145' ' ' GLY . 42.6 mm -78.44 137.42 22.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.142 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.8 t -119.09 174.6 6.22 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.088 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 24.5 m -49.41 -47.31 48.03 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.158 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.413 ' O ' ' C ' ' A' ' 93' ' ' ASP . 37.3 mt-10 -56.27 -56.4 21.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.844 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.456 ' CB ' HG21 ' A' ' 89' ' ' ILE . 3.2 m-20 -36.51 -58.26 0.72 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.865 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.441 HG23 ' CG2' ' A' ' 124' ' ' VAL . 14.0 mt -47.43 -59.5 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.159 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.501 ' O ' ' N ' ' A' ' 99' ' ' ALA . 19.2 mtmt -46.64 -39.44 11.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.892 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.26 -35.03 76.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.082 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.75 -54.92 9.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.109 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -87.35 5.37 38.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.896 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 95' ' ' LYS . . . -56.63 -60.41 9.38 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.597 0.713 . . . . 0.0 111.129 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.476 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.7 Cg_endo -69.82 -1.01 7.79 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.677 2.251 . . . . 0.0 112.287 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -100.07 12.63 36.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.866 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.45 146.23 6.69 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.53 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 70.7 mtt180 -55.5 125.72 22.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.756 0.313 . . . . 0.0 110.901 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.472 HG21 ' CG1' ' A' ' 124' ' ' VAL . 11.9 mt -100.03 133.64 42.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.128 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -102.5 -61.98 1.33 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.852 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -100.34 103.42 14.82 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.846 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -133.66 124.96 27.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.105 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 -161.32 163.21 30.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 54.9 t -111.97 125.23 69.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.118 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.506 HG21 ' CD2' ' A' ' 121' ' ' TYR . 41.4 t -57.28 135.91 20.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.137 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 18.6 mttp -135.67 150.8 49.71 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.891 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.459 ' O ' ' N ' ' A' ' 116' ' ' GLY . 15.6 t0 -59.68 123.18 16.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.861 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 26.9 ptm -75.05 -2.27 26.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.89 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.0 -38.75 9.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.081 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 25.9 p -116.18 -33.01 5.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.165 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 91.27 25.6 23.48 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.471 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 68.3 mmtt -98.94 157.17 16.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.794 0.331 . . . . 0.0 110.866 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 2.7 t -57.27 121.83 11.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.876 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 35.3 mttt -75.48 -48.02 24.5 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.896 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 142.18 -43.67 1.04 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.482 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.506 ' CD2' HG21 ' A' ' 110' ' ' VAL . 14.8 p90 -98.74 146.45 25.88 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.886 0.374 . . . . 0.0 110.933 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -129.86 179.16 17.0 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.489 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -127.11 140.1 52.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.898 0.38 . . . . 0.0 110.916 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.521 HG12 ' CZ ' ' A' ' 126' ' ' PHE . 61.9 t -137.84 116.65 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.152 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 9.5 t -104.81 148.02 27.09 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.873 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.521 ' CZ ' HG12 ' A' ' 124' ' ' VAL . 1.4 m-85 -128.37 156.38 43.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.892 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -65.16 -41.31 94.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.901 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -119.18 150.82 39.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.907 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.567 ' HB2' ' CE1' ' A' ' 78' ' ' PHE . 30.3 tttt -58.64 -65.68 0.62 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.927 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.45 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -33.17 -59.79 0.35 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.917 179.88 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 70.7 m-20 -37.78 -46.53 0.93 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.822 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . 0.413 ' N ' ' O ' ' A' ' 129' ' ' LYS . . . -73.15 -59.19 2.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.076 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -40.63 -51.93 2.94 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 30.4 t-20 -46.31 -42.07 14.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.893 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -72.67 -54.31 9.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.109 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 96.0 mt -40.56 -31.95 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.109 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -84.84 -64.9 1.08 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.957 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -62.01 -62.55 1.7 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.912 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 68.8 mmm -49.76 -43.72 48.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.862 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.443 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -51.43 109.64 0.84 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.46 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 105.95 -28.23 14.67 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.482 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 54.1 mm-40 -55.01 179.88 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.819 0.343 . . . . 0.0 110.941 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . 0.482 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 13.3 m95 -116.2 127.18 54.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.912 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 32.8 tp -126.69 130.67 50.84 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.939 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . 0.466 ' HA3' ' CD1' ' A' ' 89' ' ' ILE . . . 70.62 -3.61 11.61 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.474 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 120.86 -13.8 9.79 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.515 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 47.5 mtt180 -124.93 153.57 42.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 110.835 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . 0.482 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 20.6 mt-30 -61.49 158.51 14.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 21.6 pt -130.86 153.07 38.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.145 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.464 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 2.8 ptp180 -111.68 115.95 29.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.887 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.443 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 58.5 p -110.21 128.12 55.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.142 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 19.8 m-20 -159.94 168.68 25.13 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 14.1 m95 . . . . . 0 C--N 1.327 -0.37 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.918 -179.984 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.858 0.361 . . . . 0.0 110.91 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.484 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.7 OUTLIER -83.68 155.6 23.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.858 -179.971 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 36.8 t -134.27 135.34 54.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.112 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 15.4 t80 -87.44 128.15 35.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.84 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.437 HG21 ' CZ ' ' A' ' 98' ' ' PHE . 4.0 t -127.96 109.86 20.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.103 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -115.31 -176.91 18.65 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.519 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 59.9 40.26 19.34 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.844 0.354 . . . . 0.0 110.883 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 11.5 mt -99.04 127.37 44.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.886 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.04 154.19 5.52 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.633 0.73 . . . . 0.0 110.867 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.88 -11.74 31.28 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.67 2.247 . . . . 0.0 112.294 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -92.32 -8.07 46.13 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.894 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.471 HG21 ' N ' ' A' ' 90' ' ' THR . 45.7 mm -78.27 138.06 20.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.147 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.471 ' N ' HG21 ' A' ' 89' ' ' ILE . 14.5 t -119.55 163.73 16.88 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.118 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 27.7 m -38.85 -46.6 1.31 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.168 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.415 ' O ' ' C ' ' A' ' 93' ' ' ASP . 21.2 mt-10 -56.61 -58.95 5.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.853 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 92' ' ' GLU . 3.9 m-20 -36.42 -57.94 0.73 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.852 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 8.1 mt -47.44 -58.59 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.103 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.437 ' HG3' ' CB ' ' A' ' 107' ' ' ALA . 26.1 mtmt -49.28 -42.14 40.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.893 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -59.09 -28.77 66.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.127 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -74.75 -54.75 6.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.437 ' CZ ' HG21 ' A' ' 82' ' ' VAL . 28.6 m-85 -86.5 8.34 22.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.913 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.477 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -61.61 -60.31 10.77 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.621 0.724 . . . . 0.0 111.145 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.477 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.78 -0.95 7.68 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.681 2.254 . . . . 0.0 112.402 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -100.18 -4.48 29.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.83 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 146.46 156.87 7.09 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.517 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 31.9 mtm180 -64.84 123.79 20.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.818 0.342 . . . . 0.0 110.867 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.439 HG22 ' CG1' ' A' ' 124' ' ' VAL . 11.1 mt -100.42 139.12 22.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.18 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 8.3 t -110.03 -62.47 1.5 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -100.73 105.28 16.6 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.888 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . 0.437 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -134.16 125.73 28.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.12 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 15.0 ptt180 -160.86 161.32 31.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.87 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 72.9 t -111.5 119.45 59.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.173 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.525 HG12 ' CE2' ' A' ' 121' ' ' TYR . 42.8 t -51.45 133.13 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.113 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -132.98 151.59 52.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.458 ' O ' ' N ' ' A' ' 116' ' ' GLY . 39.5 t0 -60.33 119.29 7.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.883 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 22.7 ptp -68.68 -2.28 8.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.913 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -97.55 -47.16 5.76 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.125 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 43.2 p -110.05 -34.5 6.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.162 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.458 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 92.66 31.98 8.4 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.468 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt -99.52 148.69 24.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.779 0.323 . . . . 0.0 110.88 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 19.5 t -54.92 102.09 0.06 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.832 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 42.2 mttt -52.02 -53.46 41.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.883 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 149.75 -39.82 0.88 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.488 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.525 ' CE2' HG12 ' A' ' 110' ' ' VAL . 5.8 p90 -100.07 161.27 13.71 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.931 0.396 . . . . 0.0 110.887 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -142.27 174.96 23.06 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.455 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -124.59 137.98 54.35 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.896 0.379 . . . . 0.0 110.932 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.468 HG12 ' CZ ' ' A' ' 126' ' ' PHE . 71.0 t -138.11 120.38 18.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.105 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 21.1 m -103.06 150.88 23.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.828 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.468 ' CZ ' HG12 ' A' ' 124' ' ' VAL . 15.3 m-85 -131.03 142.89 50.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.862 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -60.9 -32.53 71.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.852 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 21.6 m-20 -117.66 169.58 9.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.849 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.498 ' HE3' ' CH2' ' A' ' 153' ' ' TRP . 20.6 tptm -78.99 -53.16 7.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.89 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.415 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.8 OUTLIER -48.07 -59.83 3.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.914 179.925 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 130' ' ' TRP . 79.4 m-20 -35.83 -40.63 0.19 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.908 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.75 -62.76 1.56 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.096 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -42.41 -58.88 2.05 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.877 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -39.97 -47.39 2.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.889 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.464 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -67.57 -54.45 19.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.079 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 54.9 mt -41.66 -35.37 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.163 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -88.62 -54.91 3.94 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.98 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 5.0 mm100 -68.11 -62.88 1.2 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.906 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.464 ' N ' ' O ' ' A' ' 135' ' ' ALA . 84.6 mmm -52.96 -35.64 59.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.874 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.442 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -52.97 110.6 1.34 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.514 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 100.97 -22.73 38.28 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.481 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 33.5 mm-40 -55.05 169.8 0.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.786 0.326 . . . . 0.0 110.925 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . 0.412 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 14.7 m95 -107.95 113.09 26.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.908 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.465 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 56.9 tp -103.98 129.74 51.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.899 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 68.83 -77.77 0.28 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.511 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -155.17 13.74 0.46 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.482 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 32.2 mtp85 -153.17 160.8 42.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . 0.412 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 24.0 mt-30 -62.03 168.7 3.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.933 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.465 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 22.4 pt -140.2 144.47 27.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.13 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 3.7 ttm180 -105.5 124.21 49.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.907 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.442 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 61.9 p -117.52 132.54 56.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.132 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -157.2 169.17 25.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . 0.498 ' CH2' ' HE3' ' A' ' 129' ' ' LYS . 7.3 m95 . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.982 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.933 0.397 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.476 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.5 OUTLIER -82.51 142.15 32.08 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.867 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 56.0 t -120.94 148.94 23.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.159 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -100.69 136.97 39.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.887 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.413 HG21 ' CZ ' ' A' ' 98' ' ' PHE . 3.5 t -136.77 109.66 8.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.134 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -120.97 179.57 16.3 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.484 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 4.0 t70 62.51 43.08 8.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.827 0.346 . . . . 0.0 110.838 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.1 mt -103.31 135.66 44.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.934 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.03 153.9 5.79 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.651 0.739 . . . . 0.0 110.901 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -16.56 37.67 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.678 2.252 . . . . 0.0 112.374 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -89.29 -7.01 56.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.907 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.463 HG22 ' CB ' ' A' ' 93' ' ' ASP . 40.3 mm -75.54 138.46 20.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.127 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.5 t -119.14 168.2 11.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.152 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.4 m -46.36 -44.12 16.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.112 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 29.6 mt-10 -58.24 -51.26 70.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.901 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.463 ' CB ' HG22 ' A' ' 89' ' ' ILE . 4.6 m-20 -44.04 -55.97 4.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.437 HG23 ' CG2' ' A' ' 124' ' ' VAL . 8.4 mt -49.53 -58.57 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.139 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.466 ' HG3' ' CB ' ' A' ' 107' ' ' ALA . 24.9 mtmt -48.99 -41.71 35.33 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.883 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -59.8 -31.89 70.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.108 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -72.52 -56.97 4.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.104 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.413 ' CZ ' HG21 ' A' ' 82' ' ' VAL . 33.5 m-85 -83.79 11.94 6.75 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.88 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.482 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -67.43 -59.95 6.41 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.583 0.706 . . . . 0.0 111.113 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.482 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.77 -0.83 7.48 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.7 2.266 . . . . 0.0 112.319 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.412 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 70.8 m-85 -99.77 -13.37 19.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.926 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 156.59 155.14 7.3 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.508 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.438 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 35.8 mtt-85 -63.31 123.21 18.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.795 0.331 . . . . 0.0 110.897 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.471 HG21 ' CG1' ' A' ' 124' ' ' VAL . 12.6 mt -100.49 142.6 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.133 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.458 ' HB2' ' CZ ' ' A' ' 127' ' ' PHE . 38.6 t -114.94 -61.53 1.74 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.827 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -100.97 101.03 11.74 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.829 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . 0.466 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -130.24 124.24 32.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.117 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 10.2 ptp180 -160.72 153.78 21.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.88 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 69.2 t -102.3 125.94 56.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.57 HG22 ' CE2' ' A' ' 121' ' ' TYR . 56.6 t -55.61 139.99 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.108 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . 0.463 ' N ' HG13 ' A' ' 110' ' ' VAL . 49.7 mttt -138.79 149.22 44.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.889 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.405 ' O ' ' N ' ' A' ' 116' ' ' GLY . 48.8 t0 -63.1 121.98 14.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.859 179.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 11.4 ptp -71.4 -1.45 13.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.901 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.97 -54.28 3.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.079 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 26.8 p -99.61 -24.99 14.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.186 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 81.35 27.17 49.42 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.457 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 73.6 mmtt -96.75 164.88 12.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.776 0.322 . . . . 0.0 110.914 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 24.6 t -66.33 115.04 5.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.86 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 7.0 mmtm -64.93 -40.92 95.78 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.894 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 130.44 -46.78 1.05 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.481 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.57 ' CE2' HG22 ' A' ' 110' ' ' VAL . 29.6 p90 -100.02 141.18 33.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.905 0.383 . . . . 0.0 110.947 -179.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -125.28 178.64 16.49 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.513 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 62.5 m-85 -121.25 139.9 52.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.878 0.37 . . . . 0.0 110.874 -179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.558 HG11 ' CZ ' ' A' ' 126' ' ' PHE . 63.9 t -136.56 115.68 15.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.118 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 43.9 t -101.63 151.43 22.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.833 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.558 ' CZ ' HG11 ' A' ' 124' ' ' VAL . 1.8 m-85 -131.0 148.04 52.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.88 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.458 ' CZ ' ' HB2' ' A' ' 105' ' ' SER . 68.0 m-85 -64.91 -40.41 95.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.867 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -111.73 155.27 23.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.877 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.466 ' O ' ' C ' ' A' ' 130' ' ' TRP . 38.4 tttt -68.38 -63.4 1.07 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.893 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.466 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -33.19 -60.09 0.34 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.949 179.897 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.4 ' C ' ' O ' ' A' ' 130' ' ' TRP . 61.9 m-20 -37.77 -54.83 1.22 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.888 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -60.09 -64.95 0.77 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.085 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -39.37 -58.57 1.2 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.919 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -42.01 -50.29 4.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.878 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.468 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -66.79 -59.95 3.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.062 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 93.4 mt -37.67 -37.74 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.5 mt-30 -84.42 -61.66 1.75 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.935 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -61.24 -59.75 4.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.907 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.468 ' N ' ' O ' ' A' ' 135' ' ' ALA . 86.9 mmm -57.38 -36.33 71.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.855 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -52.39 104.31 0.17 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.495 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 111.86 -31.72 6.85 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.488 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 17.2 mm-40 -49.41 179.82 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.798 0.332 . . . . 0.0 110.923 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . 0.425 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 13.7 m95 -115.44 126.89 54.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.893 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.463 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 40.7 tp -123.29 126.78 47.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . 0.4 ' HA3' ' CD1' ' A' ' 89' ' ' ILE . . . 71.66 -6.12 9.71 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.549 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 123.7 -11.11 8.42 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.485 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 17.8 mtt-85 -125.58 146.9 49.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.789 0.328 . . . . 0.0 110.866 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . 0.425 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 22.4 mt-30 -56.18 158.64 3.93 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.921 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.463 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 21.0 pt -132.29 143.56 39.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.143 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 11.2 ptt180 -107.07 109.32 21.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.876 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 62.4 p -101.0 131.98 46.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.188 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 17.1 t30 -155.35 172.88 17.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.881 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 82.8 m95 . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.912 179.974 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.543 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 5.1 m-85 . . . . . 0 C--O 1.232 0.142 0 CA-C-O 120.844 0.354 . . . . 0.0 110.84 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.448 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.6 OUTLIER -83.99 149.09 26.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.836 -179.987 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.46 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 39.7 t -125.0 141.25 45.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.148 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.1 t80 -92.31 134.03 35.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.894 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.466 HG22 ' CZ ' ' A' ' 98' ' ' PHE . 12.2 t -132.62 112.95 19.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.1 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -120.52 -179.63 16.31 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.431 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.408 ' O ' ' O ' ' A' ' 148' ' ' GLN . 5.2 m-20 63.9 43.79 5.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.812 0.339 . . . . 0.0 110.878 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.414 HD23 ' CG1' ' A' ' 82' ' ' VAL . 9.6 mt -102.37 129.16 48.76 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.902 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.1 t -53.26 154.27 5.99 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.705 0.764 . . . . 0.0 110.849 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -7.65 21.6 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.719 2.28 . . . . 0.0 112.341 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -99.98 -8.67 23.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.864 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.465 HG21 ' CB ' ' A' ' 93' ' ' ASP . 38.6 mm -75.29 141.2 16.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.14 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.0 t -119.46 173.13 7.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.14 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.473 ' CG2' ' HA ' ' A' ' 108' ' ' ARG . 88.0 m -50.22 -47.28 54.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.099 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -54.74 -52.97 60.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.884 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.465 ' CB ' HG21 ' A' ' 89' ' ' ILE . 1.6 m-20 -42.72 -55.78 3.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.821 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 10.2 mt -49.5 -58.66 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.112 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.459 ' O ' ' N ' ' A' ' 99' ' ' ALA . 25.3 mtmt -47.87 -39.51 18.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.82 -32.72 72.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.095 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.416 ' CB ' ' HE2' ' A' ' 139' ' ' MET . . . -71.71 -51.85 20.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.094 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.466 ' CZ ' HG22 ' A' ' 82' ' ' VAL . 14.2 m-85 -93.51 13.2 22.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.882 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.49 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -66.76 -59.82 7.33 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.538 0.685 . . . . 0.0 111.081 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.49 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.3 Cg_endo -69.78 -0.61 7.18 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.685 2.257 . . . . 0.0 112.305 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -99.75 -1.33 38.0 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.846 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 142.54 143.24 4.15 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.451 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 68.4 mtm180 -53.47 123.38 11.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.795 0.331 . . . . 0.0 110.891 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 20.1 mt -100.0 137.34 27.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.167 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.468 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 7.5 p -105.1 -62.3 1.36 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.884 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -100.74 105.14 16.44 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . 0.444 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -135.18 125.29 26.02 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.13 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.473 ' HA ' ' CG2' ' A' ' 91' ' ' THR . 8.2 ptp180 -160.22 169.17 23.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 95.8 t -116.93 117.54 55.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.133 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.568 HG21 ' CE2' ' A' ' 121' ' ' TYR . 60.6 t -47.1 141.08 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.172 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . 0.466 ' N ' HG11 ' A' ' 110' ' ' VAL . 80.1 mttt -140.31 152.09 45.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.902 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -63.88 121.55 14.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.851 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 1.1 pmm? -74.89 -1.47 22.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.856 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.14 -44.37 6.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.097 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 52.1 p -111.12 -35.16 5.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.175 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 94.63 31.01 8.08 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.505 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 22.9 mmtm -99.53 164.39 12.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.822 0.344 . . . . 0.0 110.891 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 29.6 t -65.83 109.88 2.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.866 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 11.3 mmtp -59.78 -39.36 84.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.878 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 128.6 -47.16 1.04 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.549 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.568 ' CE2' HG21 ' A' ' 110' ' ' VAL . 12.8 p90 -99.94 146.56 26.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.969 0.414 . . . . 0.0 110.902 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -127.96 178.03 17.29 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.459 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 36.9 m-85 -121.73 140.12 52.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.912 0.386 . . . . 0.0 110.908 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.491 HG12 ' CZ ' ' A' ' 126' ' ' PHE . 47.4 t -136.77 113.75 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.108 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 69.0 m -102.04 150.48 23.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.867 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.497 ' N ' ' CD1' ' A' ' 126' ' ' PHE . 1.4 m-85 -130.77 143.33 50.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.846 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.468 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 22.7 m-85 -50.27 -48.89 54.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.904 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -106.85 173.31 6.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.886 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.543 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 3.5 ttmt -79.36 -51.8 8.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.927 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.42 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.0 OUTLIER -48.03 -58.4 4.49 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.887 179.952 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 130' ' ' TRP . 81.9 m-20 -35.72 -42.74 0.26 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.86 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . 0.46 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -78.7 -60.89 2.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.128 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.4 ' C ' ' O ' ' A' ' 132' ' ' ALA . 18.6 mt-10 -37.83 -55.56 1.18 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -43.15 -55.51 3.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.902 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.466 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -59.21 -54.66 44.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.075 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 93.0 mt -38.62 -36.57 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.14 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -87.94 -60.8 1.87 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.908 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 20.1 mm-40 -61.32 -59.49 5.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.9 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.466 ' N ' ' O ' ' A' ' 135' ' ' ALA . 87.3 mmm -59.32 -35.57 74.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.429 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -53.31 111.03 1.56 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.466 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 102.11 -28.86 14.03 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -50.63 178.89 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.746 0.308 . . . . 0.0 110.898 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . 0.565 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 14.3 m95 -115.31 119.55 36.66 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.959 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.469 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 60.6 tp -109.5 129.5 55.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.918 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 70.24 -78.57 0.43 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.476 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -156.04 14.08 0.4 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.517 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 66.7 mtt180 -153.5 154.38 34.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.744 0.307 . . . . 0.0 110.883 -179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . 0.565 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 15.8 mt-30 -55.91 167.8 0.54 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.914 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.469 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 28.8 pt -140.81 147.69 22.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.155 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 15.8 ptt180 -111.83 120.47 42.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.805 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.429 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 82.5 p -111.02 133.12 53.66 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -155.06 165.52 36.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.886 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 12.9 m95 . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.945 179.954 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.495 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 75.9 m-85 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.908 0.385 . . . . 0.0 110.898 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.42 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.9 OUTLIER -88.49 163.81 15.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.895 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 49.0 t -138.32 143.66 32.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.112 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -98.11 132.08 43.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.854 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.481 HG22 ' CZ ' ' A' ' 98' ' ' PHE . 2.7 t -132.63 109.79 15.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.136 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.431 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -116.3 -179.45 18.03 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.469 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.4 ' O ' ' O ' ' A' ' 148' ' ' GLN . 14.4 m-20 63.8 26.21 14.31 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.891 0.377 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.427 ' CD2' HG11 ' A' ' 82' ' ' VAL . 10.7 mt -83.79 135.59 34.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.951 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -52.93 147.61 15.68 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.717 0.77 . . . . 0.0 110.854 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -6.2 18.04 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.638 2.225 . . . . 0.0 112.344 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -100.61 -5.02 27.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.851 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.463 ' CD1' ' HA3' ' A' ' 145' ' ' GLY . 30.8 mm -74.8 145.29 11.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.124 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.1 t -121.03 165.0 15.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.133 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 22.5 m -43.63 -50.7 7.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.107 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 93' ' ' ASP . 34.3 mt-10 -54.55 -57.26 12.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.892 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.439 ' CB ' HG22 ' A' ' 89' ' ' ILE . 0.5 OUTLIER -35.78 -57.86 0.64 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.89 179.974 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 8.7 mt -47.36 -59.31 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.117 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.467 ' HA ' ' CD1' ' A' ' 104' ' ' ILE . 22.9 mtmt -47.93 -39.21 18.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.926 179.822 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.82 -35.03 75.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.079 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -71.68 -51.81 21.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.09 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.481 ' CZ ' HG22 ' A' ' 82' ' ' VAL . 23.0 m-85 -89.43 16.82 6.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.865 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.474 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -68.05 -60.61 4.98 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.595 0.712 . . . . 0.0 111.102 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.474 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.5 Cg_endo -69.8 -1.43 8.5 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.647 2.232 . . . . 0.0 112.318 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -100.45 11.45 39.43 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.842 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 126.65 133.16 3.79 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.477 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 16.9 mtt180 -46.08 126.75 7.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.799 0.333 . . . . 0.0 110.87 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.467 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 11.0 mt -100.06 138.13 25.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.139 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.523 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 2.6 t -107.61 -62.72 1.39 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -100.56 104.27 15.62 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.842 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . 0.459 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -134.46 125.92 28.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.076 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.43 ' NH1' ' HA ' ' A' ' 110' ' ' VAL . 0.1 OUTLIER -158.88 157.51 31.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.884 -179.911 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 88.3 t -104.82 117.71 50.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.122 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.566 HG22 ' CD2' ' A' ' 121' ' ' TYR . 85.8 t -50.33 143.04 2.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.103 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 33.8 mttm -142.68 157.1 45.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.865 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -71.37 128.03 34.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.858 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 24.8 ptp -76.96 1.06 18.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -99.59 -46.04 5.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.092 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 24.4 p -108.85 -26.28 10.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.169 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 81.5 24.62 56.09 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.479 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 66.8 mttt -97.88 164.59 12.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.814 0.34 . . . . 0.0 110.902 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 2.2 m -59.39 119.04 6.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.855 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.412 ' HB3' ' CE1' ' A' ' 121' ' ' TYR . 24.4 mmtt -71.25 -39.32 71.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.945 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 128.99 -40.5 1.69 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.459 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.566 ' CD2' HG22 ' A' ' 110' ' ' VAL . 7.0 p90 -100.23 156.04 17.44 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.911 0.386 . . . . 0.0 110.956 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.17 174.8 21.53 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.56 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -130.55 139.24 50.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.888 0.375 . . . . 0.0 110.857 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.574 HG11 ' CE1' ' A' ' 126' ' ' PHE . 76.7 t -134.49 133.56 54.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.097 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 32.5 t -113.19 138.58 49.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.83 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.574 ' CE1' HG11 ' A' ' 124' ' ' VAL . 75.2 m-85 -118.65 147.38 43.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.878 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.523 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 23.3 m-85 -61.64 -36.21 80.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 4.7 m-20 -114.75 174.58 5.89 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.866 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.495 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 67.1 tttt -84.12 -39.34 19.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.93 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.42 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -61.15 -53.11 61.12 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.928 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 130' ' ' TRP . 75.6 m-20 -35.88 -52.39 0.73 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.891 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . 0.484 ' HB3' ' CD1' ' A' ' 126' ' ' PHE . . . -64.97 -66.18 0.58 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.096 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.429 ' C ' ' O ' ' A' ' 132' ' ' ALA . 3.8 mm-40 -34.7 -56.5 0.54 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.866 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -42.26 -51.68 4.69 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.924 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -64.7 -55.79 17.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.086 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 87.4 mt -39.2 -33.46 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.14 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 12.2 mt-30 -84.9 -67.38 0.8 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.889 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 -57.73 -61.58 2.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.901 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 64.8 mmm -53.47 -41.1 65.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.868 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.408 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -49.38 104.72 0.11 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.519 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 106.7 -31.16 8.51 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.454 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 50.7 mm-40 -49.33 173.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.823 0.344 . . . . 0.0 110.927 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . 0.462 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 12.9 m95 -108.89 127.41 54.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.899 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.459 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 36.6 tp -128.48 130.76 47.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.887 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . 0.463 ' HA3' ' CD1' ' A' ' 89' ' ' ILE . . . 69.77 -2.09 13.48 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.488 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 117.26 -14.27 13.58 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.48 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 20.1 mtt-85 -124.12 143.25 50.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.804 0.335 . . . . 0.0 110.829 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . 0.462 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 28.4 mt-30 -52.5 160.04 0.92 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.951 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.459 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 21.3 pt -134.15 152.74 34.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.15 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.431 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 10.7 ptp180 -113.24 118.85 35.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.408 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 41.5 p -110.49 133.33 53.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.127 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 60.5 m-20 -163.06 164.43 25.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.887 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 14.3 m95 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.922 179.99 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.56 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 17.5 m-85 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.859 0.361 . . . . 0.0 110.903 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.449 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 1.1 m-70 -86.9 149.1 25.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.835 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 40.2 t -129.06 144.43 38.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.112 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.6 t80 -94.78 135.28 36.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.843 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.431 ' CG1' HD23 ' A' ' 85' ' ' LEU . 4.0 t -132.43 119.37 38.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.066 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.409 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -129.24 170.01 20.39 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.494 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 2.2 t70 72.43 38.92 0.78 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.847 0.356 . . . . 0.0 110.904 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.431 HD23 ' CG1' ' A' ' 82' ' ' VAL . 9.9 mt -100.39 133.82 44.24 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.965 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 t -54.34 153.74 9.42 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.654 0.74 . . . . 0.0 110.804 -179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 -14.38 36.1 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.638 2.225 . . . . 0.0 112.406 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -90.4 -10.25 44.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.89 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.415 HG22 ' N ' ' A' ' 90' ' ' THR . 37.5 mm -76.64 135.7 26.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.16 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.415 ' N ' HG22 ' A' ' 89' ' ' ILE . 14.4 t -117.27 160.43 21.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.162 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.409 ' C ' ' O ' ' A' ' 90' ' ' THR . 20.2 m -36.99 -47.14 0.69 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.13 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -52.92 -54.72 30.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.875 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -42.26 -54.58 3.65 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.416 HG22 ' CG2' ' A' ' 124' ' ' VAL . 15.1 mt -51.04 -59.95 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.154 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.467 ' HG3' ' CB ' ' A' ' 107' ' ' ALA . 23.3 mtmt -48.27 -39.62 22.14 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.928 179.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.92 -32.17 73.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.043 179.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -73.15 -54.59 8.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.127 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -86.08 11.3 12.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.881 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.497 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -65.26 -59.5 9.67 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.593 0.711 . . . . 0.0 111.112 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.497 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 54.2 Cg_endo -69.76 -0.58 7.12 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.678 2.252 . . . . 0.0 112.354 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.581 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 78.6 m-85 -99.73 -8.59 24.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.885 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 147.52 133.66 2.41 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.507 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 34.4 mtp180 -45.42 123.63 4.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.775 0.322 . . . . 0.0 110.869 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.466 HG23 ' CG1' ' A' ' 124' ' ' VAL . 9.9 mt -99.39 137.96 25.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.139 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.42 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 89.5 p -104.02 -65.1 1.04 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.846 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -100.65 106.41 17.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.868 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . 0.467 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -135.05 127.9 31.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.118 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.422 ' HD3' ' N ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -161.06 158.94 28.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.886 -179.904 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.422 ' N ' ' HD3' ' A' ' 108' ' ' ARG . 88.6 t -107.64 116.9 52.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.129 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.517 HG13 ' CZ ' ' A' ' 121' ' ' TYR . 59.6 t -48.3 137.97 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.135 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . 0.407 ' N ' HG11 ' A' ' 110' ' ' VAL . 53.6 mttt -134.48 156.46 48.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.874 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 116' ' ' GLY . 10.4 t0 -60.6 122.99 16.09 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.841 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 11.0 tpt -67.63 -4.26 11.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.896 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -106.34 -52.23 2.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.078 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 53.8 p -95.14 -28.59 14.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.131 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 79.53 26.67 56.41 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.491 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 54.0 mmtt -100.0 149.75 23.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.791 0.329 . . . . 0.0 110.869 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 8.2 t -50.38 108.3 0.22 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.878 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 40.3 mttt -61.47 -43.81 98.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.917 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 142.28 -42.44 1.13 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.502 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.517 ' CZ ' HG13 ' A' ' 110' ' ' VAL . 15.5 p90 -100.04 146.13 27.11 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.927 0.394 . . . . 0.0 110.91 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -128.91 179.98 16.3 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.473 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -125.69 140.05 53.03 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.879 0.371 . . . . 0.0 110.899 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.533 HG12 ' CZ ' ' A' ' 126' ' ' PHE . 50.7 t -135.17 121.34 32.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.161 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 5.2 m -106.01 148.33 27.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.854 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.533 ' CZ ' HG12 ' A' ' 124' ' ' VAL . 21.2 m-85 -130.73 147.13 52.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.893 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.42 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 23.4 m-85 -59.17 -43.18 92.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.846 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 23.9 m120 -118.9 157.33 27.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.888 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.56 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 8.3 ttmt -60.43 -63.47 1.29 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.89 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.443 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -34.66 -52.82 0.53 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -43.89 -45.6 7.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.892 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . 0.429 ' N ' ' O ' ' A' ' 129' ' ' LYS . . . -76.53 -57.04 4.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.096 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -44.33 -56.73 3.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.861 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 51.1 t30 -45.13 -42.88 9.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.837 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.485 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -71.83 -53.95 11.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.095 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 96.8 mt -40.63 -40.84 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.119 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -78.8 -59.61 2.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.917 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 15.2 mm-40 -63.7 -63.33 1.2 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.885 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.581 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 82.3 mmm -51.6 -39.06 57.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.865 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -54.08 112.34 2.51 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.519 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 91.58 21.51 34.14 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.531 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 62.8 mm-40 -101.25 168.44 9.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.792 0.33 . . . . 0.0 110.95 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . 0.401 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 14.8 m95 -105.0 109.15 21.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.892 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 63.1 tp -102.01 128.45 48.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.917 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 68.63 -72.51 0.36 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.484 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -160.88 17.56 0.19 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.499 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 33.3 mtt85 -155.78 156.72 35.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.782 0.325 . . . . 0.0 110.89 -179.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . 0.401 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 46.7 mt-30 -59.68 173.37 0.57 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.908 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.2 pt -147.08 148.95 16.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.12 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.447 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 8.4 ptp180 -115.65 120.91 40.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.871 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 55.8 p -114.64 133.26 55.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.123 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -158.85 161.64 36.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.876 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 7.7 m95 . . . . . 0 C--N 1.328 -0.352 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.986 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.568 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 76.5 m-85 . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.863 0.363 . . . . 0.0 110.878 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.471 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.6 OUTLIER -83.92 156.73 22.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.827 -179.986 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 53.8 t -130.62 148.96 33.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.128 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 19.3 t80 -99.18 135.85 40.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.882 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 43.7 t -133.02 130.2 58.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.124 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.475 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -136.47 173.22 22.12 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.474 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 7.6 t0 64.4 52.1 1.92 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.846 0.355 . . . . 0.0 110.914 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 16.2 mt -108.26 131.64 54.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.24 154.07 6.14 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.659 0.742 . . . . 0.0 110.824 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -8.07 22.67 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.71 2.274 . . . . 0.0 112.336 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -100.06 -3.48 31.89 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.908 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.436 ' CD1' ' HA3' ' A' ' 145' ' ' GLY . 45.6 mm -78.96 137.11 22.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.102 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.3 t -119.0 168.41 10.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.135 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.437 HG22 ' CE ' ' A' ' 95' ' ' LYS . 36.8 m -47.47 -41.57 20.91 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.131 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 35.8 mt-10 -61.13 -53.21 59.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.902 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -42.87 -56.15 3.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.83 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.444 ' CD1' HG22 ' A' ' 109' ' ' VAL . 19.4 mt -50.09 -57.49 2.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.141 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.452 ' HG3' ' CB ' ' A' ' 107' ' ' ALA . 26.7 mtmt -46.93 -40.03 13.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.904 179.823 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.7 -32.58 73.7 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.106 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -68.87 -53.91 18.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.115 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 21.2 m-85 -89.43 10.44 22.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.847 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.488 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -64.51 -59.77 9.96 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.572 0.701 . . . . 0.0 111.131 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.488 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.8 -0.76 7.41 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.667 2.244 . . . . 0.0 112.345 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 -100.0 -11.76 20.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.881 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 155.7 157.01 8.05 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.494 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.514 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 27.1 mtp180 -64.52 123.46 19.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.825 0.345 . . . . 0.0 110.874 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.405 HG22 ' CG1' ' A' ' 124' ' ' VAL . 18.7 mt -100.43 144.56 12.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.112 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 65.8 p -119.91 -59.21 1.82 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.806 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . 0.429 ' HB3' ' CB ' ' A' ' 125' ' ' SER . 8.7 t0 -100.82 100.52 11.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.857 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . 0.452 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -130.59 127.11 38.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -162.23 156.54 21.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.845 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.444 HG22 ' CD1' ' A' ' 94' ' ' ILE . 72.9 t -106.16 119.98 56.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.134 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.573 HG22 ' CE2' ' A' ' 121' ' ' TYR . 95.1 t -53.47 134.43 15.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.113 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 38.7 mttt -134.7 146.37 49.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.848 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.426 ' O ' ' N ' ' A' ' 116' ' ' GLY . 29.6 t0 -57.4 120.53 8.37 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.9 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 7.7 ptp -68.61 -3.49 12.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.915 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -100.58 -50.1 3.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.111 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 44.0 p -97.69 -34.28 10.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.128 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 88.81 17.43 56.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 63.7 mttt -92.3 167.92 11.67 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.822 0.344 . . . . 0.0 110.888 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 8.2 t -69.34 113.24 6.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.849 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.444 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 37.1 mttt -62.87 -50.79 69.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.878 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 145.08 -41.4 1.07 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.447 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.573 ' CE2' HG22 ' A' ' 110' ' ' VAL . 10.2 p90 -98.99 149.7 22.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.937 0.398 . . . . 0.0 110.919 -179.791 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -129.77 175.54 19.02 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.458 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 47.8 m-85 -124.2 135.47 53.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.857 0.361 . . . . 0.0 110.882 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.568 HG12 ' CZ ' ' A' ' 126' ' ' PHE . 56.5 t -134.53 122.0 37.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.127 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' SER . . . . . 0.429 ' CB ' ' HB3' ' A' ' 106' ' ' ASP . 16.3 t -106.45 149.62 26.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.855 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.568 ' CZ ' HG12 ' A' ' 124' ' ' VAL . 16.5 m-85 -130.96 138.23 49.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.9 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.514 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 84.1 m-85 -52.44 -35.24 51.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -118.12 167.0 11.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.876 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.568 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 9.3 tttp -77.19 -41.7 40.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.878 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.423 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -57.98 -59.44 5.25 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.88 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.423 ' C ' ' O ' ' A' ' 130' ' ' TRP . 45.3 m-20 -35.91 -39.91 0.18 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.879 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.79 -58.87 3.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.084 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -42.72 -54.78 3.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.859 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 56.3 t30 -43.34 -41.42 4.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.881 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.403 ' O ' ' N ' ' A' ' 137' ' ' GLN . . . -75.72 -58.15 3.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.102 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 98.2 mt -38.92 -30.41 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.152 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . 0.403 ' N ' ' O ' ' A' ' 135' ' ' ALA . 7.0 mt-30 -87.49 -65.75 0.98 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.916 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 10.3 mm-40 -61.54 -61.03 2.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.955 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 79.0 mmm -49.18 -35.62 17.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -57.56 116.38 8.02 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.474 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 99.89 -19.09 54.69 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.45 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -66.38 177.18 1.56 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.788 0.328 . . . . 0.0 110.903 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . 0.437 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 13.8 m95 -115.04 127.11 55.44 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.908 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.474 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 55.5 tp -121.28 123.88 43.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.926 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . 0.436 ' HA3' ' CD1' ' A' ' 89' ' ' ILE . . . 73.65 -11.59 5.54 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.532 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . 0.4 ' H ' ' C ' ' A' ' 144' ' ' LEU . . . 130.25 -7.18 6.0 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.485 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 67.9 mtt180 -130.35 144.93 51.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.767 0.318 . . . . 0.0 110.902 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . 0.437 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 31.2 mt-30 -53.57 158.21 1.9 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.933 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.474 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 21.2 pt -131.7 145.29 35.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.129 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.475 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 19.3 ptp180 -106.8 120.14 41.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.874 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 42.4 p -112.71 127.85 56.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.121 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -153.4 166.2 33.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.868 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 23.2 m95 . . . . . 0 C--N 1.328 -0.368 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.953 179.972 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.563 ' CE1' ' HD3' ' A' ' 129' ' ' LYS . 90.9 m-85 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.862 0.363 . . . . 0.0 110.903 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.544 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.1 OUTLIER -81.75 150.18 28.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 55.3 t -124.75 146.28 30.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.137 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.2 t80 -98.07 134.39 41.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.919 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.3 t -130.42 130.13 65.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.109 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.475 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -136.24 179.26 18.05 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.446 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.402 ' O ' ' O ' ' A' ' 148' ' ' GLN . 5.4 t70 56.39 53.63 8.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.852 0.358 . . . . 0.0 110.845 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 15.8 mt -109.94 131.14 55.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -53.01 154.91 4.74 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.646 0.736 . . . . 0.0 110.873 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -4.19 13.53 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.653 2.236 . . . . 0.0 112.348 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -97.58 -28.81 13.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.857 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.446 HG21 ' CB ' ' A' ' 93' ' ' ASP . 47.9 mm -57.73 132.52 22.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.137 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.1 t -119.38 166.8 12.59 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.161 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 95.8 m -39.79 -49.02 2.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.169 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -56.04 -57.6 11.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.852 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.446 ' CB ' HG21 ' A' ' 89' ' ' ILE . 1.3 m-20 -39.59 -56.8 1.6 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.463 ' CD1' HG21 ' A' ' 109' ' ' VAL . 16.5 mt -48.79 -59.44 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.132 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.444 ' O ' ' N ' ' A' ' 99' ' ' ALA . 20.8 mtmt -47.41 -38.93 14.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.914 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.97 -37.01 85.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.059 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -68.05 -52.9 30.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.112 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 22.2 m-85 -89.27 6.91 38.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.93 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.491 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -59.48 -59.79 12.71 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.618 0.723 . . . . 0.0 111.082 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.491 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.6 Cg_endo -69.76 -0.92 7.62 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.72 2.28 . . . . 0.0 112.322 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -101.49 12.51 37.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.887 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.59 155.72 8.56 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.482 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.407 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 28.7 mtt180 -65.7 126.16 27.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.808 0.337 . . . . 0.0 110.841 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.47 HG22 ' CG1' ' A' ' 124' ' ' VAL . 13.8 mt -100.27 140.29 19.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.157 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 5.4 t -112.05 -62.09 1.62 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.883 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -100.81 102.91 14.09 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.867 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -130.32 125.5 34.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.083 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 15.2 ptt180 -160.81 154.98 22.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.886 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.463 HG21 ' CD1' ' A' ' 94' ' ' ILE . 60.1 t -105.2 119.14 53.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.11 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.534 HG11 ' CE2' ' A' ' 121' ' ' TYR . 61.1 t -53.12 133.06 15.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.126 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . 0.418 ' HG2' ' C ' ' A' ' 117' ' ' LYS . 37.0 mttm -134.14 149.25 51.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.94 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -62.02 132.0 51.46 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.863 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 26.0 ptm -80.47 1.36 29.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.883 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.35 -29.11 13.34 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.084 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 21.2 p -131.14 -34.28 1.45 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.15 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 96.66 17.36 33.51 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.455 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . 0.418 ' C ' ' HG2' ' A' ' 111' ' ' LYS . 42.1 mttm -85.79 154.14 21.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.815 0.34 . . . . 0.0 110.875 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 1.9 m -60.09 111.1 1.38 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.82 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.418 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 31.6 mttt -59.25 -42.8 92.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.908 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 138.36 -41.72 1.34 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.532 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.534 ' CE2' HG11 ' A' ' 110' ' ' VAL . 7.4 p90 -99.99 151.12 21.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.923 0.392 . . . . 0.0 110.922 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -130.66 178.04 17.94 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.554 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -126.52 135.72 51.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.887 0.375 . . . . 0.0 110.876 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.508 HG13 ' CZ ' ' A' ' 126' ' ' PHE . 61.0 t -136.48 122.18 28.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.118 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 12.6 m -105.34 149.92 25.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.808 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.508 ' CZ ' HG13 ' A' ' 124' ' ' VAL . 16.3 m-85 -131.06 137.85 49.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.906 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.407 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 78.3 m-85 -58.87 -36.67 75.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.841 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 13.6 m-20 -118.04 149.78 40.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.904 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.563 ' HD3' ' CE1' ' A' ' 78' ' ' PHE . 38.5 tptt -60.77 -63.39 1.31 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.463 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.9 OUTLIER -33.21 -57.92 0.39 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.917 179.921 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -40.59 -49.26 2.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.867 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -67.1 -60.47 2.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.123 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -41.05 -61.62 0.96 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.916 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 44.1 t-20 -38.88 -52.91 1.75 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.485 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -63.55 -61.44 2.33 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.122 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 86.7 mt -37.01 -36.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.128 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 -85.53 -60.1 2.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.876 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -64.85 -59.6 4.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.485 ' N ' ' O ' ' A' ' 135' ' ' ALA . 48.0 mmm -53.48 -39.92 64.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.939 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -55.66 116.59 7.31 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.49 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 100.65 -12.66 59.6 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.494 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 48.6 mm-40 -73.28 172.57 10.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.75 0.31 . . . . 0.0 110.928 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . . . . . . . . . 15.7 m95 -109.43 126.41 53.44 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.877 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.4 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 57.3 tp -123.56 125.19 44.41 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.913 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 72.82 -9.25 6.58 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.48 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 127.47 -7.7 7.03 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.487 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 28.2 mtt-85 -130.34 145.89 51.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.789 0.328 . . . . 0.0 110.86 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . 0.402 ' O ' ' O ' ' A' ' 84' ' ' ASP . 18.1 mt-30 -52.58 166.54 0.19 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.952 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.4 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 24.3 pt -137.42 146.28 28.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.066 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.475 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 16.4 ptp180 -108.07 114.86 29.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.89 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 80.9 p -110.19 122.57 47.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.134 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -150.58 168.48 24.14 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.904 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . 0.503 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 55.1 m95 . . . . . 0 C--N 1.327 -0.375 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.916 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.566 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 93.0 m-85 . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.929 0.395 . . . . 0.0 110.875 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.51 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.2 OUTLIER -89.1 150.4 22.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 179.998 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 46.0 t -125.45 145.36 32.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.131 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.8 t80 -91.22 132.72 35.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.434 ' CG1' HD22 ' A' ' 85' ' ' LEU . 16.8 t -128.57 128.91 68.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.073 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -136.52 -177.96 15.42 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.54 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 55.11 54.25 9.1 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.809 0.338 . . . . 0.0 110.843 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.434 HD22 ' CG1' ' A' ' 82' ' ' VAL . 17.0 mt -110.89 130.11 55.68 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.937 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.18 154.22 5.84 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.664 0.745 . . . . 0.0 110.843 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -6.21 18.08 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.699 2.266 . . . . 0.0 112.29 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -100.29 -15.54 18.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.898 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.457 HG21 ' CB ' ' A' ' 93' ' ' ASP . 34.3 mm -69.57 134.25 30.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.141 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.0 t -119.67 168.0 11.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.123 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.446 HG21 ' CE ' ' A' ' 95' ' ' LYS . 98.8 m -38.82 -57.76 1.18 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.111 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 29.5 mt-10 -46.44 -59.36 3.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.942 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.457 ' CB ' HG21 ' A' ' 89' ' ' ILE . 0.5 OUTLIER -38.82 -56.19 1.4 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.899 179.932 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 10.7 mt -49.55 -60.77 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.167 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.446 ' CE ' HG21 ' A' ' 91' ' ' THR . 24.3 mtmt -45.67 -39.65 8.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.887 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -59.94 -37.84 80.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.106 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -66.35 -52.98 41.48 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.103 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 11.8 m-85 -92.18 18.66 7.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.852 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.478 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -69.33 -60.44 4.08 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.581 0.705 . . . . 0.0 111.136 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.478 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.78 -0.83 7.49 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.662 2.241 . . . . 0.0 112.321 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -99.78 5.17 45.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.89 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.79 137.88 3.91 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.493 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 24.3 mtt-85 -49.89 125.1 11.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.741 0.305 . . . . 0.0 110.906 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.472 HG23 ' CG1' ' A' ' 124' ' ' VAL . 11.1 mt -98.77 138.88 22.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.142 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.403 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.1 t -107.33 -62.94 1.35 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.858 -179.864 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -100.51 109.66 21.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.905 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -138.25 129.13 26.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.13 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.1 ptm180 -162.57 154.72 18.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.873 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 41.3 t -105.33 117.38 50.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.133 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.524 HG23 ' CE2' ' A' ' 121' ' ' TYR . 48.8 t -49.84 138.04 5.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.125 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . 0.42 ' C ' ' HG3' ' A' ' 119' ' ' LYS . 52.6 mttt -138.16 154.63 49.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -69.16 138.55 54.24 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.836 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 13.5 ptp -85.75 3.45 41.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.862 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -102.64 -35.94 8.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.083 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 52.3 p -123.17 -35.17 3.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.098 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 90.86 26.61 21.74 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.481 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . 0.412 ' O ' ' C ' ' A' ' 118' ' ' SER . 86.1 mttt -97.73 136.39 38.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.769 0.318 . . . . 0.0 110.896 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 117' ' ' LYS . 2.2 m -37.7 111.76 0.18 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.853 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.433 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 9.3 mttm -61.82 -41.82 98.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.895 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 138.62 -46.75 0.96 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.531 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.524 ' CE2' HG23 ' A' ' 110' ' ' VAL . 10.1 p90 -100.04 148.65 24.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.996 0.427 . . . . 0.0 110.909 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -129.8 -177.31 14.81 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.503 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -127.47 139.29 52.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.854 0.359 . . . . 0.0 110.925 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.549 HG12 ' CZ ' ' A' ' 126' ' ' PHE . 58.3 t -138.83 120.65 16.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.146 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 42.3 m -106.65 149.81 26.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.853 -179.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.549 ' CZ ' HG12 ' A' ' 124' ' ' VAL . 2.1 m-85 -130.85 144.59 51.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.873 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.403 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 22.3 m-85 -56.38 -43.49 79.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.889 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 19.2 m120 -109.35 163.69 13.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.901 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.566 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 20.3 tptm -71.39 -59.55 2.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.902 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.417 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.8 OUTLIER -40.57 -57.39 1.86 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.9 179.922 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 130' ' ' TRP . 71.6 m-20 -35.86 -45.76 0.42 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.875 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -75.8 -58.27 3.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.065 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -44.16 -59.5 2.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.883 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -41.79 -44.49 3.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.891 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.47 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -69.23 -56.78 6.58 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.107 179.834 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 86.1 mt -38.73 -35.5 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.106 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.1 mt-30 -87.18 -57.07 3.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.892 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 37.3 mm-40 -68.3 -61.97 1.6 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.93 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.47 ' N ' ' O ' ' A' ' 135' ' ' ALA . 64.1 mmm -51.92 -38.93 58.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.858 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.44 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -57.55 93.51 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.492 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 119.44 13.17 6.39 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.508 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 87.4 mm-40 -94.27 169.66 10.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.753 0.311 . . . . 0.0 110.962 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . 0.401 ' NE1' ' HG3' ' A' ' 148' ' ' GLN . 17.2 m95 -106.3 109.47 21.41 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.899 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.402 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 60.9 tp -104.15 129.58 51.87 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.926 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 69.74 -77.0 0.4 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.475 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -156.33 15.93 0.41 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.464 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 43.2 mtp85 -157.99 161.01 38.09 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.758 0.313 . . . . 0.0 110.856 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . 0.401 ' HG3' ' NE1' ' A' ' 143' ' ' TRP . 28.9 mt-30 -64.25 167.08 7.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.923 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.402 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 21.1 pt -136.26 152.11 29.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.147 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 2.8 ttt180 -109.29 129.72 55.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.892 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.44 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 44.4 p -124.55 137.54 54.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.149 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 4.2 t30 -160.61 174.09 14.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.919 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . 0.546 ' CH2' ' CE ' ' A' ' 129' ' ' LYS . 4.6 m95 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.898 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.874 0.369 . . . . 0.0 110.862 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . 0.404 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.9 OUTLIER -82.02 135.24 35.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.872 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 38.9 t -114.2 144.57 21.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.124 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . 0.694 ' CD2' ' ND2' ' A' ' 152' ' ' ASN . 11.9 t80 -96.74 138.28 34.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.862 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 t -137.17 134.46 47.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.151 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -142.3 -173.1 14.04 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.456 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 56.93 29.3 16.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.816 0.341 . . . . 0.0 110.86 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 14.6 mt -86.31 132.25 34.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.956 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -53.87 155.3 6.2 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.639 0.733 . . . . 0.0 110.863 -179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.85 -15.96 36.98 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.688 2.259 . . . . 0.0 112.291 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -92.0 -7.14 49.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.873 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.418 HG22 ' CB ' ' A' ' 93' ' ' ASP . 33.2 mm -74.98 138.88 20.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.155 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.8 t -119.88 -176.71 3.24 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.133 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 84.9 m -53.77 -57.25 11.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.125 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.439 ' O ' ' C ' ' A' ' 93' ' ' ASP . 70.9 mt-10 -48.67 -58.48 4.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.914 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.439 ' C ' ' O ' ' A' ' 92' ' ' GLU . 2.9 m-20 -34.48 -55.28 0.54 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.841 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 4.5 mt -51.76 -60.34 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.152 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.462 ' O ' ' N ' ' A' ' 99' ' ' ALA . 25.6 mtmt -48.85 -41.93 34.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.899 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.68 -29.13 69.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.083 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -75.67 -53.74 8.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.131 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.414 ' C ' HD13 ' A' ' 104' ' ' ILE . 27.2 m-85 -86.82 3.49 45.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.915 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.478 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -56.5 -60.29 9.62 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.587 0.708 . . . . 0.0 111.154 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.478 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.3 Cg_endo -69.76 -0.81 7.45 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.708 2.272 . . . . 0.0 112.353 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.584 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 72.0 m-85 -99.77 -1.2 38.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 142.17 156.07 6.67 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.507 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.46 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 17.5 mtm105 -62.6 122.28 15.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.743 0.306 . . . . 0.0 110.871 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.468 HG21 ' CG1' ' A' ' 124' ' ' VAL . 13.9 mt -100.39 138.21 25.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.176 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.469 ' HB2' ' CZ ' ' A' ' 127' ' ' PHE . 47.8 t -112.92 -59.61 1.99 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . 0.408 ' HB3' ' CB ' ' A' ' 125' ' ' SER . 25.9 t70 -100.63 99.78 10.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -132.08 124.94 30.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.081 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 10.3 ptp180 -159.36 153.32 23.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 90.0 t -100.93 124.12 54.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.111 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.574 HG23 ' CD2' ' A' ' 121' ' ' TYR . 53.4 t -59.64 143.96 13.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.118 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . 0.446 ' N ' HG13 ' A' ' 110' ' ' VAL . 74.5 mttt -140.7 153.87 46.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.469 ' N ' ' HG2' ' A' ' 119' ' ' LYS . 7.9 t0 -60.22 127.38 31.54 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.838 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 19.9 ptm -80.12 2.81 22.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.867 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -102.66 -38.38 7.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.074 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 42.1 p -119.9 -33.82 3.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.181 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 95.35 30.2 8.35 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.444 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 34.5 mttm -99.01 164.48 12.16 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.778 0.323 . . . . 0.0 110.903 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 36.4 t -56.62 115.05 2.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.907 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.469 ' HG2' ' N ' ' A' ' 112' ' ' ASP . 0.5 OUTLIER -68.33 -38.56 81.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.909 179.962 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 126.39 -46.1 1.11 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.433 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.574 ' CD2' HG23 ' A' ' 110' ' ' VAL . 8.3 p90 -100.32 151.33 21.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.927 0.394 . . . . 0.0 110.934 -179.794 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -132.58 171.55 21.56 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.473 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -121.06 138.85 53.99 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.859 0.361 . . . . 0.0 110.907 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.468 ' CG1' HG21 ' A' ' 104' ' ' ILE . 93.9 t -138.91 112.26 6.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.103 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' SER . . . . . 0.408 ' CB ' ' HB3' ' A' ' 106' ' ' ASP . 2.7 t -97.89 148.64 23.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.83 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.442 ' CZ ' HG13 ' A' ' 124' ' ' VAL . 3.6 m-85 -127.06 148.38 50.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.882 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.469 ' CZ ' ' HB2' ' A' ' 105' ' ' SER . 77.9 m-85 -63.27 -34.66 78.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.916 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 25.4 m120 -115.93 168.88 9.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.87 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 66.8 tttt -81.0 -47.88 13.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.427 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -48.57 -62.47 1.48 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.935 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 130' ' ' TRP . 44.4 m-20 -35.87 -54.17 0.74 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.811 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -61.39 -67.08 0.44 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.107 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -37.26 -57.87 0.86 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 42.4 t-20 -41.01 -52.89 3.09 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.864 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.96 -56.71 13.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.098 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 92.3 mt -38.17 -35.82 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.175 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -85.26 -63.53 1.31 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.899 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -59.56 -61.9 2.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.584 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 81.2 mmm -52.19 -35.23 48.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.913 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.401 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -54.94 99.43 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.522 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 111.59 -20.7 22.42 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.488 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 10.8 mm-40 -56.55 -179.92 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.791 0.329 . . . . 0.0 110.927 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . 0.463 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 13.4 m95 -116.86 124.72 50.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.927 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 47.2 tp -123.88 128.75 49.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.862 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 70.54 -3.69 11.15 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.516 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 120.91 -13.5 9.79 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.496 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 60.4 mtt180 -122.85 147.4 46.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.727 0.299 . . . . 0.0 110.88 -179.866 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . 0.463 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 32.6 mt-30 -55.45 165.57 0.77 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.926 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.418 HG22 ' C ' ' A' ' 148' ' ' GLN . 19.5 pt -138.15 151.34 25.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.117 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 27.0 ptt180 -113.99 109.1 17.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.906 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.401 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 69.3 p -106.54 141.43 37.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.167 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . 0.694 ' ND2' ' CD2' ' A' ' 81' ' ' PHE . 7.4 p30 -167.15 -178.95 4.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.876 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 31.2 m95 . . . . . 0 C--N 1.328 -0.344 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.916 179.969 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.445 ' CD2' ' HE3' ' A' ' 129' ' ' LYS . 47.0 m-85 . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.911 0.386 . . . . 0.0 110.874 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 87.4 m-70 -89.3 140.49 29.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.851 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.468 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 41.5 t -118.1 138.76 47.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.073 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 15.5 t80 -92.89 135.49 34.09 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.878 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.443 ' CG1' HD21 ' A' ' 85' ' ' LEU . 3.7 t -137.58 109.51 6.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.118 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -123.21 -177.48 15.15 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.472 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.403 ' O ' ' O ' ' A' ' 148' ' ' GLN . 4.5 t70 63.83 36.45 10.4 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.859 0.362 . . . . 0.0 110.91 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.449 HD22 ' CG2' ' A' ' 149' ' ' ILE . 15.6 mt -91.7 170.54 9.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.912 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -90.01 155.4 47.33 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.672 0.749 . . . . 0.0 110.786 -179.835 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 -10.79 29.39 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.668 2.245 . . . . 0.0 112.338 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -96.5 -6.11 37.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.464 HG23 ' CB ' ' A' ' 93' ' ' ASP . 45.8 mm -79.09 136.38 23.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.116 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.6 t -118.96 164.7 15.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.19 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 35.8 m -40.24 -48.77 2.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.149 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 93' ' ' ASP . 32.7 mt-10 -55.64 -58.78 6.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.464 ' CB ' HG23 ' A' ' 89' ' ' ILE . 13.3 m-20 -34.78 -56.67 0.55 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.86 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.433 HG21 ' CG2' ' A' ' 124' ' ' VAL . 10.4 mt -49.26 -60.76 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.185 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.464 ' HA ' ' CD1' ' A' ' 104' ' ' ILE . 24.0 mtmt -46.69 -39.81 12.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.914 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -63.58 -30.77 71.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.103 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -73.92 -53.68 9.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.088 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.421 ' C ' HD13 ' A' ' 104' ' ' ILE . 22.3 m-85 -89.18 12.34 16.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.91 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.486 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -65.23 -60.07 8.56 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.661 0.743 . . . . 0.0 111.082 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.486 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.76 -0.77 7.4 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.616 2.211 . . . . 0.0 112.376 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.497 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 77.6 m-85 -99.65 -3.14 33.78 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.892 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 143.03 131.95 2.6 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.485 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 46.2 mtt85 -44.09 124.93 4.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.803 0.335 . . . . 0.0 110.875 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.468 HG22 ' CG1' ' A' ' 124' ' ' VAL . 14.1 mt -100.11 145.18 11.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.136 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.448 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 3.8 t -116.01 -61.94 1.66 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.851 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -100.57 99.47 10.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.83 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -132.92 127.18 33.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 6.7 ptm180 -160.15 155.29 24.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.871 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 96.4 t -107.06 120.35 58.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.138 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.559 HG12 ' CE2' ' A' ' 121' ' ' TYR . 66.8 t -54.33 124.66 7.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.159 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -123.72 148.74 46.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.877 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.481 ' O ' ' N ' ' A' ' 116' ' ' GLY . 24.1 t0 -56.88 121.61 10.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.871 179.817 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 8.2 ptp -73.11 -1.54 17.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.938 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -97.86 -42.52 7.52 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.134 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 29.1 p -115.75 -29.43 6.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.137 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.481 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 89.51 30.3 14.07 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.499 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 51.7 mttm -98.9 152.5 19.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.829 0.347 . . . . 0.0 110.899 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 7.8 t -60.29 110.75 1.32 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.831 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 50.9 mttt -62.73 -47.82 81.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.93 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 139.75 -38.98 1.56 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.463 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.559 ' CE2' HG12 ' A' ' 110' ' ' VAL . 25.3 p90 -100.09 144.04 29.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.953 0.406 . . . . 0.0 110.92 -179.81 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.81 175.07 21.52 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.545 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -121.85 139.93 53.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.912 0.387 . . . . 0.0 110.866 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.559 HG12 ' CZ ' ' A' ' 126' ' ' PHE . 59.4 t -135.62 111.46 12.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.122 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.8 t -100.49 145.64 28.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.856 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.559 ' CZ ' HG12 ' A' ' 124' ' ' VAL . 1.3 m-85 -124.93 162.0 25.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.896 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.448 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 22.1 m-85 -66.41 -48.17 70.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.875 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 78.6 m-20 -113.91 160.04 19.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.869 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.445 ' HE3' ' CD2' ' A' ' 78' ' ' PHE . 3.7 ttmt -63.22 -62.75 1.49 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.91 179.876 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.437 ' C ' ' O ' ' A' ' 129' ' ' LYS . 1.0 OUTLIER -35.16 -59.36 0.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.929 179.92 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.401 ' C ' ' O ' ' A' ' 130' ' ' TRP . 48.3 m-20 -37.58 -43.97 0.65 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.912 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . 0.468 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -74.71 -59.16 2.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.099 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.7 mt-10 -40.53 -54.76 2.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.829 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -43.53 -45.37 6.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.423 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -71.95 -58.49 3.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.07 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 97.1 mt -38.44 -36.37 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.124 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -83.35 -63.63 1.32 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.891 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -62.92 -62.73 1.52 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.925 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.497 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 68.8 mmm -51.8 -41.32 61.62 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.913 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -55.13 103.75 0.23 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.486 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 100.5 21.15 13.28 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.498 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 9.5 mm100 -105.64 177.42 4.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.787 0.327 . . . . 0.0 110.905 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . . . . . . . . . 17.0 m95 -106.74 121.69 44.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.903 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.47 ' C ' ' H ' ' A' ' 146' ' ' GLY . 36.4 tp -121.53 127.78 51.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.924 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 73.54 -36.62 0.84 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.477 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . 0.47 ' H ' ' C ' ' A' ' 144' ' ' LEU . . . 160.2 -14.25 0.19 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.516 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 51.2 mtt180 -127.38 149.24 50.16 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.762 0.315 . . . . 0.0 110.838 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . 0.403 ' O ' ' O ' ' A' ' 84' ' ' ASP . 38.8 mt-30 -53.89 169.35 0.16 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.915 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.449 ' CG2' HD22 ' A' ' 85' ' ' LEU . 33.8 pt -148.92 147.77 16.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.14 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 9.6 ptt180 -110.58 123.26 49.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.909 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 29.4 p -118.26 141.92 48.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.138 -179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . 0.459 ' CG ' ' N ' ' A' ' 153' ' ' TRP . 8.7 t-20 -165.08 166.91 18.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.904 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . 0.459 ' N ' ' CG ' ' A' ' 152' ' ' ASN . 11.2 m95 . . . . . 0 C--N 1.327 -0.371 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.934 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.862 0.363 . . . . 0.0 110.876 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 64.1 m-70 -90.55 161.51 15.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.913 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 49.5 t -137.64 135.83 46.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.159 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . 0.432 ' CE2' ' HG3' ' A' ' 150' ' ' ARG . 17.9 t80 -87.63 132.41 34.09 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.899 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 6.5 t -132.38 110.0 15.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.116 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -117.74 -178.77 17.41 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.459 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.403 ' O ' ' O ' ' A' ' 148' ' ' GLN . 2.0 m-20 64.02 40.11 7.4 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.874 0.368 . . . . 0.0 110.859 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -102.85 129.56 49.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.901 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.1 t -52.92 154.37 5.14 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.671 0.748 . . . . 0.0 110.832 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -4.23 13.6 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.636 2.224 . . . . 0.0 112.356 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -95.71 -29.77 14.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.459 ' CD1' ' HA3' ' A' ' 145' ' ' GLY . 48.3 mm -57.9 136.64 20.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.139 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.415 ' N ' HG23 ' A' ' 89' ' ' ILE . 14.3 t -117.18 164.05 15.36 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.145 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 16.7 m -40.78 -39.63 1.15 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.154 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 93' ' ' ASP . 29.5 mt-10 -61.92 -59.71 4.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . 0.418 ' C ' ' O ' ' A' ' 92' ' ' GLU . 0.6 OUTLIER -36.78 -56.59 0.84 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.86 -179.988 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 6.3 mt -48.19 -58.06 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.131 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.465 ' HA ' ' CD1' ' A' ' 104' ' ' ILE . 23.9 mtmt -49.65 -38.95 34.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.908 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.17 -31.37 72.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.081 179.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -72.78 -46.84 51.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.105 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.402 ' C ' HD13 ' A' ' 104' ' ' ILE . 20.1 m-85 -97.16 11.77 35.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.941 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.492 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -63.8 -59.73 10.8 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.531 0.681 . . . . 0.0 111.109 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.492 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.4 Cg_endo -69.77 -0.7 7.3 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.717 2.278 . . . . 0.0 112.315 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . 0.598 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 62.6 m-85 -99.64 -0.11 40.93 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.899 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 139.7 138.31 3.61 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.532 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.469 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 13.7 mtt85 -48.03 125.09 8.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.782 0.325 . . . . 0.0 110.862 -179.854 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.465 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 17.9 mt -100.02 138.73 23.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.102 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.458 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.3 t -111.9 -59.14 2.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.835 -179.895 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . 0.445 ' HB3' ' CB ' ' A' ' 125' ' ' SER . 23.2 t70 -100.33 100.32 11.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.888 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . 0.438 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -133.6 124.93 27.72 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.117 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.468 ' HD3' ' N ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -161.67 155.59 21.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 -179.889 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.468 ' N ' ' HD3' ' A' ' 108' ' ' ARG . 76.5 t -106.14 117.4 51.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.147 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.572 HG21 ' CD2' ' A' ' 121' ' ' TYR . 60.2 t -47.36 141.33 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.13 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . 0.468 ' N ' HG11 ' A' ' 110' ' ' VAL . 47.6 mttt -139.33 151.01 46.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.879 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.444 ' O ' ' N ' ' A' ' 116' ' ' GLY . 25.7 t0 -63.74 122.95 17.65 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.889 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 27.9 ptm -72.49 -6.61 44.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.878 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -96.74 -48.43 5.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.111 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 45.4 p -100.75 -32.19 10.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.116 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 86.71 24.13 39.89 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.452 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 44.8 mtmt -98.43 168.02 10.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.79 0.329 . . . . 0.0 110.917 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 15.8 t -64.37 114.26 4.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.826 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 27.3 mmtt -63.83 -47.25 81.54 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.887 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 139.38 -46.91 0.93 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.479 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.572 ' CD2' HG21 ' A' ' 110' ' ' VAL . 12.7 p90 -100.14 146.28 27.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.948 0.404 . . . . 0.0 110.891 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -128.11 176.94 17.91 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.445 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -122.56 141.41 51.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.86 0.362 . . . . 0.0 110.907 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.565 HG12 ' CE1' ' A' ' 126' ' ' PHE . 56.8 t -137.63 122.3 23.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.112 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' SER . . . . . 0.445 ' CB ' ' HB3' ' A' ' 106' ' ' ASP . 4.9 t -112.19 140.79 46.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.877 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.565 ' CE1' HG12 ' A' ' 124' ' ' VAL . 27.8 m-85 -121.53 147.97 45.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.843 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.469 ' CE2' ' HB3' ' A' ' 103' ' ' ARG . 21.6 m-85 -55.88 -49.8 72.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.89 -179.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 48.9 m-20 -99.47 166.73 11.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.886 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.463 ' HE3' ' CZ2' ' A' ' 153' ' ' TRP . 45.5 tptt -75.61 -45.78 35.53 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.863 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.417 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.9 OUTLIER -55.78 -54.56 42.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.918 179.915 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 130' ' ' TRP . 60.5 m-20 -35.67 -43.24 0.27 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.883 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.81 -56.9 4.13 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.129 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -45.23 -56.96 4.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.857 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 29.6 t-20 -43.35 -49.71 6.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.931 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -64.39 -53.32 50.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.087 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 94.7 mt -41.49 -34.38 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.141 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 9.6 mt-30 -84.71 -69.55 0.64 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.905 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 28.2 mt-30 -55.99 -59.38 4.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.897 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.598 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 53.9 mmm -58.12 -43.1 87.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.449 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -56.98 91.41 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.493 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 125.02 6.16 6.5 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.459 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . 0.479 ' HG2' ' CD1' ' A' ' 149' ' ' ILE . 0.5 OUTLIER -92.33 -178.57 4.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.728 0.299 . . . . 0.0 110.957 -179.915 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . 0.478 ' N ' ' HG3' ' A' ' 142' ' ' GLN . 16.6 m95 -114.47 115.16 26.81 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.923 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 62.4 tp -108.1 128.45 54.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.91 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . 0.459 ' HA3' ' CD1' ' A' ' 89' ' ' ILE . . . 69.97 -75.57 0.46 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.481 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.24 15.9 0.28 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.479 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 39.1 mtt85 -155.48 157.18 36.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.722 0.296 . . . . 0.0 110.867 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . 0.428 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 16.6 mt-30 -60.51 170.3 1.44 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.937 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.479 ' CD1' ' HG2' ' A' ' 142' ' ' GLN . 23.6 pt -135.17 152.98 33.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.179 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.432 ' HG3' ' CE2' ' A' ' 81' ' ' PHE . 12.5 ptm180 -120.38 104.23 9.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.86 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.449 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 44.9 p -99.45 127.91 45.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.174 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -150.85 173.79 13.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.878 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . 0.463 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 7.3 m95 . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.554 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 43.8 m-85 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.875 0.369 . . . . 0.0 110.864 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 58.2 m-70 -88.06 135.29 33.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.863 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 53.7 t -114.78 140.3 36.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.096 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.5 t80 -91.28 135.29 33.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.898 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 16.6 t -131.73 127.54 59.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.069 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . 0.463 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -137.39 171.75 23.04 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.491 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ASP . . . . . 0.41 ' O ' ' O ' ' A' ' 148' ' ' GLN . 6.6 t70 64.37 53.07 1.75 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.839 0.352 . . . . 0.0 110.857 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 21.3 mt -106.34 133.39 51.11 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.941 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -54.07 155.1 6.85 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.651 0.739 . . . . 0.0 110.862 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 -10.08 27.67 Favored 'Trans proline' 0 N--CA 1.465 -0.159 0 C-N-CA 122.73 2.287 . . . . 0.0 112.352 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -97.78 0.49 46.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.896 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.443 HG21 ' N ' ' A' ' 90' ' ' THR . 49.0 mm -88.02 136.83 22.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.151 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.443 ' N ' HG21 ' A' ' 89' ' ' ILE . 12.9 t -121.21 179.39 4.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.124 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 85.4 m -51.18 -45.44 61.78 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.102 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -59.34 -55.79 30.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.837 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -38.18 -57.78 1.05 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.887 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' ILE . . . . . 0.439 HG23 ' CG2' ' A' ' 124' ' ' VAL . 6.7 mt -48.37 -62.04 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.131 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.463 ' HG3' ' CB ' ' A' ' 107' ' ' ALA . 26.0 mtmt -45.18 -39.88 6.62 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.948 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.02 -32.45 74.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.097 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -69.84 -54.66 12.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.084 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' PHE . . . . . 0.408 ' C ' HD12 ' A' ' 104' ' ' ILE . 22.7 m-85 -88.23 8.55 26.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.894 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.482 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -62.06 -60.04 11.33 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.567 0.698 . . . . 0.0 111.096 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.482 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.76 -0.76 7.38 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.721 2.28 . . . . 0.0 112.351 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -100.02 -10.91 21.05 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.905 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 154.69 156.43 7.71 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.47 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.43 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 29.8 mtm180 -64.61 121.7 15.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.742 0.306 . . . . 0.0 110.891 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.454 HG23 ' CG1' ' A' ' 124' ' ' VAL . 15.3 mt -100.33 139.76 21.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.138 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 36.0 t -113.47 -59.59 2.0 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.832 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -100.82 100.97 11.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.842 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . 0.463 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -131.67 128.34 38.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.067 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.8 ptp180 -161.58 161.66 29.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.892 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 32.6 t -112.98 122.2 66.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.122 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' VAL . . . . . 0.543 HG21 ' CD2' ' A' ' 121' ' ' TYR . 58.8 t -55.83 142.94 9.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.137 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 28.5 mttp -142.19 154.48 44.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.872 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . 0.489 ' O ' ' N ' ' A' ' 116' ' ' GLY . 47.3 t0 -62.61 121.58 13.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.872 179.87 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 14.4 ptp -72.53 0.76 9.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.898 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -103.5 -34.62 8.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.099 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 6.9 p -123.39 -33.83 3.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.149 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.489 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 90.61 26.28 23.21 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.501 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -93.37 140.74 29.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.762 0.315 . . . . 0.0 110.9 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 2.8 t -46.24 113.06 0.56 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.866 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 34.5 mttt -67.23 -49.87 62.85 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.896 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 140.51 -39.95 1.42 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.497 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' TYR . . . . . 0.543 ' CD2' HG21 ' A' ' 110' ' ' VAL . 24.5 p90 -100.13 144.43 29.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.927 0.394 . . . . 0.0 110.945 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -131.77 -179.79 16.48 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.507 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 65.4 m-85 -124.57 138.94 54.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.874 0.369 . . . . 0.0 110.884 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.535 HG11 ' CZ ' ' A' ' 126' ' ' PHE . 48.4 t -138.84 113.3 7.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.113 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 20.6 t -100.97 151.49 21.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.82 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' PHE . . . . . 0.535 ' CZ ' HG11 ' A' ' 124' ' ' VAL . 3.0 m-85 -131.0 149.57 52.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.885 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' PHE . . . . . 0.43 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 81.4 m-85 -64.27 -35.73 81.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.848 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -120.49 157.26 29.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.914 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.554 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 40.4 tttt -65.89 -64.4 0.87 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.922 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' TRP . . . . . 0.453 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -34.17 -62.04 0.34 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.93 179.903 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 130' ' ' TRP . 5.7 m-20 -36.08 -43.41 0.34 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.841 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 129' ' ' LYS . . . -73.56 -60.69 2.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.084 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -42.99 -55.85 3.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.89 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -43.31 -44.65 5.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' ALA . . . . . 0.458 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -74.06 -56.06 5.37 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.094 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 76.9 mt -39.83 -37.35 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.125 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -83.04 -55.91 4.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.846 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 4.3 mm-40 -66.26 -63.45 1.08 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.883 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' MET . . . . . 0.458 ' N ' ' O ' ' A' ' 135' ' ' ALA . 84.3 mmm -51.07 -36.21 38.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.843 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -56.15 107.75 0.94 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.531 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 104.1 -17.39 48.32 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.464 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 15.1 mm-40 -67.69 -177.94 0.85 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.768 0.318 . . . . 0.0 110.945 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' TRP . . . . . 0.415 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 13.8 m95 -115.72 137.13 52.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.899 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.464 ' C ' ' H ' ' A' ' 146' ' ' GLY . 55.7 tp -130.27 121.56 26.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.937 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 75.39 -24.19 1.44 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.473 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . 0.464 ' H ' ' C ' ' A' ' 144' ' ' LEU . . . 144.99 -6.88 1.61 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.477 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 54.0 mtt85 -130.61 144.07 51.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.812 0.339 . . . . 0.0 110.843 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' GLN . . . . . 0.415 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 23.9 mt-30 -51.48 163.92 0.24 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.913 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 25.3 pt -137.69 155.22 30.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.099 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.497 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 7.6 ptm180 -118.12 118.23 31.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.874 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 34.3 p -117.64 132.35 56.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.136 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -158.55 173.35 16.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 32.8 m95 . . . . . 0 C--N 1.328 -0.369 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.871 180.0 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 60.9 p -73.36 160.39 31.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.862 0.363 . . . . 0.0 110.885 -179.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 55.3 p -52.24 106.41 0.15 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.835 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 106.22 155.29 21.19 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.503 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 23.5 t -105.64 128.48 53.66 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.885 0.374 . . . . 0.0 110.85 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.6 t -54.87 -49.97 69.86 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.87 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 151.92 -143.67 10.71 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.49 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 12.5 mm100 -57.18 91.77 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.897 0.38 . . . . 0.0 110.934 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 19.0 mtpp -109.49 141.52 41.82 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.924 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 14.0 ttmm -157.51 144.17 18.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.863 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.411 ' O ' ' C ' ' A' ' 74' ' ' THR . 31.0 t0 -115.1 73.91 0.85 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.411 ' C ' ' O ' ' A' ' 73' ' ' ASP . 6.4 p 36.63 45.43 0.39 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.161 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.6 m -60.23 -69.19 0.23 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.869 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -98.72 50.13 0.97 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.91 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 19.3 m170 -112.34 158.38 19.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.862 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -112.92 116.0 29.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.883 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 69.6 m-70 -86.62 144.45 27.16 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.861 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 23.7 t -118.86 146.71 23.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.114 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -99.26 135.59 40.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.935 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 6.0 t -134.56 131.07 54.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.152 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.459 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -137.07 -175.8 14.01 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.459 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 60.74 26.4 16.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.897 0.379 . . . . 0.0 110.899 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.9 mt -84.53 128.22 34.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.907 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.41 153.93 6.73 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.685 0.755 . . . . 0.0 110.841 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 -9.87 27.19 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.711 2.274 . . . . 0.0 112.325 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -97.44 -5.04 37.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.901 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.459 HG23 ' CB ' ' A' ' 93' ' ' ASP . 40.5 mm -77.23 139.4 18.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.131 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.6 t -116.8 163.7 15.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.131 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 6.3 m -43.8 -38.56 3.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.079 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -63.09 -56.56 15.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.896 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.459 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.4 m-20 -37.75 -52.88 1.28 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.842 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 5.1 mt -52.11 -58.7 2.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.127 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.464 ' O ' ' N ' ' A' ' 99' ' ' ALA . 24.2 mtmt -49.45 -39.2 32.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.889 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.87 -35.0 75.49 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.112 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -68.67 -55.53 11.12 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.091 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 35.6 m-85 -85.05 1.63 46.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.874 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.485 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -52.75 -60.11 7.3 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.605 0.717 . . . . 0.0 111.147 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.485 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.7 -1.03 7.72 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.689 2.26 . . . . 0.0 112.357 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -99.96 9.55 42.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.26 143.48 5.78 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.497 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 45.8 mtt85 -52.17 121.87 7.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.739 0.304 . . . . 0.0 110.857 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.435 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 13.1 mt -95.04 136.79 25.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.102 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.432 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 2.4 p -103.28 -64.53 1.07 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.86 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -100.59 109.17 21.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.822 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . 0.462 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -138.94 125.03 20.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.116 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.47 ' HB2' ' CZ ' ' A' ' 108' ' ' ARG . 2.6 ptm85 -157.39 165.08 36.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.867 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 87.3 t -112.93 112.73 41.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.168 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.503 HG13 ' CZ ' ' A' ' 121' ' ' TYR . 97.1 t -45.98 137.9 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.154 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . 0.464 ' N ' HG11 ' A' ' 110' ' ' VAL . 84.7 mttt -137.86 161.22 37.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.924 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.423 ' O ' ' N ' ' A' ' 116' ' ' GLY . 9.3 t0 -75.15 125.94 29.99 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.868 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 14.3 ptp -75.77 -1.74 26.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.929 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -96.58 -39.59 9.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 30.6 p -119.51 -33.91 3.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.16 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 93.62 24.22 21.55 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.468 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 41.2 mmtt -93.55 151.17 19.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.82 0.343 . . . . 0.0 110.874 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 1.8 m -52.53 113.18 0.98 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.855 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 26.2 mmtt -63.14 -38.54 91.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.926 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 129.81 -40.06 1.73 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.505 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.503 ' CZ ' HG13 ' A' ' 110' ' ' VAL . 3.0 p90 -100.02 155.09 17.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.943 0.402 . . . . 0.0 110.924 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.04 168.28 24.37 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.479 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 81.9 m-85 -117.47 141.54 48.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.914 0.388 . . . . 0.0 110.911 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.571 HG12 ' CZ ' ' A' ' 126' ' ' PHE . 88.9 t -141.94 114.04 3.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.132 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 45.7 t -106.06 142.99 34.84 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.816 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.571 ' CZ ' HG12 ' A' ' 124' ' ' VAL . 1.5 m-85 -119.24 158.46 25.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.898 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.432 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 20.7 m-85 -66.91 -42.3 85.67 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.883 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 25.3 m-80 -110.13 166.95 10.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.911 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 58.7 tttt -76.15 -44.2 39.39 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.898 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.429 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -54.71 -59.32 4.88 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.929 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 130' ' ' TRP . 88.8 m-20 -35.8 -56.17 0.7 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.896 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . 0.515 ' HB1' ' CD1' ' A' ' 126' ' ' PHE . . . -63.39 -65.11 0.73 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.084 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.415 ' C ' ' O ' ' A' ' 132' ' ' ALA . 4.6 mm-40 -37.31 -59.01 0.79 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -42.65 -48.58 5.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.907 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.47 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -64.64 -56.45 13.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.094 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 94.8 mt -38.6 -34.45 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.139 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 -86.09 -60.39 2.02 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.883 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 25.8 mt-30 -63.73 -58.14 7.8 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.47 ' N ' ' O ' ' A' ' 135' ' ' ALA . 50.3 mmm -54.86 -34.91 63.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.878 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.45 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -60.89 117.45 11.66 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.47 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 92.56 12.48 58.22 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.524 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 13.6 mm-40 -94.43 170.83 9.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.759 0.314 . . . . 0.0 110.901 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . . . . . . . . . 16.2 m95 -106.1 109.08 20.91 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.87 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 64.6 tp -102.51 128.88 48.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.86 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 69.03 -75.69 0.33 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.458 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.37 15.54 0.32 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.478 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . 0.422 ' HB3' ' NH1' ' A' ' 147' ' ' ARG . 8.0 mtp-105 -156.11 159.33 38.96 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.796 0.331 . . . . 0.0 110.859 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . . . . . . . . . 30.2 mt-30 -64.27 167.83 6.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.909 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 32.4 pt -140.89 145.97 24.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.136 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.459 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 6.5 ptt180 -107.25 109.76 21.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.45 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 43.8 p -103.84 137.01 42.45 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.112 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . 0.423 ' CG ' ' O ' ' A' ' 151' ' ' THR . 19.6 m120 -166.89 176.29 7.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.923 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 10.4 m95 -70.65 116.15 10.63 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -57.26 -44.42 83.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.128 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 45.0 p -92.64 115.62 28.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.136 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 11.3 ptp85 -138.11 163.0 32.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.866 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.457 ' CG ' ' HD2' ' A' ' 158' ' ' PRO . 4.5 ttpm? -91.67 140.22 25.1 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.554 0.692 . . . . 0.0 110.938 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . 0.457 ' HD2' ' CG ' ' A' ' 157' ' ' LYS . 53.7 Cg_endo -69.76 151.89 69.16 Favored 'Trans proline' 0 C--O 1.231 0.158 0 C-N-CA 122.699 2.266 . . . . 0.0 112.288 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 163.97 36.31 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.67 2.247 . . . . 0.0 112.362 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -88.84 150.65 46.11 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.554 0.692 . . . . 0.0 111.102 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 104.63 1.36 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.67 2.247 . . . . 0.0 112.304 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 34.0 tttp -166.9 120.84 1.03 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.912 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 92.4 p -134.58 142.48 46.95 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.824 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 12.5 t -157.18 151.69 25.32 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.149 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 14.5 p90 -158.52 147.97 19.31 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.922 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -144.37 146.41 32.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.888 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 35.7 p -140.76 107.41 5.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.892 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -87.02 92.34 9.01 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.89 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 24.9 p -64.27 -60.99 2.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.093 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 27.2 tttm 53.85 44.69 29.16 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.921 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -153.07 138.12 17.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 36.9 p -88.99 -53.99 4.33 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.83 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 178.95 146.16 6.51 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.464 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 148.42 65.09 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.703 2.269 . . . . 0.0 112.316 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 56.0 p -149.88 132.33 15.67 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.852 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' SER . . . . . 0.406 ' O ' ' C ' ' A' ' 177' ' ' GLY . 97.4 p -145.47 134.13 22.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.853 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . 0.406 ' C ' ' O ' ' A' ' 176' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.492 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 13.7 t -97.69 -46.76 5.87 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.841 0.353 . . . . 0.0 110.886 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 77.1 p -153.59 134.5 13.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.832 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.76 -150.75 5.31 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.528 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 41.0 p -140.47 114.86 9.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.841 0.353 . . . . 0.0 110.89 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.7 p -63.74 128.23 34.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.856 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -150.37 -134.7 2.29 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.483 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 31.4 mt-30 -69.09 156.7 38.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.852 0.358 . . . . 0.0 110.914 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.7 ttmm -91.66 158.66 16.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.899 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? 42.61 51.7 4.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -120.39 118.69 31.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.871 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 31.7 p -104.39 46.58 0.91 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.199 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 48.2 m -75.21 -49.73 18.47 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.842 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 9.3 m-20 -104.98 47.44 0.87 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.861 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 10.0 m170 -121.59 157.07 31.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.824 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.555 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 93.2 m-85 -100.7 111.37 23.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.905 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.48 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.5 OUTLIER -88.54 149.08 23.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.887 179.988 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 42.0 t -124.7 147.53 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.161 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -98.22 138.63 35.21 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.846 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 15.2 t -136.07 129.56 47.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.12 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.453 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -139.75 177.49 20.45 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.439 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 18.8 t0 64.08 41.91 6.03 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.848 0.356 . . . . 0.0 110.909 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.5 mt -102.41 137.02 41.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.929 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -54.93 153.86 10.78 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.691 0.758 . . . . 0.0 110.875 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 -12.0 31.91 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.676 2.251 . . . . 0.0 112.317 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -93.26 -9.57 38.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.915 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.447 ' CD1' ' HA3' ' A' ' 145' ' ' GLY . 42.3 mm -74.65 137.1 23.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.077 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.446 ' N ' HG23 ' A' ' 89' ' ' ILE . 11.3 t -120.46 162.48 19.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.116 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.421 ' C ' ' O ' ' A' ' 90' ' ' THR . 53.2 m -36.03 -49.27 0.64 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.14 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 93' ' ' ASP . 20.2 mt-10 -52.8 -60.33 3.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.899 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.441 ' C ' ' O ' ' A' ' 92' ' ' GLU . 1.0 OUTLIER -34.78 -57.47 0.53 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.909 179.972 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.458 HG21 ' CG2' ' A' ' 124' ' ' VAL . 12.6 mt -48.61 -60.0 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.093 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.415 ' HG3' ' CB ' ' A' ' 107' ' ' ALA . 24.5 mtmt -47.66 -39.85 18.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.931 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.49 -28.91 70.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.087 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.7 -50.68 13.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.095 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 -91.16 12.16 20.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.493 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -66.6 -59.68 7.73 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.578 0.704 . . . . 0.0 111.09 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.493 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.73 -0.6 7.12 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.637 2.225 . . . . 0.0 112.35 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.505 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 74.9 m-85 -99.61 -11.96 20.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.888 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 152.26 137.53 2.59 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.496 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.403 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 10.1 mtm-85 -48.76 122.64 5.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.81 0.338 . . . . 0.0 110.848 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.471 HG21 ' CG1' ' A' ' 124' ' ' VAL . 10.2 mt -99.99 141.75 16.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.125 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.401 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 3.5 t -109.68 -63.73 1.33 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.858 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -100.44 104.85 16.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.881 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . 0.415 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -134.67 128.91 33.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.109 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 11.5 ptm180 -161.79 163.6 29.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.841 -179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 89.9 t -110.85 120.47 61.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.098 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.483 HG12 ' CZ ' ' A' ' 121' ' ' TYR . 57.4 t -50.7 135.85 10.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.115 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 46.3 mttm -136.21 146.08 46.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.45 ' O ' ' N ' ' A' ' 116' ' ' GLY . 32.1 t0 -55.02 123.42 13.51 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.891 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 9.1 tpt -71.07 -2.52 15.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.873 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -103.08 -48.72 3.96 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.062 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 34.0 p -102.25 -29.37 11.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.138 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 80.51 28.45 47.75 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.47 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 14.5 mtpp -99.86 148.82 24.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.781 0.324 . . . . 0.0 110.891 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 5.4 t -51.8 105.64 0.12 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.842 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 36.6 mttt -58.47 -46.81 85.88 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.9 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 142.13 -41.94 1.17 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.484 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.483 ' CZ ' HG12 ' A' ' 110' ' ' VAL . 9.5 p90 -99.86 149.15 23.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.888 0.375 . . . . 0.0 110.947 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -130.58 179.64 16.77 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.479 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -126.62 142.04 51.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.876 0.37 . . . . 0.0 110.921 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.566 HG11 ' CZ ' ' A' ' 126' ' ' PHE . 60.2 t -138.94 123.9 21.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.096 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 33.0 m -112.19 144.77 41.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.877 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.566 ' CZ ' HG11 ' A' ' 124' ' ' VAL . 1.2 m-85 -125.32 150.55 47.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.403 ' CE2' ' HB3' ' A' ' 103' ' ' ARG . 21.9 m-85 -57.65 -46.48 84.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.92 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 25.7 m-20 -112.05 163.45 14.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.91 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.555 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 69.9 tttt -72.11 -61.64 1.72 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.897 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.434 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.9 OUTLIER -34.78 -56.76 0.55 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.906 179.99 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -42.08 -52.02 4.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.851 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -63.37 -60.64 3.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.115 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -39.44 -60.21 0.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 32.6 t-20 -40.29 -44.77 1.98 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.903 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.424 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -69.63 -54.39 14.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.091 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 91.7 mt -41.58 -34.83 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.14 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -87.29 -60.55 1.95 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.911 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 29.3 mm-40 -60.29 -60.17 4.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.901 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.505 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 75.7 mmm -56.84 -41.8 78.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.873 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.441 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -53.09 103.07 0.11 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.478 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 107.41 6.65 33.28 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.51 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 -90.11 173.87 7.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.799 0.333 . . . . 0.0 110.932 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . 0.459 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 17.8 m95 -109.02 121.22 44.68 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.952 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.468 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 34.2 tp -122.85 127.27 48.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.888 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . 0.447 ' HA3' ' CD1' ' A' ' 89' ' ' ILE . . . 72.12 -7.08 8.37 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.474 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 124.16 -9.71 8.36 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.507 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 17.9 mtt180 -127.63 148.9 50.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.722 0.296 . . . . 0.0 110.91 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . 0.459 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 28.1 mt-30 -60.19 152.96 23.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.923 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.468 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 24.6 pt -123.07 153.55 28.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.099 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.474 ' CG ' ' O ' ' A' ' 150' ' ' ARG . 10.1 ptm180 -114.93 114.05 24.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.441 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 73.4 p -107.86 130.4 55.0 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.159 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -157.39 172.38 18.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 24.2 m95 -71.67 124.47 24.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.896 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -73.05 78.69 1.21 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.13 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 32.4 p -121.61 157.62 30.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.103 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 11.3 ptp180 -154.52 170.73 20.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 44.0 mttt -108.84 151.03 41.6 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.581 0.705 . . . . 0.0 110.879 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 157.6 59.75 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.652 2.234 . . . . 0.0 112.314 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -176.29 1.44 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.689 2.259 . . . . 0.0 112.348 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -164.93 151.58 9.36 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.611 0.719 . . . . 0.0 111.065 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 172.23 13.02 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.724 2.282 . . . . 0.0 112.321 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 16.9 tptm -105.8 107.15 18.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.945 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 73.3 m -59.9 156.74 13.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.842 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 56.2 p -139.42 168.86 18.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.182 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -173.79 143.02 0.95 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.911 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 26.1 tp10 -144.88 125.05 13.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.883 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 29.1 m -159.02 136.4 9.95 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.833 -179.765 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 10.4 p30 -149.55 134.48 17.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.848 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 9.1 t -155.1 156.2 35.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.152 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 58.6 tttm -139.5 149.84 44.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.857 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -164.7 165.54 20.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 91.8 p -174.97 170.2 3.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.906 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 174.84 130.6 1.32 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.493 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 178.33 4.67 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.698 2.265 . . . . 0.0 112.358 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 2.4 t -168.91 123.36 0.86 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.852 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 18.0 t -153.92 164.54 38.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.838 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.506 -179.961 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.437 -0.265 . . . . 0.0 112.437 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 18.4 m -111.76 176.94 4.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.913 0.387 . . . . 0.0 110.857 -179.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 59.8 p -101.95 103.94 14.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 -179.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 137.48 -49.45 0.85 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.442 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 35.1 p -56.55 111.81 1.1 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.871 0.367 . . . . 0.0 110.867 -179.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.1 t -67.86 -45.75 73.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.839 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -135.72 118.61 1.89 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.5 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 53.9 mm-40 -53.04 -46.23 68.38 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.839 0.352 . . . . 0.0 110.926 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 14.0 mmtm -132.6 -177.33 4.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.879 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 33.1 ttpt -110.58 -44.56 3.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.43 ' O ' ' C ' ' A' ' 74' ' ' THR . 28.1 m-20 -107.05 43.75 1.13 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.886 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.43 ' C ' ' O ' ' A' ' 73' ' ' ASP . 16.7 p 35.8 45.3 0.27 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.169 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.2 t -62.47 -59.71 4.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.882 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 46.8 m-80 -109.03 54.65 0.65 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.917 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 10.8 m170 -111.07 164.64 12.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.851 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.493 ' CD2' ' HA ' ' A' ' 129' ' ' LYS . 37.3 m-85 -111.59 108.96 18.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.855 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 58.4 m-70 -86.08 155.87 20.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.866 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 45.4 t -129.07 141.55 46.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.098 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.0 t80 -90.7 133.33 35.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.414 ' CG1' HD22 ' A' ' 85' ' ' LEU . 5.6 t -129.74 110.0 19.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.123 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.463 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -118.18 168.21 13.07 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.473 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.9 t70 68.76 52.73 0.54 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.813 0.34 . . . . 0.0 110.877 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.414 HD22 ' CG1' ' A' ' 82' ' ' VAL . 16.2 mt -109.68 131.49 55.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.919 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.1 t -53.98 154.71 7.16 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.624 0.726 . . . . 0.0 110.885 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -14.51 36.15 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.693 2.262 . . . . 0.0 112.36 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -93.07 -5.24 50.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.911 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.427 HG21 ' CB ' ' A' ' 93' ' ' ASP . 40.5 mm -78.37 138.11 20.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.127 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.3 t -120.84 170.5 9.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.181 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.441 HG21 ' CE ' ' A' ' 95' ' ' LYS . 88.3 m -43.64 -49.85 7.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.168 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.437 ' O ' ' C ' ' A' ' 93' ' ' ASP . 57.7 mt-10 -52.05 -60.16 3.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.91 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.437 ' C ' ' O ' ' A' ' 92' ' ' GLU . 5.9 m-20 -34.51 -57.99 0.5 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.891 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.409 HG21 ' CG2' ' A' ' 124' ' ' VAL . 7.6 mt -49.52 -62.26 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.117 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.459 ' HA ' ' CD1' ' A' ' 104' ' ' ILE . 27.8 mtmt -46.12 -40.1 10.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.943 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.52 -31.61 71.63 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.154 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -72.97 -53.86 10.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.121 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -88.14 7.07 33.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.853 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.486 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -60.73 -59.93 12.27 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.609 0.719 . . . . 0.0 111.097 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.486 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.1 Cg_endo -69.77 -0.75 7.38 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.685 2.257 . . . . 0.0 112.314 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.593 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 73.8 m-85 -99.78 -5.04 29.3 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.914 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 144.25 136.2 3.04 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.507 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 29.5 mtt180 -46.78 124.41 6.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.795 0.331 . . . . 0.0 110.869 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.459 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 13.2 mt -100.09 138.26 24.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.151 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.483 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 47.1 p -107.33 -61.83 1.5 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.848 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -100.2 104.56 16.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.871 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -134.94 127.32 30.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.051 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 1.9 ptt-85 -160.94 157.94 27.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.886 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 86.8 t -110.26 115.42 49.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.135 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.557 HG13 ' CE2' ' A' ' 121' ' ' TYR . 48.7 t -46.97 136.82 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.147 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 54.0 mttt -137.46 148.69 46.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.945 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -58.54 130.18 45.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.879 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 28.4 ptm -78.88 1.63 22.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.866 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -102.82 -41.18 6.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.087 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 45.1 p -114.43 -29.07 6.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.167 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 84.52 21.43 56.4 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.497 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 48.4 mmtt -92.93 145.25 24.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.769 0.318 . . . . 0.0 110.902 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 4.9 t -46.69 111.86 0.44 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.853 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -62.7 -51.46 67.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 147.46 -41.56 0.93 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.486 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.557 ' CE2' HG13 ' A' ' 110' ' ' VAL . 4.9 p90 -100.06 153.13 19.47 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.928 0.394 . . . . 0.0 110.915 -179.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.42 173.7 22.14 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.468 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -122.54 140.45 52.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.897 0.379 . . . . 0.0 110.92 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.57 HG13 ' CZ ' ' A' ' 126' ' ' PHE . 59.2 t -137.62 116.38 14.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.12 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 15.5 t -104.87 147.16 28.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.852 -179.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.57 ' CZ ' HG13 ' A' ' 124' ' ' VAL . 1.2 m-85 -126.84 150.2 49.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.875 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.483 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 23.1 m-85 -56.7 -44.42 81.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 24.4 m-20 -112.86 166.47 11.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.905 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.568 ' HE3' ' CH2' ' A' ' 153' ' ' TRP . 39.2 tptt -70.99 -59.99 2.48 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.944 179.854 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.426 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.8 OUTLIER -40.93 -59.92 1.32 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.922 179.941 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.426 ' C ' ' O ' ' A' ' 130' ' ' TRP . 6.9 m-20 -35.8 -39.11 0.14 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.863 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -80.43 -58.51 3.09 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.063 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.4 mt-10 -44.38 -55.68 4.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.948 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 54.7 t30 -42.8 -42.07 3.46 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.909 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.49 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -71.81 -55.78 6.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.055 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 76.1 mt -38.76 -36.4 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.104 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.1 mt-30 -83.6 -57.19 3.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 16.8 mm-40 -68.54 -61.16 1.95 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.897 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.593 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 41.3 mmm -52.97 -31.38 40.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.905 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.447 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -63.04 107.78 1.84 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.491 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 99.94 13.73 36.12 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.487 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 66.5 mm-40 -93.1 166.88 12.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.802 0.334 . . . . 0.0 110.89 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . 0.422 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 14.5 m95 -102.89 107.06 17.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.89 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 63.6 tp -100.02 126.46 46.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.873 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 70.25 -76.95 0.46 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.493 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -155.96 14.5 0.41 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.497 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 36.7 mtp180 -153.04 157.01 39.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.783 0.325 . . . . 0.0 110.866 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . 0.422 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 30.8 mt-30 -62.16 167.2 4.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.927 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 25.7 pt -138.96 153.21 24.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.488 ' CG ' ' O ' ' A' ' 150' ' ' ARG . 7.0 ptm180 -118.82 116.47 26.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.9 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.447 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 53.5 p -107.53 135.53 48.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.134 -179.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 28.4 t30 -160.15 171.09 19.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . 0.568 ' CH2' ' HE3' ' A' ' 129' ' ' LYS . 15.3 m95 -66.87 122.29 17.37 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.937 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -77.92 -56.5 4.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.097 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 9.9 t -73.8 150.97 40.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.169 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 15.2 ptp180 -168.7 152.87 5.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.881 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 25.9 mmmt -137.07 155.01 76.34 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.56 0.695 . . . . 0.0 110.912 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 148.61 65.17 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.663 2.242 . . . . 0.0 112.346 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 157.76 59.28 Favored 'Trans proline' 0 N--CA 1.465 -0.15 0 C-N-CA 122.691 2.261 . . . . 0.0 112.369 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -80.74 154.93 73.5 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.542 0.687 . . . . 0.0 111.098 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 125.39 12.07 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.661 2.24 . . . . 0.0 112.309 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -69.36 112.32 5.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.876 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 55.0 p -145.78 133.06 20.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.849 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 13.3 t -136.22 169.75 17.13 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.155 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 3.5 t80 -108.54 99.45 8.83 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.926 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -171.94 145.51 1.88 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.894 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 33.3 p -152.79 116.21 4.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.894 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -156.53 130.53 8.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.851 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 13.0 t -170.17 152.6 4.26 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.107 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 6.8 mmpt? -113.42 118.58 34.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.916 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 18.6 pt20 -150.18 147.29 27.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.895 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 70.8 m 54.92 38.4 30.35 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.869 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -72.12 -158.64 3.88 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.488 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 124.02 10.66 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.691 2.261 . . . . 0.0 112.329 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 49.8 m -118.64 146.21 44.85 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.839 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 7.7 t -171.43 165.3 7.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.826 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.291 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.476 -179.983 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.526 -0.23 . . . . 0.0 112.526 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 82.1 p -156.81 174.23 15.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.877 0.37 . . . . 0.0 110.855 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 24.5 m -94.99 161.05 14.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.906 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -102.82 41.01 2.23 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.501 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 6.4 t -144.36 117.48 8.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.881 0.372 . . . . 0.0 110.876 -179.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.8 t -98.92 133.15 43.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.871 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 178.36 88.85 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.444 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 35.3 mm-40 -120.09 147.19 45.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.878 0.37 . . . . 0.0 110.938 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 41.0 mmtt -132.64 101.79 5.44 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.935 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 19.9 pttm -135.67 166.36 23.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.928 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -109.39 163.19 13.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.881 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.6 p -89.38 51.44 2.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.197 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 58.1 p -69.17 -55.51 10.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.837 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.4 t30 -113.02 51.96 0.81 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.885 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 17.2 m170 -117.43 155.08 30.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.877 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.56 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 84.3 m-85 -108.48 115.42 30.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.906 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 10.2 m-70 -89.65 147.84 23.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.89 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 41.4 t -119.21 143.47 30.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.157 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.1 t80 -93.56 135.3 34.96 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.4 ' O ' ' CB ' ' A' ' 121' ' ' TYR . 4.0 t -131.25 131.04 63.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.157 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.416 ' N ' ' HG2' ' A' ' 150' ' ' ARG . . . -135.8 179.41 17.82 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.524 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 52.37 47.61 24.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.86 0.362 . . . . 0.0 110.852 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 30.0 mt -99.65 132.91 44.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.938 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -53.01 156.33 3.61 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.651 0.738 . . . . 0.0 110.868 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -39.53 6.28 Favored 'Trans proline' 0 C--O 1.231 0.125 0 C-N-CA 122.675 2.25 . . . . 0.0 112.337 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -71.46 1.2 6.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.887 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.466 HG21 ' CB ' ' A' ' 93' ' ' ASP . 37.3 mm -83.01 132.37 31.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.169 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.1 t -114.74 175.34 5.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.104 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 16.2 m -52.99 -41.66 64.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.147 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -62.36 -47.03 85.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.894 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.466 ' CB ' HG21 ' A' ' 89' ' ' ILE . 17.1 m-20 -47.87 -50.08 27.54 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.911 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 8.1 mt -54.7 -54.97 17.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.132 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.418 ' O ' ' N ' ' A' ' 99' ' ' ALA . 22.0 mtmt -50.93 -42.47 59.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.866 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -58.42 -30.98 67.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.107 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -72.46 -57.16 4.39 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.101 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.418 ' C ' HD13 ' A' ' 104' ' ' ILE . 22.0 m-85 -87.37 12.22 12.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.935 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.482 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -61.79 -60.19 11.05 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.613 0.72 . . . . 0.0 111.119 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.482 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.5 Cg_endo -69.8 -0.8 7.47 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.678 2.252 . . . . 0.0 112.306 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -99.9 9.57 42.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.883 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.26 136.02 4.24 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.525 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 38.9 mtt85 -46.73 125.04 6.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.766 0.317 . . . . 0.0 110.882 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.451 HG22 ' CG1' ' A' ' 124' ' ' VAL . 10.9 mt -98.21 138.83 21.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.153 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.455 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.9 t -106.73 -62.91 1.34 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.848 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -100.25 105.2 16.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.861 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -136.46 127.01 26.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.138 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.2 ptm180 -161.91 155.85 21.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.892 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 58.4 t -102.07 119.14 49.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.557 HG13 ' CE2' ' A' ' 121' ' ' TYR . 59.8 t -53.86 136.99 15.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.141 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . 0.4 ' C ' ' HG3' ' A' ' 119' ' ' LYS . 57.5 mttt -136.59 153.89 50.83 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.501 ' O ' ' N ' ' A' ' 116' ' ' GLY . 23.2 t70 -64.99 120.21 12.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 179.871 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 16.4 ptp -67.14 -10.93 55.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.841 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -83.62 -54.81 4.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.107 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 13.5 p -104.85 -34.4 8.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.171 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.501 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 95.89 25.71 12.7 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.477 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 44.4 mtmt -95.33 154.68 17.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.781 0.324 . . . . 0.0 110.867 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 8.0 t -54.89 112.49 1.05 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.91 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.456 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 16.6 mttp -63.36 -54.23 40.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.895 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 150.2 -41.76 0.79 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.469 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.557 ' CE2' HG13 ' A' ' 110' ' ' VAL . 5.4 p90 -100.01 155.25 17.8 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.96 0.41 . . . . 0.0 110.938 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -134.46 169.88 22.9 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.464 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -118.77 138.44 52.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.873 0.368 . . . . 0.0 110.914 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.553 HG13 ' CZ ' ' A' ' 126' ' ' PHE . 61.2 t -138.77 115.08 10.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.143 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 8.2 t -107.23 140.02 40.77 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.877 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.553 ' CZ ' HG13 ' A' ' 124' ' ' VAL . 1.2 m-85 -119.51 163.45 17.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.894 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.455 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 22.9 m-85 -72.32 -42.91 64.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.902 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 68.0 m-20 -114.18 161.44 17.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.864 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.56 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 44.3 tptt -69.74 -61.63 1.71 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.464 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.9 OUTLIER -33.27 -60.7 0.33 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.883 179.972 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 -39.67 -54.07 2.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.875 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -65.02 -59.49 4.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.08 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -43.5 -60.7 1.63 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.894 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -43.57 -44.11 5.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.836 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.462 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -66.63 -56.48 10.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.132 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 82.8 mt -40.91 -37.84 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.14 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 15.7 mt-30 -76.47 -63.81 1.25 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.947 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 27.0 mt-30 -63.85 -61.24 2.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.931 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.462 ' N ' ' O ' ' A' ' 135' ' ' ALA . 65.6 mmm -51.43 -34.0 33.07 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.858 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.443 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -58.69 93.47 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.483 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 113.52 4.55 23.3 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.426 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 16.2 mm100 -80.66 171.13 15.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.797 0.332 . . . . 0.0 110.875 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . 0.4 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 15.4 m95 -106.7 111.29 23.76 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.92 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.437 ' CB ' HG23 ' A' ' 149' ' ' ILE . 66.3 tp -104.91 129.22 53.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.932 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . 0.411 ' HA3' ' CD1' ' A' ' 89' ' ' ILE . . . 70.31 -78.04 0.45 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.492 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -155.29 14.03 0.46 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.499 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 23.9 mtt85 -153.73 161.46 42.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.771 0.32 . . . . 0.0 110.893 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . 0.4 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 23.0 mt-30 -62.95 171.0 2.38 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.437 HG23 ' CB ' ' A' ' 144' ' ' LEU . 14.0 pt -142.07 158.43 20.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.124 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.487 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 7.7 ptm180 -120.82 118.6 30.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.867 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.443 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 61.0 p -111.15 132.44 54.29 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.159 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 41.2 t30 -157.66 174.07 15.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.942 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . 0.551 ' CH2' ' HE3' ' A' ' 129' ' ' LYS . 9.8 m95 -71.37 135.16 47.17 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.914 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -85.67 41.58 0.91 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.087 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -160.64 146.68 15.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.147 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -124.64 128.91 49.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.878 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 18.0 mttp -82.44 143.83 48.59 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.573 0.702 . . . . 0.0 110.89 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 148.57 65.61 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.686 2.257 . . . . 0.0 112.375 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 174.86 8.92 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.703 2.269 . . . . 0.0 112.318 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -101.17 157.74 33.1 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.613 0.721 . . . . 0.0 111.05 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . 0.405 ' O ' ' C ' ' A' ' 162' ' ' LYS . 54.0 Cg_endo -69.72 -28.73 25.11 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.703 2.268 . . . . 0.0 112.337 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . 0.405 ' C ' ' O ' ' A' ' 161' ' ' PRO . 23.9 mmtp -37.43 108.36 0.08 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.904 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 3.3 t -120.83 114.07 21.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.896 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 5.4 m -77.69 131.33 37.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.168 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 1.5 t80 -75.2 164.31 26.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.943 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -144.56 143.49 30.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.912 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 75.9 p -172.79 150.3 2.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -138.38 153.39 48.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.907 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 51.1 m -142.59 110.02 5.71 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.179 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 12.5 ttmm -125.76 112.58 16.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.905 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -127.63 136.93 52.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.938 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 88.4 p -156.0 123.15 5.38 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -122.61 68.46 0.45 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.564 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.65 157.08 61.86 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.69 2.26 . . . . 0.0 112.359 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 21.6 p -170.6 122.61 0.63 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.822 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 1.2 t -147.74 151.69 36.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.539 -179.948 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 N-CA-C 112.555 -0.218 . . . . 0.0 112.555 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.6 t -166.28 150.86 7.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.879 0.371 . . . . 0.0 110.867 -179.723 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 7.5 t -67.9 137.13 55.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.86 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 127.43 95.29 0.88 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.47 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 16.0 t -122.98 134.17 54.34 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.846 0.355 . . . . 0.0 110.878 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.8 p -163.89 170.2 17.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.849 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 124.15 -151.04 17.09 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.506 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -106.02 171.62 7.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.848 0.356 . . . . 0.0 110.914 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 19.9 mmtt -89.86 96.89 10.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.94 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 3.2 mppt? -96.33 43.21 1.08 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.963 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -56.32 -59.67 4.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.857 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 64.8 p -112.17 40.85 2.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.085 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.7 m -83.66 -42.42 16.68 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.871 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.2 m-20 -78.23 -33.45 49.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.875 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 30.2 m170 -68.47 140.97 55.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.848 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -96.45 125.08 40.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.911 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.434 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.5 OUTLIER -82.21 141.75 32.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.892 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 41.6 t -119.2 144.11 28.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.164 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.0 t80 -97.51 131.68 43.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.866 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.516 HG22 ' CZ ' ' A' ' 98' ' ' PHE . 3.6 t -133.42 109.98 14.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.148 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -116.61 -178.12 17.99 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.519 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 63.98 34.99 11.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.894 0.378 . . . . 0.0 110.923 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.411 HD23 ' CG1' ' A' ' 82' ' ' VAL . 9.9 mt -92.76 128.96 38.8 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.918 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.05 154.27 5.48 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.657 0.741 . . . . 0.0 110.874 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -13.79 35.18 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.681 2.254 . . . . 0.0 112.358 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -92.94 -7.78 45.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.87 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.463 HG22 ' N ' ' A' ' 90' ' ' THR . 30.5 mm -78.38 138.54 20.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.17 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.463 ' N ' HG22 ' A' ' 89' ' ' ILE . 11.0 t -119.27 167.26 12.04 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.11 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 21.2 m -42.4 -47.0 4.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.143 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -54.1 -57.71 10.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.885 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -38.45 -57.11 1.18 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.862 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 6.4 mt -48.16 -58.33 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.101 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 23.6 mtmt -49.93 -44.37 50.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.928 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -58.56 -30.12 66.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.095 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -74.85 -58.19 3.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.157 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.516 ' CZ ' HG22 ' A' ' 82' ' ' VAL . 42.9 m-85 -82.42 8.04 12.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.483 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -60.02 -60.21 11.35 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.591 0.71 . . . . 0.0 111.051 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.483 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.7 -0.99 7.66 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.661 2.241 . . . . 0.0 112.378 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.501 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 81.2 m-85 -99.91 3.63 44.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.903 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 136.55 156.61 7.47 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.458 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.44 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 34.0 mtt85 -64.44 125.18 23.84 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.796 0.331 . . . . 0.0 110.882 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.468 HG22 ' CG1' ' A' ' 124' ' ' VAL . 11.6 mt -100.3 137.21 28.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.115 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.534 ' OG ' ' CZ ' ' A' ' 127' ' ' PHE . 2.5 m -110.14 -60.41 1.8 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.895 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.0 t0 -101.22 102.24 13.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.878 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -131.99 125.62 31.97 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.117 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 11.9 ptp180 -159.73 157.58 29.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.841 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 99.2 t -109.36 116.0 51.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.147 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.54 HG21 ' CE2' ' A' ' 121' ' ' TYR . 94.5 t -49.16 138.32 4.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.134 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . 0.435 ' N ' HG11 ' A' ' 110' ' ' VAL . 28.7 mttm -138.39 155.95 48.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.892 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.499 ' O ' ' N ' ' A' ' 116' ' ' GLY . 36.5 t0 -65.49 121.01 13.91 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.889 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 7.0 tpt -69.6 -9.29 53.5 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.898 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.93 -47.8 5.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.105 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 21.9 p -98.35 -34.23 10.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.099 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.499 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 86.33 23.6 43.36 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.474 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 14.8 mtpp -98.93 158.13 15.85 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.797 0.332 . . . . 0.0 110.91 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 47.4 t -56.67 112.91 1.42 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.868 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 25.3 mmtt -63.09 -38.83 92.76 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.918 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 130.49 -42.77 1.37 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.444 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.54 ' CE2' HG21 ' A' ' 110' ' ' VAL . 12.0 p90 -99.91 151.42 21.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.957 0.408 . . . . 0.0 110.892 -179.813 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -136.75 172.4 22.57 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.473 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -120.07 139.06 53.12 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.889 0.376 . . . . 0.0 110.914 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.512 HG12 ' CZ ' ' A' ' 126' ' ' PHE . 53.1 t -136.84 111.0 9.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.111 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.8 t -99.38 151.58 20.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.893 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.512 ' CZ ' HG12 ' A' ' 124' ' ' VAL . 1.5 m-85 -130.83 152.37 50.24 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.875 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.534 ' CZ ' ' OG ' ' A' ' 105' ' ' SER . 76.2 m-85 -66.01 -34.95 79.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.842 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -120.74 149.96 41.73 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.87 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.463 ' O ' ' C ' ' A' ' 130' ' ' TRP . 45.0 tttt -59.05 -65.82 0.6 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.866 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.463 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -33.47 -60.83 0.34 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.923 179.951 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 130' ' ' TRP . 68.8 m-20 -35.81 -46.63 0.46 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.87 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -74.78 -59.8 2.57 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.085 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -39.07 -53.31 1.82 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.846 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 50.5 t30 -49.22 -50.04 40.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.888 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -61.91 -53.15 59.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.085 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 96.6 mt -42.28 -37.11 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.142 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 6.1 mt-30 -86.87 -62.29 1.54 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.908 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 26.3 mt-30 -54.4 -61.52 2.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.885 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.501 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 92.6 mmm -58.45 -41.07 84.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.878 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.443 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -46.88 99.48 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.462 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 101.55 17.78 20.64 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.518 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 57.0 mm-40 -96.51 172.42 7.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.782 0.325 . . . . 0.0 110.898 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . 0.499 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 16.0 m95 -107.54 110.71 22.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.873 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 57.3 tp -103.56 127.47 50.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.934 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 69.89 -75.66 0.44 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.463 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.83 15.51 0.3 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.475 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 42.3 mtt-85 -154.62 156.77 37.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.726 0.298 . . . . 0.0 110.874 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . 0.499 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 33.4 mt-30 -63.12 168.95 3.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.921 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 26.5 pt -149.23 144.73 18.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.112 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 14.0 ptt180 -105.63 124.06 48.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.863 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.443 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 69.0 p -115.28 141.12 48.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.185 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . 0.442 ' CG ' ' O ' ' A' ' 151' ' ' THR . 73.9 m-20 -165.11 177.13 7.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.885 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 11.9 m95 -67.91 111.28 4.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.942 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -54.18 -29.72 46.81 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.084 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 20.5 p -75.2 169.06 18.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.111 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -162.91 164.23 25.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.474 ' CD ' ' HD2' ' A' ' 158' ' ' PRO . 0.3 OUTLIER -105.91 137.78 19.45 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.601 0.715 . . . . 0.0 110.907 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . 0.474 ' HD2' ' CD ' ' A' ' 157' ' ' LYS . 53.4 Cg_endo -69.78 147.1 61.98 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.664 2.243 . . . . 0.0 112.361 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 161.82 44.47 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.674 2.25 . . . . 0.0 112.331 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -106.35 146.72 33.55 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.591 0.71 . . . . 0.0 111.109 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 93.99 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.675 2.25 . . . . 0.0 112.326 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 19.2 tttp -157.91 113.25 2.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.895 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 96.4 p -135.05 150.71 50.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.879 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 14.5 t -116.13 174.08 6.24 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.137 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -109.04 165.34 11.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.906 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -138.92 142.88 38.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.935 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 25.4 m -107.27 43.04 1.22 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.844 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -113.42 81.17 1.46 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.859 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 75.2 p -116.33 105.53 12.64 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.153 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 41.3 tttp -87.18 -60.69 1.91 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.879 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 7.0 tt0 -173.54 166.92 4.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.917 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 66.9 m -66.43 121.96 16.48 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.892 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 86.3 83.52 1.11 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.453 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -2.88 10.95 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.669 2.246 . . . . 0.0 112.342 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 67.6 p -140.75 161.08 38.64 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.861 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 69.8 p -159.81 126.63 4.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.838 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.485 179.957 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.369 0 N-CA-C 112.509 -0.237 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 75.3 p -123.43 153.45 40.42 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.912 0.387 . . . . 0.0 110.854 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 43.7 t -90.38 -61.7 1.62 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.896 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 145.07 66.77 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.468 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 22.8 m -112.49 83.19 1.77 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.846 0.355 . . . . 0.0 110.904 -179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 3.5 m -89.38 82.64 6.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.848 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -126.91 -59.38 0.14 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.531 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -98.77 107.92 20.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.906 0.384 . . . . 0.0 110.861 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.6 mptt -96.76 157.96 15.66 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.889 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 35.8 tttp -174.93 133.89 0.34 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.886 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.438 ' O ' ' C ' ' A' ' 74' ' ' THR . 7.0 m-20 48.6 44.98 21.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.855 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.438 ' C ' ' O ' ' A' ' 73' ' ' ASP . 2.1 p 35.22 53.26 0.71 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.126 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.2 t -75.93 -44.41 40.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.816 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -110.33 50.38 0.81 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 6.8 m170 -122.88 156.53 34.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.876 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.547 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 54.5 m-85 -111.09 114.2 27.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 40.2 m-70 -87.32 148.25 25.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.83 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 34.9 t -123.64 139.64 49.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.122 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -91.94 134.48 34.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.903 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.441 ' CG1' HD22 ' A' ' 85' ' ' LEU . 3.8 t -132.51 109.93 15.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.14 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.4 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -117.36 170.72 13.59 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.478 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.8 t70 68.83 51.67 0.57 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.847 0.356 . . . . 0.0 110.905 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.441 HD22 ' CG1' ' A' ' 82' ' ' VAL . 16.5 mt -108.91 131.92 54.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.893 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 t -54.92 153.71 11.01 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.676 0.75 . . . . 0.0 110.85 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -11.29 30.5 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.682 2.254 . . . . 0.0 112.313 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -94.0 -9.83 35.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.911 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 46.9 mm -74.42 137.99 22.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.131 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.2 t -117.84 166.52 12.37 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.162 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.442 ' CG2' ' HA ' ' A' ' 108' ' ' ARG . 86.1 m -43.37 -46.34 6.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.137 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 93' ' ' ASP . 35.2 mt-10 -55.55 -57.94 9.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.891 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 92' ' ' GLU . 3.0 m-20 -35.18 -58.59 0.54 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.879 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 10.9 mt -48.5 -58.91 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.138 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.46 ' HA ' ' CD1' ' A' ' 104' ' ' ILE . 23.9 mtmt -49.41 -39.41 32.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.929 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.03 -27.66 69.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.085 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -77.65 -52.2 9.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.121 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -89.33 13.49 13.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.481 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -67.61 -60.26 5.83 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.554 0.692 . . . . 0.0 111.082 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.481 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.5 Cg_endo -69.76 -0.84 7.49 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.689 2.259 . . . . 0.0 112.323 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -99.95 -5.14 28.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.876 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 144.2 142.0 3.84 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.494 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.423 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 57.4 mtt180 -50.81 125.91 14.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.81 0.338 . . . . 0.0 110.882 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.46 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 17.4 mt -99.32 145.72 9.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.127 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.451 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.0 OUTLIER -119.3 -60.09 1.77 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.823 -179.892 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.431 ' OD1' ' CG2' ' A' ' 74' ' ' THR . 4.2 m-20 -100.53 92.47 5.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.829 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -129.5 124.64 34.47 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.103 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.442 ' HA ' ' CG2' ' A' ' 91' ' ' THR . 10.5 ptm180 -158.13 161.84 37.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.905 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 79.5 t -113.44 116.82 53.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.562 HG22 ' CE2' ' A' ' 121' ' ' TYR . 77.1 t -52.58 137.46 12.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.131 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . 0.441 ' N ' HG12 ' A' ' 110' ' ' VAL . 1.7 mtmp? -130.19 156.97 43.72 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.906 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.515 ' O ' ' N ' ' A' ' 116' ' ' GLY . 27.5 t0 -64.47 118.85 9.37 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.855 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' MET . . . . . 0.467 ' C ' ' SD ' ' A' ' 113' ' ' MET . 2.6 tmm? -65.85 -9.79 32.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.893 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -92.92 -53.41 4.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.07 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 20.7 p -100.71 -35.41 9.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.108 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 92.76 28.05 13.14 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.483 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -100.24 156.26 17.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.738 0.304 . . . . 0.0 110.917 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 36.7 t -51.77 109.03 0.32 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.876 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 18.9 mmtt -61.14 -51.74 67.81 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.89 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 144.95 -40.59 1.12 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.533 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.562 ' CE2' HG22 ' A' ' 110' ' ' VAL . 6.2 p90 -100.09 151.99 20.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.939 0.4 . . . . 0.0 110.944 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -141.0 172.96 23.46 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.495 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -121.19 141.2 51.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.874 0.369 . . . . 0.0 110.862 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.529 HG13 ' CZ ' ' A' ' 126' ' ' PHE . 58.6 t -139.18 113.52 7.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.132 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 4.3 t -104.35 147.68 27.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.823 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.529 ' CZ ' HG13 ' A' ' 124' ' ' VAL . 1.3 m-85 -126.47 153.86 44.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.876 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.451 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 20.9 m-85 -62.02 -43.43 98.86 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.896 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -114.65 161.72 17.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.877 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.547 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 39.9 tptt -69.04 -62.07 1.53 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.917 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.459 ' C ' ' O ' ' A' ' 129' ' ' LYS . 1.0 OUTLIER -33.53 -61.83 0.31 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.937 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.408 ' C ' ' O ' ' A' ' 130' ' ' TRP . 75.2 m-20 -37.09 -57.46 0.85 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.835 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -58.88 -62.16 2.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.103 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -39.7 -59.52 1.13 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.876 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 53.3 t30 -41.07 -46.45 2.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.879 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.484 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -67.32 -51.84 47.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.107 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 97.6 mt -43.42 -35.11 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.151 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -88.33 -55.23 3.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.9 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 5.0 mm100 -67.31 -61.01 2.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.93 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.484 ' N ' ' O ' ' A' ' 135' ' ' ALA . 57.4 mmm -59.2 -26.46 64.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.434 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -65.1 113.54 5.94 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.45 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 89.36 18.25 53.27 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.494 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 89.8 mm-40 -97.47 171.2 8.54 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.788 0.328 . . . . 0.0 110.898 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . 0.414 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 15.4 m95 -104.14 110.68 22.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.949 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 59.2 tp -103.27 129.22 50.19 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.906 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 67.28 -74.74 0.19 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.493 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.81 18.05 0.28 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.511 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 72.2 mtt180 -156.69 155.41 31.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.756 0.312 . . . . 0.0 110.906 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . 0.414 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 31.1 mt-30 -60.18 170.38 1.29 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.915 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 19.2 pt -146.39 150.18 15.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.106 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.424 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 13.1 ptp180 -113.99 121.96 45.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.87 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.434 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 73.4 p -112.56 128.11 56.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.168 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -151.33 170.77 18.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.898 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . 0.528 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 9.8 m95 -69.17 109.3 3.99 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.921 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -58.2 -55.37 35.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.163 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 6.8 t -112.29 148.06 34.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.196 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 15.3 ptt85 -165.98 158.61 14.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.869 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 12.8 mtpp -135.92 131.67 19.06 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.579 0.704 . . . . 0.0 110.899 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 153.43 68.92 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.685 2.256 . . . . 0.0 112.336 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.68 165.82 29.6 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.671 2.248 . . . . 0.0 112.416 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -129.28 147.21 64.08 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.654 0.74 . . . . 0.0 111.072 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.81 105.14 1.44 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.688 2.259 . . . . 0.0 112.303 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 21.2 mmmt -130.31 93.76 3.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.889 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 1.7 t -83.54 111.85 19.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.826 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 11.4 t -96.22 135.28 38.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.172 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 10.4 p90 -113.27 131.35 55.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.967 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -127.46 82.32 2.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.902 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 78.8 p -169.53 123.93 0.8 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.91 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 4.9 t30 -173.65 129.24 0.42 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.891 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 1.6 t -102.21 149.35 24.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.114 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 27.2 ttpt -151.87 117.16 5.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.857 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 27.3 tt0 -140.45 129.28 23.18 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.965 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 48.8 m -157.53 161.46 38.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.836 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -149.2 69.18 0.34 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.52 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 145.69 58.12 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.677 2.251 . . . . 0.0 112.4 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 4.7 t -120.7 142.47 49.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.858 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 8.3 m -103.33 174.98 5.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.813 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.476 -179.992 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.448 ' O ' ' C ' ' A' ' 64' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.329 0 N-CA-C 112.451 -0.26 . . . . 0.0 112.451 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.448 ' C ' ' O ' ' A' ' 63' ' ' GLY . 60.9 p 34.6 42.16 0.07 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.899 0.38 . . . . 0.0 110.841 -179.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 63.1 p -102.9 -54.78 2.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.867 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.51 -46.57 2.78 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.447 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 5.3 t -41.25 -61.37 1.03 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.86 0.362 . . . . 0.0 110.812 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 13.1 m -149.84 -176.53 5.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.885 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 66.89 68.21 1.74 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.506 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . 0.414 ' NE2' ' O ' ' A' ' 72' ' ' LYS . 11.8 pt20 -50.78 170.03 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.831 0.348 . . . . 0.0 110.929 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.74 -0.62 23.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.85 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.414 ' O ' ' NE2' ' A' ' 70' ' ' GLN . 29.5 ttmt -125.13 126.59 45.53 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.887 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 44.1 m-20 -75.7 162.85 27.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.855 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.4 p -85.45 62.93 7.79 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.109 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 22.6 t -74.43 -53.73 8.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.88 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.4 m-20 -125.39 52.63 1.6 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.866 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 10.0 m170 -104.89 156.93 17.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.871 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.573 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 97.3 m-85 -97.58 114.61 26.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.916 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.467 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.9 OUTLIER -95.51 139.92 31.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 -180.0 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 57.4 t -113.96 152.02 15.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.06 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -102.09 132.89 47.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.915 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.1 t -129.57 129.78 66.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.142 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.45 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -136.69 -173.54 12.96 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.494 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 27.0 m-20 55.3 36.33 26.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.831 0.348 . . . . 0.0 110.851 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.3 mt -96.18 131.02 43.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.886 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 t -53.1 153.71 6.15 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.652 0.739 . . . . 0.0 110.818 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -13.84 35.25 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.7 2.267 . . . . 0.0 112.338 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -91.04 -8.75 48.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.888 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.456 HG21 ' CB ' ' A' ' 93' ' ' ASP . 39.1 mm -76.37 136.67 24.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.176 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.444 ' OG1' ' N ' ' A' ' 91' ' ' THR . 2.3 t -114.55 177.54 4.61 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.163 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.444 ' N ' ' OG1' ' A' ' 90' ' ' THR . 69.9 m -52.6 -47.67 66.78 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.177 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 93' ' ' ASP . 32.0 mt-10 -56.42 -58.26 8.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.879 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.456 ' CB ' HG21 ' A' ' 89' ' ' ILE . 2.9 m-20 -35.49 -54.63 0.68 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.911 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 6.2 mt -51.18 -60.17 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.117 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.423 ' O ' ' N ' ' A' ' 99' ' ' ALA . 21.7 mtmt -47.14 -43.13 20.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.904 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -57.43 -31.57 66.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.134 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -74.42 -52.65 11.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.12 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -88.77 12.4 15.11 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.868 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.484 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -65.72 -60.1 7.98 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.597 0.713 . . . . 0.0 111.096 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.484 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.4 Cg_endo -69.8 -0.87 7.58 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.694 2.263 . . . . 0.0 112.321 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.506 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 78.3 m-85 -99.75 4.61 45.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.887 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.06 159.63 8.74 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.475 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.494 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 39.8 mtp85 -65.72 125.71 26.16 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.804 0.335 . . . . 0.0 110.866 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.404 HG23 ' CG1' ' A' ' 124' ' ' VAL . 14.4 mt -100.46 138.14 25.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.186 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -109.86 -60.76 1.74 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.849 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -100.75 103.96 15.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.904 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -133.84 124.86 27.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.124 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.414 ' HA ' ' CG2' ' A' ' 91' ' ' THR . 17.6 ptt180 -161.94 160.16 27.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.9 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 99.4 t -110.12 116.31 51.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.148 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.568 HG11 ' CE2' ' A' ' 121' ' ' TYR . 51.5 t -50.99 132.73 12.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.101 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 69.1 mttt -133.45 148.76 51.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.867 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.44 ' O ' ' N ' ' A' ' 116' ' ' GLY . 29.6 t0 -58.28 123.66 16.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.88 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 36.3 ttp -71.77 -2.83 18.97 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.865 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -99.87 -49.91 4.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.094 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 18.7 p -102.15 -28.2 12.45 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.127 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 82.68 25.31 50.65 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.504 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 48.1 mtmt -99.99 147.08 25.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.757 0.313 . . . . 0.0 110.923 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 5.0 t -50.18 113.46 0.87 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.813 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 41.5 mttt -63.6 -51.52 64.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.898 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 148.65 -40.02 0.93 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.476 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.568 ' CE2' HG11 ' A' ' 110' ' ' VAL . 10.1 p90 -100.03 149.43 23.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.934 0.397 . . . . 0.0 110.898 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -130.88 176.94 18.75 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.505 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -123.78 139.25 54.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.884 0.373 . . . . 0.0 110.867 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.517 HG11 ' CZ ' ' A' ' 126' ' ' PHE . 42.9 t -139.67 113.31 6.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.124 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 24.4 t -102.83 149.6 24.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.843 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.517 ' CZ ' HG11 ' A' ' 124' ' ' VAL . 1.6 m-85 -129.29 141.56 51.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.874 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.494 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 82.7 m-85 -56.12 -41.16 74.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.882 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 12.7 m120 -109.21 155.28 21.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.905 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.573 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 26.8 tttt -68.51 -40.16 80.94 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.891 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.422 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.9 OUTLIER -60.87 -58.92 6.41 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.911 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.422 ' C ' ' O ' ' A' ' 130' ' ' TRP . 78.5 m-20 -36.07 -41.57 0.25 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.871 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . 0.467 ' HB3' ' CD1' ' A' ' 126' ' ' PHE . . . -80.51 -54.71 5.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.1 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -42.29 -54.28 3.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.898 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -45.42 -51.87 10.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.913 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.461 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -60.95 -56.64 18.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.114 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 85.8 mt -37.76 -35.32 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.147 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -90.07 -59.22 2.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.937 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 25.2 mm-40 -63.64 -59.49 4.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.919 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.506 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 78.3 mmm -57.08 -40.09 76.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.897 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.436 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -52.15 118.65 7.7 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.519 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.83 -24.89 29.75 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.556 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . 0.409 ' NE2' ' HA ' ' A' ' 142' ' ' GLN . 8.7 mm-40 -56.64 -177.26 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.823 0.344 . . . . 0.0 110.901 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . 0.469 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 13.6 m95 -120.42 131.32 54.73 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.914 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 41.6 tp -128.97 129.17 45.08 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.942 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 71.66 -6.07 9.84 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.467 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 123.05 -10.54 8.81 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.504 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 17.1 mtt85 -125.84 147.76 49.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.741 0.305 . . . . 0.0 110.857 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . 0.469 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 22.6 mt-30 -51.61 169.46 0.06 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.927 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.5 pt -140.62 151.19 20.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.14 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.45 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 16.9 ptp180 -113.74 118.79 35.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.862 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.436 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 72.2 p -112.08 125.28 53.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.153 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 11.2 m120 -152.76 179.13 8.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.868 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . 0.416 ' O ' ' C ' ' A' ' 154' ' ' ALA . 15.0 m95 -83.45 100.08 10.5 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.929 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.416 ' C ' ' O ' ' A' ' 153' ' ' TRP . . . -36.41 -50.96 0.79 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.097 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 54.4 p -116.44 121.46 41.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.114 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 4.7 tmm_? -146.48 109.15 4.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.839 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 85.0 mttt -121.57 133.78 24.35 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.548 0.69 . . . . 0.0 110.858 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 152.85 69.42 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.659 2.24 . . . . 0.0 112.367 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 161.22 46.76 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.68 2.253 . . . . 0.0 112.349 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -88.12 154.2 51.97 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.569 0.699 . . . . 0.0 111.1 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 -2.86 10.87 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.681 2.254 . . . . 0.0 112.359 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 27.3 ttpt -153.72 135.58 14.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.901 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 10.9 t -130.19 154.37 47.61 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.821 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 8.1 m -91.42 153.9 19.54 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.142 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -92.87 176.78 6.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.913 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -122.82 100.23 6.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.889 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 1.3 t -99.64 140.34 33.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.844 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -59.27 170.61 0.91 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.914 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 8.8 t -117.01 144.05 45.03 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.109 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 13.3 tttp -121.34 157.01 31.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.927 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 10.2 pt20 -98.88 174.02 6.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.885 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 2.7 m -163.85 174.16 11.86 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.833 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -162.71 83.02 0.12 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.503 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 176.75 6.33 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.707 2.271 . . . . 0.0 112.345 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 61.5 m -154.1 176.73 11.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.893 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 1.4 t -142.83 161.77 37.22 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.89 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.477 -179.96 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.422 ' O ' ' C ' ' A' ' 65' ' ' SER . 73.5 m -153.06 129.21 10.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.854 0.359 . . . . 0.0 110.897 -179.723 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' SER . . . . . 0.422 ' C ' ' O ' ' A' ' 64' ' ' SER . 6.5 t -36.71 115.89 0.4 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.856 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 105.1 -79.53 0.28 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.463 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 49.2 m -87.21 111.38 20.94 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.877 0.37 . . . . 0.0 110.884 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 37.5 t -85.02 -47.68 9.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.875 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.91 174.76 47.34 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.432 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 45.5 mt-30 -87.54 7.52 29.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.847 0.356 . . . . 0.0 110.893 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -108.81 121.65 45.53 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.884 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? 64.88 43.73 3.85 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.888 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -63.39 156.67 25.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.837 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.1 p 49.82 53.59 12.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.141 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 83.3 p -84.58 -35.95 22.41 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.847 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -79.28 -25.28 42.51 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.887 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 27.2 m170 -75.82 145.72 40.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.898 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.567 ' CE1' ' HB2' ' A' ' 129' ' ' LYS . 46.9 m-85 -100.19 120.44 39.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.889 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.474 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.4 OUTLIER -87.21 144.24 26.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.84 179.984 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 69.4 t -120.22 144.16 29.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.141 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 19.7 t80 -95.63 134.66 38.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.877 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.439 ' CG1' HD21 ' A' ' 85' ' ' LEU . 2.7 t -132.62 129.1 58.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.11 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.464 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -134.9 179.89 17.19 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.479 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 6.6 t0 57.75 45.05 19.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.82 0.343 . . . . 0.0 110.845 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.439 HD21 ' CG1' ' A' ' 82' ' ' VAL . 18.5 mt -100.2 131.72 45.98 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.902 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -52.92 154.1 5.39 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.671 0.748 . . . . 0.0 110.842 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.76 -16.0 37.37 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.654 2.236 . . . . 0.0 112.356 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -90.54 -6.53 54.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.853 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.466 ' CD1' ' HA3' ' A' ' 145' ' ' GLY . 42.6 mm -78.44 137.42 22.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.142 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.8 t -119.09 174.6 6.22 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.088 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 24.5 m -49.41 -47.31 48.03 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.158 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.413 ' O ' ' C ' ' A' ' 93' ' ' ASP . 37.3 mt-10 -56.27 -56.4 21.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.844 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.456 ' CB ' HG21 ' A' ' 89' ' ' ILE . 3.2 m-20 -36.51 -58.26 0.72 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.865 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.441 HG23 ' CG2' ' A' ' 124' ' ' VAL . 14.0 mt -47.43 -59.5 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.159 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.501 ' O ' ' N ' ' A' ' 99' ' ' ALA . 19.2 mtmt -46.64 -39.44 11.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.892 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.26 -35.03 76.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.082 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.75 -54.92 9.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.109 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -87.35 5.37 38.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.896 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.501 ' N ' ' O ' ' A' ' 95' ' ' LYS . . . -56.63 -60.41 9.38 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.597 0.713 . . . . 0.0 111.129 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.476 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.7 Cg_endo -69.82 -1.01 7.79 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.677 2.251 . . . . 0.0 112.287 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -100.07 12.63 36.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.866 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.45 146.23 6.69 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.53 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 70.7 mtt180 -55.5 125.72 22.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.756 0.313 . . . . 0.0 110.901 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.472 HG21 ' CG1' ' A' ' 124' ' ' VAL . 11.9 mt -100.03 133.64 42.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.128 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -102.5 -61.98 1.33 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.852 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -100.34 103.42 14.82 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.846 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -133.66 124.96 27.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.105 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 -161.32 163.21 30.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 54.9 t -111.97 125.23 69.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.118 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.506 HG21 ' CD2' ' A' ' 121' ' ' TYR . 41.4 t -57.28 135.91 20.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.137 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 18.6 mttp -135.67 150.8 49.71 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.891 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.459 ' O ' ' N ' ' A' ' 116' ' ' GLY . 15.6 t0 -59.68 123.18 16.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.861 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 26.9 ptm -75.05 -2.27 26.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.89 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.0 -38.75 9.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.081 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 25.9 p -116.18 -33.01 5.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.165 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 91.27 25.6 23.48 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.471 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 68.3 mmtt -98.94 157.17 16.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.794 0.331 . . . . 0.0 110.866 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 2.7 t -57.27 121.83 11.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.876 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 35.3 mttt -75.48 -48.02 24.5 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.896 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 142.18 -43.67 1.04 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.482 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.506 ' CD2' HG21 ' A' ' 110' ' ' VAL . 14.8 p90 -98.74 146.45 25.88 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.886 0.374 . . . . 0.0 110.933 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -129.86 179.16 17.0 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.489 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -127.11 140.1 52.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.898 0.38 . . . . 0.0 110.916 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.521 HG12 ' CZ ' ' A' ' 126' ' ' PHE . 61.9 t -137.84 116.65 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.152 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 9.5 t -104.81 148.02 27.09 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.873 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.521 ' CZ ' HG12 ' A' ' 124' ' ' VAL . 1.4 m-85 -128.37 156.38 43.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.892 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -65.16 -41.31 94.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.901 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -119.18 150.82 39.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.907 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.567 ' HB2' ' CE1' ' A' ' 78' ' ' PHE . 30.3 tttt -58.64 -65.68 0.62 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.927 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.45 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -33.17 -59.79 0.35 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.917 179.88 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 70.7 m-20 -37.78 -46.53 0.93 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.822 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . 0.413 ' N ' ' O ' ' A' ' 129' ' ' LYS . . . -73.15 -59.19 2.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.076 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -40.63 -51.93 2.94 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 30.4 t-20 -46.31 -42.07 14.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.893 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -72.67 -54.31 9.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.109 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 96.0 mt -40.56 -31.95 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.109 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -84.84 -64.9 1.08 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.957 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -62.01 -62.55 1.7 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.912 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 68.8 mmm -49.76 -43.72 48.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.862 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.443 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -51.43 109.64 0.84 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.46 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 105.95 -28.23 14.67 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.482 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 54.1 mm-40 -55.01 179.88 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.819 0.343 . . . . 0.0 110.941 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . 0.482 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 13.3 m95 -116.2 127.18 54.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.912 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 32.8 tp -126.69 130.67 50.84 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.939 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . 0.466 ' HA3' ' CD1' ' A' ' 89' ' ' ILE . . . 70.62 -3.61 11.61 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.474 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 120.86 -13.8 9.79 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.515 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 47.5 mtt180 -124.93 153.57 42.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 110.835 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . 0.482 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 20.6 mt-30 -61.49 158.51 14.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 21.6 pt -130.86 153.07 38.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.145 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.464 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 2.8 ptp180 -111.68 115.95 29.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.887 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.443 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 58.5 p -110.21 128.12 55.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.142 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 19.8 m-20 -159.94 168.68 25.13 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 14.1 m95 -61.42 139.92 58.13 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.918 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -120.96 -46.97 2.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.104 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 5.9 t -50.51 -43.49 55.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.118 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 33.4 ttt180 -158.67 158.85 34.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.876 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.461 ' CD ' ' HD2' ' A' ' 158' ' ' PRO . 13.3 tptm -92.38 136.56 25.38 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.569 0.7 . . . . 0.0 110.919 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . 0.461 ' HD2' ' CD ' ' A' ' 157' ' ' LYS . 53.2 Cg_endo -69.82 146.71 60.67 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.693 2.262 . . . . 0.0 112.314 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 158.55 56.59 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.708 2.272 . . . . 0.0 112.307 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -66.05 145.79 99.01 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.589 0.709 . . . . 0.0 111.066 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 98.26 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.645 2.23 . . . . 0.0 112.391 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 2.8 ptpp? -76.2 132.61 40.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.861 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 1.8 t -122.41 88.45 2.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -145.01 129.51 17.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.15 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -70.75 104.24 2.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.918 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -174.15 154.83 2.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.863 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 59.8 p -92.81 159.53 15.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.872 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -162.07 147.44 13.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 4.4 t -144.03 132.73 22.41 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.098 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 20.9 tttp -165.47 144.59 6.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.894 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . 0.423 ' HG2' ' N ' ' A' ' 172' ' ' SER . 41.9 tt0 -174.96 151.82 1.41 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.899 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' SER . . . . . 0.423 ' N ' ' HG2' ' A' ' 171' ' ' GLN . 4.2 t -127.4 168.05 15.38 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.845 -179.827 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -163.96 83.14 0.11 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.507 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 140.05 41.92 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.714 2.276 . . . . 0.0 112.36 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 15.5 m -122.54 167.78 12.95 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.896 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 5.9 m -69.01 160.79 30.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.85 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.548 -179.967 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.526 -0.229 . . . . 0.0 112.526 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 85.5 p 44.15 42.69 5.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.882 0.372 . . . . 0.0 110.878 -179.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 80.2 p -126.75 147.01 50.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.84 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 160.8 118.35 0.48 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.483 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 8.0 m -106.89 175.4 5.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.817 0.342 . . . . 0.0 110.918 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.0 t -134.34 42.83 2.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -104.67 -162.23 24.15 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.529 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 18.4 pt20 -117.59 -47.71 2.62 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.826 0.346 . . . . 0.0 110.93 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 11.0 mptt -108.86 -49.81 3.09 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 14.3 ptpt -166.06 156.01 12.31 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -125.84 85.0 2.33 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.837 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 53.5 p -90.93 39.72 1.0 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.135 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 66.3 m -79.76 -42.24 24.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 6.7 m-80 -113.59 43.07 1.85 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.877 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 59.6 m170 -123.53 152.95 41.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.853 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -102.23 116.42 32.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.91 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.484 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.7 OUTLIER -83.68 155.6 23.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.858 -179.971 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 36.8 t -134.27 135.34 54.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.112 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 15.4 t80 -87.44 128.15 35.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.84 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.437 HG21 ' CZ ' ' A' ' 98' ' ' PHE . 4.0 t -127.96 109.86 20.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.103 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -115.31 -176.91 18.65 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.519 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 59.9 40.26 19.34 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.844 0.354 . . . . 0.0 110.883 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 11.5 mt -99.04 127.37 44.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.886 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.04 154.19 5.52 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.633 0.73 . . . . 0.0 110.867 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.88 -11.74 31.28 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.67 2.247 . . . . 0.0 112.294 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -92.32 -8.07 46.13 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.894 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.471 HG21 ' N ' ' A' ' 90' ' ' THR . 45.7 mm -78.27 138.06 20.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.147 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.471 ' N ' HG21 ' A' ' 89' ' ' ILE . 14.5 t -119.55 163.73 16.88 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.118 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 27.7 m -38.85 -46.6 1.31 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.168 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.415 ' O ' ' C ' ' A' ' 93' ' ' ASP . 21.2 mt-10 -56.61 -58.95 5.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.853 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 92' ' ' GLU . 3.9 m-20 -36.42 -57.94 0.73 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.852 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 8.1 mt -47.44 -58.59 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.103 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.437 ' HG3' ' CB ' ' A' ' 107' ' ' ALA . 26.1 mtmt -49.28 -42.14 40.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.893 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -59.09 -28.77 66.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.127 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -74.75 -54.75 6.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.437 ' CZ ' HG21 ' A' ' 82' ' ' VAL . 28.6 m-85 -86.5 8.34 22.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.913 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.477 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -61.61 -60.31 10.77 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.621 0.724 . . . . 0.0 111.145 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.477 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.78 -0.95 7.68 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.681 2.254 . . . . 0.0 112.402 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -100.18 -4.48 29.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.83 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 146.46 156.87 7.09 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.517 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 31.9 mtm180 -64.84 123.79 20.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.818 0.342 . . . . 0.0 110.867 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.439 HG22 ' CG1' ' A' ' 124' ' ' VAL . 11.1 mt -100.42 139.12 22.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.18 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 8.3 t -110.03 -62.47 1.5 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -100.73 105.28 16.6 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.888 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . 0.437 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -134.16 125.73 28.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.12 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 15.0 ptt180 -160.86 161.32 31.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.87 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 72.9 t -111.5 119.45 59.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.173 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.525 HG12 ' CE2' ' A' ' 121' ' ' TYR . 42.8 t -51.45 133.13 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.113 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -132.98 151.59 52.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.458 ' O ' ' N ' ' A' ' 116' ' ' GLY . 39.5 t0 -60.33 119.29 7.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.883 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 22.7 ptp -68.68 -2.28 8.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.913 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -97.55 -47.16 5.76 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.125 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 43.2 p -110.05 -34.5 6.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.162 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.458 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 92.66 31.98 8.4 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.468 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt -99.52 148.69 24.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.779 0.323 . . . . 0.0 110.88 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 19.5 t -54.92 102.09 0.06 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.832 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 42.2 mttt -52.02 -53.46 41.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.883 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 149.75 -39.82 0.88 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.488 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.525 ' CE2' HG12 ' A' ' 110' ' ' VAL . 5.8 p90 -100.07 161.27 13.71 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.931 0.396 . . . . 0.0 110.887 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -142.27 174.96 23.06 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.455 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -124.59 137.98 54.35 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.896 0.379 . . . . 0.0 110.932 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.468 HG12 ' CZ ' ' A' ' 126' ' ' PHE . 71.0 t -138.11 120.38 18.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.105 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 21.1 m -103.06 150.88 23.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.828 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.468 ' CZ ' HG12 ' A' ' 124' ' ' VAL . 15.3 m-85 -131.03 142.89 50.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.862 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -60.9 -32.53 71.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.852 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 21.6 m-20 -117.66 169.58 9.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.849 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.498 ' HE3' ' CH2' ' A' ' 153' ' ' TRP . 20.6 tptm -78.99 -53.16 7.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.89 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.415 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.8 OUTLIER -48.07 -59.83 3.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.914 179.925 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 130' ' ' TRP . 79.4 m-20 -35.83 -40.63 0.19 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.908 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.75 -62.76 1.56 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.096 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -42.41 -58.88 2.05 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.877 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -39.97 -47.39 2.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.889 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.464 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -67.57 -54.45 19.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.079 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 54.9 mt -41.66 -35.37 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.163 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -88.62 -54.91 3.94 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.98 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 5.0 mm100 -68.11 -62.88 1.2 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.906 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.464 ' N ' ' O ' ' A' ' 135' ' ' ALA . 84.6 mmm -52.96 -35.64 59.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.874 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.442 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -52.97 110.6 1.34 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.514 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 100.97 -22.73 38.28 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.481 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 33.5 mm-40 -55.05 169.8 0.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.786 0.326 . . . . 0.0 110.925 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . 0.412 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 14.7 m95 -107.95 113.09 26.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.908 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.465 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 56.9 tp -103.98 129.74 51.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.899 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 68.83 -77.77 0.28 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.511 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -155.17 13.74 0.46 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.482 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 32.2 mtp85 -153.17 160.8 42.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . 0.412 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 24.0 mt-30 -62.03 168.7 3.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.933 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.465 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 22.4 pt -140.2 144.47 27.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.13 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 3.7 ttm180 -105.5 124.21 49.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.907 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.442 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 61.9 p -117.52 132.54 56.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.132 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -157.2 169.17 25.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . 0.498 ' CH2' ' HE3' ' A' ' 129' ' ' LYS . 7.3 m95 -65.94 116.57 7.23 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.982 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -64.89 -47.27 78.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.106 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 66.6 p -58.02 149.13 24.01 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.138 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 37.9 mmt180 -119.84 165.35 14.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.882 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 14.0 ptmt -163.11 150.45 10.97 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.61 0.719 . . . . 0.0 110.884 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 148.33 64.59 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.711 2.274 . . . . 0.0 112.291 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 167.64 23.85 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.706 2.271 . . . . 0.0 112.368 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -80.02 158.45 72.46 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.543 0.687 . . . . 0.0 111.139 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.69 174.71 9.05 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.734 2.29 . . . . 0.0 112.363 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . 0.435 ' HG2' ' N ' ' A' ' 163' ' ' SER . 40.9 tttm -174.1 156.36 2.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.904 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' SER . . . . . 0.435 ' N ' ' HG2' ' A' ' 162' ' ' LYS . 5.0 t -171.45 176.62 3.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.862 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 4.8 t -149.23 122.45 8.95 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.181 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 9.1 p90 -95.65 118.25 31.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.955 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? -118.88 147.49 43.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.923 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 39.3 t -154.32 131.1 10.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.864 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 9.4 p-10 -165.88 118.82 1.12 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.918 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 29.5 m -150.09 135.04 17.77 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.12 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.5 129.89 15.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.854 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -128.71 142.51 50.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.92 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 2.7 t -166.72 123.23 1.23 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.804 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 154.66 66.0 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.435 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 178.17 4.84 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.665 2.243 . . . . 0.0 112.357 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 25.4 p -139.75 165.98 25.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' SER . . . . . 0.401 ' O ' ' C ' ' A' ' 177' ' ' GLY . 16.2 m -73.53 121.68 20.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.881 -179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 176' ' ' SER . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.518 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.515 -0.234 . . . . 0.0 112.515 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 68.6 p -107.5 119.71 40.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.918 0.39 . . . . 0.0 110.844 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 34.3 t -126.58 89.17 2.95 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.876 -179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -56.66 126.95 42.99 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.538 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 46.9 m -123.45 -50.51 1.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.887 0.375 . . . . 0.0 110.844 -179.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 75.7 m 41.1 42.36 1.59 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.845 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -128.49 -45.81 0.19 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.493 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 20.6 mm-40 -95.04 167.58 11.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.857 0.361 . . . . 0.0 110.958 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -172.95 152.95 2.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.921 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 16.5 mmmt -80.19 49.4 1.11 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.907 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.405 ' O ' ' N ' ' A' ' 75' ' ' SER . 12.4 p-10 -94.91 33.99 1.42 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.868 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.54 75.74 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.176 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' SER . . . . . 0.405 ' N ' ' O ' ' A' ' 73' ' ' ASP . 74.3 m -92.68 152.82 19.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.882 -179.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.6 m-20 55.93 30.92 16.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.909 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 9.0 m170 -118.67 159.84 22.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.873 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 -115.53 112.11 21.72 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.859 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.476 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.5 OUTLIER -82.51 142.15 32.08 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.867 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 56.0 t -120.94 148.94 23.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.159 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -100.69 136.97 39.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.887 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.413 HG21 ' CZ ' ' A' ' 98' ' ' PHE . 3.5 t -136.77 109.66 8.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.134 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -120.97 179.57 16.3 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.484 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 4.0 t70 62.51 43.08 8.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.827 0.346 . . . . 0.0 110.838 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.1 mt -103.31 135.66 44.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.934 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.03 153.9 5.79 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.651 0.739 . . . . 0.0 110.901 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -16.56 37.67 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.678 2.252 . . . . 0.0 112.374 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -89.29 -7.01 56.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.907 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.463 HG22 ' CB ' ' A' ' 93' ' ' ASP . 40.3 mm -75.54 138.46 20.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.127 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.5 t -119.14 168.2 11.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.152 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 7.4 m -46.36 -44.12 16.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.112 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 29.6 mt-10 -58.24 -51.26 70.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.901 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.463 ' CB ' HG22 ' A' ' 89' ' ' ILE . 4.6 m-20 -44.04 -55.97 4.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.437 HG23 ' CG2' ' A' ' 124' ' ' VAL . 8.4 mt -49.53 -58.57 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.139 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.466 ' HG3' ' CB ' ' A' ' 107' ' ' ALA . 24.9 mtmt -48.99 -41.71 35.33 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.883 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -59.8 -31.89 70.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.108 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -72.52 -56.97 4.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.104 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.413 ' CZ ' HG21 ' A' ' 82' ' ' VAL . 33.5 m-85 -83.79 11.94 6.75 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.88 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.482 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -67.43 -59.95 6.41 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.583 0.706 . . . . 0.0 111.113 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.482 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.77 -0.83 7.48 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.7 2.266 . . . . 0.0 112.319 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.412 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 70.8 m-85 -99.77 -13.37 19.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.926 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 156.59 155.14 7.3 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.508 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.438 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 35.8 mtt-85 -63.31 123.21 18.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.795 0.331 . . . . 0.0 110.897 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.471 HG21 ' CG1' ' A' ' 124' ' ' VAL . 12.6 mt -100.49 142.6 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.133 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.458 ' HB2' ' CZ ' ' A' ' 127' ' ' PHE . 38.6 t -114.94 -61.53 1.74 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.827 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -100.97 101.03 11.74 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.829 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . 0.466 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -130.24 124.24 32.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.117 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 10.2 ptp180 -160.72 153.78 21.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.88 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 69.2 t -102.3 125.94 56.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.57 HG22 ' CE2' ' A' ' 121' ' ' TYR . 56.6 t -55.61 139.99 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.108 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . 0.463 ' N ' HG13 ' A' ' 110' ' ' VAL . 49.7 mttt -138.79 149.22 44.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.889 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.405 ' O ' ' N ' ' A' ' 116' ' ' GLY . 48.8 t0 -63.1 121.98 14.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.859 179.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 11.4 ptp -71.4 -1.45 13.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.901 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.97 -54.28 3.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.079 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 26.8 p -99.61 -24.99 14.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.186 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 81.35 27.17 49.42 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.457 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 73.6 mmtt -96.75 164.88 12.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.776 0.322 . . . . 0.0 110.914 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 24.6 t -66.33 115.04 5.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.86 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 7.0 mmtm -64.93 -40.92 95.78 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.894 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 130.44 -46.78 1.05 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.481 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.57 ' CE2' HG22 ' A' ' 110' ' ' VAL . 29.6 p90 -100.02 141.18 33.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.905 0.383 . . . . 0.0 110.947 -179.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -125.28 178.64 16.49 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.513 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 62.5 m-85 -121.25 139.9 52.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.878 0.37 . . . . 0.0 110.874 -179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.558 HG11 ' CZ ' ' A' ' 126' ' ' PHE . 63.9 t -136.56 115.68 15.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.118 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 43.9 t -101.63 151.43 22.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.833 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.558 ' CZ ' HG11 ' A' ' 124' ' ' VAL . 1.8 m-85 -131.0 148.04 52.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.88 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.458 ' CZ ' ' HB2' ' A' ' 105' ' ' SER . 68.0 m-85 -64.91 -40.41 95.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.867 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -111.73 155.27 23.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.877 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.466 ' O ' ' C ' ' A' ' 130' ' ' TRP . 38.4 tttt -68.38 -63.4 1.07 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.893 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.466 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -33.19 -60.09 0.34 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.949 179.897 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.4 ' C ' ' O ' ' A' ' 130' ' ' TRP . 61.9 m-20 -37.77 -54.83 1.22 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.888 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -60.09 -64.95 0.77 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.085 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -39.37 -58.57 1.2 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.919 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -42.01 -50.29 4.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.878 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.468 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -66.79 -59.95 3.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.062 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 93.4 mt -37.67 -37.74 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.5 mt-30 -84.42 -61.66 1.75 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.935 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -61.24 -59.75 4.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.907 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.468 ' N ' ' O ' ' A' ' 135' ' ' ALA . 86.9 mmm -57.38 -36.33 71.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.855 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -52.39 104.31 0.17 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.495 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 111.86 -31.72 6.85 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.488 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 17.2 mm-40 -49.41 179.82 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.798 0.332 . . . . 0.0 110.923 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . 0.425 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 13.7 m95 -115.44 126.89 54.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.893 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.463 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 40.7 tp -123.29 126.78 47.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . 0.4 ' HA3' ' CD1' ' A' ' 89' ' ' ILE . . . 71.66 -6.12 9.71 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.549 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 123.7 -11.11 8.42 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.485 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 17.8 mtt-85 -125.58 146.9 49.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.789 0.328 . . . . 0.0 110.866 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . 0.425 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 22.4 mt-30 -56.18 158.64 3.93 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.921 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.463 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 21.0 pt -132.29 143.56 39.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.143 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 11.2 ptt180 -107.07 109.32 21.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.876 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 62.4 p -101.0 131.98 46.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.188 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 17.1 t30 -155.35 172.88 17.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.881 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 82.8 m95 -72.93 119.67 17.49 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.912 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -52.93 -59.85 4.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.098 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 9.3 t -42.36 160.28 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.178 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 18.0 ptt180 -130.04 146.02 51.69 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.882 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.428 ' CD ' ' HD2' ' A' ' 158' ' ' PRO . 0.0 OUTLIER -117.92 137.07 24.05 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-O 121.626 0.727 . . . . 0.0 110.909 179.972 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . 0.428 ' HD2' ' CD ' ' A' ' 157' ' ' LYS . 53.6 Cg_endo -69.73 145.39 57.18 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.689 2.259 . . . . 0.0 112.291 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.81 167.04 25.67 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.695 2.263 . . . . 0.0 112.368 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -164.16 143.64 6.22 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.56 0.695 . . . . 0.0 111.097 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 137.71 36.01 Favored 'Trans proline' 0 N--CA 1.465 -0.179 0 C-N-CA 122.72 2.28 . . . . 0.0 112.356 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . 0.444 ' HD2' ' N ' ' A' ' 162' ' ' LYS . 0.0 OUTLIER -154.6 142.31 19.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.894 179.955 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 26.9 t -173.75 122.05 0.33 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.871 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 14.6 t -148.33 118.77 7.38 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.156 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . 0.498 ' O ' ' CG ' ' A' ' 165' ' ' TYR . 8.3 p90 -168.65 110.88 0.54 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.876 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -109.76 97.82 7.28 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.873 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 26.5 t -172.01 159.32 4.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.84 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -158.27 151.54 23.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.875 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 74.9 p -133.51 132.52 41.06 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.15 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 2.2 tmtp? -109.12 -45.4 3.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.926 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -157.96 121.82 4.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.913 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 88.2 p -112.62 133.95 54.39 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.825 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 69.18 83.5 0.16 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.441 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 108.04 2.0 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.688 2.258 . . . . 0.0 112.349 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 44.9 t -128.09 125.06 38.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.9 -179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 61.4 p -166.86 132.04 2.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.866 -179.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.527 179.986 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 74.4 m -132.14 135.28 46.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.916 0.388 . . . . 0.0 110.86 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 13.6 t -45.41 -51.67 11.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.855 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 141.74 135.65 3.15 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.451 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 5.1 m -95.24 104.14 16.02 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.831 0.348 . . . . 0.0 110.873 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.8 p -56.87 161.81 2.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.849 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 151.3 116.94 0.75 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.495 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 14.6 mm-40 -62.6 97.46 0.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.885 0.374 . . . . 0.0 110.892 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 27.6 mtmm -73.01 88.07 1.37 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.889 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.52 -23.5 56.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.909 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -88.4 160.64 17.48 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.88 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.426 HG21 ' CG ' ' A' ' 106' ' ' ASP . 5.4 p -120.33 33.94 5.4 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.153 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 90.8 p -63.63 -52.42 60.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.837 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -99.2 41.56 1.14 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.907 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . 0.401 ' ND1' HG23 ' A' ' 74' ' ' THR . 8.9 m170 -113.48 158.04 21.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.86 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.543 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 5.1 m-85 -108.75 110.12 21.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.84 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.448 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.6 OUTLIER -83.99 149.09 26.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.836 -179.987 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.46 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 39.7 t -125.0 141.25 45.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.148 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.1 t80 -92.31 134.03 35.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.894 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.466 HG22 ' CZ ' ' A' ' 98' ' ' PHE . 12.2 t -132.62 112.95 19.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.1 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -120.52 -179.63 16.31 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.431 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.408 ' O ' ' O ' ' A' ' 148' ' ' GLN . 5.2 m-20 63.9 43.79 5.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.812 0.339 . . . . 0.0 110.878 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.414 HD23 ' CG1' ' A' ' 82' ' ' VAL . 9.6 mt -102.37 129.16 48.76 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.902 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.1 t -53.26 154.27 5.99 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.705 0.764 . . . . 0.0 110.849 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -7.65 21.6 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.719 2.28 . . . . 0.0 112.341 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -99.98 -8.67 23.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.864 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.465 HG21 ' CB ' ' A' ' 93' ' ' ASP . 38.6 mm -75.29 141.2 16.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.14 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.0 t -119.46 173.13 7.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.14 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.473 ' CG2' ' HA ' ' A' ' 108' ' ' ARG . 88.0 m -50.22 -47.28 54.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.099 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -54.74 -52.97 60.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.884 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.465 ' CB ' HG21 ' A' ' 89' ' ' ILE . 1.6 m-20 -42.72 -55.78 3.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.821 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 10.2 mt -49.5 -58.66 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.112 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.459 ' O ' ' N ' ' A' ' 99' ' ' ALA . 25.3 mtmt -47.87 -39.51 18.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.82 -32.72 72.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.095 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.416 ' CB ' ' HE2' ' A' ' 139' ' ' MET . . . -71.71 -51.85 20.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.094 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.466 ' CZ ' HG22 ' A' ' 82' ' ' VAL . 14.2 m-85 -93.51 13.2 22.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.882 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.49 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -66.76 -59.82 7.33 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.538 0.685 . . . . 0.0 111.081 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.49 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.3 Cg_endo -69.78 -0.61 7.18 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.685 2.257 . . . . 0.0 112.305 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -99.75 -1.33 38.0 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.846 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 142.54 143.24 4.15 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.451 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 68.4 mtm180 -53.47 123.38 11.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.795 0.331 . . . . 0.0 110.891 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 20.1 mt -100.0 137.34 27.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.167 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.468 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 7.5 p -105.1 -62.3 1.36 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.884 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.426 ' CG ' HG21 ' A' ' 74' ' ' THR . 0.8 OUTLIER -100.74 105.14 16.44 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 179.948 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . 0.444 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -135.18 125.29 26.02 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.13 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.473 ' HA ' ' CG2' ' A' ' 91' ' ' THR . 8.2 ptp180 -160.22 169.17 23.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 95.8 t -116.93 117.54 55.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.133 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.568 HG21 ' CE2' ' A' ' 121' ' ' TYR . 60.6 t -47.1 141.08 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.172 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . 0.466 ' N ' HG11 ' A' ' 110' ' ' VAL . 80.1 mttt -140.31 152.09 45.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.902 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -63.88 121.55 14.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.851 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 1.1 pmm? -74.89 -1.47 22.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.856 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.14 -44.37 6.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.097 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 52.1 p -111.12 -35.16 5.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.175 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 94.63 31.01 8.08 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.505 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 22.9 mmtm -99.53 164.39 12.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.822 0.344 . . . . 0.0 110.891 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 29.6 t -65.83 109.88 2.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.866 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 11.3 mmtp -59.78 -39.36 84.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.878 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 128.6 -47.16 1.04 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.549 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.568 ' CE2' HG21 ' A' ' 110' ' ' VAL . 12.8 p90 -99.94 146.56 26.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.969 0.414 . . . . 0.0 110.902 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -127.96 178.03 17.29 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.459 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 36.9 m-85 -121.73 140.12 52.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.912 0.386 . . . . 0.0 110.908 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.491 HG12 ' CZ ' ' A' ' 126' ' ' PHE . 47.4 t -136.77 113.75 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.108 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 69.0 m -102.04 150.48 23.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.867 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.497 ' N ' ' CD1' ' A' ' 126' ' ' PHE . 1.4 m-85 -130.77 143.33 50.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.846 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.468 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 22.7 m-85 -50.27 -48.89 54.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.904 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -106.85 173.31 6.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.886 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.543 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 3.5 ttmt -79.36 -51.8 8.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.927 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.42 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.0 OUTLIER -48.03 -58.4 4.49 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.887 179.952 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 130' ' ' TRP . 81.9 m-20 -35.72 -42.74 0.26 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.86 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . 0.46 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -78.7 -60.89 2.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.128 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.4 ' C ' ' O ' ' A' ' 132' ' ' ALA . 18.6 mt-10 -37.83 -55.56 1.18 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -43.15 -55.51 3.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.902 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.466 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -59.21 -54.66 44.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.075 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 93.0 mt -38.62 -36.57 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.14 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -87.94 -60.8 1.87 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.908 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 20.1 mm-40 -61.32 -59.49 5.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.9 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.466 ' N ' ' O ' ' A' ' 135' ' ' ALA . 87.3 mmm -59.32 -35.57 74.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.429 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -53.31 111.03 1.56 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.466 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 102.11 -28.86 14.03 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -50.63 178.89 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.746 0.308 . . . . 0.0 110.898 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . 0.565 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 14.3 m95 -115.31 119.55 36.66 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.959 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.469 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 60.6 tp -109.5 129.5 55.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.918 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 70.24 -78.57 0.43 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.476 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -156.04 14.08 0.4 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.517 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 66.7 mtt180 -153.5 154.38 34.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.744 0.307 . . . . 0.0 110.883 -179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . 0.565 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 15.8 mt-30 -55.91 167.8 0.54 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.914 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.469 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 28.8 pt -140.81 147.69 22.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.155 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 15.8 ptt180 -111.83 120.47 42.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.805 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.429 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 82.5 p -111.02 133.12 53.66 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -155.06 165.52 36.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.886 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 12.9 m95 -62.04 102.78 0.31 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.945 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -39.92 -40.75 1.06 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.107 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.401 ' HB ' ' CD ' ' A' ' 157' ' ' LYS . 39.9 p -96.75 128.49 43.74 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.189 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 35.0 ttt180 -85.91 94.7 9.25 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.827 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.401 ' CD ' ' HB ' ' A' ' 155' ' ' THR . 0.8 OUTLIER -128.84 142.81 46.31 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.58 0.705 . . . . 0.0 110.86 179.967 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 148.7 65.57 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.706 2.271 . . . . 0.0 112.295 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 174.71 9.13 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.646 2.231 . . . . 0.0 112.327 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -166.0 145.97 5.34 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.584 0.706 . . . . 0.0 111.118 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.74 134.33 27.77 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.718 2.279 . . . . 0.0 112.335 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 21.8 ttpp -95.08 138.77 32.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.929 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 9.1 t -73.08 -60.66 2.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.84 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 9.3 t -166.47 130.04 2.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.118 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -49.97 -60.55 2.82 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.932 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -171.56 154.96 3.93 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.857 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 6.7 t -133.56 99.22 4.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.859 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -171.88 168.16 6.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 44.0 p -98.81 156.7 16.73 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.149 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 8.4 tmtm? -55.74 131.49 46.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 22.7 tt0 -147.52 149.4 32.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 87.6 p -138.62 172.49 12.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.863 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -139.58 146.38 17.91 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.442 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -171.68 0.5 Allowed 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.753 2.302 . . . . 0.0 112.328 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 23.2 t -157.07 137.73 13.18 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.895 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 1.2 t -153.49 121.83 6.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.848 -179.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.451 179.955 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.272 0 N-CA-C 112.448 -0.261 . . . . 0.0 112.448 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 59.4 p -52.25 -56.81 12.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.927 0.394 . . . . 0.0 110.854 -179.737 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.5 m -58.0 135.43 56.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.891 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -177.81 79.91 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.451 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.0 m -50.84 -58.76 5.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.902 0.382 . . . . 0.0 110.858 -179.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 78.1 p 48.81 44.59 21.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.838 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -146.28 105.25 0.32 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.504 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -109.75 34.94 3.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.815 0.341 . . . . 0.0 110.889 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.448 ' HE3' ' N ' ' A' ' 71' ' ' LYS . 0.0 OUTLIER -51.05 170.59 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.921 179.945 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 13.2 tptt -124.08 -43.75 2.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.863 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 62.2 m-20 -75.21 178.7 5.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.902 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 37.2 p -119.17 78.7 1.32 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.127 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 91.8 p -93.84 143.48 26.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 43.73 35.43 1.04 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.86 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 8.8 m170 -106.49 159.87 15.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.888 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.495 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 75.9 m-85 -108.85 112.38 24.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.42 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.9 OUTLIER -88.49 163.81 15.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.895 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 49.0 t -138.32 143.66 32.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.112 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -98.11 132.08 43.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.854 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.481 HG22 ' CZ ' ' A' ' 98' ' ' PHE . 2.7 t -132.63 109.79 15.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.136 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.431 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -116.3 -179.45 18.03 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.469 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.4 ' O ' ' O ' ' A' ' 148' ' ' GLN . 14.4 m-20 63.8 26.21 14.31 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.891 0.377 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.427 ' CD2' HG11 ' A' ' 82' ' ' VAL . 10.7 mt -83.79 135.59 34.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.951 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -52.93 147.61 15.68 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.717 0.77 . . . . 0.0 110.854 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -6.2 18.04 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.638 2.225 . . . . 0.0 112.344 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -100.61 -5.02 27.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.851 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.463 ' CD1' ' HA3' ' A' ' 145' ' ' GLY . 30.8 mm -74.8 145.29 11.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.124 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.1 t -121.03 165.0 15.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.133 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 22.5 m -43.63 -50.7 7.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.107 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 93' ' ' ASP . 34.3 mt-10 -54.55 -57.26 12.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.892 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.439 ' CB ' HG22 ' A' ' 89' ' ' ILE . 0.5 OUTLIER -35.78 -57.86 0.64 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.89 179.974 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 8.7 mt -47.36 -59.31 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.117 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.467 ' HA ' ' CD1' ' A' ' 104' ' ' ILE . 22.9 mtmt -47.93 -39.21 18.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.926 179.822 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.82 -35.03 75.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.079 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -71.68 -51.81 21.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.09 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.481 ' CZ ' HG22 ' A' ' 82' ' ' VAL . 23.0 m-85 -89.43 16.82 6.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.865 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.474 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -68.05 -60.61 4.98 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.595 0.712 . . . . 0.0 111.102 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.474 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.5 Cg_endo -69.8 -1.43 8.5 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.647 2.232 . . . . 0.0 112.318 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -100.45 11.45 39.43 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.842 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 126.65 133.16 3.79 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.477 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 16.9 mtt180 -46.08 126.75 7.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.799 0.333 . . . . 0.0 110.87 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.467 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 11.0 mt -100.06 138.13 25.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.139 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.523 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 2.6 t -107.61 -62.72 1.39 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -100.56 104.27 15.62 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.842 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . 0.459 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -134.46 125.92 28.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.076 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.43 ' NH1' ' HA ' ' A' ' 110' ' ' VAL . 0.1 OUTLIER -158.88 157.51 31.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.884 -179.911 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 88.3 t -104.82 117.71 50.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.122 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.566 HG22 ' CD2' ' A' ' 121' ' ' TYR . 85.8 t -50.33 143.04 2.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.103 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 33.8 mttm -142.68 157.1 45.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.865 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -71.37 128.03 34.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.858 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 24.8 ptp -76.96 1.06 18.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -99.59 -46.04 5.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.092 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 24.4 p -108.85 -26.28 10.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.169 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 81.5 24.62 56.09 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.479 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 66.8 mttt -97.88 164.59 12.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.814 0.34 . . . . 0.0 110.902 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 2.2 m -59.39 119.04 6.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.855 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.412 ' HB3' ' CE1' ' A' ' 121' ' ' TYR . 24.4 mmtt -71.25 -39.32 71.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.945 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 128.99 -40.5 1.69 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.459 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.566 ' CD2' HG22 ' A' ' 110' ' ' VAL . 7.0 p90 -100.23 156.04 17.44 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.911 0.386 . . . . 0.0 110.956 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.17 174.8 21.53 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.56 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -130.55 139.24 50.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.888 0.375 . . . . 0.0 110.857 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.574 HG11 ' CE1' ' A' ' 126' ' ' PHE . 76.7 t -134.49 133.56 54.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.097 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 32.5 t -113.19 138.58 49.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.83 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.574 ' CE1' HG11 ' A' ' 124' ' ' VAL . 75.2 m-85 -118.65 147.38 43.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.878 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.523 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 23.3 m-85 -61.64 -36.21 80.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 4.7 m-20 -114.75 174.58 5.89 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.866 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.495 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 67.1 tttt -84.12 -39.34 19.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.93 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.42 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -61.15 -53.11 61.12 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.928 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 130' ' ' TRP . 75.6 m-20 -35.88 -52.39 0.73 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.891 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . 0.484 ' HB3' ' CD1' ' A' ' 126' ' ' PHE . . . -64.97 -66.18 0.58 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.096 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.429 ' C ' ' O ' ' A' ' 132' ' ' ALA . 3.8 mm-40 -34.7 -56.5 0.54 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.866 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -42.26 -51.68 4.69 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.924 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -64.7 -55.79 17.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.086 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 87.4 mt -39.2 -33.46 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.14 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 12.2 mt-30 -84.9 -67.38 0.8 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.889 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 -57.73 -61.58 2.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.901 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 64.8 mmm -53.47 -41.1 65.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.868 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.408 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -49.38 104.72 0.11 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.519 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 106.7 -31.16 8.51 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.454 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 50.7 mm-40 -49.33 173.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.823 0.344 . . . . 0.0 110.927 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . 0.462 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 12.9 m95 -108.89 127.41 54.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.899 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.459 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 36.6 tp -128.48 130.76 47.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.887 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . 0.463 ' HA3' ' CD1' ' A' ' 89' ' ' ILE . . . 69.77 -2.09 13.48 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.488 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 117.26 -14.27 13.58 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.48 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 20.1 mtt-85 -124.12 143.25 50.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.804 0.335 . . . . 0.0 110.829 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . 0.462 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 28.4 mt-30 -52.5 160.04 0.92 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.951 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.459 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 21.3 pt -134.15 152.74 34.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.15 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.431 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 10.7 ptp180 -113.24 118.85 35.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.408 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 41.5 p -110.49 133.33 53.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.127 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 60.5 m-20 -163.06 164.43 25.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.887 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 14.3 m95 -58.05 126.61 28.21 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.922 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -75.57 -34.31 60.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.114 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 1.2 p -83.03 20.95 1.12 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.174 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 45.4 ttt180 -174.28 119.92 0.25 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.885 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 26.0 ttpt -126.14 127.35 24.7 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.585 0.707 . . . . 0.0 110.894 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 167.42 24.44 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.668 2.245 . . . . 0.0 112.387 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 157.99 58.55 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.697 2.265 . . . . 0.0 112.376 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -79.49 152.37 75.56 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.6 0.714 . . . . 0.0 111.104 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 136.86 34.06 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.725 2.283 . . . . 0.0 112.319 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 34.3 mtmt -122.52 148.63 44.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.905 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 29.3 t -63.97 116.42 5.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.903 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 38.4 p -118.51 100.65 7.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.099 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 3.4 p90 -69.29 -177.99 1.25 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.901 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -174.67 135.77 0.41 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.896 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 39.4 t -137.62 114.5 10.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.87 -179.789 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 2.7 p30 -165.08 122.43 1.56 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.855 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 79.8 m -125.43 144.3 50.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.13 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 28.2 tttp -163.45 120.18 1.79 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.932 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -107.92 93.95 4.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 60.1 p -92.0 164.6 13.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.818 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -129.2 70.92 0.51 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.524 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 -27.76 25.9 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.628 2.219 . . . . 0.0 112.319 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 72.8 p -93.51 141.58 28.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.872 -179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 7.0 t -43.89 -59.7 2.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.882 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.489 179.977 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 28.3 t -66.52 112.12 3.94 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.906 0.384 . . . . 0.0 110.879 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 26.8 t -170.25 157.16 6.12 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.863 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -72.61 -147.92 0.81 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.467 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 60.9 m -85.09 141.33 30.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.914 0.388 . . . . 0.0 110.893 -179.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 60.9 p -159.05 141.1 13.7 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -165.91 133.26 2.89 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.501 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 46.1 mt-30 -125.49 -49.29 1.66 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.848 0.356 . . . . 0.0 110.892 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.23 156.35 18.36 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 11.0 pttm -87.16 44.86 1.21 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.906 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -112.81 158.3 20.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 39.1 p -119.13 90.84 3.41 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.173 -179.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 31.1 p -119.17 -56.91 2.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.871 -179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 2.7 m-80 -53.22 -38.86 63.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.891 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 53.2 m170 -65.16 174.05 2.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.822 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.56 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 17.5 m-85 -112.6 118.66 35.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.903 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.449 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 1.1 m-70 -86.9 149.1 25.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.835 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 40.2 t -129.06 144.43 38.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.112 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.6 t80 -94.78 135.28 36.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.843 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.431 ' CG1' HD23 ' A' ' 85' ' ' LEU . 4.0 t -132.43 119.37 38.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.066 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.409 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -129.24 170.01 20.39 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.494 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 2.2 t70 72.43 38.92 0.78 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.847 0.356 . . . . 0.0 110.904 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.431 HD23 ' CG1' ' A' ' 82' ' ' VAL . 9.9 mt -100.39 133.82 44.24 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.965 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 t -54.34 153.74 9.42 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.654 0.74 . . . . 0.0 110.804 -179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 -14.38 36.1 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.638 2.225 . . . . 0.0 112.406 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -90.4 -10.25 44.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.89 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.415 HG22 ' N ' ' A' ' 90' ' ' THR . 37.5 mm -76.64 135.7 26.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.16 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.415 ' N ' HG22 ' A' ' 89' ' ' ILE . 14.4 t -117.27 160.43 21.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.162 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.409 ' C ' ' O ' ' A' ' 90' ' ' THR . 20.2 m -36.99 -47.14 0.69 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.13 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -52.92 -54.72 30.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.875 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -42.26 -54.58 3.65 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.416 HG22 ' CG2' ' A' ' 124' ' ' VAL . 15.1 mt -51.04 -59.95 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.154 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.467 ' HG3' ' CB ' ' A' ' 107' ' ' ALA . 23.3 mtmt -48.27 -39.62 22.14 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.928 179.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.92 -32.17 73.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.043 179.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -73.15 -54.59 8.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.127 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -86.08 11.3 12.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.881 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.497 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -65.26 -59.5 9.67 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.593 0.711 . . . . 0.0 111.112 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.497 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 54.2 Cg_endo -69.76 -0.58 7.12 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.678 2.252 . . . . 0.0 112.354 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.581 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 78.6 m-85 -99.73 -8.59 24.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.885 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 147.52 133.66 2.41 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.507 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 34.4 mtp180 -45.42 123.63 4.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.775 0.322 . . . . 0.0 110.869 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.466 HG23 ' CG1' ' A' ' 124' ' ' VAL . 9.9 mt -99.39 137.96 25.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.139 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.42 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 89.5 p -104.02 -65.1 1.04 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.846 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -100.65 106.41 17.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.868 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . 0.467 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -135.05 127.9 31.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.118 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.422 ' HD3' ' N ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -161.06 158.94 28.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.886 -179.904 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.422 ' N ' ' HD3' ' A' ' 108' ' ' ARG . 88.6 t -107.64 116.9 52.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.129 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.517 HG13 ' CZ ' ' A' ' 121' ' ' TYR . 59.6 t -48.3 137.97 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.135 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . 0.407 ' N ' HG11 ' A' ' 110' ' ' VAL . 53.6 mttt -134.48 156.46 48.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.874 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 116' ' ' GLY . 10.4 t0 -60.6 122.99 16.09 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.841 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 11.0 tpt -67.63 -4.26 11.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.896 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -106.34 -52.23 2.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.078 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 53.8 p -95.14 -28.59 14.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.131 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 79.53 26.67 56.41 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.491 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 54.0 mmtt -100.0 149.75 23.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.791 0.329 . . . . 0.0 110.869 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 8.2 t -50.38 108.3 0.22 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.878 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 40.3 mttt -61.47 -43.81 98.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.917 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 142.28 -42.44 1.13 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.502 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.517 ' CZ ' HG13 ' A' ' 110' ' ' VAL . 15.5 p90 -100.04 146.13 27.11 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.927 0.394 . . . . 0.0 110.91 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -128.91 179.98 16.3 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.473 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -125.69 140.05 53.03 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.879 0.371 . . . . 0.0 110.899 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.533 HG12 ' CZ ' ' A' ' 126' ' ' PHE . 50.7 t -135.17 121.34 32.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.161 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 5.2 m -106.01 148.33 27.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.854 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.533 ' CZ ' HG12 ' A' ' 124' ' ' VAL . 21.2 m-85 -130.73 147.13 52.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.893 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.42 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 23.4 m-85 -59.17 -43.18 92.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.846 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 23.9 m120 -118.9 157.33 27.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.888 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.56 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 8.3 ttmt -60.43 -63.47 1.29 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.89 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.443 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -34.66 -52.82 0.53 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -43.89 -45.6 7.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.892 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . 0.429 ' N ' ' O ' ' A' ' 129' ' ' LYS . . . -76.53 -57.04 4.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.096 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -44.33 -56.73 3.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.861 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 51.1 t30 -45.13 -42.88 9.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.837 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.485 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -71.83 -53.95 11.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.095 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 96.8 mt -40.63 -40.84 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.119 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -78.8 -59.61 2.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.917 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 15.2 mm-40 -63.7 -63.33 1.2 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.885 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.581 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 82.3 mmm -51.6 -39.06 57.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.865 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -54.08 112.34 2.51 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.519 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 91.58 21.51 34.14 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.531 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 62.8 mm-40 -101.25 168.44 9.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.792 0.33 . . . . 0.0 110.95 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . 0.401 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 14.8 m95 -105.0 109.15 21.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.892 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 63.1 tp -102.01 128.45 48.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.917 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 68.63 -72.51 0.36 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.484 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -160.88 17.56 0.19 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.499 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 33.3 mtt85 -155.78 156.72 35.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.782 0.325 . . . . 0.0 110.89 -179.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . 0.401 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 46.7 mt-30 -59.68 173.37 0.57 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.908 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.2 pt -147.08 148.95 16.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.12 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.447 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 8.4 ptp180 -115.65 120.91 40.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.871 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 55.8 p -114.64 133.26 55.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.123 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -158.85 161.64 36.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.876 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 7.7 m95 -54.77 104.5 0.12 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -49.04 -47.94 44.3 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.109 179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 77.7 p -70.18 161.74 29.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.107 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 9.1 ptm180 -161.9 166.04 26.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.896 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.5 mttm -128.16 151.49 76.24 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.613 0.721 . . . . 0.0 110.879 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 167.13 25.25 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.644 2.23 . . . . 0.0 112.4 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 174.41 9.6 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.649 2.233 . . . . 0.0 112.339 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -100.73 153.24 37.85 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.587 0.708 . . . . 0.0 111.089 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 174.22 9.78 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.701 2.267 . . . . 0.0 112.35 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 6.6 pttm -155.19 125.12 6.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.888 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 1.7 t -161.07 135.89 7.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.902 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 2.5 t -171.35 139.31 1.29 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.186 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . 0.412 ' CD1' ' N ' ' A' ' 165' ' ' TYR . 1.1 p90 -169.52 119.13 0.66 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.949 -179.885 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 7.2 tm-20 -143.19 120.27 11.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 89.3 p -158.62 108.97 2.06 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.91 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -152.84 138.71 18.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.905 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 45.1 m -151.32 118.04 5.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.145 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 5.3 mtpm? -120.78 144.24 48.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.863 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 27.0 mm-40 -146.64 138.87 24.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.895 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 18.8 m -78.24 -50.65 11.48 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.911 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 67.66 68.73 1.56 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.493 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -0.08 6.41 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.668 2.245 . . . . 0.0 112.321 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 3.1 t 72.05 51.01 0.21 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.892 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 72.0 p -139.81 119.28 13.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.86 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.355 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.491 179.981 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.8 m 62.46 42.04 9.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.893 0.378 . . . . 0.0 110.861 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 64.6 m -97.37 -56.05 2.65 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.834 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -84.47 141.41 19.68 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.486 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.2 t -64.2 -48.61 75.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.887 0.375 . . . . 0.0 110.875 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 37.6 p -71.7 163.54 27.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.846 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -174.35 92.52 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.466 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 15.3 mt-30 -41.2 124.75 2.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.896 0.379 . . . . 0.0 110.914 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 52.3 mmtt -147.41 177.84 8.91 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.918 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.87 26.77 4.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.912 179.863 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -133.88 172.64 12.52 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 10.2 p -124.11 84.82 2.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.092 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 69.7 m -97.98 -60.53 1.54 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.847 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 42.2 t-20 -104.68 41.46 1.33 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.859 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . 0.447 ' CE1' ' HA ' ' A' ' 127' ' ' PHE . 14.2 m170 -110.72 159.76 17.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.834 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.568 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 76.5 m-85 -103.52 113.16 26.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.878 -179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.471 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.6 OUTLIER -83.92 156.73 22.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.827 -179.986 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 53.8 t -130.62 148.96 33.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.128 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 19.3 t80 -99.18 135.85 40.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.882 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 43.7 t -133.02 130.2 58.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.124 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.475 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -136.47 173.22 22.12 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.474 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 7.6 t0 64.4 52.1 1.92 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.846 0.355 . . . . 0.0 110.914 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 16.2 mt -108.26 131.64 54.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.24 154.07 6.14 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.659 0.742 . . . . 0.0 110.824 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -8.07 22.67 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.71 2.274 . . . . 0.0 112.336 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -100.06 -3.48 31.89 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.908 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.436 ' CD1' ' HA3' ' A' ' 145' ' ' GLY . 45.6 mm -78.96 137.11 22.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.102 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.3 t -119.0 168.41 10.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.135 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.437 HG22 ' CE ' ' A' ' 95' ' ' LYS . 36.8 m -47.47 -41.57 20.91 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.131 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 35.8 mt-10 -61.13 -53.21 59.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.902 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -42.87 -56.15 3.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.83 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.444 ' CD1' HG22 ' A' ' 109' ' ' VAL . 19.4 mt -50.09 -57.49 2.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.141 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.452 ' HG3' ' CB ' ' A' ' 107' ' ' ALA . 26.7 mtmt -46.93 -40.03 13.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.904 179.823 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.7 -32.58 73.7 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.106 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -68.87 -53.91 18.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.115 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 21.2 m-85 -89.43 10.44 22.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.847 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.488 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -64.51 -59.77 9.96 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.572 0.701 . . . . 0.0 111.131 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.488 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.8 -0.76 7.41 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.667 2.244 . . . . 0.0 112.345 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 -100.0 -11.76 20.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.881 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 155.7 157.01 8.05 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.494 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.514 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 27.1 mtp180 -64.52 123.46 19.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.825 0.345 . . . . 0.0 110.874 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.405 HG22 ' CG1' ' A' ' 124' ' ' VAL . 18.7 mt -100.43 144.56 12.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.112 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 65.8 p -119.91 -59.21 1.82 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.806 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.429 ' HB3' ' CB ' ' A' ' 125' ' ' SER . 8.7 t0 -100.82 100.52 11.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.857 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . 0.452 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -130.59 127.11 38.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -162.23 156.54 21.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.845 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.444 HG22 ' CD1' ' A' ' 94' ' ' ILE . 72.9 t -106.16 119.98 56.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.134 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.573 HG22 ' CE2' ' A' ' 121' ' ' TYR . 95.1 t -53.47 134.43 15.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.113 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 38.7 mttt -134.7 146.37 49.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.848 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.426 ' O ' ' N ' ' A' ' 116' ' ' GLY . 29.6 t0 -57.4 120.53 8.37 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.9 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 7.7 ptp -68.61 -3.49 12.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.915 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -100.58 -50.1 3.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.111 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 44.0 p -97.69 -34.28 10.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.128 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 88.81 17.43 56.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 63.7 mttt -92.3 167.92 11.67 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.822 0.344 . . . . 0.0 110.888 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 8.2 t -69.34 113.24 6.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.849 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.444 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 37.1 mttt -62.87 -50.79 69.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.878 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 145.08 -41.4 1.07 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.447 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.573 ' CE2' HG22 ' A' ' 110' ' ' VAL . 10.2 p90 -98.99 149.7 22.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.937 0.398 . . . . 0.0 110.919 -179.791 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -129.77 175.54 19.02 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.458 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 47.8 m-85 -124.2 135.47 53.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.857 0.361 . . . . 0.0 110.882 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.568 HG12 ' CZ ' ' A' ' 126' ' ' PHE . 56.5 t -134.53 122.0 37.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.127 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' SER . . . . . 0.429 ' CB ' ' HB3' ' A' ' 106' ' ' ASP . 16.3 t -106.45 149.62 26.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.855 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.568 ' CZ ' HG12 ' A' ' 124' ' ' VAL . 16.5 m-85 -130.96 138.23 49.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.9 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.514 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 84.1 m-85 -52.44 -35.24 51.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -118.12 167.0 11.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.876 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.568 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 9.3 tttp -77.19 -41.7 40.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.878 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.423 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -57.98 -59.44 5.25 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.88 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.423 ' C ' ' O ' ' A' ' 130' ' ' TRP . 45.3 m-20 -35.91 -39.91 0.18 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.879 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.79 -58.87 3.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.084 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -42.72 -54.78 3.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.859 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 56.3 t30 -43.34 -41.42 4.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.881 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.403 ' O ' ' N ' ' A' ' 137' ' ' GLN . . . -75.72 -58.15 3.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.102 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 98.2 mt -38.92 -30.41 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.152 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . 0.403 ' N ' ' O ' ' A' ' 135' ' ' ALA . 7.0 mt-30 -87.49 -65.75 0.98 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.916 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 10.3 mm-40 -61.54 -61.03 2.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.955 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 79.0 mmm -49.18 -35.62 17.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -57.56 116.38 8.02 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.474 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 99.89 -19.09 54.69 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.45 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -66.38 177.18 1.56 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.788 0.328 . . . . 0.0 110.903 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . 0.437 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 13.8 m95 -115.04 127.11 55.44 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.908 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.474 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 55.5 tp -121.28 123.88 43.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.926 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . 0.436 ' HA3' ' CD1' ' A' ' 89' ' ' ILE . . . 73.65 -11.59 5.54 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.532 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . 0.4 ' H ' ' C ' ' A' ' 144' ' ' LEU . . . 130.25 -7.18 6.0 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.485 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 67.9 mtt180 -130.35 144.93 51.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.767 0.318 . . . . 0.0 110.902 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . 0.437 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 31.2 mt-30 -53.57 158.21 1.9 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.933 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.474 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 21.2 pt -131.7 145.29 35.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.129 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.475 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 19.3 ptp180 -106.8 120.14 41.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.874 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 42.4 p -112.71 127.85 56.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.121 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -153.4 166.2 33.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.868 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 23.2 m95 -62.58 136.81 58.07 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.953 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.413 ' C ' HG22 ' A' ' 155' ' ' THR . . . -97.88 149.85 21.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.108 179.883 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.413 HG22 ' C ' ' A' ' 154' ' ' ALA . 44.1 p -138.6 154.35 48.69 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.128 -179.868 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -82.59 166.98 18.76 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.889 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 28.4 ttpt -59.6 137.07 89.61 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.588 0.708 . . . . 0.0 110.909 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 148.38 65.08 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.723 2.282 . . . . 0.0 112.317 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 156.69 62.79 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.689 2.259 . . . . 0.0 112.352 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -49.27 150.88 2.83 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.542 0.687 . . . . 0.0 111.139 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -50.2 0.49 Allowed 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.68 2.254 . . . . 0.0 112.323 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 21.3 tttm -169.43 152.7 4.91 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.879 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 68.5 m -79.42 166.06 22.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.863 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 60.1 p -64.45 136.81 57.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.103 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -119.78 20.53 12.25 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.865 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -57.56 99.87 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.914 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 8.9 t -157.13 118.15 3.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.842 -179.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -111.86 87.77 2.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.868 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 90.3 m -98.22 85.67 3.5 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.175 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 7.7 ptmm? -166.94 141.39 3.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.916 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 17.7 mm-40 -125.6 120.63 31.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.938 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 9.0 t -148.04 162.59 39.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.846 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 140.79 69.8 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.503 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . 0.431 ' O ' ' C ' ' A' ' 175' ' ' SER . 53.6 Cg_endo -69.75 -50.65 0.45 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.651 2.234 . . . . 0.0 112.354 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' SER . . . . . 0.431 ' C ' ' O ' ' A' ' 174' ' ' PRO . 61.7 p 35.19 39.75 0.05 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.846 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 51.8 p -96.37 115.86 28.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.805 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.462 179.997 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 61.4 m -129.88 161.54 30.59 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.875 0.369 . . . . 0.0 110.886 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 56.6 p -84.19 153.51 23.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.852 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 115.58 142.86 7.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.536 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 51.6 p -82.19 172.6 12.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.842 0.353 . . . . 0.0 110.867 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 70.8 m -104.81 -54.78 2.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.823 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 81.99 108.18 0.4 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.491 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 13.7 mp0 -71.36 84.29 0.79 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.897 0.38 . . . . 0.0 110.924 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 14.0 ptpt -106.42 174.01 6.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.868 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 74.0 tttt -59.15 -63.78 1.18 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.883 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -45.81 155.87 0.16 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.891 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.5 p -97.7 86.34 3.78 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.137 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 59.7 m -108.89 132.09 54.38 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.837 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 49.9 t30 55.8 31.51 17.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.865 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 20.5 m170 -100.03 168.65 9.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.894 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.563 ' CE1' ' HD3' ' A' ' 129' ' ' LYS . 90.9 m-85 -115.68 105.93 13.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.903 -179.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.544 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.1 OUTLIER -81.75 150.18 28.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 55.3 t -124.75 146.28 30.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.137 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.2 t80 -98.07 134.39 41.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.919 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 4.3 t -130.42 130.13 65.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.109 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.475 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -136.24 179.26 18.05 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.446 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.402 ' O ' ' O ' ' A' ' 148' ' ' GLN . 5.4 t70 56.39 53.63 8.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.852 0.358 . . . . 0.0 110.845 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 15.8 mt -109.94 131.14 55.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -53.01 154.91 4.74 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.646 0.736 . . . . 0.0 110.873 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -4.19 13.53 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.653 2.236 . . . . 0.0 112.348 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -97.58 -28.81 13.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.857 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.446 HG21 ' CB ' ' A' ' 93' ' ' ASP . 47.9 mm -57.73 132.52 22.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.137 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.1 t -119.38 166.8 12.59 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.161 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 95.8 m -39.79 -49.02 2.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.169 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -56.04 -57.6 11.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.852 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.446 ' CB ' HG21 ' A' ' 89' ' ' ILE . 1.3 m-20 -39.59 -56.8 1.6 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.463 ' CD1' HG21 ' A' ' 109' ' ' VAL . 16.5 mt -48.79 -59.44 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.132 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.444 ' O ' ' N ' ' A' ' 99' ' ' ALA . 20.8 mtmt -47.41 -38.93 14.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.914 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.97 -37.01 85.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.059 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -68.05 -52.9 30.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.112 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 22.2 m-85 -89.27 6.91 38.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.93 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.491 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -59.48 -59.79 12.71 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.618 0.723 . . . . 0.0 111.082 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.491 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.6 Cg_endo -69.76 -0.92 7.62 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.72 2.28 . . . . 0.0 112.322 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -101.49 12.51 37.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.887 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 129.59 155.72 8.56 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.482 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.407 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 28.7 mtt180 -65.7 126.16 27.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.808 0.337 . . . . 0.0 110.841 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.47 HG22 ' CG1' ' A' ' 124' ' ' VAL . 13.8 mt -100.27 140.29 19.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.157 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 5.4 t -112.05 -62.09 1.62 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.883 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -100.81 102.91 14.09 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.867 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -130.32 125.5 34.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.083 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 15.2 ptt180 -160.81 154.98 22.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.886 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.463 HG21 ' CD1' ' A' ' 94' ' ' ILE . 60.1 t -105.2 119.14 53.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.11 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.534 HG11 ' CE2' ' A' ' 121' ' ' TYR . 61.1 t -53.12 133.06 15.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.126 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . 0.418 ' HG2' ' C ' ' A' ' 117' ' ' LYS . 37.0 mttm -134.14 149.25 51.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.94 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -62.02 132.0 51.46 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.863 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 26.0 ptm -80.47 1.36 29.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.883 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.35 -29.11 13.34 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.084 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 21.2 p -131.14 -34.28 1.45 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.15 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 96.66 17.36 33.51 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.455 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . 0.418 ' C ' ' HG2' ' A' ' 111' ' ' LYS . 42.1 mttm -85.79 154.14 21.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.815 0.34 . . . . 0.0 110.875 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 1.9 m -60.09 111.1 1.38 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.82 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.418 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 31.6 mttt -59.25 -42.8 92.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.908 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 138.36 -41.72 1.34 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.532 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.534 ' CE2' HG11 ' A' ' 110' ' ' VAL . 7.4 p90 -99.99 151.12 21.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.923 0.392 . . . . 0.0 110.922 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -130.66 178.04 17.94 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.554 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -126.52 135.72 51.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.887 0.375 . . . . 0.0 110.876 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.508 HG13 ' CZ ' ' A' ' 126' ' ' PHE . 61.0 t -136.48 122.18 28.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.118 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 12.6 m -105.34 149.92 25.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.808 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.508 ' CZ ' HG13 ' A' ' 124' ' ' VAL . 16.3 m-85 -131.06 137.85 49.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.906 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.407 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 78.3 m-85 -58.87 -36.67 75.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.841 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 13.6 m-20 -118.04 149.78 40.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.904 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.563 ' HD3' ' CE1' ' A' ' 78' ' ' PHE . 38.5 tptt -60.77 -63.39 1.31 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.463 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.9 OUTLIER -33.21 -57.92 0.39 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.917 179.921 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -40.59 -49.26 2.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.867 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -67.1 -60.47 2.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.123 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -41.05 -61.62 0.96 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.916 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 44.1 t-20 -38.88 -52.91 1.75 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.485 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -63.55 -61.44 2.33 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.122 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 86.7 mt -37.01 -36.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.128 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 -85.53 -60.1 2.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.876 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -64.85 -59.6 4.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.485 ' N ' ' O ' ' A' ' 135' ' ' ALA . 48.0 mmm -53.48 -39.92 64.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.939 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -55.66 116.59 7.31 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.49 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 100.65 -12.66 59.6 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.494 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 48.6 mm-40 -73.28 172.57 10.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.75 0.31 . . . . 0.0 110.928 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . . . . . . . . . 15.7 m95 -109.43 126.41 53.44 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.877 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.4 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 57.3 tp -123.56 125.19 44.41 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.913 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 72.82 -9.25 6.58 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.48 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 127.47 -7.7 7.03 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.487 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 28.2 mtt-85 -130.34 145.89 51.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.789 0.328 . . . . 0.0 110.86 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . 0.402 ' O ' ' O ' ' A' ' 84' ' ' ASP . 18.1 mt-30 -52.58 166.54 0.19 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.952 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.4 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 24.3 pt -137.42 146.28 28.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.066 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.475 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 16.4 ptp180 -108.07 114.86 29.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.89 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 80.9 p -110.19 122.57 47.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.134 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -150.58 168.48 24.14 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.904 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . 0.503 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 55.1 m95 -69.55 123.2 20.68 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.916 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -71.12 -53.6 14.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.095 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 62.7 p -50.75 154.89 1.26 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.162 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 18.1 ptt85 -134.69 144.0 47.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.9 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 13.5 pttp -79.4 148.71 70.88 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.552 0.691 . . . . 0.0 110.919 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 149.5 66.72 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.678 2.252 . . . . 0.0 112.344 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 175.57 7.89 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.721 2.28 . . . . 0.0 112.324 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -121.83 162.03 38.99 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.603 0.716 . . . . 0.0 111.112 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 123.48 10.13 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.69 2.26 . . . . 0.0 112.348 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 5.1 mtmp? -69.79 125.7 27.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 37.5 t -91.34 112.11 23.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.902 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 21.2 p -122.1 129.21 52.16 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.124 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . 0.426 ' CD1' ' C ' ' A' ' 165' ' ' TYR . 4.6 p90 -152.2 164.52 37.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.976 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -159.17 134.21 8.23 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.907 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 47.5 t -171.78 131.37 0.69 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.864 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 28.3 m120 -134.94 156.16 49.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.848 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.3 m -150.38 126.37 10.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.148 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.54 118.69 8.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -118.42 135.09 54.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.911 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 8.2 t -173.42 150.12 1.79 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.828 -179.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 147.09 65.88 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.466 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 156.65 62.82 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.713 2.275 . . . . 0.0 112.348 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 9.5 t -174.45 166.84 3.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.83 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 49.4 p -165.72 106.89 0.74 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.867 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.28 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.461 179.99 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.466 -0.254 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.7 m -40.72 120.17 1.24 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.883 0.373 . . . . 0.0 110.825 -179.746 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 74.0 m -142.99 169.44 17.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.858 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -160.58 -157.15 8.53 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.492 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 25.7 t -78.85 127.92 32.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.909 0.385 . . . . 0.0 110.857 -179.75 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 48.7 m -133.63 79.82 1.84 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.821 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 129.13 95.01 0.78 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.477 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 61.8 mm-40 -61.27 -45.83 92.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.845 0.355 . . . . 0.0 110.874 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.0 53.68 2.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.874 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -113.18 176.69 4.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.941 179.825 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 23.3 t0 -53.05 137.8 32.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.84 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 61.8 p -78.07 53.43 1.19 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 22.5 t -89.09 -38.36 14.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.86 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 26.5 m-20 -80.53 -34.19 35.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.844 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 47.4 m170 -64.54 144.33 57.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.848 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.566 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 93.0 m-85 -96.88 124.52 40.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.875 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.51 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.2 OUTLIER -89.1 150.4 22.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 179.998 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 46.0 t -125.45 145.36 32.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.131 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.8 t80 -91.22 132.72 35.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.434 ' CG1' HD22 ' A' ' 85' ' ' LEU . 16.8 t -128.57 128.91 68.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.073 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -136.52 -177.96 15.42 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.54 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 55.11 54.25 9.1 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.809 0.338 . . . . 0.0 110.843 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.434 HD22 ' CG1' ' A' ' 82' ' ' VAL . 17.0 mt -110.89 130.11 55.68 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.937 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.18 154.22 5.84 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.664 0.745 . . . . 0.0 110.843 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -6.21 18.08 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.699 2.266 . . . . 0.0 112.29 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -100.29 -15.54 18.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.898 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.457 HG21 ' CB ' ' A' ' 93' ' ' ASP . 34.3 mm -69.57 134.25 30.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.141 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.0 t -119.67 168.0 11.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.123 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.446 HG21 ' CE ' ' A' ' 95' ' ' LYS . 98.8 m -38.82 -57.76 1.18 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.111 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 29.5 mt-10 -46.44 -59.36 3.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.942 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.457 ' CB ' HG21 ' A' ' 89' ' ' ILE . 0.5 OUTLIER -38.82 -56.19 1.4 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.899 179.932 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 10.7 mt -49.55 -60.77 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.167 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.446 ' CE ' HG21 ' A' ' 91' ' ' THR . 24.3 mtmt -45.67 -39.65 8.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.887 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -59.94 -37.84 80.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.106 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -66.35 -52.98 41.48 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.103 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 11.8 m-85 -92.18 18.66 7.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.852 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.478 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -69.33 -60.44 4.08 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.581 0.705 . . . . 0.0 111.136 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.478 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.78 -0.83 7.49 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.662 2.241 . . . . 0.0 112.321 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -99.78 5.17 45.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.89 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.79 137.88 3.91 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.493 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 24.3 mtt-85 -49.89 125.1 11.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.741 0.305 . . . . 0.0 110.906 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.472 HG23 ' CG1' ' A' ' 124' ' ' VAL . 11.1 mt -98.77 138.88 22.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.142 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.403 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.1 t -107.33 -62.94 1.35 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.858 -179.864 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -100.51 109.66 21.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.905 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -138.25 129.13 26.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.13 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.1 ptm180 -162.57 154.72 18.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.873 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 41.3 t -105.33 117.38 50.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.133 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.524 HG23 ' CE2' ' A' ' 121' ' ' TYR . 48.8 t -49.84 138.04 5.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.125 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . 0.42 ' C ' ' HG3' ' A' ' 119' ' ' LYS . 52.6 mttt -138.16 154.63 49.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -69.16 138.55 54.24 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.836 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 13.5 ptp -85.75 3.45 41.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.862 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -102.64 -35.94 8.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.083 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 52.3 p -123.17 -35.17 3.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.098 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 90.86 26.61 21.74 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.481 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . 0.412 ' O ' ' C ' ' A' ' 118' ' ' SER . 86.1 mttt -97.73 136.39 38.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.769 0.318 . . . . 0.0 110.896 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 117' ' ' LYS . 2.2 m -37.7 111.76 0.18 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.853 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.433 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 9.3 mttm -61.82 -41.82 98.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.895 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 138.62 -46.75 0.96 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.531 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.524 ' CE2' HG23 ' A' ' 110' ' ' VAL . 10.1 p90 -100.04 148.65 24.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.996 0.427 . . . . 0.0 110.909 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -129.8 -177.31 14.81 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.503 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -127.47 139.29 52.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.854 0.359 . . . . 0.0 110.925 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.549 HG12 ' CZ ' ' A' ' 126' ' ' PHE . 58.3 t -138.83 120.65 16.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.146 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 42.3 m -106.65 149.81 26.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.853 -179.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.549 ' CZ ' HG12 ' A' ' 124' ' ' VAL . 2.1 m-85 -130.85 144.59 51.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.873 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.403 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 22.3 m-85 -56.38 -43.49 79.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.889 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 19.2 m120 -109.35 163.69 13.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.901 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.566 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 20.3 tptm -71.39 -59.55 2.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.902 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.417 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.8 OUTLIER -40.57 -57.39 1.86 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.9 179.922 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 130' ' ' TRP . 71.6 m-20 -35.86 -45.76 0.42 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.875 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -75.8 -58.27 3.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.065 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -44.16 -59.5 2.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.883 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -41.79 -44.49 3.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.891 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.47 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -69.23 -56.78 6.58 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.107 179.834 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 86.1 mt -38.73 -35.5 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.106 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.1 mt-30 -87.18 -57.07 3.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.892 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 37.3 mm-40 -68.3 -61.97 1.6 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.93 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.47 ' N ' ' O ' ' A' ' 135' ' ' ALA . 64.1 mmm -51.92 -38.93 58.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.858 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.44 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -57.55 93.51 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.492 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 119.44 13.17 6.39 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.508 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 87.4 mm-40 -94.27 169.66 10.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.753 0.311 . . . . 0.0 110.962 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . 0.401 ' NE1' ' HG3' ' A' ' 148' ' ' GLN . 17.2 m95 -106.3 109.47 21.41 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.899 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.402 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 60.9 tp -104.15 129.58 51.87 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.926 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 69.74 -77.0 0.4 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.475 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -156.33 15.93 0.41 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.464 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 43.2 mtp85 -157.99 161.01 38.09 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.758 0.313 . . . . 0.0 110.856 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . 0.401 ' HG3' ' NE1' ' A' ' 143' ' ' TRP . 28.9 mt-30 -64.25 167.08 7.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.923 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.402 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 21.1 pt -136.26 152.11 29.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.147 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 2.8 ttt180 -109.29 129.72 55.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.892 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.44 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 44.4 p -124.55 137.54 54.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.149 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 4.2 t30 -160.61 174.09 14.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.919 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . 0.546 ' CH2' ' CE ' ' A' ' 129' ' ' LYS . 4.6 m95 -69.15 128.27 36.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.898 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . 0.432 ' O ' ' C ' ' A' ' 155' ' ' THR . . . -96.66 123.59 40.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.066 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.432 ' C ' ' O ' ' A' ' 154' ' ' ALA . 16.3 p 34.95 41.42 0.06 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.115 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 4.8 tpt180 -139.5 150.95 45.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.879 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 15.7 mmmt -125.36 141.49 38.96 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.57 0.7 . . . . 0.0 110.884 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 157.74 59.32 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.651 2.234 . . . . 0.0 112.311 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 146.53 60.35 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.698 2.265 . . . . 0.0 112.329 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -46.07 161.65 0.26 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.575 0.702 . . . . 0.0 111.074 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 -19.6 36.02 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.7 2.267 . . . . 0.0 112.328 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 40.5 tttt -125.03 81.81 2.0 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.93 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 7.6 t -163.8 133.17 3.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.84 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 15.0 t -112.04 130.11 55.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.134 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 16.4 p90 -139.96 141.79 36.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.93 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 13.8 tt0 -172.05 147.05 2.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.911 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 7.0 t -132.32 164.2 26.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.892 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 37.7 t-20 -134.08 96.0 3.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.842 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 1.7 t -172.88 141.52 1.03 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.117 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 1.1 ttmp? -170.68 136.12 1.2 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.86 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 48.9 mt-30 -122.24 170.74 9.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.889 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 55.7 p -157.07 112.34 2.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.838 -179.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 165.11 146.18 4.68 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.506 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . 0.421 ' O ' ' C ' ' A' ' 175' ' ' SER . 53.9 Cg_endo -69.77 -20.66 34.51 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.724 2.283 . . . . 0.0 112.331 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 174' ' ' PRO . 8.0 t -36.71 137.37 0.31 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.841 -179.841 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 36.0 t -66.78 -49.87 64.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.863 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.489 -179.962 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 82.7 p -116.68 109.02 16.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.863 0.363 . . . . 0.0 110.844 -179.712 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 20.8 m -51.78 164.89 0.21 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.854 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 138.29 113.16 1.14 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.501 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 46.2 m -86.78 153.36 21.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.93 0.395 . . . . 0.0 110.793 -179.683 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 71.6 m -85.55 -44.77 12.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.884 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -171.12 108.49 0.29 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.488 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 15.1 tt0 -103.49 -45.12 4.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.893 0.378 . . . . 0.0 110.915 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.1 tppt? -66.04 122.41 17.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.94 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.23 -42.48 99.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.88 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -64.24 131.22 46.72 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.92 179.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.6 p -90.76 88.84 7.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.15 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 37.2 m -108.77 -58.83 1.96 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.829 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 72.4 m-20 -56.73 -36.4 69.69 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.896 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 15.8 m170 -67.6 137.84 55.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.879 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -87.65 121.63 30.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.862 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . 0.404 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.9 OUTLIER -82.02 135.24 35.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.872 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 38.9 t -114.2 144.57 21.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.124 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . 0.694 ' CD2' ' ND2' ' A' ' 152' ' ' ASN . 11.9 t80 -96.74 138.28 34.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.862 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.2 t -137.17 134.46 47.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.151 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -142.3 -173.1 14.04 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.456 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 56.93 29.3 16.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.816 0.341 . . . . 0.0 110.86 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 14.6 mt -86.31 132.25 34.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.956 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -53.87 155.3 6.2 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.639 0.733 . . . . 0.0 110.863 -179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.85 -15.96 36.98 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.688 2.259 . . . . 0.0 112.291 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -92.0 -7.14 49.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.873 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.418 HG22 ' CB ' ' A' ' 93' ' ' ASP . 33.2 mm -74.98 138.88 20.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.155 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.8 t -119.88 -176.71 3.24 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.133 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 84.9 m -53.77 -57.25 11.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.125 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.439 ' O ' ' C ' ' A' ' 93' ' ' ASP . 70.9 mt-10 -48.67 -58.48 4.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.914 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.439 ' C ' ' O ' ' A' ' 92' ' ' GLU . 2.9 m-20 -34.48 -55.28 0.54 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.841 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 4.5 mt -51.76 -60.34 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.152 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.462 ' O ' ' N ' ' A' ' 99' ' ' ALA . 25.6 mtmt -48.85 -41.93 34.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.899 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.68 -29.13 69.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.083 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -75.67 -53.74 8.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.131 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.414 ' C ' HD13 ' A' ' 104' ' ' ILE . 27.2 m-85 -86.82 3.49 45.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.915 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.478 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -56.5 -60.29 9.62 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.587 0.708 . . . . 0.0 111.154 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.478 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.3 Cg_endo -69.76 -0.81 7.45 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.708 2.272 . . . . 0.0 112.353 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.584 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 72.0 m-85 -99.77 -1.2 38.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 142.17 156.07 6.67 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.507 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.46 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 17.5 mtm105 -62.6 122.28 15.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.743 0.306 . . . . 0.0 110.871 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.468 HG21 ' CG1' ' A' ' 124' ' ' VAL . 13.9 mt -100.39 138.21 25.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.176 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.469 ' HB2' ' CZ ' ' A' ' 127' ' ' PHE . 47.8 t -112.92 -59.61 1.99 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.408 ' HB3' ' CB ' ' A' ' 125' ' ' SER . 25.9 t70 -100.63 99.78 10.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -132.08 124.94 30.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.081 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 10.3 ptp180 -159.36 153.32 23.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 90.0 t -100.93 124.12 54.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.111 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.574 HG23 ' CD2' ' A' ' 121' ' ' TYR . 53.4 t -59.64 143.96 13.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.118 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . 0.446 ' N ' HG13 ' A' ' 110' ' ' VAL . 74.5 mttt -140.7 153.87 46.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.469 ' N ' ' HG2' ' A' ' 119' ' ' LYS . 7.9 t0 -60.22 127.38 31.54 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.838 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 19.9 ptm -80.12 2.81 22.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.867 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -102.66 -38.38 7.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.074 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 42.1 p -119.9 -33.82 3.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.181 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 95.35 30.2 8.35 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.444 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 34.5 mttm -99.01 164.48 12.16 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.778 0.323 . . . . 0.0 110.903 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 36.4 t -56.62 115.05 2.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.907 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.469 ' HG2' ' N ' ' A' ' 112' ' ' ASP . 0.5 OUTLIER -68.33 -38.56 81.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.909 179.962 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 126.39 -46.1 1.11 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.433 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.574 ' CD2' HG23 ' A' ' 110' ' ' VAL . 8.3 p90 -100.32 151.33 21.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.927 0.394 . . . . 0.0 110.934 -179.794 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -132.58 171.55 21.56 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.473 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -121.06 138.85 53.99 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.859 0.361 . . . . 0.0 110.907 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.468 ' CG1' HG21 ' A' ' 104' ' ' ILE . 93.9 t -138.91 112.26 6.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.103 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' SER . . . . . 0.408 ' CB ' ' HB3' ' A' ' 106' ' ' ASP . 2.7 t -97.89 148.64 23.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.83 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.442 ' CZ ' HG13 ' A' ' 124' ' ' VAL . 3.6 m-85 -127.06 148.38 50.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.882 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.469 ' CZ ' ' HB2' ' A' ' 105' ' ' SER . 77.9 m-85 -63.27 -34.66 78.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.916 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 25.4 m120 -115.93 168.88 9.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.87 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 66.8 tttt -81.0 -47.88 13.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.427 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -48.57 -62.47 1.48 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.935 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 130' ' ' TRP . 44.4 m-20 -35.87 -54.17 0.74 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.811 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -61.39 -67.08 0.44 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.107 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -37.26 -57.87 0.86 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 42.4 t-20 -41.01 -52.89 3.09 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.864 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.96 -56.71 13.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.098 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 92.3 mt -38.17 -35.82 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.175 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -85.26 -63.53 1.31 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.899 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -59.56 -61.9 2.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.584 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 81.2 mmm -52.19 -35.23 48.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.913 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.401 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -54.94 99.43 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.522 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 111.59 -20.7 22.42 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.488 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 10.8 mm-40 -56.55 -179.92 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.791 0.329 . . . . 0.0 110.927 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . 0.463 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 13.4 m95 -116.86 124.72 50.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.927 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 47.2 tp -123.88 128.75 49.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.862 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 70.54 -3.69 11.15 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.516 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 120.91 -13.5 9.79 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.496 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 60.4 mtt180 -122.85 147.4 46.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.727 0.299 . . . . 0.0 110.88 -179.866 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . 0.463 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 32.6 mt-30 -55.45 165.57 0.77 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.926 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.418 HG22 ' C ' ' A' ' 148' ' ' GLN . 19.5 pt -138.15 151.34 25.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.117 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 27.0 ptt180 -113.99 109.1 17.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.906 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.401 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 69.3 p -106.54 141.43 37.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.167 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . 0.694 ' ND2' ' CD2' ' A' ' 81' ' ' PHE . 7.4 p30 -167.15 -178.95 4.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.876 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 31.2 m95 -74.73 135.37 41.79 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.916 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -80.34 -51.98 8.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.093 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.6 t -121.62 146.04 47.38 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.162 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -159.32 161.14 35.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.829 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.47 ' CG ' ' HD2' ' A' ' 158' ' ' PRO . 53.6 tttp -124.18 139.25 32.31 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.594 0.712 . . . . 0.0 110.853 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . 0.47 ' HD2' ' CG ' ' A' ' 157' ' ' LYS . 53.5 Cg_endo -69.8 145.23 56.28 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.722 2.282 . . . . 0.0 112.335 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -172.09 0.54 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.686 2.257 . . . . 0.0 112.361 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -97.02 147.81 33.46 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.62 0.724 . . . . 0.0 111.069 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 -50.67 0.45 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.667 2.245 . . . . 0.0 112.367 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . 0.456 ' HE3' ' CG2' ' A' ' 164' ' ' THR . 6.2 tmtm? -174.95 147.78 0.98 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.87 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 15.6 t -137.41 136.33 37.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.83 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' THR . . . . . 0.456 ' CG2' ' HE3' ' A' ' 162' ' ' LYS . 33.4 p -142.48 177.68 8.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.15 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 3.9 t80 -112.98 146.1 39.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.933 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -161.53 143.3 11.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.902 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 64.8 p -108.98 81.5 1.45 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.891 -179.809 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 44.7 t30 -113.89 40.47 2.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 91.7 m -149.92 121.27 7.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.163 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 18.0 tptp -163.45 146.19 10.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -172.49 159.08 4.42 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.922 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 40.0 t -112.17 -58.06 2.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.873 -179.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 67.4 82.86 0.13 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.513 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 115.76 4.25 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.726 2.284 . . . . 0.0 112.28 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 78.3 p -173.92 124.06 0.34 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.812 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 54.9 p -121.54 125.46 46.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.872 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.506 -179.929 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 31.3 t -64.84 98.66 0.29 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.837 0.351 . . . . 0.0 110.847 -179.72 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.8 m -169.81 139.55 1.97 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 161.66 97.03 0.11 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.468 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 13.8 t -94.43 84.43 4.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.915 0.388 . . . . 0.0 110.862 -179.788 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.7 p -166.47 115.54 0.91 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.886 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -147.77 139.97 8.13 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.469 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -125.82 168.99 13.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.846 0.355 . . . . 0.0 110.916 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.435 ' HG3' ' N ' ' A' ' 72' ' ' LYS . 0.1 OUTLIER -171.31 150.57 2.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.9 179.951 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.435 ' N ' ' HG3' ' A' ' 71' ' ' LYS . 29.2 mttm -79.51 -54.16 6.17 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.899 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -67.97 149.01 50.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.863 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 26.2 p -79.44 95.28 5.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.138 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.3 t -87.54 -57.64 2.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.887 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -121.47 52.47 1.23 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.909 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 21.6 m170 -108.67 156.35 19.67 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.835 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.445 ' CD2' ' HE3' ' A' ' 129' ' ' LYS . 47.0 m-85 -98.05 115.78 28.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.874 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 87.4 m-70 -89.3 140.49 29.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.851 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.468 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 41.5 t -118.1 138.76 47.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.073 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 15.5 t80 -92.89 135.49 34.09 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.878 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.443 ' CG1' HD21 ' A' ' 85' ' ' LEU . 3.7 t -137.58 109.51 6.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.118 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -123.21 -177.48 15.15 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.472 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.403 ' O ' ' O ' ' A' ' 148' ' ' GLN . 4.5 t70 63.83 36.45 10.4 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.859 0.362 . . . . 0.0 110.91 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.449 HD22 ' CG2' ' A' ' 149' ' ' ILE . 15.6 mt -91.7 170.54 9.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.912 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -90.01 155.4 47.33 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.672 0.749 . . . . 0.0 110.786 -179.835 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 -10.79 29.39 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.668 2.245 . . . . 0.0 112.338 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -96.5 -6.11 37.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.464 HG23 ' CB ' ' A' ' 93' ' ' ASP . 45.8 mm -79.09 136.38 23.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.116 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.6 t -118.96 164.7 15.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.19 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 35.8 m -40.24 -48.77 2.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.149 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 93' ' ' ASP . 32.7 mt-10 -55.64 -58.78 6.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.464 ' CB ' HG23 ' A' ' 89' ' ' ILE . 13.3 m-20 -34.78 -56.67 0.55 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.86 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.433 HG21 ' CG2' ' A' ' 124' ' ' VAL . 10.4 mt -49.26 -60.76 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.185 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.464 ' HA ' ' CD1' ' A' ' 104' ' ' ILE . 24.0 mtmt -46.69 -39.81 12.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.914 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -63.58 -30.77 71.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.103 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -73.92 -53.68 9.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.088 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.421 ' C ' HD13 ' A' ' 104' ' ' ILE . 22.3 m-85 -89.18 12.34 16.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.91 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.486 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -65.23 -60.07 8.56 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.661 0.743 . . . . 0.0 111.082 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.486 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.76 -0.77 7.4 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.616 2.211 . . . . 0.0 112.376 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.497 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 77.6 m-85 -99.65 -3.14 33.78 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.892 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 143.03 131.95 2.6 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.485 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 46.2 mtt85 -44.09 124.93 4.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.803 0.335 . . . . 0.0 110.875 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.468 HG22 ' CG1' ' A' ' 124' ' ' VAL . 14.1 mt -100.11 145.18 11.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.136 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.448 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 3.8 t -116.01 -61.94 1.66 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.851 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -100.57 99.47 10.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.83 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -132.92 127.18 33.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 6.7 ptm180 -160.15 155.29 24.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.871 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 96.4 t -107.06 120.35 58.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.138 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.559 HG12 ' CE2' ' A' ' 121' ' ' TYR . 66.8 t -54.33 124.66 7.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.159 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -123.72 148.74 46.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.877 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.481 ' O ' ' N ' ' A' ' 116' ' ' GLY . 24.1 t0 -56.88 121.61 10.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.871 179.817 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 8.2 ptp -73.11 -1.54 17.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.938 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -97.86 -42.52 7.52 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.134 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 29.1 p -115.75 -29.43 6.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.137 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.481 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 89.51 30.3 14.07 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.499 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 51.7 mttm -98.9 152.5 19.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.829 0.347 . . . . 0.0 110.899 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 7.8 t -60.29 110.75 1.32 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.831 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 50.9 mttt -62.73 -47.82 81.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.93 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 139.75 -38.98 1.56 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.463 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.559 ' CE2' HG12 ' A' ' 110' ' ' VAL . 25.3 p90 -100.09 144.04 29.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.953 0.406 . . . . 0.0 110.92 -179.81 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.81 175.07 21.52 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.545 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -121.85 139.93 53.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.912 0.387 . . . . 0.0 110.866 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.559 HG12 ' CZ ' ' A' ' 126' ' ' PHE . 59.4 t -135.62 111.46 12.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.122 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.8 t -100.49 145.64 28.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.856 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.559 ' CZ ' HG12 ' A' ' 124' ' ' VAL . 1.3 m-85 -124.93 162.0 25.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.896 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.448 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 22.1 m-85 -66.41 -48.17 70.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.875 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 78.6 m-20 -113.91 160.04 19.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.869 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.445 ' HE3' ' CD2' ' A' ' 78' ' ' PHE . 3.7 ttmt -63.22 -62.75 1.49 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.91 179.876 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.437 ' C ' ' O ' ' A' ' 129' ' ' LYS . 1.0 OUTLIER -35.16 -59.36 0.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.929 179.92 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.401 ' C ' ' O ' ' A' ' 130' ' ' TRP . 48.3 m-20 -37.58 -43.97 0.65 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.912 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . 0.468 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -74.71 -59.16 2.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.099 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.7 mt-10 -40.53 -54.76 2.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.829 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -43.53 -45.37 6.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.423 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -71.95 -58.49 3.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.07 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 97.1 mt -38.44 -36.37 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.124 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -83.35 -63.63 1.32 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.891 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -62.92 -62.73 1.52 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.925 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.497 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 68.8 mmm -51.8 -41.32 61.62 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.913 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -55.13 103.75 0.23 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.486 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 100.5 21.15 13.28 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.498 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 9.5 mm100 -105.64 177.42 4.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.787 0.327 . . . . 0.0 110.905 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . . . . . . . . . 17.0 m95 -106.74 121.69 44.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.903 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.47 ' C ' ' H ' ' A' ' 146' ' ' GLY . 36.4 tp -121.53 127.78 51.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.924 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 73.54 -36.62 0.84 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.477 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . 0.47 ' H ' ' C ' ' A' ' 144' ' ' LEU . . . 160.2 -14.25 0.19 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.516 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 51.2 mtt180 -127.38 149.24 50.16 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.762 0.315 . . . . 0.0 110.838 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . 0.403 ' O ' ' O ' ' A' ' 84' ' ' ASP . 38.8 mt-30 -53.89 169.35 0.16 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.915 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.449 ' CG2' HD22 ' A' ' 85' ' ' LEU . 33.8 pt -148.92 147.77 16.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.14 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 9.6 ptt180 -110.58 123.26 49.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.909 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 29.4 p -118.26 141.92 48.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.138 -179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . 0.459 ' CG ' ' N ' ' A' ' 153' ' ' TRP . 8.7 t-20 -165.08 166.91 18.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.904 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . 0.459 ' N ' ' CG ' ' A' ' 152' ' ' ASN . 11.2 m95 -56.51 112.25 1.22 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.934 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -51.23 -59.12 4.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.086 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 3.3 t -98.94 126.26 44.58 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.105 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 6.7 tpt85 -116.5 50.17 1.08 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.884 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . 0.427 ' CG ' ' HD2' ' A' ' 158' ' ' PRO . 44.2 tttm -63.97 140.26 97.83 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.581 0.705 . . . . 0.0 110.848 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . 0.427 ' HD2' ' CG ' ' A' ' 157' ' ' LYS . 54.0 Cg_endo -69.74 150.34 68.21 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.709 2.273 . . . . 0.0 112.336 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.82 -174.45 0.92 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.649 2.233 . . . . 0.0 112.346 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -137.9 147.62 57.31 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.597 0.713 . . . . 0.0 111.088 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.84 -28.19 25.17 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.691 2.26 . . . . 0.0 112.313 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 4.9 tppt? -50.06 124.59 10.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.886 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 5.4 t -108.25 -48.82 3.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.869 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 3.0 m 61.69 28.29 17.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.14 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -39.15 157.91 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.906 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? -166.85 144.93 5.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.908 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 98.7 p -149.63 126.13 10.91 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.848 -179.74 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . 0.409 ' OD1' ' N ' ' A' ' 169' ' ' THR . 4.0 t-20 -135.44 153.74 51.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.937 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' THR . . . . . 0.409 ' N ' ' OD1' ' A' ' 168' ' ' ASN . 58.6 m -113.45 91.96 3.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.108 -179.963 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 8.4 tptm -124.52 128.12 48.48 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.941 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -62.63 147.37 49.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.89 -179.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 16.9 t -72.5 95.95 1.87 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.853 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -73.07 174.13 47.31 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.464 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 97.55 0.65 Allowed 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.669 2.246 . . . . 0.0 112.337 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 32.5 t -55.59 165.89 0.76 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.89 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 1.5 t -89.0 150.2 22.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.874 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.503 -179.992 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 N-CA-C 112.478 -0.249 . . . . 0.0 112.478 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 51.6 p -63.94 141.15 58.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.925 0.393 . . . . 0.0 110.824 -179.684 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 24.0 m -120.91 133.42 55.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.887 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 139.3 139.57 3.81 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.52 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 8.1 t -45.92 136.58 6.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.835 0.35 . . . . 0.0 110.873 -179.733 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 3.6 m -62.35 162.46 9.95 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.854 -179.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -141.06 -117.45 1.37 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.446 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 7.5 mm-40 -134.4 158.87 42.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.897 0.38 . . . . 0.0 110.91 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 33.7 ttmt -115.46 -47.34 2.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.924 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 2.5 ttmp? -53.56 -55.56 24.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.955 179.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -77.78 131.48 37.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.88 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 37.8 p -106.37 43.06 1.18 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.138 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 38.9 m -65.99 -45.43 81.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.844 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 40.1 t30 -105.55 46.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.877 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 6.7 m170 -121.07 157.54 29.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.855 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 -106.94 116.65 32.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.876 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 64.1 m-70 -90.55 161.51 15.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.913 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 49.5 t -137.64 135.83 46.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.159 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . 0.432 ' CE2' ' HG3' ' A' ' 150' ' ' ARG . 17.9 t80 -87.63 132.41 34.09 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.899 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 6.5 t -132.38 110.0 15.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.116 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -117.74 -178.77 17.41 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.459 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.403 ' O ' ' O ' ' A' ' 148' ' ' GLN . 2.0 m-20 64.02 40.11 7.4 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.874 0.368 . . . . 0.0 110.859 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 9.4 mt -102.85 129.56 49.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.901 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.1 t -52.92 154.37 5.14 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.671 0.748 . . . . 0.0 110.832 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -4.23 13.6 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.636 2.224 . . . . 0.0 112.356 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -95.71 -29.77 14.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.459 ' CD1' ' HA3' ' A' ' 145' ' ' GLY . 48.3 mm -57.9 136.64 20.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.139 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.415 ' N ' HG23 ' A' ' 89' ' ' ILE . 14.3 t -117.18 164.05 15.36 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.145 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 16.7 m -40.78 -39.63 1.15 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.154 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 93' ' ' ASP . 29.5 mt-10 -61.92 -59.71 4.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . 0.418 ' C ' ' O ' ' A' ' 92' ' ' GLU . 0.6 OUTLIER -36.78 -56.59 0.84 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.86 -179.988 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 6.3 mt -48.19 -58.06 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.131 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.465 ' HA ' ' CD1' ' A' ' 104' ' ' ILE . 23.9 mtmt -49.65 -38.95 34.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.908 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.17 -31.37 72.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.081 179.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -72.78 -46.84 51.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.105 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.402 ' C ' HD13 ' A' ' 104' ' ' ILE . 20.1 m-85 -97.16 11.77 35.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.941 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.492 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -63.8 -59.73 10.8 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.531 0.681 . . . . 0.0 111.109 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.492 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 53.4 Cg_endo -69.77 -0.7 7.3 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.717 2.278 . . . . 0.0 112.315 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . 0.598 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 62.6 m-85 -99.64 -0.11 40.93 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.899 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 139.7 138.31 3.61 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.532 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.469 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 13.7 mtt85 -48.03 125.09 8.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.782 0.325 . . . . 0.0 110.862 -179.854 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.465 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 17.9 mt -100.02 138.73 23.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.102 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.458 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.3 t -111.9 -59.14 2.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.835 -179.895 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.445 ' HB3' ' CB ' ' A' ' 125' ' ' SER . 23.2 t70 -100.33 100.32 11.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.888 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . 0.438 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -133.6 124.93 27.72 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.117 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.468 ' HD3' ' N ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -161.67 155.59 21.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 -179.889 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.468 ' N ' ' HD3' ' A' ' 108' ' ' ARG . 76.5 t -106.14 117.4 51.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.147 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.572 HG21 ' CD2' ' A' ' 121' ' ' TYR . 60.2 t -47.36 141.33 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.13 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . 0.468 ' N ' HG11 ' A' ' 110' ' ' VAL . 47.6 mttt -139.33 151.01 46.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.879 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.444 ' O ' ' N ' ' A' ' 116' ' ' GLY . 25.7 t0 -63.74 122.95 17.65 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.889 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 27.9 ptm -72.49 -6.61 44.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.878 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -96.74 -48.43 5.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.111 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 45.4 p -100.75 -32.19 10.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.116 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 86.71 24.13 39.89 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.452 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 44.8 mtmt -98.43 168.02 10.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.79 0.329 . . . . 0.0 110.917 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 15.8 t -64.37 114.26 4.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.826 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 27.3 mmtt -63.83 -47.25 81.54 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.887 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 139.38 -46.91 0.93 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.479 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.572 ' CD2' HG21 ' A' ' 110' ' ' VAL . 12.7 p90 -100.14 146.28 27.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.948 0.404 . . . . 0.0 110.891 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -128.11 176.94 17.91 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.445 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -122.56 141.41 51.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.86 0.362 . . . . 0.0 110.907 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.565 HG12 ' CE1' ' A' ' 126' ' ' PHE . 56.8 t -137.63 122.3 23.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.112 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' SER . . . . . 0.445 ' CB ' ' HB3' ' A' ' 106' ' ' ASP . 4.9 t -112.19 140.79 46.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.877 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.565 ' CE1' HG12 ' A' ' 124' ' ' VAL . 27.8 m-85 -121.53 147.97 45.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.843 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.469 ' CE2' ' HB3' ' A' ' 103' ' ' ARG . 21.6 m-85 -55.88 -49.8 72.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.89 -179.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 48.9 m-20 -99.47 166.73 11.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.886 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.463 ' HE3' ' CZ2' ' A' ' 153' ' ' TRP . 45.5 tptt -75.61 -45.78 35.53 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.863 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.417 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.9 OUTLIER -55.78 -54.56 42.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.918 179.915 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 130' ' ' TRP . 60.5 m-20 -35.67 -43.24 0.27 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.883 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.81 -56.9 4.13 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.129 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.5 mt-10 -45.23 -56.96 4.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.857 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 29.6 t-20 -43.35 -49.71 6.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.931 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -64.39 -53.32 50.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.087 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 94.7 mt -41.49 -34.38 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.141 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 9.6 mt-30 -84.71 -69.55 0.64 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.905 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 28.2 mt-30 -55.99 -59.38 4.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.897 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.598 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 53.9 mmm -58.12 -43.1 87.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.449 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -56.98 91.41 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.493 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 125.02 6.16 6.5 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.459 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . 0.479 ' HG2' ' CD1' ' A' ' 149' ' ' ILE . 0.5 OUTLIER -92.33 -178.57 4.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.728 0.299 . . . . 0.0 110.957 -179.915 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . 0.478 ' N ' ' HG3' ' A' ' 142' ' ' GLN . 16.6 m95 -114.47 115.16 26.81 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.923 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 62.4 tp -108.1 128.45 54.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.91 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . 0.459 ' HA3' ' CD1' ' A' ' 89' ' ' ILE . . . 69.97 -75.57 0.46 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.481 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.24 15.9 0.28 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.479 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 39.1 mtt85 -155.48 157.18 36.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.722 0.296 . . . . 0.0 110.867 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . 0.428 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 16.6 mt-30 -60.51 170.3 1.44 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.937 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.479 ' CD1' ' HG2' ' A' ' 142' ' ' GLN . 23.6 pt -135.17 152.98 33.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.179 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.432 ' HG3' ' CE2' ' A' ' 81' ' ' PHE . 12.5 ptm180 -120.38 104.23 9.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.86 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.449 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 44.9 p -99.45 127.91 45.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.174 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -150.85 173.79 13.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.878 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . 0.463 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 7.3 m95 -68.99 138.23 54.37 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -99.83 77.05 2.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.117 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 77.7 p -153.71 138.52 17.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.171 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 33.6 ttp180 -73.1 104.04 4.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.839 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 79.5 tttt -139.44 133.95 16.16 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.601 0.715 . . . . 0.0 110.909 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 152.67 69.47 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.672 2.248 . . . . 0.0 112.352 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 176.53 6.67 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.679 2.253 . . . . 0.0 112.36 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -97.96 154.31 37.83 Favored Pre-proline 0 C--N 1.33 -0.283 0 CA-C-O 121.562 0.696 . . . . 0.0 111.097 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.77 165.07 32.2 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.718 2.278 . . . . 0.0 112.355 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 18.1 mmtp -139.63 156.41 46.86 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.906 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 94.0 p -135.16 110.75 9.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.837 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 12.2 t -95.18 133.71 38.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.138 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 11.9 p90 -128.51 160.64 31.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.932 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 9.2 mm-40 -142.3 136.58 29.88 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 3.0 m -165.52 167.62 17.28 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.848 -179.761 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 35.8 t30 -137.25 173.58 11.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.847 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 13.8 t -156.17 163.4 39.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.134 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 15.4 ttpt -143.43 118.71 10.2 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.877 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.58 161.06 14.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.87 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 1.8 m -111.74 152.7 27.48 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.906 -179.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -106.33 86.62 0.48 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.469 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.73 95.66 0.56 Allowed 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.697 2.264 . . . . 0.0 112.328 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 16.7 m -43.09 166.6 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.884 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 45.1 t -121.22 -54.61 1.99 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.844 -179.823 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.535 -179.967 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.516 -0.234 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 9.0 t -72.4 117.58 14.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.927 0.394 . . . . 0.0 110.824 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 94.5 p -155.36 176.88 12.01 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.829 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 75.35 41.18 31.39 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.476 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 73.3 m -79.17 87.96 4.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.843 0.354 . . . . 0.0 110.803 -179.746 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 5.8 t 62.84 42.3 7.98 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.884 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -132.48 115.88 1.7 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.546 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 -82.87 139.79 33.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.876 0.369 . . . . 0.0 110.925 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -116.52 152.86 33.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.933 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 9.5 ptmm? -89.23 -43.19 11.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.892 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -79.83 98.23 6.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.865 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.7 p -53.56 115.01 1.73 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.187 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 19.8 m -119.5 -53.02 2.24 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.814 -179.811 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.5 m120 -108.33 42.02 1.46 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.902 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 36.8 m170 -115.44 160.07 20.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.85 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.554 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 43.8 m-85 -108.16 116.49 32.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.864 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 58.2 m-70 -88.06 135.29 33.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.863 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 53.7 t -114.78 140.3 36.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.096 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.5 t80 -91.28 135.29 33.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.898 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 16.6 t -131.73 127.54 59.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.069 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . 0.463 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -137.39 171.75 23.04 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.491 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ASP . . . . . 0.41 ' O ' ' O ' ' A' ' 148' ' ' GLN . 6.6 t70 64.37 53.07 1.75 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.839 0.352 . . . . 0.0 110.857 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 21.3 mt -106.34 133.39 51.11 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.941 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -54.07 155.1 6.85 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.651 0.739 . . . . 0.0 110.862 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 -10.08 27.67 Favored 'Trans proline' 0 N--CA 1.465 -0.159 0 C-N-CA 122.73 2.287 . . . . 0.0 112.352 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -97.78 0.49 46.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.896 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.443 HG21 ' N ' ' A' ' 90' ' ' THR . 49.0 mm -88.02 136.83 22.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.151 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.443 ' N ' HG21 ' A' ' 89' ' ' ILE . 12.9 t -121.21 179.39 4.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.124 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 85.4 m -51.18 -45.44 61.78 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.102 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -59.34 -55.79 30.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.837 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -38.18 -57.78 1.05 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.887 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.439 HG23 ' CG2' ' A' ' 124' ' ' VAL . 6.7 mt -48.37 -62.04 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.131 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.463 ' HG3' ' CB ' ' A' ' 107' ' ' ALA . 26.0 mtmt -45.18 -39.88 6.62 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.948 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.02 -32.45 74.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.097 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -69.84 -54.66 12.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.084 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' PHE . . . . . 0.408 ' C ' HD12 ' A' ' 104' ' ' ILE . 22.7 m-85 -88.23 8.55 26.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.894 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.482 ' N ' ' HD2' ' A' ' 100' ' ' PRO . . . -62.06 -60.04 11.33 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.567 0.698 . . . . 0.0 111.096 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.482 ' HD2' ' N ' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.76 -0.76 7.38 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.721 2.28 . . . . 0.0 112.351 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -100.02 -10.91 21.05 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.905 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 154.69 156.43 7.71 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.47 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.43 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 29.8 mtm180 -64.61 121.7 15.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.742 0.306 . . . . 0.0 110.891 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.454 HG23 ' CG1' ' A' ' 124' ' ' VAL . 15.3 mt -100.33 139.76 21.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.138 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 36.0 t -113.47 -59.59 2.0 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.832 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -100.82 100.97 11.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.842 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . 0.463 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -131.67 128.34 38.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.067 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.8 ptp180 -161.58 161.66 29.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.892 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 32.6 t -112.98 122.2 66.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.122 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.543 HG21 ' CD2' ' A' ' 121' ' ' TYR . 58.8 t -55.83 142.94 9.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.137 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 28.5 mttp -142.19 154.48 44.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.872 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.489 ' O ' ' N ' ' A' ' 116' ' ' GLY . 47.3 t0 -62.61 121.58 13.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.872 179.87 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 14.4 ptp -72.53 0.76 9.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.898 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -103.5 -34.62 8.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.099 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 6.9 p -123.39 -33.83 3.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.149 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.489 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 90.61 26.28 23.21 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.501 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -93.37 140.74 29.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.762 0.315 . . . . 0.0 110.9 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 2.8 t -46.24 113.06 0.56 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.866 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 34.5 mttt -67.23 -49.87 62.85 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.896 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 140.51 -39.95 1.42 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.497 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' TYR . . . . . 0.543 ' CD2' HG21 ' A' ' 110' ' ' VAL . 24.5 p90 -100.13 144.43 29.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.927 0.394 . . . . 0.0 110.945 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -131.77 -179.79 16.48 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.507 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 65.4 m-85 -124.57 138.94 54.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.874 0.369 . . . . 0.0 110.884 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.535 HG11 ' CZ ' ' A' ' 126' ' ' PHE . 48.4 t -138.84 113.3 7.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.113 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 20.6 t -100.97 151.49 21.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.82 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' PHE . . . . . 0.535 ' CZ ' HG11 ' A' ' 124' ' ' VAL . 3.0 m-85 -131.0 149.57 52.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.885 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' PHE . . . . . 0.43 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 81.4 m-85 -64.27 -35.73 81.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.848 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -120.49 157.26 29.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.914 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.554 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 40.4 tttt -65.89 -64.4 0.87 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.922 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' TRP . . . . . 0.453 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -34.17 -62.04 0.34 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.93 179.903 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 130' ' ' TRP . 5.7 m-20 -36.08 -43.41 0.34 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.841 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 129' ' ' LYS . . . -73.56 -60.69 2.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.084 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -42.99 -55.85 3.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.89 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -43.31 -44.65 5.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' ALA . . . . . 0.458 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -74.06 -56.06 5.37 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.094 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 76.9 mt -39.83 -37.35 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.125 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -83.04 -55.91 4.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.846 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 4.3 mm-40 -66.26 -63.45 1.08 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.883 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' MET . . . . . 0.458 ' N ' ' O ' ' A' ' 135' ' ' ALA . 84.3 mmm -51.07 -36.21 38.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.843 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -56.15 107.75 0.94 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.531 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 104.1 -17.39 48.32 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.464 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 15.1 mm-40 -67.69 -177.94 0.85 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.768 0.318 . . . . 0.0 110.945 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' TRP . . . . . 0.415 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 13.8 m95 -115.72 137.13 52.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.899 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.464 ' C ' ' H ' ' A' ' 146' ' ' GLY . 55.7 tp -130.27 121.56 26.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.937 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' GLY . . . . . . . . . . . . . . . 75.39 -24.19 1.44 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.473 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . 0.464 ' H ' ' C ' ' A' ' 144' ' ' LEU . . . 144.99 -6.88 1.61 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.477 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 54.0 mtt85 -130.61 144.07 51.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.812 0.339 . . . . 0.0 110.843 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' GLN . . . . . 0.415 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 23.9 mt-30 -51.48 163.92 0.24 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.913 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 25.3 pt -137.69 155.22 30.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.099 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.497 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 7.6 ptm180 -118.12 118.23 31.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.874 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 34.3 p -117.64 132.35 56.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.136 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -158.55 173.35 16.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 32.8 m95 -65.15 118.0 8.58 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.871 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -49.12 -55.42 12.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.097 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 73.3 p -106.6 118.18 35.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.146 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 5.1 ptm180 -140.82 156.38 46.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.872 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 40.1 tttm -166.2 137.55 2.93 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.557 0.694 . . . . 0.0 110.906 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 148.46 65.34 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.661 2.241 . . . . 0.0 112.403 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 177.04 6.0 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.632 2.221 . . . . 0.0 112.366 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . 0.404 ' CB ' ' HD2' ' A' ' 161' ' ' PRO . . . -145.34 165.67 20.77 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.581 0.705 . . . . 0.0 111.063 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' PRO . . . . . 0.404 ' HD2' ' CB ' ' A' ' 160' ' ' ALA . 54.2 Cg_endo -69.71 -10.29 28.24 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.695 2.263 . . . . 0.0 112.343 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 25.7 tptp -81.77 129.67 34.81 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.874 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 9.8 t -131.99 108.22 9.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.876 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 67.3 p -39.75 136.6 1.02 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.157 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' TYR . . . . . 0.463 ' O ' ' CG ' ' A' ' 165' ' ' TYR . 4.6 p90 -132.02 100.46 5.07 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.879 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -153.78 133.58 13.06 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.832 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 78.0 p -111.42 130.53 55.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.85 -179.795 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -139.95 167.99 20.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.89 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 14.0 t -67.64 152.21 46.0 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.157 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.12 159.31 34.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.908 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -123.61 -48.84 1.91 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.919 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 4.3 m -109.2 149.78 28.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.855 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -173.5 76.99 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.488 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 97.35 0.63 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.665 2.243 . . . . 0.0 112.348 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 31.0 m -130.1 171.65 12.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.893 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 1.3 t -125.96 -61.02 1.26 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.914 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.526 179.988 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.93 0.395 . . . . 0.0 110.883 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 69.6 m-70 -86.62 144.45 27.16 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.861 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 23.7 t -118.86 146.71 23.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.114 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -99.26 135.59 40.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.935 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.799 HG12 HD21 ' A' ' 85' ' ' LEU . 6.0 t -134.56 131.07 54.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.152 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.478 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -137.07 -175.8 14.01 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.459 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 60.74 26.4 16.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.897 0.379 . . . . 0.0 110.899 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.799 HD21 HG12 ' A' ' 82' ' ' VAL . 10.9 mt -84.53 128.22 34.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.907 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.41 153.93 6.73 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.685 0.755 . . . . 0.0 110.841 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 -9.87 27.19 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.711 2.274 . . . . 0.0 112.325 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -97.44 -5.04 37.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.901 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.812 HD11 ' HA3' ' A' ' 145' ' ' GLY . 40.5 mm -77.23 139.4 18.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.131 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.6 t -116.8 163.7 15.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.131 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.666 ' HA ' HG23 ' A' ' 109' ' ' VAL . 6.3 m -43.8 -38.56 3.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.079 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -63.09 -56.56 15.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.896 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.548 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.4 m-20 -37.75 -52.88 1.28 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.842 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.508 HD11 HG22 ' A' ' 109' ' ' VAL . 5.1 mt -52.11 -58.7 2.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.127 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.603 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 24.2 mtmt -49.45 -39.2 32.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.889 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.87 -35.0 75.49 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.112 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.566 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -68.67 -55.53 11.12 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.091 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 35.6 m-85 -85.05 1.63 46.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.874 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.786 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -52.75 -60.11 7.3 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.605 0.717 . . . . 0.0 111.147 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.786 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.7 -1.03 7.72 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.689 2.26 . . . . 0.0 112.357 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -99.96 9.55 42.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.26 143.48 5.78 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.497 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 45.8 mtt85 -52.17 121.87 7.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.739 0.304 . . . . 0.0 110.857 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.446 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 13.1 mt -95.04 136.79 25.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.102 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.434 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 2.4 p -103.28 -64.53 1.07 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.86 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -100.59 109.17 21.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.822 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.555 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -138.94 125.03 20.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.116 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.476 ' HB2' ' CZ ' ' A' ' 108' ' ' ARG . 2.6 ptm85 -157.39 165.08 36.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.867 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.666 HG23 ' HA ' ' A' ' 91' ' ' THR . 87.3 t -112.93 112.73 41.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.168 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.916 HG11 ' CE2' ' A' ' 121' ' ' TYR . 97.1 t -45.98 137.9 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.154 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 84.7 mttt -137.86 161.22 37.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.924 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.475 ' OD2' ' HB3' ' A' ' 114' ' ' ALA . 9.3 t0 -75.15 125.94 29.99 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.868 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 14.3 ptp -75.77 -1.74 26.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.929 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.475 ' HB3' ' OD2' ' A' ' 112' ' ' ASP . . . -96.58 -39.59 9.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 30.6 p -119.51 -33.91 3.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.16 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 93.62 24.22 21.55 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.468 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 41.2 mmtt -93.55 151.17 19.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.82 0.343 . . . . 0.0 110.874 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 1.8 m -52.53 113.18 0.98 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.855 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.739 ' HG3' HG12 ' A' ' 110' ' ' VAL . 26.2 mmtt -63.14 -38.54 91.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.926 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.408 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 129.81 -40.06 1.73 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.505 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.916 ' CE2' HG11 ' A' ' 110' ' ' VAL . 3.0 p90 -100.02 155.09 17.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.943 0.402 . . . . 0.0 110.924 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.04 168.28 24.37 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.479 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 81.9 m-85 -117.47 141.54 48.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.914 0.388 . . . . 0.0 110.911 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.699 HG12 ' CE1' ' A' ' 126' ' ' PHE . 88.9 t -141.94 114.04 3.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.132 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 45.7 t -106.06 142.99 34.84 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.816 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.699 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.5 m-85 -119.24 158.46 25.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.898 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.434 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 20.7 m-85 -66.91 -42.3 85.67 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.883 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 25.3 m-80 -110.13 166.95 10.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.911 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 58.7 tttt -76.15 -44.2 39.39 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.898 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.429 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -54.71 -59.32 4.88 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.929 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 130' ' ' TRP . 88.8 m-20 -35.8 -56.17 0.7 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.896 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.415 ' HB2' ' CD1' ' A' ' 126' ' ' PHE . . . -63.39 -65.11 0.73 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.084 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.428 ' HA ' HD12 ' A' ' 136' ' ' ILE . 4.6 mm-40 -37.31 -59.01 0.79 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -42.65 -48.58 5.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.907 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.47 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -64.64 -56.45 13.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.094 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' ILE . . . . . 0.428 HD12 ' HA ' ' A' ' 133' ' ' GLU . 94.8 mt -38.6 -34.45 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.139 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -86.09 -60.39 2.02 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.883 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 9.6 mt-30 -63.73 -58.14 7.8 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.47 ' N ' ' O ' ' A' ' 135' ' ' ALA . 50.3 mmm -54.86 -34.91 63.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.878 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.45 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -60.89 117.45 11.66 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.47 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 92.56 12.48 58.22 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.524 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 13.6 mm-40 -94.43 170.83 9.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.759 0.314 . . . . 0.0 110.901 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' TRP . . . . . 0.42 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 16.2 m95 -106.1 109.08 20.91 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.87 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.566 HD13 ' HB2' ' A' ' 97' ' ' ALA . 64.6 tp -102.51 128.88 48.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.86 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 0.812 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.03 -75.69 0.33 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.458 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.37 15.54 0.32 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.478 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 147' ' ' ARG . . . . . 0.431 ' NH1' ' HB3' ' A' ' 147' ' ' ARG . 8.0 mtp-105 -156.11 159.33 38.96 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.796 0.331 . . . . 0.0 110.859 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.42 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 30.2 mt-30 -64.27 167.83 6.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.909 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 32.4 pt -140.89 145.97 24.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.136 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.478 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 6.5 ptt180 -107.25 109.76 21.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.45 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 43.8 p -103.84 137.01 42.45 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.112 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' ASN . . . . . 0.423 ' CG ' ' O ' ' A' ' 151' ' ' THR . 19.6 m120 -166.89 176.29 7.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.923 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 10.4 m95 . . . . . 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 179.98 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.561 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 93.2 m-85 . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.839 0.352 . . . . 0.0 110.905 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.48 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.5 OUTLIER -88.54 149.08 23.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.887 179.988 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 42.0 t -124.7 147.53 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.161 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -98.22 138.63 35.21 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.846 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.606 HG12 HD21 ' A' ' 85' ' ' LEU . 15.2 t -136.07 129.56 47.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.12 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.461 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -139.75 177.49 20.45 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.439 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 18.8 t0 64.08 41.91 6.03 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.848 0.356 . . . . 0.0 110.909 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.606 HD21 HG12 ' A' ' 82' ' ' VAL . 9.5 mt -102.41 137.02 41.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.929 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -54.93 153.86 10.78 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.691 0.758 . . . . 0.0 110.875 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 -12.0 31.91 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.676 2.251 . . . . 0.0 112.317 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -93.26 -9.57 38.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.915 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.972 HD11 ' HA3' ' A' ' 145' ' ' GLY . 42.3 mm -74.65 137.1 23.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.077 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.421 ' O ' ' C ' ' A' ' 91' ' ' THR . 11.3 t -120.46 162.48 19.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.116 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.5 ' HA ' HG23 ' A' ' 109' ' ' VAL . 53.2 m -36.03 -49.27 0.64 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.14 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 93' ' ' ASP . 20.2 mt-10 -52.8 -60.33 3.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.899 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.623 ' CB ' HG23 ' A' ' 89' ' ' ILE . 1.0 OUTLIER -34.78 -57.47 0.53 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.909 179.972 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.525 HD11 HG22 ' A' ' 109' ' ' VAL . 12.6 mt -48.61 -60.0 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.093 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.648 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 24.5 mtmt -47.66 -39.85 18.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.931 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.49 -28.91 70.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.087 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.7 -50.68 13.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.095 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.47 ' C ' HD11 ' A' ' 104' ' ' ILE . 19.1 m-85 -91.16 12.16 20.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.763 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -66.6 -59.68 7.73 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.578 0.704 . . . . 0.0 111.09 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.763 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.73 -0.6 7.12 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.637 2.225 . . . . 0.0 112.35 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.505 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 74.9 m-85 -99.61 -11.96 20.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.888 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 152.26 137.53 2.59 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.496 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.424 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 10.1 mtm-85 -48.76 122.64 5.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.81 0.338 . . . . 0.0 110.848 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.47 HD11 ' C ' ' A' ' 98' ' ' PHE . 10.2 mt -99.99 141.75 16.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.125 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.4 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 3.5 t -109.68 -63.73 1.33 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.858 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -100.44 104.85 16.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.881 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.56 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -134.67 128.91 33.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.109 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.477 ' HA ' HG23 ' A' ' 91' ' ' THR . 11.5 ptm180 -161.79 163.6 29.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.841 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.525 HG22 HD11 ' A' ' 94' ' ' ILE . 89.9 t -110.85 120.47 61.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.098 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.605 HG21 ' CE2' ' A' ' 121' ' ' TYR . 57.4 t -50.7 135.85 10.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.115 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 46.3 mttm -136.21 146.08 46.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.442 ' O ' ' N ' ' A' ' 116' ' ' GLY . 32.1 t0 -55.02 123.42 13.51 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.891 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 9.1 tpt -71.07 -2.52 15.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.873 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -103.08 -48.72 3.96 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.062 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 34.0 p -102.25 -29.37 11.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.138 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 80.51 28.45 47.75 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.47 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 14.5 mtpp -99.86 148.82 24.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.781 0.324 . . . . 0.0 110.891 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 5.4 t -51.8 105.64 0.12 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.842 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 36.6 mttt -58.47 -46.81 85.88 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.9 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.406 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 142.13 -41.94 1.17 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.484 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.605 ' CE2' HG21 ' A' ' 110' ' ' VAL . 9.5 p90 -99.86 149.15 23.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.888 0.375 . . . . 0.0 110.947 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -130.58 179.64 16.77 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.479 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -126.62 142.04 51.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.876 0.37 . . . . 0.0 110.921 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.664 HG12 ' CE1' ' A' ' 126' ' ' PHE . 60.2 t -138.94 123.9 21.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.096 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' SER . . . . . 0.432 ' O ' HG23 ' A' ' 104' ' ' ILE . 33.0 m -112.19 144.77 41.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.877 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.664 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.2 m-85 -125.32 150.55 47.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.424 ' CE2' ' HB3' ' A' ' 103' ' ' ARG . 21.9 m-85 -57.65 -46.48 84.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.92 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 25.7 m-20 -112.05 163.45 14.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.91 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.561 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 69.9 tttt -72.11 -61.64 1.72 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.897 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.434 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.9 OUTLIER -34.78 -56.76 0.55 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.906 179.99 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -42.08 -52.02 4.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.851 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -63.37 -60.64 3.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.115 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.411 ' HA ' HD12 ' A' ' 136' ' ' ILE . 5.7 mm-40 -39.44 -60.21 0.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 32.6 t-20 -40.29 -44.77 1.98 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.903 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.424 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -69.63 -54.39 14.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.091 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 136' ' ' ILE . . . . . 0.411 HD12 ' HA ' ' A' ' 133' ' ' GLU . 91.7 mt -41.58 -34.83 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.14 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 19.0 mt-30 -87.29 -60.55 1.95 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.911 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 29.3 mm-40 -60.29 -60.17 4.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.901 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.505 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 75.7 mmm -56.84 -41.8 78.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.873 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.441 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -53.09 103.07 0.11 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.478 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 107.41 6.65 33.28 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.51 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 -90.11 173.87 7.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.799 0.333 . . . . 0.0 110.932 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' TRP . . . . . 0.48 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 17.8 m95 -109.02 121.22 44.68 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.952 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.534 HD23 HD22 ' A' ' 85' ' ' LEU . 34.2 tp -122.85 127.27 48.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.888 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 0.972 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 72.12 -7.08 8.37 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.474 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 124.16 -9.71 8.36 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.507 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 17.9 mtt180 -127.63 148.9 50.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.722 0.296 . . . . 0.0 110.91 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.48 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 28.1 mt-30 -60.19 152.96 23.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.923 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.592 HG22 HD23 ' A' ' 85' ' ' LEU . 24.6 pt -123.07 153.55 28.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.099 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.474 ' CG ' ' O ' ' A' ' 150' ' ' ARG . 10.1 ptm180 -114.93 114.05 24.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.441 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 73.4 p -107.86 130.4 55.0 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.159 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -157.39 172.38 18.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 24.2 m95 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.896 179.968 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.491 ' CD2' ' HA ' ' A' ' 129' ' ' LYS . 37.3 m-85 . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.881 0.372 . . . . 0.0 110.855 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 58.4 m-70 -86.08 155.87 20.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.866 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 45.4 t -129.07 141.55 46.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.098 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.0 t80 -90.7 133.33 35.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.876 HG12 HD21 ' A' ' 85' ' ' LEU . 5.6 t -129.74 110.0 19.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.123 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.47 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -118.18 168.21 13.07 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.473 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.9 t70 68.76 52.73 0.54 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.813 0.34 . . . . 0.0 110.877 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.876 HD21 HG12 ' A' ' 82' ' ' VAL . 16.2 mt -109.68 131.49 55.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.919 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.1 t -53.98 154.71 7.16 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.624 0.726 . . . . 0.0 110.885 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -14.51 36.15 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.693 2.262 . . . . 0.0 112.36 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -93.07 -5.24 50.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.911 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.626 HD11 ' HA3' ' A' ' 145' ' ' GLY . 40.5 mm -78.37 138.11 20.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.127 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.3 t -120.84 170.5 9.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.181 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.526 ' HA ' HG23 ' A' ' 109' ' ' VAL . 88.3 m -43.64 -49.85 7.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.168 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.437 ' O ' ' C ' ' A' ' 93' ' ' ASP . 57.7 mt-10 -52.05 -60.16 3.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.91 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.525 ' CB ' HG23 ' A' ' 89' ' ' ILE . 5.9 m-20 -34.51 -57.99 0.5 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.891 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.506 ' CD1' HG22 ' A' ' 109' ' ' VAL . 7.6 mt -49.52 -62.26 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.117 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.693 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 27.8 mtmt -46.12 -40.1 10.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.943 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.52 -31.61 71.63 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.154 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.582 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -72.97 -53.86 10.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.121 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -88.14 7.07 33.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.853 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.774 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -60.73 -59.93 12.27 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.609 0.719 . . . . 0.0 111.097 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.774 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.1 Cg_endo -69.77 -0.75 7.38 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.685 2.257 . . . . 0.0 112.314 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.593 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 73.8 m-85 -99.78 -5.04 29.3 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.914 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 144.25 136.2 3.04 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.507 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 29.5 mtt180 -46.78 124.41 6.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.795 0.331 . . . . 0.0 110.869 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.469 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 13.2 mt -100.09 138.26 24.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.151 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.495 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 47.1 p -107.33 -61.83 1.5 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.848 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -100.2 104.56 16.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.871 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.491 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -134.94 127.32 30.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.051 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.45 ' HA ' HG23 ' A' ' 91' ' ' THR . 1.9 ptt-85 -160.94 157.94 27.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.886 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.526 HG23 ' HA ' ' A' ' 91' ' ' THR . 86.8 t -110.26 115.42 49.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.135 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.641 HG21 ' CD2' ' A' ' 121' ' ' TYR . 48.7 t -46.97 136.82 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.147 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 54.0 mttt -137.46 148.69 46.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.945 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.638 ' OD2' ' HB3' ' A' ' 114' ' ' ALA . 25.8 t70 -58.54 130.18 45.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.879 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 28.4 ptm -78.88 1.63 22.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.866 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.638 ' HB3' ' OD2' ' A' ' 112' ' ' ASP . . . -102.82 -41.18 6.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.087 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 45.1 p -114.43 -29.07 6.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.167 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 84.52 21.43 56.4 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.497 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 48.4 mmtt -92.93 145.25 24.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.769 0.318 . . . . 0.0 110.902 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 4.9 t -46.69 111.86 0.44 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.853 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -62.7 -51.46 67.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 147.46 -41.56 0.93 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.486 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.641 ' CD2' HG21 ' A' ' 110' ' ' VAL . 4.9 p90 -100.06 153.13 19.47 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.928 0.394 . . . . 0.0 110.915 -179.791 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.42 173.7 22.14 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.468 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -122.54 140.45 52.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.897 0.379 . . . . 0.0 110.92 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.678 HG12 ' CE1' ' A' ' 126' ' ' PHE . 59.2 t -137.62 116.38 14.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.12 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 15.5 t -104.87 147.16 28.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.852 -179.84 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.678 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.2 m-85 -126.84 150.2 49.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.875 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.495 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 23.1 m-85 -56.7 -44.42 81.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 24.4 m-20 -112.86 166.47 11.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.905 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.561 ' HE3' ' CZ2' ' A' ' 153' ' ' TRP . 39.2 tptt -70.99 -59.99 2.48 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.944 179.854 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.426 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.8 OUTLIER -40.93 -59.92 1.32 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.922 179.941 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.426 ' C ' ' O ' ' A' ' 130' ' ' TRP . 6.9 m-20 -35.8 -39.11 0.14 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.863 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -80.43 -58.51 3.09 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.063 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.4 mt-10 -44.38 -55.68 4.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.948 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 54.7 t30 -42.8 -42.07 3.46 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.909 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.49 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -71.81 -55.78 6.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.055 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 76.1 mt -38.76 -36.4 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.104 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -83.6 -57.19 3.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 16.8 mm-40 -68.54 -61.16 1.95 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.897 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.593 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 41.3 mmm -52.97 -31.38 40.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.905 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.447 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -63.04 107.78 1.84 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.491 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 99.94 13.73 36.12 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.487 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 66.5 mm-40 -93.1 166.88 12.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.802 0.334 . . . . 0.0 110.89 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 143' ' ' TRP . . . . . 0.444 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 14.5 m95 -102.89 107.06 17.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.89 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.582 HD13 ' HB2' ' A' ' 97' ' ' ALA . 63.6 tp -100.02 126.46 46.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.873 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 0.626 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.25 -76.95 0.46 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.493 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -155.96 14.5 0.41 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.497 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 36.7 mtp180 -153.04 157.01 39.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.783 0.325 . . . . 0.0 110.866 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.444 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 30.8 mt-30 -62.16 167.2 4.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.927 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.413 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 25.7 pt -138.96 153.21 24.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.488 ' CG ' ' O ' ' A' ' 150' ' ' ARG . 7.0 ptm180 -118.82 116.47 26.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.9 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.447 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 53.5 p -107.53 135.53 48.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.134 -179.898 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 28.4 t30 -160.15 171.09 19.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' TRP . . . . . 0.561 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 15.3 m95 . . . . . 0 C--N 1.328 -0.344 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.937 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.564 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 84.3 m-85 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.85 0.357 . . . . 0.0 110.906 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 10.2 m-70 -89.65 147.84 23.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.89 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 41.4 t -119.21 143.47 30.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.157 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.1 t80 -93.56 135.3 34.96 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.666 ' CG1' HD21 ' A' ' 85' ' ' LEU . 4.0 t -131.25 131.04 63.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.157 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.432 ' N ' ' HG2' ' A' ' 150' ' ' ARG . . . -135.8 179.41 17.82 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.524 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 52.37 47.61 24.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.86 0.362 . . . . 0.0 110.852 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.668 HD22 HD23 ' A' ' 144' ' ' LEU . 30.0 mt -99.65 132.91 44.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.938 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -53.01 156.33 3.61 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.651 0.738 . . . . 0.0 110.868 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -39.53 6.28 Favored 'Trans proline' 0 C--O 1.231 0.125 0 C-N-CA 122.675 2.25 . . . . 0.0 112.337 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -71.46 1.2 6.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.887 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.91 HD11 ' HA3' ' A' ' 145' ' ' GLY . 37.3 mm -83.01 132.37 31.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.169 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.1 t -114.74 175.34 5.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.104 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.555 ' HA ' HG23 ' A' ' 109' ' ' VAL . 16.2 m -52.99 -41.66 64.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.147 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -62.36 -47.03 85.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.894 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.414 ' CB ' HG23 ' A' ' 89' ' ' ILE . 17.1 m-20 -47.87 -50.08 27.54 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.911 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.746 HD11 HG22 ' A' ' 109' ' ' VAL . 8.1 mt -54.7 -54.97 17.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.132 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.587 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 22.0 mtmt -50.93 -42.47 59.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.866 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -58.42 -30.98 67.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.107 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.535 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -72.46 -57.16 4.39 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.101 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.429 ' C ' HD11 ' A' ' 104' ' ' ILE . 22.0 m-85 -87.37 12.22 12.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.935 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.789 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -61.79 -60.19 11.05 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.613 0.72 . . . . 0.0 111.119 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.789 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.5 Cg_endo -69.8 -0.8 7.47 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.678 2.252 . . . . 0.0 112.306 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -99.9 9.57 42.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.883 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.26 136.02 4.24 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.525 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 38.9 mtt85 -46.73 125.04 6.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.766 0.317 . . . . 0.0 110.882 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.429 HD11 ' C ' ' A' ' 98' ' ' PHE . 10.9 mt -98.21 138.83 21.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.153 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.449 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.9 t -106.73 -62.91 1.34 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.848 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -100.25 105.2 16.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.861 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.481 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -136.46 127.01 26.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.138 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.2 ptm180 -161.91 155.85 21.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.892 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.746 HG22 HD11 ' A' ' 94' ' ' ILE . 58.4 t -102.07 119.14 49.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.642 HG21 ' CD2' ' A' ' 121' ' ' TYR . 59.8 t -53.86 136.99 15.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.141 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 111' ' ' LYS . . . . . 0.412 ' C ' ' HG3' ' A' ' 119' ' ' LYS . 57.5 mttt -136.59 153.89 50.83 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.755 ' OD2' ' HB3' ' A' ' 114' ' ' ALA . 23.2 t70 -64.99 120.21 12.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 16.4 ptp -67.14 -10.93 55.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.841 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.755 ' HB3' ' OD2' ' A' ' 112' ' ' ASP . . . -83.62 -54.81 4.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.107 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 13.5 p -104.85 -34.4 8.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.171 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 95.89 25.71 12.7 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.477 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 44.4 mtmt -95.33 154.68 17.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.781 0.324 . . . . 0.0 110.867 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 8.0 t -54.89 112.49 1.05 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.91 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.453 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 16.6 mttp -63.36 -54.23 40.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.895 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 150.2 -41.76 0.79 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.469 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.642 ' CD2' HG21 ' A' ' 110' ' ' VAL . 5.4 p90 -100.01 155.25 17.8 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.96 0.41 . . . . 0.0 110.938 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -134.46 169.88 22.9 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.464 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -118.77 138.44 52.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.873 0.368 . . . . 0.0 110.914 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.678 HG12 ' CE1' ' A' ' 126' ' ' PHE . 61.2 t -138.77 115.08 10.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.143 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 8.2 t -107.23 140.02 40.77 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.877 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.678 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.2 m-85 -119.51 163.45 17.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.894 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.449 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 22.9 m-85 -72.32 -42.91 64.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.902 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 68.0 m-20 -114.18 161.44 17.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.864 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.564 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 44.3 tptt -69.74 -61.63 1.71 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.464 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.9 OUTLIER -33.27 -60.7 0.33 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.883 179.972 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 -39.67 -54.07 2.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.875 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -65.02 -59.49 4.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.08 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -43.5 -60.7 1.63 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.894 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -43.57 -44.11 5.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.836 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.462 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -66.63 -56.48 10.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.132 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 82.8 mt -40.91 -37.84 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.14 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 -76.47 -63.81 1.25 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.947 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 27.0 mt-30 -63.85 -61.24 2.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.931 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.462 ' N ' ' O ' ' A' ' 135' ' ' ALA . 65.6 mmm -51.43 -34.0 33.07 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.858 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.443 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -58.69 93.47 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.483 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 113.52 4.55 23.3 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.426 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 16.2 mm100 -80.66 171.13 15.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.797 0.332 . . . . 0.0 110.875 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' TRP . . . . . 0.425 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 15.4 m95 -106.7 111.29 23.76 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.92 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.668 HD23 HD22 ' A' ' 85' ' ' LEU . 66.3 tp -104.91 129.22 53.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.932 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 0.91 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.31 -78.04 0.45 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.492 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -155.29 14.03 0.46 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.499 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 23.9 mtt85 -153.73 161.46 42.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.771 0.32 . . . . 0.0 110.893 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.425 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 23.0 mt-30 -62.95 171.0 2.38 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.429 HG21 ' CB ' ' A' ' 144' ' ' LEU . 14.0 pt -142.07 158.43 20.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.124 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.487 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 7.7 ptm180 -120.82 118.6 30.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.867 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.443 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 61.0 p -111.15 132.44 54.29 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.159 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 41.2 t30 -157.66 174.07 15.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.942 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' TRP . . . . . 0.545 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 9.8 m95 . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.914 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.897 0.379 . . . . 0.0 110.911 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.434 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.5 OUTLIER -82.21 141.75 32.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.892 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.515 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 41.6 t -119.2 144.11 28.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.164 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.0 t80 -97.51 131.68 43.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.866 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.939 HG12 HD21 ' A' ' 85' ' ' LEU . 3.6 t -133.42 109.98 14.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.148 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -116.61 -178.12 17.99 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.519 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 63.98 34.99 11.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.894 0.378 . . . . 0.0 110.923 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.939 HD21 HG12 ' A' ' 82' ' ' VAL . 9.9 mt -92.76 128.96 38.8 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.918 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.05 154.27 5.48 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.657 0.741 . . . . 0.0 110.874 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -13.79 35.18 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.681 2.254 . . . . 0.0 112.358 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -92.94 -7.78 45.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.87 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.682 HD11 ' HA3' ' A' ' 145' ' ' GLY . 30.5 mm -78.38 138.54 20.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.17 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.0 t -119.27 167.26 12.04 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.11 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.597 ' HA ' HG23 ' A' ' 109' ' ' VAL . 21.2 m -42.4 -47.0 4.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.143 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -54.1 -57.71 10.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.885 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.602 ' CB ' HG23 ' A' ' 89' ' ' ILE . 4.0 m-20 -38.45 -57.11 1.18 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.862 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.492 HD11 HG22 ' A' ' 109' ' ' VAL . 6.4 mt -48.16 -58.33 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.101 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.578 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 23.6 mtmt -49.93 -44.37 50.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.928 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -58.56 -30.12 66.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.095 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.488 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -74.85 -58.19 3.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.157 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.45 ' CD2' ' HB1' ' A' ' 135' ' ' ALA . 42.9 m-85 -82.42 8.04 12.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.784 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -60.02 -60.21 11.35 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.591 0.71 . . . . 0.0 111.051 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.784 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.7 -0.99 7.66 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.661 2.241 . . . . 0.0 112.378 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.501 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 81.2 m-85 -99.91 3.63 44.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.903 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 136.55 156.61 7.47 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.458 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.459 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 34.0 mtt85 -64.44 125.18 23.84 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.796 0.331 . . . . 0.0 110.882 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.407 HD13 ' HA ' ' A' ' 95' ' ' LYS . 11.6 mt -100.3 137.21 28.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.115 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.534 ' OG ' ' CZ ' ' A' ' 127' ' ' PHE . 2.5 m -110.14 -60.41 1.8 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.895 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.0 t0 -101.22 102.24 13.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.878 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -131.99 125.62 31.97 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.117 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 11.9 ptp180 -159.73 157.58 29.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.841 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.597 HG23 ' HA ' ' A' ' 91' ' ' THR . 99.2 t -109.36 116.0 51.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.147 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.804 HG21 ' CE2' ' A' ' 121' ' ' TYR . 94.5 t -49.16 138.32 4.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.134 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 28.7 mttm -138.39 155.95 48.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.892 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.499 ' O ' ' N ' ' A' ' 116' ' ' GLY . 36.5 t0 -65.49 121.01 13.91 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.889 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 7.0 tpt -69.6 -9.29 53.5 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.898 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.93 -47.8 5.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.105 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 21.9 p -98.35 -34.23 10.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.099 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.499 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 86.33 23.6 43.36 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.474 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 14.8 mtpp -98.93 158.13 15.85 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.797 0.332 . . . . 0.0 110.91 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 47.4 t -56.67 112.91 1.42 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.868 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.713 ' HG3' HG12 ' A' ' 110' ' ' VAL . 25.3 mmtt -63.09 -38.83 92.76 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.918 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 130.49 -42.77 1.37 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.444 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.804 ' CE2' HG21 ' A' ' 110' ' ' VAL . 12.0 p90 -99.91 151.42 21.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.957 0.408 . . . . 0.0 110.892 -179.813 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -136.75 172.4 22.57 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.473 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -120.07 139.06 53.12 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.889 0.376 . . . . 0.0 110.914 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.721 HG12 ' CE1' ' A' ' 126' ' ' PHE . 53.1 t -136.84 111.0 9.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.111 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.8 t -99.38 151.58 20.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.893 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.721 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.5 m-85 -130.83 152.37 50.24 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.875 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.534 ' CZ ' ' OG ' ' A' ' 105' ' ' SER . 76.2 m-85 -66.01 -34.95 79.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.842 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -120.74 149.96 41.73 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.87 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.463 ' O ' ' C ' ' A' ' 130' ' ' TRP . 45.0 tttt -59.05 -65.82 0.6 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.866 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.463 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -33.47 -60.83 0.34 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.923 179.951 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 130' ' ' TRP . 68.8 m-20 -35.81 -46.63 0.46 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.87 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.515 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -74.78 -59.8 2.57 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.085 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -39.07 -53.31 1.82 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.846 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 50.5 t30 -49.22 -50.04 40.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.888 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.45 ' HB1' ' CD2' ' A' ' 98' ' ' PHE . . . -61.91 -53.15 59.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.085 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 136' ' ' ILE . . . . . 0.461 HG23 ' HA ' ' A' ' 152' ' ' ASN . 96.6 mt -42.28 -37.11 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.142 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 29.8 mt-30 -86.87 -62.29 1.54 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.908 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 26.3 mt-30 -54.4 -61.52 2.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.885 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.501 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 92.6 mmm -58.45 -41.07 84.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.878 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.443 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -46.88 99.48 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.462 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 101.55 17.78 20.64 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.518 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 57.0 mm-40 -96.51 172.42 7.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.782 0.325 . . . . 0.0 110.898 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' TRP . . . . . 0.523 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 16.0 m95 -107.54 110.71 22.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.873 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.488 HD13 ' HB2' ' A' ' 97' ' ' ALA . 57.3 tp -103.56 127.47 50.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.934 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 0.682 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.89 -75.66 0.44 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.463 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.83 15.51 0.3 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.475 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 42.3 mtt-85 -154.62 156.77 37.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.726 0.298 . . . . 0.0 110.874 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.523 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 33.4 mt-30 -63.12 168.95 3.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.921 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 26.5 pt -149.23 144.73 18.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.112 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 14.0 ptt180 -105.63 124.06 48.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.863 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.443 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 69.0 p -115.28 141.12 48.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.185 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 152' ' ' ASN . . . . . 0.461 ' HA ' HG23 ' A' ' 136' ' ' ILE . 73.9 m-20 -165.11 177.13 7.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.885 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 11.9 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.942 179.969 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.551 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 54.5 m-85 . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.87 0.366 . . . . 0.0 110.856 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 40.2 m-70 -87.32 148.25 25.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.83 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 34.9 t -123.64 139.64 49.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.122 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -91.94 134.48 34.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.903 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.832 HG12 HD21 ' A' ' 85' ' ' LEU . 3.8 t -132.51 109.93 15.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.14 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.41 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -117.36 170.72 13.59 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.478 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.8 t70 68.83 51.67 0.57 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.847 0.356 . . . . 0.0 110.905 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.832 HD21 HG12 ' A' ' 82' ' ' VAL . 16.5 mt -108.91 131.92 54.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.893 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 t -54.92 153.71 11.01 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.676 0.75 . . . . 0.0 110.85 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -11.29 30.5 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.682 2.254 . . . . 0.0 112.313 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -94.0 -9.83 35.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.911 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.644 HD11 ' HA3' ' A' ' 145' ' ' GLY . 46.9 mm -74.42 137.99 22.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.131 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.2 t -117.84 166.52 12.37 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.162 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.769 HG23 ' HA ' ' A' ' 108' ' ' ARG . 86.1 m -43.37 -46.34 6.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.137 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 93' ' ' ASP . 35.2 mt-10 -55.55 -57.94 9.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.891 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.533 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.0 m-20 -35.18 -58.59 0.54 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.879 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.5 ' CD1' HG22 ' A' ' 109' ' ' VAL . 10.9 mt -48.5 -58.91 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.138 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.604 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 23.9 mtmt -49.41 -39.41 32.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.929 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.03 -27.66 69.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.085 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.501 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -77.65 -52.2 9.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.121 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.404 ' C ' HD11 ' A' ' 104' ' ' ILE . 31.6 m-85 -89.33 13.49 13.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.781 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -67.61 -60.26 5.83 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.554 0.692 . . . . 0.0 111.082 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.781 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.5 Cg_endo -69.76 -0.84 7.49 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.689 2.259 . . . . 0.0 112.323 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -99.95 -5.14 28.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.876 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 144.2 142.0 3.84 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.494 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.444 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 57.4 mtt180 -50.81 125.91 14.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.81 0.338 . . . . 0.0 110.882 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.491 HG21 ' HB2' ' A' ' 107' ' ' ALA . 17.4 mt -99.32 145.72 9.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.127 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.446 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.0 OUTLIER -119.3 -60.09 1.77 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.823 -179.892 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -100.53 92.47 5.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.829 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.491 ' HB2' HG21 ' A' ' 104' ' ' ILE . . . -129.5 124.64 34.47 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.103 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.769 ' HA ' HG23 ' A' ' 91' ' ' THR . 10.5 ptm180 -158.13 161.84 37.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.905 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.723 HG23 ' HA ' ' A' ' 91' ' ' THR . 79.5 t -113.44 116.82 53.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.629 HG12 ' HG3' ' A' ' 119' ' ' LYS . 77.1 t -52.58 137.46 12.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.131 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 1.7 mtmp? -130.19 156.97 43.72 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.906 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.515 ' O ' ' N ' ' A' ' 116' ' ' GLY . 27.5 t0 -64.47 118.85 9.37 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.855 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' MET . . . . . 0.467 ' SD ' ' C ' ' A' ' 113' ' ' MET . 2.6 tmm? -65.85 -9.79 32.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.893 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -92.92 -53.41 4.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.07 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 20.7 p -100.71 -35.41 9.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.108 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 92.76 28.05 13.14 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.483 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -100.24 156.26 17.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.738 0.304 . . . . 0.0 110.917 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 36.7 t -51.77 109.03 0.32 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.876 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.629 ' HG3' HG12 ' A' ' 110' ' ' VAL . 18.9 mmtt -61.14 -51.74 67.81 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.89 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 144.95 -40.59 1.12 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.533 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.597 ' CZ ' HG11 ' A' ' 110' ' ' VAL . 6.2 p90 -100.09 151.99 20.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.939 0.4 . . . . 0.0 110.944 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -141.0 172.96 23.46 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.495 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -121.19 141.2 51.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.874 0.369 . . . . 0.0 110.862 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.725 HG12 ' CE1' ' A' ' 126' ' ' PHE . 58.6 t -139.18 113.52 7.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.132 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 4.3 t -104.35 147.68 27.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.823 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.725 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.3 m-85 -126.47 153.86 44.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.876 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.446 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 20.9 m-85 -62.02 -43.43 98.86 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.896 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -114.65 161.72 17.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.877 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.551 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 39.9 tptt -69.04 -62.07 1.53 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.917 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.459 ' C ' ' O ' ' A' ' 129' ' ' LYS . 1.0 OUTLIER -33.53 -61.83 0.31 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.937 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.408 ' C ' ' O ' ' A' ' 130' ' ' TRP . 75.2 m-20 -37.09 -57.46 0.85 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.835 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -58.88 -62.16 2.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.103 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.407 ' HA ' HD12 ' A' ' 136' ' ' ILE . 2.4 mm-40 -39.7 -59.52 1.13 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.876 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 53.3 t30 -41.07 -46.45 2.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.879 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.484 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -67.32 -51.84 47.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.107 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' ILE . . . . . 0.407 HD12 ' HA ' ' A' ' 133' ' ' GLU . 97.6 mt -43.42 -35.11 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.151 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 19.2 mt-30 -88.33 -55.23 3.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.9 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 5.0 mm100 -67.31 -61.01 2.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.93 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.484 ' N ' ' O ' ' A' ' 135' ' ' ALA . 57.4 mmm -59.2 -26.46 64.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.434 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -65.1 113.54 5.94 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.45 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 89.36 18.25 53.27 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.494 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 89.8 mm-40 -97.47 171.2 8.54 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.788 0.328 . . . . 0.0 110.898 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' TRP . . . . . 0.436 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 15.4 m95 -104.14 110.68 22.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.949 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.501 HD13 ' HB2' ' A' ' 97' ' ' ALA . 59.2 tp -103.27 129.22 50.19 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.906 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 0.644 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 67.28 -74.74 0.19 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.493 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.81 18.05 0.28 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.511 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 72.2 mtt180 -156.69 155.41 31.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.756 0.312 . . . . 0.0 110.906 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.436 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 31.1 mt-30 -60.18 170.38 1.29 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.915 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.462 HG21 ' HB3' ' A' ' 144' ' ' LEU . 19.2 pt -146.39 150.18 15.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.106 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.424 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 13.1 ptp180 -113.99 121.96 45.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.87 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.434 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 73.4 p -112.56 128.11 56.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.168 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -151.33 170.77 18.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.898 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' TRP . . . . . 0.529 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 9.8 m95 . . . . . 0 C--N 1.328 -0.362 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.921 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.581 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 97.3 m-85 . . . . . 0 C--O 1.232 0.154 0 CA-C-O 120.911 0.386 . . . . 0.0 110.916 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.467 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.9 OUTLIER -95.51 139.92 31.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 -180.0 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 57.4 t -113.96 152.02 15.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.06 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -102.09 132.89 47.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.915 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.922 HG12 HD21 ' A' ' 85' ' ' LEU . 4.1 t -129.57 129.78 66.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.142 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.473 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -136.69 -173.54 12.96 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.494 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 27.0 m-20 55.3 36.33 26.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.831 0.348 . . . . 0.0 110.851 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.922 HD21 HG12 ' A' ' 82' ' ' VAL . 8.3 mt -96.18 131.02 43.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.886 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 t -53.1 153.71 6.15 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.652 0.739 . . . . 0.0 110.818 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -13.84 35.25 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.7 2.267 . . . . 0.0 112.338 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -91.04 -8.75 48.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.888 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.863 HD11 ' HA3' ' A' ' 145' ' ' GLY . 39.1 mm -76.37 136.67 24.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.176 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.444 ' OG1' ' N ' ' A' ' 91' ' ' THR . 2.3 t -114.55 177.54 4.61 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.163 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.726 HG23 ' HA ' ' A' ' 108' ' ' ARG . 69.9 m -52.6 -47.67 66.78 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.177 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 93' ' ' ASP . 32.0 mt-10 -56.42 -58.26 8.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.879 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.447 ' CB ' HG23 ' A' ' 89' ' ' ILE . 2.9 m-20 -35.49 -54.63 0.68 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.911 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.522 HD11 HG22 ' A' ' 109' ' ' VAL . 6.2 mt -51.18 -60.17 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.117 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.528 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 21.7 mtmt -47.14 -43.13 20.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.904 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -57.43 -31.57 66.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.134 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.402 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -74.42 -52.65 11.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.12 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.454 ' C ' HD11 ' A' ' 104' ' ' ILE . 23.6 m-85 -88.77 12.4 15.11 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.868 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.779 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -65.72 -60.1 7.98 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.597 0.713 . . . . 0.0 111.096 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.779 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.4 Cg_endo -69.8 -0.87 7.58 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.694 2.263 . . . . 0.0 112.321 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.506 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 78.3 m-85 -99.75 4.61 45.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.887 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.06 159.63 8.74 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.475 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.51 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 39.8 mtp85 -65.72 125.71 26.16 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.804 0.335 . . . . 0.0 110.866 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.454 HD11 ' C ' ' A' ' 98' ' ' PHE . 14.4 mt -100.46 138.14 25.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.186 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -109.86 -60.76 1.74 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.849 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -100.75 103.96 15.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.904 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.486 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -133.84 124.86 27.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.124 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.726 ' HA ' HG23 ' A' ' 91' ' ' THR . 17.6 ptt180 -161.94 160.16 27.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.9 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.611 HG23 ' HA ' ' A' ' 91' ' ' THR . 99.4 t -110.12 116.31 51.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.148 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.686 HG21 ' CE2' ' A' ' 121' ' ' TYR . 51.5 t -50.99 132.73 12.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.101 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' LYS . . . . . 0.418 ' HG2' ' N ' ' A' ' 118' ' ' SER . 69.1 mttt -133.45 148.76 51.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.867 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.44 ' O ' ' N ' ' A' ' 116' ' ' GLY . 29.6 t0 -58.28 123.66 16.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.88 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 36.3 ttp -71.77 -2.83 18.97 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.865 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -99.87 -49.91 4.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.094 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 18.7 p -102.15 -28.2 12.45 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.127 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 82.68 25.31 50.65 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.504 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 48.1 mtmt -99.99 147.08 25.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.757 0.313 . . . . 0.0 110.923 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' SER . . . . . 0.418 ' N ' ' HG2' ' A' ' 111' ' ' LYS . 5.0 t -50.18 113.46 0.87 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.813 -179.841 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 41.5 mttt -63.6 -51.52 64.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.898 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.405 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 148.65 -40.02 0.93 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.476 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.686 ' CE2' HG21 ' A' ' 110' ' ' VAL . 10.1 p90 -100.03 149.43 23.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.934 0.397 . . . . 0.0 110.898 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -130.88 176.94 18.75 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.505 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -123.78 139.25 54.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.884 0.373 . . . . 0.0 110.867 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.658 HG12 ' CE1' ' A' ' 126' ' ' PHE . 42.9 t -139.67 113.31 6.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.124 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 24.4 t -102.83 149.6 24.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.843 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.658 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.6 m-85 -129.29 141.56 51.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.874 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.51 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 82.7 m-85 -56.12 -41.16 74.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.882 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 19.6 m-80 -109.21 155.28 21.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.905 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.581 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 26.8 tttt -68.51 -40.16 80.94 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.891 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.422 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.9 OUTLIER -60.87 -58.92 6.41 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.911 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.422 ' C ' ' O ' ' A' ' 130' ' ' TRP . 78.5 m-20 -36.07 -41.57 0.25 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.871 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.462 ' HB2' ' CD1' ' A' ' 126' ' ' PHE . . . -80.51 -54.71 5.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.1 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.512 ' HA ' HD12 ' A' ' 136' ' ' ILE . 12.5 mt-10 -42.29 -54.28 3.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.898 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -45.42 -51.87 10.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.913 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.461 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -60.95 -56.64 18.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.114 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 136' ' ' ILE . . . . . 0.512 HD12 ' HA ' ' A' ' 133' ' ' GLU . 85.8 mt -37.76 -35.32 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.147 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 18.1 mt-30 -90.07 -59.22 2.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.937 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 25.2 mm-40 -63.64 -59.49 4.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.919 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.506 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 78.3 mmm -57.08 -40.09 76.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.897 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.436 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -52.15 118.65 7.7 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.519 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.83 -24.89 29.75 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.556 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 14.7 mm100 -56.64 -177.26 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.823 0.344 . . . . 0.0 110.901 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' TRP . . . . . 0.492 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 13.6 m95 -120.42 131.32 54.73 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.914 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.534 HD23 HD22 ' A' ' 85' ' ' LEU . 41.6 tp -128.97 129.17 45.08 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.942 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 0.863 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 71.66 -6.07 9.84 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.467 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 123.05 -10.54 8.81 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.504 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 17.1 mtt85 -125.84 147.76 49.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.741 0.305 . . . . 0.0 110.857 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.492 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 22.6 mt-30 -51.61 169.46 0.06 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.927 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.5 pt -140.62 151.19 20.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.14 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.473 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 16.9 ptp180 -113.74 118.79 35.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.862 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.436 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 72.2 p -112.08 125.28 53.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.153 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 11.2 m120 -152.76 179.13 8.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.868 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 15.0 m95 . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.929 179.98 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.574 ' CE1' ' HB2' ' A' ' 129' ' ' LYS . 46.9 m-85 . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.83 0.348 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.474 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.4 OUTLIER -87.21 144.24 26.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.84 179.984 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.407 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 69.4 t -120.22 144.16 29.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.141 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 19.7 t80 -95.63 134.66 38.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.877 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.845 HG12 HD21 ' A' ' 85' ' ' LEU . 2.7 t -132.62 129.1 58.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.11 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.486 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -134.9 179.89 17.19 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.479 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 6.6 t0 57.75 45.05 19.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.82 0.343 . . . . 0.0 110.845 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.845 HD21 HG12 ' A' ' 82' ' ' VAL . 18.5 mt -100.2 131.72 45.98 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.902 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -52.92 154.1 5.39 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.671 0.748 . . . . 0.0 110.842 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.76 -16.0 37.37 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.654 2.236 . . . . 0.0 112.356 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -90.54 -6.53 54.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.853 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.96 HD11 ' HA3' ' A' ' 145' ' ' GLY . 42.6 mm -78.44 137.42 22.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.142 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.8 t -119.09 174.6 6.22 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.088 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.432 ' HA ' HG23 ' A' ' 109' ' ' VAL . 24.5 m -49.41 -47.31 48.03 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.158 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.413 ' O ' ' C ' ' A' ' 93' ' ' ASP . 37.3 mt-10 -56.27 -56.4 21.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.844 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.459 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.2 m-20 -36.51 -58.26 0.72 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.865 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.511 HD11 HG22 ' A' ' 109' ' ' VAL . 14.0 mt -47.43 -59.5 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.159 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.741 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 19.2 mtmt -46.64 -39.44 11.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.892 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.42 ' HB3' ' O ' ' A' ' 93' ' ' ASP . . . -61.26 -35.03 76.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.082 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.75 -54.92 9.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.109 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -87.35 5.37 38.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.896 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.794 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -56.63 -60.41 9.38 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.597 0.713 . . . . 0.0 111.129 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.794 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.7 Cg_endo -69.82 -1.01 7.79 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.677 2.251 . . . . 0.0 112.287 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -100.07 12.63 36.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.866 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.45 146.23 6.69 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.53 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 70.7 mtt180 -55.5 125.72 22.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.756 0.313 . . . . 0.0 110.901 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.43 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 11.9 mt -100.03 133.64 42.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.128 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -102.5 -61.98 1.33 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.852 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -100.34 103.42 14.82 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.846 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.455 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -133.66 124.96 27.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.105 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.401 ' HA ' HG23 ' A' ' 91' ' ' THR . 2.1 ptp180 -161.32 163.21 30.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.511 HG22 HD11 ' A' ' 94' ' ' ILE . 54.9 t -111.97 125.23 69.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.118 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.654 HG21 ' CE2' ' A' ' 121' ' ' TYR . 41.4 t -57.28 135.91 20.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.137 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 18.6 mttp -135.67 150.8 49.71 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.891 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.459 ' O ' ' N ' ' A' ' 116' ' ' GLY . 15.6 t0 -59.68 123.18 16.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.861 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 26.9 ptm -75.05 -2.27 26.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.89 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.0 -38.75 9.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.081 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.435 HG23 ' OD2' ' A' ' 112' ' ' ASP . 25.9 p -116.18 -33.01 5.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.165 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 91.27 25.6 23.48 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.471 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 68.3 mmtt -98.94 157.17 16.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.794 0.331 . . . . 0.0 110.866 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 2.7 t -57.27 121.83 11.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.876 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 35.3 mttt -75.48 -48.02 24.5 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.896 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 142.18 -43.67 1.04 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.482 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.654 ' CE2' HG21 ' A' ' 110' ' ' VAL . 14.8 p90 -98.74 146.45 25.88 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.886 0.374 . . . . 0.0 110.933 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -129.86 179.16 17.0 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.489 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -127.11 140.1 52.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.898 0.38 . . . . 0.0 110.916 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.71 HG12 ' CE1' ' A' ' 126' ' ' PHE . 61.9 t -137.84 116.65 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.152 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 9.5 t -104.81 148.02 27.09 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.873 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.71 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.4 m-85 -128.37 156.38 43.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.892 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -65.16 -41.31 94.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.901 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -119.18 150.82 39.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.907 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.574 ' HB2' ' CE1' ' A' ' 78' ' ' PHE . 30.3 tttt -58.64 -65.68 0.62 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.927 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.45 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -33.17 -59.79 0.35 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.917 179.88 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 70.7 m-20 -37.78 -46.53 0.93 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.822 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.413 ' N ' ' O ' ' A' ' 129' ' ' LYS . . . -73.15 -59.19 2.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.076 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -40.63 -51.93 2.94 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 30.4 t-20 -46.31 -42.07 14.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.893 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -72.67 -54.31 9.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.109 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 96.0 mt -40.56 -31.95 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.109 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 48.1 mt-30 -84.84 -64.9 1.08 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.957 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -62.01 -62.55 1.7 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.912 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 68.8 mmm -49.76 -43.72 48.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.862 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.443 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -51.43 109.64 0.84 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.46 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 105.95 -28.23 14.67 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.482 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 54.1 mm-40 -55.01 179.88 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.819 0.343 . . . . 0.0 110.941 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' TRP . . . . . 0.506 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 13.3 m95 -116.2 127.18 54.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.912 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.416 ' HB3' HG21 ' A' ' 149' ' ' ILE . 32.8 tp -126.69 130.67 50.84 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.939 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 0.96 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.62 -3.61 11.61 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.474 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 120.86 -13.8 9.79 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.515 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 47.5 mtt180 -124.93 153.57 42.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 110.835 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.506 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 20.6 mt-30 -61.49 158.51 14.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.752 HG22 HD23 ' A' ' 85' ' ' LEU . 21.6 pt -130.86 153.07 38.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.145 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.486 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 2.8 ptp180 -111.68 115.95 29.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.887 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.443 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 58.5 p -110.21 128.12 55.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.142 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 19.8 m-20 -159.94 168.68 25.13 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 14.1 m95 . . . . . 0 C--N 1.327 -0.37 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.918 -179.984 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.858 0.361 . . . . 0.0 110.91 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.484 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.7 OUTLIER -83.68 155.6 23.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.858 -179.971 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 36.8 t -134.27 135.34 54.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.112 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' PHE . . . . . 0.406 ' CE2' ' HG2' ' A' ' 150' ' ' ARG . 15.4 t80 -87.44 128.15 35.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.84 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.978 HG12 HD21 ' A' ' 85' ' ' LEU . 4.0 t -127.96 109.86 20.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.103 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -115.31 -176.91 18.65 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.519 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 59.9 40.26 19.34 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.844 0.354 . . . . 0.0 110.883 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.978 HD21 HG12 ' A' ' 82' ' ' VAL . 11.5 mt -99.04 127.37 44.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.886 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.04 154.19 5.52 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.633 0.73 . . . . 0.0 110.867 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.88 -11.74 31.28 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.67 2.247 . . . . 0.0 112.294 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -92.32 -8.07 46.13 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.894 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.661 HD11 ' HA3' ' A' ' 145' ' ' GLY . 45.7 mm -78.27 138.06 20.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.147 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.5 t -119.55 163.73 16.88 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.118 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.489 ' HA ' HG23 ' A' ' 109' ' ' VAL . 27.7 m -38.85 -46.6 1.31 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.168 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.415 ' O ' ' C ' ' A' ' 93' ' ' ASP . 21.2 mt-10 -56.61 -58.95 5.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.853 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.59 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.9 m-20 -36.42 -57.94 0.73 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.852 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.539 HD11 HG22 ' A' ' 109' ' ' VAL . 8.1 mt -47.44 -58.59 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.103 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.58 ' HE2' ' HB3' ' A' ' 107' ' ' ALA . 26.1 mtmt -49.28 -42.14 40.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.893 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -59.09 -28.77 66.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.127 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.621 ' HB1' ' HE1' ' A' ' 139' ' ' MET . . . -74.75 -54.75 6.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -86.5 8.34 22.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.913 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.783 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -61.61 -60.31 10.77 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.621 0.724 . . . . 0.0 111.145 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.783 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.78 -0.95 7.68 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.681 2.254 . . . . 0.0 112.402 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -100.18 -4.48 29.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.83 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 146.46 156.87 7.09 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.517 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.415 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 31.9 mtm180 -64.84 123.79 20.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.818 0.342 . . . . 0.0 110.867 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 11.1 mt -100.42 139.12 22.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.18 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 8.3 t -110.03 -62.47 1.5 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -100.73 105.28 16.6 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.888 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.58 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -134.16 125.73 28.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.12 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 15.0 ptt180 -160.86 161.32 31.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.87 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.539 HG22 HD11 ' A' ' 94' ' ' ILE . 72.9 t -111.5 119.45 59.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.173 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.774 HG21 ' CE2' ' A' ' 121' ' ' TYR . 42.8 t -51.45 133.13 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.113 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -132.98 151.59 52.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.457 ' O ' ' N ' ' A' ' 116' ' ' GLY . 39.5 t0 -60.33 119.29 7.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.883 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 22.7 ptp -68.68 -2.28 8.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.913 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -97.55 -47.16 5.76 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.125 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 43.2 p -110.05 -34.5 6.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.162 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 92.66 31.98 8.4 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.468 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt -99.52 148.69 24.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.779 0.323 . . . . 0.0 110.88 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 19.5 t -54.92 102.09 0.06 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.832 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 42.2 mttt -52.02 -53.46 41.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.883 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 149.75 -39.82 0.88 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.488 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.774 ' CE2' HG21 ' A' ' 110' ' ' VAL . 5.8 p90 -100.07 161.27 13.71 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.931 0.396 . . . . 0.0 110.887 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -142.27 174.96 23.06 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.455 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -124.59 137.98 54.35 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.896 0.379 . . . . 0.0 110.932 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.591 HG12 ' CE1' ' A' ' 126' ' ' PHE . 71.0 t -138.11 120.38 18.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.105 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 21.1 m -103.06 150.88 23.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.828 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.591 ' CE1' HG12 ' A' ' 124' ' ' VAL . 15.3 m-85 -131.03 142.89 50.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.862 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.415 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 97.5 m-85 -60.9 -32.53 71.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.852 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 21.6 m-20 -117.66 169.58 9.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.849 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.519 ' HE3' ' CH2' ' A' ' 153' ' ' TRP . 20.6 tptm -78.99 -53.16 7.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.89 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.415 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.8 OUTLIER -48.07 -59.83 3.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.914 179.925 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 130' ' ' TRP . 79.4 m-20 -35.83 -40.63 0.19 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.908 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.75 -62.76 1.56 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.096 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -42.41 -58.88 2.05 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.877 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -39.97 -47.39 2.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.889 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.464 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -67.57 -54.45 19.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.079 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 54.9 mt -41.66 -35.37 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.163 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 17.2 mt-30 -88.62 -54.91 3.94 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.98 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 5.0 mm100 -68.11 -62.88 1.2 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.906 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.621 ' HE1' ' HB1' ' A' ' 97' ' ' ALA . 84.6 mmm -52.96 -35.64 59.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.874 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.442 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -52.97 110.6 1.34 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.514 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 100.97 -22.73 38.28 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.481 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 33.5 mm-40 -55.05 169.8 0.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.786 0.326 . . . . 0.0 110.925 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' TRP . . . . . 0.436 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 14.7 m95 -107.95 113.09 26.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.908 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.58 HD13 ' HB2' ' A' ' 97' ' ' ALA . 56.9 tp -103.98 129.74 51.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.899 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 0.661 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 68.83 -77.77 0.28 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.511 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -155.17 13.74 0.46 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.482 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 32.2 mtp85 -153.17 160.8 42.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.436 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 24.0 mt-30 -62.03 168.7 3.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.933 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.542 HD11 ' HE3' ' A' ' 139' ' ' MET . 22.4 pt -140.2 144.47 27.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.13 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.406 ' HG2' ' CE2' ' A' ' 81' ' ' PHE . 3.7 ttm180 -105.5 124.21 49.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.907 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.442 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 61.9 p -117.52 132.54 56.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.132 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -157.2 169.17 25.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' TRP . . . . . 0.519 ' CH2' ' HE3' ' A' ' 129' ' ' LYS . 7.3 m95 . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.982 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.933 0.397 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.476 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.5 OUTLIER -82.51 142.15 32.08 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.867 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 56.0 t -120.94 148.94 23.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.159 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -100.69 136.97 39.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.887 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.884 HG12 HD21 ' A' ' 85' ' ' LEU . 3.5 t -136.77 109.66 8.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.134 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -120.97 179.57 16.3 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.484 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 4.0 t70 62.51 43.08 8.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.827 0.346 . . . . 0.0 110.838 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.884 HD21 HG12 ' A' ' 82' ' ' VAL . 9.1 mt -103.31 135.66 44.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.934 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.03 153.9 5.79 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.651 0.739 . . . . 0.0 110.901 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -16.56 37.67 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.678 2.252 . . . . 0.0 112.374 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -89.29 -7.01 56.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.907 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.909 HD11 ' HA3' ' A' ' 145' ' ' GLY . 40.3 mm -75.54 138.46 20.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.127 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.5 t -119.14 168.2 11.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.152 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.464 ' HA ' HG23 ' A' ' 109' ' ' VAL . 7.4 m -46.36 -44.12 16.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.112 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 29.6 mt-10 -58.24 -51.26 70.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.901 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.469 ' CB ' HG23 ' A' ' 89' ' ' ILE . 4.6 m-20 -44.04 -55.97 4.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.523 HD11 HG22 ' A' ' 109' ' ' VAL . 8.4 mt -49.53 -58.57 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.139 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.59 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 24.9 mtmt -48.99 -41.71 35.33 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.883 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -59.8 -31.89 70.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.108 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.429 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -72.52 -56.97 4.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.104 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.424 ' C ' HD11 ' A' ' 104' ' ' ILE . 33.5 m-85 -83.79 11.94 6.75 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.88 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.761 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -67.43 -59.95 6.41 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.583 0.706 . . . . 0.0 111.113 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.761 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.77 -0.83 7.48 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.7 2.266 . . . . 0.0 112.319 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.412 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 70.8 m-85 -99.77 -13.37 19.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.926 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 156.59 155.14 7.3 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.508 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.455 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 35.8 mtt-85 -63.31 123.21 18.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.795 0.331 . . . . 0.0 110.897 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.424 HD11 ' C ' ' A' ' 98' ' ' PHE . 12.6 mt -100.49 142.6 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.133 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.461 ' HB2' ' CZ ' ' A' ' 127' ' ' PHE . 38.6 t -114.94 -61.53 1.74 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.827 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -100.97 101.03 11.74 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.829 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.518 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -130.24 124.24 32.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.117 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 10.2 ptp180 -160.72 153.78 21.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.88 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.523 HG22 HD11 ' A' ' 94' ' ' ILE . 69.2 t -102.3 125.94 56.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.75 HG12 ' HG3' ' A' ' 119' ' ' LYS . 56.6 t -55.61 139.99 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.108 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 49.7 mttt -138.79 149.22 44.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.889 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 48.8 t0 -63.1 121.98 14.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.859 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 11.4 ptp -71.4 -1.45 13.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.901 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.97 -54.28 3.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.079 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 26.8 p -99.61 -24.99 14.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.186 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 81.35 27.17 49.42 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.457 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 73.6 mmtt -96.75 164.88 12.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.776 0.322 . . . . 0.0 110.914 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 24.6 t -66.33 115.04 5.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.86 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.75 ' HG3' HG12 ' A' ' 110' ' ' VAL . 7.0 mmtm -64.93 -40.92 95.78 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.894 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.549 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 130.44 -46.78 1.05 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.481 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.612 ' CE2' HG21 ' A' ' 110' ' ' VAL . 29.6 p90 -100.02 141.18 33.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.905 0.383 . . . . 0.0 110.947 -179.814 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -125.28 178.64 16.49 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.513 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 62.5 m-85 -121.25 139.9 52.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.878 0.37 . . . . 0.0 110.874 -179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.703 HG12 ' CE1' ' A' ' 126' ' ' PHE . 63.9 t -136.56 115.68 15.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.118 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 43.9 t -101.63 151.43 22.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.833 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.703 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.8 m-85 -131.0 148.04 52.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.88 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.461 ' CZ ' ' HB2' ' A' ' 105' ' ' SER . 68.0 m-85 -64.91 -40.41 95.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.867 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -111.73 155.27 23.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.877 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.466 ' O ' ' C ' ' A' ' 130' ' ' TRP . 38.4 tttt -68.38 -63.4 1.07 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.893 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.466 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -33.19 -60.09 0.34 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.949 179.897 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.4 ' C ' ' O ' ' A' ' 130' ' ' TRP . 61.9 m-20 -37.77 -54.83 1.22 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.888 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -60.09 -64.95 0.77 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.085 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -39.37 -58.57 1.2 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.919 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -42.01 -50.29 4.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.878 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.468 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -66.79 -59.95 3.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.062 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 93.4 mt -37.67 -37.74 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 18.4 mt-30 -84.42 -61.66 1.75 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.935 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -61.24 -59.75 4.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.907 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.468 ' N ' ' O ' ' A' ' 135' ' ' ALA . 86.9 mmm -57.38 -36.33 71.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.855 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -52.39 104.31 0.17 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.495 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 111.86 -31.72 6.85 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.488 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 13.0 mm100 -49.41 179.82 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.798 0.332 . . . . 0.0 110.923 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' TRP . . . . . 0.45 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 13.7 m95 -115.44 126.89 54.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.893 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.696 HD23 HD22 ' A' ' 85' ' ' LEU . 40.7 tp -123.29 126.78 47.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 0.909 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 71.66 -6.12 9.71 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.549 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 123.7 -11.11 8.42 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.485 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 17.8 mtt-85 -125.58 146.9 49.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.789 0.328 . . . . 0.0 110.866 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.45 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 22.4 mt-30 -56.18 158.64 3.93 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.921 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.699 HG22 HD23 ' A' ' 85' ' ' LEU . 21.0 pt -132.29 143.56 39.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.143 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 11.2 ptt180 -107.07 109.32 21.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.876 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 62.4 p -101.0 131.98 46.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.188 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 17.1 t30 -155.35 172.88 17.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.881 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 82.8 m95 . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.912 179.974 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.55 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 5.1 m-85 . . . . . 0 C--O 1.232 0.142 0 CA-C-O 120.844 0.354 . . . . 0.0 110.84 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.448 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.6 OUTLIER -83.99 149.09 26.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.836 -179.987 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.554 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 39.7 t -125.0 141.25 45.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.148 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.1 t80 -92.31 134.03 35.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.894 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.984 HG12 HD21 ' A' ' 85' ' ' LEU . 12.2 t -132.62 112.95 19.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.1 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.41 ' C ' ' HG2' ' A' ' 150' ' ' ARG . . . -120.52 -179.63 16.31 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.431 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.408 ' O ' ' O ' ' A' ' 148' ' ' GLN . 5.2 m-20 63.9 43.79 5.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.812 0.339 . . . . 0.0 110.878 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.984 HD21 HG12 ' A' ' 82' ' ' VAL . 9.6 mt -102.37 129.16 48.76 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.902 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.1 t -53.26 154.27 5.99 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.705 0.764 . . . . 0.0 110.849 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -7.65 21.6 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.719 2.28 . . . . 0.0 112.341 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -99.98 -8.67 23.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.864 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.826 HD11 ' HA3' ' A' ' 145' ' ' GLY . 38.6 mm -75.29 141.2 16.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.14 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.0 t -119.46 173.13 7.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.14 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.7 HG23 ' HA ' ' A' ' 108' ' ' ARG . 88.0 m -50.22 -47.28 54.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.099 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -54.74 -52.97 60.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.884 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.498 ' CB ' HG23 ' A' ' 89' ' ' ILE . 1.6 m-20 -42.72 -55.78 3.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.821 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.631 HD11 HG22 ' A' ' 109' ' ' VAL . 10.2 mt -49.5 -58.66 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.112 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.717 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 25.3 mtmt -47.87 -39.51 18.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.82 -32.72 72.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.095 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.629 ' HB1' ' HE1' ' A' ' 139' ' ' MET . . . -71.71 -51.85 20.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.094 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.488 ' C ' HD11 ' A' ' 104' ' ' ILE . 14.2 m-85 -93.51 13.2 22.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.882 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.767 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -66.76 -59.82 7.33 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.538 0.685 . . . . 0.0 111.081 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.767 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.3 Cg_endo -69.78 -0.61 7.18 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.685 2.257 . . . . 0.0 112.305 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -99.75 -1.33 38.0 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.846 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 142.54 143.24 4.15 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.451 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 68.4 mtm180 -53.47 123.38 11.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.795 0.331 . . . . 0.0 110.891 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.488 HD11 ' C ' ' A' ' 98' ' ' PHE . 20.1 mt -100.0 137.34 27.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.167 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.472 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 7.5 p -105.1 -62.3 1.36 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.884 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -100.74 105.14 16.44 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.501 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -135.18 125.29 26.02 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.13 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.7 ' HA ' HG23 ' A' ' 91' ' ' THR . 8.2 ptp180 -160.22 169.17 23.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.631 HG22 HD11 ' A' ' 94' ' ' ILE . 95.8 t -116.93 117.54 55.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.133 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.852 HG12 ' HG3' ' A' ' 119' ' ' LYS . 60.6 t -47.1 141.08 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.172 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 80.1 mttt -140.31 152.09 45.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.902 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -63.88 121.55 14.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.851 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 1.1 pmm? -74.89 -1.47 22.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.856 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.14 -44.37 6.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.097 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 52.1 p -111.12 -35.16 5.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.175 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 94.63 31.01 8.08 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.505 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 22.9 mmtm -99.53 164.39 12.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.822 0.344 . . . . 0.0 110.891 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 29.6 t -65.83 109.88 2.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.866 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.852 ' HG3' HG12 ' A' ' 110' ' ' VAL . 11.3 mmtp -59.78 -39.36 84.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.878 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.508 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 128.6 -47.16 1.04 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.549 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.577 ' CE2' HG21 ' A' ' 110' ' ' VAL . 12.8 p90 -99.94 146.56 26.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.969 0.414 . . . . 0.0 110.902 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -127.96 178.03 17.29 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.459 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 36.9 m-85 -121.73 140.12 52.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.912 0.386 . . . . 0.0 110.908 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.68 HG12 ' CE1' ' A' ' 126' ' ' PHE . 47.4 t -136.77 113.75 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.108 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 125' ' ' SER . . . . . 0.436 ' O ' HG23 ' A' ' 104' ' ' ILE . 69.0 m -102.04 150.48 23.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.867 -179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.68 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.4 m-85 -130.77 143.33 50.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.846 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.472 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 22.7 m-85 -50.27 -48.89 54.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.904 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -106.85 173.31 6.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.886 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.55 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 3.5 ttmt -79.36 -51.8 8.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.927 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.42 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.0 OUTLIER -48.03 -58.4 4.49 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.887 179.952 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 130' ' ' TRP . 81.9 m-20 -35.72 -42.74 0.26 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.86 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.554 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -78.7 -60.89 2.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.128 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.595 ' HA ' HD12 ' A' ' 136' ' ' ILE . 18.6 mt-10 -37.83 -55.56 1.18 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -43.15 -55.51 3.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.902 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.466 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -59.21 -54.66 44.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.075 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' ILE . . . . . 0.595 HD12 ' HA ' ' A' ' 133' ' ' GLU . 93.0 mt -38.62 -36.57 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.14 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 22.1 mt-30 -87.94 -60.8 1.87 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.908 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 20.1 mm-40 -61.32 -59.49 5.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.9 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.629 ' HE1' ' HB1' ' A' ' 97' ' ' ALA . 87.3 mmm -59.32 -35.57 74.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.429 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -53.31 111.03 1.56 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.466 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 102.11 -28.86 14.03 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -50.63 178.89 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.746 0.308 . . . . 0.0 110.898 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 143' ' ' TRP . . . . . 0.588 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 14.3 m95 -115.31 119.55 36.66 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.959 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.595 HD13 ' HB2' ' A' ' 97' ' ' ALA . 60.6 tp -109.5 129.5 55.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.918 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 0.826 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.24 -78.57 0.43 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.476 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -156.04 14.08 0.4 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.517 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 66.7 mtt180 -153.5 154.38 34.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.744 0.307 . . . . 0.0 110.883 -179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.588 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 15.8 mt-30 -55.91 167.8 0.54 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.914 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.499 HG21 ' HB3' ' A' ' 144' ' ' LEU . 28.8 pt -140.81 147.69 22.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.155 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.41 ' HG2' ' C ' ' A' ' 83' ' ' GLY . 15.8 ptt180 -111.83 120.47 42.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.805 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.429 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 82.5 p -111.02 133.12 53.66 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -155.06 165.52 36.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.886 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 12.9 m95 . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.945 179.954 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.498 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 75.9 m-85 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.908 0.385 . . . . 0.0 110.898 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.42 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.9 OUTLIER -88.49 163.81 15.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.895 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.407 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 49.0 t -138.32 143.66 32.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.112 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -98.11 132.08 43.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.854 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.983 HG12 HD21 ' A' ' 85' ' ' LEU . 2.7 t -132.63 109.79 15.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.136 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.446 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -116.3 -179.45 18.03 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.469 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.4 ' O ' ' O ' ' A' ' 148' ' ' GLN . 14.4 m-20 63.8 26.21 14.31 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.891 0.377 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.983 HD21 HG12 ' A' ' 82' ' ' VAL . 10.7 mt -83.79 135.59 34.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.951 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -52.93 147.61 15.68 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.717 0.77 . . . . 0.0 110.854 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -6.2 18.04 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.638 2.225 . . . . 0.0 112.344 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -100.61 -5.02 27.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.851 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.917 HD11 ' HA3' ' A' ' 145' ' ' GLY . 30.8 mm -74.8 145.29 11.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.124 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.411 HG22 ' OD1' ' A' ' 93' ' ' ASP . 9.1 t -121.03 165.0 15.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.133 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.631 ' HA ' HG23 ' A' ' 109' ' ' VAL . 22.5 m -43.63 -50.7 7.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.107 -179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 93' ' ' ASP . 34.3 mt-10 -54.55 -57.26 12.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.892 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.431 ' CB ' HG23 ' A' ' 89' ' ' ILE . 0.5 OUTLIER -35.78 -57.86 0.64 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.89 179.974 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.446 ' CD1' HG22 ' A' ' 109' ' ' VAL . 8.7 mt -47.36 -59.31 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.117 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.593 ' HE2' ' HB3' ' A' ' 107' ' ' ALA . 22.9 mtmt -47.93 -39.21 18.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.926 179.822 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 93' ' ' ASP . . . -60.82 -35.03 75.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.079 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -71.68 -51.81 21.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.09 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.529 ' C ' HD11 ' A' ' 104' ' ' ILE . 23.0 m-85 -89.43 16.82 6.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.865 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.8 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -68.05 -60.61 4.98 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.595 0.712 . . . . 0.0 111.102 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.8 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.5 Cg_endo -69.8 -1.43 8.5 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.647 2.232 . . . . 0.0 112.318 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -100.45 11.45 39.43 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.842 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 126.65 133.16 3.79 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.477 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 16.9 mtt180 -46.08 126.75 7.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.799 0.333 . . . . 0.0 110.87 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.621 ' CG2' HG13 ' A' ' 124' ' ' VAL . 11.0 mt -100.06 138.13 25.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.139 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.52 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 2.6 t -107.61 -62.72 1.39 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -100.56 104.27 15.62 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.842 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.593 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -134.46 125.92 28.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.076 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.441 ' NH1' ' HA ' ' A' ' 110' ' ' VAL . 0.1 OUTLIER -158.88 157.51 31.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.884 -179.911 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.631 HG23 ' HA ' ' A' ' 91' ' ' THR . 88.3 t -104.82 117.71 50.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.122 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.856 HG11 ' CZ ' ' A' ' 121' ' ' TYR . 85.8 t -50.33 143.04 2.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.103 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 33.8 mttm -142.68 157.1 45.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.865 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -71.37 128.03 34.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.858 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 24.8 ptp -76.96 1.06 18.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -99.59 -46.04 5.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.092 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 24.4 p -108.85 -26.28 10.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.169 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 81.5 24.62 56.09 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.479 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 66.8 mttt -97.88 164.59 12.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.814 0.34 . . . . 0.0 110.902 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 2.2 m -59.39 119.04 6.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.855 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.647 ' HG3' HG12 ' A' ' 110' ' ' VAL . 24.4 mmtt -71.25 -39.32 71.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.945 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 128.99 -40.5 1.69 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.459 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.856 ' CZ ' HG11 ' A' ' 110' ' ' VAL . 7.0 p90 -100.23 156.04 17.44 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.911 0.386 . . . . 0.0 110.956 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.17 174.8 21.53 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.56 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -130.55 139.24 50.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.888 0.375 . . . . 0.0 110.857 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.621 HG13 ' CG2' ' A' ' 104' ' ' ILE . 76.7 t -134.49 133.56 54.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.097 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 32.5 t -113.19 138.58 49.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.83 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.619 ' CD1' ' HB2' ' A' ' 132' ' ' ALA . 75.2 m-85 -118.65 147.38 43.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.878 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.52 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 23.3 m-85 -61.64 -36.21 80.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 4.7 m-20 -114.75 174.58 5.89 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.866 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.498 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 67.1 tttt -84.12 -39.34 19.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.93 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.42 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -61.15 -53.11 61.12 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.928 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 130' ' ' TRP . 75.6 m-20 -35.88 -52.39 0.73 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.891 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.619 ' HB2' ' CD1' ' A' ' 126' ' ' PHE . . . -64.97 -66.18 0.58 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.096 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.482 ' HA ' HD12 ' A' ' 136' ' ' ILE . 3.8 mm-40 -34.7 -56.5 0.54 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.866 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -42.26 -51.68 4.69 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.924 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -64.7 -55.79 17.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.086 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' ILE . . . . . 0.482 HD12 ' HA ' ' A' ' 133' ' ' GLU . 87.4 mt -39.2 -33.46 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.14 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 49.7 mt-30 -84.9 -67.38 0.8 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.889 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 -57.73 -61.58 2.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.901 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 64.8 mmm -53.47 -41.1 65.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.868 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.408 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -49.38 104.72 0.11 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.519 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 106.7 -31.16 8.51 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.454 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 50.7 mm-40 -49.33 173.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.823 0.344 . . . . 0.0 110.927 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 143' ' ' TRP . . . . . 0.485 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 12.9 m95 -108.89 127.41 54.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.899 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.537 ' HB3' HG21 ' A' ' 149' ' ' ILE . 36.6 tp -128.48 130.76 47.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.887 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 0.917 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.77 -2.09 13.48 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.488 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 117.26 -14.27 13.58 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.48 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 20.1 mtt-85 -124.12 143.25 50.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.804 0.335 . . . . 0.0 110.829 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.485 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 28.4 mt-30 -52.5 160.04 0.92 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.951 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.56 HG22 HD23 ' A' ' 85' ' ' LEU . 21.3 pt -134.15 152.74 34.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.15 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.446 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 10.7 ptp180 -113.24 118.85 35.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.408 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 41.5 p -110.49 133.33 53.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.127 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 60.5 m-20 -163.06 164.43 25.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.887 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 14.3 m95 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.922 179.99 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.564 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 17.5 m-85 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.859 0.361 . . . . 0.0 110.903 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.449 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 1.1 m-70 -86.9 149.1 25.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.835 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.475 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 40.2 t -129.06 144.43 38.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.112 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.6 t80 -94.78 135.28 36.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.843 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.761 HG12 HD21 ' A' ' 85' ' ' LEU . 4.0 t -132.43 119.37 38.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.066 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.418 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -129.24 170.01 20.39 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.494 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 2.2 t70 72.43 38.92 0.78 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.847 0.356 . . . . 0.0 110.904 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.761 HD21 HG12 ' A' ' 82' ' ' VAL . 9.9 mt -100.39 133.82 44.24 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.965 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 t -54.34 153.74 9.42 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.654 0.74 . . . . 0.0 110.804 -179.869 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 -14.38 36.1 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.638 2.225 . . . . 0.0 112.406 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -90.4 -10.25 44.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.89 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.671 HD11 ' HA3' ' A' ' 145' ' ' GLY . 37.5 mm -76.64 135.7 26.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.16 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.409 ' O ' ' C ' ' A' ' 91' ' ' THR . 14.4 t -117.27 160.43 21.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.162 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.622 ' HA ' HG23 ' A' ' 109' ' ' VAL . 20.2 m -36.99 -47.14 0.69 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.13 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -52.92 -54.72 30.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.875 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.613 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.1 m-20 -42.26 -54.58 3.65 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.441 ' CD1' HG22 ' A' ' 109' ' ' VAL . 15.1 mt -51.04 -59.95 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.154 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.642 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 23.3 mtmt -48.27 -39.62 22.14 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.928 179.845 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.92 -32.17 73.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.043 179.859 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -73.15 -54.59 8.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.127 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.412 ' C ' HD11 ' A' ' 104' ' ' ILE . 28.9 m-85 -86.08 11.3 12.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.881 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.763 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -65.26 -59.5 9.67 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.593 0.711 . . . . 0.0 111.112 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.763 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.2 Cg_endo -69.76 -0.58 7.12 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.678 2.252 . . . . 0.0 112.354 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.581 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 78.6 m-85 -99.73 -8.59 24.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.885 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 147.52 133.66 2.41 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.507 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 34.4 mtp180 -45.42 123.63 4.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.775 0.322 . . . . 0.0 110.869 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.552 HG23 ' O ' ' A' ' 125' ' ' SER . 9.9 mt -99.39 137.96 25.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.139 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.436 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 89.5 p -104.02 -65.1 1.04 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.846 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -100.65 106.41 17.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.868 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.587 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -135.05 127.9 31.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.118 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.427 ' HD3' ' N ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -161.06 158.94 28.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.886 -179.904 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.622 HG23 ' HA ' ' A' ' 91' ' ' THR . 88.6 t -107.64 116.9 52.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.129 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.668 HG21 ' CE2' ' A' ' 121' ' ' TYR . 59.6 t -48.3 137.97 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.135 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 53.6 mttt -134.48 156.46 48.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.874 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 116' ' ' GLY . 10.4 t0 -60.6 122.99 16.09 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.841 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 11.0 tpt -67.63 -4.26 11.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.896 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -106.34 -52.23 2.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.078 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 53.8 p -95.14 -28.59 14.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.131 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 79.53 26.67 56.41 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.491 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 54.0 mmtt -100.0 149.75 23.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.791 0.329 . . . . 0.0 110.869 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 8.2 t -50.38 108.3 0.22 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.878 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 40.3 mttt -61.47 -43.81 98.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.917 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 142.28 -42.44 1.13 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.502 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.668 ' CE2' HG21 ' A' ' 110' ' ' VAL . 15.5 p90 -100.04 146.13 27.11 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.927 0.394 . . . . 0.0 110.91 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -128.91 179.98 16.3 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.473 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -125.69 140.05 53.03 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.879 0.371 . . . . 0.0 110.899 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.539 HG12 ' CE1' ' A' ' 126' ' ' PHE . 50.7 t -135.17 121.34 32.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.161 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 125' ' ' SER . . . . . 0.552 ' O ' HG23 ' A' ' 104' ' ' ILE . 5.2 m -106.01 148.33 27.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.854 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.539 ' CE1' HG12 ' A' ' 124' ' ' VAL . 21.2 m-85 -130.73 147.13 52.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.893 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.436 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 23.4 m-85 -59.17 -43.18 92.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.846 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 23.9 m120 -118.9 157.33 27.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.888 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.564 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 8.3 ttmt -60.43 -63.47 1.29 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.89 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.443 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -34.66 -52.82 0.53 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -43.89 -45.6 7.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.892 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.475 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -76.53 -57.04 4.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.096 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.404 ' HG2' ' CZ2' ' A' ' 153' ' ' TRP . 11.2 mt-10 -44.33 -56.73 3.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.861 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 51.1 t30 -45.13 -42.88 9.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.837 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.485 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -71.83 -53.95 11.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.095 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 96.8 mt -40.63 -40.84 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.119 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 -78.8 -59.61 2.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.917 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 15.2 mm-40 -63.7 -63.33 1.2 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.885 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.581 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 82.3 mmm -51.6 -39.06 57.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.865 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -54.08 112.34 2.51 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.519 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 91.58 21.51 34.14 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.531 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 62.8 mm-40 -101.25 168.44 9.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.792 0.33 . . . . 0.0 110.95 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 143' ' ' TRP . . . . . 0.426 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 14.8 m95 -105.0 109.15 21.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.892 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.497 HD23 HD22 ' A' ' 85' ' ' LEU . 63.1 tp -102.01 128.45 48.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.917 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 0.671 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 68.63 -72.51 0.36 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.484 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -160.88 17.56 0.19 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.499 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 33.3 mtt85 -155.78 156.72 35.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.782 0.325 . . . . 0.0 110.89 -179.809 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.426 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 46.7 mt-30 -59.68 173.37 0.57 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.908 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.4 HG21 ' HB3' ' A' ' 144' ' ' LEU . 20.2 pt -147.08 148.95 16.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.12 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.447 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 8.4 ptp180 -115.65 120.91 40.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.871 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 55.8 p -114.64 133.26 55.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.123 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -158.85 161.64 36.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.876 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 153' ' ' TRP . . . . . 0.404 ' CZ2' ' HG2' ' A' ' 133' ' ' GLU . 7.7 m95 . . . . . 0 C--N 1.328 -0.352 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.582 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 76.5 m-85 . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.863 0.363 . . . . 0.0 110.878 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.471 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.6 OUTLIER -83.92 156.73 22.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.827 -179.986 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.461 HG22 HD11 ' A' ' 136' ' ' ILE . 53.8 t -130.62 148.96 33.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.128 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 19.3 t80 -99.18 135.85 40.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.882 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.551 ' CG1' HD21 ' A' ' 85' ' ' LEU . 43.7 t -133.02 130.2 58.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.124 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.492 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -136.47 173.22 22.12 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.474 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 7.6 t0 64.4 52.1 1.92 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.846 0.355 . . . . 0.0 110.914 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.632 HD22 HD23 ' A' ' 144' ' ' LEU . 16.2 mt -108.26 131.64 54.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.24 154.07 6.14 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.659 0.742 . . . . 0.0 110.824 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -8.07 22.67 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.71 2.274 . . . . 0.0 112.336 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -100.06 -3.48 31.89 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.908 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.964 HD11 ' HA3' ' A' ' 145' ' ' GLY . 45.6 mm -78.96 137.11 22.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.102 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.3 t -119.0 168.41 10.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.135 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.547 HG22 ' CE ' ' A' ' 95' ' ' LYS . 36.8 m -47.47 -41.57 20.91 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.131 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 35.8 mt-10 -61.13 -53.21 59.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.902 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -42.87 -56.15 3.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.83 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.466 HD11 HG22 ' A' ' 109' ' ' VAL . 19.4 mt -50.09 -57.49 2.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.141 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.605 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 26.7 mtmt -46.93 -40.03 13.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.904 179.823 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.7 -32.58 73.7 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.106 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -68.87 -53.91 18.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.115 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 21.2 m-85 -89.43 10.44 22.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.847 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.758 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -64.51 -59.77 9.96 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.572 0.701 . . . . 0.0 111.131 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.758 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.8 -0.76 7.41 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.667 2.244 . . . . 0.0 112.345 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 -100.0 -11.76 20.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.881 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 155.7 157.01 8.05 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.494 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.529 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 27.1 mtp180 -64.52 123.46 19.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.825 0.345 . . . . 0.0 110.874 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 18.7 mt -100.43 144.56 12.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.112 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 65.8 p -119.91 -59.21 1.82 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.806 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' ASP . . . . . 0.443 ' HB3' ' CB ' ' A' ' 125' ' ' SER . 8.7 t0 -100.82 100.52 11.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.857 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.479 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -130.59 127.11 38.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -162.23 156.54 21.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.845 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.466 HG22 HD11 ' A' ' 94' ' ' ILE . 72.9 t -106.16 119.98 56.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.134 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.611 HG21 ' CE2' ' A' ' 121' ' ' TYR . 95.1 t -53.47 134.43 15.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.113 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 38.7 mttt -134.7 146.37 49.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.848 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.426 ' O ' ' N ' ' A' ' 116' ' ' GLY . 29.6 t0 -57.4 120.53 8.37 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.9 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 7.7 ptp -68.61 -3.49 12.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.915 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -100.58 -50.1 3.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.111 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 44.0 p -97.69 -34.28 10.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.128 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 88.81 17.43 56.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 63.7 mttt -92.3 167.92 11.67 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.822 0.344 . . . . 0.0 110.888 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 8.2 t -69.34 113.24 6.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.849 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.442 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 37.1 mttt -62.87 -50.79 69.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.878 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 145.08 -41.4 1.07 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.447 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.611 ' CE2' HG21 ' A' ' 110' ' ' VAL . 10.2 p90 -98.99 149.7 22.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.937 0.398 . . . . 0.0 110.919 -179.791 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -129.77 175.54 19.02 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.458 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 47.8 m-85 -124.2 135.47 53.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.857 0.361 . . . . 0.0 110.882 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.546 HG12 ' CE1' ' A' ' 126' ' ' PHE . 56.5 t -134.53 122.0 37.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.127 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' SER . . . . . 0.443 ' CB ' ' HB3' ' A' ' 106' ' ' ASP . 16.3 t -106.45 149.62 26.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.855 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.546 ' CE1' HG12 ' A' ' 124' ' ' VAL . 16.5 m-85 -130.96 138.23 49.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.9 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.529 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 84.1 m-85 -52.44 -35.24 51.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -118.12 167.0 11.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.876 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.582 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 9.3 tttp -77.19 -41.7 40.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.878 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.423 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -57.98 -59.44 5.25 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.88 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.423 ' C ' ' O ' ' A' ' 130' ' ' TRP . 45.3 m-20 -35.91 -39.91 0.18 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.879 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.423 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -77.79 -58.87 3.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.084 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -42.72 -54.78 3.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.859 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 56.3 t30 -43.34 -41.42 4.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.881 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.403 ' O ' ' N ' ' A' ' 137' ' ' GLN . . . -75.72 -58.15 3.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.102 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 136' ' ' ILE . . . . . 0.461 HD11 HG22 ' A' ' 80' ' ' VAL . 98.2 mt -38.92 -30.41 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.152 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 137' ' ' GLN . . . . . 0.403 ' N ' ' O ' ' A' ' 135' ' ' ALA . 34.4 mt-30 -87.49 -65.75 0.98 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.916 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 10.3 mm-40 -61.54 -61.03 2.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.955 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.652 ' HE3' HD11 ' A' ' 149' ' ' ILE . 79.0 mmm -49.18 -35.62 17.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.929 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -57.56 116.38 8.02 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.474 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 99.89 -19.09 54.69 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.45 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -66.38 177.18 1.56 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.788 0.328 . . . . 0.0 110.903 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 143' ' ' TRP . . . . . 0.459 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 13.8 m95 -115.04 127.11 55.44 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.908 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.632 HD23 HD22 ' A' ' 85' ' ' LEU . 55.5 tp -121.28 123.88 43.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.926 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 0.964 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 73.65 -11.59 5.54 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.532 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 130.25 -7.18 6.0 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.485 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 67.9 mtt180 -130.35 144.93 51.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.767 0.318 . . . . 0.0 110.902 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.459 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 31.2 mt-30 -53.57 158.21 1.9 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.933 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.652 HD11 ' HE3' ' A' ' 139' ' ' MET . 21.2 pt -131.7 145.29 35.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.129 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.492 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 19.3 ptp180 -106.8 120.14 41.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.874 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 42.4 p -112.71 127.85 56.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.121 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -153.4 166.2 33.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.868 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 23.2 m95 . . . . . 0 C--N 1.328 -0.368 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.953 179.972 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.577 ' CE1' ' HD3' ' A' ' 129' ' ' LYS . 90.9 m-85 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.862 0.363 . . . . 0.0 110.903 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.544 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.1 OUTLIER -81.75 150.18 28.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 55.3 t -124.75 146.28 30.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.137 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.2 t80 -98.07 134.39 41.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.919 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.7 HG12 HD21 ' A' ' 85' ' ' LEU . 4.3 t -130.42 130.13 65.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.109 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.495 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -136.24 179.26 18.05 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.446 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.402 ' O ' ' O ' ' A' ' 148' ' ' GLN . 5.4 t70 56.39 53.63 8.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.852 0.358 . . . . 0.0 110.845 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.7 HD21 HG12 ' A' ' 82' ' ' VAL . 15.8 mt -109.94 131.14 55.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -53.01 154.91 4.74 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.646 0.736 . . . . 0.0 110.873 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -4.19 13.53 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.653 2.236 . . . . 0.0 112.348 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' GLU . . . . . 0.412 ' O ' ' HG3' ' A' ' 88' ' ' GLU . 1.4 tt0 -97.58 -28.81 13.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.857 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.838 HD11 ' HA3' ' A' ' 145' ' ' GLY . 47.9 mm -57.73 132.52 22.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.137 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.1 t -119.38 166.8 12.59 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.161 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.522 HG22 ' CE ' ' A' ' 95' ' ' LYS . 95.8 m -39.79 -49.02 2.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.169 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -56.04 -57.6 11.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.852 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -39.59 -56.8 1.6 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.483 ' CD1' HG22 ' A' ' 109' ' ' VAL . 16.5 mt -48.79 -59.44 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.132 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.717 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 20.8 mtmt -47.41 -38.93 14.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.914 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.97 -37.01 85.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.059 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -68.05 -52.9 30.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.112 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 22.2 m-85 -89.27 6.91 38.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.93 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.778 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -59.48 -59.79 12.71 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.618 0.723 . . . . 0.0 111.082 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.778 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.6 Cg_endo -69.76 -0.92 7.62 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.72 2.28 . . . . 0.0 112.322 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -101.49 12.51 37.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.887 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.419 ' HA3' ' CG ' ' A' ' 131' ' ' ASP . . . 129.59 155.72 8.56 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.482 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.427 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 28.7 mtt180 -65.7 126.16 27.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.808 0.337 . . . . 0.0 110.841 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.436 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 13.8 mt -100.27 140.29 19.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.157 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 5.4 t -112.05 -62.09 1.62 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.883 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -100.81 102.91 14.09 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.867 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.529 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -130.32 125.5 34.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.083 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 15.2 ptt180 -160.81 154.98 22.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.886 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.483 HG22 ' CD1' ' A' ' 94' ' ' ILE . 60.1 t -105.2 119.14 53.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.11 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.611 HG21 ' CD2' ' A' ' 121' ' ' TYR . 61.1 t -53.12 133.06 15.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.126 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 111' ' ' LYS . . . . . 0.423 ' HG2' ' C ' ' A' ' 117' ' ' LYS . 37.0 mttm -134.14 149.25 51.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.94 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.548 ' OD2' ' HB3' ' A' ' 114' ' ' ALA . 1.7 t70 -62.02 132.0 51.46 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.863 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 26.0 ptm -80.47 1.36 29.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.883 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' ALA . . . . . 0.548 ' HB3' ' OD2' ' A' ' 112' ' ' ASP . . . -98.35 -29.11 13.34 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.084 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 21.2 p -131.14 -34.28 1.45 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.15 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 96.66 17.36 33.51 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.455 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' LYS . . . . . 0.423 ' C ' ' HG2' ' A' ' 111' ' ' LYS . 42.1 mttm -85.79 154.14 21.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.815 0.34 . . . . 0.0 110.875 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 1.9 m -60.09 111.1 1.38 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.82 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.415 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 31.6 mttt -59.25 -42.8 92.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.908 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 138.36 -41.72 1.34 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.532 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.611 ' CD2' HG21 ' A' ' 110' ' ' VAL . 7.4 p90 -99.99 151.12 21.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.923 0.392 . . . . 0.0 110.922 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -130.66 178.04 17.94 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.554 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -126.52 135.72 51.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.887 0.375 . . . . 0.0 110.876 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.549 HG12 ' CE1' ' A' ' 126' ' ' PHE . 61.0 t -136.48 122.18 28.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.118 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 12.6 m -105.34 149.92 25.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.808 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.549 ' CE1' HG12 ' A' ' 124' ' ' VAL . 16.3 m-85 -131.06 137.85 49.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.906 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.427 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 78.3 m-85 -58.87 -36.67 75.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.841 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 13.6 m-20 -118.04 149.78 40.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.904 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.577 ' HD3' ' CE1' ' A' ' 78' ' ' PHE . 38.5 tptt -60.77 -63.39 1.31 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.463 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.9 OUTLIER -33.21 -57.92 0.39 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.917 179.921 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.419 ' CG ' ' HA3' ' A' ' 102' ' ' GLY . 80.7 m-20 -40.59 -49.26 2.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.867 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -67.1 -60.47 2.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.123 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -41.05 -61.62 0.96 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.916 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 44.1 t-20 -38.88 -52.91 1.75 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.485 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -63.55 -61.44 2.33 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.122 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 86.7 mt -37.01 -36.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.128 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 27.4 mt-30 -85.53 -60.1 2.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.876 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -64.85 -59.6 4.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.485 ' N ' ' O ' ' A' ' 135' ' ' ALA . 48.0 mmm -53.48 -39.92 64.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.939 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -55.66 116.59 7.31 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.49 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 100.65 -12.66 59.6 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.494 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 48.6 mm-40 -73.28 172.57 10.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.75 0.31 . . . . 0.0 110.928 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 143' ' ' TRP . . . . . . . . . . . . . 15.7 m95 -109.43 126.41 53.44 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.877 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.536 HD23 HD22 ' A' ' 85' ' ' LEU . 57.3 tp -123.56 125.19 44.41 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.913 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 0.838 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 72.82 -9.25 6.58 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.48 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 127.47 -7.7 7.03 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.487 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 28.2 mtt-85 -130.34 145.89 51.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.789 0.328 . . . . 0.0 110.86 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.402 ' O ' ' O ' ' A' ' 84' ' ' ASP . 18.1 mt-30 -52.58 166.54 0.19 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.952 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.422 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 24.3 pt -137.42 146.28 28.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.066 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.495 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 16.4 ptp180 -108.07 114.86 29.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.89 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 80.9 p -110.19 122.57 47.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.134 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -150.58 168.48 24.14 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.904 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 153' ' ' TRP . . . . . 0.498 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 55.1 m95 . . . . . 0 C--N 1.327 -0.375 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.916 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.564 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 93.0 m-85 . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.929 0.395 . . . . 0.0 110.875 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.51 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.2 OUTLIER -89.1 150.4 22.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 179.998 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.55 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 46.0 t -125.45 145.36 32.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.131 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' PHE . . . . . 0.413 ' CE2' ' HG2' ' A' ' 150' ' ' ARG . 17.8 t80 -91.22 132.72 35.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.526 HG12 HD21 ' A' ' 85' ' ' LEU . 16.8 t -128.57 128.91 68.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.073 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -136.52 -177.96 15.42 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.54 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 55.11 54.25 9.1 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.809 0.338 . . . . 0.0 110.843 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.526 HD21 HG12 ' A' ' 82' ' ' VAL . 17.0 mt -110.89 130.11 55.68 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.937 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.18 154.22 5.84 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.664 0.745 . . . . 0.0 110.843 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -6.21 18.08 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.699 2.266 . . . . 0.0 112.29 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -100.29 -15.54 18.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.898 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.708 HD11 ' HA3' ' A' ' 145' ' ' GLY . 34.3 mm -69.57 134.25 30.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.141 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.0 t -119.67 168.0 11.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.123 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.648 HG22 ' CE ' ' A' ' 95' ' ' LYS . 98.8 m -38.82 -57.76 1.18 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.111 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 29.5 mt-10 -46.44 -59.36 3.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.942 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.437 ' CB ' HG23 ' A' ' 89' ' ' ILE . 0.5 OUTLIER -38.82 -56.19 1.4 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.899 179.932 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.626 ' CD1' HG22 ' A' ' 109' ' ' VAL . 10.7 mt -49.55 -60.77 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.167 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.648 ' CE ' HG22 ' A' ' 91' ' ' THR . 24.3 mtmt -45.67 -39.65 8.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.887 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' ALA . . . . . 0.435 ' HB3' ' O ' ' A' ' 93' ' ' ASP . . . -59.94 -37.84 80.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.106 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.636 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -66.35 -52.98 41.48 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.103 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.467 ' C ' HD11 ' A' ' 104' ' ' ILE . 11.8 m-85 -92.18 18.66 7.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.852 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.792 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -69.33 -60.44 4.08 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.581 0.705 . . . . 0.0 111.136 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.792 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.78 -0.83 7.49 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.662 2.241 . . . . 0.0 112.321 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -99.78 5.17 45.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.89 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.79 137.88 3.91 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.493 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.408 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 24.3 mtt-85 -49.89 125.1 11.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.741 0.305 . . . . 0.0 110.906 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.467 HD11 ' C ' ' A' ' 98' ' ' PHE . 11.1 mt -98.77 138.88 22.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.142 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.1 t -107.33 -62.94 1.35 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.858 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -100.51 109.66 21.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.905 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.508 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -138.25 129.13 26.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.13 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.1 ptm180 -162.57 154.72 18.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.873 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.626 HG22 ' CD1' ' A' ' 94' ' ' ILE . 41.3 t -105.33 117.38 50.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.133 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.531 HG21 ' CE2' ' A' ' 121' ' ' TYR . 48.8 t -49.84 138.04 5.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.125 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 111' ' ' LYS . . . . . 0.432 ' C ' ' HG3' ' A' ' 119' ' ' LYS . 52.6 mttt -138.16 154.63 49.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -69.16 138.55 54.24 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.836 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 13.5 ptp -85.75 3.45 41.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.862 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -102.64 -35.94 8.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.083 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 52.3 p -123.17 -35.17 3.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.098 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 90.86 26.61 21.74 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.481 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' LYS . . . . . 0.412 ' O ' ' C ' ' A' ' 118' ' ' SER . 86.1 mttt -97.73 136.39 38.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.769 0.318 . . . . 0.0 110.896 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 118' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 117' ' ' LYS . 2.2 m -37.7 111.76 0.18 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.853 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.491 ' HD2' HG12 ' A' ' 110' ' ' VAL . 9.3 mttm -61.82 -41.82 98.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.895 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.446 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 138.62 -46.75 0.96 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.531 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.531 ' CE2' HG21 ' A' ' 110' ' ' VAL . 10.1 p90 -100.04 148.65 24.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.996 0.427 . . . . 0.0 110.909 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -129.8 -177.31 14.81 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.503 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -127.47 139.29 52.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.854 0.359 . . . . 0.0 110.925 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.647 HG12 ' CE1' ' A' ' 126' ' ' PHE . 58.3 t -138.83 120.65 16.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.146 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 125' ' ' SER . . . . . 0.408 ' O ' HG23 ' A' ' 104' ' ' ILE . 42.3 m -106.65 149.81 26.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.853 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.647 ' CE1' HG12 ' A' ' 124' ' ' VAL . 2.1 m-85 -130.85 144.59 51.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.873 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.408 ' CE2' ' HB3' ' A' ' 103' ' ' ARG . 22.3 m-85 -56.38 -43.49 79.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.889 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 19.2 m120 -109.35 163.69 13.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.901 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.564 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 20.3 tptm -71.39 -59.55 2.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.902 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.417 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.8 OUTLIER -40.57 -57.39 1.86 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.9 179.922 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 130' ' ' TRP . 71.6 m-20 -35.86 -45.76 0.42 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.875 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.55 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -75.8 -58.27 3.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.065 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -44.16 -59.5 2.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.883 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -41.79 -44.49 3.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.891 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.47 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -69.23 -56.78 6.58 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.107 179.834 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 86.1 mt -38.73 -35.5 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.106 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 20.8 mt-30 -87.18 -57.07 3.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.892 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 37.3 mm-40 -68.3 -61.97 1.6 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.93 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.899 ' HE3' HD11 ' A' ' 149' ' ' ILE . 64.1 mmm -51.92 -38.93 58.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.858 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.44 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -57.55 93.51 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.492 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 119.44 13.17 6.39 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.508 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 87.4 mm-40 -94.27 169.66 10.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.753 0.311 . . . . 0.0 110.962 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 143' ' ' TRP . . . . . 0.42 ' NE1' ' HG3' ' A' ' 148' ' ' GLN . 17.2 m95 -106.3 109.47 21.41 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.899 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.636 HD13 ' HB2' ' A' ' 97' ' ' ALA . 60.9 tp -104.15 129.58 51.87 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.926 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 0.708 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.74 -77.0 0.4 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.475 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -156.33 15.93 0.41 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.464 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 43.2 mtp85 -157.99 161.01 38.09 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.758 0.313 . . . . 0.0 110.856 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.42 ' HG3' ' NE1' ' A' ' 143' ' ' TRP . 28.9 mt-30 -64.25 167.08 7.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.923 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.899 HD11 ' HE3' ' A' ' 139' ' ' MET . 21.1 pt -136.26 152.11 29.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.147 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.413 ' HG2' ' CE2' ' A' ' 81' ' ' PHE . 2.8 ttt180 -109.29 129.72 55.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.892 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.44 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 44.4 p -124.55 137.54 54.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.149 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 4.2 t30 -160.61 174.09 14.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.919 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 153' ' ' TRP . . . . . 0.546 ' CH2' ' CE ' ' A' ' 129' ' ' LYS . 4.6 m95 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.898 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.874 0.369 . . . . 0.0 110.862 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 79' ' ' HIS . . . . . 0.404 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.9 OUTLIER -82.02 135.24 35.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.872 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 38.9 t -114.2 144.57 21.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.124 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' PHE . . . . . 0.694 ' CD2' ' ND2' ' A' ' 152' ' ' ASN . 11.9 t80 -96.74 138.28 34.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.862 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.776 HG12 HD21 ' A' ' 85' ' ' LEU . 3.2 t -137.17 134.46 47.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.151 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -142.3 -173.1 14.04 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.456 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 56.93 29.3 16.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.816 0.341 . . . . 0.0 110.86 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.776 HD21 HG12 ' A' ' 82' ' ' VAL . 14.6 mt -86.31 132.25 34.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.956 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -53.87 155.3 6.2 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.639 0.733 . . . . 0.0 110.863 -179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.85 -15.96 36.98 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.688 2.259 . . . . 0.0 112.291 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -92.0 -7.14 49.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.873 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.825 HD11 ' HA3' ' A' ' 145' ' ' GLY . 33.2 mm -74.98 138.88 20.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.155 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.8 t -119.88 -176.71 3.24 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.133 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.6 ' HA ' HG23 ' A' ' 109' ' ' VAL . 84.9 m -53.77 -57.25 11.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.125 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.439 ' O ' ' C ' ' A' ' 93' ' ' ASP . 70.9 mt-10 -48.67 -58.48 4.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.914 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.439 ' C ' ' O ' ' A' ' 92' ' ' GLU . 2.9 m-20 -34.48 -55.28 0.54 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.841 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.605 HD11 HG22 ' A' ' 109' ' ' VAL . 4.5 mt -51.76 -60.34 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.152 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.638 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 25.6 mtmt -48.85 -41.93 34.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.899 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.68 -29.13 69.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.083 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.442 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -75.67 -53.74 8.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.131 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.423 ' C ' HD11 ' A' ' 104' ' ' ILE . 27.2 m-85 -86.82 3.49 45.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.915 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.776 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -56.5 -60.29 9.62 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.587 0.708 . . . . 0.0 111.154 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.776 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.3 Cg_endo -69.76 -0.81 7.45 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.708 2.272 . . . . 0.0 112.353 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.584 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 72.0 m-85 -99.77 -1.2 38.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 142.17 156.07 6.67 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.507 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.476 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 17.5 mtm105 -62.6 122.28 15.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.743 0.306 . . . . 0.0 110.871 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.452 ' CG2' HG13 ' A' ' 124' ' ' VAL . 13.9 mt -100.39 138.21 25.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.176 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.467 ' HB2' ' CZ ' ' A' ' 127' ' ' PHE . 47.8 t -112.92 -59.61 1.99 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' ASP . . . . . 0.422 ' HB3' ' CB ' ' A' ' 125' ' ' SER . 25.9 t70 -100.63 99.78 10.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.449 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -132.08 124.94 30.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.081 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.446 ' HA ' HG23 ' A' ' 91' ' ' THR . 10.3 ptp180 -159.36 153.32 23.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 -179.904 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.605 HG22 HD11 ' A' ' 94' ' ' ILE . 90.0 t -100.93 124.12 54.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.111 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.955 HG12 ' HG3' ' A' ' 119' ' ' LYS . 53.4 t -59.64 143.96 13.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.118 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 111' ' ' LYS . . . . . 0.451 ' C ' ' HG2' ' A' ' 119' ' ' LYS . 74.5 mttt -140.7 153.87 46.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.492 ' N ' ' HG2' ' A' ' 119' ' ' LYS . 7.9 t0 -60.22 127.38 31.54 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.838 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 19.9 ptm -80.12 2.81 22.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.867 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -102.66 -38.38 7.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.074 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 42.1 p -119.9 -33.82 3.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.181 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 95.35 30.2 8.35 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.444 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 34.5 mttm -99.01 164.48 12.16 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.778 0.323 . . . . 0.0 110.903 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 36.4 t -56.62 115.05 2.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.907 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.955 ' HG3' HG12 ' A' ' 110' ' ' VAL . 0.5 OUTLIER -68.33 -38.56 81.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.909 179.962 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 126.39 -46.1 1.11 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.433 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.528 ' CE2' HG21 ' A' ' 110' ' ' VAL . 8.3 p90 -100.32 151.33 21.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.927 0.394 . . . . 0.0 110.934 -179.794 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -132.58 171.55 21.56 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.473 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -121.06 138.85 53.99 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.859 0.361 . . . . 0.0 110.907 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.661 HG12 ' CE1' ' A' ' 126' ' ' PHE . 93.9 t -138.91 112.26 6.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.103 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' SER . . . . . 0.422 ' CB ' ' HB3' ' A' ' 106' ' ' ASP . 2.7 t -97.89 148.64 23.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.83 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.661 ' CE1' HG12 ' A' ' 124' ' ' VAL . 3.6 m-85 -127.06 148.38 50.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.882 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.476 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 77.9 m-85 -63.27 -34.66 78.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.916 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 25.4 m120 -115.93 168.88 9.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.87 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 66.8 tttt -81.0 -47.88 13.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.427 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -48.57 -62.47 1.48 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.935 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 130' ' ' TRP . 44.4 m-20 -35.87 -54.17 0.74 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.811 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -61.39 -67.08 0.44 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.107 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -37.26 -57.87 0.86 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 42.4 t-20 -41.01 -52.89 3.09 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.864 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.96 -56.71 13.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.098 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 92.3 mt -38.17 -35.82 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.175 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -85.26 -63.53 1.31 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.899 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 22.2 mt-30 -59.56 -61.9 2.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.584 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 81.2 mmm -52.19 -35.23 48.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.913 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.401 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -54.94 99.43 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.522 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 111.59 -20.7 22.42 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.488 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 10.8 mm-40 -56.55 -179.92 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.791 0.329 . . . . 0.0 110.927 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 143' ' ' TRP . . . . . 0.486 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 13.4 m95 -116.86 124.72 50.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.927 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.592 HD23 HD22 ' A' ' 85' ' ' LEU . 47.2 tp -123.88 128.75 49.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.862 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 0.825 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.54 -3.69 11.15 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.516 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 120.91 -13.5 9.79 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.496 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 60.4 mtt180 -122.85 147.4 46.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.727 0.299 . . . . 0.0 110.88 -179.866 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.486 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 32.6 mt-30 -55.45 165.57 0.77 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.926 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.423 HG21 ' HB3' ' A' ' 144' ' ' LEU . 19.5 pt -138.15 151.34 25.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.117 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 27.0 ptt180 -113.99 109.1 17.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.906 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.401 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 69.3 p -106.54 141.43 37.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.167 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 152' ' ' ASN . . . . . 0.694 ' ND2' ' CD2' ' A' ' 81' ' ' PHE . 7.4 p30 -167.15 -178.95 4.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.876 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 31.2 m95 . . . . . 0 C--N 1.328 -0.344 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.916 179.969 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.45 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 47.0 m-85 . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.911 0.386 . . . . 0.0 110.874 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 87.4 m-70 -89.3 140.49 29.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.851 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.461 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 41.5 t -118.1 138.76 47.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.073 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 15.5 t80 -92.89 135.49 34.09 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.878 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.859 HG12 HD21 ' A' ' 85' ' ' LEU . 3.7 t -137.58 109.51 6.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.118 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -123.21 -177.48 15.15 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.472 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.403 ' O ' ' O ' ' A' ' 148' ' ' GLN . 4.5 t70 63.83 36.45 10.4 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.859 0.362 . . . . 0.0 110.91 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.859 HD21 HG12 ' A' ' 82' ' ' VAL . 15.6 mt -91.7 170.54 9.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.912 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -90.01 155.4 47.33 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.672 0.749 . . . . 0.0 110.786 -179.835 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 -10.79 29.39 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.668 2.245 . . . . 0.0 112.338 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -96.5 -6.11 37.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.841 HD11 ' HA3' ' A' ' 145' ' ' GLY . 45.8 mm -79.09 136.38 23.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.116 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.6 t -118.96 164.7 15.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.19 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.737 ' HA ' HG23 ' A' ' 109' ' ' VAL . 35.8 m -40.24 -48.77 2.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.149 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 93' ' ' ASP . 32.7 mt-10 -55.64 -58.78 6.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.444 ' CB ' HG23 ' A' ' 89' ' ' ILE . 13.3 m-20 -34.78 -56.67 0.55 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.86 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.565 HD11 HG22 ' A' ' 109' ' ' VAL . 10.4 mt -49.26 -60.76 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.185 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.693 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 24.0 mtmt -46.69 -39.81 12.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.914 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -63.58 -30.77 71.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.103 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.656 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -73.92 -53.68 9.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.088 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.423 ' C ' HD11 ' A' ' 104' ' ' ILE . 22.3 m-85 -89.18 12.34 16.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.91 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.77 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -65.23 -60.07 8.56 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.661 0.743 . . . . 0.0 111.082 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.77 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.76 -0.77 7.4 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.616 2.211 . . . . 0.0 112.376 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.497 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 77.6 m-85 -99.65 -3.14 33.78 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.892 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 143.03 131.95 2.6 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.485 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 46.2 mtt85 -44.09 124.93 4.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.803 0.335 . . . . 0.0 110.875 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.475 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 14.1 mt -100.11 145.18 11.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.136 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.448 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 3.8 t -116.01 -61.94 1.66 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.851 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -100.57 99.47 10.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.83 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.418 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -132.92 127.18 33.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.483 ' HA ' HG23 ' A' ' 91' ' ' THR . 6.7 ptm180 -160.15 155.29 24.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.871 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.737 HG23 ' HA ' ' A' ' 91' ' ' THR . 96.4 t -107.06 120.35 58.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.138 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.578 HG21 ' CE2' ' A' ' 121' ' ' TYR . 66.8 t -54.33 124.66 7.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.159 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -123.72 148.74 46.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.877 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.472 ' O ' ' N ' ' A' ' 116' ' ' GLY . 24.1 t0 -56.88 121.61 10.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.871 179.817 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 8.2 ptp -73.11 -1.54 17.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.938 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -97.86 -42.52 7.52 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.134 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 29.1 p -115.75 -29.43 6.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.137 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 89.51 30.3 14.07 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.499 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 51.7 mttm -98.9 152.5 19.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.829 0.347 . . . . 0.0 110.899 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 7.8 t -60.29 110.75 1.32 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.831 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 50.9 mttt -62.73 -47.82 81.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.93 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.678 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 139.75 -38.98 1.56 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.463 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.578 ' CE2' HG21 ' A' ' 110' ' ' VAL . 25.3 p90 -100.09 144.04 29.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.953 0.406 . . . . 0.0 110.92 -179.81 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.81 175.07 21.52 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.545 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -121.85 139.93 53.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.912 0.387 . . . . 0.0 110.866 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.682 HG12 ' CE1' ' A' ' 126' ' ' PHE . 59.4 t -135.62 111.46 12.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.122 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.8 t -100.49 145.64 28.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.856 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.682 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.3 m-85 -124.93 162.0 25.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.896 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.448 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 22.1 m-85 -66.41 -48.17 70.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.875 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 78.6 m-20 -113.91 160.04 19.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.869 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.45 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 3.7 ttmt -63.22 -62.75 1.49 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.91 179.876 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.437 ' C ' ' O ' ' A' ' 129' ' ' LYS . 1.0 OUTLIER -35.16 -59.36 0.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.929 179.92 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.401 ' C ' ' O ' ' A' ' 130' ' ' TRP . 48.3 m-20 -37.58 -43.97 0.65 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.912 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.461 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -74.71 -59.16 2.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.099 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.7 mt-10 -40.53 -54.76 2.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.829 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -43.53 -45.37 6.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.423 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -71.95 -58.49 3.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.07 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 97.1 mt -38.44 -36.37 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.124 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 23.8 mt-30 -83.35 -63.63 1.32 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.891 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -62.92 -62.73 1.52 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.925 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.497 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 68.8 mmm -51.8 -41.32 61.62 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.913 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -55.13 103.75 0.23 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.486 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 100.5 21.15 13.28 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.498 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 9.5 mm100 -105.64 177.42 4.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.787 0.327 . . . . 0.0 110.905 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 143' ' ' TRP . . . . . . . . . . . . . 17.0 m95 -106.74 121.69 44.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.903 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.656 HD13 ' HB2' ' A' ' 97' ' ' ALA . 36.4 tp -121.53 127.78 51.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.924 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 0.841 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 73.54 -36.62 0.84 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.477 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 146' ' ' GLY . . . . . 0.425 ' H ' ' C ' ' A' ' 144' ' ' LEU . . . 160.2 -14.25 0.19 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.516 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 51.2 mtt180 -127.38 149.24 50.16 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.762 0.315 . . . . 0.0 110.838 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.403 ' O ' ' O ' ' A' ' 84' ' ' ASP . 38.8 mt-30 -53.89 169.35 0.16 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.915 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.509 HG22 HD23 ' A' ' 85' ' ' LEU . 33.8 pt -148.92 147.77 16.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.14 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 9.6 ptt180 -110.58 123.26 49.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.909 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 29.4 p -118.26 141.92 48.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.138 -179.9 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 152' ' ' ASN . . . . . 0.459 ' CG ' ' N ' ' A' ' 153' ' ' TRP . 5.4 t30 -165.08 166.91 18.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.904 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 153' ' ' TRP . . . . . 0.459 ' N ' ' CG ' ' A' ' 152' ' ' ASN . 11.2 m95 . . . . . 0 C--N 1.327 -0.371 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.934 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.862 0.363 . . . . 0.0 110.876 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 64.1 m-70 -90.55 161.51 15.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.913 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.423 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 49.5 t -137.64 135.83 46.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.159 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' PHE . . . . . 0.439 ' CE2' ' HG3' ' A' ' 150' ' ' ARG . 17.9 t80 -87.63 132.41 34.09 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.899 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.846 HG12 HD21 ' A' ' 85' ' ' LEU . 6.5 t -132.38 110.0 15.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.116 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -117.74 -178.77 17.41 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.459 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.403 ' O ' ' O ' ' A' ' 148' ' ' GLN . 2.0 m-20 64.02 40.11 7.4 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.874 0.368 . . . . 0.0 110.859 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.846 HD21 HG12 ' A' ' 82' ' ' VAL . 9.4 mt -102.85 129.56 49.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.901 -179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.1 t -52.92 154.37 5.14 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.671 0.748 . . . . 0.0 110.832 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -4.23 13.6 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.636 2.224 . . . . 0.0 112.356 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' GLU . . . . . 0.401 ' O ' ' HG3' ' A' ' 88' ' ' GLU . 1.3 tt0 -95.71 -29.77 14.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 1.014 HD11 ' HA3' ' A' ' 145' ' ' GLY . 48.3 mm -57.9 136.64 20.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.139 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.3 t -117.18 164.05 15.36 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.145 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.549 ' HA ' HG23 ' A' ' 109' ' ' VAL . 16.7 m -40.78 -39.63 1.15 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.154 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 93' ' ' ASP . 29.5 mt-10 -61.92 -59.71 4.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.61 ' CB ' HG23 ' A' ' 89' ' ' ILE . 0.6 OUTLIER -36.78 -56.59 0.84 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.86 -179.988 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.557 HD11 HG22 ' A' ' 109' ' ' VAL . 6.3 mt -48.19 -58.06 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.131 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.634 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 23.9 mtmt -49.65 -38.95 34.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.908 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.17 -31.37 72.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.081 179.824 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.498 ' HB1' ' HE1' ' A' ' 139' ' ' MET . . . -72.78 -46.84 51.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.105 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.413 ' C ' HD11 ' A' ' 104' ' ' ILE . 20.1 m-85 -97.16 11.77 35.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.941 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.77 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -63.8 -59.73 10.8 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.531 0.681 . . . . 0.0 111.109 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.77 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.4 Cg_endo -69.77 -0.7 7.3 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.717 2.278 . . . . 0.0 112.315 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' PHE . . . . . 0.598 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 62.6 m-85 -99.64 -0.11 40.93 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.899 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 139.7 138.31 3.61 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.532 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.489 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 13.7 mtt85 -48.03 125.09 8.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.782 0.325 . . . . 0.0 110.862 -179.854 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.476 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 17.9 mt -100.02 138.73 23.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.102 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.453 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.3 t -111.9 -59.14 2.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.835 -179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' ASP . . . . . 0.457 ' HB3' ' CB ' ' A' ' 125' ' ' SER . 23.2 t70 -100.33 100.32 11.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.888 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.546 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -133.6 124.93 27.72 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.117 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.475 ' HD3' ' N ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -161.67 155.59 21.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 -179.889 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.557 HG22 HD11 ' A' ' 94' ' ' ILE . 76.5 t -106.14 117.4 51.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.147 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.798 HG12 ' HG3' ' A' ' 119' ' ' LYS . 60.2 t -47.36 141.33 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.13 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 47.6 mttt -139.33 151.01 46.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.879 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.434 ' O ' ' N ' ' A' ' 116' ' ' GLY . 25.7 t0 -63.74 122.95 17.65 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.889 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 27.9 ptm -72.49 -6.61 44.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.878 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -96.74 -48.43 5.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.111 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 45.4 p -100.75 -32.19 10.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.116 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.434 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 86.71 24.13 39.89 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.452 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 44.8 mtmt -98.43 168.02 10.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.79 0.329 . . . . 0.0 110.917 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 15.8 t -64.37 114.26 4.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.826 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.798 ' HG3' HG12 ' A' ' 110' ' ' VAL . 27.3 mmtt -63.83 -47.25 81.54 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.887 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.473 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 139.38 -46.91 0.93 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.479 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.664 ' CE2' HG21 ' A' ' 110' ' ' VAL . 12.7 p90 -100.14 146.28 27.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.948 0.404 . . . . 0.0 110.891 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -128.11 176.94 17.91 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.445 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -122.56 141.41 51.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.86 0.362 . . . . 0.0 110.907 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.686 HG12 ' CE1' ' A' ' 126' ' ' PHE . 56.8 t -137.63 122.3 23.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.112 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 125' ' ' SER . . . . . 0.457 ' CB ' ' HB3' ' A' ' 106' ' ' ASP . 4.9 t -112.19 140.79 46.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.877 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.686 ' CE1' HG12 ' A' ' 124' ' ' VAL . 27.8 m-85 -121.53 147.97 45.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.843 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.489 ' CE2' ' HB3' ' A' ' 103' ' ' ARG . 21.6 m-85 -55.88 -49.8 72.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.89 -179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 48.9 m-20 -99.47 166.73 11.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.886 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.461 ' HE3' ' CZ2' ' A' ' 153' ' ' TRP . 45.5 tptt -75.61 -45.78 35.53 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.863 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.417 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.9 OUTLIER -55.78 -54.56 42.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.918 179.915 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 130' ' ' TRP . 60.5 m-20 -35.67 -43.24 0.27 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.883 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.504 ' HB2' ' CD1' ' A' ' 126' ' ' PHE . . . -77.81 -56.9 4.13 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.129 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.476 ' HA ' HD12 ' A' ' 136' ' ' ILE . 13.5 mt-10 -45.23 -56.96 4.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.857 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 29.6 t-20 -43.35 -49.71 6.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.931 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.547 ' HB1' ' HG3' ' A' ' 139' ' ' MET . . . -64.39 -53.32 50.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.087 179.856 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' ILE . . . . . 0.476 HD12 ' HA ' ' A' ' 133' ' ' GLU . 94.7 mt -41.49 -34.38 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.141 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 -84.71 -69.55 0.64 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.905 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 28.2 mt-30 -55.99 -59.38 4.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.897 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.598 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 53.9 mmm -58.12 -43.1 87.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.449 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -56.98 91.41 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.493 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 125.02 6.16 6.5 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.459 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 142' ' ' GLN . . . . . 0.492 ' HG2' ' CD1' ' A' ' 149' ' ' ILE . 0.5 OUTLIER -92.33 -178.57 4.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.728 0.299 . . . . 0.0 110.957 -179.915 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 143' ' ' TRP . . . . . 0.48 ' N ' ' HG3' ' A' ' 142' ' ' GLN . 16.6 m95 -114.47 115.16 26.81 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.923 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.59 HD23 HD22 ' A' ' 85' ' ' LEU . 62.4 tp -108.1 128.45 54.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.91 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 1.014 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.97 -75.57 0.46 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.481 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.24 15.9 0.28 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.479 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 39.1 mtt85 -155.48 157.18 36.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.722 0.296 . . . . 0.0 110.867 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.45 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 16.6 mt-30 -60.51 170.3 1.44 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.937 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.492 ' CD1' ' HG2' ' A' ' 142' ' ' GLN . 23.6 pt -135.17 152.98 33.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.179 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.439 ' HG3' ' CE2' ' A' ' 81' ' ' PHE . 12.5 ptm180 -120.38 104.23 9.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.86 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.449 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 44.9 p -99.45 127.91 45.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.174 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -150.85 173.79 13.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.878 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 153' ' ' TRP . . . . . 0.461 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 7.3 m95 . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.561 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 43.8 m-85 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.875 0.369 . . . . 0.0 110.864 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 58.2 m-70 -88.06 135.29 33.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.863 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 53.7 t -114.78 140.3 36.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.096 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.5 t80 -91.28 135.29 33.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.898 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.502 HG12 HD21 ' A' ' 85' ' ' LEU . 16.6 t -131.73 127.54 59.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.069 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.469 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -137.39 171.75 23.04 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.491 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ASP . . . . . 0.41 ' O ' ' O ' ' A' ' 148' ' ' GLN . 6.6 t70 64.37 53.07 1.75 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.839 0.352 . . . . 0.0 110.857 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.511 HD22 HD23 ' A' ' 144' ' ' LEU . 21.3 mt -106.34 133.39 51.11 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.941 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -54.07 155.1 6.85 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.651 0.739 . . . . 0.0 110.862 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 -10.08 27.67 Favored 'Trans proline' 0 N--CA 1.465 -0.159 0 C-N-CA 122.73 2.287 . . . . 0.0 112.352 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -97.78 0.49 46.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.896 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.944 HD11 ' HA3' ' A' ' 145' ' ' GLY . 49.0 mm -88.02 136.83 22.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.151 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.9 t -121.21 179.39 4.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.124 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.625 HG23 ' HA ' ' A' ' 108' ' ' ARG . 85.4 m -51.18 -45.44 61.78 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.102 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -59.34 -55.79 30.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.837 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' ASP . . . . . 0.55 ' CB ' HG23 ' A' ' 89' ' ' ILE . 6.8 m-20 -38.18 -57.78 1.05 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.887 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' ILE . . . . . 0.414 HD11 HG22 ' A' ' 109' ' ' VAL . 6.7 mt -48.37 -62.04 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.131 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.672 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 26.0 mtmt -45.18 -39.88 6.62 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.948 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.02 -32.45 74.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.097 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.536 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -69.84 -54.66 12.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.084 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' PHE . . . . . 0.407 ' C ' HD11 ' A' ' 104' ' ' ILE . 22.7 m-85 -88.23 8.55 26.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.894 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.76 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -62.06 -60.04 11.33 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.567 0.698 . . . . 0.0 111.096 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.76 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.76 -0.76 7.38 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.721 2.28 . . . . 0.0 112.351 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -100.02 -10.91 21.05 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.905 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 154.69 156.43 7.71 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.47 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.449 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 29.8 mtm180 -64.61 121.7 15.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.742 0.306 . . . . 0.0 110.891 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.407 HD11 ' C ' ' A' ' 98' ' ' PHE . 15.3 mt -100.33 139.76 21.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.138 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 36.0 t -113.47 -59.59 2.0 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.832 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -100.82 100.97 11.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.842 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.48 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -131.67 128.34 38.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.067 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.625 ' HA ' HG23 ' A' ' 91' ' ' THR . 8.8 ptp180 -161.58 161.66 29.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.414 HG22 HD11 ' A' ' 94' ' ' ILE . 32.6 t -112.98 122.2 66.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.122 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' VAL . . . . . 0.693 HG21 ' CE2' ' A' ' 121' ' ' TYR . 58.8 t -55.83 142.94 9.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.137 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 28.5 mttp -142.19 154.48 44.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.872 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' ASP . . . . . 0.489 ' O ' ' N ' ' A' ' 116' ' ' GLY . 47.3 t0 -62.61 121.58 13.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.872 179.87 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 14.4 ptp -72.53 0.76 9.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.898 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -103.5 -34.62 8.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.099 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 6.9 p -123.39 -33.83 3.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.149 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.489 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 90.61 26.28 23.21 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.501 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -93.37 140.74 29.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.762 0.315 . . . . 0.0 110.9 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 2.8 t -46.24 113.06 0.56 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.866 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 34.5 mttt -67.23 -49.87 62.85 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.896 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.443 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 140.51 -39.95 1.42 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.497 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' TYR . . . . . 0.693 ' CE2' HG21 ' A' ' 110' ' ' VAL . 24.5 p90 -100.13 144.43 29.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.927 0.394 . . . . 0.0 110.945 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -131.77 -179.79 16.48 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.507 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 65.4 m-85 -124.57 138.94 54.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.874 0.369 . . . . 0.0 110.884 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.681 HG12 ' CE1' ' A' ' 126' ' ' PHE . 48.4 t -138.84 113.3 7.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.113 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 20.6 t -100.97 151.49 21.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.82 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' PHE . . . . . 0.681 ' CE1' HG12 ' A' ' 124' ' ' VAL . 3.0 m-85 -131.0 149.57 52.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.885 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 127' ' ' PHE . . . . . 0.449 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 81.4 m-85 -64.27 -35.73 81.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.848 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -120.49 157.26 29.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.914 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.561 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 40.4 tttt -65.89 -64.4 0.87 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.922 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' TRP . . . . . 0.453 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -34.17 -62.04 0.34 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.93 179.903 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 130' ' ' TRP . 5.7 m-20 -36.08 -43.41 0.34 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.841 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 129' ' ' LYS . . . -73.56 -60.69 2.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.084 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -42.99 -55.85 3.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.89 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -43.31 -44.65 5.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' ALA . . . . . 0.458 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -74.06 -56.06 5.37 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.094 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 76.9 mt -39.83 -37.35 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.125 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -83.04 -55.91 4.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.846 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 4.3 mm-40 -66.26 -63.45 1.08 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.883 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 139' ' ' MET . . . . . 0.521 ' HE3' HD11 ' A' ' 149' ' ' ILE . 84.3 mmm -51.07 -36.21 38.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.843 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -56.15 107.75 0.94 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.531 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 104.1 -17.39 48.32 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.464 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 15.1 mm-40 -67.69 -177.94 0.85 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.768 0.318 . . . . 0.0 110.945 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 143' ' ' TRP . . . . . 0.439 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 13.8 m95 -115.72 137.13 52.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.899 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.536 HD13 ' HB2' ' A' ' 97' ' ' ALA . 55.7 tp -130.27 121.56 26.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.937 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' GLY . . . . . 0.944 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 75.39 -24.19 1.44 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.473 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 146' ' ' GLY . . . . . 0.417 ' H ' ' C ' ' A' ' 144' ' ' LEU . . . 144.99 -6.88 1.61 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.477 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 54.0 mtt85 -130.61 144.07 51.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.812 0.339 . . . . 0.0 110.843 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 148' ' ' GLN . . . . . 0.439 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 23.9 mt-30 -51.48 163.92 0.24 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.913 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.521 HD11 ' HE3' ' A' ' 139' ' ' MET . 25.3 pt -137.69 155.22 30.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.099 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.497 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 7.6 ptm180 -118.12 118.23 31.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.874 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 34.3 p -117.64 132.35 56.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.136 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -158.55 173.35 16.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 32.8 m95 . . . . . 0 C--N 1.328 -0.369 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.871 180.0 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 60.9 p -73.36 160.39 31.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.862 0.363 . . . . 0.0 110.885 -179.695 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 55.3 p -52.24 106.41 0.15 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.835 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 106.22 155.29 21.19 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.503 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 23.5 t -105.64 128.48 53.66 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.885 0.374 . . . . 0.0 110.85 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.6 t -54.87 -49.97 69.86 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.87 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 151.92 -143.67 10.71 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.49 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 12.5 mm100 -57.18 91.77 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.897 0.38 . . . . 0.0 110.934 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 19.0 mtpp -109.49 141.52 41.82 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.924 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 14.0 ttmm -157.51 144.17 18.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.863 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.411 ' O ' ' C ' ' A' ' 74' ' ' THR . 31.0 t0 -115.1 73.91 0.85 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.411 ' C ' ' O ' ' A' ' 73' ' ' ASP . 6.4 p 36.63 45.43 0.39 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.161 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.6 m -60.23 -69.19 0.23 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.869 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -98.72 50.13 0.97 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.91 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 19.3 m170 -112.34 158.38 19.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.862 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -112.92 116.0 29.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.883 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 69.6 m-70 -86.62 144.45 27.16 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.861 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 23.7 t -118.86 146.71 23.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.114 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -99.26 135.59 40.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.935 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.799 HG12 HD21 ' A' ' 85' ' ' LEU . 6.0 t -134.56 131.07 54.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.152 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.478 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -137.07 -175.8 14.01 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.459 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 60.74 26.4 16.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.897 0.379 . . . . 0.0 110.899 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.799 HD21 HG12 ' A' ' 82' ' ' VAL . 10.9 mt -84.53 128.22 34.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.907 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.41 153.93 6.73 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.685 0.755 . . . . 0.0 110.841 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 -9.87 27.19 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.711 2.274 . . . . 0.0 112.325 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -97.44 -5.04 37.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.901 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.812 HD11 ' HA3' ' A' ' 145' ' ' GLY . 40.5 mm -77.23 139.4 18.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.131 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.6 t -116.8 163.7 15.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.131 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.666 ' HA ' HG23 ' A' ' 109' ' ' VAL . 6.3 m -43.8 -38.56 3.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.079 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -63.09 -56.56 15.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.896 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.548 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.4 m-20 -37.75 -52.88 1.28 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.842 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.508 HD11 HG22 ' A' ' 109' ' ' VAL . 5.1 mt -52.11 -58.7 2.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.127 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.603 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 24.2 mtmt -49.45 -39.2 32.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.889 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.87 -35.0 75.49 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.112 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.566 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -68.67 -55.53 11.12 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.091 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 35.6 m-85 -85.05 1.63 46.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.874 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.786 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -52.75 -60.11 7.3 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.605 0.717 . . . . 0.0 111.147 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.786 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.7 -1.03 7.72 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.689 2.26 . . . . 0.0 112.357 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -99.96 9.55 42.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.26 143.48 5.78 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.497 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 45.8 mtt85 -52.17 121.87 7.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.739 0.304 . . . . 0.0 110.857 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.446 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 13.1 mt -95.04 136.79 25.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.102 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.434 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 2.4 p -103.28 -64.53 1.07 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.86 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -100.59 109.17 21.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.822 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.555 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -138.94 125.03 20.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.116 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.476 ' HB2' ' CZ ' ' A' ' 108' ' ' ARG . 2.6 ptm85 -157.39 165.08 36.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.867 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.666 HG23 ' HA ' ' A' ' 91' ' ' THR . 87.3 t -112.93 112.73 41.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.168 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.916 HG11 ' CE2' ' A' ' 121' ' ' TYR . 97.1 t -45.98 137.9 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.154 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 84.7 mttt -137.86 161.22 37.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.924 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.475 ' OD2' ' HB3' ' A' ' 114' ' ' ALA . 9.3 t0 -75.15 125.94 29.99 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.868 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 14.3 ptp -75.77 -1.74 26.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.929 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.475 ' HB3' ' OD2' ' A' ' 112' ' ' ASP . . . -96.58 -39.59 9.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 30.6 p -119.51 -33.91 3.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.16 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 93.62 24.22 21.55 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.468 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 41.2 mmtt -93.55 151.17 19.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.82 0.343 . . . . 0.0 110.874 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 1.8 m -52.53 113.18 0.98 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.855 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.739 ' HG3' HG12 ' A' ' 110' ' ' VAL . 26.2 mmtt -63.14 -38.54 91.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.926 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.408 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 129.81 -40.06 1.73 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.505 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.916 ' CE2' HG11 ' A' ' 110' ' ' VAL . 3.0 p90 -100.02 155.09 17.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.943 0.402 . . . . 0.0 110.924 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.04 168.28 24.37 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.479 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 81.9 m-85 -117.47 141.54 48.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.914 0.388 . . . . 0.0 110.911 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.699 HG12 ' CE1' ' A' ' 126' ' ' PHE . 88.9 t -141.94 114.04 3.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.132 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 45.7 t -106.06 142.99 34.84 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.816 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.699 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.5 m-85 -119.24 158.46 25.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.898 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.434 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 20.7 m-85 -66.91 -42.3 85.67 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.883 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 25.3 m-80 -110.13 166.95 10.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.911 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 58.7 tttt -76.15 -44.2 39.39 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.898 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.429 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -54.71 -59.32 4.88 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.929 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 130' ' ' TRP . 88.8 m-20 -35.8 -56.17 0.7 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.896 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.415 ' HB2' ' CD1' ' A' ' 126' ' ' PHE . . . -63.39 -65.11 0.73 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.084 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.428 ' HA ' HD12 ' A' ' 136' ' ' ILE . 4.6 mm-40 -37.31 -59.01 0.79 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -42.65 -48.58 5.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.907 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.47 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -64.64 -56.45 13.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.094 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' ILE . . . . . 0.428 HD12 ' HA ' ' A' ' 133' ' ' GLU . 94.8 mt -38.6 -34.45 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.139 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -86.09 -60.39 2.02 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.883 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 9.6 mt-30 -63.73 -58.14 7.8 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.47 ' N ' ' O ' ' A' ' 135' ' ' ALA . 50.3 mmm -54.86 -34.91 63.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.878 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.45 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -60.89 117.45 11.66 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.47 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 92.56 12.48 58.22 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.524 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 13.6 mm-40 -94.43 170.83 9.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.759 0.314 . . . . 0.0 110.901 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' TRP . . . . . 0.42 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 16.2 m95 -106.1 109.08 20.91 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.87 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.566 HD13 ' HB2' ' A' ' 97' ' ' ALA . 64.6 tp -102.51 128.88 48.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.86 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 0.812 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.03 -75.69 0.33 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.458 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.37 15.54 0.32 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.478 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' ARG . . . . . 0.431 ' NH1' ' HB3' ' A' ' 147' ' ' ARG . 8.0 mtp-105 -156.11 159.33 38.96 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.796 0.331 . . . . 0.0 110.859 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.42 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 30.2 mt-30 -64.27 167.83 6.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.909 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 32.4 pt -140.89 145.97 24.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.136 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.478 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 6.5 ptt180 -107.25 109.76 21.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.45 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 43.8 p -103.84 137.01 42.45 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.112 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' ASN . . . . . 0.423 ' CG ' ' O ' ' A' ' 151' ' ' THR . 19.6 m120 -166.89 176.29 7.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.923 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 10.4 m95 -70.65 116.15 10.63 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -57.26 -44.42 83.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.128 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 45.0 p -92.64 115.62 28.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.136 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 11.3 ptp85 -138.11 163.0 32.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.866 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.454 ' CG ' ' HD2' ' A' ' 158' ' ' PRO . 4.5 ttpm? -91.67 140.22 25.1 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.554 0.692 . . . . 0.0 110.938 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 158' ' ' PRO . . . . . 0.454 ' HD2' ' CG ' ' A' ' 157' ' ' LYS . 53.7 Cg_endo -69.76 151.89 69.16 Favored 'Trans proline' 0 C--O 1.231 0.158 0 C-N-CA 122.699 2.266 . . . . 0.0 112.288 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 163.97 36.31 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.67 2.247 . . . . 0.0 112.362 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -88.84 150.65 46.11 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.554 0.692 . . . . 0.0 111.102 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 104.63 1.36 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.67 2.247 . . . . 0.0 112.304 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 34.0 tttp -166.9 120.84 1.03 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.912 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 92.4 p -134.58 142.48 46.95 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.824 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 12.5 t -157.18 151.69 25.32 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.149 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 14.5 p90 -158.52 147.97 19.31 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.922 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -144.37 146.41 32.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.888 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 35.7 p -140.76 107.41 5.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.892 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -87.02 92.34 9.01 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.89 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 24.9 p -64.27 -60.99 2.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.093 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 27.2 tttm 53.85 44.69 29.16 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.921 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -153.07 138.12 17.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 36.9 p -88.99 -53.99 4.33 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.83 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 178.95 146.16 6.51 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.464 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 148.42 65.09 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.703 2.269 . . . . 0.0 112.316 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 56.0 p -149.88 132.33 15.67 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.852 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 176' ' ' SER . . . . . 0.406 ' O ' ' C ' ' A' ' 177' ' ' GLY . 97.4 p -145.47 134.13 22.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.853 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 177' ' ' GLY . . . . . 0.406 ' C ' ' O ' ' A' ' 176' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.492 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 13.7 t -97.69 -46.76 5.87 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.841 0.353 . . . . 0.0 110.886 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 77.1 p -153.59 134.5 13.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.832 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.76 -150.75 5.31 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.528 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 41.0 p -140.47 114.86 9.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.841 0.353 . . . . 0.0 110.89 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.7 p -63.74 128.23 34.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.856 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -150.37 -134.7 2.29 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.483 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 31.4 mt-30 -69.09 156.7 38.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.852 0.358 . . . . 0.0 110.914 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.7 ttmm -91.66 158.66 16.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.899 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? 42.61 51.7 4.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -120.39 118.69 31.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.871 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 31.7 p -104.39 46.58 0.91 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.199 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 48.2 m -75.21 -49.73 18.47 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.842 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 9.3 m-20 -104.98 47.44 0.87 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.861 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -121.59 157.07 31.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.824 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.561 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 93.2 m-85 -100.7 111.37 23.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.905 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.48 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.5 OUTLIER -88.54 149.08 23.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.887 179.988 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 42.0 t -124.7 147.53 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.161 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -98.22 138.63 35.21 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.846 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.606 HG12 HD21 ' A' ' 85' ' ' LEU . 15.2 t -136.07 129.56 47.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.12 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.461 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -139.75 177.49 20.45 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.439 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 18.8 t0 64.08 41.91 6.03 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.848 0.356 . . . . 0.0 110.909 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.606 HD21 HG12 ' A' ' 82' ' ' VAL . 9.5 mt -102.41 137.02 41.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.929 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -54.93 153.86 10.78 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.691 0.758 . . . . 0.0 110.875 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 -12.0 31.91 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.676 2.251 . . . . 0.0 112.317 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -93.26 -9.57 38.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.915 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.972 HD11 ' HA3' ' A' ' 145' ' ' GLY . 42.3 mm -74.65 137.1 23.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.077 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.421 ' O ' ' C ' ' A' ' 91' ' ' THR . 11.3 t -120.46 162.48 19.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.116 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.5 ' HA ' HG23 ' A' ' 109' ' ' VAL . 53.2 m -36.03 -49.27 0.64 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.14 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 93' ' ' ASP . 20.2 mt-10 -52.8 -60.33 3.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.899 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.623 ' CB ' HG23 ' A' ' 89' ' ' ILE . 1.0 OUTLIER -34.78 -57.47 0.53 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.909 179.972 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.525 HD11 HG22 ' A' ' 109' ' ' VAL . 12.6 mt -48.61 -60.0 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.093 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.648 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 24.5 mtmt -47.66 -39.85 18.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.931 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.49 -28.91 70.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.087 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.7 -50.68 13.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.095 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.47 ' C ' HD11 ' A' ' 104' ' ' ILE . 19.1 m-85 -91.16 12.16 20.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.763 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -66.6 -59.68 7.73 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.578 0.704 . . . . 0.0 111.09 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.763 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.73 -0.6 7.12 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.637 2.225 . . . . 0.0 112.35 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.505 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 74.9 m-85 -99.61 -11.96 20.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.888 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 152.26 137.53 2.59 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.496 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.424 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 10.1 mtm-85 -48.76 122.64 5.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.81 0.338 . . . . 0.0 110.848 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.47 HD11 ' C ' ' A' ' 98' ' ' PHE . 10.2 mt -99.99 141.75 16.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.125 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.4 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 3.5 t -109.68 -63.73 1.33 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.858 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -100.44 104.85 16.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.881 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.56 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -134.67 128.91 33.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.109 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.477 ' HA ' HG23 ' A' ' 91' ' ' THR . 11.5 ptm180 -161.79 163.6 29.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.841 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.525 HG22 HD11 ' A' ' 94' ' ' ILE . 89.9 t -110.85 120.47 61.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.098 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.605 HG21 ' CE2' ' A' ' 121' ' ' TYR . 57.4 t -50.7 135.85 10.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.115 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 46.3 mttm -136.21 146.08 46.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.442 ' O ' ' N ' ' A' ' 116' ' ' GLY . 32.1 t0 -55.02 123.42 13.51 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.891 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 9.1 tpt -71.07 -2.52 15.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.873 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -103.08 -48.72 3.96 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.062 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 34.0 p -102.25 -29.37 11.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.138 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 80.51 28.45 47.75 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.47 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 14.5 mtpp -99.86 148.82 24.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.781 0.324 . . . . 0.0 110.891 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 5.4 t -51.8 105.64 0.12 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.842 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 36.6 mttt -58.47 -46.81 85.88 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.9 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.406 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 142.13 -41.94 1.17 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.484 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.605 ' CE2' HG21 ' A' ' 110' ' ' VAL . 9.5 p90 -99.86 149.15 23.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.888 0.375 . . . . 0.0 110.947 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -130.58 179.64 16.77 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.479 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -126.62 142.04 51.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.876 0.37 . . . . 0.0 110.921 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.664 HG12 ' CE1' ' A' ' 126' ' ' PHE . 60.2 t -138.94 123.9 21.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.096 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' SER . . . . . 0.432 ' O ' HG23 ' A' ' 104' ' ' ILE . 33.0 m -112.19 144.77 41.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.877 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.664 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.2 m-85 -125.32 150.55 47.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.424 ' CE2' ' HB3' ' A' ' 103' ' ' ARG . 21.9 m-85 -57.65 -46.48 84.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.92 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 25.7 m-20 -112.05 163.45 14.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.91 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.561 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 69.9 tttt -72.11 -61.64 1.72 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.897 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.434 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.9 OUTLIER -34.78 -56.76 0.55 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.906 179.99 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -42.08 -52.02 4.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.851 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -63.37 -60.64 3.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.115 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.411 ' HA ' HD12 ' A' ' 136' ' ' ILE . 5.7 mm-40 -39.44 -60.21 0.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 32.6 t-20 -40.29 -44.77 1.98 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.903 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.424 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -69.63 -54.39 14.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.091 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' ILE . . . . . 0.411 HD12 ' HA ' ' A' ' 133' ' ' GLU . 91.7 mt -41.58 -34.83 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.14 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 19.0 mt-30 -87.29 -60.55 1.95 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.911 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 29.3 mm-40 -60.29 -60.17 4.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.901 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.505 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 75.7 mmm -56.84 -41.8 78.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.873 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.441 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -53.09 103.07 0.11 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.478 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 107.41 6.65 33.28 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.51 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 -90.11 173.87 7.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.799 0.333 . . . . 0.0 110.932 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' TRP . . . . . 0.48 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 17.8 m95 -109.02 121.22 44.68 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.952 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.534 HD23 HD22 ' A' ' 85' ' ' LEU . 34.2 tp -122.85 127.27 48.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.888 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 0.972 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 72.12 -7.08 8.37 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.474 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 124.16 -9.71 8.36 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.507 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 17.9 mtt180 -127.63 148.9 50.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.722 0.296 . . . . 0.0 110.91 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.48 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 28.1 mt-30 -60.19 152.96 23.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.923 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.592 HG22 HD23 ' A' ' 85' ' ' LEU . 24.6 pt -123.07 153.55 28.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.099 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.474 ' CG ' ' O ' ' A' ' 150' ' ' ARG . 10.1 ptm180 -114.93 114.05 24.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.441 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 73.4 p -107.86 130.4 55.0 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.159 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -157.39 172.38 18.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 24.2 m95 -71.67 124.47 24.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.896 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -73.05 78.69 1.21 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.13 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 32.4 p -121.61 157.62 30.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.103 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 11.3 ptp180 -154.52 170.73 20.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 44.0 mttt -108.84 151.03 41.6 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.581 0.705 . . . . 0.0 110.879 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 157.6 59.75 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.652 2.234 . . . . 0.0 112.314 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -176.29 1.44 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.689 2.259 . . . . 0.0 112.348 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -164.93 151.58 9.36 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.611 0.719 . . . . 0.0 111.065 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 172.23 13.02 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.724 2.282 . . . . 0.0 112.321 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 16.9 tptm -105.8 107.15 18.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.945 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 73.3 m -59.9 156.74 13.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.842 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 56.2 p -139.42 168.86 18.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.182 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -173.79 143.02 0.95 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.911 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 26.1 tp10 -144.88 125.05 13.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.883 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 29.1 m -159.02 136.4 9.95 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.833 -179.765 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 10.4 p30 -149.55 134.48 17.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.848 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 9.1 t -155.1 156.2 35.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.152 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 58.6 tttm -139.5 149.84 44.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.857 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -164.7 165.54 20.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 91.8 p -174.97 170.2 3.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.906 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 174.84 130.6 1.32 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.493 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 178.33 4.67 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.698 2.265 . . . . 0.0 112.358 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 2.4 t -168.91 123.36 0.86 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.852 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 18.0 t -153.92 164.54 38.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.838 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.506 -179.961 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.437 -0.265 . . . . 0.0 112.437 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 18.4 m -111.76 176.94 4.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.913 0.387 . . . . 0.0 110.857 -179.735 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 59.8 p -101.95 103.94 14.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 -179.83 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 137.48 -49.45 0.85 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.442 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 35.1 p -56.55 111.81 1.1 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.871 0.367 . . . . 0.0 110.867 -179.741 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.1 t -67.86 -45.75 73.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.839 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -135.72 118.61 1.89 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.5 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 53.9 mm-40 -53.04 -46.23 68.38 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.839 0.352 . . . . 0.0 110.926 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 14.0 mmtm -132.6 -177.33 4.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.879 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 33.1 ttpt -110.58 -44.56 3.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.43 ' O ' ' C ' ' A' ' 74' ' ' THR . 28.1 m-20 -107.05 43.75 1.13 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.886 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.591 HG22 ' ND1' ' A' ' 77' ' ' HIS . 16.7 p 35.8 45.3 0.27 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.169 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.2 t -62.47 -59.71 4.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.882 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 46.8 m-80 -109.03 54.65 0.65 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.917 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' HIS . . . . . 0.591 ' ND1' HG22 ' A' ' 74' ' ' THR . 10.8 m170 -111.07 164.64 12.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.851 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.491 ' CD2' ' HA ' ' A' ' 129' ' ' LYS . 37.3 m-85 -111.59 108.96 18.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.855 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 58.4 m-70 -86.08 155.87 20.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.866 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 45.4 t -129.07 141.55 46.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.098 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.0 t80 -90.7 133.33 35.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.876 HG12 HD21 ' A' ' 85' ' ' LEU . 5.6 t -129.74 110.0 19.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.123 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.47 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -118.18 168.21 13.07 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.473 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.9 t70 68.76 52.73 0.54 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.813 0.34 . . . . 0.0 110.877 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.876 HD21 HG12 ' A' ' 82' ' ' VAL . 16.2 mt -109.68 131.49 55.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.919 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.1 t -53.98 154.71 7.16 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.624 0.726 . . . . 0.0 110.885 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -14.51 36.15 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.693 2.262 . . . . 0.0 112.36 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -93.07 -5.24 50.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.911 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.626 HD11 ' HA3' ' A' ' 145' ' ' GLY . 40.5 mm -78.37 138.11 20.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.127 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.3 t -120.84 170.5 9.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.181 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.526 ' HA ' HG23 ' A' ' 109' ' ' VAL . 88.3 m -43.64 -49.85 7.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.168 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.437 ' O ' ' C ' ' A' ' 93' ' ' ASP . 57.7 mt-10 -52.05 -60.16 3.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.91 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.525 ' CB ' HG23 ' A' ' 89' ' ' ILE . 5.9 m-20 -34.51 -57.99 0.5 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.891 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.506 ' CD1' HG22 ' A' ' 109' ' ' VAL . 7.6 mt -49.52 -62.26 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.117 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.693 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 27.8 mtmt -46.12 -40.1 10.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.943 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.52 -31.61 71.63 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.154 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.582 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -72.97 -53.86 10.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.121 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -88.14 7.07 33.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.853 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.774 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -60.73 -59.93 12.27 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.609 0.719 . . . . 0.0 111.097 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.774 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.1 Cg_endo -69.77 -0.75 7.38 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.685 2.257 . . . . 0.0 112.314 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.593 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 73.8 m-85 -99.78 -5.04 29.3 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.914 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 144.25 136.2 3.04 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.507 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 29.5 mtt180 -46.78 124.41 6.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.795 0.331 . . . . 0.0 110.869 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.469 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 13.2 mt -100.09 138.26 24.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.151 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.495 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 47.1 p -107.33 -61.83 1.5 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.848 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -100.2 104.56 16.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.871 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.491 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -134.94 127.32 30.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.051 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.45 ' HA ' HG23 ' A' ' 91' ' ' THR . 1.9 ptt-85 -160.94 157.94 27.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.886 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.526 HG23 ' HA ' ' A' ' 91' ' ' THR . 86.8 t -110.26 115.42 49.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.135 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.641 HG21 ' CD2' ' A' ' 121' ' ' TYR . 48.7 t -46.97 136.82 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.147 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 54.0 mttt -137.46 148.69 46.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.945 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.638 ' OD2' ' HB3' ' A' ' 114' ' ' ALA . 25.8 t70 -58.54 130.18 45.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.879 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 28.4 ptm -78.88 1.63 22.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.866 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.638 ' HB3' ' OD2' ' A' ' 112' ' ' ASP . . . -102.82 -41.18 6.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.087 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 45.1 p -114.43 -29.07 6.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.167 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 84.52 21.43 56.4 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.497 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 48.4 mmtt -92.93 145.25 24.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.769 0.318 . . . . 0.0 110.902 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 4.9 t -46.69 111.86 0.44 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.853 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -62.7 -51.46 67.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 147.46 -41.56 0.93 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.486 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.641 ' CD2' HG21 ' A' ' 110' ' ' VAL . 4.9 p90 -100.06 153.13 19.47 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.928 0.394 . . . . 0.0 110.915 -179.791 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.42 173.7 22.14 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.468 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -122.54 140.45 52.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.897 0.379 . . . . 0.0 110.92 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.678 HG12 ' CE1' ' A' ' 126' ' ' PHE . 59.2 t -137.62 116.38 14.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.12 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 15.5 t -104.87 147.16 28.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.852 -179.84 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.678 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.2 m-85 -126.84 150.2 49.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.875 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.495 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 23.1 m-85 -56.7 -44.42 81.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 24.4 m-20 -112.86 166.47 11.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.905 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.561 ' HE3' ' CZ2' ' A' ' 153' ' ' TRP . 39.2 tptt -70.99 -59.99 2.48 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.944 179.854 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.426 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.8 OUTLIER -40.93 -59.92 1.32 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.922 179.941 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.426 ' C ' ' O ' ' A' ' 130' ' ' TRP . 6.9 m-20 -35.8 -39.11 0.14 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.863 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -80.43 -58.51 3.09 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.063 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.4 mt-10 -44.38 -55.68 4.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.948 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 54.7 t30 -42.8 -42.07 3.46 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.909 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.49 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -71.81 -55.78 6.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.055 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 76.1 mt -38.76 -36.4 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.104 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -83.6 -57.19 3.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 16.8 mm-40 -68.54 -61.16 1.95 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.897 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.593 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 41.3 mmm -52.97 -31.38 40.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.905 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.447 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -63.04 107.78 1.84 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.491 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 99.94 13.73 36.12 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.487 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 66.5 mm-40 -93.1 166.88 12.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.802 0.334 . . . . 0.0 110.89 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' TRP . . . . . 0.444 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 14.5 m95 -102.89 107.06 17.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.89 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.582 HD13 ' HB2' ' A' ' 97' ' ' ALA . 63.6 tp -100.02 126.46 46.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.873 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 0.626 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.25 -76.95 0.46 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.493 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -155.96 14.5 0.41 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.497 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 36.7 mtp180 -153.04 157.01 39.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.783 0.325 . . . . 0.0 110.866 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.444 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 30.8 mt-30 -62.16 167.2 4.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.927 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.413 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 25.7 pt -138.96 153.21 24.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.488 ' CG ' ' O ' ' A' ' 150' ' ' ARG . 7.0 ptm180 -118.82 116.47 26.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.9 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.447 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 53.5 p -107.53 135.53 48.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.134 -179.898 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 28.4 t30 -160.15 171.09 19.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' TRP . . . . . 0.561 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 15.3 m95 -66.87 122.29 17.37 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.937 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -77.92 -56.5 4.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.097 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 9.9 t -73.8 150.97 40.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.169 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 15.2 ptp180 -168.7 152.87 5.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.881 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 25.9 mmmt -137.07 155.01 76.34 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.56 0.695 . . . . 0.0 110.912 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 148.61 65.17 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.663 2.242 . . . . 0.0 112.346 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 157.76 59.28 Favored 'Trans proline' 0 N--CA 1.465 -0.15 0 C-N-CA 122.691 2.261 . . . . 0.0 112.369 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.405 ' HB1' ' HD2' ' A' ' 161' ' ' PRO . . . -80.74 154.93 73.5 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.542 0.687 . . . . 0.0 111.098 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 161' ' ' PRO . . . . . 0.405 ' HD2' ' HB1' ' A' ' 160' ' ' ALA . 53.3 Cg_endo -69.81 125.39 12.07 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.661 2.24 . . . . 0.0 112.309 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -69.36 112.32 5.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.876 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 55.0 p -145.78 133.06 20.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.849 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 164' ' ' THR . . . . . 0.422 HG23 ' HG2' ' A' ' 166' ' ' GLU . 13.3 t -136.22 169.75 17.13 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.155 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 3.5 t80 -108.54 99.45 8.83 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.926 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 166' ' ' GLU . . . . . 0.422 ' HG2' HG23 ' A' ' 164' ' ' THR . 16.8 pt-20 -171.94 145.51 1.88 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.894 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 33.3 p -152.79 116.21 4.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.894 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -156.53 130.53 8.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.851 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 13.0 t -170.17 152.6 4.26 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.107 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 6.8 mmpt? -113.42 118.58 34.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.916 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 18.6 pt20 -150.18 147.29 27.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.895 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 70.8 m 54.92 38.4 30.35 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.869 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -72.12 -158.64 3.88 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.488 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 124.02 10.66 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.691 2.261 . . . . 0.0 112.329 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 49.8 m -118.64 146.21 44.85 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.839 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 7.7 t -171.43 165.3 7.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.826 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.291 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.476 -179.983 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.526 -0.23 . . . . 0.0 112.526 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 82.1 p -156.81 174.23 15.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.877 0.37 . . . . 0.0 110.855 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 24.5 m -94.99 161.05 14.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.906 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -102.82 41.01 2.23 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.501 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 6.4 t -144.36 117.48 8.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.881 0.372 . . . . 0.0 110.876 -179.726 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.8 t -98.92 133.15 43.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.871 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 178.36 88.85 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.444 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 35.3 mm-40 -120.09 147.19 45.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.878 0.37 . . . . 0.0 110.938 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 41.0 mmtt -132.64 101.79 5.44 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.935 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 19.9 pttm -135.67 166.36 23.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.928 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -109.39 163.19 13.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.881 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.6 p -89.38 51.44 2.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.197 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 58.1 p -69.17 -55.51 10.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.837 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.4 t30 -113.02 51.96 0.81 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.885 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 17.2 m170 -117.43 155.08 30.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.877 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.564 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 84.3 m-85 -108.48 115.42 30.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.906 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 10.2 m-70 -89.65 147.84 23.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.89 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 41.4 t -119.21 143.47 30.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.157 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.1 t80 -93.56 135.3 34.96 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.666 ' CG1' HD21 ' A' ' 85' ' ' LEU . 4.0 t -131.25 131.04 63.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.157 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.432 ' N ' ' HG2' ' A' ' 150' ' ' ARG . . . -135.8 179.41 17.82 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.524 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 52.37 47.61 24.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.86 0.362 . . . . 0.0 110.852 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.668 HD22 HD23 ' A' ' 144' ' ' LEU . 30.0 mt -99.65 132.91 44.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.938 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -53.01 156.33 3.61 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.651 0.738 . . . . 0.0 110.868 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -39.53 6.28 Favored 'Trans proline' 0 C--O 1.231 0.125 0 C-N-CA 122.675 2.25 . . . . 0.0 112.337 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -71.46 1.2 6.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.887 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.91 HD11 ' HA3' ' A' ' 145' ' ' GLY . 37.3 mm -83.01 132.37 31.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.169 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.1 t -114.74 175.34 5.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.104 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.555 ' HA ' HG23 ' A' ' 109' ' ' VAL . 16.2 m -52.99 -41.66 64.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.147 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -62.36 -47.03 85.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.894 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.414 ' CB ' HG23 ' A' ' 89' ' ' ILE . 17.1 m-20 -47.87 -50.08 27.54 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.911 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.746 HD11 HG22 ' A' ' 109' ' ' VAL . 8.1 mt -54.7 -54.97 17.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.132 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.587 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 22.0 mtmt -50.93 -42.47 59.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.866 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -58.42 -30.98 67.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.107 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.535 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -72.46 -57.16 4.39 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.101 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.429 ' C ' HD11 ' A' ' 104' ' ' ILE . 22.0 m-85 -87.37 12.22 12.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.935 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.789 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -61.79 -60.19 11.05 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.613 0.72 . . . . 0.0 111.119 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.789 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.5 Cg_endo -69.8 -0.8 7.47 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.678 2.252 . . . . 0.0 112.306 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -99.9 9.57 42.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.883 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.26 136.02 4.24 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.525 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 38.9 mtt85 -46.73 125.04 6.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.766 0.317 . . . . 0.0 110.882 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.429 HD11 ' C ' ' A' ' 98' ' ' PHE . 10.9 mt -98.21 138.83 21.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.153 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.449 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.9 t -106.73 -62.91 1.34 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.848 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -100.25 105.2 16.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.861 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.481 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -136.46 127.01 26.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.138 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.2 ptm180 -161.91 155.85 21.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.892 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.746 HG22 HD11 ' A' ' 94' ' ' ILE . 58.4 t -102.07 119.14 49.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.642 HG21 ' CD2' ' A' ' 121' ' ' TYR . 59.8 t -53.86 136.99 15.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.141 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' LYS . . . . . 0.412 ' C ' ' HG3' ' A' ' 119' ' ' LYS . 57.5 mttt -136.59 153.89 50.83 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.755 ' OD2' ' HB3' ' A' ' 114' ' ' ALA . 23.2 t70 -64.99 120.21 12.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 16.4 ptp -67.14 -10.93 55.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.841 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.755 ' HB3' ' OD2' ' A' ' 112' ' ' ASP . . . -83.62 -54.81 4.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.107 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 13.5 p -104.85 -34.4 8.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.171 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 95.89 25.71 12.7 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.477 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 44.4 mtmt -95.33 154.68 17.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.781 0.324 . . . . 0.0 110.867 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 8.0 t -54.89 112.49 1.05 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.91 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.453 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 16.6 mttp -63.36 -54.23 40.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.895 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 150.2 -41.76 0.79 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.469 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.642 ' CD2' HG21 ' A' ' 110' ' ' VAL . 5.4 p90 -100.01 155.25 17.8 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.96 0.41 . . . . 0.0 110.938 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -134.46 169.88 22.9 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.464 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -118.77 138.44 52.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.873 0.368 . . . . 0.0 110.914 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.678 HG12 ' CE1' ' A' ' 126' ' ' PHE . 61.2 t -138.77 115.08 10.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.143 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 8.2 t -107.23 140.02 40.77 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.877 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.678 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.2 m-85 -119.51 163.45 17.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.894 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.449 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 22.9 m-85 -72.32 -42.91 64.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.902 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 68.0 m-20 -114.18 161.44 17.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.864 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.564 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 44.3 tptt -69.74 -61.63 1.71 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.464 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.9 OUTLIER -33.27 -60.7 0.33 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.883 179.972 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 -39.67 -54.07 2.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.875 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -65.02 -59.49 4.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.08 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -43.5 -60.7 1.63 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.894 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -43.57 -44.11 5.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.836 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.462 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -66.63 -56.48 10.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.132 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 82.8 mt -40.91 -37.84 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.14 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 -76.47 -63.81 1.25 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.947 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 27.0 mt-30 -63.85 -61.24 2.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.931 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.462 ' N ' ' O ' ' A' ' 135' ' ' ALA . 65.6 mmm -51.43 -34.0 33.07 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.858 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.443 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -58.69 93.47 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.483 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 113.52 4.55 23.3 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.426 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 16.2 mm100 -80.66 171.13 15.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.797 0.332 . . . . 0.0 110.875 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' TRP . . . . . 0.425 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 15.4 m95 -106.7 111.29 23.76 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.92 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.668 HD23 HD22 ' A' ' 85' ' ' LEU . 66.3 tp -104.91 129.22 53.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.932 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 0.91 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.31 -78.04 0.45 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.492 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -155.29 14.03 0.46 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.499 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 23.9 mtt85 -153.73 161.46 42.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.771 0.32 . . . . 0.0 110.893 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.425 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 23.0 mt-30 -62.95 171.0 2.38 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.429 HG21 ' CB ' ' A' ' 144' ' ' LEU . 14.0 pt -142.07 158.43 20.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.124 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.487 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 7.7 ptm180 -120.82 118.6 30.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.867 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.443 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 61.0 p -111.15 132.44 54.29 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.159 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 41.2 t30 -157.66 174.07 15.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.942 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' TRP . . . . . 0.545 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 9.8 m95 -71.37 135.16 47.17 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.914 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -85.67 41.58 0.91 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.087 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -160.64 146.68 15.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.147 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -124.64 128.91 49.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.878 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 18.0 mttp -82.44 143.83 48.59 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.573 0.702 . . . . 0.0 110.89 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 148.57 65.61 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.686 2.257 . . . . 0.0 112.375 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 174.86 8.92 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.703 2.269 . . . . 0.0 112.318 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.494 ' HB1' ' HD2' ' A' ' 161' ' ' PRO . . . -101.17 157.74 33.1 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.613 0.721 . . . . 0.0 111.05 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 161' ' ' PRO . . . . . 0.494 ' HD2' ' HB1' ' A' ' 160' ' ' ALA . 54.0 Cg_endo -69.72 -28.73 25.11 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.703 2.268 . . . . 0.0 112.337 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.405 ' C ' ' O ' ' A' ' 161' ' ' PRO . 23.9 mmtp -37.43 108.36 0.08 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.904 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 3.3 t -120.83 114.07 21.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.896 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 5.4 m -77.69 131.33 37.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.168 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 1.5 t80 -75.2 164.31 26.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.943 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -144.56 143.49 30.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.912 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 75.9 p -172.79 150.3 2.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -138.38 153.39 48.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.907 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 51.1 m -142.59 110.02 5.71 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.179 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 12.5 ttmm -125.76 112.58 16.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.905 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -127.63 136.93 52.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.938 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 88.4 p -156.0 123.15 5.38 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -122.61 68.46 0.45 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.564 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.65 157.08 61.86 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.69 2.26 . . . . 0.0 112.359 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 21.6 p -170.6 122.61 0.63 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.822 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 1.2 t -147.74 151.69 36.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.539 -179.948 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 N-CA-C 112.555 -0.218 . . . . 0.0 112.555 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.6 t -166.28 150.86 7.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.879 0.371 . . . . 0.0 110.867 -179.723 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 7.5 t -67.9 137.13 55.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.86 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 127.43 95.29 0.88 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.47 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 16.0 t -122.98 134.17 54.34 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.846 0.355 . . . . 0.0 110.878 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.8 p -163.89 170.2 17.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.849 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 124.15 -151.04 17.09 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.506 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -106.02 171.62 7.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.848 0.356 . . . . 0.0 110.914 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 19.9 mmtt -89.86 96.89 10.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.94 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 3.2 mppt? -96.33 43.21 1.08 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.963 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -56.32 -59.67 4.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.857 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 64.8 p -112.17 40.85 2.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.085 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.7 m -83.66 -42.42 16.68 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.871 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.2 m-20 -78.23 -33.45 49.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.875 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 2.4 m-70 -68.47 140.97 55.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.848 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -96.45 125.08 40.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.911 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.434 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.5 OUTLIER -82.21 141.75 32.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.892 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.515 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 41.6 t -119.2 144.11 28.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.164 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.0 t80 -97.51 131.68 43.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.866 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.939 HG12 HD21 ' A' ' 85' ' ' LEU . 3.6 t -133.42 109.98 14.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.148 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -116.61 -178.12 17.99 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.519 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 63.98 34.99 11.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.894 0.378 . . . . 0.0 110.923 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.939 HD21 HG12 ' A' ' 82' ' ' VAL . 9.9 mt -92.76 128.96 38.8 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.918 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.05 154.27 5.48 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.657 0.741 . . . . 0.0 110.874 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -13.79 35.18 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.681 2.254 . . . . 0.0 112.358 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -92.94 -7.78 45.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.87 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.682 HD11 ' HA3' ' A' ' 145' ' ' GLY . 30.5 mm -78.38 138.54 20.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.17 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.0 t -119.27 167.26 12.04 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.11 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.597 ' HA ' HG23 ' A' ' 109' ' ' VAL . 21.2 m -42.4 -47.0 4.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.143 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -54.1 -57.71 10.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.885 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.602 ' CB ' HG23 ' A' ' 89' ' ' ILE . 4.0 m-20 -38.45 -57.11 1.18 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.862 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.492 HD11 HG22 ' A' ' 109' ' ' VAL . 6.4 mt -48.16 -58.33 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.101 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.578 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 23.6 mtmt -49.93 -44.37 50.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.928 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -58.56 -30.12 66.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.095 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.488 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -74.85 -58.19 3.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.157 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.45 ' CD2' ' HB1' ' A' ' 135' ' ' ALA . 42.9 m-85 -82.42 8.04 12.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.784 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -60.02 -60.21 11.35 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.591 0.71 . . . . 0.0 111.051 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.784 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.7 -0.99 7.66 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.661 2.241 . . . . 0.0 112.378 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.501 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 81.2 m-85 -99.91 3.63 44.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.903 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 136.55 156.61 7.47 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.458 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.459 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 34.0 mtt85 -64.44 125.18 23.84 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.796 0.331 . . . . 0.0 110.882 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.407 HD13 ' HA ' ' A' ' 95' ' ' LYS . 11.6 mt -100.3 137.21 28.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.115 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.534 ' OG ' ' CZ ' ' A' ' 127' ' ' PHE . 2.5 m -110.14 -60.41 1.8 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.895 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.0 t0 -101.22 102.24 13.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.878 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -131.99 125.62 31.97 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.117 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 11.9 ptp180 -159.73 157.58 29.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.841 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.597 HG23 ' HA ' ' A' ' 91' ' ' THR . 99.2 t -109.36 116.0 51.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.147 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.804 HG21 ' CE2' ' A' ' 121' ' ' TYR . 94.5 t -49.16 138.32 4.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.134 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 28.7 mttm -138.39 155.95 48.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.892 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.499 ' O ' ' N ' ' A' ' 116' ' ' GLY . 36.5 t0 -65.49 121.01 13.91 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.889 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 7.0 tpt -69.6 -9.29 53.5 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.898 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.93 -47.8 5.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.105 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 21.9 p -98.35 -34.23 10.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.099 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.499 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 86.33 23.6 43.36 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.474 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 14.8 mtpp -98.93 158.13 15.85 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.797 0.332 . . . . 0.0 110.91 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 47.4 t -56.67 112.91 1.42 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.868 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.713 ' HG3' HG12 ' A' ' 110' ' ' VAL . 25.3 mmtt -63.09 -38.83 92.76 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.918 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 130.49 -42.77 1.37 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.444 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.804 ' CE2' HG21 ' A' ' 110' ' ' VAL . 12.0 p90 -99.91 151.42 21.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.957 0.408 . . . . 0.0 110.892 -179.813 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -136.75 172.4 22.57 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.473 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -120.07 139.06 53.12 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.889 0.376 . . . . 0.0 110.914 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.721 HG12 ' CE1' ' A' ' 126' ' ' PHE . 53.1 t -136.84 111.0 9.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.111 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.8 t -99.38 151.58 20.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.893 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.721 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.5 m-85 -130.83 152.37 50.24 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.875 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.534 ' CZ ' ' OG ' ' A' ' 105' ' ' SER . 76.2 m-85 -66.01 -34.95 79.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.842 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -120.74 149.96 41.73 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.87 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.463 ' O ' ' C ' ' A' ' 130' ' ' TRP . 45.0 tttt -59.05 -65.82 0.6 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.866 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.463 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -33.47 -60.83 0.34 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.923 179.951 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 130' ' ' TRP . 68.8 m-20 -35.81 -46.63 0.46 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.87 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.515 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -74.78 -59.8 2.57 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.085 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -39.07 -53.31 1.82 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.846 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 50.5 t30 -49.22 -50.04 40.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.888 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.45 ' HB1' ' CD2' ' A' ' 98' ' ' PHE . . . -61.91 -53.15 59.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.085 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' ILE . . . . . 0.461 HG23 ' HA ' ' A' ' 152' ' ' ASN . 96.6 mt -42.28 -37.11 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.142 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 29.8 mt-30 -86.87 -62.29 1.54 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.908 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 26.3 mt-30 -54.4 -61.52 2.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.885 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.501 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 92.6 mmm -58.45 -41.07 84.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.878 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.443 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -46.88 99.48 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.462 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 101.55 17.78 20.64 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.518 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 57.0 mm-40 -96.51 172.42 7.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.782 0.325 . . . . 0.0 110.898 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' TRP . . . . . 0.523 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 16.0 m95 -107.54 110.71 22.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.873 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.488 HD13 ' HB2' ' A' ' 97' ' ' ALA . 57.3 tp -103.56 127.47 50.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.934 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 0.682 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.89 -75.66 0.44 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.463 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.83 15.51 0.3 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.475 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 42.3 mtt-85 -154.62 156.77 37.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.726 0.298 . . . . 0.0 110.874 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.523 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 33.4 mt-30 -63.12 168.95 3.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.921 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 26.5 pt -149.23 144.73 18.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.112 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 14.0 ptt180 -105.63 124.06 48.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.863 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.443 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 69.0 p -115.28 141.12 48.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.185 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 152' ' ' ASN . . . . . 0.461 ' HA ' HG23 ' A' ' 136' ' ' ILE . 73.9 m-20 -165.11 177.13 7.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.885 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 11.9 m95 -67.91 111.28 4.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.942 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -54.18 -29.72 46.81 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.084 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 20.5 p -75.2 169.06 18.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.111 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -162.91 164.23 25.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.457 ' CD ' ' HD2' ' A' ' 158' ' ' PRO . 0.3 OUTLIER -105.91 137.78 19.45 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.601 0.715 . . . . 0.0 110.907 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 158' ' ' PRO . . . . . 0.457 ' HD2' ' CD ' ' A' ' 157' ' ' LYS . 53.4 Cg_endo -69.78 147.1 61.98 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.664 2.243 . . . . 0.0 112.361 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 161.82 44.47 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.674 2.25 . . . . 0.0 112.331 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -106.35 146.72 33.55 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.591 0.71 . . . . 0.0 111.109 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 93.99 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.675 2.25 . . . . 0.0 112.326 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 19.2 tttp -157.91 113.25 2.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.895 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 96.4 p -135.05 150.71 50.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.879 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 14.5 t -116.13 174.08 6.24 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.137 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -109.04 165.34 11.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.906 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -138.92 142.88 38.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.935 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 25.4 m -107.27 43.04 1.22 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.844 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -113.42 81.17 1.46 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.859 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 75.2 p -116.33 105.53 12.64 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.153 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 41.3 tttp -87.18 -60.69 1.91 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.879 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 7.0 tt0 -173.54 166.92 4.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.917 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 66.9 m -66.43 121.96 16.48 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.892 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 86.3 83.52 1.11 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.453 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -2.88 10.95 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.669 2.246 . . . . 0.0 112.342 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 67.6 p -140.75 161.08 38.64 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.861 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 69.8 p -159.81 126.63 4.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.838 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.485 179.957 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.369 0 N-CA-C 112.509 -0.237 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 75.3 p -123.43 153.45 40.42 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.912 0.387 . . . . 0.0 110.854 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 43.7 t -90.38 -61.7 1.62 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.896 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 145.07 66.77 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.468 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 22.8 m -112.49 83.19 1.77 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.846 0.355 . . . . 0.0 110.904 -179.801 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 3.5 m -89.38 82.64 6.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.848 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -126.91 -59.38 0.14 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.531 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -98.77 107.92 20.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.906 0.384 . . . . 0.0 110.861 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.6 mptt -96.76 157.96 15.66 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.889 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 35.8 tttp -174.93 133.89 0.34 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.886 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.438 ' O ' ' C ' ' A' ' 74' ' ' THR . 7.0 m-20 48.6 44.98 21.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.855 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.496 HG21 ' OD1' ' A' ' 106' ' ' ASP . 2.1 p 35.22 53.26 0.71 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.126 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.2 t -75.93 -44.41 40.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.816 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -110.33 50.38 0.81 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 6.8 m170 -122.88 156.53 34.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.876 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.551 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 54.5 m-85 -111.09 114.2 27.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 40.2 m-70 -87.32 148.25 25.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.83 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 34.9 t -123.64 139.64 49.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.122 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -91.94 134.48 34.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.903 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.832 HG12 HD21 ' A' ' 85' ' ' LEU . 3.8 t -132.51 109.93 15.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.14 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.41 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -117.36 170.72 13.59 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.478 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.8 t70 68.83 51.67 0.57 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.847 0.356 . . . . 0.0 110.905 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.832 HD21 HG12 ' A' ' 82' ' ' VAL . 16.5 mt -108.91 131.92 54.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.893 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 t -54.92 153.71 11.01 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.676 0.75 . . . . 0.0 110.85 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -11.29 30.5 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.682 2.254 . . . . 0.0 112.313 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -94.0 -9.83 35.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.911 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.644 HD11 ' HA3' ' A' ' 145' ' ' GLY . 46.9 mm -74.42 137.99 22.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.131 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.2 t -117.84 166.52 12.37 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.162 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.769 HG23 ' HA ' ' A' ' 108' ' ' ARG . 86.1 m -43.37 -46.34 6.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.137 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 93' ' ' ASP . 35.2 mt-10 -55.55 -57.94 9.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.891 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.533 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.0 m-20 -35.18 -58.59 0.54 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.879 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.5 ' CD1' HG22 ' A' ' 109' ' ' VAL . 10.9 mt -48.5 -58.91 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.138 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.604 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 23.9 mtmt -49.41 -39.41 32.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.929 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.03 -27.66 69.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.085 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.501 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -77.65 -52.2 9.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.121 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.404 ' C ' HD11 ' A' ' 104' ' ' ILE . 31.6 m-85 -89.33 13.49 13.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.781 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -67.61 -60.26 5.83 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.554 0.692 . . . . 0.0 111.082 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.781 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.5 Cg_endo -69.76 -0.84 7.49 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.689 2.259 . . . . 0.0 112.323 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -99.95 -5.14 28.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.876 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 144.2 142.0 3.84 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.494 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.444 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 57.4 mtt180 -50.81 125.91 14.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.81 0.338 . . . . 0.0 110.882 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.491 HG21 ' HB2' ' A' ' 107' ' ' ALA . 17.4 mt -99.32 145.72 9.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.127 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.446 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.0 OUTLIER -119.3 -60.09 1.77 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.823 -179.892 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.496 ' OD1' HG21 ' A' ' 74' ' ' THR . 4.2 m-20 -100.53 92.47 5.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.829 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.491 ' HB2' HG21 ' A' ' 104' ' ' ILE . . . -129.5 124.64 34.47 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.103 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.769 ' HA ' HG23 ' A' ' 91' ' ' THR . 10.5 ptm180 -158.13 161.84 37.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.905 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.723 HG23 ' HA ' ' A' ' 91' ' ' THR . 79.5 t -113.44 116.82 53.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.629 HG12 ' HG3' ' A' ' 119' ' ' LYS . 77.1 t -52.58 137.46 12.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.131 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 1.7 mtmp? -130.19 156.97 43.72 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.906 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.515 ' O ' ' N ' ' A' ' 116' ' ' GLY . 27.5 t0 -64.47 118.85 9.37 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.855 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' MET . . . . . 0.467 ' SD ' ' C ' ' A' ' 113' ' ' MET . 2.6 tmm? -65.85 -9.79 32.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.893 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -92.92 -53.41 4.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.07 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 20.7 p -100.71 -35.41 9.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.108 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 92.76 28.05 13.14 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.483 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -100.24 156.26 17.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.738 0.304 . . . . 0.0 110.917 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 36.7 t -51.77 109.03 0.32 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.876 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.629 ' HG3' HG12 ' A' ' 110' ' ' VAL . 18.9 mmtt -61.14 -51.74 67.81 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.89 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 144.95 -40.59 1.12 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.533 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.597 ' CZ ' HG11 ' A' ' 110' ' ' VAL . 6.2 p90 -100.09 151.99 20.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.939 0.4 . . . . 0.0 110.944 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -141.0 172.96 23.46 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.495 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -121.19 141.2 51.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.874 0.369 . . . . 0.0 110.862 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.725 HG12 ' CE1' ' A' ' 126' ' ' PHE . 58.6 t -139.18 113.52 7.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.132 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 4.3 t -104.35 147.68 27.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.823 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.725 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.3 m-85 -126.47 153.86 44.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.876 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.446 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 20.9 m-85 -62.02 -43.43 98.86 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.896 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -114.65 161.72 17.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.877 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.551 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 39.9 tptt -69.04 -62.07 1.53 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.917 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.459 ' C ' ' O ' ' A' ' 129' ' ' LYS . 1.0 OUTLIER -33.53 -61.83 0.31 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.937 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.408 ' C ' ' O ' ' A' ' 130' ' ' TRP . 75.2 m-20 -37.09 -57.46 0.85 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.835 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -58.88 -62.16 2.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.103 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.407 ' HA ' HD12 ' A' ' 136' ' ' ILE . 2.4 mm-40 -39.7 -59.52 1.13 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.876 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 53.3 t30 -41.07 -46.45 2.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.879 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.484 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -67.32 -51.84 47.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.107 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' ILE . . . . . 0.407 HD12 ' HA ' ' A' ' 133' ' ' GLU . 97.6 mt -43.42 -35.11 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.151 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 19.2 mt-30 -88.33 -55.23 3.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.9 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 5.0 mm100 -67.31 -61.01 2.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.93 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.484 ' N ' ' O ' ' A' ' 135' ' ' ALA . 57.4 mmm -59.2 -26.46 64.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.434 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -65.1 113.54 5.94 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.45 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 89.36 18.25 53.27 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.494 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 89.8 mm-40 -97.47 171.2 8.54 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.788 0.328 . . . . 0.0 110.898 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' TRP . . . . . 0.436 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 15.4 m95 -104.14 110.68 22.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.949 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.501 HD13 ' HB2' ' A' ' 97' ' ' ALA . 59.2 tp -103.27 129.22 50.19 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.906 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 0.644 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 67.28 -74.74 0.19 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.493 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.81 18.05 0.28 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.511 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 72.2 mtt180 -156.69 155.41 31.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.756 0.312 . . . . 0.0 110.906 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.436 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 31.1 mt-30 -60.18 170.38 1.29 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.915 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.462 HG21 ' HB3' ' A' ' 144' ' ' LEU . 19.2 pt -146.39 150.18 15.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.106 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.424 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 13.1 ptp180 -113.99 121.96 45.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.87 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.434 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 73.4 p -112.56 128.11 56.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.168 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -151.33 170.77 18.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.898 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' TRP . . . . . 0.529 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 9.8 m95 -69.17 109.3 3.99 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.921 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -58.2 -55.37 35.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.163 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 6.8 t -112.29 148.06 34.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.196 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 15.3 ptt85 -165.98 158.61 14.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.869 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 12.8 mtpp -135.92 131.67 19.06 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.579 0.704 . . . . 0.0 110.899 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 153.43 68.92 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.685 2.256 . . . . 0.0 112.336 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.68 165.82 29.6 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.671 2.248 . . . . 0.0 112.416 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -129.28 147.21 64.08 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.654 0.74 . . . . 0.0 111.072 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.81 105.14 1.44 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.688 2.259 . . . . 0.0 112.303 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 21.2 mmmt -130.31 93.76 3.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.889 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 1.7 t -83.54 111.85 19.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.826 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 11.4 t -96.22 135.28 38.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.172 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 10.4 p90 -113.27 131.35 55.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.967 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -127.46 82.32 2.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.902 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 78.8 p -169.53 123.93 0.8 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.91 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 4.9 t30 -173.65 129.24 0.42 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.891 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 1.6 t -102.21 149.35 24.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.114 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 27.2 ttpt -151.87 117.16 5.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.857 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 27.3 tt0 -140.45 129.28 23.18 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.965 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 48.8 m -157.53 161.46 38.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.836 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -149.2 69.18 0.34 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.52 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 145.69 58.12 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.677 2.251 . . . . 0.0 112.4 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 4.7 t -120.7 142.47 49.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.858 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 8.3 m -103.33 174.98 5.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.813 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.476 -179.992 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.448 ' O ' ' C ' ' A' ' 64' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.329 0 N-CA-C 112.451 -0.26 . . . . 0.0 112.451 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.448 ' C ' ' O ' ' A' ' 63' ' ' GLY . 60.9 p 34.6 42.16 0.07 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.899 0.38 . . . . 0.0 110.841 -179.73 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 63.1 p -102.9 -54.78 2.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.867 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.51 -46.57 2.78 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.447 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 5.3 t -41.25 -61.37 1.03 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.86 0.362 . . . . 0.0 110.812 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 13.1 m -149.84 -176.53 5.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.885 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 66.89 68.21 1.74 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.506 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' GLN . . . . . 0.414 ' NE2' ' O ' ' A' ' 72' ' ' LYS . 11.8 pt20 -50.78 170.03 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.831 0.348 . . . . 0.0 110.929 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.74 -0.62 23.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.85 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.414 ' O ' ' NE2' ' A' ' 70' ' ' GLN . 29.5 ttmt -125.13 126.59 45.53 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.887 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 44.1 m-20 -75.7 162.85 27.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.855 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.4 p -85.45 62.93 7.79 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.109 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 22.6 t -74.43 -53.73 8.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.88 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.4 m-20 -125.39 52.63 1.6 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.866 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 10.0 m170 -104.89 156.93 17.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.871 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.581 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 97.3 m-85 -97.58 114.61 26.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.916 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.467 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.9 OUTLIER -95.51 139.92 31.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 -180.0 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 57.4 t -113.96 152.02 15.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.06 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -102.09 132.89 47.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.915 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.922 HG12 HD21 ' A' ' 85' ' ' LEU . 4.1 t -129.57 129.78 66.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.142 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.473 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -136.69 -173.54 12.96 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.494 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 27.0 m-20 55.3 36.33 26.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.831 0.348 . . . . 0.0 110.851 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.922 HD21 HG12 ' A' ' 82' ' ' VAL . 8.3 mt -96.18 131.02 43.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.886 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 t -53.1 153.71 6.15 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.652 0.739 . . . . 0.0 110.818 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -13.84 35.25 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.7 2.267 . . . . 0.0 112.338 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -91.04 -8.75 48.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.888 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.863 HD11 ' HA3' ' A' ' 145' ' ' GLY . 39.1 mm -76.37 136.67 24.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.176 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.444 ' OG1' ' N ' ' A' ' 91' ' ' THR . 2.3 t -114.55 177.54 4.61 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.163 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.726 HG23 ' HA ' ' A' ' 108' ' ' ARG . 69.9 m -52.6 -47.67 66.78 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.177 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 93' ' ' ASP . 32.0 mt-10 -56.42 -58.26 8.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.879 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.447 ' CB ' HG23 ' A' ' 89' ' ' ILE . 2.9 m-20 -35.49 -54.63 0.68 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.911 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.522 HD11 HG22 ' A' ' 109' ' ' VAL . 6.2 mt -51.18 -60.17 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.117 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.528 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 21.7 mtmt -47.14 -43.13 20.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.904 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -57.43 -31.57 66.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.134 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.402 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -74.42 -52.65 11.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.12 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.454 ' C ' HD11 ' A' ' 104' ' ' ILE . 23.6 m-85 -88.77 12.4 15.11 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.868 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.779 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -65.72 -60.1 7.98 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.597 0.713 . . . . 0.0 111.096 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.779 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.4 Cg_endo -69.8 -0.87 7.58 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.694 2.263 . . . . 0.0 112.321 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.506 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 78.3 m-85 -99.75 4.61 45.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.887 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.06 159.63 8.74 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.475 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.51 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 39.8 mtp85 -65.72 125.71 26.16 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.804 0.335 . . . . 0.0 110.866 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.454 HD11 ' C ' ' A' ' 98' ' ' PHE . 14.4 mt -100.46 138.14 25.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.186 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -109.86 -60.76 1.74 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.849 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -100.75 103.96 15.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.904 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.486 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -133.84 124.86 27.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.124 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.726 ' HA ' HG23 ' A' ' 91' ' ' THR . 17.6 ptt180 -161.94 160.16 27.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.9 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.611 HG23 ' HA ' ' A' ' 91' ' ' THR . 99.4 t -110.12 116.31 51.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.148 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.686 HG21 ' CE2' ' A' ' 121' ' ' TYR . 51.5 t -50.99 132.73 12.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.101 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' LYS . . . . . 0.418 ' HG2' ' N ' ' A' ' 118' ' ' SER . 69.1 mttt -133.45 148.76 51.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.867 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.44 ' O ' ' N ' ' A' ' 116' ' ' GLY . 29.6 t0 -58.28 123.66 16.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.88 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 36.3 ttp -71.77 -2.83 18.97 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.865 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -99.87 -49.91 4.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.094 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 18.7 p -102.15 -28.2 12.45 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.127 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 82.68 25.31 50.65 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.504 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 48.1 mtmt -99.99 147.08 25.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.757 0.313 . . . . 0.0 110.923 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' SER . . . . . 0.418 ' N ' ' HG2' ' A' ' 111' ' ' LYS . 5.0 t -50.18 113.46 0.87 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.813 -179.841 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 41.5 mttt -63.6 -51.52 64.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.898 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.405 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 148.65 -40.02 0.93 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.476 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.686 ' CE2' HG21 ' A' ' 110' ' ' VAL . 10.1 p90 -100.03 149.43 23.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.934 0.397 . . . . 0.0 110.898 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -130.88 176.94 18.75 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.505 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -123.78 139.25 54.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.884 0.373 . . . . 0.0 110.867 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.658 HG12 ' CE1' ' A' ' 126' ' ' PHE . 42.9 t -139.67 113.31 6.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.124 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 24.4 t -102.83 149.6 24.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.843 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.658 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.6 m-85 -129.29 141.56 51.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.874 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.51 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 82.7 m-85 -56.12 -41.16 74.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.882 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 19.6 m-80 -109.21 155.28 21.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.905 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.581 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 26.8 tttt -68.51 -40.16 80.94 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.891 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.422 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.9 OUTLIER -60.87 -58.92 6.41 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.911 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.422 ' C ' ' O ' ' A' ' 130' ' ' TRP . 78.5 m-20 -36.07 -41.57 0.25 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.871 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.462 ' HB2' ' CD1' ' A' ' 126' ' ' PHE . . . -80.51 -54.71 5.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.1 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.512 ' HA ' HD12 ' A' ' 136' ' ' ILE . 12.5 mt-10 -42.29 -54.28 3.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.898 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -45.42 -51.87 10.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.913 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.461 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -60.95 -56.64 18.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.114 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' ILE . . . . . 0.512 HD12 ' HA ' ' A' ' 133' ' ' GLU . 85.8 mt -37.76 -35.32 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.147 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 18.1 mt-30 -90.07 -59.22 2.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.937 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 25.2 mm-40 -63.64 -59.49 4.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.919 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.506 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 78.3 mmm -57.08 -40.09 76.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.897 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.436 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -52.15 118.65 7.7 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.519 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.83 -24.89 29.75 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.556 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 14.7 mm100 -56.64 -177.26 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.823 0.344 . . . . 0.0 110.901 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' TRP . . . . . 0.492 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 13.6 m95 -120.42 131.32 54.73 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.914 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.534 HD23 HD22 ' A' ' 85' ' ' LEU . 41.6 tp -128.97 129.17 45.08 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.942 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 0.863 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 71.66 -6.07 9.84 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.467 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 123.05 -10.54 8.81 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.504 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 17.1 mtt85 -125.84 147.76 49.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.741 0.305 . . . . 0.0 110.857 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.492 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 22.6 mt-30 -51.61 169.46 0.06 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.927 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.5 pt -140.62 151.19 20.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.14 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.473 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 16.9 ptp180 -113.74 118.79 35.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.862 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.436 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 72.2 p -112.08 125.28 53.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.153 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 11.2 m120 -152.76 179.13 8.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.868 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' TRP . . . . . 0.416 ' O ' ' C ' ' A' ' 154' ' ' ALA . 15.0 m95 -83.45 100.08 10.5 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.929 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.416 ' C ' ' O ' ' A' ' 153' ' ' TRP . . . -36.41 -50.96 0.79 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.097 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 54.4 p -116.44 121.46 41.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.114 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 4.7 tmm_? -146.48 109.15 4.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.839 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 85.0 mttt -121.57 133.78 24.35 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.548 0.69 . . . . 0.0 110.858 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 152.85 69.42 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.659 2.24 . . . . 0.0 112.367 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 161.22 46.76 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.68 2.253 . . . . 0.0 112.349 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -88.12 154.2 51.97 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.569 0.699 . . . . 0.0 111.1 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 -2.86 10.87 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.681 2.254 . . . . 0.0 112.359 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 27.3 ttpt -153.72 135.58 14.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.901 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 10.9 t -130.19 154.37 47.61 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.821 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 8.1 m -91.42 153.9 19.54 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.142 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -92.87 176.78 6.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.913 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -122.82 100.23 6.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.889 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 1.3 t -99.64 140.34 33.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.844 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -59.27 170.61 0.91 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.914 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 8.8 t -117.01 144.05 45.03 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.109 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 13.3 tttp -121.34 157.01 31.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.927 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 10.2 pt20 -98.88 174.02 6.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.885 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 2.7 m -163.85 174.16 11.86 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.833 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -162.71 83.02 0.12 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.503 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 176.75 6.33 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.707 2.271 . . . . 0.0 112.345 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 61.5 m -154.1 176.73 11.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.893 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 1.4 t -142.83 161.77 37.22 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.89 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.477 -179.96 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.422 ' O ' ' C ' ' A' ' 65' ' ' SER . 73.5 m -153.06 129.21 10.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.854 0.359 . . . . 0.0 110.897 -179.723 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' SER . . . . . 0.422 ' C ' ' O ' ' A' ' 64' ' ' SER . 6.5 t -36.71 115.89 0.4 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.856 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 105.1 -79.53 0.28 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.463 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 49.2 m -87.21 111.38 20.94 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.877 0.37 . . . . 0.0 110.884 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 37.5 t -85.02 -47.68 9.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.875 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.91 174.76 47.34 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.432 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 45.5 mt-30 -87.54 7.52 29.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.847 0.356 . . . . 0.0 110.893 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -108.81 121.65 45.53 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.884 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? 64.88 43.73 3.85 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.888 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -63.39 156.67 25.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.837 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.1 p 49.82 53.59 12.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.141 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 83.3 p -84.58 -35.95 22.41 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.847 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -79.28 -25.28 42.51 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.887 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 27.2 m170 -75.82 145.72 40.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.898 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.574 ' CE1' ' HB2' ' A' ' 129' ' ' LYS . 46.9 m-85 -100.19 120.44 39.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.889 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.474 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.4 OUTLIER -87.21 144.24 26.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.84 179.984 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.407 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 69.4 t -120.22 144.16 29.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.141 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.469 ' HB2' ' HB2' ' A' ' 154' ' ' ALA . 19.7 t80 -95.63 134.66 38.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.877 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.845 HG12 HD21 ' A' ' 85' ' ' LEU . 2.7 t -132.62 129.1 58.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.11 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.486 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -134.9 179.89 17.19 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.479 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 6.6 t0 57.75 45.05 19.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.82 0.343 . . . . 0.0 110.845 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.845 HD21 HG12 ' A' ' 82' ' ' VAL . 18.5 mt -100.2 131.72 45.98 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.902 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -52.92 154.1 5.39 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.671 0.748 . . . . 0.0 110.842 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.76 -16.0 37.37 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.654 2.236 . . . . 0.0 112.356 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -90.54 -6.53 54.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.853 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.96 HD11 ' HA3' ' A' ' 145' ' ' GLY . 42.6 mm -78.44 137.42 22.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.142 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.8 t -119.09 174.6 6.22 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.088 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.432 ' HA ' HG23 ' A' ' 109' ' ' VAL . 24.5 m -49.41 -47.31 48.03 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.158 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.413 ' O ' ' C ' ' A' ' 93' ' ' ASP . 37.3 mt-10 -56.27 -56.4 21.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.844 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.459 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.2 m-20 -36.51 -58.26 0.72 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.865 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.511 HD11 HG22 ' A' ' 109' ' ' VAL . 14.0 mt -47.43 -59.5 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.159 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.741 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 19.2 mtmt -46.64 -39.44 11.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.892 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.42 ' HB3' ' O ' ' A' ' 93' ' ' ASP . . . -61.26 -35.03 76.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.082 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.75 -54.92 9.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.109 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -87.35 5.37 38.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.896 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.794 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -56.63 -60.41 9.38 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.597 0.713 . . . . 0.0 111.129 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.794 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.7 Cg_endo -69.82 -1.01 7.79 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.677 2.251 . . . . 0.0 112.287 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -100.07 12.63 36.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.866 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.45 146.23 6.69 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.53 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 70.7 mtt180 -55.5 125.72 22.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.756 0.313 . . . . 0.0 110.901 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.43 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 11.9 mt -100.03 133.64 42.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.128 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -102.5 -61.98 1.33 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.852 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -100.34 103.42 14.82 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.846 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.455 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -133.66 124.96 27.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.105 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.401 ' HA ' HG23 ' A' ' 91' ' ' THR . 2.1 ptp180 -161.32 163.21 30.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.511 HG22 HD11 ' A' ' 94' ' ' ILE . 54.9 t -111.97 125.23 69.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.118 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.654 HG21 ' CE2' ' A' ' 121' ' ' TYR . 41.4 t -57.28 135.91 20.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.137 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 18.6 mttp -135.67 150.8 49.71 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.891 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.459 ' O ' ' N ' ' A' ' 116' ' ' GLY . 15.6 t0 -59.68 123.18 16.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.861 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 26.9 ptm -75.05 -2.27 26.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.89 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.0 -38.75 9.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.081 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.435 HG23 ' OD2' ' A' ' 112' ' ' ASP . 25.9 p -116.18 -33.01 5.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.165 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 91.27 25.6 23.48 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.471 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 68.3 mmtt -98.94 157.17 16.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.794 0.331 . . . . 0.0 110.866 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 2.7 t -57.27 121.83 11.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.876 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 35.3 mttt -75.48 -48.02 24.5 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.896 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 142.18 -43.67 1.04 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.482 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.654 ' CE2' HG21 ' A' ' 110' ' ' VAL . 14.8 p90 -98.74 146.45 25.88 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.886 0.374 . . . . 0.0 110.933 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -129.86 179.16 17.0 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.489 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -127.11 140.1 52.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.898 0.38 . . . . 0.0 110.916 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.71 HG12 ' CE1' ' A' ' 126' ' ' PHE . 61.9 t -137.84 116.65 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.152 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 9.5 t -104.81 148.02 27.09 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.873 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.71 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.4 m-85 -128.37 156.38 43.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.892 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -65.16 -41.31 94.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.901 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -119.18 150.82 39.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.907 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.574 ' HB2' ' CE1' ' A' ' 78' ' ' PHE . 30.3 tttt -58.64 -65.68 0.62 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.927 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.45 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -33.17 -59.79 0.35 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.917 179.88 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 70.7 m-20 -37.78 -46.53 0.93 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.822 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.413 ' N ' ' O ' ' A' ' 129' ' ' LYS . . . -73.15 -59.19 2.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.076 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -40.63 -51.93 2.94 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 30.4 t-20 -46.31 -42.07 14.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.893 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -72.67 -54.31 9.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.109 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 96.0 mt -40.56 -31.95 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.109 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 48.1 mt-30 -84.84 -64.9 1.08 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.957 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -62.01 -62.55 1.7 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.912 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 68.8 mmm -49.76 -43.72 48.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.862 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.443 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -51.43 109.64 0.84 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.46 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 105.95 -28.23 14.67 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.482 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 54.1 mm-40 -55.01 179.88 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.819 0.343 . . . . 0.0 110.941 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' TRP . . . . . 0.506 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 13.3 m95 -116.2 127.18 54.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.912 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.416 ' HB3' HG21 ' A' ' 149' ' ' ILE . 32.8 tp -126.69 130.67 50.84 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.939 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 0.96 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.62 -3.61 11.61 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.474 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 120.86 -13.8 9.79 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.515 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 47.5 mtt180 -124.93 153.57 42.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 110.835 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.506 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 20.6 mt-30 -61.49 158.51 14.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.752 HG22 HD23 ' A' ' 85' ' ' LEU . 21.6 pt -130.86 153.07 38.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.145 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.486 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 2.8 ptp180 -111.68 115.95 29.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.887 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.443 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 58.5 p -110.21 128.12 55.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.142 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 19.8 m-20 -159.94 168.68 25.13 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 14.1 m95 -61.42 139.92 58.13 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.918 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.469 ' HB2' ' HB2' ' A' ' 81' ' ' PHE . . . -120.96 -46.97 2.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.104 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.419 HG23 ' N ' ' A' ' 156' ' ' ARG . 5.9 t -50.51 -43.49 55.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.118 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 156' ' ' ARG . . . . . 0.419 ' N ' HG23 ' A' ' 155' ' ' THR . 33.4 ttt180 -158.67 158.85 34.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.876 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.478 ' CD ' ' HD2' ' A' ' 158' ' ' PRO . 13.3 tptm -92.38 136.56 25.38 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.569 0.7 . . . . 0.0 110.919 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 158' ' ' PRO . . . . . 0.478 ' HD2' ' CD ' ' A' ' 157' ' ' LYS . 53.2 Cg_endo -69.82 146.71 60.67 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.693 2.262 . . . . 0.0 112.314 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 158.55 56.59 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.708 2.272 . . . . 0.0 112.307 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -66.05 145.79 99.01 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.589 0.709 . . . . 0.0 111.066 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 98.26 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.645 2.23 . . . . 0.0 112.391 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 2.8 ptpp? -76.2 132.61 40.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.861 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 1.8 t -122.41 88.45 2.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -145.01 129.51 17.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.15 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -70.75 104.24 2.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.918 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -174.15 154.83 2.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.863 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 59.8 p -92.81 159.53 15.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.872 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -162.07 147.44 13.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 4.4 t -144.03 132.73 22.41 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.098 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 20.9 tttp -165.47 144.59 6.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.894 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 171' ' ' GLN . . . . . 0.438 ' HG2' ' N ' ' A' ' 172' ' ' SER . 41.9 tt0 -174.96 151.82 1.41 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.899 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 172' ' ' SER . . . . . 0.438 ' N ' ' HG2' ' A' ' 171' ' ' GLN . 4.2 t -127.4 168.05 15.38 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.845 -179.827 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -163.96 83.14 0.11 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.507 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 140.05 41.92 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.714 2.276 . . . . 0.0 112.36 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 15.5 m -122.54 167.78 12.95 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.896 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 5.9 m -69.01 160.79 30.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.85 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.548 -179.967 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.526 -0.229 . . . . 0.0 112.526 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 85.5 p 44.15 42.69 5.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.882 0.372 . . . . 0.0 110.878 -179.723 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 80.2 p -126.75 147.01 50.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.84 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 160.8 118.35 0.48 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.483 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 8.0 m -106.89 175.4 5.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.817 0.342 . . . . 0.0 110.918 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.0 t -134.34 42.83 2.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -104.67 -162.23 24.15 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.529 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 18.4 pt20 -117.59 -47.71 2.62 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.826 0.346 . . . . 0.0 110.93 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 11.0 mptt -108.86 -49.81 3.09 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 14.3 ptpt -166.06 156.01 12.31 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -125.84 85.0 2.33 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.837 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 53.5 p -90.93 39.72 1.0 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.135 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 66.3 m -79.76 -42.24 24.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 6.7 m-80 -113.59 43.07 1.85 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.877 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 59.6 m170 -123.53 152.95 41.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.853 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -102.23 116.42 32.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.91 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.484 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.7 OUTLIER -83.68 155.6 23.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.858 -179.971 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 36.8 t -134.27 135.34 54.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.112 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.406 ' CE2' ' HG2' ' A' ' 150' ' ' ARG . 15.4 t80 -87.44 128.15 35.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.84 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.978 HG12 HD21 ' A' ' 85' ' ' LEU . 4.0 t -127.96 109.86 20.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.103 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -115.31 -176.91 18.65 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.519 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 59.9 40.26 19.34 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.844 0.354 . . . . 0.0 110.883 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.978 HD21 HG12 ' A' ' 82' ' ' VAL . 11.5 mt -99.04 127.37 44.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.886 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.04 154.19 5.52 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.633 0.73 . . . . 0.0 110.867 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.88 -11.74 31.28 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.67 2.247 . . . . 0.0 112.294 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -92.32 -8.07 46.13 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.894 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.661 HD11 ' HA3' ' A' ' 145' ' ' GLY . 45.7 mm -78.27 138.06 20.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.147 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.5 t -119.55 163.73 16.88 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.118 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.489 ' HA ' HG23 ' A' ' 109' ' ' VAL . 27.7 m -38.85 -46.6 1.31 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.168 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.415 ' O ' ' C ' ' A' ' 93' ' ' ASP . 21.2 mt-10 -56.61 -58.95 5.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.853 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.59 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.9 m-20 -36.42 -57.94 0.73 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.852 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.539 HD11 HG22 ' A' ' 109' ' ' VAL . 8.1 mt -47.44 -58.59 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.103 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.58 ' HE2' ' HB3' ' A' ' 107' ' ' ALA . 26.1 mtmt -49.28 -42.14 40.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.893 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -59.09 -28.77 66.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.127 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.621 ' HB1' ' HE1' ' A' ' 139' ' ' MET . . . -74.75 -54.75 6.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -86.5 8.34 22.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.913 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.783 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -61.61 -60.31 10.77 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.621 0.724 . . . . 0.0 111.145 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.783 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.78 -0.95 7.68 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.681 2.254 . . . . 0.0 112.402 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -100.18 -4.48 29.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.83 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 146.46 156.87 7.09 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.517 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.415 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 31.9 mtm180 -64.84 123.79 20.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.818 0.342 . . . . 0.0 110.867 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 11.1 mt -100.42 139.12 22.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.18 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 8.3 t -110.03 -62.47 1.5 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -100.73 105.28 16.6 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.888 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.58 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -134.16 125.73 28.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.12 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 15.0 ptt180 -160.86 161.32 31.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.87 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.539 HG22 HD11 ' A' ' 94' ' ' ILE . 72.9 t -111.5 119.45 59.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.173 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.774 HG21 ' CE2' ' A' ' 121' ' ' TYR . 42.8 t -51.45 133.13 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.113 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -132.98 151.59 52.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.457 ' O ' ' N ' ' A' ' 116' ' ' GLY . 39.5 t0 -60.33 119.29 7.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.883 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 22.7 ptp -68.68 -2.28 8.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.913 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -97.55 -47.16 5.76 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.125 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 43.2 p -110.05 -34.5 6.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.162 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 92.66 31.98 8.4 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.468 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt -99.52 148.69 24.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.779 0.323 . . . . 0.0 110.88 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 19.5 t -54.92 102.09 0.06 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.832 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 42.2 mttt -52.02 -53.46 41.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.883 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 149.75 -39.82 0.88 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.488 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.774 ' CE2' HG21 ' A' ' 110' ' ' VAL . 5.8 p90 -100.07 161.27 13.71 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.931 0.396 . . . . 0.0 110.887 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -142.27 174.96 23.06 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.455 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -124.59 137.98 54.35 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.896 0.379 . . . . 0.0 110.932 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.591 HG12 ' CE1' ' A' ' 126' ' ' PHE . 71.0 t -138.11 120.38 18.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.105 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 21.1 m -103.06 150.88 23.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.828 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.591 ' CE1' HG12 ' A' ' 124' ' ' VAL . 15.3 m-85 -131.03 142.89 50.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.862 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.415 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 97.5 m-85 -60.9 -32.53 71.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.852 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 21.6 m-20 -117.66 169.58 9.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.849 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.519 ' HE3' ' CH2' ' A' ' 153' ' ' TRP . 20.6 tptm -78.99 -53.16 7.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.89 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.415 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.8 OUTLIER -48.07 -59.83 3.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.914 179.925 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 130' ' ' TRP . 79.4 m-20 -35.83 -40.63 0.19 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.908 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.75 -62.76 1.56 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.096 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -42.41 -58.88 2.05 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.877 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -39.97 -47.39 2.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.889 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.464 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -67.57 -54.45 19.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.079 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 54.9 mt -41.66 -35.37 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.163 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 17.2 mt-30 -88.62 -54.91 3.94 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.98 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 5.0 mm100 -68.11 -62.88 1.2 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.906 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.621 ' HE1' ' HB1' ' A' ' 97' ' ' ALA . 84.6 mmm -52.96 -35.64 59.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.874 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.442 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -52.97 110.6 1.34 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.514 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 100.97 -22.73 38.28 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.481 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 33.5 mm-40 -55.05 169.8 0.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.786 0.326 . . . . 0.0 110.925 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' TRP . . . . . 0.436 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 14.7 m95 -107.95 113.09 26.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.908 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.58 HD13 ' HB2' ' A' ' 97' ' ' ALA . 56.9 tp -103.98 129.74 51.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.899 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 0.661 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 68.83 -77.77 0.28 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.511 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -155.17 13.74 0.46 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.482 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 32.2 mtp85 -153.17 160.8 42.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.436 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 24.0 mt-30 -62.03 168.7 3.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.933 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.542 HD11 ' HE3' ' A' ' 139' ' ' MET . 22.4 pt -140.2 144.47 27.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.13 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.406 ' HG2' ' CE2' ' A' ' 81' ' ' PHE . 3.7 ttm180 -105.5 124.21 49.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.907 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.442 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 61.9 p -117.52 132.54 56.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.132 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -157.2 169.17 25.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' TRP . . . . . 0.519 ' CH2' ' HE3' ' A' ' 129' ' ' LYS . 7.3 m95 -65.94 116.57 7.23 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.982 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -64.89 -47.27 78.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.106 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 66.6 p -58.02 149.13 24.01 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.138 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 37.9 mmt180 -119.84 165.35 14.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.882 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 14.0 ptmt -163.11 150.45 10.97 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.61 0.719 . . . . 0.0 110.884 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 148.33 64.59 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.711 2.274 . . . . 0.0 112.291 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 167.64 23.85 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.706 2.271 . . . . 0.0 112.368 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.517 ' HB1' ' HD2' ' A' ' 161' ' ' PRO . . . -80.02 158.45 72.46 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.543 0.687 . . . . 0.0 111.139 179.867 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 161' ' ' PRO . . . . . 0.517 ' HD2' ' HB1' ' A' ' 160' ' ' ALA . 54.5 Cg_endo -69.69 174.71 9.05 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.734 2.29 . . . . 0.0 112.363 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.443 ' HG2' ' N ' ' A' ' 163' ' ' SER . 40.9 tttm -174.1 156.36 2.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.904 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 163' ' ' SER . . . . . 0.443 ' N ' ' HG2' ' A' ' 162' ' ' LYS . 5.0 t -171.45 176.62 3.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.862 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 4.8 t -149.23 122.45 8.95 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.181 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 9.1 p90 -95.65 118.25 31.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.955 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? -118.88 147.49 43.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.923 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 39.3 t -154.32 131.1 10.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.864 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 9.4 p-10 -165.88 118.82 1.12 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.918 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 29.5 m -150.09 135.04 17.77 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.12 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.5 129.89 15.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.854 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -128.71 142.51 50.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.92 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 2.7 t -166.72 123.23 1.23 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.804 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 154.66 66.0 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.435 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 178.17 4.84 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.665 2.243 . . . . 0.0 112.357 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 25.4 p -139.75 165.98 25.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 176' ' ' SER . . . . . 0.401 ' O ' ' C ' ' A' ' 177' ' ' GLY . 16.2 m -73.53 121.68 20.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.881 -179.879 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 177' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 176' ' ' SER . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.518 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.515 -0.234 . . . . 0.0 112.515 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 68.6 p -107.5 119.71 40.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.918 0.39 . . . . 0.0 110.844 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 34.3 t -126.58 89.17 2.95 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.876 -179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -56.66 126.95 42.99 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.538 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 46.9 m -123.45 -50.51 1.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.887 0.375 . . . . 0.0 110.844 -179.688 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 75.7 m 41.1 42.36 1.59 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.845 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -128.49 -45.81 0.19 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.493 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 20.6 mm-40 -95.04 167.58 11.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.857 0.361 . . . . 0.0 110.958 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -172.95 152.95 2.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.921 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 16.5 mmmt -80.19 49.4 1.11 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.907 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.405 ' O ' ' N ' ' A' ' 75' ' ' SER . 12.4 p-10 -94.91 33.99 1.42 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.868 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.596 HG22 ' HB2' ' A' ' 77' ' ' HIS . 0.6 OUTLIER -64.54 75.74 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.176 -179.891 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 75' ' ' SER . . . . . 0.405 ' N ' ' O ' ' A' ' 73' ' ' ASP . 74.3 m -92.68 152.82 19.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.882 -179.831 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.6 m-20 55.93 30.92 16.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.909 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' HIS . . . . . 0.596 ' HB2' HG22 ' A' ' 74' ' ' THR . 9.0 m170 -118.67 159.84 22.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.873 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 -115.53 112.11 21.72 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.859 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.476 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.5 OUTLIER -82.51 142.15 32.08 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.867 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 56.0 t -120.94 148.94 23.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.159 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -100.69 136.97 39.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.887 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.884 HG12 HD21 ' A' ' 85' ' ' LEU . 3.5 t -136.77 109.66 8.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.134 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -120.97 179.57 16.3 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.484 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 4.0 t70 62.51 43.08 8.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.827 0.346 . . . . 0.0 110.838 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.884 HD21 HG12 ' A' ' 82' ' ' VAL . 9.1 mt -103.31 135.66 44.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.934 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.03 153.9 5.79 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.651 0.739 . . . . 0.0 110.901 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -16.56 37.67 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.678 2.252 . . . . 0.0 112.374 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -89.29 -7.01 56.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.907 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.909 HD11 ' HA3' ' A' ' 145' ' ' GLY . 40.3 mm -75.54 138.46 20.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.127 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.5 t -119.14 168.2 11.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.152 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.464 ' HA ' HG23 ' A' ' 109' ' ' VAL . 7.4 m -46.36 -44.12 16.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.112 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 29.6 mt-10 -58.24 -51.26 70.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.901 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.469 ' CB ' HG23 ' A' ' 89' ' ' ILE . 4.6 m-20 -44.04 -55.97 4.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.523 HD11 HG22 ' A' ' 109' ' ' VAL . 8.4 mt -49.53 -58.57 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.139 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.59 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 24.9 mtmt -48.99 -41.71 35.33 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.883 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -59.8 -31.89 70.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.108 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.429 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -72.52 -56.97 4.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.104 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.424 ' C ' HD11 ' A' ' 104' ' ' ILE . 33.5 m-85 -83.79 11.94 6.75 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.88 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.761 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -67.43 -59.95 6.41 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.583 0.706 . . . . 0.0 111.113 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.761 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.77 -0.83 7.48 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.7 2.266 . . . . 0.0 112.319 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.412 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 70.8 m-85 -99.77 -13.37 19.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.926 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 156.59 155.14 7.3 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.508 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.455 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 35.8 mtt-85 -63.31 123.21 18.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.795 0.331 . . . . 0.0 110.897 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.424 HD11 ' C ' ' A' ' 98' ' ' PHE . 12.6 mt -100.49 142.6 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.133 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.461 ' HB2' ' CZ ' ' A' ' 127' ' ' PHE . 38.6 t -114.94 -61.53 1.74 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.827 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -100.97 101.03 11.74 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.829 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.518 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -130.24 124.24 32.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.117 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 10.2 ptp180 -160.72 153.78 21.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.88 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.523 HG22 HD11 ' A' ' 94' ' ' ILE . 69.2 t -102.3 125.94 56.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.75 HG12 ' HG3' ' A' ' 119' ' ' LYS . 56.6 t -55.61 139.99 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.108 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 49.7 mttt -138.79 149.22 44.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.889 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 48.8 t0 -63.1 121.98 14.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.859 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 11.4 ptp -71.4 -1.45 13.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.901 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.97 -54.28 3.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.079 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 26.8 p -99.61 -24.99 14.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.186 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 81.35 27.17 49.42 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.457 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 73.6 mmtt -96.75 164.88 12.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.776 0.322 . . . . 0.0 110.914 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 24.6 t -66.33 115.04 5.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.86 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.75 ' HG3' HG12 ' A' ' 110' ' ' VAL . 7.0 mmtm -64.93 -40.92 95.78 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.894 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.549 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 130.44 -46.78 1.05 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.481 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.612 ' CE2' HG21 ' A' ' 110' ' ' VAL . 29.6 p90 -100.02 141.18 33.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.905 0.383 . . . . 0.0 110.947 -179.814 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -125.28 178.64 16.49 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.513 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 62.5 m-85 -121.25 139.9 52.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.878 0.37 . . . . 0.0 110.874 -179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.703 HG12 ' CE1' ' A' ' 126' ' ' PHE . 63.9 t -136.56 115.68 15.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.118 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 43.9 t -101.63 151.43 22.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.833 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.703 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.8 m-85 -131.0 148.04 52.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.88 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.461 ' CZ ' ' HB2' ' A' ' 105' ' ' SER . 68.0 m-85 -64.91 -40.41 95.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.867 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -111.73 155.27 23.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.877 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.466 ' O ' ' C ' ' A' ' 130' ' ' TRP . 38.4 tttt -68.38 -63.4 1.07 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.893 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.466 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -33.19 -60.09 0.34 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.949 179.897 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.4 ' C ' ' O ' ' A' ' 130' ' ' TRP . 61.9 m-20 -37.77 -54.83 1.22 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.888 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -60.09 -64.95 0.77 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.085 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -39.37 -58.57 1.2 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.919 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -42.01 -50.29 4.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.878 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.468 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -66.79 -59.95 3.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.062 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 93.4 mt -37.67 -37.74 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 18.4 mt-30 -84.42 -61.66 1.75 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.935 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -61.24 -59.75 4.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.907 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.468 ' N ' ' O ' ' A' ' 135' ' ' ALA . 86.9 mmm -57.38 -36.33 71.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.855 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -52.39 104.31 0.17 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.495 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 111.86 -31.72 6.85 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.488 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 13.0 mm100 -49.41 179.82 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.798 0.332 . . . . 0.0 110.923 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' TRP . . . . . 0.45 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 13.7 m95 -115.44 126.89 54.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.893 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.696 HD23 HD22 ' A' ' 85' ' ' LEU . 40.7 tp -123.29 126.78 47.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 0.909 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 71.66 -6.12 9.71 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.549 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 123.7 -11.11 8.42 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.485 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 17.8 mtt-85 -125.58 146.9 49.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.789 0.328 . . . . 0.0 110.866 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.45 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 22.4 mt-30 -56.18 158.64 3.93 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.921 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.699 HG22 HD23 ' A' ' 85' ' ' LEU . 21.0 pt -132.29 143.56 39.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.143 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 11.2 ptt180 -107.07 109.32 21.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.876 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 62.4 p -101.0 131.98 46.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.188 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 17.1 t30 -155.35 172.88 17.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.881 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 82.8 m95 -72.93 119.67 17.49 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.912 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -52.93 -59.85 4.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.098 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 9.3 t -42.36 160.28 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.178 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 18.0 ptt180 -130.04 146.02 51.69 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.882 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.434 ' HD2' ' N ' ' A' ' 158' ' ' PRO . 0.0 OUTLIER -117.92 137.07 24.05 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-O 121.626 0.727 . . . . 0.0 110.909 179.972 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 158' ' ' PRO . . . . . 0.434 ' N ' ' HD2' ' A' ' 157' ' ' LYS . 53.6 Cg_endo -69.73 145.39 57.18 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.689 2.259 . . . . 0.0 112.291 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.81 167.04 25.67 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.695 2.263 . . . . 0.0 112.368 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -164.16 143.64 6.22 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.56 0.695 . . . . 0.0 111.097 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 137.71 36.01 Favored 'Trans proline' 0 N--CA 1.465 -0.179 0 C-N-CA 122.72 2.28 . . . . 0.0 112.356 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.438 ' HD2' ' N ' ' A' ' 162' ' ' LYS . 0.0 OUTLIER -154.6 142.31 19.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.894 179.955 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 26.9 t -173.75 122.05 0.33 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.871 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 164' ' ' THR . . . . . 0.568 HG23 ' O ' ' A' ' 164' ' ' THR . 14.6 t -148.33 118.77 7.38 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.156 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 165' ' ' TYR . . . . . 0.498 ' CG ' ' O ' ' A' ' 165' ' ' TYR . 8.3 p90 -168.65 110.88 0.54 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.876 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -109.76 97.82 7.28 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.873 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 26.5 t -172.01 159.32 4.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.84 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -158.27 151.54 23.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.875 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 74.9 p -133.51 132.52 41.06 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.15 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 2.2 tmtp? -109.12 -45.4 3.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.926 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -157.96 121.82 4.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.913 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 88.2 p -112.62 133.95 54.39 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.825 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 69.18 83.5 0.16 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.441 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 108.04 2.0 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.688 2.258 . . . . 0.0 112.349 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 44.9 t -128.09 125.06 38.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.9 -179.835 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 61.4 p -166.86 132.04 2.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.866 -179.762 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.527 179.986 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 74.4 m -132.14 135.28 46.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.916 0.388 . . . . 0.0 110.86 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 13.6 t -45.41 -51.67 11.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.855 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 141.74 135.65 3.15 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.451 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 5.1 m -95.24 104.14 16.02 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.831 0.348 . . . . 0.0 110.873 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.8 p -56.87 161.81 2.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.849 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 151.3 116.94 0.75 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.495 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 14.6 mm-40 -62.6 97.46 0.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.885 0.374 . . . . 0.0 110.892 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 27.6 mtmm -73.01 88.07 1.37 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.889 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.52 -23.5 56.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.909 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -88.4 160.64 17.48 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.88 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.5 HG21 ' CG ' ' A' ' 106' ' ' ASP . 5.4 p -120.33 33.94 5.4 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.153 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 90.8 p -63.63 -52.42 60.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.837 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -99.2 41.56 1.14 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.907 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' HIS . . . . . 0.413 ' ND1' HG22 ' A' ' 74' ' ' THR . 8.9 m170 -113.48 158.04 21.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.86 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.55 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 5.1 m-85 -108.75 110.12 21.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.84 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.448 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.6 OUTLIER -83.99 149.09 26.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.836 -179.987 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.554 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 39.7 t -125.0 141.25 45.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.148 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.1 t80 -92.31 134.03 35.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.894 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.984 HG12 HD21 ' A' ' 85' ' ' LEU . 12.2 t -132.62 112.95 19.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.1 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.41 ' C ' ' HG2' ' A' ' 150' ' ' ARG . . . -120.52 -179.63 16.31 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.431 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.408 ' O ' ' O ' ' A' ' 148' ' ' GLN . 5.2 m-20 63.9 43.79 5.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.812 0.339 . . . . 0.0 110.878 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.984 HD21 HG12 ' A' ' 82' ' ' VAL . 9.6 mt -102.37 129.16 48.76 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.902 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.1 t -53.26 154.27 5.99 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.705 0.764 . . . . 0.0 110.849 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -7.65 21.6 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.719 2.28 . . . . 0.0 112.341 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -99.98 -8.67 23.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.864 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.826 HD11 ' HA3' ' A' ' 145' ' ' GLY . 38.6 mm -75.29 141.2 16.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.14 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.0 t -119.46 173.13 7.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.14 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.7 HG23 ' HA ' ' A' ' 108' ' ' ARG . 88.0 m -50.22 -47.28 54.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.099 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -54.74 -52.97 60.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.884 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.498 ' CB ' HG23 ' A' ' 89' ' ' ILE . 1.6 m-20 -42.72 -55.78 3.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.821 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.631 HD11 HG22 ' A' ' 109' ' ' VAL . 10.2 mt -49.5 -58.66 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.112 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.717 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 25.3 mtmt -47.87 -39.51 18.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.82 -32.72 72.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.095 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.629 ' HB1' ' HE1' ' A' ' 139' ' ' MET . . . -71.71 -51.85 20.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.094 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.488 ' C ' HD11 ' A' ' 104' ' ' ILE . 14.2 m-85 -93.51 13.2 22.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.882 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.767 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -66.76 -59.82 7.33 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.538 0.685 . . . . 0.0 111.081 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.767 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.3 Cg_endo -69.78 -0.61 7.18 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.685 2.257 . . . . 0.0 112.305 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -99.75 -1.33 38.0 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.846 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 142.54 143.24 4.15 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.451 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 68.4 mtm180 -53.47 123.38 11.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.795 0.331 . . . . 0.0 110.891 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.488 HD11 ' C ' ' A' ' 98' ' ' PHE . 20.1 mt -100.0 137.34 27.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.167 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.472 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 7.5 p -105.1 -62.3 1.36 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.884 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.5 ' CG ' HG21 ' A' ' 74' ' ' THR . 0.8 OUTLIER -100.74 105.14 16.44 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 179.948 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.501 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -135.18 125.29 26.02 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.13 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.7 ' HA ' HG23 ' A' ' 91' ' ' THR . 8.2 ptp180 -160.22 169.17 23.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.631 HG22 HD11 ' A' ' 94' ' ' ILE . 95.8 t -116.93 117.54 55.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.133 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.852 HG12 ' HG3' ' A' ' 119' ' ' LYS . 60.6 t -47.1 141.08 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.172 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 80.1 mttt -140.31 152.09 45.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.902 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -63.88 121.55 14.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.851 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 1.1 pmm? -74.89 -1.47 22.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.856 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.14 -44.37 6.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.097 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 52.1 p -111.12 -35.16 5.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.175 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 94.63 31.01 8.08 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.505 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 22.9 mmtm -99.53 164.39 12.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.822 0.344 . . . . 0.0 110.891 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 29.6 t -65.83 109.88 2.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.866 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.852 ' HG3' HG12 ' A' ' 110' ' ' VAL . 11.3 mmtp -59.78 -39.36 84.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.878 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.508 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 128.6 -47.16 1.04 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.549 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.577 ' CE2' HG21 ' A' ' 110' ' ' VAL . 12.8 p90 -99.94 146.56 26.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.969 0.414 . . . . 0.0 110.902 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -127.96 178.03 17.29 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.459 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 36.9 m-85 -121.73 140.12 52.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.912 0.386 . . . . 0.0 110.908 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.68 HG12 ' CE1' ' A' ' 126' ' ' PHE . 47.4 t -136.77 113.75 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.108 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 125' ' ' SER . . . . . 0.436 ' O ' HG23 ' A' ' 104' ' ' ILE . 69.0 m -102.04 150.48 23.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.867 -179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.68 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.4 m-85 -130.77 143.33 50.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.846 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.472 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 22.7 m-85 -50.27 -48.89 54.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.904 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -106.85 173.31 6.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.886 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.55 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 3.5 ttmt -79.36 -51.8 8.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.927 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.42 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.0 OUTLIER -48.03 -58.4 4.49 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.887 179.952 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 130' ' ' TRP . 81.9 m-20 -35.72 -42.74 0.26 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.86 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.554 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -78.7 -60.89 2.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.128 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.595 ' HA ' HD12 ' A' ' 136' ' ' ILE . 18.6 mt-10 -37.83 -55.56 1.18 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -43.15 -55.51 3.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.902 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.466 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -59.21 -54.66 44.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.075 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' ILE . . . . . 0.595 HD12 ' HA ' ' A' ' 133' ' ' GLU . 93.0 mt -38.62 -36.57 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.14 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 22.1 mt-30 -87.94 -60.8 1.87 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.908 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 20.1 mm-40 -61.32 -59.49 5.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.9 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.629 ' HE1' ' HB1' ' A' ' 97' ' ' ALA . 87.3 mmm -59.32 -35.57 74.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.429 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -53.31 111.03 1.56 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.466 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 102.11 -28.86 14.03 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -50.63 178.89 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.746 0.308 . . . . 0.0 110.898 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 143' ' ' TRP . . . . . 0.588 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 14.3 m95 -115.31 119.55 36.66 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.959 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.595 HD13 ' HB2' ' A' ' 97' ' ' ALA . 60.6 tp -109.5 129.5 55.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.918 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 0.826 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.24 -78.57 0.43 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.476 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -156.04 14.08 0.4 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.517 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 66.7 mtt180 -153.5 154.38 34.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.744 0.307 . . . . 0.0 110.883 -179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.588 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 15.8 mt-30 -55.91 167.8 0.54 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.914 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.499 HG21 ' HB3' ' A' ' 144' ' ' LEU . 28.8 pt -140.81 147.69 22.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.155 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.41 ' HG2' ' C ' ' A' ' 83' ' ' GLY . 15.8 ptt180 -111.83 120.47 42.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.805 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.429 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 82.5 p -111.02 133.12 53.66 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -155.06 165.52 36.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.886 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 12.9 m95 -62.04 102.78 0.31 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.945 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -39.92 -40.75 1.06 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.107 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.405 ' HB ' ' CD ' ' A' ' 157' ' ' LYS . 39.9 p -96.75 128.49 43.74 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.189 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 35.0 ttt180 -85.91 94.7 9.25 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.827 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.405 ' CD ' ' HB ' ' A' ' 155' ' ' THR . 0.8 OUTLIER -128.84 142.81 46.31 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.58 0.705 . . . . 0.0 110.86 179.967 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 148.7 65.57 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.706 2.271 . . . . 0.0 112.295 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 174.71 9.13 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.646 2.231 . . . . 0.0 112.327 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -166.0 145.97 5.34 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.584 0.706 . . . . 0.0 111.118 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.74 134.33 27.77 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.718 2.279 . . . . 0.0 112.335 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 21.8 ttpp -95.08 138.77 32.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.929 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 9.1 t -73.08 -60.66 2.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.84 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 9.3 t -166.47 130.04 2.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.118 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -49.97 -60.55 2.82 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.932 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -171.56 154.96 3.93 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.857 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 6.7 t -133.56 99.22 4.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.859 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -171.88 168.16 6.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 44.0 p -98.81 156.7 16.73 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.149 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 8.4 tmtm? -55.74 131.49 46.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 22.7 tt0 -147.52 149.4 32.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 87.6 p -138.62 172.49 12.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.863 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -139.58 146.38 17.91 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.442 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -171.68 0.5 Allowed 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.753 2.302 . . . . 0.0 112.328 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 23.2 t -157.07 137.73 13.18 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.895 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 1.2 t -153.49 121.83 6.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.848 -179.757 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.451 179.955 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.272 0 N-CA-C 112.448 -0.261 . . . . 0.0 112.448 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 59.4 p -52.25 -56.81 12.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.927 0.394 . . . . 0.0 110.854 -179.737 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.5 m -58.0 135.43 56.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.891 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -177.81 79.91 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.451 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.0 m -50.84 -58.76 5.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.902 0.382 . . . . 0.0 110.858 -179.718 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 78.1 p 48.81 44.59 21.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.838 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -146.28 105.25 0.32 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.504 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -109.75 34.94 3.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.815 0.341 . . . . 0.0 110.889 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.46 ' HE3' ' N ' ' A' ' 71' ' ' LYS . 0.0 OUTLIER -51.05 170.59 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.921 179.945 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 13.2 tptt -124.08 -43.75 2.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.863 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 62.2 m-20 -75.21 178.7 5.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.902 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 37.2 p -119.17 78.7 1.32 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.127 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 91.8 p -93.84 143.48 26.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 43.73 35.43 1.04 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.86 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 8.8 m170 -106.49 159.87 15.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.888 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.498 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 75.9 m-85 -108.85 112.38 24.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.42 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.9 OUTLIER -88.49 163.81 15.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.895 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.407 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 49.0 t -138.32 143.66 32.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.112 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -98.11 132.08 43.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.854 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.983 HG12 HD21 ' A' ' 85' ' ' LEU . 2.7 t -132.63 109.79 15.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.136 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.446 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -116.3 -179.45 18.03 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.469 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.4 ' O ' ' O ' ' A' ' 148' ' ' GLN . 14.4 m-20 63.8 26.21 14.31 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.891 0.377 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.983 HD21 HG12 ' A' ' 82' ' ' VAL . 10.7 mt -83.79 135.59 34.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.951 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -52.93 147.61 15.68 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.717 0.77 . . . . 0.0 110.854 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -6.2 18.04 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.638 2.225 . . . . 0.0 112.344 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -100.61 -5.02 27.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.851 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.917 HD11 ' HA3' ' A' ' 145' ' ' GLY . 30.8 mm -74.8 145.29 11.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.124 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.411 HG22 ' OD1' ' A' ' 93' ' ' ASP . 9.1 t -121.03 165.0 15.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.133 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.631 ' HA ' HG23 ' A' ' 109' ' ' VAL . 22.5 m -43.63 -50.7 7.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.107 -179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 93' ' ' ASP . 34.3 mt-10 -54.55 -57.26 12.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.892 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.431 ' CB ' HG23 ' A' ' 89' ' ' ILE . 0.5 OUTLIER -35.78 -57.86 0.64 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.89 179.974 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.446 ' CD1' HG22 ' A' ' 109' ' ' VAL . 8.7 mt -47.36 -59.31 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.117 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.593 ' HE2' ' HB3' ' A' ' 107' ' ' ALA . 22.9 mtmt -47.93 -39.21 18.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.926 179.822 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 93' ' ' ASP . . . -60.82 -35.03 75.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.079 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -71.68 -51.81 21.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.09 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.529 ' C ' HD11 ' A' ' 104' ' ' ILE . 23.0 m-85 -89.43 16.82 6.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.865 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.8 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -68.05 -60.61 4.98 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.595 0.712 . . . . 0.0 111.102 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.8 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.5 Cg_endo -69.8 -1.43 8.5 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.647 2.232 . . . . 0.0 112.318 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -100.45 11.45 39.43 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.842 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 126.65 133.16 3.79 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.477 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 16.9 mtt180 -46.08 126.75 7.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.799 0.333 . . . . 0.0 110.87 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.621 ' CG2' HG13 ' A' ' 124' ' ' VAL . 11.0 mt -100.06 138.13 25.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.139 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.52 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 2.6 t -107.61 -62.72 1.39 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -100.56 104.27 15.62 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.842 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.593 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -134.46 125.92 28.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.076 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.441 ' NH1' ' HA ' ' A' ' 110' ' ' VAL . 0.1 OUTLIER -158.88 157.51 31.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.884 -179.911 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.631 HG23 ' HA ' ' A' ' 91' ' ' THR . 88.3 t -104.82 117.71 50.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.122 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.856 HG11 ' CZ ' ' A' ' 121' ' ' TYR . 85.8 t -50.33 143.04 2.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.103 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 33.8 mttm -142.68 157.1 45.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.865 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -71.37 128.03 34.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.858 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 24.8 ptp -76.96 1.06 18.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -99.59 -46.04 5.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.092 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 24.4 p -108.85 -26.28 10.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.169 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 81.5 24.62 56.09 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.479 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 66.8 mttt -97.88 164.59 12.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.814 0.34 . . . . 0.0 110.902 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 2.2 m -59.39 119.04 6.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.855 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.647 ' HG3' HG12 ' A' ' 110' ' ' VAL . 24.4 mmtt -71.25 -39.32 71.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.945 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 128.99 -40.5 1.69 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.459 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.856 ' CZ ' HG11 ' A' ' 110' ' ' VAL . 7.0 p90 -100.23 156.04 17.44 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.911 0.386 . . . . 0.0 110.956 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.17 174.8 21.53 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.56 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -130.55 139.24 50.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.888 0.375 . . . . 0.0 110.857 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.621 HG13 ' CG2' ' A' ' 104' ' ' ILE . 76.7 t -134.49 133.56 54.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.097 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 32.5 t -113.19 138.58 49.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.83 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.619 ' CD1' ' HB2' ' A' ' 132' ' ' ALA . 75.2 m-85 -118.65 147.38 43.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.878 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.52 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 23.3 m-85 -61.64 -36.21 80.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 4.7 m-20 -114.75 174.58 5.89 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.866 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.498 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 67.1 tttt -84.12 -39.34 19.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.93 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.42 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -61.15 -53.11 61.12 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.928 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 130' ' ' TRP . 75.6 m-20 -35.88 -52.39 0.73 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.891 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.619 ' HB2' ' CD1' ' A' ' 126' ' ' PHE . . . -64.97 -66.18 0.58 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.096 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.482 ' HA ' HD12 ' A' ' 136' ' ' ILE . 3.8 mm-40 -34.7 -56.5 0.54 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.866 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -42.26 -51.68 4.69 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.924 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -64.7 -55.79 17.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.086 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' ILE . . . . . 0.482 HD12 ' HA ' ' A' ' 133' ' ' GLU . 87.4 mt -39.2 -33.46 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.14 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 49.7 mt-30 -84.9 -67.38 0.8 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.889 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 -57.73 -61.58 2.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.901 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 64.8 mmm -53.47 -41.1 65.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.868 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.408 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -49.38 104.72 0.11 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.519 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 106.7 -31.16 8.51 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.454 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 50.7 mm-40 -49.33 173.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.823 0.344 . . . . 0.0 110.927 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' TRP . . . . . 0.485 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 12.9 m95 -108.89 127.41 54.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.899 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.537 ' HB3' HG21 ' A' ' 149' ' ' ILE . 36.6 tp -128.48 130.76 47.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.887 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 0.917 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.77 -2.09 13.48 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.488 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 117.26 -14.27 13.58 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.48 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 20.1 mtt-85 -124.12 143.25 50.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.804 0.335 . . . . 0.0 110.829 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.485 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 28.4 mt-30 -52.5 160.04 0.92 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.951 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.56 HG22 HD23 ' A' ' 85' ' ' LEU . 21.3 pt -134.15 152.74 34.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.15 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.446 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 10.7 ptp180 -113.24 118.85 35.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.408 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 41.5 p -110.49 133.33 53.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.127 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 60.5 m-20 -163.06 164.43 25.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.887 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 14.3 m95 -58.05 126.61 28.21 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.922 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -75.57 -34.31 60.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.114 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 1.2 p -83.03 20.95 1.12 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.174 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 45.4 ttt180 -174.28 119.92 0.25 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.885 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 26.0 ttpt -126.14 127.35 24.7 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.585 0.707 . . . . 0.0 110.894 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 167.42 24.44 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.668 2.245 . . . . 0.0 112.387 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 157.99 58.55 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.697 2.265 . . . . 0.0 112.376 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -79.49 152.37 75.56 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.6 0.714 . . . . 0.0 111.104 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 136.86 34.06 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.725 2.283 . . . . 0.0 112.319 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.422 ' O ' HG23 ' A' ' 164' ' ' THR . 34.3 mtmt -122.52 148.63 44.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.905 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 29.3 t -63.97 116.42 5.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.903 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 164' ' ' THR . . . . . 0.422 HG23 ' O ' ' A' ' 162' ' ' LYS . 38.4 p -118.51 100.65 7.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.099 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 3.4 p90 -69.29 -177.99 1.25 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.901 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -174.67 135.77 0.41 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.896 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 39.4 t -137.62 114.5 10.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.87 -179.789 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 2.7 p30 -165.08 122.43 1.56 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.855 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 79.8 m -125.43 144.3 50.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.13 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 28.2 tttp -163.45 120.18 1.79 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.932 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -107.92 93.95 4.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 60.1 p -92.0 164.6 13.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.818 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -129.2 70.92 0.51 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.524 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 -27.76 25.9 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.628 2.219 . . . . 0.0 112.319 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 72.8 p -93.51 141.58 28.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.872 -179.844 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 7.0 t -43.89 -59.7 2.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.882 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.489 179.977 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 28.3 t -66.52 112.12 3.94 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.906 0.384 . . . . 0.0 110.879 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 26.8 t -170.25 157.16 6.12 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.863 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -72.61 -147.92 0.81 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.467 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 60.9 m -85.09 141.33 30.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.914 0.388 . . . . 0.0 110.893 -179.791 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 60.9 p -159.05 141.1 13.7 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -165.91 133.26 2.89 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.501 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 46.1 mt-30 -125.49 -49.29 1.66 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.848 0.356 . . . . 0.0 110.892 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.23 156.35 18.36 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 11.0 pttm -87.16 44.86 1.21 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.906 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -112.81 158.3 20.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 179.821 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.769 HG21 ' HB2' ' A' ' 106' ' ' ASP . 39.1 p -119.13 90.84 3.41 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.173 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 31.1 p -119.17 -56.91 2.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.871 -179.869 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 2.7 m-80 -53.22 -38.86 63.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.891 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 53.2 m170 -65.16 174.05 2.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.822 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.564 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 17.5 m-85 -112.6 118.66 35.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.903 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.449 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 1.1 m-70 -86.9 149.1 25.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.835 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.475 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 40.2 t -129.06 144.43 38.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.112 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.6 t80 -94.78 135.28 36.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.843 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.761 HG12 HD21 ' A' ' 85' ' ' LEU . 4.0 t -132.43 119.37 38.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.066 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.418 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -129.24 170.01 20.39 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.494 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 2.2 t70 72.43 38.92 0.78 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.847 0.356 . . . . 0.0 110.904 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.761 HD21 HG12 ' A' ' 82' ' ' VAL . 9.9 mt -100.39 133.82 44.24 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.965 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 t -54.34 153.74 9.42 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.654 0.74 . . . . 0.0 110.804 -179.869 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 -14.38 36.1 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.638 2.225 . . . . 0.0 112.406 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -90.4 -10.25 44.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.89 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.671 HD11 ' HA3' ' A' ' 145' ' ' GLY . 37.5 mm -76.64 135.7 26.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.16 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.409 ' O ' ' C ' ' A' ' 91' ' ' THR . 14.4 t -117.27 160.43 21.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.162 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.622 ' HA ' HG23 ' A' ' 109' ' ' VAL . 20.2 m -36.99 -47.14 0.69 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.13 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -52.92 -54.72 30.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.875 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.613 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.1 m-20 -42.26 -54.58 3.65 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.441 ' CD1' HG22 ' A' ' 109' ' ' VAL . 15.1 mt -51.04 -59.95 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.154 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.642 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 23.3 mtmt -48.27 -39.62 22.14 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.928 179.845 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.92 -32.17 73.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.043 179.859 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -73.15 -54.59 8.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.127 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.412 ' C ' HD11 ' A' ' 104' ' ' ILE . 28.9 m-85 -86.08 11.3 12.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.881 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.763 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -65.26 -59.5 9.67 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.593 0.711 . . . . 0.0 111.112 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.763 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.2 Cg_endo -69.76 -0.58 7.12 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.678 2.252 . . . . 0.0 112.354 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.581 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 78.6 m-85 -99.73 -8.59 24.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.885 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 147.52 133.66 2.41 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.507 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 34.4 mtp180 -45.42 123.63 4.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.775 0.322 . . . . 0.0 110.869 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.552 HG23 ' O ' ' A' ' 125' ' ' SER . 9.9 mt -99.39 137.96 25.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.139 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.436 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 89.5 p -104.02 -65.1 1.04 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.846 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.769 ' HB2' HG21 ' A' ' 74' ' ' THR . 35.2 t70 -100.65 106.41 17.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.868 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.587 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -135.05 127.9 31.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.118 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.427 ' HD3' ' N ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -161.06 158.94 28.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.886 -179.904 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.622 HG23 ' HA ' ' A' ' 91' ' ' THR . 88.6 t -107.64 116.9 52.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.129 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.668 HG21 ' CE2' ' A' ' 121' ' ' TYR . 59.6 t -48.3 137.97 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.135 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 53.6 mttt -134.48 156.46 48.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.874 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 116' ' ' GLY . 10.4 t0 -60.6 122.99 16.09 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.841 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 11.0 tpt -67.63 -4.26 11.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.896 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -106.34 -52.23 2.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.078 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 53.8 p -95.14 -28.59 14.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.131 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 79.53 26.67 56.41 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.491 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 54.0 mmtt -100.0 149.75 23.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.791 0.329 . . . . 0.0 110.869 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 8.2 t -50.38 108.3 0.22 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.878 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 40.3 mttt -61.47 -43.81 98.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.917 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 142.28 -42.44 1.13 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.502 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.668 ' CE2' HG21 ' A' ' 110' ' ' VAL . 15.5 p90 -100.04 146.13 27.11 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.927 0.394 . . . . 0.0 110.91 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -128.91 179.98 16.3 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.473 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -125.69 140.05 53.03 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.879 0.371 . . . . 0.0 110.899 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.539 HG12 ' CE1' ' A' ' 126' ' ' PHE . 50.7 t -135.17 121.34 32.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.161 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 125' ' ' SER . . . . . 0.552 ' O ' HG23 ' A' ' 104' ' ' ILE . 5.2 m -106.01 148.33 27.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.854 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.539 ' CE1' HG12 ' A' ' 124' ' ' VAL . 21.2 m-85 -130.73 147.13 52.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.893 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.436 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 23.4 m-85 -59.17 -43.18 92.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.846 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 23.9 m120 -118.9 157.33 27.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.888 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.564 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 8.3 ttmt -60.43 -63.47 1.29 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.89 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.443 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -34.66 -52.82 0.53 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -43.89 -45.6 7.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.892 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.475 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -76.53 -57.04 4.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.096 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.404 ' HG2' ' CZ2' ' A' ' 153' ' ' TRP . 11.2 mt-10 -44.33 -56.73 3.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.861 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 51.1 t30 -45.13 -42.88 9.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.837 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.485 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -71.83 -53.95 11.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.095 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 96.8 mt -40.63 -40.84 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.119 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 -78.8 -59.61 2.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.917 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 15.2 mm-40 -63.7 -63.33 1.2 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.885 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.581 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 82.3 mmm -51.6 -39.06 57.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.865 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -54.08 112.34 2.51 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.519 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 91.58 21.51 34.14 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.531 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 62.8 mm-40 -101.25 168.44 9.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.792 0.33 . . . . 0.0 110.95 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 143' ' ' TRP . . . . . 0.426 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 14.8 m95 -105.0 109.15 21.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.892 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.497 HD23 HD22 ' A' ' 85' ' ' LEU . 63.1 tp -102.01 128.45 48.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.917 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 0.671 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 68.63 -72.51 0.36 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.484 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -160.88 17.56 0.19 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.499 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 33.3 mtt85 -155.78 156.72 35.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.782 0.325 . . . . 0.0 110.89 -179.809 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.426 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 46.7 mt-30 -59.68 173.37 0.57 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.908 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.4 HG21 ' HB3' ' A' ' 144' ' ' LEU . 20.2 pt -147.08 148.95 16.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.12 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.447 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 8.4 ptp180 -115.65 120.91 40.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.871 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 55.8 p -114.64 133.26 55.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.123 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -158.85 161.64 36.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.876 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' TRP . . . . . 0.404 ' CZ2' ' HG2' ' A' ' 133' ' ' GLU . 7.7 m95 -54.77 104.5 0.12 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.457 ' HB2' ' C ' ' A' ' 80' ' ' VAL . . . -49.04 -47.94 44.3 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.109 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 77.7 p -70.18 161.74 29.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.107 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 9.1 ptm180 -161.9 166.04 26.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.896 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.5 mttm -128.16 151.49 76.24 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.613 0.721 . . . . 0.0 110.879 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 167.13 25.25 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.644 2.23 . . . . 0.0 112.4 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 174.41 9.6 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.649 2.233 . . . . 0.0 112.339 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -100.73 153.24 37.85 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.587 0.708 . . . . 0.0 111.089 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 174.22 9.78 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.701 2.267 . . . . 0.0 112.35 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 6.6 pttm -155.19 125.12 6.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.888 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 1.7 t -161.07 135.89 7.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.902 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 2.5 t -171.35 139.31 1.29 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.186 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 165' ' ' TYR . . . . . 0.412 ' CD1' ' N ' ' A' ' 165' ' ' TYR . 1.1 p90 -169.52 119.13 0.66 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.949 -179.885 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 7.2 tm-20 -143.19 120.27 11.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 89.3 p -158.62 108.97 2.06 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.91 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -152.84 138.71 18.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.905 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 45.1 m -151.32 118.04 5.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.145 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 5.3 mtpm? -120.78 144.24 48.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.863 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 27.0 mm-40 -146.64 138.87 24.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.895 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 18.8 m -78.24 -50.65 11.48 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.911 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 67.66 68.73 1.56 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.493 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -0.08 6.41 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.668 2.245 . . . . 0.0 112.321 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 3.1 t 72.05 51.01 0.21 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.892 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 72.0 p -139.81 119.28 13.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.86 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.355 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.491 179.981 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.8 m 62.46 42.04 9.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.893 0.378 . . . . 0.0 110.861 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 64.6 m -97.37 -56.05 2.65 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.834 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -84.47 141.41 19.68 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.486 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.2 t -64.2 -48.61 75.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.887 0.375 . . . . 0.0 110.875 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 37.6 p -71.7 163.54 27.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.846 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -174.35 92.52 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.466 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 15.3 mt-30 -41.2 124.75 2.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.896 0.379 . . . . 0.0 110.914 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 52.3 mmtt -147.41 177.84 8.91 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.918 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.87 26.77 4.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.912 179.863 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -133.88 172.64 12.52 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 10.2 p -124.11 84.82 2.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.092 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 69.7 m -97.98 -60.53 1.54 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.847 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 42.2 t-20 -104.68 41.46 1.33 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.859 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' HIS . . . . . 0.455 ' CE1' ' HA ' ' A' ' 127' ' ' PHE . 14.2 m170 -110.72 159.76 17.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.834 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.582 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 76.5 m-85 -103.52 113.16 26.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.878 -179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.471 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.6 OUTLIER -83.92 156.73 22.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.827 -179.986 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.461 HG22 HD11 ' A' ' 136' ' ' ILE . 53.8 t -130.62 148.96 33.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.128 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 19.3 t80 -99.18 135.85 40.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.882 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.551 ' CG1' HD21 ' A' ' 85' ' ' LEU . 43.7 t -133.02 130.2 58.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.124 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.492 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -136.47 173.22 22.12 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.474 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 7.6 t0 64.4 52.1 1.92 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.846 0.355 . . . . 0.0 110.914 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.632 HD22 HD23 ' A' ' 144' ' ' LEU . 16.2 mt -108.26 131.64 54.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.24 154.07 6.14 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.659 0.742 . . . . 0.0 110.824 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -8.07 22.67 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.71 2.274 . . . . 0.0 112.336 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -100.06 -3.48 31.89 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.908 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.964 HD11 ' HA3' ' A' ' 145' ' ' GLY . 45.6 mm -78.96 137.11 22.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.102 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.3 t -119.0 168.41 10.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.135 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.547 HG22 ' CE ' ' A' ' 95' ' ' LYS . 36.8 m -47.47 -41.57 20.91 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.131 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 35.8 mt-10 -61.13 -53.21 59.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.902 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -42.87 -56.15 3.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.83 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.466 HD11 HG22 ' A' ' 109' ' ' VAL . 19.4 mt -50.09 -57.49 2.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.141 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.605 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 26.7 mtmt -46.93 -40.03 13.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.904 179.823 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.7 -32.58 73.7 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.106 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -68.87 -53.91 18.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.115 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 21.2 m-85 -89.43 10.44 22.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.847 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.758 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -64.51 -59.77 9.96 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.572 0.701 . . . . 0.0 111.131 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.758 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.8 -0.76 7.41 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.667 2.244 . . . . 0.0 112.345 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 -100.0 -11.76 20.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.881 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 155.7 157.01 8.05 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.494 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.529 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 27.1 mtp180 -64.52 123.46 19.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.825 0.345 . . . . 0.0 110.874 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 18.7 mt -100.43 144.56 12.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.112 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 65.8 p -119.91 -59.21 1.82 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.806 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.443 ' HB3' ' CB ' ' A' ' 125' ' ' SER . 8.7 t0 -100.82 100.52 11.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.857 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.479 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -130.59 127.11 38.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -162.23 156.54 21.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.845 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.466 HG22 HD11 ' A' ' 94' ' ' ILE . 72.9 t -106.16 119.98 56.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.134 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.611 HG21 ' CE2' ' A' ' 121' ' ' TYR . 95.1 t -53.47 134.43 15.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.113 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 38.7 mttt -134.7 146.37 49.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.848 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.426 ' O ' ' N ' ' A' ' 116' ' ' GLY . 29.6 t0 -57.4 120.53 8.37 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.9 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 7.7 ptp -68.61 -3.49 12.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.915 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -100.58 -50.1 3.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.111 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 44.0 p -97.69 -34.28 10.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.128 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 88.81 17.43 56.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 63.7 mttt -92.3 167.92 11.67 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.822 0.344 . . . . 0.0 110.888 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 8.2 t -69.34 113.24 6.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.849 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.442 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 37.1 mttt -62.87 -50.79 69.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.878 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 145.08 -41.4 1.07 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.447 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.611 ' CE2' HG21 ' A' ' 110' ' ' VAL . 10.2 p90 -98.99 149.7 22.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.937 0.398 . . . . 0.0 110.919 -179.791 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -129.77 175.54 19.02 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.458 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 47.8 m-85 -124.2 135.47 53.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.857 0.361 . . . . 0.0 110.882 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.546 HG12 ' CE1' ' A' ' 126' ' ' PHE . 56.5 t -134.53 122.0 37.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.127 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' SER . . . . . 0.443 ' CB ' ' HB3' ' A' ' 106' ' ' ASP . 16.3 t -106.45 149.62 26.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.855 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.546 ' CE1' HG12 ' A' ' 124' ' ' VAL . 16.5 m-85 -130.96 138.23 49.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.9 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.529 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 84.1 m-85 -52.44 -35.24 51.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -118.12 167.0 11.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.876 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.582 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 9.3 tttp -77.19 -41.7 40.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.878 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.423 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -57.98 -59.44 5.25 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.88 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.423 ' C ' ' O ' ' A' ' 130' ' ' TRP . 45.3 m-20 -35.91 -39.91 0.18 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.879 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.423 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -77.79 -58.87 3.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.084 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -42.72 -54.78 3.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.859 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 56.3 t30 -43.34 -41.42 4.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.881 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.403 ' O ' ' N ' ' A' ' 137' ' ' GLN . . . -75.72 -58.15 3.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.102 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 136' ' ' ILE . . . . . 0.461 HD11 HG22 ' A' ' 80' ' ' VAL . 98.2 mt -38.92 -30.41 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.152 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 137' ' ' GLN . . . . . 0.403 ' N ' ' O ' ' A' ' 135' ' ' ALA . 34.4 mt-30 -87.49 -65.75 0.98 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.916 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 10.3 mm-40 -61.54 -61.03 2.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.955 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.652 ' HE3' HD11 ' A' ' 149' ' ' ILE . 79.0 mmm -49.18 -35.62 17.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.929 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -57.56 116.38 8.02 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.474 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 99.89 -19.09 54.69 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.45 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -66.38 177.18 1.56 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.788 0.328 . . . . 0.0 110.903 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' TRP . . . . . 0.459 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 13.8 m95 -115.04 127.11 55.44 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.908 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.632 HD23 HD22 ' A' ' 85' ' ' LEU . 55.5 tp -121.28 123.88 43.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.926 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 0.964 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 73.65 -11.59 5.54 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.532 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 130.25 -7.18 6.0 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.485 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 67.9 mtt180 -130.35 144.93 51.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.767 0.318 . . . . 0.0 110.902 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.459 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 31.2 mt-30 -53.57 158.21 1.9 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.933 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.652 HD11 ' HE3' ' A' ' 139' ' ' MET . 21.2 pt -131.7 145.29 35.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.129 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.492 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 19.3 ptp180 -106.8 120.14 41.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.874 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 42.4 p -112.71 127.85 56.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.121 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -153.4 166.2 33.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.868 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 23.2 m95 -62.58 136.81 58.07 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.953 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -97.88 149.85 21.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.108 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 44.1 p -138.6 154.35 48.69 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.128 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -82.59 166.98 18.76 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.889 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 28.4 ttpt -59.6 137.07 89.61 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.588 0.708 . . . . 0.0 110.909 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 148.38 65.08 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.723 2.282 . . . . 0.0 112.317 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 156.69 62.79 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.689 2.259 . . . . 0.0 112.352 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -49.27 150.88 2.83 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.542 0.687 . . . . 0.0 111.139 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -50.2 0.49 Allowed 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.68 2.254 . . . . 0.0 112.323 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 21.3 tttm -169.43 152.7 4.91 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.879 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 68.5 m -79.42 166.06 22.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.863 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 60.1 p -64.45 136.81 57.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.103 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -119.78 20.53 12.25 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.865 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -57.56 99.87 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.914 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 8.9 t -157.13 118.15 3.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.842 -179.748 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -111.86 87.77 2.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.868 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 90.3 m -98.22 85.67 3.5 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.175 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 7.7 ptmm? -166.94 141.39 3.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.916 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 17.7 mm-40 -125.6 120.63 31.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.938 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 9.0 t -148.04 162.59 39.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.846 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 140.79 69.8 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.503 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 174' ' ' PRO . . . . . 0.431 ' O ' ' C ' ' A' ' 175' ' ' SER . 53.6 Cg_endo -69.75 -50.65 0.45 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.651 2.234 . . . . 0.0 112.354 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 175' ' ' SER . . . . . 0.431 ' C ' ' O ' ' A' ' 174' ' ' PRO . 61.7 p 35.19 39.75 0.05 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.846 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 51.8 p -96.37 115.86 28.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.805 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.462 179.997 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 61.4 m -129.88 161.54 30.59 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.875 0.369 . . . . 0.0 110.886 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 56.6 p -84.19 153.51 23.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.852 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 115.58 142.86 7.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.536 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 51.6 p -82.19 172.6 12.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.842 0.353 . . . . 0.0 110.867 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 70.8 m -104.81 -54.78 2.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.823 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 81.99 108.18 0.4 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.491 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 13.7 mp0 -71.36 84.29 0.79 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.897 0.38 . . . . 0.0 110.924 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 14.0 ptpt -106.42 174.01 6.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.868 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 74.0 tttt -59.15 -63.78 1.18 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.883 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -45.81 155.87 0.16 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.891 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.5 p -97.7 86.34 3.78 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.137 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 59.7 m -108.89 132.09 54.38 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.837 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 49.9 t30 55.8 31.51 17.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.865 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 20.5 m170 -100.03 168.65 9.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.894 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.577 ' CE1' ' HD3' ' A' ' 129' ' ' LYS . 90.9 m-85 -115.68 105.93 13.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.903 -179.937 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.544 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.1 OUTLIER -81.75 150.18 28.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 55.3 t -124.75 146.28 30.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.137 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.2 t80 -98.07 134.39 41.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.919 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.7 HG12 HD21 ' A' ' 85' ' ' LEU . 4.3 t -130.42 130.13 65.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.109 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.495 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -136.24 179.26 18.05 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.446 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.402 ' O ' ' O ' ' A' ' 148' ' ' GLN . 5.4 t70 56.39 53.63 8.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.852 0.358 . . . . 0.0 110.845 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.7 HD21 HG12 ' A' ' 82' ' ' VAL . 15.8 mt -109.94 131.14 55.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -53.01 154.91 4.74 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.646 0.736 . . . . 0.0 110.873 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -4.19 13.53 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.653 2.236 . . . . 0.0 112.348 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLU . . . . . 0.412 ' O ' ' HG3' ' A' ' 88' ' ' GLU . 1.4 tt0 -97.58 -28.81 13.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.857 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.838 HD11 ' HA3' ' A' ' 145' ' ' GLY . 47.9 mm -57.73 132.52 22.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.137 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.1 t -119.38 166.8 12.59 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.161 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.522 HG22 ' CE ' ' A' ' 95' ' ' LYS . 95.8 m -39.79 -49.02 2.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.169 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -56.04 -57.6 11.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.852 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -39.59 -56.8 1.6 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.483 ' CD1' HG22 ' A' ' 109' ' ' VAL . 16.5 mt -48.79 -59.44 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.132 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.717 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 20.8 mtmt -47.41 -38.93 14.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.914 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.97 -37.01 85.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.059 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -68.05 -52.9 30.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.112 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 22.2 m-85 -89.27 6.91 38.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.93 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.778 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -59.48 -59.79 12.71 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.618 0.723 . . . . 0.0 111.082 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.778 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.6 Cg_endo -69.76 -0.92 7.62 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.72 2.28 . . . . 0.0 112.322 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -101.49 12.51 37.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.887 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.419 ' HA3' ' CG ' ' A' ' 131' ' ' ASP . . . 129.59 155.72 8.56 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.482 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.427 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 28.7 mtt180 -65.7 126.16 27.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.808 0.337 . . . . 0.0 110.841 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.436 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 13.8 mt -100.27 140.29 19.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.157 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 5.4 t -112.05 -62.09 1.62 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.883 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -100.81 102.91 14.09 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.867 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.529 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -130.32 125.5 34.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.083 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 15.2 ptt180 -160.81 154.98 22.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.886 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.483 HG22 ' CD1' ' A' ' 94' ' ' ILE . 60.1 t -105.2 119.14 53.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.11 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.611 HG21 ' CD2' ' A' ' 121' ' ' TYR . 61.1 t -53.12 133.06 15.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.126 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' LYS . . . . . 0.423 ' HG2' ' C ' ' A' ' 117' ' ' LYS . 37.0 mttm -134.14 149.25 51.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.94 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.548 ' OD2' ' HB3' ' A' ' 114' ' ' ALA . 1.7 t70 -62.02 132.0 51.46 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.863 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 26.0 ptm -80.47 1.36 29.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.883 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' ALA . . . . . 0.548 ' HB3' ' OD2' ' A' ' 112' ' ' ASP . . . -98.35 -29.11 13.34 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.084 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 21.2 p -131.14 -34.28 1.45 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.15 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 96.66 17.36 33.51 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.455 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' LYS . . . . . 0.423 ' C ' ' HG2' ' A' ' 111' ' ' LYS . 42.1 mttm -85.79 154.14 21.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.815 0.34 . . . . 0.0 110.875 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 1.9 m -60.09 111.1 1.38 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.82 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.415 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 31.6 mttt -59.25 -42.8 92.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.908 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 138.36 -41.72 1.34 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.532 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.611 ' CD2' HG21 ' A' ' 110' ' ' VAL . 7.4 p90 -99.99 151.12 21.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.923 0.392 . . . . 0.0 110.922 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -130.66 178.04 17.94 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.554 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -126.52 135.72 51.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.887 0.375 . . . . 0.0 110.876 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.549 HG12 ' CE1' ' A' ' 126' ' ' PHE . 61.0 t -136.48 122.18 28.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.118 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 12.6 m -105.34 149.92 25.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.808 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.549 ' CE1' HG12 ' A' ' 124' ' ' VAL . 16.3 m-85 -131.06 137.85 49.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.906 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.427 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 78.3 m-85 -58.87 -36.67 75.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.841 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 13.6 m-20 -118.04 149.78 40.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.904 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.577 ' HD3' ' CE1' ' A' ' 78' ' ' PHE . 38.5 tptt -60.77 -63.39 1.31 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.463 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.9 OUTLIER -33.21 -57.92 0.39 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.917 179.921 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.419 ' CG ' ' HA3' ' A' ' 102' ' ' GLY . 80.7 m-20 -40.59 -49.26 2.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.867 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -67.1 -60.47 2.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.123 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -41.05 -61.62 0.96 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.916 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 44.1 t-20 -38.88 -52.91 1.75 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.485 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -63.55 -61.44 2.33 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.122 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 86.7 mt -37.01 -36.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.128 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 27.4 mt-30 -85.53 -60.1 2.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.876 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -64.85 -59.6 4.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.485 ' N ' ' O ' ' A' ' 135' ' ' ALA . 48.0 mmm -53.48 -39.92 64.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.939 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -55.66 116.59 7.31 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.49 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 100.65 -12.66 59.6 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.494 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 48.6 mm-40 -73.28 172.57 10.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.75 0.31 . . . . 0.0 110.928 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 143' ' ' TRP . . . . . . . . . . . . . 15.7 m95 -109.43 126.41 53.44 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.877 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.536 HD23 HD22 ' A' ' 85' ' ' LEU . 57.3 tp -123.56 125.19 44.41 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.913 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 0.838 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 72.82 -9.25 6.58 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.48 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 127.47 -7.7 7.03 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.487 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 28.2 mtt-85 -130.34 145.89 51.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.789 0.328 . . . . 0.0 110.86 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.402 ' O ' ' O ' ' A' ' 84' ' ' ASP . 18.1 mt-30 -52.58 166.54 0.19 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.952 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.422 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 24.3 pt -137.42 146.28 28.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.066 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.495 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 16.4 ptp180 -108.07 114.86 29.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.89 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 80.9 p -110.19 122.57 47.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.134 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -150.58 168.48 24.14 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.904 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 153' ' ' TRP . . . . . 0.498 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 55.1 m95 -69.55 123.2 20.68 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.916 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -71.12 -53.6 14.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.095 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 62.7 p -50.75 154.89 1.26 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.162 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 18.1 ptt85 -134.69 144.0 47.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.9 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 13.5 pttp -79.4 148.71 70.88 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.552 0.691 . . . . 0.0 110.919 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 149.5 66.72 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.678 2.252 . . . . 0.0 112.344 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 175.57 7.89 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.721 2.28 . . . . 0.0 112.324 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.65 ' HB1' ' HD2' ' A' ' 161' ' ' PRO . . . -121.83 162.03 38.99 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.603 0.716 . . . . 0.0 111.112 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 161' ' ' PRO . . . . . 0.65 ' HD2' ' HB1' ' A' ' 160' ' ' ALA . 53.4 Cg_endo -69.79 123.48 10.13 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.69 2.26 . . . . 0.0 112.348 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 5.1 mtmp? -69.79 125.7 27.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 37.5 t -91.34 112.11 23.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.902 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 21.2 p -122.1 129.21 52.16 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.124 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 165' ' ' TYR . . . . . 0.426 ' CD1' ' C ' ' A' ' 165' ' ' TYR . 4.6 p90 -152.2 164.52 37.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.976 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -159.17 134.21 8.23 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.907 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 47.5 t -171.78 131.37 0.69 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.864 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 28.3 m120 -134.94 156.16 49.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.848 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.3 m -150.38 126.37 10.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.148 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.54 118.69 8.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -118.42 135.09 54.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.911 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 8.2 t -173.42 150.12 1.79 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.828 -179.794 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 147.09 65.88 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.466 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 156.65 62.82 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.713 2.275 . . . . 0.0 112.348 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 9.5 t -174.45 166.84 3.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.83 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 49.4 p -165.72 106.89 0.74 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.867 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.28 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.461 179.99 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.466 -0.254 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.7 m -40.72 120.17 1.24 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.883 0.373 . . . . 0.0 110.825 -179.746 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 74.0 m -142.99 169.44 17.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.858 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -160.58 -157.15 8.53 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.492 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 25.7 t -78.85 127.92 32.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.909 0.385 . . . . 0.0 110.857 -179.75 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 48.7 m -133.63 79.82 1.84 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.821 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 129.13 95.01 0.78 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.477 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 61.8 mm-40 -61.27 -45.83 92.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.845 0.355 . . . . 0.0 110.874 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.0 53.68 2.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.874 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -113.18 176.69 4.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.941 179.825 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 23.3 t0 -53.05 137.8 32.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.84 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 61.8 p -78.07 53.43 1.19 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 22.5 t -89.09 -38.36 14.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.86 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 26.5 m-20 -80.53 -34.19 35.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.844 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 2.4 m-70 -64.54 144.33 57.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.848 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.564 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 93.0 m-85 -96.88 124.52 40.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.875 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.51 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 0.2 OUTLIER -89.1 150.4 22.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 179.998 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.55 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 46.0 t -125.45 145.36 32.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.131 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.413 ' CE2' ' HG2' ' A' ' 150' ' ' ARG . 17.8 t80 -91.22 132.72 35.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.526 HG12 HD21 ' A' ' 85' ' ' LEU . 16.8 t -128.57 128.91 68.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.073 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -136.52 -177.96 15.42 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.54 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 55.11 54.25 9.1 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.809 0.338 . . . . 0.0 110.843 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.526 HD21 HG12 ' A' ' 82' ' ' VAL . 17.0 mt -110.89 130.11 55.68 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.937 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.18 154.22 5.84 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.664 0.745 . . . . 0.0 110.843 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -6.21 18.08 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.699 2.266 . . . . 0.0 112.29 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -100.29 -15.54 18.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.898 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.708 HD11 ' HA3' ' A' ' 145' ' ' GLY . 34.3 mm -69.57 134.25 30.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.141 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.0 t -119.67 168.0 11.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.123 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.648 HG22 ' CE ' ' A' ' 95' ' ' LYS . 98.8 m -38.82 -57.76 1.18 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.111 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 29.5 mt-10 -46.44 -59.36 3.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.942 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.437 ' CB ' HG23 ' A' ' 89' ' ' ILE . 0.5 OUTLIER -38.82 -56.19 1.4 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.899 179.932 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.626 ' CD1' HG22 ' A' ' 109' ' ' VAL . 10.7 mt -49.55 -60.77 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.167 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.648 ' CE ' HG22 ' A' ' 91' ' ' THR . 24.3 mtmt -45.67 -39.65 8.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.887 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' ALA . . . . . 0.435 ' HB3' ' O ' ' A' ' 93' ' ' ASP . . . -59.94 -37.84 80.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.106 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.636 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -66.35 -52.98 41.48 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.103 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.467 ' C ' HD11 ' A' ' 104' ' ' ILE . 11.8 m-85 -92.18 18.66 7.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.852 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.792 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -69.33 -60.44 4.08 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.581 0.705 . . . . 0.0 111.136 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.792 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.78 -0.83 7.49 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.662 2.241 . . . . 0.0 112.321 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -99.78 5.17 45.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.89 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.79 137.88 3.91 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.493 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.408 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 24.3 mtt-85 -49.89 125.1 11.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.741 0.305 . . . . 0.0 110.906 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.467 HD11 ' C ' ' A' ' 98' ' ' PHE . 11.1 mt -98.77 138.88 22.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.142 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.1 t -107.33 -62.94 1.35 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.858 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -100.51 109.66 21.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.905 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.508 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -138.25 129.13 26.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.13 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.1 ptm180 -162.57 154.72 18.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.873 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.626 HG22 ' CD1' ' A' ' 94' ' ' ILE . 41.3 t -105.33 117.38 50.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.133 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.531 HG21 ' CE2' ' A' ' 121' ' ' TYR . 48.8 t -49.84 138.04 5.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.125 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 111' ' ' LYS . . . . . 0.432 ' C ' ' HG3' ' A' ' 119' ' ' LYS . 52.6 mttt -138.16 154.63 49.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -69.16 138.55 54.24 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.836 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 13.5 ptp -85.75 3.45 41.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.862 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -102.64 -35.94 8.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.083 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 52.3 p -123.17 -35.17 3.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.098 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 90.86 26.61 21.74 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.481 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' LYS . . . . . 0.412 ' O ' ' C ' ' A' ' 118' ' ' SER . 86.1 mttt -97.73 136.39 38.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.769 0.318 . . . . 0.0 110.896 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 118' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 117' ' ' LYS . 2.2 m -37.7 111.76 0.18 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.853 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.491 ' HD2' HG12 ' A' ' 110' ' ' VAL . 9.3 mttm -61.82 -41.82 98.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.895 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.446 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 138.62 -46.75 0.96 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.531 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.531 ' CE2' HG21 ' A' ' 110' ' ' VAL . 10.1 p90 -100.04 148.65 24.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.996 0.427 . . . . 0.0 110.909 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -129.8 -177.31 14.81 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.503 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -127.47 139.29 52.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.854 0.359 . . . . 0.0 110.925 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.647 HG12 ' CE1' ' A' ' 126' ' ' PHE . 58.3 t -138.83 120.65 16.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.146 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' SER . . . . . 0.408 ' O ' HG23 ' A' ' 104' ' ' ILE . 42.3 m -106.65 149.81 26.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.853 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.647 ' CE1' HG12 ' A' ' 124' ' ' VAL . 2.1 m-85 -130.85 144.59 51.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.873 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.408 ' CE2' ' HB3' ' A' ' 103' ' ' ARG . 22.3 m-85 -56.38 -43.49 79.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.889 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 19.2 m120 -109.35 163.69 13.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.901 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.564 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 20.3 tptm -71.39 -59.55 2.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.902 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.417 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.8 OUTLIER -40.57 -57.39 1.86 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.9 179.922 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 130' ' ' TRP . 71.6 m-20 -35.86 -45.76 0.42 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.875 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.55 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -75.8 -58.27 3.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.065 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -44.16 -59.5 2.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.883 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -41.79 -44.49 3.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.891 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.47 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -69.23 -56.78 6.58 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.107 179.834 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 86.1 mt -38.73 -35.5 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.106 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 20.8 mt-30 -87.18 -57.07 3.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.892 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 37.3 mm-40 -68.3 -61.97 1.6 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.93 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.899 ' HE3' HD11 ' A' ' 149' ' ' ILE . 64.1 mmm -51.92 -38.93 58.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.858 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.44 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -57.55 93.51 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.492 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 119.44 13.17 6.39 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.508 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 87.4 mm-40 -94.27 169.66 10.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.753 0.311 . . . . 0.0 110.962 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 143' ' ' TRP . . . . . 0.42 ' NE1' ' HG3' ' A' ' 148' ' ' GLN . 17.2 m95 -106.3 109.47 21.41 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.899 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.636 HD13 ' HB2' ' A' ' 97' ' ' ALA . 60.9 tp -104.15 129.58 51.87 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.926 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 0.708 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.74 -77.0 0.4 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.475 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -156.33 15.93 0.41 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.464 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 43.2 mtp85 -157.99 161.01 38.09 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.758 0.313 . . . . 0.0 110.856 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.42 ' HG3' ' NE1' ' A' ' 143' ' ' TRP . 28.9 mt-30 -64.25 167.08 7.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.923 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.899 HD11 ' HE3' ' A' ' 139' ' ' MET . 21.1 pt -136.26 152.11 29.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.147 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.413 ' HG2' ' CE2' ' A' ' 81' ' ' PHE . 2.8 ttt180 -109.29 129.72 55.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.892 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.44 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 44.4 p -124.55 137.54 54.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.149 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 4.2 t30 -160.61 174.09 14.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.919 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' TRP . . . . . 0.546 ' CH2' ' CE ' ' A' ' 129' ' ' LYS . 4.6 m95 -69.15 128.27 36.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.898 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 154' ' ' ALA . . . . . 0.432 ' O ' ' C ' ' A' ' 155' ' ' THR . . . -96.66 123.59 40.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.066 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.432 ' C ' ' O ' ' A' ' 154' ' ' ALA . 16.3 p 34.95 41.42 0.06 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.115 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 4.8 tpt180 -139.5 150.95 45.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.879 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 15.7 mmmt -125.36 141.49 38.96 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.57 0.7 . . . . 0.0 110.884 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 157.74 59.32 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.651 2.234 . . . . 0.0 112.311 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 146.53 60.35 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.698 2.265 . . . . 0.0 112.329 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.626 ' HB1' ' HD2' ' A' ' 161' ' ' PRO . . . -46.07 161.65 0.26 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.575 0.702 . . . . 0.0 111.074 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 161' ' ' PRO . . . . . 0.626 ' HD2' ' HB1' ' A' ' 160' ' ' ALA . 53.6 Cg_endo -69.74 -19.6 36.02 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.7 2.267 . . . . 0.0 112.328 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 40.5 tttt -125.03 81.81 2.0 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.93 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 7.6 t -163.8 133.17 3.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.84 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 15.0 t -112.04 130.11 55.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.134 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 16.4 p90 -139.96 141.79 36.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.93 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 13.8 tt0 -172.05 147.05 2.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.911 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 7.0 t -132.32 164.2 26.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.892 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 37.7 t-20 -134.08 96.0 3.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.842 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 1.7 t -172.88 141.52 1.03 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.117 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 1.1 ttmp? -170.68 136.12 1.2 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.86 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 48.9 mt-30 -122.24 170.74 9.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.889 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 55.7 p -157.07 112.34 2.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.838 -179.828 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 165.11 146.18 4.68 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.506 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 174' ' ' PRO . . . . . 0.421 ' O ' ' C ' ' A' ' 175' ' ' SER . 53.9 Cg_endo -69.77 -20.66 34.51 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.724 2.283 . . . . 0.0 112.331 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 175' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 174' ' ' PRO . 8.0 t -36.71 137.37 0.31 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.841 -179.841 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 36.0 t -66.78 -49.87 64.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.863 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.489 -179.962 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 82.7 p -116.68 109.02 16.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.863 0.363 . . . . 0.0 110.844 -179.712 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 20.8 m -51.78 164.89 0.21 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.854 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 138.29 113.16 1.14 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.501 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 46.2 m -86.78 153.36 21.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.93 0.395 . . . . 0.0 110.793 -179.683 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 71.6 m -85.55 -44.77 12.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.884 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -171.12 108.49 0.29 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.488 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 15.1 tt0 -103.49 -45.12 4.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.893 0.378 . . . . 0.0 110.915 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.1 tppt? -66.04 122.41 17.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.94 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.23 -42.48 99.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.88 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -64.24 131.22 46.72 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.92 179.827 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.6 p -90.76 88.84 7.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.15 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 37.2 m -108.77 -58.83 1.96 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.829 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 72.4 m-20 -56.73 -36.4 69.69 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.896 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -67.6 137.84 55.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.879 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -87.65 121.63 30.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.862 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' HIS . . . . . 0.404 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.9 OUTLIER -82.02 135.24 35.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.872 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 38.9 t -114.2 144.57 21.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.124 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.694 ' CD2' ' ND2' ' A' ' 152' ' ' ASN . 11.9 t80 -96.74 138.28 34.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.862 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.776 HG12 HD21 ' A' ' 85' ' ' LEU . 3.2 t -137.17 134.46 47.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.151 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -142.3 -173.1 14.04 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.456 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 56.93 29.3 16.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.816 0.341 . . . . 0.0 110.86 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.776 HD21 HG12 ' A' ' 82' ' ' VAL . 14.6 mt -86.31 132.25 34.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.956 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -53.87 155.3 6.2 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.639 0.733 . . . . 0.0 110.863 -179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.85 -15.96 36.98 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.688 2.259 . . . . 0.0 112.291 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -92.0 -7.14 49.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.873 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.825 HD11 ' HA3' ' A' ' 145' ' ' GLY . 33.2 mm -74.98 138.88 20.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.155 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.8 t -119.88 -176.71 3.24 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.133 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.6 ' HA ' HG23 ' A' ' 109' ' ' VAL . 84.9 m -53.77 -57.25 11.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.125 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.439 ' O ' ' C ' ' A' ' 93' ' ' ASP . 70.9 mt-10 -48.67 -58.48 4.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.914 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.439 ' C ' ' O ' ' A' ' 92' ' ' GLU . 2.9 m-20 -34.48 -55.28 0.54 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.841 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.605 HD11 HG22 ' A' ' 109' ' ' VAL . 4.5 mt -51.76 -60.34 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.152 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.638 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 25.6 mtmt -48.85 -41.93 34.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.899 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.68 -29.13 69.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.083 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.442 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -75.67 -53.74 8.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.131 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.423 ' C ' HD11 ' A' ' 104' ' ' ILE . 27.2 m-85 -86.82 3.49 45.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.915 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.776 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -56.5 -60.29 9.62 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.587 0.708 . . . . 0.0 111.154 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.776 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.3 Cg_endo -69.76 -0.81 7.45 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.708 2.272 . . . . 0.0 112.353 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.584 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 72.0 m-85 -99.77 -1.2 38.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 142.17 156.07 6.67 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.507 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.476 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 17.5 mtm105 -62.6 122.28 15.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.743 0.306 . . . . 0.0 110.871 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.452 ' CG2' HG13 ' A' ' 124' ' ' VAL . 13.9 mt -100.39 138.21 25.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.176 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.467 ' HB2' ' CZ ' ' A' ' 127' ' ' PHE . 47.8 t -112.92 -59.61 1.99 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.422 ' HB3' ' CB ' ' A' ' 125' ' ' SER . 25.9 t70 -100.63 99.78 10.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.449 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -132.08 124.94 30.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.081 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.446 ' HA ' HG23 ' A' ' 91' ' ' THR . 10.3 ptp180 -159.36 153.32 23.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 -179.904 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.605 HG22 HD11 ' A' ' 94' ' ' ILE . 90.0 t -100.93 124.12 54.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.111 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.955 HG12 ' HG3' ' A' ' 119' ' ' LYS . 53.4 t -59.64 143.96 13.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.118 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' LYS . . . . . 0.451 ' C ' ' HG2' ' A' ' 119' ' ' LYS . 74.5 mttt -140.7 153.87 46.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.492 ' N ' ' HG2' ' A' ' 119' ' ' LYS . 7.9 t0 -60.22 127.38 31.54 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.838 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 19.9 ptm -80.12 2.81 22.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.867 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -102.66 -38.38 7.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.074 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 42.1 p -119.9 -33.82 3.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.181 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 95.35 30.2 8.35 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.444 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 34.5 mttm -99.01 164.48 12.16 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.778 0.323 . . . . 0.0 110.903 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 36.4 t -56.62 115.05 2.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.907 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.955 ' HG3' HG12 ' A' ' 110' ' ' VAL . 0.5 OUTLIER -68.33 -38.56 81.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.909 179.962 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 126.39 -46.1 1.11 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.433 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.528 ' CE2' HG21 ' A' ' 110' ' ' VAL . 8.3 p90 -100.32 151.33 21.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.927 0.394 . . . . 0.0 110.934 -179.794 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -132.58 171.55 21.56 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.473 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -121.06 138.85 53.99 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.859 0.361 . . . . 0.0 110.907 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.661 HG12 ' CE1' ' A' ' 126' ' ' PHE . 93.9 t -138.91 112.26 6.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.103 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 125' ' ' SER . . . . . 0.422 ' CB ' ' HB3' ' A' ' 106' ' ' ASP . 2.7 t -97.89 148.64 23.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.83 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.661 ' CE1' HG12 ' A' ' 124' ' ' VAL . 3.6 m-85 -127.06 148.38 50.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.882 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.476 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 77.9 m-85 -63.27 -34.66 78.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.916 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 25.4 m120 -115.93 168.88 9.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.87 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 66.8 tttt -81.0 -47.88 13.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.427 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -48.57 -62.47 1.48 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.935 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 130' ' ' TRP . 44.4 m-20 -35.87 -54.17 0.74 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.811 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -61.39 -67.08 0.44 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.107 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -37.26 -57.87 0.86 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 42.4 t-20 -41.01 -52.89 3.09 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.864 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.96 -56.71 13.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.098 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 92.3 mt -38.17 -35.82 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.175 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -85.26 -63.53 1.31 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.899 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 22.2 mt-30 -59.56 -61.9 2.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.584 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 81.2 mmm -52.19 -35.23 48.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.913 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.401 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -54.94 99.43 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.522 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 111.59 -20.7 22.42 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.488 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 10.8 mm-40 -56.55 -179.92 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.791 0.329 . . . . 0.0 110.927 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' TRP . . . . . 0.486 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 13.4 m95 -116.86 124.72 50.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.927 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.592 HD23 HD22 ' A' ' 85' ' ' LEU . 47.2 tp -123.88 128.75 49.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.862 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 0.825 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.54 -3.69 11.15 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.516 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 120.91 -13.5 9.79 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.496 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 60.4 mtt180 -122.85 147.4 46.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.727 0.299 . . . . 0.0 110.88 -179.866 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.486 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 32.6 mt-30 -55.45 165.57 0.77 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.926 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.423 HG21 ' HB3' ' A' ' 144' ' ' LEU . 19.5 pt -138.15 151.34 25.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.117 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 27.0 ptt180 -113.99 109.1 17.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.906 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.401 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 69.3 p -106.54 141.43 37.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.167 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 152' ' ' ASN . . . . . 0.694 ' ND2' ' CD2' ' A' ' 81' ' ' PHE . 7.4 p30 -167.15 -178.95 4.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.876 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 31.2 m95 -74.73 135.37 41.79 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.916 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -80.34 -51.98 8.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.093 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.6 t -121.62 146.04 47.38 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.162 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -159.32 161.14 35.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.829 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.473 ' CG ' ' HD2' ' A' ' 158' ' ' PRO . 53.6 tttp -124.18 139.25 32.31 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.594 0.712 . . . . 0.0 110.853 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 158' ' ' PRO . . . . . 0.473 ' HD2' ' CG ' ' A' ' 157' ' ' LYS . 53.5 Cg_endo -69.8 145.23 56.28 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.722 2.282 . . . . 0.0 112.335 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -172.09 0.54 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.686 2.257 . . . . 0.0 112.361 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -97.02 147.81 33.46 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.62 0.724 . . . . 0.0 111.069 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 -50.67 0.45 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.667 2.245 . . . . 0.0 112.367 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.449 ' HE3' ' CG2' ' A' ' 164' ' ' THR . 6.2 tmtm? -174.95 147.78 0.98 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.87 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 163' ' ' SER . . . . . 0.408 ' N ' ' HD3' ' A' ' 162' ' ' LYS . 15.6 t -137.41 136.33 37.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.83 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 164' ' ' THR . . . . . 0.449 ' CG2' ' HE3' ' A' ' 162' ' ' LYS . 33.4 p -142.48 177.68 8.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.15 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 3.9 t80 -112.98 146.1 39.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.933 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -161.53 143.3 11.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.902 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 64.8 p -108.98 81.5 1.45 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.891 -179.809 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 44.7 t30 -113.89 40.47 2.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 91.7 m -149.92 121.27 7.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.163 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 18.0 tptp -163.45 146.19 10.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -172.49 159.08 4.42 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.922 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 40.0 t -112.17 -58.06 2.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.873 -179.769 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 67.4 82.86 0.13 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.513 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 115.76 4.25 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.726 2.284 . . . . 0.0 112.28 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 78.3 p -173.92 124.06 0.34 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.812 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 54.9 p -121.54 125.46 46.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.872 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.506 -179.929 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 31.3 t -64.84 98.66 0.29 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.837 0.351 . . . . 0.0 110.847 -179.72 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.8 m -169.81 139.55 1.97 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 161.66 97.03 0.11 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.468 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 13.8 t -94.43 84.43 4.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.915 0.388 . . . . 0.0 110.862 -179.788 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.7 p -166.47 115.54 0.91 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.886 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -147.77 139.97 8.13 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.469 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -125.82 168.99 13.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.846 0.355 . . . . 0.0 110.916 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.425 ' HG3' ' N ' ' A' ' 72' ' ' LYS . 0.1 OUTLIER -171.31 150.57 2.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.9 179.951 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.425 ' N ' ' HG3' ' A' ' 71' ' ' LYS . 29.2 mttm -79.51 -54.16 6.17 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.899 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -67.97 149.01 50.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.863 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 26.2 p -79.44 95.28 5.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.138 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.3 t -87.54 -57.64 2.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.887 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -121.47 52.47 1.23 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.909 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 21.6 m170 -108.67 156.35 19.67 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.835 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.45 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 47.0 m-85 -98.05 115.78 28.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.874 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 87.4 m-70 -89.3 140.49 29.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.851 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.461 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 41.5 t -118.1 138.76 47.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.073 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 15.5 t80 -92.89 135.49 34.09 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.878 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.859 HG12 HD21 ' A' ' 85' ' ' LEU . 3.7 t -137.58 109.51 6.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.118 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -123.21 -177.48 15.15 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.472 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.403 ' O ' ' O ' ' A' ' 148' ' ' GLN . 4.5 t70 63.83 36.45 10.4 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.859 0.362 . . . . 0.0 110.91 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.859 HD21 HG12 ' A' ' 82' ' ' VAL . 15.6 mt -91.7 170.54 9.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.912 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -90.01 155.4 47.33 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.672 0.749 . . . . 0.0 110.786 -179.835 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 -10.79 29.39 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.668 2.245 . . . . 0.0 112.338 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -96.5 -6.11 37.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.841 HD11 ' HA3' ' A' ' 145' ' ' GLY . 45.8 mm -79.09 136.38 23.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.116 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.6 t -118.96 164.7 15.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.19 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.737 ' HA ' HG23 ' A' ' 109' ' ' VAL . 35.8 m -40.24 -48.77 2.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.149 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 93' ' ' ASP . 32.7 mt-10 -55.64 -58.78 6.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.444 ' CB ' HG23 ' A' ' 89' ' ' ILE . 13.3 m-20 -34.78 -56.67 0.55 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.86 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.565 HD11 HG22 ' A' ' 109' ' ' VAL . 10.4 mt -49.26 -60.76 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.185 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.693 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 24.0 mtmt -46.69 -39.81 12.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.914 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -63.58 -30.77 71.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.103 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.656 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -73.92 -53.68 9.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.088 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.423 ' C ' HD11 ' A' ' 104' ' ' ILE . 22.3 m-85 -89.18 12.34 16.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.91 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.77 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -65.23 -60.07 8.56 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.661 0.743 . . . . 0.0 111.082 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.77 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.76 -0.77 7.4 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.616 2.211 . . . . 0.0 112.376 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.497 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 77.6 m-85 -99.65 -3.14 33.78 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.892 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 143.03 131.95 2.6 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.485 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 46.2 mtt85 -44.09 124.93 4.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.803 0.335 . . . . 0.0 110.875 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.475 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 14.1 mt -100.11 145.18 11.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.136 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.448 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 3.8 t -116.01 -61.94 1.66 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.851 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -100.57 99.47 10.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.83 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.418 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -132.92 127.18 33.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.483 ' HA ' HG23 ' A' ' 91' ' ' THR . 6.7 ptm180 -160.15 155.29 24.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.871 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.737 HG23 ' HA ' ' A' ' 91' ' ' THR . 96.4 t -107.06 120.35 58.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.138 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.578 HG21 ' CE2' ' A' ' 121' ' ' TYR . 66.8 t -54.33 124.66 7.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.159 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -123.72 148.74 46.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.877 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.472 ' O ' ' N ' ' A' ' 116' ' ' GLY . 24.1 t0 -56.88 121.61 10.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.871 179.817 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 8.2 ptp -73.11 -1.54 17.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.938 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -97.86 -42.52 7.52 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.134 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 29.1 p -115.75 -29.43 6.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.137 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 89.51 30.3 14.07 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.499 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 51.7 mttm -98.9 152.5 19.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.829 0.347 . . . . 0.0 110.899 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 7.8 t -60.29 110.75 1.32 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.831 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 50.9 mttt -62.73 -47.82 81.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.93 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.678 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 139.75 -38.98 1.56 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.463 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.578 ' CE2' HG21 ' A' ' 110' ' ' VAL . 25.3 p90 -100.09 144.04 29.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.953 0.406 . . . . 0.0 110.92 -179.81 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.81 175.07 21.52 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.545 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -121.85 139.93 53.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.912 0.387 . . . . 0.0 110.866 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.682 HG12 ' CE1' ' A' ' 126' ' ' PHE . 59.4 t -135.62 111.46 12.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.122 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.8 t -100.49 145.64 28.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.856 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.682 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.3 m-85 -124.93 162.0 25.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.896 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.448 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 22.1 m-85 -66.41 -48.17 70.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.875 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 78.6 m-20 -113.91 160.04 19.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.869 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.45 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 3.7 ttmt -63.22 -62.75 1.49 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.91 179.876 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.437 ' C ' ' O ' ' A' ' 129' ' ' LYS . 1.0 OUTLIER -35.16 -59.36 0.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.929 179.92 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.401 ' C ' ' O ' ' A' ' 130' ' ' TRP . 48.3 m-20 -37.58 -43.97 0.65 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.912 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.461 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -74.71 -59.16 2.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.099 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.7 mt-10 -40.53 -54.76 2.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.829 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -43.53 -45.37 6.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.423 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -71.95 -58.49 3.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.07 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 97.1 mt -38.44 -36.37 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.124 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 23.8 mt-30 -83.35 -63.63 1.32 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.891 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -62.92 -62.73 1.52 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.925 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.497 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 68.8 mmm -51.8 -41.32 61.62 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.913 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -55.13 103.75 0.23 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.486 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 100.5 21.15 13.28 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.498 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 9.5 mm100 -105.64 177.42 4.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.787 0.327 . . . . 0.0 110.905 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' TRP . . . . . . . . . . . . . 17.0 m95 -106.74 121.69 44.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.903 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.656 HD13 ' HB2' ' A' ' 97' ' ' ALA . 36.4 tp -121.53 127.78 51.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.924 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 0.841 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 73.54 -36.62 0.84 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.477 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 146' ' ' GLY . . . . . 0.425 ' H ' ' C ' ' A' ' 144' ' ' LEU . . . 160.2 -14.25 0.19 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.516 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 51.2 mtt180 -127.38 149.24 50.16 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.762 0.315 . . . . 0.0 110.838 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.403 ' O ' ' O ' ' A' ' 84' ' ' ASP . 38.8 mt-30 -53.89 169.35 0.16 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.915 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.509 HG22 HD23 ' A' ' 85' ' ' LEU . 33.8 pt -148.92 147.77 16.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.14 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 9.6 ptt180 -110.58 123.26 49.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.909 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 29.4 p -118.26 141.92 48.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.138 -179.9 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 152' ' ' ASN . . . . . 0.459 ' CG ' ' N ' ' A' ' 153' ' ' TRP . 5.4 t30 -165.08 166.91 18.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.904 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 153' ' ' TRP . . . . . 0.459 ' N ' ' CG ' ' A' ' 152' ' ' ASN . 11.2 m95 -56.51 112.25 1.22 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.934 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -51.23 -59.12 4.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.086 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 3.3 t -98.94 126.26 44.58 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.105 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 6.7 tpt85 -116.5 50.17 1.08 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.884 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 157' ' ' LYS . . . . . 0.423 ' CG ' ' HD2' ' A' ' 158' ' ' PRO . 44.2 tttm -63.97 140.26 97.83 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.581 0.705 . . . . 0.0 110.848 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 158' ' ' PRO . . . . . 0.423 ' HD2' ' CG ' ' A' ' 157' ' ' LYS . 54.0 Cg_endo -69.74 150.34 68.21 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.709 2.273 . . . . 0.0 112.336 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.82 -174.45 0.92 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.649 2.233 . . . . 0.0 112.346 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -137.9 147.62 57.31 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.597 0.713 . . . . 0.0 111.088 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.84 -28.19 25.17 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.691 2.26 . . . . 0.0 112.313 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 4.9 tppt? -50.06 124.59 10.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.886 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 5.4 t -108.25 -48.82 3.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.869 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 3.0 m 61.69 28.29 17.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.14 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -39.15 157.91 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.906 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? -166.85 144.93 5.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.908 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 98.7 p -149.63 126.13 10.91 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.848 -179.74 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 168' ' ' ASN . . . . . 0.409 ' OD1' ' N ' ' A' ' 169' ' ' THR . 4.0 t-20 -135.44 153.74 51.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.937 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.409 ' N ' ' OD1' ' A' ' 168' ' ' ASN . 58.6 m -113.45 91.96 3.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.108 -179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 8.4 tptm -124.52 128.12 48.48 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.941 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -62.63 147.37 49.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.89 -179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 16.9 t -72.5 95.95 1.87 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.853 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -73.07 174.13 47.31 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.464 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 97.55 0.65 Allowed 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.669 2.246 . . . . 0.0 112.337 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 32.5 t -55.59 165.89 0.76 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.89 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 1.5 t -89.0 150.2 22.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.874 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.503 -179.992 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 N-CA-C 112.478 -0.249 . . . . 0.0 112.478 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 51.6 p -63.94 141.15 58.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.925 0.393 . . . . 0.0 110.824 -179.684 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 24.0 m -120.91 133.42 55.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.887 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 139.3 139.57 3.81 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.52 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 8.1 t -45.92 136.58 6.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.835 0.35 . . . . 0.0 110.873 -179.733 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 3.6 m -62.35 162.46 9.95 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.854 -179.825 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -141.06 -117.45 1.37 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.446 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 10.4 mm100 -134.4 158.87 42.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.897 0.38 . . . . 0.0 110.91 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 33.7 ttmt -115.46 -47.34 2.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.924 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 2.5 ttmp? -53.56 -55.56 24.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.955 179.825 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -77.78 131.48 37.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.88 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 37.8 p -106.37 43.06 1.18 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.138 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 38.9 m -65.99 -45.43 81.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.844 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 40.1 t30 -105.55 46.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.877 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 6.7 m170 -121.07 157.54 29.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.855 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 -106.94 116.65 32.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.876 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 64.1 m-70 -90.55 161.51 15.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.913 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.423 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 49.5 t -137.64 135.83 46.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.159 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.439 ' CE2' ' HG3' ' A' ' 150' ' ' ARG . 17.9 t80 -87.63 132.41 34.09 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.899 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.846 HG12 HD21 ' A' ' 85' ' ' LEU . 6.5 t -132.38 110.0 15.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.116 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -117.74 -178.77 17.41 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.459 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.403 ' O ' ' O ' ' A' ' 148' ' ' GLN . 2.0 m-20 64.02 40.11 7.4 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.874 0.368 . . . . 0.0 110.859 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.846 HD21 HG12 ' A' ' 82' ' ' VAL . 9.4 mt -102.85 129.56 49.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.901 -179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.1 t -52.92 154.37 5.14 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.671 0.748 . . . . 0.0 110.832 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -4.23 13.6 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.636 2.224 . . . . 0.0 112.356 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' GLU . . . . . 0.401 ' O ' ' HG3' ' A' ' 88' ' ' GLU . 1.3 tt0 -95.71 -29.77 14.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 1.014 HD11 ' HA3' ' A' ' 145' ' ' GLY . 48.3 mm -57.9 136.64 20.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.139 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.3 t -117.18 164.05 15.36 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.145 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.549 ' HA ' HG23 ' A' ' 109' ' ' VAL . 16.7 m -40.78 -39.63 1.15 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.154 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 93' ' ' ASP . 29.5 mt-10 -61.92 -59.71 4.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.61 ' CB ' HG23 ' A' ' 89' ' ' ILE . 0.6 OUTLIER -36.78 -56.59 0.84 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.86 -179.988 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.557 HD11 HG22 ' A' ' 109' ' ' VAL . 6.3 mt -48.19 -58.06 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.131 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.634 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 23.9 mtmt -49.65 -38.95 34.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.908 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.17 -31.37 72.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.081 179.824 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.498 ' HB1' ' HE1' ' A' ' 139' ' ' MET . . . -72.78 -46.84 51.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.105 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.413 ' C ' HD11 ' A' ' 104' ' ' ILE . 20.1 m-85 -97.16 11.77 35.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.941 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.77 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -63.8 -59.73 10.8 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.531 0.681 . . . . 0.0 111.109 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.77 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.4 Cg_endo -69.77 -0.7 7.3 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.717 2.278 . . . . 0.0 112.315 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' PHE . . . . . 0.598 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 62.6 m-85 -99.64 -0.11 40.93 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.899 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 139.7 138.31 3.61 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.532 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.489 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 13.7 mtt85 -48.03 125.09 8.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.782 0.325 . . . . 0.0 110.862 -179.854 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.476 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 17.9 mt -100.02 138.73 23.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.102 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.453 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.3 t -111.9 -59.14 2.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.835 -179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.457 ' HB3' ' CB ' ' A' ' 125' ' ' SER . 23.2 t70 -100.33 100.32 11.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.888 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.546 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -133.6 124.93 27.72 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.117 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.475 ' HD3' ' N ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -161.67 155.59 21.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 -179.889 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.557 HG22 HD11 ' A' ' 94' ' ' ILE . 76.5 t -106.14 117.4 51.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.147 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.798 HG12 ' HG3' ' A' ' 119' ' ' LYS . 60.2 t -47.36 141.33 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.13 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 47.6 mttt -139.33 151.01 46.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.879 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.434 ' O ' ' N ' ' A' ' 116' ' ' GLY . 25.7 t0 -63.74 122.95 17.65 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.889 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 27.9 ptm -72.49 -6.61 44.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.878 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -96.74 -48.43 5.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.111 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 45.4 p -100.75 -32.19 10.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.116 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.434 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 86.71 24.13 39.89 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.452 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 44.8 mtmt -98.43 168.02 10.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.79 0.329 . . . . 0.0 110.917 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 15.8 t -64.37 114.26 4.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.826 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.798 ' HG3' HG12 ' A' ' 110' ' ' VAL . 27.3 mmtt -63.83 -47.25 81.54 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.887 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.473 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 139.38 -46.91 0.93 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.479 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.664 ' CE2' HG21 ' A' ' 110' ' ' VAL . 12.7 p90 -100.14 146.28 27.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.948 0.404 . . . . 0.0 110.891 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -128.11 176.94 17.91 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.445 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -122.56 141.41 51.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.86 0.362 . . . . 0.0 110.907 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.686 HG12 ' CE1' ' A' ' 126' ' ' PHE . 56.8 t -137.63 122.3 23.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.112 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 125' ' ' SER . . . . . 0.457 ' CB ' ' HB3' ' A' ' 106' ' ' ASP . 4.9 t -112.19 140.79 46.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.877 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.686 ' CE1' HG12 ' A' ' 124' ' ' VAL . 27.8 m-85 -121.53 147.97 45.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.843 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.489 ' CE2' ' HB3' ' A' ' 103' ' ' ARG . 21.6 m-85 -55.88 -49.8 72.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.89 -179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 48.9 m-20 -99.47 166.73 11.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.886 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.461 ' HE3' ' CZ2' ' A' ' 153' ' ' TRP . 45.5 tptt -75.61 -45.78 35.53 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.863 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.417 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.9 OUTLIER -55.78 -54.56 42.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.918 179.915 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 130' ' ' TRP . 60.5 m-20 -35.67 -43.24 0.27 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.883 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.504 ' HB2' ' CD1' ' A' ' 126' ' ' PHE . . . -77.81 -56.9 4.13 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.129 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.476 ' HA ' HD12 ' A' ' 136' ' ' ILE . 13.5 mt-10 -45.23 -56.96 4.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.857 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 29.6 t-20 -43.35 -49.71 6.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.931 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.547 ' HB1' ' HG3' ' A' ' 139' ' ' MET . . . -64.39 -53.32 50.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.087 179.856 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' ILE . . . . . 0.476 HD12 ' HA ' ' A' ' 133' ' ' GLU . 94.7 mt -41.49 -34.38 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.141 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 -84.71 -69.55 0.64 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.905 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 28.2 mt-30 -55.99 -59.38 4.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.897 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.598 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 53.9 mmm -58.12 -43.1 87.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.449 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -56.98 91.41 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.493 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 125.02 6.16 6.5 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.459 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 142' ' ' GLN . . . . . 0.492 ' HG2' ' CD1' ' A' ' 149' ' ' ILE . 0.5 OUTLIER -92.33 -178.57 4.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.728 0.299 . . . . 0.0 110.957 -179.915 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 143' ' ' TRP . . . . . 0.48 ' N ' ' HG3' ' A' ' 142' ' ' GLN . 16.6 m95 -114.47 115.16 26.81 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.923 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.59 HD23 HD22 ' A' ' 85' ' ' LEU . 62.4 tp -108.1 128.45 54.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.91 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 1.014 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.97 -75.57 0.46 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.481 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.24 15.9 0.28 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.479 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 39.1 mtt85 -155.48 157.18 36.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.722 0.296 . . . . 0.0 110.867 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.45 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 16.6 mt-30 -60.51 170.3 1.44 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.937 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.492 ' CD1' ' HG2' ' A' ' 142' ' ' GLN . 23.6 pt -135.17 152.98 33.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.179 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.439 ' HG3' ' CE2' ' A' ' 81' ' ' PHE . 12.5 ptm180 -120.38 104.23 9.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.86 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.449 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 44.9 p -99.45 127.91 45.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.174 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -150.85 173.79 13.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.878 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 153' ' ' TRP . . . . . 0.461 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 7.3 m95 -68.99 138.23 54.37 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -99.83 77.05 2.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.117 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 77.7 p -153.71 138.52 17.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.171 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 33.6 ttp180 -73.1 104.04 4.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.839 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 79.5 tttt -139.44 133.95 16.16 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.601 0.715 . . . . 0.0 110.909 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 152.67 69.47 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.672 2.248 . . . . 0.0 112.352 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 176.53 6.67 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.679 2.253 . . . . 0.0 112.36 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -97.96 154.31 37.83 Favored Pre-proline 0 C--N 1.33 -0.283 0 CA-C-O 121.562 0.696 . . . . 0.0 111.097 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.77 165.07 32.2 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.718 2.278 . . . . 0.0 112.355 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 18.1 mmtp -139.63 156.41 46.86 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.906 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 94.0 p -135.16 110.75 9.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.837 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 12.2 t -95.18 133.71 38.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.138 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 11.9 p90 -128.51 160.64 31.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.932 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 9.2 mm-40 -142.3 136.58 29.88 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 3.0 m -165.52 167.62 17.28 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.848 -179.761 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 35.8 t30 -137.25 173.58 11.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.847 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 13.8 t -156.17 163.4 39.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.134 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 15.4 ttpt -143.43 118.71 10.2 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.877 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.58 161.06 14.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.87 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 1.8 m -111.74 152.7 27.48 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.906 -179.834 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -106.33 86.62 0.48 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.469 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.73 95.66 0.56 Allowed 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.697 2.264 . . . . 0.0 112.328 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 16.7 m -43.09 166.6 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.884 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 45.1 t -121.22 -54.61 1.99 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.844 -179.823 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.535 -179.967 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.516 -0.234 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 9.0 t -72.4 117.58 14.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.927 0.394 . . . . 0.0 110.824 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 94.5 p -155.36 176.88 12.01 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.829 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 75.35 41.18 31.39 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.476 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 73.3 m -79.17 87.96 4.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.843 0.354 . . . . 0.0 110.803 -179.746 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 5.8 t 62.84 42.3 7.98 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.884 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -132.48 115.88 1.7 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.546 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 -82.87 139.79 33.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.876 0.369 . . . . 0.0 110.925 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -116.52 152.86 33.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.933 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 9.5 ptmm? -89.23 -43.19 11.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.892 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -79.83 98.23 6.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.865 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.407 HG22 ' ND1' ' A' ' 77' ' ' HIS . 1.7 p -53.56 115.01 1.73 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.187 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 19.8 m -119.5 -53.02 2.24 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.814 -179.811 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.5 m120 -108.33 42.02 1.46 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.902 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' HIS . . . . . 0.407 ' ND1' HG22 ' A' ' 74' ' ' THR . 36.8 m170 -115.44 160.07 20.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.85 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.561 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 43.8 m-85 -108.16 116.49 32.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.864 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 58.2 m-70 -88.06 135.29 33.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.863 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 53.7 t -114.78 140.3 36.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.096 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.5 t80 -91.28 135.29 33.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.898 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.502 HG12 HD21 ' A' ' 85' ' ' LEU . 16.6 t -131.73 127.54 59.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.069 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.469 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -137.39 171.75 23.04 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.491 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ASP . . . . . 0.41 ' O ' ' O ' ' A' ' 148' ' ' GLN . 6.6 t70 64.37 53.07 1.75 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.839 0.352 . . . . 0.0 110.857 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.511 HD22 HD23 ' A' ' 144' ' ' LEU . 21.3 mt -106.34 133.39 51.11 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.941 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -54.07 155.1 6.85 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.651 0.739 . . . . 0.0 110.862 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 -10.08 27.67 Favored 'Trans proline' 0 N--CA 1.465 -0.159 0 C-N-CA 122.73 2.287 . . . . 0.0 112.352 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -97.78 0.49 46.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.896 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.944 HD11 ' HA3' ' A' ' 145' ' ' GLY . 49.0 mm -88.02 136.83 22.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.151 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.9 t -121.21 179.39 4.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.124 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.625 HG23 ' HA ' ' A' ' 108' ' ' ARG . 85.4 m -51.18 -45.44 61.78 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.102 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -59.34 -55.79 30.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.837 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' ASP . . . . . 0.55 ' CB ' HG23 ' A' ' 89' ' ' ILE . 6.8 m-20 -38.18 -57.78 1.05 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.887 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.414 HD11 HG22 ' A' ' 109' ' ' VAL . 6.7 mt -48.37 -62.04 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.131 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.672 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 26.0 mtmt -45.18 -39.88 6.62 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.948 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.02 -32.45 74.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.097 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.536 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -69.84 -54.66 12.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.084 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' PHE . . . . . 0.407 ' C ' HD11 ' A' ' 104' ' ' ILE . 22.7 m-85 -88.23 8.55 26.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.894 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.76 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -62.06 -60.04 11.33 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.567 0.698 . . . . 0.0 111.096 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.76 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.76 -0.76 7.38 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.721 2.28 . . . . 0.0 112.351 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -100.02 -10.91 21.05 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.905 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 154.69 156.43 7.71 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.47 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.449 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 29.8 mtm180 -64.61 121.7 15.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.742 0.306 . . . . 0.0 110.891 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.407 HD11 ' C ' ' A' ' 98' ' ' PHE . 15.3 mt -100.33 139.76 21.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.138 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 36.0 t -113.47 -59.59 2.0 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.832 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -100.82 100.97 11.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.842 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.48 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -131.67 128.34 38.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.067 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.625 ' HA ' HG23 ' A' ' 91' ' ' THR . 8.8 ptp180 -161.58 161.66 29.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.414 HG22 HD11 ' A' ' 94' ' ' ILE . 32.6 t -112.98 122.2 66.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.122 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.693 HG21 ' CE2' ' A' ' 121' ' ' TYR . 58.8 t -55.83 142.94 9.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.137 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 28.5 mttp -142.19 154.48 44.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.872 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.489 ' O ' ' N ' ' A' ' 116' ' ' GLY . 47.3 t0 -62.61 121.58 13.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.872 179.87 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 14.4 ptp -72.53 0.76 9.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.898 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -103.5 -34.62 8.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.099 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 6.9 p -123.39 -33.83 3.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.149 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.489 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 90.61 26.28 23.21 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.501 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -93.37 140.74 29.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.762 0.315 . . . . 0.0 110.9 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 2.8 t -46.24 113.06 0.56 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.866 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 34.5 mttt -67.23 -49.87 62.85 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.896 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.443 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 140.51 -39.95 1.42 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.497 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' TYR . . . . . 0.693 ' CE2' HG21 ' A' ' 110' ' ' VAL . 24.5 p90 -100.13 144.43 29.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.927 0.394 . . . . 0.0 110.945 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -131.77 -179.79 16.48 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.507 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 65.4 m-85 -124.57 138.94 54.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.874 0.369 . . . . 0.0 110.884 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.681 HG12 ' CE1' ' A' ' 126' ' ' PHE . 48.4 t -138.84 113.3 7.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.113 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 20.6 t -100.97 151.49 21.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.82 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' PHE . . . . . 0.681 ' CE1' HG12 ' A' ' 124' ' ' VAL . 3.0 m-85 -131.0 149.57 52.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.885 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 127' ' ' PHE . . . . . 0.449 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 81.4 m-85 -64.27 -35.73 81.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.848 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -120.49 157.26 29.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.914 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.561 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 40.4 tttt -65.89 -64.4 0.87 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.922 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' TRP . . . . . 0.453 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -34.17 -62.04 0.34 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.93 179.903 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 130' ' ' TRP . 5.7 m-20 -36.08 -43.41 0.34 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.841 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 129' ' ' LYS . . . -73.56 -60.69 2.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.084 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -42.99 -55.85 3.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.89 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -43.31 -44.65 5.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' ALA . . . . . 0.458 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -74.06 -56.06 5.37 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.094 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 76.9 mt -39.83 -37.35 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.125 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -83.04 -55.91 4.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.846 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 4.3 mm-40 -66.26 -63.45 1.08 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.883 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' MET . . . . . 0.521 ' HE3' HD11 ' A' ' 149' ' ' ILE . 84.3 mmm -51.07 -36.21 38.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.843 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -56.15 107.75 0.94 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.531 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 104.1 -17.39 48.32 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.464 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 15.1 mm-40 -67.69 -177.94 0.85 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.768 0.318 . . . . 0.0 110.945 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 143' ' ' TRP . . . . . 0.439 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 13.8 m95 -115.72 137.13 52.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.899 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.536 HD13 ' HB2' ' A' ' 97' ' ' ALA . 55.7 tp -130.27 121.56 26.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.937 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' GLY . . . . . 0.944 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 75.39 -24.19 1.44 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.473 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 146' ' ' GLY . . . . . 0.417 ' H ' ' C ' ' A' ' 144' ' ' LEU . . . 144.99 -6.88 1.61 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.477 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 54.0 mtt85 -130.61 144.07 51.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.812 0.339 . . . . 0.0 110.843 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 148' ' ' GLN . . . . . 0.439 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 23.9 mt-30 -51.48 163.92 0.24 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.913 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.521 HD11 ' HE3' ' A' ' 139' ' ' MET . 25.3 pt -137.69 155.22 30.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.099 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.497 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 7.6 ptm180 -118.12 118.23 31.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.874 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 34.3 p -117.64 132.35 56.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.136 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -158.55 173.35 16.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 32.8 m95 -65.15 118.0 8.58 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.871 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -49.12 -55.42 12.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.097 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 73.3 p -106.6 118.18 35.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.146 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 5.1 ptm180 -140.82 156.38 46.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.872 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 40.1 tttm -166.2 137.55 2.93 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.557 0.694 . . . . 0.0 110.906 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 148.46 65.34 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.661 2.241 . . . . 0.0 112.403 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 177.04 6.0 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.632 2.221 . . . . 0.0 112.366 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.758 ' HB1' ' HD2' ' A' ' 161' ' ' PRO . . . -145.34 165.67 20.77 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.581 0.705 . . . . 0.0 111.063 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 161' ' ' PRO . . . . . 0.758 ' HD2' ' HB1' ' A' ' 160' ' ' ALA . 54.2 Cg_endo -69.71 -10.29 28.24 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.695 2.263 . . . . 0.0 112.343 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 25.7 tptp -81.77 129.67 34.81 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.874 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 9.8 t -131.99 108.22 9.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.876 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 67.3 p -39.75 136.6 1.02 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.157 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 165' ' ' TYR . . . . . 0.463 ' CG ' ' O ' ' A' ' 165' ' ' TYR . 4.6 p90 -132.02 100.46 5.07 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.879 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -153.78 133.58 13.06 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.832 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 78.0 p -111.42 130.53 55.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.85 -179.795 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -139.95 167.99 20.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.89 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 14.0 t -67.64 152.21 46.0 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.157 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.12 159.31 34.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.908 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -123.61 -48.84 1.91 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.919 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 4.3 m -109.2 149.78 28.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.855 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -173.5 76.99 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.488 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 97.35 0.63 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.665 2.243 . . . . 0.0 112.348 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 31.0 m -130.1 171.65 12.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.893 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 1.3 t -125.96 -61.02 1.26 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.914 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.526 179.988 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.93 0.395 . . . . 0.0 110.883 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 69.6 m-70 -86.62 144.45 27.16 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.861 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 23.7 t -118.86 146.71 23.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.114 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -99.26 135.59 40.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.935 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.799 HG12 HD21 ' A' ' 85' ' ' LEU . 6.0 t -134.56 131.07 54.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.152 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.478 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -137.07 -175.8 14.01 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.459 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 60.74 26.4 16.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.897 0.379 . . . . 0.0 110.899 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.799 HD21 HG12 ' A' ' 82' ' ' VAL . 10.9 mt -84.53 128.22 34.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.907 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.41 153.93 6.73 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.685 0.755 . . . . 0.0 110.841 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 -9.87 27.19 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.711 2.274 . . . . 0.0 112.325 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -97.44 -5.04 37.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.901 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.812 HD11 ' HA3' ' A' ' 145' ' ' GLY . 40.5 mm -77.23 139.4 18.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.131 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.6 t -116.8 163.7 15.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.131 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.666 ' HA ' HG23 ' A' ' 109' ' ' VAL . 6.3 m -43.8 -38.56 3.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.079 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -63.09 -56.56 15.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.896 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.548 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.4 m-20 -37.75 -52.88 1.28 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.842 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.508 HD11 HG22 ' A' ' 109' ' ' VAL . 5.1 mt -52.11 -58.7 2.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.127 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.603 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 24.2 mtmt -49.45 -39.2 32.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.889 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.87 -35.0 75.49 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.112 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.566 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -68.67 -55.53 11.12 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.091 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 35.6 m-85 -85.05 1.63 46.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.874 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.786 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -52.75 -60.11 7.3 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.605 0.717 . . . . 0.0 111.147 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.786 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.7 -1.03 7.72 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.689 2.26 . . . . 0.0 112.357 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -99.96 9.55 42.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.26 143.48 5.78 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.497 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 45.8 mtt85 -52.17 121.87 7.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.739 0.304 . . . . 0.0 110.857 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.446 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 13.1 mt -95.04 136.79 25.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.102 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.434 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 2.4 p -103.28 -64.53 1.07 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.86 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -100.59 109.17 21.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.822 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.555 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -138.94 125.03 20.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.116 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.476 ' HB2' ' CZ ' ' A' ' 108' ' ' ARG . 2.6 ptm85 -157.39 165.08 36.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.867 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.666 HG23 ' HA ' ' A' ' 91' ' ' THR . 87.3 t -112.93 112.73 41.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.168 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.916 HG11 ' CE2' ' A' ' 121' ' ' TYR . 97.1 t -45.98 137.9 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.154 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 84.7 mttt -137.86 161.22 37.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.924 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.475 ' OD2' ' HB3' ' A' ' 114' ' ' ALA . 9.3 t0 -75.15 125.94 29.99 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.868 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 14.3 ptp -75.77 -1.74 26.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.929 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.475 ' HB3' ' OD2' ' A' ' 112' ' ' ASP . . . -96.58 -39.59 9.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 30.6 p -119.51 -33.91 3.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.16 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 93.62 24.22 21.55 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.468 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 41.2 mmtt -93.55 151.17 19.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.82 0.343 . . . . 0.0 110.874 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 1.8 m -52.53 113.18 0.98 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.855 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.739 ' HG3' HG12 ' A' ' 110' ' ' VAL . 26.2 mmtt -63.14 -38.54 91.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.926 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.408 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 129.81 -40.06 1.73 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.505 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.916 ' CE2' HG11 ' A' ' 110' ' ' VAL . 3.0 p90 -100.02 155.09 17.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.943 0.402 . . . . 0.0 110.924 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.04 168.28 24.37 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.479 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 81.9 m-85 -117.47 141.54 48.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.914 0.388 . . . . 0.0 110.911 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.699 HG12 ' CE1' ' A' ' 126' ' ' PHE . 88.9 t -141.94 114.04 3.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.132 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 45.7 t -106.06 142.99 34.84 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.816 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.699 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.5 m-85 -119.24 158.46 25.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.898 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.434 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 20.7 m-85 -66.91 -42.3 85.67 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.883 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 25.3 m-80 -110.13 166.95 10.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.911 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 58.7 tttt -76.15 -44.2 39.39 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.898 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.429 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -54.71 -59.32 4.88 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.929 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 130' ' ' TRP . 88.8 m-20 -35.8 -56.17 0.7 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.896 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.415 ' HB2' ' CD1' ' A' ' 126' ' ' PHE . . . -63.39 -65.11 0.73 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.084 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.428 ' HA ' HD12 ' A' ' 136' ' ' ILE . 4.6 mm-40 -37.31 -59.01 0.79 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -42.65 -48.58 5.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.907 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.47 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -64.64 -56.45 13.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.094 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . 0.428 HD12 ' HA ' ' A' ' 133' ' ' GLU . 94.8 mt -38.6 -34.45 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.139 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 -86.09 -60.39 2.02 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.883 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 25.8 mt-30 -63.73 -58.14 7.8 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.47 ' N ' ' O ' ' A' ' 135' ' ' ALA . 50.3 mmm -54.86 -34.91 63.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.878 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.45 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -60.89 117.45 11.66 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.47 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 92.56 12.48 58.22 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.524 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 13.6 mm-40 -94.43 170.83 9.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.759 0.314 . . . . 0.0 110.901 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . 0.42 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 16.2 m95 -106.1 109.08 20.91 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.87 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.566 HD13 ' HB2' ' A' ' 97' ' ' ALA . 64.6 tp -102.51 128.88 48.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.86 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 0.812 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.03 -75.69 0.33 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.458 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.37 15.54 0.32 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.478 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . 0.431 ' HB3' ' NH1' ' A' ' 147' ' ' ARG . 8.0 mtp-105 -156.11 159.33 38.96 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.796 0.331 . . . . 0.0 110.859 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.42 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 30.2 mt-30 -64.27 167.83 6.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.909 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 32.4 pt -140.89 145.97 24.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.136 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.478 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 6.5 ptt180 -107.25 109.76 21.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.45 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 43.8 p -103.84 137.01 42.45 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.112 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . 0.423 ' CG ' ' O ' ' A' ' 151' ' ' THR . 19.6 m120 -166.89 176.29 7.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.923 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 10.4 m95 . . . . . 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 179.98 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.561 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 93.2 m-85 . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.839 0.352 . . . . 0.0 110.905 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.48 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.5 OUTLIER -88.54 149.08 23.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.887 179.988 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 42.0 t -124.7 147.53 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.161 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -98.22 138.63 35.21 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.846 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.606 HG12 HD21 ' A' ' 85' ' ' LEU . 15.2 t -136.07 129.56 47.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.12 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.461 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -139.75 177.49 20.45 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.439 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 18.8 t0 64.08 41.91 6.03 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.848 0.356 . . . . 0.0 110.909 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.606 HD21 HG12 ' A' ' 82' ' ' VAL . 9.5 mt -102.41 137.02 41.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.929 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -54.93 153.86 10.78 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.691 0.758 . . . . 0.0 110.875 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 -12.0 31.91 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.676 2.251 . . . . 0.0 112.317 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -93.26 -9.57 38.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.915 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.972 HD11 ' HA3' ' A' ' 145' ' ' GLY . 42.3 mm -74.65 137.1 23.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.077 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.421 ' O ' ' C ' ' A' ' 91' ' ' THR . 11.3 t -120.46 162.48 19.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.116 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.5 ' HA ' HG23 ' A' ' 109' ' ' VAL . 53.2 m -36.03 -49.27 0.64 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.14 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 93' ' ' ASP . 20.2 mt-10 -52.8 -60.33 3.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.899 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.623 ' CB ' HG23 ' A' ' 89' ' ' ILE . 1.0 OUTLIER -34.78 -57.47 0.53 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.909 179.972 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.525 HD11 HG22 ' A' ' 109' ' ' VAL . 12.6 mt -48.61 -60.0 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.093 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.648 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 24.5 mtmt -47.66 -39.85 18.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.931 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.49 -28.91 70.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.087 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.7 -50.68 13.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.095 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.47 ' C ' HD11 ' A' ' 104' ' ' ILE . 19.1 m-85 -91.16 12.16 20.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.763 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -66.6 -59.68 7.73 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.578 0.704 . . . . 0.0 111.09 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.763 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.73 -0.6 7.12 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.637 2.225 . . . . 0.0 112.35 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.505 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 74.9 m-85 -99.61 -11.96 20.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.888 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 152.26 137.53 2.59 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.496 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.424 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 10.1 mtm-85 -48.76 122.64 5.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.81 0.338 . . . . 0.0 110.848 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.47 HD11 ' C ' ' A' ' 98' ' ' PHE . 10.2 mt -99.99 141.75 16.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.125 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.4 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 3.5 t -109.68 -63.73 1.33 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.858 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -100.44 104.85 16.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.881 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.56 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -134.67 128.91 33.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.109 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.477 ' HA ' HG23 ' A' ' 91' ' ' THR . 11.5 ptm180 -161.79 163.6 29.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.841 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.525 HG22 HD11 ' A' ' 94' ' ' ILE . 89.9 t -110.85 120.47 61.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.098 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.605 HG21 ' CE2' ' A' ' 121' ' ' TYR . 57.4 t -50.7 135.85 10.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.115 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 46.3 mttm -136.21 146.08 46.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.442 ' O ' ' N ' ' A' ' 116' ' ' GLY . 32.1 t0 -55.02 123.42 13.51 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.891 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 9.1 tpt -71.07 -2.52 15.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.873 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -103.08 -48.72 3.96 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.062 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 34.0 p -102.25 -29.37 11.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.138 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 80.51 28.45 47.75 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.47 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 14.5 mtpp -99.86 148.82 24.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.781 0.324 . . . . 0.0 110.891 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 5.4 t -51.8 105.64 0.12 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.842 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 36.6 mttt -58.47 -46.81 85.88 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.9 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.406 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 142.13 -41.94 1.17 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.484 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.605 ' CE2' HG21 ' A' ' 110' ' ' VAL . 9.5 p90 -99.86 149.15 23.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.888 0.375 . . . . 0.0 110.947 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -130.58 179.64 16.77 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.479 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -126.62 142.04 51.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.876 0.37 . . . . 0.0 110.921 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.664 HG12 ' CE1' ' A' ' 126' ' ' PHE . 60.2 t -138.94 123.9 21.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.096 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . 0.432 ' O ' HG23 ' A' ' 104' ' ' ILE . 33.0 m -112.19 144.77 41.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.877 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.664 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.2 m-85 -125.32 150.55 47.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.424 ' CE2' ' HB3' ' A' ' 103' ' ' ARG . 21.9 m-85 -57.65 -46.48 84.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.92 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 25.7 m-20 -112.05 163.45 14.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.91 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.561 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 69.9 tttt -72.11 -61.64 1.72 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.897 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.434 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.9 OUTLIER -34.78 -56.76 0.55 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.906 179.99 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -42.08 -52.02 4.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.851 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -63.37 -60.64 3.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.115 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.411 ' HA ' HD12 ' A' ' 136' ' ' ILE . 5.7 mm-40 -39.44 -60.21 0.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 32.6 t-20 -40.29 -44.77 1.98 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.903 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.424 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -69.63 -54.39 14.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.091 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . 0.411 HD12 ' HA ' ' A' ' 133' ' ' GLU . 91.7 mt -41.58 -34.83 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.14 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -87.29 -60.55 1.95 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.911 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 29.3 mm-40 -60.29 -60.17 4.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.901 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.505 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 75.7 mmm -56.84 -41.8 78.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.873 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.441 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -53.09 103.07 0.11 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.478 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 107.41 6.65 33.28 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.51 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 -90.11 173.87 7.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.799 0.333 . . . . 0.0 110.932 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . 0.48 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 17.8 m95 -109.02 121.22 44.68 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.952 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.534 HD23 HD22 ' A' ' 85' ' ' LEU . 34.2 tp -122.85 127.27 48.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.888 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 0.972 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 72.12 -7.08 8.37 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.474 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 124.16 -9.71 8.36 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.507 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 17.9 mtt180 -127.63 148.9 50.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.722 0.296 . . . . 0.0 110.91 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.48 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 28.1 mt-30 -60.19 152.96 23.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.923 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.592 HG22 HD23 ' A' ' 85' ' ' LEU . 24.6 pt -123.07 153.55 28.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.099 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.474 ' CG ' ' O ' ' A' ' 150' ' ' ARG . 10.1 ptm180 -114.93 114.05 24.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.441 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 73.4 p -107.86 130.4 55.0 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.159 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -157.39 172.38 18.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 24.2 m95 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.896 179.968 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.491 ' CD2' ' HA ' ' A' ' 129' ' ' LYS . 37.3 m-85 . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.881 0.372 . . . . 0.0 110.855 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 58.4 m-70 -86.08 155.87 20.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.866 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 45.4 t -129.07 141.55 46.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.098 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.0 t80 -90.7 133.33 35.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.876 HG12 HD21 ' A' ' 85' ' ' LEU . 5.6 t -129.74 110.0 19.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.123 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.47 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -118.18 168.21 13.07 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.473 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.9 t70 68.76 52.73 0.54 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.813 0.34 . . . . 0.0 110.877 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.876 HD21 HG12 ' A' ' 82' ' ' VAL . 16.2 mt -109.68 131.49 55.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.919 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.1 t -53.98 154.71 7.16 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.624 0.726 . . . . 0.0 110.885 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -14.51 36.15 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.693 2.262 . . . . 0.0 112.36 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -93.07 -5.24 50.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.911 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.626 HD11 ' HA3' ' A' ' 145' ' ' GLY . 40.5 mm -78.37 138.11 20.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.127 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.3 t -120.84 170.5 9.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.181 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.526 ' HA ' HG23 ' A' ' 109' ' ' VAL . 88.3 m -43.64 -49.85 7.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.168 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.437 ' O ' ' C ' ' A' ' 93' ' ' ASP . 57.7 mt-10 -52.05 -60.16 3.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.91 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.525 ' CB ' HG23 ' A' ' 89' ' ' ILE . 5.9 m-20 -34.51 -57.99 0.5 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.891 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.506 ' CD1' HG22 ' A' ' 109' ' ' VAL . 7.6 mt -49.52 -62.26 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.117 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.693 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 27.8 mtmt -46.12 -40.1 10.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.943 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.52 -31.61 71.63 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.154 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.582 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -72.97 -53.86 10.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.121 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -88.14 7.07 33.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.853 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.774 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -60.73 -59.93 12.27 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.609 0.719 . . . . 0.0 111.097 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.774 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.1 Cg_endo -69.77 -0.75 7.38 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.685 2.257 . . . . 0.0 112.314 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.593 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 73.8 m-85 -99.78 -5.04 29.3 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.914 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 144.25 136.2 3.04 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.507 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 29.5 mtt180 -46.78 124.41 6.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.795 0.331 . . . . 0.0 110.869 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.469 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 13.2 mt -100.09 138.26 24.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.151 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.495 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 47.1 p -107.33 -61.83 1.5 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.848 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -100.2 104.56 16.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.871 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.491 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -134.94 127.32 30.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.051 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.45 ' HA ' HG23 ' A' ' 91' ' ' THR . 1.9 ptt-85 -160.94 157.94 27.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.886 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.526 HG23 ' HA ' ' A' ' 91' ' ' THR . 86.8 t -110.26 115.42 49.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.135 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.641 HG21 ' CD2' ' A' ' 121' ' ' TYR . 48.7 t -46.97 136.82 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.147 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 54.0 mttt -137.46 148.69 46.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.945 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.638 ' OD2' ' HB3' ' A' ' 114' ' ' ALA . 25.8 t70 -58.54 130.18 45.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.879 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 28.4 ptm -78.88 1.63 22.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.866 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.638 ' HB3' ' OD2' ' A' ' 112' ' ' ASP . . . -102.82 -41.18 6.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.087 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 45.1 p -114.43 -29.07 6.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.167 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 84.52 21.43 56.4 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.497 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 48.4 mmtt -92.93 145.25 24.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.769 0.318 . . . . 0.0 110.902 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 4.9 t -46.69 111.86 0.44 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.853 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -62.7 -51.46 67.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 147.46 -41.56 0.93 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.486 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.641 ' CD2' HG21 ' A' ' 110' ' ' VAL . 4.9 p90 -100.06 153.13 19.47 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.928 0.394 . . . . 0.0 110.915 -179.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.42 173.7 22.14 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.468 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -122.54 140.45 52.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.897 0.379 . . . . 0.0 110.92 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.678 HG12 ' CE1' ' A' ' 126' ' ' PHE . 59.2 t -137.62 116.38 14.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.12 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 15.5 t -104.87 147.16 28.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.852 -179.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.678 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.2 m-85 -126.84 150.2 49.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.875 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.495 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 23.1 m-85 -56.7 -44.42 81.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 24.4 m-20 -112.86 166.47 11.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.905 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.561 ' HE3' ' CZ2' ' A' ' 153' ' ' TRP . 39.2 tptt -70.99 -59.99 2.48 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.944 179.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.426 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.8 OUTLIER -40.93 -59.92 1.32 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.922 179.941 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.426 ' C ' ' O ' ' A' ' 130' ' ' TRP . 6.9 m-20 -35.8 -39.11 0.14 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.863 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -80.43 -58.51 3.09 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.063 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.4 mt-10 -44.38 -55.68 4.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.948 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 54.7 t30 -42.8 -42.07 3.46 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.909 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.49 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -71.81 -55.78 6.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.055 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 76.1 mt -38.76 -36.4 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.104 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.1 mt-30 -83.6 -57.19 3.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 16.8 mm-40 -68.54 -61.16 1.95 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.897 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.593 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 41.3 mmm -52.97 -31.38 40.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.905 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.447 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -63.04 107.78 1.84 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.491 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 99.94 13.73 36.12 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.487 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 66.5 mm-40 -93.1 166.88 12.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.802 0.334 . . . . 0.0 110.89 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . 0.444 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 14.5 m95 -102.89 107.06 17.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.89 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.582 HD13 ' HB2' ' A' ' 97' ' ' ALA . 63.6 tp -100.02 126.46 46.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.873 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 0.626 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.25 -76.95 0.46 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.493 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -155.96 14.5 0.41 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.497 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 36.7 mtp180 -153.04 157.01 39.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.783 0.325 . . . . 0.0 110.866 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.444 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 30.8 mt-30 -62.16 167.2 4.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.927 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.413 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 25.7 pt -138.96 153.21 24.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.488 ' CG ' ' O ' ' A' ' 150' ' ' ARG . 7.0 ptm180 -118.82 116.47 26.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.9 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.447 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 53.5 p -107.53 135.53 48.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.134 -179.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 28.4 t30 -160.15 171.09 19.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . 0.561 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 15.3 m95 . . . . . 0 C--N 1.328 -0.344 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.937 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.564 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 84.3 m-85 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.85 0.357 . . . . 0.0 110.906 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 10.2 m-70 -89.65 147.84 23.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.89 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 41.4 t -119.21 143.47 30.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.157 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.1 t80 -93.56 135.3 34.96 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.666 ' CG1' HD21 ' A' ' 85' ' ' LEU . 4.0 t -131.25 131.04 63.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.157 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.432 ' N ' ' HG2' ' A' ' 150' ' ' ARG . . . -135.8 179.41 17.82 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.524 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 52.37 47.61 24.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.86 0.362 . . . . 0.0 110.852 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.668 HD22 HD23 ' A' ' 144' ' ' LEU . 30.0 mt -99.65 132.91 44.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.938 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -53.01 156.33 3.61 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.651 0.738 . . . . 0.0 110.868 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -39.53 6.28 Favored 'Trans proline' 0 C--O 1.231 0.125 0 C-N-CA 122.675 2.25 . . . . 0.0 112.337 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -71.46 1.2 6.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.887 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.91 HD11 ' HA3' ' A' ' 145' ' ' GLY . 37.3 mm -83.01 132.37 31.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.169 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.1 t -114.74 175.34 5.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.104 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.555 ' HA ' HG23 ' A' ' 109' ' ' VAL . 16.2 m -52.99 -41.66 64.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.147 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -62.36 -47.03 85.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.894 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.414 ' CB ' HG23 ' A' ' 89' ' ' ILE . 17.1 m-20 -47.87 -50.08 27.54 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.911 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.746 HD11 HG22 ' A' ' 109' ' ' VAL . 8.1 mt -54.7 -54.97 17.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.132 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.587 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 22.0 mtmt -50.93 -42.47 59.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.866 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -58.42 -30.98 67.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.107 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.535 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -72.46 -57.16 4.39 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.101 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.429 ' C ' HD11 ' A' ' 104' ' ' ILE . 22.0 m-85 -87.37 12.22 12.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.935 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.789 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -61.79 -60.19 11.05 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.613 0.72 . . . . 0.0 111.119 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.789 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.5 Cg_endo -69.8 -0.8 7.47 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.678 2.252 . . . . 0.0 112.306 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -99.9 9.57 42.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.883 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.26 136.02 4.24 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.525 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 38.9 mtt85 -46.73 125.04 6.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.766 0.317 . . . . 0.0 110.882 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.429 HD11 ' C ' ' A' ' 98' ' ' PHE . 10.9 mt -98.21 138.83 21.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.153 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.449 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.9 t -106.73 -62.91 1.34 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.848 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -100.25 105.2 16.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.861 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.481 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -136.46 127.01 26.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.138 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.2 ptm180 -161.91 155.85 21.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.892 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.746 HG22 HD11 ' A' ' 94' ' ' ILE . 58.4 t -102.07 119.14 49.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.642 HG21 ' CD2' ' A' ' 121' ' ' TYR . 59.8 t -53.86 136.99 15.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.141 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . 0.412 ' C ' ' HG3' ' A' ' 119' ' ' LYS . 57.5 mttt -136.59 153.89 50.83 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.755 ' OD2' ' HB3' ' A' ' 114' ' ' ALA . 23.2 t70 -64.99 120.21 12.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 16.4 ptp -67.14 -10.93 55.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.841 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.755 ' HB3' ' OD2' ' A' ' 112' ' ' ASP . . . -83.62 -54.81 4.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.107 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 13.5 p -104.85 -34.4 8.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.171 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 95.89 25.71 12.7 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.477 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 44.4 mtmt -95.33 154.68 17.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.781 0.324 . . . . 0.0 110.867 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 8.0 t -54.89 112.49 1.05 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.91 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.453 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 16.6 mttp -63.36 -54.23 40.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.895 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 150.2 -41.76 0.79 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.469 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.642 ' CD2' HG21 ' A' ' 110' ' ' VAL . 5.4 p90 -100.01 155.25 17.8 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.96 0.41 . . . . 0.0 110.938 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -134.46 169.88 22.9 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.464 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -118.77 138.44 52.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.873 0.368 . . . . 0.0 110.914 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.678 HG12 ' CE1' ' A' ' 126' ' ' PHE . 61.2 t -138.77 115.08 10.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.143 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 8.2 t -107.23 140.02 40.77 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.877 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.678 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.2 m-85 -119.51 163.45 17.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.894 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.449 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 22.9 m-85 -72.32 -42.91 64.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.902 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 68.0 m-20 -114.18 161.44 17.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.864 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.564 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 44.3 tptt -69.74 -61.63 1.71 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.464 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.9 OUTLIER -33.27 -60.7 0.33 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.883 179.972 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 -39.67 -54.07 2.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.875 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -65.02 -59.49 4.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.08 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -43.5 -60.7 1.63 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.894 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -43.57 -44.11 5.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.836 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.462 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -66.63 -56.48 10.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.132 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 82.8 mt -40.91 -37.84 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.14 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 15.7 mt-30 -76.47 -63.81 1.25 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.947 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 27.0 mt-30 -63.85 -61.24 2.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.931 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.462 ' N ' ' O ' ' A' ' 135' ' ' ALA . 65.6 mmm -51.43 -34.0 33.07 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.858 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.443 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -58.69 93.47 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.483 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 113.52 4.55 23.3 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.426 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 16.2 mm100 -80.66 171.13 15.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.797 0.332 . . . . 0.0 110.875 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . 0.425 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 15.4 m95 -106.7 111.29 23.76 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.92 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.668 HD23 HD22 ' A' ' 85' ' ' LEU . 66.3 tp -104.91 129.22 53.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.932 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 0.91 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.31 -78.04 0.45 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.492 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -155.29 14.03 0.46 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.499 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 23.9 mtt85 -153.73 161.46 42.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.771 0.32 . . . . 0.0 110.893 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.425 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 23.0 mt-30 -62.95 171.0 2.38 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.429 HG21 ' CB ' ' A' ' 144' ' ' LEU . 14.0 pt -142.07 158.43 20.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.124 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.487 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 7.7 ptm180 -120.82 118.6 30.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.867 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.443 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 61.0 p -111.15 132.44 54.29 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.159 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 41.2 t30 -157.66 174.07 15.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.942 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . 0.545 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 9.8 m95 . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.914 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.897 0.379 . . . . 0.0 110.911 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.434 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.5 OUTLIER -82.21 141.75 32.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.892 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.515 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 41.6 t -119.2 144.11 28.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.164 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.0 t80 -97.51 131.68 43.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.866 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.939 HG12 HD21 ' A' ' 85' ' ' LEU . 3.6 t -133.42 109.98 14.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.148 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -116.61 -178.12 17.99 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.519 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 63.98 34.99 11.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.894 0.378 . . . . 0.0 110.923 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.939 HD21 HG12 ' A' ' 82' ' ' VAL . 9.9 mt -92.76 128.96 38.8 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.918 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.05 154.27 5.48 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.657 0.741 . . . . 0.0 110.874 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -13.79 35.18 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.681 2.254 . . . . 0.0 112.358 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -92.94 -7.78 45.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.87 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.682 HD11 ' HA3' ' A' ' 145' ' ' GLY . 30.5 mm -78.38 138.54 20.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.17 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.0 t -119.27 167.26 12.04 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.11 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.597 ' HA ' HG23 ' A' ' 109' ' ' VAL . 21.2 m -42.4 -47.0 4.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.143 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -54.1 -57.71 10.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.885 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.602 ' CB ' HG23 ' A' ' 89' ' ' ILE . 4.0 m-20 -38.45 -57.11 1.18 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.862 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.492 HD11 HG22 ' A' ' 109' ' ' VAL . 6.4 mt -48.16 -58.33 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.101 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.578 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 23.6 mtmt -49.93 -44.37 50.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.928 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -58.56 -30.12 66.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.095 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.488 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -74.85 -58.19 3.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.157 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.45 ' CD2' ' HB1' ' A' ' 135' ' ' ALA . 42.9 m-85 -82.42 8.04 12.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.784 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -60.02 -60.21 11.35 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.591 0.71 . . . . 0.0 111.051 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.784 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.7 -0.99 7.66 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.661 2.241 . . . . 0.0 112.378 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.501 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 81.2 m-85 -99.91 3.63 44.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.903 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 136.55 156.61 7.47 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.458 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.459 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 34.0 mtt85 -64.44 125.18 23.84 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.796 0.331 . . . . 0.0 110.882 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.407 HD13 ' HA ' ' A' ' 95' ' ' LYS . 11.6 mt -100.3 137.21 28.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.115 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.534 ' OG ' ' CZ ' ' A' ' 127' ' ' PHE . 2.5 m -110.14 -60.41 1.8 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.895 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.0 t0 -101.22 102.24 13.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.878 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -131.99 125.62 31.97 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.117 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 11.9 ptp180 -159.73 157.58 29.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.841 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.597 HG23 ' HA ' ' A' ' 91' ' ' THR . 99.2 t -109.36 116.0 51.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.147 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.804 HG21 ' CE2' ' A' ' 121' ' ' TYR . 94.5 t -49.16 138.32 4.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.134 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 28.7 mttm -138.39 155.95 48.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.892 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.499 ' O ' ' N ' ' A' ' 116' ' ' GLY . 36.5 t0 -65.49 121.01 13.91 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.889 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 7.0 tpt -69.6 -9.29 53.5 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.898 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.93 -47.8 5.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.105 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 21.9 p -98.35 -34.23 10.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.099 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.499 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 86.33 23.6 43.36 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.474 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 14.8 mtpp -98.93 158.13 15.85 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.797 0.332 . . . . 0.0 110.91 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 47.4 t -56.67 112.91 1.42 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.868 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.713 ' HG3' HG12 ' A' ' 110' ' ' VAL . 25.3 mmtt -63.09 -38.83 92.76 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.918 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 130.49 -42.77 1.37 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.444 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.804 ' CE2' HG21 ' A' ' 110' ' ' VAL . 12.0 p90 -99.91 151.42 21.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.957 0.408 . . . . 0.0 110.892 -179.813 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -136.75 172.4 22.57 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.473 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -120.07 139.06 53.12 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.889 0.376 . . . . 0.0 110.914 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.721 HG12 ' CE1' ' A' ' 126' ' ' PHE . 53.1 t -136.84 111.0 9.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.111 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.8 t -99.38 151.58 20.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.893 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.721 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.5 m-85 -130.83 152.37 50.24 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.875 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.534 ' CZ ' ' OG ' ' A' ' 105' ' ' SER . 76.2 m-85 -66.01 -34.95 79.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.842 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -120.74 149.96 41.73 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.87 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.463 ' O ' ' C ' ' A' ' 130' ' ' TRP . 45.0 tttt -59.05 -65.82 0.6 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.866 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.463 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -33.47 -60.83 0.34 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.923 179.951 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 130' ' ' TRP . 68.8 m-20 -35.81 -46.63 0.46 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.87 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.515 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -74.78 -59.8 2.57 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.085 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -39.07 -53.31 1.82 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.846 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 50.5 t30 -49.22 -50.04 40.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.888 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.45 ' HB1' ' CD2' ' A' ' 98' ' ' PHE . . . -61.91 -53.15 59.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.085 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . 0.461 HG23 ' HA ' ' A' ' 152' ' ' ASN . 96.6 mt -42.28 -37.11 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.142 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 6.1 mt-30 -86.87 -62.29 1.54 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.908 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 26.3 mt-30 -54.4 -61.52 2.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.885 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.501 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 92.6 mmm -58.45 -41.07 84.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.878 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.443 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -46.88 99.48 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.462 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 101.55 17.78 20.64 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.518 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 57.0 mm-40 -96.51 172.42 7.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.782 0.325 . . . . 0.0 110.898 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . 0.523 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 16.0 m95 -107.54 110.71 22.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.873 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.488 HD13 ' HB2' ' A' ' 97' ' ' ALA . 57.3 tp -103.56 127.47 50.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.934 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 0.682 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.89 -75.66 0.44 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.463 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.83 15.51 0.3 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.475 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 42.3 mtt-85 -154.62 156.77 37.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.726 0.298 . . . . 0.0 110.874 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.523 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 33.4 mt-30 -63.12 168.95 3.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.921 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 26.5 pt -149.23 144.73 18.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.112 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 14.0 ptt180 -105.63 124.06 48.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.863 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.443 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 69.0 p -115.28 141.12 48.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.185 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . 0.461 ' HA ' HG23 ' A' ' 136' ' ' ILE . 73.9 m-20 -165.11 177.13 7.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.885 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 11.9 m95 . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.942 179.969 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.551 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 54.5 m-85 . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.87 0.366 . . . . 0.0 110.856 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 40.2 m-70 -87.32 148.25 25.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.83 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 34.9 t -123.64 139.64 49.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.122 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -91.94 134.48 34.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.903 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.832 HG12 HD21 ' A' ' 85' ' ' LEU . 3.8 t -132.51 109.93 15.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.14 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.41 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -117.36 170.72 13.59 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.478 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.8 t70 68.83 51.67 0.57 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.847 0.356 . . . . 0.0 110.905 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.832 HD21 HG12 ' A' ' 82' ' ' VAL . 16.5 mt -108.91 131.92 54.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.893 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 t -54.92 153.71 11.01 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.676 0.75 . . . . 0.0 110.85 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -11.29 30.5 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.682 2.254 . . . . 0.0 112.313 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -94.0 -9.83 35.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.911 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.644 HD11 ' HA3' ' A' ' 145' ' ' GLY . 46.9 mm -74.42 137.99 22.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.131 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.2 t -117.84 166.52 12.37 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.162 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.769 HG23 ' HA ' ' A' ' 108' ' ' ARG . 86.1 m -43.37 -46.34 6.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.137 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 93' ' ' ASP . 35.2 mt-10 -55.55 -57.94 9.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.891 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.533 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.0 m-20 -35.18 -58.59 0.54 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.879 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.5 ' CD1' HG22 ' A' ' 109' ' ' VAL . 10.9 mt -48.5 -58.91 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.138 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.604 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 23.9 mtmt -49.41 -39.41 32.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.929 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.03 -27.66 69.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.085 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.501 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -77.65 -52.2 9.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.121 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.404 ' C ' HD11 ' A' ' 104' ' ' ILE . 31.6 m-85 -89.33 13.49 13.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.781 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -67.61 -60.26 5.83 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.554 0.692 . . . . 0.0 111.082 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.781 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.5 Cg_endo -69.76 -0.84 7.49 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.689 2.259 . . . . 0.0 112.323 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -99.95 -5.14 28.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.876 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 144.2 142.0 3.84 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.494 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.444 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 57.4 mtt180 -50.81 125.91 14.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.81 0.338 . . . . 0.0 110.882 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.491 HG21 ' HB2' ' A' ' 107' ' ' ALA . 17.4 mt -99.32 145.72 9.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.127 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.446 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.0 OUTLIER -119.3 -60.09 1.77 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.823 -179.892 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -100.53 92.47 5.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.829 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.491 ' HB2' HG21 ' A' ' 104' ' ' ILE . . . -129.5 124.64 34.47 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.103 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.769 ' HA ' HG23 ' A' ' 91' ' ' THR . 10.5 ptm180 -158.13 161.84 37.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.905 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.723 HG23 ' HA ' ' A' ' 91' ' ' THR . 79.5 t -113.44 116.82 53.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.629 HG12 ' HG3' ' A' ' 119' ' ' LYS . 77.1 t -52.58 137.46 12.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.131 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 1.7 mtmp? -130.19 156.97 43.72 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.906 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.515 ' O ' ' N ' ' A' ' 116' ' ' GLY . 27.5 t0 -64.47 118.85 9.37 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.855 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . 0.467 ' C ' ' SD ' ' A' ' 113' ' ' MET . 2.6 tmm? -65.85 -9.79 32.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.893 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -92.92 -53.41 4.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.07 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 20.7 p -100.71 -35.41 9.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.108 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 92.76 28.05 13.14 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.483 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -100.24 156.26 17.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.738 0.304 . . . . 0.0 110.917 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 36.7 t -51.77 109.03 0.32 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.876 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.629 ' HG3' HG12 ' A' ' 110' ' ' VAL . 18.9 mmtt -61.14 -51.74 67.81 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.89 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 144.95 -40.59 1.12 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.533 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.597 ' CZ ' HG11 ' A' ' 110' ' ' VAL . 6.2 p90 -100.09 151.99 20.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.939 0.4 . . . . 0.0 110.944 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -141.0 172.96 23.46 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.495 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -121.19 141.2 51.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.874 0.369 . . . . 0.0 110.862 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.725 HG12 ' CE1' ' A' ' 126' ' ' PHE . 58.6 t -139.18 113.52 7.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.132 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 4.3 t -104.35 147.68 27.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.823 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.725 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.3 m-85 -126.47 153.86 44.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.876 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.446 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 20.9 m-85 -62.02 -43.43 98.86 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.896 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -114.65 161.72 17.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.877 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.551 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 39.9 tptt -69.04 -62.07 1.53 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.917 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.459 ' C ' ' O ' ' A' ' 129' ' ' LYS . 1.0 OUTLIER -33.53 -61.83 0.31 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.937 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.408 ' C ' ' O ' ' A' ' 130' ' ' TRP . 75.2 m-20 -37.09 -57.46 0.85 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.835 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -58.88 -62.16 2.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.103 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.407 ' HA ' HD12 ' A' ' 136' ' ' ILE . 2.4 mm-40 -39.7 -59.52 1.13 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.876 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 53.3 t30 -41.07 -46.45 2.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.879 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.484 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -67.32 -51.84 47.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.107 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . 0.407 HD12 ' HA ' ' A' ' 133' ' ' GLU . 97.6 mt -43.42 -35.11 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.151 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -88.33 -55.23 3.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.9 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 5.0 mm100 -67.31 -61.01 2.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.93 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.484 ' N ' ' O ' ' A' ' 135' ' ' ALA . 57.4 mmm -59.2 -26.46 64.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.434 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -65.1 113.54 5.94 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.45 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 89.36 18.25 53.27 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.494 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 89.8 mm-40 -97.47 171.2 8.54 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.788 0.328 . . . . 0.0 110.898 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . 0.436 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 15.4 m95 -104.14 110.68 22.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.949 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.501 HD13 ' HB2' ' A' ' 97' ' ' ALA . 59.2 tp -103.27 129.22 50.19 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.906 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 0.644 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 67.28 -74.74 0.19 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.493 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.81 18.05 0.28 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.511 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 72.2 mtt180 -156.69 155.41 31.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.756 0.312 . . . . 0.0 110.906 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.436 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 31.1 mt-30 -60.18 170.38 1.29 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.915 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.462 HG21 ' HB3' ' A' ' 144' ' ' LEU . 19.2 pt -146.39 150.18 15.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.106 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.424 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 13.1 ptp180 -113.99 121.96 45.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.87 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.434 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 73.4 p -112.56 128.11 56.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.168 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -151.33 170.77 18.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.898 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . 0.529 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 9.8 m95 . . . . . 0 C--N 1.328 -0.362 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.921 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.581 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 97.3 m-85 . . . . . 0 C--O 1.232 0.154 0 CA-C-O 120.911 0.386 . . . . 0.0 110.916 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.467 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.9 OUTLIER -95.51 139.92 31.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 -180.0 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 57.4 t -113.96 152.02 15.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.06 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -102.09 132.89 47.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.915 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.922 HG12 HD21 ' A' ' 85' ' ' LEU . 4.1 t -129.57 129.78 66.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.142 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.473 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -136.69 -173.54 12.96 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.494 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 27.0 m-20 55.3 36.33 26.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.831 0.348 . . . . 0.0 110.851 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.922 HD21 HG12 ' A' ' 82' ' ' VAL . 8.3 mt -96.18 131.02 43.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.886 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 t -53.1 153.71 6.15 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.652 0.739 . . . . 0.0 110.818 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -13.84 35.25 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.7 2.267 . . . . 0.0 112.338 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -91.04 -8.75 48.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.888 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.863 HD11 ' HA3' ' A' ' 145' ' ' GLY . 39.1 mm -76.37 136.67 24.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.176 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.444 ' OG1' ' N ' ' A' ' 91' ' ' THR . 2.3 t -114.55 177.54 4.61 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.163 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.726 HG23 ' HA ' ' A' ' 108' ' ' ARG . 69.9 m -52.6 -47.67 66.78 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.177 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 93' ' ' ASP . 32.0 mt-10 -56.42 -58.26 8.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.879 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.447 ' CB ' HG23 ' A' ' 89' ' ' ILE . 2.9 m-20 -35.49 -54.63 0.68 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.911 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.522 HD11 HG22 ' A' ' 109' ' ' VAL . 6.2 mt -51.18 -60.17 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.117 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.528 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 21.7 mtmt -47.14 -43.13 20.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.904 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -57.43 -31.57 66.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.134 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.402 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -74.42 -52.65 11.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.12 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.454 ' C ' HD11 ' A' ' 104' ' ' ILE . 23.6 m-85 -88.77 12.4 15.11 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.868 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.779 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -65.72 -60.1 7.98 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.597 0.713 . . . . 0.0 111.096 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.779 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.4 Cg_endo -69.8 -0.87 7.58 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.694 2.263 . . . . 0.0 112.321 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.506 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 78.3 m-85 -99.75 4.61 45.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.887 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.06 159.63 8.74 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.475 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.51 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 39.8 mtp85 -65.72 125.71 26.16 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.804 0.335 . . . . 0.0 110.866 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.454 HD11 ' C ' ' A' ' 98' ' ' PHE . 14.4 mt -100.46 138.14 25.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.186 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -109.86 -60.76 1.74 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.849 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -100.75 103.96 15.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.904 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.486 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -133.84 124.86 27.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.124 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.726 ' HA ' HG23 ' A' ' 91' ' ' THR . 17.6 ptt180 -161.94 160.16 27.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.9 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.611 HG23 ' HA ' ' A' ' 91' ' ' THR . 99.4 t -110.12 116.31 51.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.148 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.686 HG21 ' CE2' ' A' ' 121' ' ' TYR . 51.5 t -50.99 132.73 12.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.101 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . 0.418 ' HG2' ' N ' ' A' ' 118' ' ' SER . 69.1 mttt -133.45 148.76 51.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.867 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.44 ' O ' ' N ' ' A' ' 116' ' ' GLY . 29.6 t0 -58.28 123.66 16.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.88 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 36.3 ttp -71.77 -2.83 18.97 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.865 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -99.87 -49.91 4.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.094 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 18.7 p -102.15 -28.2 12.45 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.127 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 82.68 25.31 50.65 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.504 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 48.1 mtmt -99.99 147.08 25.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.757 0.313 . . . . 0.0 110.923 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . 0.418 ' N ' ' HG2' ' A' ' 111' ' ' LYS . 5.0 t -50.18 113.46 0.87 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.813 -179.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 41.5 mttt -63.6 -51.52 64.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.898 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.405 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 148.65 -40.02 0.93 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.476 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.686 ' CE2' HG21 ' A' ' 110' ' ' VAL . 10.1 p90 -100.03 149.43 23.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.934 0.397 . . . . 0.0 110.898 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -130.88 176.94 18.75 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.505 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -123.78 139.25 54.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.884 0.373 . . . . 0.0 110.867 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.658 HG12 ' CE1' ' A' ' 126' ' ' PHE . 42.9 t -139.67 113.31 6.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.124 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 24.4 t -102.83 149.6 24.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.843 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.658 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.6 m-85 -129.29 141.56 51.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.874 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.51 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 82.7 m-85 -56.12 -41.16 74.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.882 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 12.7 m120 -109.21 155.28 21.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.905 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.581 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 26.8 tttt -68.51 -40.16 80.94 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.891 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.422 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.9 OUTLIER -60.87 -58.92 6.41 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.911 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.422 ' C ' ' O ' ' A' ' 130' ' ' TRP . 78.5 m-20 -36.07 -41.57 0.25 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.871 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.462 ' HB2' ' CD1' ' A' ' 126' ' ' PHE . . . -80.51 -54.71 5.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.1 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.512 ' HA ' HD12 ' A' ' 136' ' ' ILE . 12.5 mt-10 -42.29 -54.28 3.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.898 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -45.42 -51.87 10.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.913 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.461 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -60.95 -56.64 18.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.114 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . 0.512 HD12 ' HA ' ' A' ' 133' ' ' GLU . 85.8 mt -37.76 -35.32 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.147 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -90.07 -59.22 2.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.937 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 25.2 mm-40 -63.64 -59.49 4.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.919 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.506 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 78.3 mmm -57.08 -40.09 76.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.897 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.436 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -52.15 118.65 7.7 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.519 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.83 -24.89 29.75 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.556 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . 0.411 ' NE2' ' HA ' ' A' ' 142' ' ' GLN . 8.7 mm-40 -56.64 -177.26 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.823 0.344 . . . . 0.0 110.901 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . 0.492 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 13.6 m95 -120.42 131.32 54.73 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.914 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.534 HD23 HD22 ' A' ' 85' ' ' LEU . 41.6 tp -128.97 129.17 45.08 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.942 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 0.863 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 71.66 -6.07 9.84 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.467 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 123.05 -10.54 8.81 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.504 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 17.1 mtt85 -125.84 147.76 49.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.741 0.305 . . . . 0.0 110.857 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.492 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 22.6 mt-30 -51.61 169.46 0.06 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.927 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.5 pt -140.62 151.19 20.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.14 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.473 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 16.9 ptp180 -113.74 118.79 35.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.862 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.436 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 72.2 p -112.08 125.28 53.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.153 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 11.2 m120 -152.76 179.13 8.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.868 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 15.0 m95 . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.929 179.98 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.574 ' CE1' ' HB2' ' A' ' 129' ' ' LYS . 46.9 m-85 . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.83 0.348 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.474 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.4 OUTLIER -87.21 144.24 26.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.84 179.984 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.407 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 69.4 t -120.22 144.16 29.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.141 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 19.7 t80 -95.63 134.66 38.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.877 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.845 HG12 HD21 ' A' ' 85' ' ' LEU . 2.7 t -132.62 129.1 58.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.11 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.486 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -134.9 179.89 17.19 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.479 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 6.6 t0 57.75 45.05 19.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.82 0.343 . . . . 0.0 110.845 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.845 HD21 HG12 ' A' ' 82' ' ' VAL . 18.5 mt -100.2 131.72 45.98 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.902 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -52.92 154.1 5.39 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.671 0.748 . . . . 0.0 110.842 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.76 -16.0 37.37 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.654 2.236 . . . . 0.0 112.356 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -90.54 -6.53 54.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.853 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.96 HD11 ' HA3' ' A' ' 145' ' ' GLY . 42.6 mm -78.44 137.42 22.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.142 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.8 t -119.09 174.6 6.22 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.088 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.432 ' HA ' HG23 ' A' ' 109' ' ' VAL . 24.5 m -49.41 -47.31 48.03 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.158 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.413 ' O ' ' C ' ' A' ' 93' ' ' ASP . 37.3 mt-10 -56.27 -56.4 21.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.844 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.459 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.2 m-20 -36.51 -58.26 0.72 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.865 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.511 HD11 HG22 ' A' ' 109' ' ' VAL . 14.0 mt -47.43 -59.5 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.159 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.741 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 19.2 mtmt -46.64 -39.44 11.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.892 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.42 ' HB3' ' O ' ' A' ' 93' ' ' ASP . . . -61.26 -35.03 76.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.082 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.75 -54.92 9.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.109 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -87.35 5.37 38.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.896 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.794 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -56.63 -60.41 9.38 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.597 0.713 . . . . 0.0 111.129 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.794 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.7 Cg_endo -69.82 -1.01 7.79 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.677 2.251 . . . . 0.0 112.287 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -100.07 12.63 36.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.866 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.45 146.23 6.69 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.53 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 70.7 mtt180 -55.5 125.72 22.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.756 0.313 . . . . 0.0 110.901 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.43 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 11.9 mt -100.03 133.64 42.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.128 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -102.5 -61.98 1.33 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.852 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -100.34 103.42 14.82 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.846 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.455 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -133.66 124.96 27.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.105 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.401 ' HA ' HG23 ' A' ' 91' ' ' THR . 2.1 ptp180 -161.32 163.21 30.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.511 HG22 HD11 ' A' ' 94' ' ' ILE . 54.9 t -111.97 125.23 69.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.118 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.654 HG21 ' CE2' ' A' ' 121' ' ' TYR . 41.4 t -57.28 135.91 20.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.137 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 18.6 mttp -135.67 150.8 49.71 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.891 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.459 ' O ' ' N ' ' A' ' 116' ' ' GLY . 15.6 t0 -59.68 123.18 16.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.861 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 26.9 ptm -75.05 -2.27 26.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.89 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.0 -38.75 9.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.081 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.435 HG23 ' OD2' ' A' ' 112' ' ' ASP . 25.9 p -116.18 -33.01 5.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.165 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 91.27 25.6 23.48 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.471 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 68.3 mmtt -98.94 157.17 16.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.794 0.331 . . . . 0.0 110.866 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 2.7 t -57.27 121.83 11.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.876 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 35.3 mttt -75.48 -48.02 24.5 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.896 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 142.18 -43.67 1.04 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.482 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.654 ' CE2' HG21 ' A' ' 110' ' ' VAL . 14.8 p90 -98.74 146.45 25.88 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.886 0.374 . . . . 0.0 110.933 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -129.86 179.16 17.0 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.489 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -127.11 140.1 52.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.898 0.38 . . . . 0.0 110.916 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.71 HG12 ' CE1' ' A' ' 126' ' ' PHE . 61.9 t -137.84 116.65 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.152 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 9.5 t -104.81 148.02 27.09 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.873 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.71 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.4 m-85 -128.37 156.38 43.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.892 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -65.16 -41.31 94.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.901 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -119.18 150.82 39.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.907 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.574 ' HB2' ' CE1' ' A' ' 78' ' ' PHE . 30.3 tttt -58.64 -65.68 0.62 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.927 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.45 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -33.17 -59.79 0.35 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.917 179.88 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 70.7 m-20 -37.78 -46.53 0.93 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.822 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.413 ' N ' ' O ' ' A' ' 129' ' ' LYS . . . -73.15 -59.19 2.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.076 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -40.63 -51.93 2.94 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 30.4 t-20 -46.31 -42.07 14.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.893 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -72.67 -54.31 9.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.109 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 96.0 mt -40.56 -31.95 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.109 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -84.84 -64.9 1.08 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.957 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -62.01 -62.55 1.7 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.912 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 68.8 mmm -49.76 -43.72 48.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.862 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.443 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -51.43 109.64 0.84 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.46 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 105.95 -28.23 14.67 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.482 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 54.1 mm-40 -55.01 179.88 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.819 0.343 . . . . 0.0 110.941 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . 0.506 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 13.3 m95 -116.2 127.18 54.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.912 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.416 ' HB3' HG21 ' A' ' 149' ' ' ILE . 32.8 tp -126.69 130.67 50.84 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.939 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 0.96 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.62 -3.61 11.61 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.474 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 120.86 -13.8 9.79 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.515 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 47.5 mtt180 -124.93 153.57 42.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 110.835 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.506 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 20.6 mt-30 -61.49 158.51 14.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.752 HG22 HD23 ' A' ' 85' ' ' LEU . 21.6 pt -130.86 153.07 38.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.145 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.486 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 2.8 ptp180 -111.68 115.95 29.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.887 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.443 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 58.5 p -110.21 128.12 55.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.142 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 19.8 m-20 -159.94 168.68 25.13 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 14.1 m95 . . . . . 0 C--N 1.327 -0.37 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.918 -179.984 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.858 0.361 . . . . 0.0 110.91 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.484 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.7 OUTLIER -83.68 155.6 23.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.858 -179.971 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 36.8 t -134.27 135.34 54.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.112 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . 0.406 ' CE2' ' HG2' ' A' ' 150' ' ' ARG . 15.4 t80 -87.44 128.15 35.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.84 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.978 HG12 HD21 ' A' ' 85' ' ' LEU . 4.0 t -127.96 109.86 20.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.103 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -115.31 -176.91 18.65 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.519 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 59.9 40.26 19.34 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.844 0.354 . . . . 0.0 110.883 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.978 HD21 HG12 ' A' ' 82' ' ' VAL . 11.5 mt -99.04 127.37 44.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.886 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.04 154.19 5.52 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.633 0.73 . . . . 0.0 110.867 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.88 -11.74 31.28 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.67 2.247 . . . . 0.0 112.294 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -92.32 -8.07 46.13 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.894 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.661 HD11 ' HA3' ' A' ' 145' ' ' GLY . 45.7 mm -78.27 138.06 20.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.147 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.5 t -119.55 163.73 16.88 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.118 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.489 ' HA ' HG23 ' A' ' 109' ' ' VAL . 27.7 m -38.85 -46.6 1.31 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.168 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.415 ' O ' ' C ' ' A' ' 93' ' ' ASP . 21.2 mt-10 -56.61 -58.95 5.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.853 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.59 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.9 m-20 -36.42 -57.94 0.73 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.852 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.539 HD11 HG22 ' A' ' 109' ' ' VAL . 8.1 mt -47.44 -58.59 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.103 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.58 ' HE2' ' HB3' ' A' ' 107' ' ' ALA . 26.1 mtmt -49.28 -42.14 40.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.893 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -59.09 -28.77 66.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.127 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.621 ' HB1' ' HE1' ' A' ' 139' ' ' MET . . . -74.75 -54.75 6.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -86.5 8.34 22.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.913 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.783 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -61.61 -60.31 10.77 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.621 0.724 . . . . 0.0 111.145 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.783 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.78 -0.95 7.68 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.681 2.254 . . . . 0.0 112.402 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -100.18 -4.48 29.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.83 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 146.46 156.87 7.09 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.517 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.415 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 31.9 mtm180 -64.84 123.79 20.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.818 0.342 . . . . 0.0 110.867 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 11.1 mt -100.42 139.12 22.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.18 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 8.3 t -110.03 -62.47 1.5 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -100.73 105.28 16.6 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.888 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.58 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -134.16 125.73 28.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.12 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 15.0 ptt180 -160.86 161.32 31.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.87 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.539 HG22 HD11 ' A' ' 94' ' ' ILE . 72.9 t -111.5 119.45 59.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.173 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.774 HG21 ' CE2' ' A' ' 121' ' ' TYR . 42.8 t -51.45 133.13 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.113 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -132.98 151.59 52.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.457 ' O ' ' N ' ' A' ' 116' ' ' GLY . 39.5 t0 -60.33 119.29 7.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.883 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 22.7 ptp -68.68 -2.28 8.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.913 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -97.55 -47.16 5.76 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.125 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 43.2 p -110.05 -34.5 6.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.162 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 92.66 31.98 8.4 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.468 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt -99.52 148.69 24.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.779 0.323 . . . . 0.0 110.88 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 19.5 t -54.92 102.09 0.06 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.832 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 42.2 mttt -52.02 -53.46 41.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.883 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 149.75 -39.82 0.88 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.488 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.774 ' CE2' HG21 ' A' ' 110' ' ' VAL . 5.8 p90 -100.07 161.27 13.71 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.931 0.396 . . . . 0.0 110.887 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -142.27 174.96 23.06 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.455 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -124.59 137.98 54.35 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.896 0.379 . . . . 0.0 110.932 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.591 HG12 ' CE1' ' A' ' 126' ' ' PHE . 71.0 t -138.11 120.38 18.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.105 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 21.1 m -103.06 150.88 23.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.828 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.591 ' CE1' HG12 ' A' ' 124' ' ' VAL . 15.3 m-85 -131.03 142.89 50.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.862 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.415 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 97.5 m-85 -60.9 -32.53 71.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.852 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 21.6 m-20 -117.66 169.58 9.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.849 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.519 ' HE3' ' CH2' ' A' ' 153' ' ' TRP . 20.6 tptm -78.99 -53.16 7.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.89 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.415 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.8 OUTLIER -48.07 -59.83 3.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.914 179.925 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 130' ' ' TRP . 79.4 m-20 -35.83 -40.63 0.19 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.908 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.75 -62.76 1.56 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.096 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -42.41 -58.88 2.05 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.877 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -39.97 -47.39 2.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.889 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.464 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -67.57 -54.45 19.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.079 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 54.9 mt -41.66 -35.37 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.163 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -88.62 -54.91 3.94 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.98 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 5.0 mm100 -68.11 -62.88 1.2 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.906 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.621 ' HE1' ' HB1' ' A' ' 97' ' ' ALA . 84.6 mmm -52.96 -35.64 59.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.874 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.442 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -52.97 110.6 1.34 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.514 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 100.97 -22.73 38.28 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.481 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 33.5 mm-40 -55.05 169.8 0.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.786 0.326 . . . . 0.0 110.925 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . 0.436 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 14.7 m95 -107.95 113.09 26.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.908 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.58 HD13 ' HB2' ' A' ' 97' ' ' ALA . 56.9 tp -103.98 129.74 51.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.899 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 0.661 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 68.83 -77.77 0.28 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.511 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -155.17 13.74 0.46 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.482 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 32.2 mtp85 -153.17 160.8 42.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.436 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 24.0 mt-30 -62.03 168.7 3.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.933 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.542 HD11 ' HE3' ' A' ' 139' ' ' MET . 22.4 pt -140.2 144.47 27.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.13 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.406 ' HG2' ' CE2' ' A' ' 81' ' ' PHE . 3.7 ttm180 -105.5 124.21 49.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.907 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.442 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 61.9 p -117.52 132.54 56.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.132 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -157.2 169.17 25.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . 0.519 ' CH2' ' HE3' ' A' ' 129' ' ' LYS . 7.3 m95 . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.982 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.933 0.397 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.476 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.5 OUTLIER -82.51 142.15 32.08 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.867 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 56.0 t -120.94 148.94 23.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.159 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -100.69 136.97 39.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.887 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.884 HG12 HD21 ' A' ' 85' ' ' LEU . 3.5 t -136.77 109.66 8.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.134 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -120.97 179.57 16.3 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.484 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 4.0 t70 62.51 43.08 8.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.827 0.346 . . . . 0.0 110.838 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.884 HD21 HG12 ' A' ' 82' ' ' VAL . 9.1 mt -103.31 135.66 44.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.934 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.03 153.9 5.79 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.651 0.739 . . . . 0.0 110.901 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -16.56 37.67 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.678 2.252 . . . . 0.0 112.374 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -89.29 -7.01 56.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.907 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.909 HD11 ' HA3' ' A' ' 145' ' ' GLY . 40.3 mm -75.54 138.46 20.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.127 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.5 t -119.14 168.2 11.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.152 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.464 ' HA ' HG23 ' A' ' 109' ' ' VAL . 7.4 m -46.36 -44.12 16.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.112 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 29.6 mt-10 -58.24 -51.26 70.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.901 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.469 ' CB ' HG23 ' A' ' 89' ' ' ILE . 4.6 m-20 -44.04 -55.97 4.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.523 HD11 HG22 ' A' ' 109' ' ' VAL . 8.4 mt -49.53 -58.57 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.139 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.59 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 24.9 mtmt -48.99 -41.71 35.33 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.883 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -59.8 -31.89 70.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.108 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.429 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -72.52 -56.97 4.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.104 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.424 ' C ' HD11 ' A' ' 104' ' ' ILE . 33.5 m-85 -83.79 11.94 6.75 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.88 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.761 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -67.43 -59.95 6.41 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.583 0.706 . . . . 0.0 111.113 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.761 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.77 -0.83 7.48 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.7 2.266 . . . . 0.0 112.319 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.412 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 70.8 m-85 -99.77 -13.37 19.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.926 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 156.59 155.14 7.3 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.508 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.455 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 35.8 mtt-85 -63.31 123.21 18.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.795 0.331 . . . . 0.0 110.897 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.424 HD11 ' C ' ' A' ' 98' ' ' PHE . 12.6 mt -100.49 142.6 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.133 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.461 ' HB2' ' CZ ' ' A' ' 127' ' ' PHE . 38.6 t -114.94 -61.53 1.74 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.827 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -100.97 101.03 11.74 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.829 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.518 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -130.24 124.24 32.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.117 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 10.2 ptp180 -160.72 153.78 21.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.88 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.523 HG22 HD11 ' A' ' 94' ' ' ILE . 69.2 t -102.3 125.94 56.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.75 HG12 ' HG3' ' A' ' 119' ' ' LYS . 56.6 t -55.61 139.99 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.108 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 49.7 mttt -138.79 149.22 44.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.889 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 48.8 t0 -63.1 121.98 14.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.859 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 11.4 ptp -71.4 -1.45 13.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.901 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.97 -54.28 3.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.079 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 26.8 p -99.61 -24.99 14.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.186 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 81.35 27.17 49.42 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.457 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 73.6 mmtt -96.75 164.88 12.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.776 0.322 . . . . 0.0 110.914 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 24.6 t -66.33 115.04 5.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.86 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.75 ' HG3' HG12 ' A' ' 110' ' ' VAL . 7.0 mmtm -64.93 -40.92 95.78 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.894 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.549 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 130.44 -46.78 1.05 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.481 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.612 ' CE2' HG21 ' A' ' 110' ' ' VAL . 29.6 p90 -100.02 141.18 33.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.905 0.383 . . . . 0.0 110.947 -179.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -125.28 178.64 16.49 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.513 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 62.5 m-85 -121.25 139.9 52.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.878 0.37 . . . . 0.0 110.874 -179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.703 HG12 ' CE1' ' A' ' 126' ' ' PHE . 63.9 t -136.56 115.68 15.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.118 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 43.9 t -101.63 151.43 22.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.833 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.703 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.8 m-85 -131.0 148.04 52.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.88 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.461 ' CZ ' ' HB2' ' A' ' 105' ' ' SER . 68.0 m-85 -64.91 -40.41 95.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.867 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -111.73 155.27 23.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.877 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.466 ' O ' ' C ' ' A' ' 130' ' ' TRP . 38.4 tttt -68.38 -63.4 1.07 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.893 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.466 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -33.19 -60.09 0.34 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.949 179.897 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.4 ' C ' ' O ' ' A' ' 130' ' ' TRP . 61.9 m-20 -37.77 -54.83 1.22 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.888 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -60.09 -64.95 0.77 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.085 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -39.37 -58.57 1.2 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.919 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -42.01 -50.29 4.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.878 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.468 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -66.79 -59.95 3.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.062 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 93.4 mt -37.67 -37.74 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.5 mt-30 -84.42 -61.66 1.75 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.935 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -61.24 -59.75 4.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.907 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.468 ' N ' ' O ' ' A' ' 135' ' ' ALA . 86.9 mmm -57.38 -36.33 71.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.855 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -52.39 104.31 0.17 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.495 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 111.86 -31.72 6.85 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.488 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 17.2 mm-40 -49.41 179.82 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.798 0.332 . . . . 0.0 110.923 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . 0.45 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 13.7 m95 -115.44 126.89 54.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.893 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.696 HD23 HD22 ' A' ' 85' ' ' LEU . 40.7 tp -123.29 126.78 47.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 0.909 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 71.66 -6.12 9.71 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.549 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 123.7 -11.11 8.42 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.485 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 17.8 mtt-85 -125.58 146.9 49.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.789 0.328 . . . . 0.0 110.866 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.45 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 22.4 mt-30 -56.18 158.64 3.93 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.921 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.699 HG22 HD23 ' A' ' 85' ' ' LEU . 21.0 pt -132.29 143.56 39.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.143 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 11.2 ptt180 -107.07 109.32 21.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.876 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 62.4 p -101.0 131.98 46.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.188 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 17.1 t30 -155.35 172.88 17.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.881 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 82.8 m95 . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.912 179.974 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.55 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 5.1 m-85 . . . . . 0 C--O 1.232 0.142 0 CA-C-O 120.844 0.354 . . . . 0.0 110.84 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.448 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.6 OUTLIER -83.99 149.09 26.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.836 -179.987 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.554 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 39.7 t -125.0 141.25 45.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.148 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.1 t80 -92.31 134.03 35.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.894 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.984 HG12 HD21 ' A' ' 85' ' ' LEU . 12.2 t -132.62 112.95 19.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.1 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.41 ' C ' ' HG2' ' A' ' 150' ' ' ARG . . . -120.52 -179.63 16.31 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.431 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.408 ' O ' ' O ' ' A' ' 148' ' ' GLN . 5.2 m-20 63.9 43.79 5.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.812 0.339 . . . . 0.0 110.878 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.984 HD21 HG12 ' A' ' 82' ' ' VAL . 9.6 mt -102.37 129.16 48.76 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.902 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.1 t -53.26 154.27 5.99 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.705 0.764 . . . . 0.0 110.849 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -7.65 21.6 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.719 2.28 . . . . 0.0 112.341 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -99.98 -8.67 23.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.864 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.826 HD11 ' HA3' ' A' ' 145' ' ' GLY . 38.6 mm -75.29 141.2 16.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.14 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.0 t -119.46 173.13 7.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.14 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.7 HG23 ' HA ' ' A' ' 108' ' ' ARG . 88.0 m -50.22 -47.28 54.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.099 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -54.74 -52.97 60.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.884 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.498 ' CB ' HG23 ' A' ' 89' ' ' ILE . 1.6 m-20 -42.72 -55.78 3.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.821 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.631 HD11 HG22 ' A' ' 109' ' ' VAL . 10.2 mt -49.5 -58.66 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.112 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.717 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 25.3 mtmt -47.87 -39.51 18.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.82 -32.72 72.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.095 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.629 ' HB1' ' HE1' ' A' ' 139' ' ' MET . . . -71.71 -51.85 20.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.094 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.488 ' C ' HD11 ' A' ' 104' ' ' ILE . 14.2 m-85 -93.51 13.2 22.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.882 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.767 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -66.76 -59.82 7.33 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.538 0.685 . . . . 0.0 111.081 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.767 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.3 Cg_endo -69.78 -0.61 7.18 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.685 2.257 . . . . 0.0 112.305 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -99.75 -1.33 38.0 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.846 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 142.54 143.24 4.15 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.451 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 68.4 mtm180 -53.47 123.38 11.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.795 0.331 . . . . 0.0 110.891 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.488 HD11 ' C ' ' A' ' 98' ' ' PHE . 20.1 mt -100.0 137.34 27.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.167 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.472 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 7.5 p -105.1 -62.3 1.36 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.884 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -100.74 105.14 16.44 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.501 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -135.18 125.29 26.02 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.13 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.7 ' HA ' HG23 ' A' ' 91' ' ' THR . 8.2 ptp180 -160.22 169.17 23.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.631 HG22 HD11 ' A' ' 94' ' ' ILE . 95.8 t -116.93 117.54 55.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.133 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.852 HG12 ' HG3' ' A' ' 119' ' ' LYS . 60.6 t -47.1 141.08 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.172 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 80.1 mttt -140.31 152.09 45.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.902 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -63.88 121.55 14.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.851 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 1.1 pmm? -74.89 -1.47 22.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.856 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.14 -44.37 6.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.097 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 52.1 p -111.12 -35.16 5.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.175 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 94.63 31.01 8.08 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.505 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 22.9 mmtm -99.53 164.39 12.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.822 0.344 . . . . 0.0 110.891 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 29.6 t -65.83 109.88 2.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.866 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.852 ' HG3' HG12 ' A' ' 110' ' ' VAL . 11.3 mmtp -59.78 -39.36 84.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.878 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.508 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 128.6 -47.16 1.04 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.549 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.577 ' CE2' HG21 ' A' ' 110' ' ' VAL . 12.8 p90 -99.94 146.56 26.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.969 0.414 . . . . 0.0 110.902 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -127.96 178.03 17.29 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.459 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 36.9 m-85 -121.73 140.12 52.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.912 0.386 . . . . 0.0 110.908 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.68 HG12 ' CE1' ' A' ' 126' ' ' PHE . 47.4 t -136.77 113.75 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.108 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . 0.436 ' O ' HG23 ' A' ' 104' ' ' ILE . 69.0 m -102.04 150.48 23.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.867 -179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.68 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.4 m-85 -130.77 143.33 50.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.846 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.472 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 22.7 m-85 -50.27 -48.89 54.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.904 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -106.85 173.31 6.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.886 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.55 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 3.5 ttmt -79.36 -51.8 8.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.927 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.42 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.0 OUTLIER -48.03 -58.4 4.49 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.887 179.952 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 130' ' ' TRP . 81.9 m-20 -35.72 -42.74 0.26 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.86 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.554 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -78.7 -60.89 2.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.128 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.595 ' HA ' HD12 ' A' ' 136' ' ' ILE . 18.6 mt-10 -37.83 -55.56 1.18 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -43.15 -55.51 3.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.902 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.466 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -59.21 -54.66 44.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.075 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . 0.595 HD12 ' HA ' ' A' ' 133' ' ' GLU . 93.0 mt -38.62 -36.57 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.14 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -87.94 -60.8 1.87 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.908 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 20.1 mm-40 -61.32 -59.49 5.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.9 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.629 ' HE1' ' HB1' ' A' ' 97' ' ' ALA . 87.3 mmm -59.32 -35.57 74.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.429 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -53.31 111.03 1.56 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.466 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 102.11 -28.86 14.03 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -50.63 178.89 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.746 0.308 . . . . 0.0 110.898 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . 0.588 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 14.3 m95 -115.31 119.55 36.66 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.959 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.595 HD13 ' HB2' ' A' ' 97' ' ' ALA . 60.6 tp -109.5 129.5 55.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.918 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 0.826 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.24 -78.57 0.43 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.476 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -156.04 14.08 0.4 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.517 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 66.7 mtt180 -153.5 154.38 34.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.744 0.307 . . . . 0.0 110.883 -179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.588 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 15.8 mt-30 -55.91 167.8 0.54 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.914 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.499 HG21 ' HB3' ' A' ' 144' ' ' LEU . 28.8 pt -140.81 147.69 22.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.155 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.41 ' HG2' ' C ' ' A' ' 83' ' ' GLY . 15.8 ptt180 -111.83 120.47 42.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.805 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.429 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 82.5 p -111.02 133.12 53.66 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -155.06 165.52 36.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.886 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 12.9 m95 . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.945 179.954 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.498 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 75.9 m-85 . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.908 0.385 . . . . 0.0 110.898 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.42 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.9 OUTLIER -88.49 163.81 15.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.895 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.407 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 49.0 t -138.32 143.66 32.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.112 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -98.11 132.08 43.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.854 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.983 HG12 HD21 ' A' ' 85' ' ' LEU . 2.7 t -132.63 109.79 15.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.136 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.446 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -116.3 -179.45 18.03 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.469 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.4 ' O ' ' O ' ' A' ' 148' ' ' GLN . 14.4 m-20 63.8 26.21 14.31 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.891 0.377 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.983 HD21 HG12 ' A' ' 82' ' ' VAL . 10.7 mt -83.79 135.59 34.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.951 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -52.93 147.61 15.68 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.717 0.77 . . . . 0.0 110.854 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -6.2 18.04 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.638 2.225 . . . . 0.0 112.344 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -100.61 -5.02 27.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.851 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.917 HD11 ' HA3' ' A' ' 145' ' ' GLY . 30.8 mm -74.8 145.29 11.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.124 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.411 HG22 ' OD1' ' A' ' 93' ' ' ASP . 9.1 t -121.03 165.0 15.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.133 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.631 ' HA ' HG23 ' A' ' 109' ' ' VAL . 22.5 m -43.63 -50.7 7.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.107 -179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 93' ' ' ASP . 34.3 mt-10 -54.55 -57.26 12.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.892 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.431 ' CB ' HG23 ' A' ' 89' ' ' ILE . 0.5 OUTLIER -35.78 -57.86 0.64 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.89 179.974 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.446 ' CD1' HG22 ' A' ' 109' ' ' VAL . 8.7 mt -47.36 -59.31 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.117 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.593 ' HE2' ' HB3' ' A' ' 107' ' ' ALA . 22.9 mtmt -47.93 -39.21 18.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.926 179.822 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 93' ' ' ASP . . . -60.82 -35.03 75.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.079 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -71.68 -51.81 21.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.09 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.529 ' C ' HD11 ' A' ' 104' ' ' ILE . 23.0 m-85 -89.43 16.82 6.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.865 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.8 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -68.05 -60.61 4.98 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.595 0.712 . . . . 0.0 111.102 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.8 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.5 Cg_endo -69.8 -1.43 8.5 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.647 2.232 . . . . 0.0 112.318 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -100.45 11.45 39.43 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.842 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 126.65 133.16 3.79 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.477 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 16.9 mtt180 -46.08 126.75 7.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.799 0.333 . . . . 0.0 110.87 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.621 ' CG2' HG13 ' A' ' 124' ' ' VAL . 11.0 mt -100.06 138.13 25.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.139 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.52 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 2.6 t -107.61 -62.72 1.39 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -100.56 104.27 15.62 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.842 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.593 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -134.46 125.92 28.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.076 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.441 ' NH1' ' HA ' ' A' ' 110' ' ' VAL . 0.1 OUTLIER -158.88 157.51 31.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.884 -179.911 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.631 HG23 ' HA ' ' A' ' 91' ' ' THR . 88.3 t -104.82 117.71 50.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.122 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.856 HG11 ' CZ ' ' A' ' 121' ' ' TYR . 85.8 t -50.33 143.04 2.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.103 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 33.8 mttm -142.68 157.1 45.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.865 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -71.37 128.03 34.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.858 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 24.8 ptp -76.96 1.06 18.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -99.59 -46.04 5.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.092 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 24.4 p -108.85 -26.28 10.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.169 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 81.5 24.62 56.09 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.479 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 66.8 mttt -97.88 164.59 12.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.814 0.34 . . . . 0.0 110.902 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 2.2 m -59.39 119.04 6.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.855 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.647 ' HG3' HG12 ' A' ' 110' ' ' VAL . 24.4 mmtt -71.25 -39.32 71.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.945 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 128.99 -40.5 1.69 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.459 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.856 ' CZ ' HG11 ' A' ' 110' ' ' VAL . 7.0 p90 -100.23 156.04 17.44 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.911 0.386 . . . . 0.0 110.956 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.17 174.8 21.53 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.56 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -130.55 139.24 50.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.888 0.375 . . . . 0.0 110.857 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.621 HG13 ' CG2' ' A' ' 104' ' ' ILE . 76.7 t -134.49 133.56 54.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.097 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 32.5 t -113.19 138.58 49.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.83 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.619 ' CD1' ' HB2' ' A' ' 132' ' ' ALA . 75.2 m-85 -118.65 147.38 43.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.878 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.52 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 23.3 m-85 -61.64 -36.21 80.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 4.7 m-20 -114.75 174.58 5.89 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.866 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.498 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 67.1 tttt -84.12 -39.34 19.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.93 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.42 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -61.15 -53.11 61.12 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.928 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 130' ' ' TRP . 75.6 m-20 -35.88 -52.39 0.73 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.891 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.619 ' HB2' ' CD1' ' A' ' 126' ' ' PHE . . . -64.97 -66.18 0.58 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.096 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.482 ' HA ' HD12 ' A' ' 136' ' ' ILE . 3.8 mm-40 -34.7 -56.5 0.54 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.866 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -42.26 -51.68 4.69 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.924 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -64.7 -55.79 17.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.086 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . 0.482 HD12 ' HA ' ' A' ' 133' ' ' GLU . 87.4 mt -39.2 -33.46 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.14 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 12.2 mt-30 -84.9 -67.38 0.8 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.889 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 -57.73 -61.58 2.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.901 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 64.8 mmm -53.47 -41.1 65.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.868 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.408 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -49.38 104.72 0.11 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.519 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 106.7 -31.16 8.51 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.454 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 50.7 mm-40 -49.33 173.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.823 0.344 . . . . 0.0 110.927 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . 0.485 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 12.9 m95 -108.89 127.41 54.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.899 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.537 ' HB3' HG21 ' A' ' 149' ' ' ILE . 36.6 tp -128.48 130.76 47.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.887 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 0.917 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.77 -2.09 13.48 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.488 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 117.26 -14.27 13.58 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.48 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 20.1 mtt-85 -124.12 143.25 50.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.804 0.335 . . . . 0.0 110.829 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.485 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 28.4 mt-30 -52.5 160.04 0.92 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.951 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.56 HG22 HD23 ' A' ' 85' ' ' LEU . 21.3 pt -134.15 152.74 34.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.15 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.446 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 10.7 ptp180 -113.24 118.85 35.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.408 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 41.5 p -110.49 133.33 53.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.127 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 60.5 m-20 -163.06 164.43 25.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.887 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 14.3 m95 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.922 179.99 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.564 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 17.5 m-85 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.859 0.361 . . . . 0.0 110.903 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.449 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 1.1 m-70 -86.9 149.1 25.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.835 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.475 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 40.2 t -129.06 144.43 38.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.112 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.6 t80 -94.78 135.28 36.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.843 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.761 HG12 HD21 ' A' ' 85' ' ' LEU . 4.0 t -132.43 119.37 38.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.066 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.418 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -129.24 170.01 20.39 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.494 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 2.2 t70 72.43 38.92 0.78 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.847 0.356 . . . . 0.0 110.904 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.761 HD21 HG12 ' A' ' 82' ' ' VAL . 9.9 mt -100.39 133.82 44.24 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.965 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 t -54.34 153.74 9.42 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.654 0.74 . . . . 0.0 110.804 -179.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 -14.38 36.1 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.638 2.225 . . . . 0.0 112.406 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -90.4 -10.25 44.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.89 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.671 HD11 ' HA3' ' A' ' 145' ' ' GLY . 37.5 mm -76.64 135.7 26.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.16 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.409 ' O ' ' C ' ' A' ' 91' ' ' THR . 14.4 t -117.27 160.43 21.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.162 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.622 ' HA ' HG23 ' A' ' 109' ' ' VAL . 20.2 m -36.99 -47.14 0.69 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.13 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -52.92 -54.72 30.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.875 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.613 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.1 m-20 -42.26 -54.58 3.65 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.441 ' CD1' HG22 ' A' ' 109' ' ' VAL . 15.1 mt -51.04 -59.95 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.154 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.642 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 23.3 mtmt -48.27 -39.62 22.14 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.928 179.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.92 -32.17 73.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.043 179.859 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -73.15 -54.59 8.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.127 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.412 ' C ' HD11 ' A' ' 104' ' ' ILE . 28.9 m-85 -86.08 11.3 12.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.881 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.763 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -65.26 -59.5 9.67 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.593 0.711 . . . . 0.0 111.112 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.763 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.2 Cg_endo -69.76 -0.58 7.12 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.678 2.252 . . . . 0.0 112.354 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.581 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 78.6 m-85 -99.73 -8.59 24.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.885 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 147.52 133.66 2.41 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.507 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 34.4 mtp180 -45.42 123.63 4.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.775 0.322 . . . . 0.0 110.869 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.552 HG23 ' O ' ' A' ' 125' ' ' SER . 9.9 mt -99.39 137.96 25.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.139 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.436 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 89.5 p -104.02 -65.1 1.04 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.846 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -100.65 106.41 17.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.868 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.587 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -135.05 127.9 31.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.118 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.427 ' HD3' ' N ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -161.06 158.94 28.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.886 -179.904 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.622 HG23 ' HA ' ' A' ' 91' ' ' THR . 88.6 t -107.64 116.9 52.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.129 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.668 HG21 ' CE2' ' A' ' 121' ' ' TYR . 59.6 t -48.3 137.97 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.135 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 53.6 mttt -134.48 156.46 48.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.874 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 116' ' ' GLY . 10.4 t0 -60.6 122.99 16.09 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.841 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 11.0 tpt -67.63 -4.26 11.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.896 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -106.34 -52.23 2.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.078 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 53.8 p -95.14 -28.59 14.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.131 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 79.53 26.67 56.41 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.491 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 54.0 mmtt -100.0 149.75 23.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.791 0.329 . . . . 0.0 110.869 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 8.2 t -50.38 108.3 0.22 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.878 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 40.3 mttt -61.47 -43.81 98.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.917 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 142.28 -42.44 1.13 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.502 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.668 ' CE2' HG21 ' A' ' 110' ' ' VAL . 15.5 p90 -100.04 146.13 27.11 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.927 0.394 . . . . 0.0 110.91 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -128.91 179.98 16.3 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.473 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -125.69 140.05 53.03 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.879 0.371 . . . . 0.0 110.899 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.539 HG12 ' CE1' ' A' ' 126' ' ' PHE . 50.7 t -135.17 121.34 32.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.161 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . 0.552 ' O ' HG23 ' A' ' 104' ' ' ILE . 5.2 m -106.01 148.33 27.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.854 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.539 ' CE1' HG12 ' A' ' 124' ' ' VAL . 21.2 m-85 -130.73 147.13 52.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.893 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.436 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 23.4 m-85 -59.17 -43.18 92.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.846 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 23.9 m120 -118.9 157.33 27.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.888 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.564 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 8.3 ttmt -60.43 -63.47 1.29 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.89 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.443 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -34.66 -52.82 0.53 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -43.89 -45.6 7.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.892 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.475 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -76.53 -57.04 4.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.096 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.404 ' HG2' ' CZ2' ' A' ' 153' ' ' TRP . 11.2 mt-10 -44.33 -56.73 3.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.861 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 51.1 t30 -45.13 -42.88 9.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.837 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.485 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -71.83 -53.95 11.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.095 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 96.8 mt -40.63 -40.84 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.119 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -78.8 -59.61 2.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.917 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 15.2 mm-40 -63.7 -63.33 1.2 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.885 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.581 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 82.3 mmm -51.6 -39.06 57.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.865 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -54.08 112.34 2.51 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.519 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 91.58 21.51 34.14 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.531 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 62.8 mm-40 -101.25 168.44 9.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.792 0.33 . . . . 0.0 110.95 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . 0.426 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 14.8 m95 -105.0 109.15 21.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.892 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.497 HD23 HD22 ' A' ' 85' ' ' LEU . 63.1 tp -102.01 128.45 48.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.917 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 0.671 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 68.63 -72.51 0.36 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.484 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -160.88 17.56 0.19 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.499 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 33.3 mtt85 -155.78 156.72 35.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.782 0.325 . . . . 0.0 110.89 -179.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.426 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 46.7 mt-30 -59.68 173.37 0.57 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.908 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.4 HG21 ' HB3' ' A' ' 144' ' ' LEU . 20.2 pt -147.08 148.95 16.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.12 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.447 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 8.4 ptp180 -115.65 120.91 40.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.871 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 55.8 p -114.64 133.26 55.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.123 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -158.85 161.64 36.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.876 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . 0.404 ' CZ2' ' HG2' ' A' ' 133' ' ' GLU . 7.7 m95 . . . . . 0 C--N 1.328 -0.352 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.582 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 76.5 m-85 . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.863 0.363 . . . . 0.0 110.878 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.471 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.6 OUTLIER -83.92 156.73 22.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.827 -179.986 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.461 HG22 HD11 ' A' ' 136' ' ' ILE . 53.8 t -130.62 148.96 33.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.128 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 19.3 t80 -99.18 135.85 40.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.882 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.551 ' CG1' HD21 ' A' ' 85' ' ' LEU . 43.7 t -133.02 130.2 58.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.124 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.492 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -136.47 173.22 22.12 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.474 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 7.6 t0 64.4 52.1 1.92 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.846 0.355 . . . . 0.0 110.914 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.632 HD22 HD23 ' A' ' 144' ' ' LEU . 16.2 mt -108.26 131.64 54.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.24 154.07 6.14 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.659 0.742 . . . . 0.0 110.824 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -8.07 22.67 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.71 2.274 . . . . 0.0 112.336 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -100.06 -3.48 31.89 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.908 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.964 HD11 ' HA3' ' A' ' 145' ' ' GLY . 45.6 mm -78.96 137.11 22.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.102 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.3 t -119.0 168.41 10.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.135 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.547 HG22 ' CE ' ' A' ' 95' ' ' LYS . 36.8 m -47.47 -41.57 20.91 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.131 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 35.8 mt-10 -61.13 -53.21 59.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.902 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -42.87 -56.15 3.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.83 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.466 HD11 HG22 ' A' ' 109' ' ' VAL . 19.4 mt -50.09 -57.49 2.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.141 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.605 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 26.7 mtmt -46.93 -40.03 13.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.904 179.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.7 -32.58 73.7 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.106 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -68.87 -53.91 18.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.115 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 21.2 m-85 -89.43 10.44 22.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.847 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.758 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -64.51 -59.77 9.96 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.572 0.701 . . . . 0.0 111.131 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.758 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.8 -0.76 7.41 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.667 2.244 . . . . 0.0 112.345 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 -100.0 -11.76 20.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.881 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 155.7 157.01 8.05 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.494 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.529 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 27.1 mtp180 -64.52 123.46 19.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.825 0.345 . . . . 0.0 110.874 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 18.7 mt -100.43 144.56 12.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.112 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 65.8 p -119.91 -59.21 1.82 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.806 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . 0.443 ' HB3' ' CB ' ' A' ' 125' ' ' SER . 8.7 t0 -100.82 100.52 11.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.857 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.479 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -130.59 127.11 38.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -162.23 156.54 21.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.845 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.466 HG22 HD11 ' A' ' 94' ' ' ILE . 72.9 t -106.16 119.98 56.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.134 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.611 HG21 ' CE2' ' A' ' 121' ' ' TYR . 95.1 t -53.47 134.43 15.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.113 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 38.7 mttt -134.7 146.37 49.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.848 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.426 ' O ' ' N ' ' A' ' 116' ' ' GLY . 29.6 t0 -57.4 120.53 8.37 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.9 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 7.7 ptp -68.61 -3.49 12.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.915 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -100.58 -50.1 3.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.111 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 44.0 p -97.69 -34.28 10.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.128 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 88.81 17.43 56.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 63.7 mttt -92.3 167.92 11.67 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.822 0.344 . . . . 0.0 110.888 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 8.2 t -69.34 113.24 6.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.849 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.442 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 37.1 mttt -62.87 -50.79 69.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.878 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 145.08 -41.4 1.07 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.447 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.611 ' CE2' HG21 ' A' ' 110' ' ' VAL . 10.2 p90 -98.99 149.7 22.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.937 0.398 . . . . 0.0 110.919 -179.791 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -129.77 175.54 19.02 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.458 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 47.8 m-85 -124.2 135.47 53.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.857 0.361 . . . . 0.0 110.882 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.546 HG12 ' CE1' ' A' ' 126' ' ' PHE . 56.5 t -134.53 122.0 37.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.127 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . 0.443 ' CB ' ' HB3' ' A' ' 106' ' ' ASP . 16.3 t -106.45 149.62 26.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.855 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.546 ' CE1' HG12 ' A' ' 124' ' ' VAL . 16.5 m-85 -130.96 138.23 49.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.9 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.529 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 84.1 m-85 -52.44 -35.24 51.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -118.12 167.0 11.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.876 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.582 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 9.3 tttp -77.19 -41.7 40.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.878 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.423 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -57.98 -59.44 5.25 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.88 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.423 ' C ' ' O ' ' A' ' 130' ' ' TRP . 45.3 m-20 -35.91 -39.91 0.18 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.879 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.423 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -77.79 -58.87 3.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.084 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -42.72 -54.78 3.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.859 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 56.3 t30 -43.34 -41.42 4.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.881 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.403 ' O ' ' N ' ' A' ' 137' ' ' GLN . . . -75.72 -58.15 3.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.102 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . 0.461 HD11 HG22 ' A' ' 80' ' ' VAL . 98.2 mt -38.92 -30.41 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.152 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . 0.403 ' N ' ' O ' ' A' ' 135' ' ' ALA . 7.0 mt-30 -87.49 -65.75 0.98 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.916 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 10.3 mm-40 -61.54 -61.03 2.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.955 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.652 ' HE3' HD11 ' A' ' 149' ' ' ILE . 79.0 mmm -49.18 -35.62 17.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -57.56 116.38 8.02 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.474 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 99.89 -19.09 54.69 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.45 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -66.38 177.18 1.56 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.788 0.328 . . . . 0.0 110.903 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . 0.459 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 13.8 m95 -115.04 127.11 55.44 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.908 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.632 HD23 HD22 ' A' ' 85' ' ' LEU . 55.5 tp -121.28 123.88 43.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.926 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 0.964 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 73.65 -11.59 5.54 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.532 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 130.25 -7.18 6.0 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.485 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 67.9 mtt180 -130.35 144.93 51.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.767 0.318 . . . . 0.0 110.902 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.459 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 31.2 mt-30 -53.57 158.21 1.9 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.933 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.652 HD11 ' HE3' ' A' ' 139' ' ' MET . 21.2 pt -131.7 145.29 35.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.129 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.492 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 19.3 ptp180 -106.8 120.14 41.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.874 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 42.4 p -112.71 127.85 56.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.121 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -153.4 166.2 33.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.868 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 23.2 m95 . . . . . 0 C--N 1.328 -0.368 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.953 179.972 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.577 ' CE1' ' HD3' ' A' ' 129' ' ' LYS . 90.9 m-85 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.862 0.363 . . . . 0.0 110.903 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.544 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.1 OUTLIER -81.75 150.18 28.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 55.3 t -124.75 146.28 30.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.137 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.2 t80 -98.07 134.39 41.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.919 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.7 HG12 HD21 ' A' ' 85' ' ' LEU . 4.3 t -130.42 130.13 65.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.109 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.495 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -136.24 179.26 18.05 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.446 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.402 ' O ' ' O ' ' A' ' 148' ' ' GLN . 5.4 t70 56.39 53.63 8.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.852 0.358 . . . . 0.0 110.845 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.7 HD21 HG12 ' A' ' 82' ' ' VAL . 15.8 mt -109.94 131.14 55.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -53.01 154.91 4.74 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.646 0.736 . . . . 0.0 110.873 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -4.19 13.53 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.653 2.236 . . . . 0.0 112.348 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . 0.412 ' O ' ' HG3' ' A' ' 88' ' ' GLU . 1.4 tt0 -97.58 -28.81 13.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.857 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.838 HD11 ' HA3' ' A' ' 145' ' ' GLY . 47.9 mm -57.73 132.52 22.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.137 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.1 t -119.38 166.8 12.59 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.161 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.522 HG22 ' CE ' ' A' ' 95' ' ' LYS . 95.8 m -39.79 -49.02 2.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.169 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -56.04 -57.6 11.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.852 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -39.59 -56.8 1.6 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.483 ' CD1' HG22 ' A' ' 109' ' ' VAL . 16.5 mt -48.79 -59.44 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.132 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.717 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 20.8 mtmt -47.41 -38.93 14.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.914 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.97 -37.01 85.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.059 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -68.05 -52.9 30.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.112 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 22.2 m-85 -89.27 6.91 38.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.93 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.778 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -59.48 -59.79 12.71 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.618 0.723 . . . . 0.0 111.082 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.778 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.6 Cg_endo -69.76 -0.92 7.62 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.72 2.28 . . . . 0.0 112.322 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -101.49 12.51 37.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.887 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.419 ' HA3' ' CG ' ' A' ' 131' ' ' ASP . . . 129.59 155.72 8.56 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.482 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.427 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 28.7 mtt180 -65.7 126.16 27.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.808 0.337 . . . . 0.0 110.841 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.436 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 13.8 mt -100.27 140.29 19.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.157 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 5.4 t -112.05 -62.09 1.62 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.883 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -100.81 102.91 14.09 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.867 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.529 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -130.32 125.5 34.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.083 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 15.2 ptt180 -160.81 154.98 22.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.886 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.483 HG22 ' CD1' ' A' ' 94' ' ' ILE . 60.1 t -105.2 119.14 53.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.11 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.611 HG21 ' CD2' ' A' ' 121' ' ' TYR . 61.1 t -53.12 133.06 15.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.126 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . 0.423 ' HG2' ' C ' ' A' ' 117' ' ' LYS . 37.0 mttm -134.14 149.25 51.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.94 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.548 ' OD2' ' HB3' ' A' ' 114' ' ' ALA . 1.7 t70 -62.02 132.0 51.46 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.863 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 26.0 ptm -80.47 1.36 29.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.883 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . 0.548 ' HB3' ' OD2' ' A' ' 112' ' ' ASP . . . -98.35 -29.11 13.34 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.084 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 21.2 p -131.14 -34.28 1.45 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.15 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 96.66 17.36 33.51 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.455 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . 0.423 ' C ' ' HG2' ' A' ' 111' ' ' LYS . 42.1 mttm -85.79 154.14 21.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.815 0.34 . . . . 0.0 110.875 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 1.9 m -60.09 111.1 1.38 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.82 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.415 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 31.6 mttt -59.25 -42.8 92.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.908 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 138.36 -41.72 1.34 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.532 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.611 ' CD2' HG21 ' A' ' 110' ' ' VAL . 7.4 p90 -99.99 151.12 21.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.923 0.392 . . . . 0.0 110.922 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -130.66 178.04 17.94 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.554 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -126.52 135.72 51.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.887 0.375 . . . . 0.0 110.876 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.549 HG12 ' CE1' ' A' ' 126' ' ' PHE . 61.0 t -136.48 122.18 28.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.118 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 12.6 m -105.34 149.92 25.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.808 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.549 ' CE1' HG12 ' A' ' 124' ' ' VAL . 16.3 m-85 -131.06 137.85 49.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.906 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.427 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 78.3 m-85 -58.87 -36.67 75.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.841 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 13.6 m-20 -118.04 149.78 40.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.904 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.577 ' HD3' ' CE1' ' A' ' 78' ' ' PHE . 38.5 tptt -60.77 -63.39 1.31 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.463 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.9 OUTLIER -33.21 -57.92 0.39 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.917 179.921 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.419 ' CG ' ' HA3' ' A' ' 102' ' ' GLY . 80.7 m-20 -40.59 -49.26 2.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.867 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -67.1 -60.47 2.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.123 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -41.05 -61.62 0.96 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.916 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 44.1 t-20 -38.88 -52.91 1.75 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.485 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -63.55 -61.44 2.33 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.122 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 86.7 mt -37.01 -36.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.128 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 -85.53 -60.1 2.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.876 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -64.85 -59.6 4.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.485 ' N ' ' O ' ' A' ' 135' ' ' ALA . 48.0 mmm -53.48 -39.92 64.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.939 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -55.66 116.59 7.31 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.49 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 100.65 -12.66 59.6 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.494 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 48.6 mm-40 -73.28 172.57 10.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.75 0.31 . . . . 0.0 110.928 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . . . . . . . . . 15.7 m95 -109.43 126.41 53.44 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.877 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.536 HD23 HD22 ' A' ' 85' ' ' LEU . 57.3 tp -123.56 125.19 44.41 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.913 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 0.838 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 72.82 -9.25 6.58 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.48 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 127.47 -7.7 7.03 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.487 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 28.2 mtt-85 -130.34 145.89 51.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.789 0.328 . . . . 0.0 110.86 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.402 ' O ' ' O ' ' A' ' 84' ' ' ASP . 18.1 mt-30 -52.58 166.54 0.19 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.952 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.422 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 24.3 pt -137.42 146.28 28.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.066 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.495 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 16.4 ptp180 -108.07 114.86 29.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.89 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 80.9 p -110.19 122.57 47.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.134 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -150.58 168.48 24.14 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.904 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . 0.498 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 55.1 m95 . . . . . 0 C--N 1.327 -0.375 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.916 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.564 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 93.0 m-85 . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.929 0.395 . . . . 0.0 110.875 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.51 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.2 OUTLIER -89.1 150.4 22.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 179.998 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.55 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 46.0 t -125.45 145.36 32.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.131 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . 0.413 ' CE2' ' HG2' ' A' ' 150' ' ' ARG . 17.8 t80 -91.22 132.72 35.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.526 HG12 HD21 ' A' ' 85' ' ' LEU . 16.8 t -128.57 128.91 68.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.073 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -136.52 -177.96 15.42 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.54 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 55.11 54.25 9.1 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.809 0.338 . . . . 0.0 110.843 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.526 HD21 HG12 ' A' ' 82' ' ' VAL . 17.0 mt -110.89 130.11 55.68 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.937 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.18 154.22 5.84 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.664 0.745 . . . . 0.0 110.843 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -6.21 18.08 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.699 2.266 . . . . 0.0 112.29 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -100.29 -15.54 18.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.898 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.708 HD11 ' HA3' ' A' ' 145' ' ' GLY . 34.3 mm -69.57 134.25 30.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.141 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.0 t -119.67 168.0 11.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.123 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.648 HG22 ' CE ' ' A' ' 95' ' ' LYS . 98.8 m -38.82 -57.76 1.18 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.111 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 29.5 mt-10 -46.44 -59.36 3.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.942 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.437 ' CB ' HG23 ' A' ' 89' ' ' ILE . 0.5 OUTLIER -38.82 -56.19 1.4 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.899 179.932 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.626 ' CD1' HG22 ' A' ' 109' ' ' VAL . 10.7 mt -49.55 -60.77 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.167 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.648 ' CE ' HG22 ' A' ' 91' ' ' THR . 24.3 mtmt -45.67 -39.65 8.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.887 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . 0.435 ' HB3' ' O ' ' A' ' 93' ' ' ASP . . . -59.94 -37.84 80.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.106 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.636 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -66.35 -52.98 41.48 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.103 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.467 ' C ' HD11 ' A' ' 104' ' ' ILE . 11.8 m-85 -92.18 18.66 7.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.852 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.792 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -69.33 -60.44 4.08 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.581 0.705 . . . . 0.0 111.136 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.792 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.78 -0.83 7.49 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.662 2.241 . . . . 0.0 112.321 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -99.78 5.17 45.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.89 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.79 137.88 3.91 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.493 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.408 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 24.3 mtt-85 -49.89 125.1 11.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.741 0.305 . . . . 0.0 110.906 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.467 HD11 ' C ' ' A' ' 98' ' ' PHE . 11.1 mt -98.77 138.88 22.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.142 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.1 t -107.33 -62.94 1.35 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.858 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -100.51 109.66 21.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.905 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.508 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -138.25 129.13 26.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.13 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.1 ptm180 -162.57 154.72 18.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.873 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.626 HG22 ' CD1' ' A' ' 94' ' ' ILE . 41.3 t -105.33 117.38 50.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.133 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.531 HG21 ' CE2' ' A' ' 121' ' ' TYR . 48.8 t -49.84 138.04 5.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.125 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . 0.432 ' C ' ' HG3' ' A' ' 119' ' ' LYS . 52.6 mttt -138.16 154.63 49.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -69.16 138.55 54.24 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.836 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 13.5 ptp -85.75 3.45 41.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.862 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -102.64 -35.94 8.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.083 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 52.3 p -123.17 -35.17 3.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.098 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 90.86 26.61 21.74 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.481 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . 0.412 ' O ' ' C ' ' A' ' 118' ' ' SER . 86.1 mttt -97.73 136.39 38.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.769 0.318 . . . . 0.0 110.896 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 117' ' ' LYS . 2.2 m -37.7 111.76 0.18 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.853 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.491 ' HD2' HG12 ' A' ' 110' ' ' VAL . 9.3 mttm -61.82 -41.82 98.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.895 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.446 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 138.62 -46.75 0.96 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.531 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.531 ' CE2' HG21 ' A' ' 110' ' ' VAL . 10.1 p90 -100.04 148.65 24.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.996 0.427 . . . . 0.0 110.909 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -129.8 -177.31 14.81 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.503 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -127.47 139.29 52.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.854 0.359 . . . . 0.0 110.925 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.647 HG12 ' CE1' ' A' ' 126' ' ' PHE . 58.3 t -138.83 120.65 16.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.146 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . 0.408 ' O ' HG23 ' A' ' 104' ' ' ILE . 42.3 m -106.65 149.81 26.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.853 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.647 ' CE1' HG12 ' A' ' 124' ' ' VAL . 2.1 m-85 -130.85 144.59 51.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.873 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.408 ' CE2' ' HB3' ' A' ' 103' ' ' ARG . 22.3 m-85 -56.38 -43.49 79.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.889 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 19.2 m120 -109.35 163.69 13.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.901 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.564 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 20.3 tptm -71.39 -59.55 2.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.902 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.417 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.8 OUTLIER -40.57 -57.39 1.86 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.9 179.922 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 130' ' ' TRP . 71.6 m-20 -35.86 -45.76 0.42 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.875 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.55 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -75.8 -58.27 3.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.065 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -44.16 -59.5 2.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.883 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -41.79 -44.49 3.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.891 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.47 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -69.23 -56.78 6.58 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.107 179.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 86.1 mt -38.73 -35.5 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.106 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.1 mt-30 -87.18 -57.07 3.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.892 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 37.3 mm-40 -68.3 -61.97 1.6 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.93 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.899 ' HE3' HD11 ' A' ' 149' ' ' ILE . 64.1 mmm -51.92 -38.93 58.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.858 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.44 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -57.55 93.51 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.492 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 119.44 13.17 6.39 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.508 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 87.4 mm-40 -94.27 169.66 10.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.753 0.311 . . . . 0.0 110.962 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . 0.42 ' NE1' ' HG3' ' A' ' 148' ' ' GLN . 17.2 m95 -106.3 109.47 21.41 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.899 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.636 HD13 ' HB2' ' A' ' 97' ' ' ALA . 60.9 tp -104.15 129.58 51.87 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.926 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 0.708 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.74 -77.0 0.4 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.475 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -156.33 15.93 0.41 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.464 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 43.2 mtp85 -157.99 161.01 38.09 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.758 0.313 . . . . 0.0 110.856 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.42 ' HG3' ' NE1' ' A' ' 143' ' ' TRP . 28.9 mt-30 -64.25 167.08 7.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.923 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.899 HD11 ' HE3' ' A' ' 139' ' ' MET . 21.1 pt -136.26 152.11 29.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.147 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.413 ' HG2' ' CE2' ' A' ' 81' ' ' PHE . 2.8 ttt180 -109.29 129.72 55.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.892 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.44 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 44.4 p -124.55 137.54 54.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.149 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 4.2 t30 -160.61 174.09 14.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.919 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . 0.546 ' CH2' ' CE ' ' A' ' 129' ' ' LYS . 4.6 m95 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.898 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.874 0.369 . . . . 0.0 110.862 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . 0.404 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.9 OUTLIER -82.02 135.24 35.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.872 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 38.9 t -114.2 144.57 21.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.124 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . 0.694 ' CD2' ' ND2' ' A' ' 152' ' ' ASN . 11.9 t80 -96.74 138.28 34.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.862 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.776 HG12 HD21 ' A' ' 85' ' ' LEU . 3.2 t -137.17 134.46 47.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.151 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -142.3 -173.1 14.04 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.456 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 56.93 29.3 16.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.816 0.341 . . . . 0.0 110.86 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.776 HD21 HG12 ' A' ' 82' ' ' VAL . 14.6 mt -86.31 132.25 34.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.956 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -53.87 155.3 6.2 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.639 0.733 . . . . 0.0 110.863 -179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.85 -15.96 36.98 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.688 2.259 . . . . 0.0 112.291 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -92.0 -7.14 49.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.873 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.825 HD11 ' HA3' ' A' ' 145' ' ' GLY . 33.2 mm -74.98 138.88 20.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.155 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.8 t -119.88 -176.71 3.24 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.133 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.6 ' HA ' HG23 ' A' ' 109' ' ' VAL . 84.9 m -53.77 -57.25 11.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.125 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.439 ' O ' ' C ' ' A' ' 93' ' ' ASP . 70.9 mt-10 -48.67 -58.48 4.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.914 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.439 ' C ' ' O ' ' A' ' 92' ' ' GLU . 2.9 m-20 -34.48 -55.28 0.54 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.841 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.605 HD11 HG22 ' A' ' 109' ' ' VAL . 4.5 mt -51.76 -60.34 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.152 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.638 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 25.6 mtmt -48.85 -41.93 34.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.899 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.68 -29.13 69.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.083 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.442 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -75.67 -53.74 8.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.131 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.423 ' C ' HD11 ' A' ' 104' ' ' ILE . 27.2 m-85 -86.82 3.49 45.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.915 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.776 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -56.5 -60.29 9.62 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.587 0.708 . . . . 0.0 111.154 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.776 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.3 Cg_endo -69.76 -0.81 7.45 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.708 2.272 . . . . 0.0 112.353 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.584 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 72.0 m-85 -99.77 -1.2 38.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 142.17 156.07 6.67 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.507 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.476 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 17.5 mtm105 -62.6 122.28 15.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.743 0.306 . . . . 0.0 110.871 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.452 ' CG2' HG13 ' A' ' 124' ' ' VAL . 13.9 mt -100.39 138.21 25.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.176 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.467 ' HB2' ' CZ ' ' A' ' 127' ' ' PHE . 47.8 t -112.92 -59.61 1.99 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . 0.422 ' HB3' ' CB ' ' A' ' 125' ' ' SER . 25.9 t70 -100.63 99.78 10.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.449 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -132.08 124.94 30.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.081 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.446 ' HA ' HG23 ' A' ' 91' ' ' THR . 10.3 ptp180 -159.36 153.32 23.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 -179.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.605 HG22 HD11 ' A' ' 94' ' ' ILE . 90.0 t -100.93 124.12 54.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.111 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.955 HG12 ' HG3' ' A' ' 119' ' ' LYS . 53.4 t -59.64 143.96 13.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.118 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . 0.451 ' C ' ' HG2' ' A' ' 119' ' ' LYS . 74.5 mttt -140.7 153.87 46.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.492 ' N ' ' HG2' ' A' ' 119' ' ' LYS . 7.9 t0 -60.22 127.38 31.54 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.838 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 19.9 ptm -80.12 2.81 22.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.867 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -102.66 -38.38 7.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.074 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 42.1 p -119.9 -33.82 3.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.181 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 95.35 30.2 8.35 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.444 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 34.5 mttm -99.01 164.48 12.16 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.778 0.323 . . . . 0.0 110.903 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 36.4 t -56.62 115.05 2.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.907 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.955 ' HG3' HG12 ' A' ' 110' ' ' VAL . 0.5 OUTLIER -68.33 -38.56 81.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.909 179.962 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 126.39 -46.1 1.11 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.433 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.528 ' CE2' HG21 ' A' ' 110' ' ' VAL . 8.3 p90 -100.32 151.33 21.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.927 0.394 . . . . 0.0 110.934 -179.794 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -132.58 171.55 21.56 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.473 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -121.06 138.85 53.99 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.859 0.361 . . . . 0.0 110.907 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.661 HG12 ' CE1' ' A' ' 126' ' ' PHE . 93.9 t -138.91 112.26 6.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.103 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . 0.422 ' CB ' ' HB3' ' A' ' 106' ' ' ASP . 2.7 t -97.89 148.64 23.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.83 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.661 ' CE1' HG12 ' A' ' 124' ' ' VAL . 3.6 m-85 -127.06 148.38 50.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.882 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.476 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 77.9 m-85 -63.27 -34.66 78.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.916 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 25.4 m120 -115.93 168.88 9.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.87 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 66.8 tttt -81.0 -47.88 13.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.427 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -48.57 -62.47 1.48 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.935 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 130' ' ' TRP . 44.4 m-20 -35.87 -54.17 0.74 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.811 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -61.39 -67.08 0.44 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.107 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -37.26 -57.87 0.86 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 42.4 t-20 -41.01 -52.89 3.09 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.864 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.96 -56.71 13.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.098 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 92.3 mt -38.17 -35.82 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.175 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -85.26 -63.53 1.31 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.899 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -59.56 -61.9 2.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.584 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 81.2 mmm -52.19 -35.23 48.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.913 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.401 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -54.94 99.43 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.522 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 111.59 -20.7 22.42 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.488 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 10.8 mm-40 -56.55 -179.92 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.791 0.329 . . . . 0.0 110.927 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . 0.486 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 13.4 m95 -116.86 124.72 50.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.927 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.592 HD23 HD22 ' A' ' 85' ' ' LEU . 47.2 tp -123.88 128.75 49.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.862 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 0.825 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.54 -3.69 11.15 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.516 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 120.91 -13.5 9.79 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.496 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 60.4 mtt180 -122.85 147.4 46.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.727 0.299 . . . . 0.0 110.88 -179.866 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.486 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 32.6 mt-30 -55.45 165.57 0.77 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.926 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.423 HG21 ' HB3' ' A' ' 144' ' ' LEU . 19.5 pt -138.15 151.34 25.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.117 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 27.0 ptt180 -113.99 109.1 17.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.906 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.401 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 69.3 p -106.54 141.43 37.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.167 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . 0.694 ' ND2' ' CD2' ' A' ' 81' ' ' PHE . 7.4 p30 -167.15 -178.95 4.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.876 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 31.2 m95 . . . . . 0 C--N 1.328 -0.344 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.916 179.969 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.45 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 47.0 m-85 . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.911 0.386 . . . . 0.0 110.874 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 87.4 m-70 -89.3 140.49 29.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.851 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.461 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 41.5 t -118.1 138.76 47.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.073 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 15.5 t80 -92.89 135.49 34.09 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.878 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.859 HG12 HD21 ' A' ' 85' ' ' LEU . 3.7 t -137.58 109.51 6.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.118 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -123.21 -177.48 15.15 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.472 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.403 ' O ' ' O ' ' A' ' 148' ' ' GLN . 4.5 t70 63.83 36.45 10.4 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.859 0.362 . . . . 0.0 110.91 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.859 HD21 HG12 ' A' ' 82' ' ' VAL . 15.6 mt -91.7 170.54 9.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.912 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -90.01 155.4 47.33 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.672 0.749 . . . . 0.0 110.786 -179.835 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 -10.79 29.39 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.668 2.245 . . . . 0.0 112.338 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -96.5 -6.11 37.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.841 HD11 ' HA3' ' A' ' 145' ' ' GLY . 45.8 mm -79.09 136.38 23.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.116 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.6 t -118.96 164.7 15.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.19 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.737 ' HA ' HG23 ' A' ' 109' ' ' VAL . 35.8 m -40.24 -48.77 2.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.149 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 93' ' ' ASP . 32.7 mt-10 -55.64 -58.78 6.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.444 ' CB ' HG23 ' A' ' 89' ' ' ILE . 13.3 m-20 -34.78 -56.67 0.55 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.86 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.565 HD11 HG22 ' A' ' 109' ' ' VAL . 10.4 mt -49.26 -60.76 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.185 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.693 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 24.0 mtmt -46.69 -39.81 12.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.914 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -63.58 -30.77 71.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.103 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.656 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -73.92 -53.68 9.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.088 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.423 ' C ' HD11 ' A' ' 104' ' ' ILE . 22.3 m-85 -89.18 12.34 16.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.91 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.77 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -65.23 -60.07 8.56 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.661 0.743 . . . . 0.0 111.082 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.77 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.76 -0.77 7.4 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.616 2.211 . . . . 0.0 112.376 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.497 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 77.6 m-85 -99.65 -3.14 33.78 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.892 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 143.03 131.95 2.6 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.485 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 46.2 mtt85 -44.09 124.93 4.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.803 0.335 . . . . 0.0 110.875 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.475 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 14.1 mt -100.11 145.18 11.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.136 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.448 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 3.8 t -116.01 -61.94 1.66 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.851 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -100.57 99.47 10.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.83 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.418 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -132.92 127.18 33.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.483 ' HA ' HG23 ' A' ' 91' ' ' THR . 6.7 ptm180 -160.15 155.29 24.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.871 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.737 HG23 ' HA ' ' A' ' 91' ' ' THR . 96.4 t -107.06 120.35 58.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.138 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.578 HG21 ' CE2' ' A' ' 121' ' ' TYR . 66.8 t -54.33 124.66 7.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.159 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -123.72 148.74 46.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.877 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.472 ' O ' ' N ' ' A' ' 116' ' ' GLY . 24.1 t0 -56.88 121.61 10.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.871 179.817 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 8.2 ptp -73.11 -1.54 17.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.938 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -97.86 -42.52 7.52 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.134 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 29.1 p -115.75 -29.43 6.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.137 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 89.51 30.3 14.07 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.499 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 51.7 mttm -98.9 152.5 19.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.829 0.347 . . . . 0.0 110.899 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 7.8 t -60.29 110.75 1.32 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.831 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 50.9 mttt -62.73 -47.82 81.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.93 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.678 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 139.75 -38.98 1.56 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.463 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.578 ' CE2' HG21 ' A' ' 110' ' ' VAL . 25.3 p90 -100.09 144.04 29.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.953 0.406 . . . . 0.0 110.92 -179.81 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.81 175.07 21.52 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.545 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -121.85 139.93 53.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.912 0.387 . . . . 0.0 110.866 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.682 HG12 ' CE1' ' A' ' 126' ' ' PHE . 59.4 t -135.62 111.46 12.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.122 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.8 t -100.49 145.64 28.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.856 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.682 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.3 m-85 -124.93 162.0 25.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.896 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.448 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 22.1 m-85 -66.41 -48.17 70.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.875 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 78.6 m-20 -113.91 160.04 19.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.869 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.45 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 3.7 ttmt -63.22 -62.75 1.49 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.91 179.876 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.437 ' C ' ' O ' ' A' ' 129' ' ' LYS . 1.0 OUTLIER -35.16 -59.36 0.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.929 179.92 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.401 ' C ' ' O ' ' A' ' 130' ' ' TRP . 48.3 m-20 -37.58 -43.97 0.65 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.912 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.461 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -74.71 -59.16 2.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.099 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.7 mt-10 -40.53 -54.76 2.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.829 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -43.53 -45.37 6.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.423 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -71.95 -58.49 3.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.07 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 97.1 mt -38.44 -36.37 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.124 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -83.35 -63.63 1.32 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.891 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -62.92 -62.73 1.52 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.925 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.497 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 68.8 mmm -51.8 -41.32 61.62 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.913 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -55.13 103.75 0.23 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.486 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 100.5 21.15 13.28 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.498 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 9.5 mm100 -105.64 177.42 4.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.787 0.327 . . . . 0.0 110.905 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . . . . . . . . . 17.0 m95 -106.74 121.69 44.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.903 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.656 HD13 ' HB2' ' A' ' 97' ' ' ALA . 36.4 tp -121.53 127.78 51.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.924 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 0.841 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 73.54 -36.62 0.84 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.477 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . 0.425 ' H ' ' C ' ' A' ' 144' ' ' LEU . . . 160.2 -14.25 0.19 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.516 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 51.2 mtt180 -127.38 149.24 50.16 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.762 0.315 . . . . 0.0 110.838 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.403 ' O ' ' O ' ' A' ' 84' ' ' ASP . 38.8 mt-30 -53.89 169.35 0.16 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.915 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.509 HG22 HD23 ' A' ' 85' ' ' LEU . 33.8 pt -148.92 147.77 16.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.14 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 9.6 ptt180 -110.58 123.26 49.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.909 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 29.4 p -118.26 141.92 48.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.138 -179.9 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . 0.459 ' CG ' ' N ' ' A' ' 153' ' ' TRP . 8.7 t-20 -165.08 166.91 18.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.904 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . 0.459 ' N ' ' CG ' ' A' ' 152' ' ' ASN . 11.2 m95 . . . . . 0 C--N 1.327 -0.371 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.934 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.862 0.363 . . . . 0.0 110.876 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 64.1 m-70 -90.55 161.51 15.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.913 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.423 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 49.5 t -137.64 135.83 46.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.159 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . 0.439 ' CE2' ' HG3' ' A' ' 150' ' ' ARG . 17.9 t80 -87.63 132.41 34.09 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.899 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.846 HG12 HD21 ' A' ' 85' ' ' LEU . 6.5 t -132.38 110.0 15.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.116 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -117.74 -178.77 17.41 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.459 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.403 ' O ' ' O ' ' A' ' 148' ' ' GLN . 2.0 m-20 64.02 40.11 7.4 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.874 0.368 . . . . 0.0 110.859 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.846 HD21 HG12 ' A' ' 82' ' ' VAL . 9.4 mt -102.85 129.56 49.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.901 -179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.1 t -52.92 154.37 5.14 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.671 0.748 . . . . 0.0 110.832 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -4.23 13.6 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.636 2.224 . . . . 0.0 112.356 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . 0.401 ' O ' ' HG3' ' A' ' 88' ' ' GLU . 1.3 tt0 -95.71 -29.77 14.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 1.014 HD11 ' HA3' ' A' ' 145' ' ' GLY . 48.3 mm -57.9 136.64 20.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.139 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.3 t -117.18 164.05 15.36 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.145 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.549 ' HA ' HG23 ' A' ' 109' ' ' VAL . 16.7 m -40.78 -39.63 1.15 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.154 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 93' ' ' ASP . 29.5 mt-10 -61.92 -59.71 4.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.61 ' CB ' HG23 ' A' ' 89' ' ' ILE . 0.6 OUTLIER -36.78 -56.59 0.84 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.86 -179.988 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.557 HD11 HG22 ' A' ' 109' ' ' VAL . 6.3 mt -48.19 -58.06 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.131 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.634 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 23.9 mtmt -49.65 -38.95 34.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.908 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.17 -31.37 72.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.081 179.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.498 ' HB1' ' HE1' ' A' ' 139' ' ' MET . . . -72.78 -46.84 51.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.105 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.413 ' C ' HD11 ' A' ' 104' ' ' ILE . 20.1 m-85 -97.16 11.77 35.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.941 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.77 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -63.8 -59.73 10.8 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.531 0.681 . . . . 0.0 111.109 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.77 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.4 Cg_endo -69.77 -0.7 7.3 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.717 2.278 . . . . 0.0 112.315 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . 0.598 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 62.6 m-85 -99.64 -0.11 40.93 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.899 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 139.7 138.31 3.61 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.532 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.489 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 13.7 mtt85 -48.03 125.09 8.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.782 0.325 . . . . 0.0 110.862 -179.854 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.476 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 17.9 mt -100.02 138.73 23.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.102 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.453 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.3 t -111.9 -59.14 2.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.835 -179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . 0.457 ' HB3' ' CB ' ' A' ' 125' ' ' SER . 23.2 t70 -100.33 100.32 11.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.888 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.546 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -133.6 124.93 27.72 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.117 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.475 ' HD3' ' N ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -161.67 155.59 21.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 -179.889 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.557 HG22 HD11 ' A' ' 94' ' ' ILE . 76.5 t -106.14 117.4 51.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.147 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.798 HG12 ' HG3' ' A' ' 119' ' ' LYS . 60.2 t -47.36 141.33 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.13 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 47.6 mttt -139.33 151.01 46.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.879 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.434 ' O ' ' N ' ' A' ' 116' ' ' GLY . 25.7 t0 -63.74 122.95 17.65 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.889 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 27.9 ptm -72.49 -6.61 44.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.878 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -96.74 -48.43 5.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.111 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 45.4 p -100.75 -32.19 10.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.116 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.434 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 86.71 24.13 39.89 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.452 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 44.8 mtmt -98.43 168.02 10.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.79 0.329 . . . . 0.0 110.917 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 15.8 t -64.37 114.26 4.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.826 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.798 ' HG3' HG12 ' A' ' 110' ' ' VAL . 27.3 mmtt -63.83 -47.25 81.54 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.887 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.473 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 139.38 -46.91 0.93 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.479 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.664 ' CE2' HG21 ' A' ' 110' ' ' VAL . 12.7 p90 -100.14 146.28 27.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.948 0.404 . . . . 0.0 110.891 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -128.11 176.94 17.91 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.445 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -122.56 141.41 51.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.86 0.362 . . . . 0.0 110.907 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.686 HG12 ' CE1' ' A' ' 126' ' ' PHE . 56.8 t -137.63 122.3 23.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.112 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . 0.457 ' CB ' ' HB3' ' A' ' 106' ' ' ASP . 4.9 t -112.19 140.79 46.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.877 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.686 ' CE1' HG12 ' A' ' 124' ' ' VAL . 27.8 m-85 -121.53 147.97 45.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.843 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.489 ' CE2' ' HB3' ' A' ' 103' ' ' ARG . 21.6 m-85 -55.88 -49.8 72.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.89 -179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 48.9 m-20 -99.47 166.73 11.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.886 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.461 ' HE3' ' CZ2' ' A' ' 153' ' ' TRP . 45.5 tptt -75.61 -45.78 35.53 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.863 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.417 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.9 OUTLIER -55.78 -54.56 42.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.918 179.915 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 130' ' ' TRP . 60.5 m-20 -35.67 -43.24 0.27 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.883 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.504 ' HB2' ' CD1' ' A' ' 126' ' ' PHE . . . -77.81 -56.9 4.13 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.129 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.476 ' HA ' HD12 ' A' ' 136' ' ' ILE . 13.5 mt-10 -45.23 -56.96 4.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.857 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 29.6 t-20 -43.35 -49.71 6.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.931 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.547 ' HB1' ' HG3' ' A' ' 139' ' ' MET . . . -64.39 -53.32 50.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.087 179.856 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . 0.476 HD12 ' HA ' ' A' ' 133' ' ' GLU . 94.7 mt -41.49 -34.38 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.141 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 9.6 mt-30 -84.71 -69.55 0.64 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.905 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 28.2 mt-30 -55.99 -59.38 4.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.897 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.598 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 53.9 mmm -58.12 -43.1 87.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.449 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -56.98 91.41 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.493 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 125.02 6.16 6.5 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.459 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . 0.492 ' HG2' ' CD1' ' A' ' 149' ' ' ILE . 0.5 OUTLIER -92.33 -178.57 4.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.728 0.299 . . . . 0.0 110.957 -179.915 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . 0.48 ' N ' ' HG3' ' A' ' 142' ' ' GLN . 16.6 m95 -114.47 115.16 26.81 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.923 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.59 HD23 HD22 ' A' ' 85' ' ' LEU . 62.4 tp -108.1 128.45 54.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.91 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 1.014 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.97 -75.57 0.46 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.481 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.24 15.9 0.28 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.479 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 39.1 mtt85 -155.48 157.18 36.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.722 0.296 . . . . 0.0 110.867 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.45 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 16.6 mt-30 -60.51 170.3 1.44 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.937 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.492 ' CD1' ' HG2' ' A' ' 142' ' ' GLN . 23.6 pt -135.17 152.98 33.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.179 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.439 ' HG3' ' CE2' ' A' ' 81' ' ' PHE . 12.5 ptm180 -120.38 104.23 9.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.86 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.449 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 44.9 p -99.45 127.91 45.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.174 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -150.85 173.79 13.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.878 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . 0.461 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 7.3 m95 . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.561 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 43.8 m-85 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.875 0.369 . . . . 0.0 110.864 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 58.2 m-70 -88.06 135.29 33.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.863 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 53.7 t -114.78 140.3 36.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.096 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.5 t80 -91.28 135.29 33.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.898 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.502 HG12 HD21 ' A' ' 85' ' ' LEU . 16.6 t -131.73 127.54 59.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.069 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.469 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -137.39 171.75 23.04 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.491 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ASP . . . . . 0.41 ' O ' ' O ' ' A' ' 148' ' ' GLN . 6.6 t70 64.37 53.07 1.75 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.839 0.352 . . . . 0.0 110.857 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.511 HD22 HD23 ' A' ' 144' ' ' LEU . 21.3 mt -106.34 133.39 51.11 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.941 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -54.07 155.1 6.85 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.651 0.739 . . . . 0.0 110.862 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 -10.08 27.67 Favored 'Trans proline' 0 N--CA 1.465 -0.159 0 C-N-CA 122.73 2.287 . . . . 0.0 112.352 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -97.78 0.49 46.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.896 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.944 HD11 ' HA3' ' A' ' 145' ' ' GLY . 49.0 mm -88.02 136.83 22.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.151 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.9 t -121.21 179.39 4.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.124 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.625 HG23 ' HA ' ' A' ' 108' ' ' ARG . 85.4 m -51.18 -45.44 61.78 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.102 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -59.34 -55.79 30.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.837 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' ASP . . . . . 0.55 ' CB ' HG23 ' A' ' 89' ' ' ILE . 6.8 m-20 -38.18 -57.78 1.05 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.887 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' ILE . . . . . 0.414 HD11 HG22 ' A' ' 109' ' ' VAL . 6.7 mt -48.37 -62.04 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.131 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.672 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 26.0 mtmt -45.18 -39.88 6.62 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.948 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.02 -32.45 74.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.097 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.536 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -69.84 -54.66 12.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.084 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' PHE . . . . . 0.407 ' C ' HD11 ' A' ' 104' ' ' ILE . 22.7 m-85 -88.23 8.55 26.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.894 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.76 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -62.06 -60.04 11.33 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.567 0.698 . . . . 0.0 111.096 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.76 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.76 -0.76 7.38 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.721 2.28 . . . . 0.0 112.351 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -100.02 -10.91 21.05 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.905 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 154.69 156.43 7.71 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.47 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.449 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 29.8 mtm180 -64.61 121.7 15.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.742 0.306 . . . . 0.0 110.891 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.407 HD11 ' C ' ' A' ' 98' ' ' PHE . 15.3 mt -100.33 139.76 21.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.138 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 36.0 t -113.47 -59.59 2.0 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.832 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -100.82 100.97 11.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.842 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.48 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -131.67 128.34 38.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.067 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.625 ' HA ' HG23 ' A' ' 91' ' ' THR . 8.8 ptp180 -161.58 161.66 29.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.414 HG22 HD11 ' A' ' 94' ' ' ILE . 32.6 t -112.98 122.2 66.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.122 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' VAL . . . . . 0.693 HG21 ' CE2' ' A' ' 121' ' ' TYR . 58.8 t -55.83 142.94 9.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.137 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 28.5 mttp -142.19 154.48 44.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.872 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . 0.489 ' O ' ' N ' ' A' ' 116' ' ' GLY . 47.3 t0 -62.61 121.58 13.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.872 179.87 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 14.4 ptp -72.53 0.76 9.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.898 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -103.5 -34.62 8.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.099 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 6.9 p -123.39 -33.83 3.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.149 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.489 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 90.61 26.28 23.21 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.501 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -93.37 140.74 29.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.762 0.315 . . . . 0.0 110.9 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 2.8 t -46.24 113.06 0.56 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.866 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 34.5 mttt -67.23 -49.87 62.85 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.896 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.443 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 140.51 -39.95 1.42 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.497 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' TYR . . . . . 0.693 ' CE2' HG21 ' A' ' 110' ' ' VAL . 24.5 p90 -100.13 144.43 29.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.927 0.394 . . . . 0.0 110.945 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -131.77 -179.79 16.48 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.507 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 65.4 m-85 -124.57 138.94 54.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.874 0.369 . . . . 0.0 110.884 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.681 HG12 ' CE1' ' A' ' 126' ' ' PHE . 48.4 t -138.84 113.3 7.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.113 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 20.6 t -100.97 151.49 21.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.82 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' PHE . . . . . 0.681 ' CE1' HG12 ' A' ' 124' ' ' VAL . 3.0 m-85 -131.0 149.57 52.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.885 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' PHE . . . . . 0.449 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 81.4 m-85 -64.27 -35.73 81.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.848 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -120.49 157.26 29.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.914 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.561 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 40.4 tttt -65.89 -64.4 0.87 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.922 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' TRP . . . . . 0.453 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -34.17 -62.04 0.34 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.93 179.903 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 130' ' ' TRP . 5.7 m-20 -36.08 -43.41 0.34 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.841 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 129' ' ' LYS . . . -73.56 -60.69 2.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.084 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -42.99 -55.85 3.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.89 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -43.31 -44.65 5.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' ALA . . . . . 0.458 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -74.06 -56.06 5.37 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.094 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 76.9 mt -39.83 -37.35 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.125 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -83.04 -55.91 4.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.846 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 4.3 mm-40 -66.26 -63.45 1.08 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.883 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' MET . . . . . 0.521 ' HE3' HD11 ' A' ' 149' ' ' ILE . 84.3 mmm -51.07 -36.21 38.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.843 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -56.15 107.75 0.94 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.531 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 104.1 -17.39 48.32 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.464 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 15.1 mm-40 -67.69 -177.94 0.85 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.768 0.318 . . . . 0.0 110.945 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' TRP . . . . . 0.439 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 13.8 m95 -115.72 137.13 52.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.899 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.536 HD13 ' HB2' ' A' ' 97' ' ' ALA . 55.7 tp -130.27 121.56 26.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.937 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' GLY . . . . . 0.944 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 75.39 -24.19 1.44 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.473 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . 0.417 ' H ' ' C ' ' A' ' 144' ' ' LEU . . . 144.99 -6.88 1.61 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.477 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 54.0 mtt85 -130.61 144.07 51.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.812 0.339 . . . . 0.0 110.843 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' GLN . . . . . 0.439 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 23.9 mt-30 -51.48 163.92 0.24 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.913 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.521 HD11 ' HE3' ' A' ' 139' ' ' MET . 25.3 pt -137.69 155.22 30.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.099 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.497 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 7.6 ptm180 -118.12 118.23 31.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.874 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 34.3 p -117.64 132.35 56.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.136 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -158.55 173.35 16.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 32.8 m95 . . . . . 0 C--N 1.328 -0.369 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.871 180.0 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 60.9 p -73.36 160.39 31.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.862 0.363 . . . . 0.0 110.885 -179.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 55.3 p -52.24 106.41 0.15 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.835 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 106.22 155.29 21.19 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.503 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 23.5 t -105.64 128.48 53.66 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.885 0.374 . . . . 0.0 110.85 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 7.6 t -54.87 -49.97 69.86 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.87 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 151.92 -143.67 10.71 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.49 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 12.5 mm100 -57.18 91.77 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.897 0.38 . . . . 0.0 110.934 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 19.0 mtpp -109.49 141.52 41.82 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.924 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 14.0 ttmm -157.51 144.17 18.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.863 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.411 ' O ' ' C ' ' A' ' 74' ' ' THR . 31.0 t0 -115.1 73.91 0.85 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.411 ' C ' ' O ' ' A' ' 73' ' ' ASP . 6.4 p 36.63 45.43 0.39 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.161 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.6 m -60.23 -69.19 0.23 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.869 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -98.72 50.13 0.97 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.91 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 19.3 m170 -112.34 158.38 19.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.862 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -112.92 116.0 29.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.883 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 69.6 m-70 -86.62 144.45 27.16 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.861 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 23.7 t -118.86 146.71 23.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.114 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -99.26 135.59 40.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.935 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.799 HG12 HD21 ' A' ' 85' ' ' LEU . 6.0 t -134.56 131.07 54.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.152 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.478 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -137.07 -175.8 14.01 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.459 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 60.74 26.4 16.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.897 0.379 . . . . 0.0 110.899 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.799 HD21 HG12 ' A' ' 82' ' ' VAL . 10.9 mt -84.53 128.22 34.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.907 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.41 153.93 6.73 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.685 0.755 . . . . 0.0 110.841 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 -9.87 27.19 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.711 2.274 . . . . 0.0 112.325 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -97.44 -5.04 37.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.901 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.812 HD11 ' HA3' ' A' ' 145' ' ' GLY . 40.5 mm -77.23 139.4 18.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.131 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.6 t -116.8 163.7 15.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.131 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.666 ' HA ' HG23 ' A' ' 109' ' ' VAL . 6.3 m -43.8 -38.56 3.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.079 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 27.5 mt-10 -63.09 -56.56 15.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.896 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.548 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.4 m-20 -37.75 -52.88 1.28 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.842 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.508 HD11 HG22 ' A' ' 109' ' ' VAL . 5.1 mt -52.11 -58.7 2.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.127 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.603 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 24.2 mtmt -49.45 -39.2 32.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.889 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.87 -35.0 75.49 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.112 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.566 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -68.67 -55.53 11.12 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.091 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 35.6 m-85 -85.05 1.63 46.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.874 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.786 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -52.75 -60.11 7.3 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.605 0.717 . . . . 0.0 111.147 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.786 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.7 -1.03 7.72 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.689 2.26 . . . . 0.0 112.357 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -99.96 9.55 42.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.9 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.26 143.48 5.78 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.497 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 45.8 mtt85 -52.17 121.87 7.59 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.739 0.304 . . . . 0.0 110.857 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.446 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 13.1 mt -95.04 136.79 25.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.102 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.434 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 2.4 p -103.28 -64.53 1.07 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.86 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -100.59 109.17 21.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.822 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.555 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -138.94 125.03 20.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.116 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.476 ' HB2' ' CZ ' ' A' ' 108' ' ' ARG . 2.6 ptm85 -157.39 165.08 36.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.867 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.666 HG23 ' HA ' ' A' ' 91' ' ' THR . 87.3 t -112.93 112.73 41.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.168 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.916 HG11 ' CE2' ' A' ' 121' ' ' TYR . 97.1 t -45.98 137.9 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.154 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 84.7 mttt -137.86 161.22 37.19 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.924 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.475 ' OD2' ' HB3' ' A' ' 114' ' ' ALA . 9.3 t0 -75.15 125.94 29.99 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.868 179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 14.3 ptp -75.77 -1.74 26.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.929 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.475 ' HB3' ' OD2' ' A' ' 112' ' ' ASP . . . -96.58 -39.59 9.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 30.6 p -119.51 -33.91 3.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.16 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 93.62 24.22 21.55 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.468 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 41.2 mmtt -93.55 151.17 19.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.82 0.343 . . . . 0.0 110.874 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 1.8 m -52.53 113.18 0.98 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.855 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.739 ' HG3' HG12 ' A' ' 110' ' ' VAL . 26.2 mmtt -63.14 -38.54 91.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.926 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.408 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 129.81 -40.06 1.73 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.505 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.916 ' CE2' HG11 ' A' ' 110' ' ' VAL . 3.0 p90 -100.02 155.09 17.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.943 0.402 . . . . 0.0 110.924 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.04 168.28 24.37 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.479 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 81.9 m-85 -117.47 141.54 48.22 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.914 0.388 . . . . 0.0 110.911 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.699 HG12 ' CE1' ' A' ' 126' ' ' PHE . 88.9 t -141.94 114.04 3.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.132 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 45.7 t -106.06 142.99 34.84 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.816 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.699 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.5 m-85 -119.24 158.46 25.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.898 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.434 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 20.7 m-85 -66.91 -42.3 85.67 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.883 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 25.3 m-80 -110.13 166.95 10.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.911 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 58.7 tttt -76.15 -44.2 39.39 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.898 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.429 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -54.71 -59.32 4.88 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.929 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.429 ' C ' ' O ' ' A' ' 130' ' ' TRP . 88.8 m-20 -35.8 -56.17 0.7 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.896 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.415 ' HB2' ' CD1' ' A' ' 126' ' ' PHE . . . -63.39 -65.11 0.73 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.084 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.428 ' HA ' HD12 ' A' ' 136' ' ' ILE . 4.6 mm-40 -37.31 -59.01 0.79 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 49.3 t30 -42.65 -48.58 5.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.907 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.47 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -64.64 -56.45 13.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.094 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . 0.428 HD12 ' HA ' ' A' ' 133' ' ' GLU . 94.8 mt -38.6 -34.45 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.139 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 8.3 mt-30 -86.09 -60.39 2.02 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.883 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 25.8 mt-30 -63.73 -58.14 7.8 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.899 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.47 ' N ' ' O ' ' A' ' 135' ' ' ALA . 50.3 mmm -54.86 -34.91 63.46 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.878 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.45 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -60.89 117.45 11.66 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.47 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 92.56 12.48 58.22 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.524 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 13.6 mm-40 -94.43 170.83 9.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.759 0.314 . . . . 0.0 110.901 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . 0.42 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 16.2 m95 -106.1 109.08 20.91 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.87 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.566 HD13 ' HB2' ' A' ' 97' ' ' ALA . 64.6 tp -102.51 128.88 48.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.86 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 0.812 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.03 -75.69 0.33 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.458 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.37 15.54 0.32 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.478 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . 0.431 ' HB3' ' NH1' ' A' ' 147' ' ' ARG . 8.0 mtp-105 -156.11 159.33 38.96 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.796 0.331 . . . . 0.0 110.859 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.42 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 30.2 mt-30 -64.27 167.83 6.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.909 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 32.4 pt -140.89 145.97 24.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.136 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.478 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 6.5 ptt180 -107.25 109.76 21.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.45 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 43.8 p -103.84 137.01 42.45 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.112 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . 0.423 ' CG ' ' O ' ' A' ' 151' ' ' THR . 19.6 m120 -166.89 176.29 7.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.923 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 10.4 m95 -70.65 116.15 10.63 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.916 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -57.26 -44.42 83.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.128 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 45.0 p -92.64 115.62 28.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.136 -179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 11.3 ptp85 -138.11 163.0 32.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.866 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.454 ' CG ' ' HD2' ' A' ' 158' ' ' PRO . 4.5 ttpm? -91.67 140.22 25.1 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.554 0.692 . . . . 0.0 110.938 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . 0.454 ' HD2' ' CG ' ' A' ' 157' ' ' LYS . 53.7 Cg_endo -69.76 151.89 69.16 Favored 'Trans proline' 0 C--O 1.231 0.158 0 C-N-CA 122.699 2.266 . . . . 0.0 112.288 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 163.97 36.31 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.67 2.247 . . . . 0.0 112.362 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -88.84 150.65 46.11 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.554 0.692 . . . . 0.0 111.102 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 104.63 1.36 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.67 2.247 . . . . 0.0 112.304 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 34.0 tttp -166.9 120.84 1.03 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.912 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 92.4 p -134.58 142.48 46.95 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.824 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 12.5 t -157.18 151.69 25.32 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.149 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 14.5 p90 -158.52 147.97 19.31 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.922 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 24.4 tt0 -144.37 146.41 32.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.888 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 35.7 p -140.76 107.41 5.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.892 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -87.02 92.34 9.01 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.89 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 24.9 p -64.27 -60.99 2.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.093 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 27.2 tttm 53.85 44.69 29.16 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.921 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -153.07 138.12 17.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 36.9 p -88.99 -53.99 4.33 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.83 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 178.95 146.16 6.51 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.464 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 148.42 65.09 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.703 2.269 . . . . 0.0 112.316 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 56.0 p -149.88 132.33 15.67 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.852 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . 0.406 ' O ' ' C ' ' A' ' 177' ' ' GLY . 97.4 p -145.47 134.13 22.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.853 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . 0.406 ' C ' ' O ' ' A' ' 176' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.492 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 13.7 t -97.69 -46.76 5.87 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.841 0.353 . . . . 0.0 110.886 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 77.1 p -153.59 134.5 13.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.832 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.76 -150.75 5.31 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.528 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 41.0 p -140.47 114.86 9.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.841 0.353 . . . . 0.0 110.89 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.7 p -63.74 128.23 34.89 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.856 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -150.37 -134.7 2.29 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.483 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 31.4 mt-30 -69.09 156.7 38.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.852 0.358 . . . . 0.0 110.914 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 6.7 ttmm -91.66 158.66 16.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.899 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? 42.61 51.7 4.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -120.39 118.69 31.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.871 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 31.7 p -104.39 46.58 0.91 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.199 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 48.2 m -75.21 -49.73 18.47 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.842 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 9.3 m-20 -104.98 47.44 0.87 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.861 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 10.0 m170 -121.59 157.07 31.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.824 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.561 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 93.2 m-85 -100.7 111.37 23.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.905 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.48 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.5 OUTLIER -88.54 149.08 23.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.887 179.988 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 42.0 t -124.7 147.53 29.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.161 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -98.22 138.63 35.21 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.846 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.606 HG12 HD21 ' A' ' 85' ' ' LEU . 15.2 t -136.07 129.56 47.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.12 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.461 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -139.75 177.49 20.45 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.439 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 18.8 t0 64.08 41.91 6.03 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.848 0.356 . . . . 0.0 110.909 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.606 HD21 HG12 ' A' ' 82' ' ' VAL . 9.5 mt -102.41 137.02 41.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.929 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -54.93 153.86 10.78 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.691 0.758 . . . . 0.0 110.875 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 -12.0 31.91 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.676 2.251 . . . . 0.0 112.317 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -93.26 -9.57 38.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.915 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.972 HD11 ' HA3' ' A' ' 145' ' ' GLY . 42.3 mm -74.65 137.1 23.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.077 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.421 ' O ' ' C ' ' A' ' 91' ' ' THR . 11.3 t -120.46 162.48 19.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.116 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.5 ' HA ' HG23 ' A' ' 109' ' ' VAL . 53.2 m -36.03 -49.27 0.64 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.14 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 93' ' ' ASP . 20.2 mt-10 -52.8 -60.33 3.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.899 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.623 ' CB ' HG23 ' A' ' 89' ' ' ILE . 1.0 OUTLIER -34.78 -57.47 0.53 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.909 179.972 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.525 HD11 HG22 ' A' ' 109' ' ' VAL . 12.6 mt -48.61 -60.0 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.093 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.648 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 24.5 mtmt -47.66 -39.85 18.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.931 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.49 -28.91 70.16 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.087 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.7 -50.68 13.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.095 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.47 ' C ' HD11 ' A' ' 104' ' ' ILE . 19.1 m-85 -91.16 12.16 20.96 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.896 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.763 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -66.6 -59.68 7.73 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.578 0.704 . . . . 0.0 111.09 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.763 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.73 -0.6 7.12 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.637 2.225 . . . . 0.0 112.35 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.505 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 74.9 m-85 -99.61 -11.96 20.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.888 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 152.26 137.53 2.59 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.496 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.424 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 10.1 mtm-85 -48.76 122.64 5.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.81 0.338 . . . . 0.0 110.848 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.47 HD11 ' C ' ' A' ' 98' ' ' PHE . 10.2 mt -99.99 141.75 16.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.125 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.4 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 3.5 t -109.68 -63.73 1.33 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.858 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -100.44 104.85 16.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.881 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.56 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -134.67 128.91 33.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.109 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.477 ' HA ' HG23 ' A' ' 91' ' ' THR . 11.5 ptm180 -161.79 163.6 29.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.841 -179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.525 HG22 HD11 ' A' ' 94' ' ' ILE . 89.9 t -110.85 120.47 61.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.098 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.605 HG21 ' CE2' ' A' ' 121' ' ' TYR . 57.4 t -50.7 135.85 10.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.115 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 46.3 mttm -136.21 146.08 46.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.442 ' O ' ' N ' ' A' ' 116' ' ' GLY . 32.1 t0 -55.02 123.42 13.51 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.891 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 9.1 tpt -71.07 -2.52 15.85 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.873 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -103.08 -48.72 3.96 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.062 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 34.0 p -102.25 -29.37 11.73 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.138 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 80.51 28.45 47.75 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.47 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 14.5 mtpp -99.86 148.82 24.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.781 0.324 . . . . 0.0 110.891 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 5.4 t -51.8 105.64 0.12 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.842 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 36.6 mttt -58.47 -46.81 85.88 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.9 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.406 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 142.13 -41.94 1.17 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.484 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.605 ' CE2' HG21 ' A' ' 110' ' ' VAL . 9.5 p90 -99.86 149.15 23.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.888 0.375 . . . . 0.0 110.947 -179.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -130.58 179.64 16.77 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.479 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -126.62 142.04 51.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.876 0.37 . . . . 0.0 110.921 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.664 HG12 ' CE1' ' A' ' 126' ' ' PHE . 60.2 t -138.94 123.9 21.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.096 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . 0.432 ' O ' HG23 ' A' ' 104' ' ' ILE . 33.0 m -112.19 144.77 41.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.877 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.664 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.2 m-85 -125.32 150.55 47.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.424 ' CE2' ' HB3' ' A' ' 103' ' ' ARG . 21.9 m-85 -57.65 -46.48 84.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.92 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 25.7 m-20 -112.05 163.45 14.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.91 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.561 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 69.9 tttt -72.11 -61.64 1.72 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.897 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.434 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.9 OUTLIER -34.78 -56.76 0.55 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.906 179.99 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 -42.08 -52.02 4.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.851 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -63.37 -60.64 3.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.115 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.411 ' HA ' HD12 ' A' ' 136' ' ' ILE . 5.7 mm-40 -39.44 -60.21 0.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 32.6 t-20 -40.29 -44.77 1.98 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.903 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.424 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -69.63 -54.39 14.18 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.091 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . 0.411 HD12 ' HA ' ' A' ' 133' ' ' GLU . 91.7 mt -41.58 -34.83 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.14 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -87.29 -60.55 1.95 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.911 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 29.3 mm-40 -60.29 -60.17 4.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.901 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.505 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 75.7 mmm -56.84 -41.8 78.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.873 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.441 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -53.09 103.07 0.11 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.478 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 107.41 6.65 33.28 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.51 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 -90.11 173.87 7.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.799 0.333 . . . . 0.0 110.932 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . 0.48 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 17.8 m95 -109.02 121.22 44.68 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.952 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.534 HD23 HD22 ' A' ' 85' ' ' LEU . 34.2 tp -122.85 127.27 48.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.888 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 0.972 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 72.12 -7.08 8.37 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.474 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 124.16 -9.71 8.36 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.507 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 17.9 mtt180 -127.63 148.9 50.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.722 0.296 . . . . 0.0 110.91 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.48 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 28.1 mt-30 -60.19 152.96 23.28 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.923 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.592 HG22 HD23 ' A' ' 85' ' ' LEU . 24.6 pt -123.07 153.55 28.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.099 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.474 ' CG ' ' O ' ' A' ' 150' ' ' ARG . 10.1 ptm180 -114.93 114.05 24.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.441 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 73.4 p -107.86 130.4 55.0 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.159 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -157.39 172.38 18.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 24.2 m95 -71.67 124.47 24.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.896 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -73.05 78.69 1.21 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.13 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 32.4 p -121.61 157.62 30.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.103 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 11.3 ptp180 -154.52 170.73 20.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 44.0 mttt -108.84 151.03 41.6 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.581 0.705 . . . . 0.0 110.879 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 157.6 59.75 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.652 2.234 . . . . 0.0 112.314 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -176.29 1.44 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.689 2.259 . . . . 0.0 112.348 179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -164.93 151.58 9.36 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.611 0.719 . . . . 0.0 111.065 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 172.23 13.02 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.724 2.282 . . . . 0.0 112.321 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 16.9 tptm -105.8 107.15 18.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.945 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 73.3 m -59.9 156.74 13.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.842 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 56.2 p -139.42 168.86 18.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.182 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -173.79 143.02 0.95 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.911 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 26.1 tp10 -144.88 125.05 13.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.883 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 29.1 m -159.02 136.4 9.95 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.833 -179.765 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 10.4 p30 -149.55 134.48 17.92 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.848 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 9.1 t -155.1 156.2 35.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.152 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 58.6 tttm -139.5 149.84 44.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.857 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -164.7 165.54 20.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 91.8 p -174.97 170.2 3.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.906 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 174.84 130.6 1.32 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.493 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 178.33 4.67 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.698 2.265 . . . . 0.0 112.358 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 2.4 t -168.91 123.36 0.86 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.852 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 18.0 t -153.92 164.54 38.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.838 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.506 -179.961 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.437 -0.265 . . . . 0.0 112.437 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 18.4 m -111.76 176.94 4.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.913 0.387 . . . . 0.0 110.857 -179.735 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 59.8 p -101.95 103.94 14.61 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.862 -179.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 137.48 -49.45 0.85 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.442 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 35.1 p -56.55 111.81 1.1 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.871 0.367 . . . . 0.0 110.867 -179.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.1 t -67.86 -45.75 73.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.839 -179.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -135.72 118.61 1.89 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.5 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 53.9 mm-40 -53.04 -46.23 68.38 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.839 0.352 . . . . 0.0 110.926 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 14.0 mmtm -132.6 -177.33 4.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.879 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 33.1 ttpt -110.58 -44.56 3.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.43 ' O ' ' C ' ' A' ' 74' ' ' THR . 28.1 m-20 -107.05 43.75 1.13 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.886 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.591 HG22 ' ND1' ' A' ' 77' ' ' HIS . 16.7 p 35.8 45.3 0.27 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.169 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.2 t -62.47 -59.71 4.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.882 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 46.8 m-80 -109.03 54.65 0.65 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.917 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . 0.591 ' ND1' HG22 ' A' ' 74' ' ' THR . 10.8 m170 -111.07 164.64 12.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.851 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.491 ' CD2' ' HA ' ' A' ' 129' ' ' LYS . 37.3 m-85 -111.59 108.96 18.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.855 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 58.4 m-70 -86.08 155.87 20.63 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.866 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 45.4 t -129.07 141.55 46.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.098 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.0 t80 -90.7 133.33 35.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.893 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.876 HG12 HD21 ' A' ' 85' ' ' LEU . 5.6 t -129.74 110.0 19.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.123 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.47 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -118.18 168.21 13.07 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.473 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.9 t70 68.76 52.73 0.54 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.813 0.34 . . . . 0.0 110.877 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.876 HD21 HG12 ' A' ' 82' ' ' VAL . 16.2 mt -109.68 131.49 55.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.919 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.1 t -53.98 154.71 7.16 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.624 0.726 . . . . 0.0 110.885 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -14.51 36.15 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.693 2.262 . . . . 0.0 112.36 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -93.07 -5.24 50.86 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.911 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.626 HD11 ' HA3' ' A' ' 145' ' ' GLY . 40.5 mm -78.37 138.11 20.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.127 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.3 t -120.84 170.5 9.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.181 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.526 ' HA ' HG23 ' A' ' 109' ' ' VAL . 88.3 m -43.64 -49.85 7.59 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.168 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.437 ' O ' ' C ' ' A' ' 93' ' ' ASP . 57.7 mt-10 -52.05 -60.16 3.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.91 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.525 ' CB ' HG23 ' A' ' 89' ' ' ILE . 5.9 m-20 -34.51 -57.99 0.5 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.891 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.506 ' CD1' HG22 ' A' ' 109' ' ' VAL . 7.6 mt -49.52 -62.26 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.117 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.693 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 27.8 mtmt -46.12 -40.1 10.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.943 179.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -61.52 -31.61 71.63 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.154 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.582 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -72.97 -53.86 10.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.121 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -88.14 7.07 33.45 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.853 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.774 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -60.73 -59.93 12.27 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.609 0.719 . . . . 0.0 111.097 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.774 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.1 Cg_endo -69.77 -0.75 7.38 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.685 2.257 . . . . 0.0 112.314 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.593 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 73.8 m-85 -99.78 -5.04 29.3 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.914 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 144.25 136.2 3.04 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.507 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 29.5 mtt180 -46.78 124.41 6.12 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.795 0.331 . . . . 0.0 110.869 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.469 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 13.2 mt -100.09 138.26 24.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.151 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.495 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 47.1 p -107.33 -61.83 1.5 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.848 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -100.2 104.56 16.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.871 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.491 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -134.94 127.32 30.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.051 179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.45 ' HA ' HG23 ' A' ' 91' ' ' THR . 1.9 ptt-85 -160.94 157.94 27.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.886 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.526 HG23 ' HA ' ' A' ' 91' ' ' THR . 86.8 t -110.26 115.42 49.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.135 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.641 HG21 ' CD2' ' A' ' 121' ' ' TYR . 48.7 t -46.97 136.82 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.147 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 54.0 mttt -137.46 148.69 46.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.945 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.638 ' OD2' ' HB3' ' A' ' 114' ' ' ALA . 25.8 t70 -58.54 130.18 45.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.879 179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 28.4 ptm -78.88 1.63 22.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.866 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.638 ' HB3' ' OD2' ' A' ' 112' ' ' ASP . . . -102.82 -41.18 6.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.087 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 45.1 p -114.43 -29.07 6.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.167 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 84.52 21.43 56.4 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.497 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 48.4 mmtt -92.93 145.25 24.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.769 0.318 . . . . 0.0 110.902 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 4.9 t -46.69 111.86 0.44 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.853 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -62.7 -51.46 67.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 147.46 -41.56 0.93 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.486 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.641 ' CD2' HG21 ' A' ' 110' ' ' VAL . 4.9 p90 -100.06 153.13 19.47 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.928 0.394 . . . . 0.0 110.915 -179.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.42 173.7 22.14 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.468 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -122.54 140.45 52.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.897 0.379 . . . . 0.0 110.92 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.678 HG12 ' CE1' ' A' ' 126' ' ' PHE . 59.2 t -137.62 116.38 14.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.12 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 15.5 t -104.87 147.16 28.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.852 -179.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.678 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.2 m-85 -126.84 150.2 49.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.875 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.495 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 23.1 m-85 -56.7 -44.42 81.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 24.4 m-20 -112.86 166.47 11.35 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.905 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.561 ' HE3' ' CZ2' ' A' ' 153' ' ' TRP . 39.2 tptt -70.99 -59.99 2.48 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.944 179.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.426 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.8 OUTLIER -40.93 -59.92 1.32 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.922 179.941 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.426 ' C ' ' O ' ' A' ' 130' ' ' TRP . 6.9 m-20 -35.8 -39.11 0.14 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.863 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -80.43 -58.51 3.09 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.063 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.4 mt-10 -44.38 -55.68 4.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.948 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 54.7 t30 -42.8 -42.07 3.46 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.909 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.49 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -71.81 -55.78 6.96 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.055 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 76.1 mt -38.76 -36.4 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.104 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.1 mt-30 -83.6 -57.19 3.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.898 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 16.8 mm-40 -68.54 -61.16 1.95 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.897 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.593 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 41.3 mmm -52.97 -31.38 40.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.905 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.447 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -63.04 107.78 1.84 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.491 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 99.94 13.73 36.12 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.487 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 66.5 mm-40 -93.1 166.88 12.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.802 0.334 . . . . 0.0 110.89 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . 0.444 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 14.5 m95 -102.89 107.06 17.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.89 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.582 HD13 ' HB2' ' A' ' 97' ' ' ALA . 63.6 tp -100.02 126.46 46.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.873 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 0.626 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.25 -76.95 0.46 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.493 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -155.96 14.5 0.41 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.497 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 36.7 mtp180 -153.04 157.01 39.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.783 0.325 . . . . 0.0 110.866 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.444 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 30.8 mt-30 -62.16 167.2 4.17 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.927 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.413 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 25.7 pt -138.96 153.21 24.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.488 ' CG ' ' O ' ' A' ' 150' ' ' ARG . 7.0 ptm180 -118.82 116.47 26.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.9 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.447 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 53.5 p -107.53 135.53 48.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.134 -179.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 28.4 t30 -160.15 171.09 19.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . 0.561 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 15.3 m95 -66.87 122.29 17.37 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.937 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -77.92 -56.5 4.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.097 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 9.9 t -73.8 150.97 40.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.169 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 15.2 ptp180 -168.7 152.87 5.73 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.881 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 25.9 mmmt -137.07 155.01 76.34 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.56 0.695 . . . . 0.0 110.912 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 148.61 65.17 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.663 2.242 . . . . 0.0 112.346 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 157.76 59.28 Favored 'Trans proline' 0 N--CA 1.465 -0.15 0 C-N-CA 122.691 2.261 . . . . 0.0 112.369 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.405 ' HB1' ' HD2' ' A' ' 161' ' ' PRO . . . -80.74 154.93 73.5 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.542 0.687 . . . . 0.0 111.098 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . 0.405 ' HD2' ' HB1' ' A' ' 160' ' ' ALA . 53.3 Cg_endo -69.81 125.39 12.07 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.661 2.24 . . . . 0.0 112.309 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -69.36 112.32 5.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.876 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 55.0 p -145.78 133.06 20.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.849 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . 0.422 HG23 ' HG2' ' A' ' 166' ' ' GLU . 13.3 t -136.22 169.75 17.13 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.155 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 3.5 t80 -108.54 99.45 8.83 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.926 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . 0.422 ' HG2' HG23 ' A' ' 164' ' ' THR . 16.8 pt-20 -171.94 145.51 1.88 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.894 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 33.3 p -152.79 116.21 4.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.894 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 3.0 t30 -156.53 130.53 8.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.851 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 13.0 t -170.17 152.6 4.26 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.107 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 6.8 mmpt? -113.42 118.58 34.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.916 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 18.6 pt20 -150.18 147.29 27.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.895 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 70.8 m 54.92 38.4 30.35 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.869 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -72.12 -158.64 3.88 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.488 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 124.02 10.66 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.691 2.261 . . . . 0.0 112.329 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 49.8 m -118.64 146.21 44.85 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.839 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 7.7 t -171.43 165.3 7.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.826 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.291 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.476 -179.983 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.526 -0.23 . . . . 0.0 112.526 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 82.1 p -156.81 174.23 15.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.877 0.37 . . . . 0.0 110.855 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 24.5 m -94.99 161.05 14.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.906 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -102.82 41.01 2.23 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.501 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 6.4 t -144.36 117.48 8.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.881 0.372 . . . . 0.0 110.876 -179.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 1.8 t -98.92 133.15 43.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.871 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 178.36 88.85 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.444 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 35.3 mm-40 -120.09 147.19 45.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.878 0.37 . . . . 0.0 110.938 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 41.0 mmtt -132.64 101.79 5.44 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.935 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 19.9 pttm -135.67 166.36 23.42 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.928 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -109.39 163.19 13.63 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.881 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.6 p -89.38 51.44 2.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.197 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 58.1 p -69.17 -55.51 10.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.837 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.4 t30 -113.02 51.96 0.81 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.885 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 17.2 m170 -117.43 155.08 30.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.877 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.564 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 84.3 m-85 -108.48 115.42 30.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.906 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 10.2 m-70 -89.65 147.84 23.66 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.89 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 41.4 t -119.21 143.47 30.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.157 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.1 t80 -93.56 135.3 34.96 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.666 ' CG1' HD21 ' A' ' 85' ' ' LEU . 4.0 t -131.25 131.04 63.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.157 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.432 ' N ' ' HG2' ' A' ' 150' ' ' ARG . . . -135.8 179.41 17.82 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.524 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 52.37 47.61 24.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.86 0.362 . . . . 0.0 110.852 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.668 HD22 HD23 ' A' ' 144' ' ' LEU . 30.0 mt -99.65 132.91 44.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.938 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -53.01 156.33 3.61 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.651 0.738 . . . . 0.0 110.868 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 -39.53 6.28 Favored 'Trans proline' 0 C--O 1.231 0.125 0 C-N-CA 122.675 2.25 . . . . 0.0 112.337 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -71.46 1.2 6.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.887 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.91 HD11 ' HA3' ' A' ' 145' ' ' GLY . 37.3 mm -83.01 132.37 31.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.169 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.1 t -114.74 175.34 5.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.104 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.555 ' HA ' HG23 ' A' ' 109' ' ' VAL . 16.2 m -52.99 -41.66 64.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.147 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -62.36 -47.03 85.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.894 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.414 ' CB ' HG23 ' A' ' 89' ' ' ILE . 17.1 m-20 -47.87 -50.08 27.54 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.911 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.746 HD11 HG22 ' A' ' 109' ' ' VAL . 8.1 mt -54.7 -54.97 17.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.132 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.587 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 22.0 mtmt -50.93 -42.47 59.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.866 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -58.42 -30.98 67.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.107 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.535 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -72.46 -57.16 4.39 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.101 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.429 ' C ' HD11 ' A' ' 104' ' ' ILE . 22.0 m-85 -87.37 12.22 12.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.935 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.789 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -61.79 -60.19 11.05 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.613 0.72 . . . . 0.0 111.119 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.789 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.5 Cg_endo -69.8 -0.8 7.47 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.678 2.252 . . . . 0.0 112.306 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -99.9 9.57 42.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.883 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 127.26 136.02 4.24 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.525 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 38.9 mtt85 -46.73 125.04 6.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.766 0.317 . . . . 0.0 110.882 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.429 HD11 ' C ' ' A' ' 98' ' ' PHE . 10.9 mt -98.21 138.83 21.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.153 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.449 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.9 t -106.73 -62.91 1.34 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.848 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -100.25 105.2 16.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.861 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.481 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -136.46 127.01 26.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.138 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.2 ptm180 -161.91 155.85 21.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.892 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.746 HG22 HD11 ' A' ' 94' ' ' ILE . 58.4 t -102.07 119.14 49.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.642 HG21 ' CD2' ' A' ' 121' ' ' TYR . 59.8 t -53.86 136.99 15.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.141 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . 0.412 ' C ' ' HG3' ' A' ' 119' ' ' LYS . 57.5 mttt -136.59 153.89 50.83 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.755 ' OD2' ' HB3' ' A' ' 114' ' ' ALA . 23.2 t70 -64.99 120.21 12.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 16.4 ptp -67.14 -10.93 55.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.841 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.755 ' HB3' ' OD2' ' A' ' 112' ' ' ASP . . . -83.62 -54.81 4.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.107 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 13.5 p -104.85 -34.4 8.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.171 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 95.89 25.71 12.7 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.477 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 44.4 mtmt -95.33 154.68 17.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.781 0.324 . . . . 0.0 110.867 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 8.0 t -54.89 112.49 1.05 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.91 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.453 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 16.6 mttp -63.36 -54.23 40.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.895 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 150.2 -41.76 0.79 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.469 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.642 ' CD2' HG21 ' A' ' 110' ' ' VAL . 5.4 p90 -100.01 155.25 17.8 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.96 0.41 . . . . 0.0 110.938 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -134.46 169.88 22.9 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.464 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -118.77 138.44 52.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.873 0.368 . . . . 0.0 110.914 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.678 HG12 ' CE1' ' A' ' 126' ' ' PHE . 61.2 t -138.77 115.08 10.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.143 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 8.2 t -107.23 140.02 40.77 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.877 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.678 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.2 m-85 -119.51 163.45 17.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.894 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.449 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 22.9 m-85 -72.32 -42.91 64.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.902 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 68.0 m-20 -114.18 161.44 17.8 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.864 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.564 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 44.3 tptt -69.74 -61.63 1.71 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.464 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.9 OUTLIER -33.27 -60.7 0.33 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.883 179.972 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 -39.67 -54.07 2.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.875 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -65.02 -59.49 4.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.08 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -43.5 -60.7 1.63 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.894 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -43.57 -44.11 5.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.836 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.462 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -66.63 -56.48 10.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.132 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 82.8 mt -40.91 -37.84 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.14 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 15.7 mt-30 -76.47 -63.81 1.25 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.947 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 27.0 mt-30 -63.85 -61.24 2.42 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.931 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.462 ' N ' ' O ' ' A' ' 135' ' ' ALA . 65.6 mmm -51.43 -34.0 33.07 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.858 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.443 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -58.69 93.47 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.483 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 113.52 4.55 23.3 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.426 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 16.2 mm100 -80.66 171.13 15.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.797 0.332 . . . . 0.0 110.875 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . 0.425 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 15.4 m95 -106.7 111.29 23.76 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.92 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.668 HD23 HD22 ' A' ' 85' ' ' LEU . 66.3 tp -104.91 129.22 53.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.932 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 0.91 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.31 -78.04 0.45 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.492 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -155.29 14.03 0.46 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.499 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 23.9 mtt85 -153.73 161.46 42.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.771 0.32 . . . . 0.0 110.893 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.425 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 23.0 mt-30 -62.95 171.0 2.38 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.429 HG21 ' CB ' ' A' ' 144' ' ' LEU . 14.0 pt -142.07 158.43 20.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.124 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.487 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 7.7 ptm180 -120.82 118.6 30.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.867 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.443 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 61.0 p -111.15 132.44 54.29 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.159 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 41.2 t30 -157.66 174.07 15.89 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.942 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . 0.545 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 9.8 m95 -71.37 135.16 47.17 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.914 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -85.67 41.58 0.91 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.087 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -160.64 146.68 15.03 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.147 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -124.64 128.91 49.57 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.878 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 18.0 mttp -82.44 143.83 48.59 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.573 0.702 . . . . 0.0 110.89 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 148.57 65.61 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.686 2.257 . . . . 0.0 112.375 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 174.86 8.92 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.703 2.269 . . . . 0.0 112.318 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.494 ' HB1' ' HD2' ' A' ' 161' ' ' PRO . . . -101.17 157.74 33.1 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.613 0.721 . . . . 0.0 111.05 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . 0.494 ' HD2' ' HB1' ' A' ' 160' ' ' ALA . 54.0 Cg_endo -69.72 -28.73 25.11 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.703 2.268 . . . . 0.0 112.337 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.405 ' C ' ' O ' ' A' ' 161' ' ' PRO . 23.9 mmtp -37.43 108.36 0.08 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.904 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 3.3 t -120.83 114.07 21.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.896 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 5.4 m -77.69 131.33 37.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.168 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 1.5 t80 -75.2 164.31 26.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.943 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -144.56 143.49 30.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.912 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 75.9 p -172.79 150.3 2.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -138.38 153.39 48.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.907 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 51.1 m -142.59 110.02 5.71 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.179 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 12.5 ttmm -125.76 112.58 16.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.905 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -127.63 136.93 52.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.938 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 88.4 p -156.0 123.15 5.38 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -122.61 68.46 0.45 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.564 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.65 157.08 61.86 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.69 2.26 . . . . 0.0 112.359 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 21.6 p -170.6 122.61 0.63 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.822 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 1.2 t -147.74 151.69 36.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.539 -179.948 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 N-CA-C 112.555 -0.218 . . . . 0.0 112.555 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.6 t -166.28 150.86 7.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.879 0.371 . . . . 0.0 110.867 -179.723 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 7.5 t -67.9 137.13 55.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.86 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 127.43 95.29 0.88 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.47 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 16.0 t -122.98 134.17 54.34 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.846 0.355 . . . . 0.0 110.878 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.8 p -163.89 170.2 17.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.849 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 124.15 -151.04 17.09 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.506 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 9.0 tt0 -106.02 171.62 7.25 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.848 0.356 . . . . 0.0 110.914 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 19.9 mmtt -89.86 96.89 10.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.94 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 3.2 mppt? -96.33 43.21 1.08 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.963 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -56.32 -59.67 4.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.857 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 64.8 p -112.17 40.85 2.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.085 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.7 m -83.66 -42.42 16.68 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.871 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.2 m-20 -78.23 -33.45 49.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.875 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . 0.409 ' CD2' ' HA ' ' A' ' 127' ' ' PHE . 30.2 m170 -68.47 140.97 55.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.848 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -96.45 125.08 40.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.911 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.434 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.5 OUTLIER -82.21 141.75 32.73 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.892 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.515 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 41.6 t -119.2 144.11 28.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.164 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.0 t80 -97.51 131.68 43.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.866 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.939 HG12 HD21 ' A' ' 85' ' ' LEU . 3.6 t -133.42 109.98 14.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.148 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -116.61 -178.12 17.99 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.519 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 16.0 m-20 63.98 34.99 11.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.894 0.378 . . . . 0.0 110.923 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.939 HD21 HG12 ' A' ' 82' ' ' VAL . 9.9 mt -92.76 128.96 38.8 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.918 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.05 154.27 5.48 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.657 0.741 . . . . 0.0 110.874 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -13.79 35.18 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.681 2.254 . . . . 0.0 112.358 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -92.94 -7.78 45.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.87 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.682 HD11 ' HA3' ' A' ' 145' ' ' GLY . 30.5 mm -78.38 138.54 20.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.17 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 11.0 t -119.27 167.26 12.04 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.11 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.597 ' HA ' HG23 ' A' ' 109' ' ' VAL . 21.2 m -42.4 -47.0 4.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.143 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -54.1 -57.71 10.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.885 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.602 ' CB ' HG23 ' A' ' 89' ' ' ILE . 4.0 m-20 -38.45 -57.11 1.18 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.862 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.492 HD11 HG22 ' A' ' 109' ' ' VAL . 6.4 mt -48.16 -58.33 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.101 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.578 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 23.6 mtmt -49.93 -44.37 50.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.928 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -58.56 -30.12 66.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.095 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.488 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -74.85 -58.19 3.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.157 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.45 ' CD2' ' HB1' ' A' ' 135' ' ' ALA . 42.9 m-85 -82.42 8.04 12.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.784 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -60.02 -60.21 11.35 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.591 0.71 . . . . 0.0 111.051 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.784 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.7 -0.99 7.66 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.661 2.241 . . . . 0.0 112.378 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.501 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 81.2 m-85 -99.91 3.63 44.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.903 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 136.55 156.61 7.47 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.458 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.459 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 34.0 mtt85 -64.44 125.18 23.84 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.796 0.331 . . . . 0.0 110.882 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.407 HD13 ' HA ' ' A' ' 95' ' ' LYS . 11.6 mt -100.3 137.21 28.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.115 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.534 ' OG ' ' CZ ' ' A' ' 127' ' ' PHE . 2.5 m -110.14 -60.41 1.8 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.895 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 6.0 t0 -101.22 102.24 13.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.878 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -131.99 125.62 31.97 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.117 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 11.9 ptp180 -159.73 157.58 29.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.841 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.597 HG23 ' HA ' ' A' ' 91' ' ' THR . 99.2 t -109.36 116.0 51.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.147 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.804 HG21 ' CE2' ' A' ' 121' ' ' TYR . 94.5 t -49.16 138.32 4.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.134 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 28.7 mttm -138.39 155.95 48.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.892 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.499 ' O ' ' N ' ' A' ' 116' ' ' GLY . 36.5 t0 -65.49 121.01 13.91 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.889 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 7.0 tpt -69.6 -9.29 53.5 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.898 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.93 -47.8 5.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.105 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 21.9 p -98.35 -34.23 10.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.099 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.499 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 86.33 23.6 43.36 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.474 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 14.8 mtpp -98.93 158.13 15.85 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.797 0.332 . . . . 0.0 110.91 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 47.4 t -56.67 112.91 1.42 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.868 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.713 ' HG3' HG12 ' A' ' 110' ' ' VAL . 25.3 mmtt -63.09 -38.83 92.76 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.918 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 130.49 -42.77 1.37 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.444 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.804 ' CE2' HG21 ' A' ' 110' ' ' VAL . 12.0 p90 -99.91 151.42 21.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.957 0.408 . . . . 0.0 110.892 -179.813 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -136.75 172.4 22.57 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.473 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -120.07 139.06 53.12 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.889 0.376 . . . . 0.0 110.914 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.721 HG12 ' CE1' ' A' ' 126' ' ' PHE . 53.1 t -136.84 111.0 9.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.111 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.8 t -99.38 151.58 20.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.893 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.721 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.5 m-85 -130.83 152.37 50.24 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.875 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.534 ' CZ ' ' OG ' ' A' ' 105' ' ' SER . 76.2 m-85 -66.01 -34.95 79.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.842 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -120.74 149.96 41.73 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.87 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.463 ' O ' ' C ' ' A' ' 130' ' ' TRP . 45.0 tttt -59.05 -65.82 0.6 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.866 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.463 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -33.47 -60.83 0.34 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.923 179.951 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 130' ' ' TRP . 68.8 m-20 -35.81 -46.63 0.46 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.87 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.515 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -74.78 -59.8 2.57 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.085 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -39.07 -53.31 1.82 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.846 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 50.5 t30 -49.22 -50.04 40.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.888 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.45 ' HB1' ' CD2' ' A' ' 98' ' ' PHE . . . -61.91 -53.15 59.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.085 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . 0.461 HG23 ' HA ' ' A' ' 152' ' ' ASN . 96.6 mt -42.28 -37.11 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.142 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 6.1 mt-30 -86.87 -62.29 1.54 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.908 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 26.3 mt-30 -54.4 -61.52 2.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.885 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.501 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 92.6 mmm -58.45 -41.07 84.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.878 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.443 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -46.88 99.48 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.462 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 101.55 17.78 20.64 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.518 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 57.0 mm-40 -96.51 172.42 7.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.782 0.325 . . . . 0.0 110.898 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . 0.523 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 16.0 m95 -107.54 110.71 22.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.873 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.488 HD13 ' HB2' ' A' ' 97' ' ' ALA . 57.3 tp -103.56 127.47 50.97 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.934 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 0.682 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.89 -75.66 0.44 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.463 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.83 15.51 0.3 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.475 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 42.3 mtt-85 -154.62 156.77 37.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.726 0.298 . . . . 0.0 110.874 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.523 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 33.4 mt-30 -63.12 168.95 3.75 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.921 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 26.5 pt -149.23 144.73 18.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.112 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 14.0 ptt180 -105.63 124.06 48.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.863 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.443 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 69.0 p -115.28 141.12 48.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.185 -179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . 0.461 ' HA ' HG23 ' A' ' 136' ' ' ILE . 73.9 m-20 -165.11 177.13 7.94 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.885 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 11.9 m95 -67.91 111.28 4.27 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.942 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -54.18 -29.72 46.81 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.084 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 20.5 p -75.2 169.06 18.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.111 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -162.91 164.23 25.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.457 ' CD ' ' HD2' ' A' ' 158' ' ' PRO . 0.3 OUTLIER -105.91 137.78 19.45 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.601 0.715 . . . . 0.0 110.907 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . 0.457 ' HD2' ' CD ' ' A' ' 157' ' ' LYS . 53.4 Cg_endo -69.78 147.1 61.98 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.664 2.243 . . . . 0.0 112.361 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 161.82 44.47 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.674 2.25 . . . . 0.0 112.331 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -106.35 146.72 33.55 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.591 0.71 . . . . 0.0 111.109 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 93.99 0.52 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.675 2.25 . . . . 0.0 112.326 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 19.2 tttp -157.91 113.25 2.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.895 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 96.4 p -135.05 150.71 50.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.879 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 14.5 t -116.13 174.08 6.24 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.137 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -109.04 165.34 11.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.906 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -138.92 142.88 38.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.935 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 25.4 m -107.27 43.04 1.22 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.844 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -113.42 81.17 1.46 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.859 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 75.2 p -116.33 105.53 12.64 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.153 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 41.3 tttp -87.18 -60.69 1.91 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.879 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 7.0 tt0 -173.54 166.92 4.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.917 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 66.9 m -66.43 121.96 16.48 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.892 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 86.3 83.52 1.11 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.453 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -2.88 10.95 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.669 2.246 . . . . 0.0 112.342 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 67.6 p -140.75 161.08 38.64 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.861 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 69.8 p -159.81 126.63 4.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.838 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 C-N-CA 120.737 -0.745 . . . . 0.0 112.485 179.957 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.369 0 N-CA-C 112.509 -0.237 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 75.3 p -123.43 153.45 40.42 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.912 0.387 . . . . 0.0 110.854 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 43.7 t -90.38 -61.7 1.62 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.896 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 145.07 66.77 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.468 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 22.8 m -112.49 83.19 1.77 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.846 0.355 . . . . 0.0 110.904 -179.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 3.5 m -89.38 82.64 6.44 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.848 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -126.91 -59.38 0.14 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.531 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -98.77 107.92 20.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.906 0.384 . . . . 0.0 110.861 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.6 mptt -96.76 157.96 15.66 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.889 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 35.8 tttp -174.93 133.89 0.34 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.886 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.438 ' O ' ' C ' ' A' ' 74' ' ' THR . 7.0 m-20 48.6 44.98 21.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.855 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.496 HG21 ' OD1' ' A' ' 106' ' ' ASP . 2.1 p 35.22 53.26 0.71 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.126 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.2 t -75.93 -44.41 40.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.816 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -110.33 50.38 0.81 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.864 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 6.8 m170 -122.88 156.53 34.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.876 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.551 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 54.5 m-85 -111.09 114.2 27.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 40.2 m-70 -87.32 148.25 25.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.83 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 34.9 t -123.64 139.64 49.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.122 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -91.94 134.48 34.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.903 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.832 HG12 HD21 ' A' ' 85' ' ' LEU . 3.8 t -132.51 109.93 15.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.14 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.41 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -117.36 170.72 13.59 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.478 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.8 t70 68.83 51.67 0.57 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.847 0.356 . . . . 0.0 110.905 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.832 HD21 HG12 ' A' ' 82' ' ' VAL . 16.5 mt -108.91 131.92 54.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.893 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 t -54.92 153.71 11.01 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.676 0.75 . . . . 0.0 110.85 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -11.29 30.5 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.682 2.254 . . . . 0.0 112.313 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -94.0 -9.83 35.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.911 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.644 HD11 ' HA3' ' A' ' 145' ' ' GLY . 46.9 mm -74.42 137.99 22.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.131 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.2 t -117.84 166.52 12.37 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.162 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.769 HG23 ' HA ' ' A' ' 108' ' ' ARG . 86.1 m -43.37 -46.34 6.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.137 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 93' ' ' ASP . 35.2 mt-10 -55.55 -57.94 9.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.891 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.533 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.0 m-20 -35.18 -58.59 0.54 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.879 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.5 ' CD1' HG22 ' A' ' 109' ' ' VAL . 10.9 mt -48.5 -58.91 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.138 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.604 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 23.9 mtmt -49.41 -39.41 32.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.929 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.03 -27.66 69.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.085 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.501 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -77.65 -52.2 9.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.121 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.404 ' C ' HD11 ' A' ' 104' ' ' ILE . 31.6 m-85 -89.33 13.49 13.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.781 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -67.61 -60.26 5.83 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.554 0.692 . . . . 0.0 111.082 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.781 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.5 Cg_endo -69.76 -0.84 7.49 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.689 2.259 . . . . 0.0 112.323 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -99.95 -5.14 28.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.876 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 144.2 142.0 3.84 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.494 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.444 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 57.4 mtt180 -50.81 125.91 14.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.81 0.338 . . . . 0.0 110.882 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.491 HG21 ' HB2' ' A' ' 107' ' ' ALA . 17.4 mt -99.32 145.72 9.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.127 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.446 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.0 OUTLIER -119.3 -60.09 1.77 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.823 -179.892 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.496 ' OD1' HG21 ' A' ' 74' ' ' THR . 4.2 m-20 -100.53 92.47 5.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.829 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.491 ' HB2' HG21 ' A' ' 104' ' ' ILE . . . -129.5 124.64 34.47 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.103 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.769 ' HA ' HG23 ' A' ' 91' ' ' THR . 10.5 ptm180 -158.13 161.84 37.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.905 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.723 HG23 ' HA ' ' A' ' 91' ' ' THR . 79.5 t -113.44 116.82 53.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.629 HG12 ' HG3' ' A' ' 119' ' ' LYS . 77.1 t -52.58 137.46 12.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.131 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 1.7 mtmp? -130.19 156.97 43.72 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.906 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.515 ' O ' ' N ' ' A' ' 116' ' ' GLY . 27.5 t0 -64.47 118.85 9.37 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.855 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . 0.467 ' C ' ' SD ' ' A' ' 113' ' ' MET . 2.6 tmm? -65.85 -9.79 32.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.893 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -92.92 -53.41 4.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.07 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 20.7 p -100.71 -35.41 9.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.108 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 92.76 28.05 13.14 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.483 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -100.24 156.26 17.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.738 0.304 . . . . 0.0 110.917 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 36.7 t -51.77 109.03 0.32 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.876 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.629 ' HG3' HG12 ' A' ' 110' ' ' VAL . 18.9 mmtt -61.14 -51.74 67.81 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.89 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 144.95 -40.59 1.12 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.533 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.597 ' CZ ' HG11 ' A' ' 110' ' ' VAL . 6.2 p90 -100.09 151.99 20.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.939 0.4 . . . . 0.0 110.944 -179.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -141.0 172.96 23.46 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.495 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -121.19 141.2 51.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.874 0.369 . . . . 0.0 110.862 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.725 HG12 ' CE1' ' A' ' 126' ' ' PHE . 58.6 t -139.18 113.52 7.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.132 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 4.3 t -104.35 147.68 27.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.823 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.725 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.3 m-85 -126.47 153.86 44.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.876 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.446 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 20.9 m-85 -62.02 -43.43 98.86 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.896 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -114.65 161.72 17.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.877 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.551 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 39.9 tptt -69.04 -62.07 1.53 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.917 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.459 ' C ' ' O ' ' A' ' 129' ' ' LYS . 1.0 OUTLIER -33.53 -61.83 0.31 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.937 179.916 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.408 ' C ' ' O ' ' A' ' 130' ' ' TRP . 75.2 m-20 -37.09 -57.46 0.85 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.835 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -58.88 -62.16 2.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.103 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.407 ' HA ' HD12 ' A' ' 136' ' ' ILE . 2.4 mm-40 -39.7 -59.52 1.13 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.876 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 53.3 t30 -41.07 -46.45 2.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.879 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.484 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -67.32 -51.84 47.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.107 179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . 0.407 HD12 ' HA ' ' A' ' 133' ' ' GLU . 97.6 mt -43.42 -35.11 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.151 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -88.33 -55.23 3.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.9 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 5.0 mm100 -67.31 -61.01 2.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.93 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.484 ' N ' ' O ' ' A' ' 135' ' ' ALA . 57.4 mmm -59.2 -26.46 64.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.434 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -65.1 113.54 5.94 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.45 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 89.36 18.25 53.27 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.494 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 89.8 mm-40 -97.47 171.2 8.54 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.788 0.328 . . . . 0.0 110.898 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . 0.436 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 15.4 m95 -104.14 110.68 22.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.949 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.501 HD13 ' HB2' ' A' ' 97' ' ' ALA . 59.2 tp -103.27 129.22 50.19 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.906 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 0.644 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 67.28 -74.74 0.19 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.493 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.81 18.05 0.28 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.511 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 72.2 mtt180 -156.69 155.41 31.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.756 0.312 . . . . 0.0 110.906 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.436 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 31.1 mt-30 -60.18 170.38 1.29 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.915 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.462 HG21 ' HB3' ' A' ' 144' ' ' LEU . 19.2 pt -146.39 150.18 15.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.106 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.424 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 13.1 ptp180 -113.99 121.96 45.48 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.87 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.434 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 73.4 p -112.56 128.11 56.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.168 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -151.33 170.77 18.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.898 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . 0.529 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 9.8 m95 -69.17 109.3 3.99 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.921 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -58.2 -55.37 35.83 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.163 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 6.8 t -112.29 148.06 34.97 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.196 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 15.3 ptt85 -165.98 158.61 14.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.869 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 12.8 mtpp -135.92 131.67 19.06 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.579 0.704 . . . . 0.0 110.899 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 153.43 68.92 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.685 2.256 . . . . 0.0 112.336 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.68 165.82 29.6 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.671 2.248 . . . . 0.0 112.416 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -129.28 147.21 64.08 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.654 0.74 . . . . 0.0 111.072 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.81 105.14 1.44 Allowed 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.688 2.259 . . . . 0.0 112.303 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 21.2 mmmt -130.31 93.76 3.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.889 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 1.7 t -83.54 111.85 19.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.826 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 11.4 t -96.22 135.28 38.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.172 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 10.4 p90 -113.27 131.35 55.95 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.967 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -127.46 82.32 2.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.902 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 78.8 p -169.53 123.93 0.8 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.91 -179.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 4.9 t30 -173.65 129.24 0.42 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.891 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 1.6 t -102.21 149.35 24.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.114 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 27.2 ttpt -151.87 117.16 5.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.857 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 27.3 tt0 -140.45 129.28 23.18 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.965 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 48.8 m -157.53 161.46 38.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.836 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -149.2 69.18 0.34 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.52 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 145.69 58.12 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.677 2.251 . . . . 0.0 112.4 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 4.7 t -120.7 142.47 49.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.858 -179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 8.3 m -103.33 174.98 5.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.813 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.373 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.476 -179.992 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.448 ' O ' ' C ' ' A' ' 64' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.329 0 N-CA-C 112.451 -0.26 . . . . 0.0 112.451 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.448 ' C ' ' O ' ' A' ' 63' ' ' GLY . 60.9 p 34.6 42.16 0.07 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.899 0.38 . . . . 0.0 110.841 -179.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 63.1 p -102.9 -54.78 2.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.867 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.51 -46.57 2.78 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.447 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 5.3 t -41.25 -61.37 1.03 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.86 0.362 . . . . 0.0 110.812 -179.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 13.1 m -149.84 -176.53 5.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.885 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 66.89 68.21 1.74 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.506 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . 0.414 ' NE2' ' O ' ' A' ' 72' ' ' LYS . 11.8 pt20 -50.78 170.03 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.831 0.348 . . . . 0.0 110.929 -179.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.74 -0.62 23.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.85 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.414 ' O ' ' NE2' ' A' ' 70' ' ' GLN . 29.5 ttmt -125.13 126.59 45.53 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.887 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 44.1 m-20 -75.7 162.85 27.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.855 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.4 p -85.45 62.93 7.79 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.109 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 22.6 t -74.43 -53.73 8.98 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.88 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 29.4 m-20 -125.39 52.63 1.6 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.866 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 10.0 m170 -104.89 156.93 17.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.871 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.581 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 97.3 m-85 -97.58 114.61 26.56 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.916 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.467 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.9 OUTLIER -95.51 139.92 31.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.847 -180.0 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 57.4 t -113.96 152.02 15.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.06 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -102.09 132.89 47.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.915 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.922 HG12 HD21 ' A' ' 85' ' ' LEU . 4.1 t -129.57 129.78 66.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.142 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.473 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -136.69 -173.54 12.96 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.758 -0.735 . . . . 0.0 112.494 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 27.0 m-20 55.3 36.33 26.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.831 0.348 . . . . 0.0 110.851 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.922 HD21 HG12 ' A' ' 82' ' ' VAL . 8.3 mt -96.18 131.02 43.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.886 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 t -53.1 153.71 6.15 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.652 0.739 . . . . 0.0 110.818 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -13.84 35.25 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.7 2.267 . . . . 0.0 112.338 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -91.04 -8.75 48.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.888 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.863 HD11 ' HA3' ' A' ' 145' ' ' GLY . 39.1 mm -76.37 136.67 24.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.176 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.444 ' OG1' ' N ' ' A' ' 91' ' ' THR . 2.3 t -114.55 177.54 4.61 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.163 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.726 HG23 ' HA ' ' A' ' 108' ' ' ARG . 69.9 m -52.6 -47.67 66.78 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.177 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 93' ' ' ASP . 32.0 mt-10 -56.42 -58.26 8.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.879 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.447 ' CB ' HG23 ' A' ' 89' ' ' ILE . 2.9 m-20 -35.49 -54.63 0.68 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.911 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.522 HD11 HG22 ' A' ' 109' ' ' VAL . 6.2 mt -51.18 -60.17 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.117 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.528 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 21.7 mtmt -47.14 -43.13 20.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.904 179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -57.43 -31.57 66.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.134 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.402 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -74.42 -52.65 11.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.12 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.454 ' C ' HD11 ' A' ' 104' ' ' ILE . 23.6 m-85 -88.77 12.4 15.11 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.868 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.779 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -65.72 -60.1 7.98 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.597 0.713 . . . . 0.0 111.096 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.779 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.4 Cg_endo -69.8 -0.87 7.58 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.694 2.263 . . . . 0.0 112.321 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.506 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 78.3 m-85 -99.75 4.61 45.51 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.887 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 135.06 159.63 8.74 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.475 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.51 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 39.8 mtp85 -65.72 125.71 26.16 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.804 0.335 . . . . 0.0 110.866 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.454 HD11 ' C ' ' A' ' 98' ' ' PHE . 14.4 mt -100.46 138.14 25.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.186 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -109.86 -60.76 1.74 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.849 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -100.75 103.96 15.21 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.904 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.486 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -133.84 124.86 27.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.124 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.726 ' HA ' HG23 ' A' ' 91' ' ' THR . 17.6 ptt180 -161.94 160.16 27.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.9 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.611 HG23 ' HA ' ' A' ' 91' ' ' THR . 99.4 t -110.12 116.31 51.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.148 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.686 HG21 ' CE2' ' A' ' 121' ' ' TYR . 51.5 t -50.99 132.73 12.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.101 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . 0.418 ' HG2' ' N ' ' A' ' 118' ' ' SER . 69.1 mttt -133.45 148.76 51.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.867 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.44 ' O ' ' N ' ' A' ' 116' ' ' GLY . 29.6 t0 -58.28 123.66 16.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.88 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 36.3 ttp -71.77 -2.83 18.97 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.865 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -99.87 -49.91 4.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.094 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 18.7 p -102.15 -28.2 12.45 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.127 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 82.68 25.31 50.65 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.504 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 48.1 mtmt -99.99 147.08 25.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.757 0.313 . . . . 0.0 110.923 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . 0.418 ' N ' ' HG2' ' A' ' 111' ' ' LYS . 5.0 t -50.18 113.46 0.87 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.813 -179.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 41.5 mttt -63.6 -51.52 64.93 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.898 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.405 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 148.65 -40.02 0.93 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.476 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.686 ' CE2' HG21 ' A' ' 110' ' ' VAL . 10.1 p90 -100.03 149.43 23.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.934 0.397 . . . . 0.0 110.898 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -130.88 176.94 18.75 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.505 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -123.78 139.25 54.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.884 0.373 . . . . 0.0 110.867 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.658 HG12 ' CE1' ' A' ' 126' ' ' PHE . 42.9 t -139.67 113.31 6.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.124 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 24.4 t -102.83 149.6 24.34 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.843 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.658 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.6 m-85 -129.29 141.56 51.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.874 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.51 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 82.7 m-85 -56.12 -41.16 74.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.882 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 12.7 m120 -109.21 155.28 21.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.905 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.581 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 26.8 tttt -68.51 -40.16 80.94 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.891 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.422 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.9 OUTLIER -60.87 -58.92 6.41 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.911 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.422 ' C ' ' O ' ' A' ' 130' ' ' TRP . 78.5 m-20 -36.07 -41.57 0.25 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.871 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.462 ' HB2' ' CD1' ' A' ' 126' ' ' PHE . . . -80.51 -54.71 5.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.1 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.512 ' HA ' HD12 ' A' ' 136' ' ' ILE . 12.5 mt-10 -42.29 -54.28 3.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.898 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -45.42 -51.87 10.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.913 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.461 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -60.95 -56.64 18.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.114 179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . 0.512 HD12 ' HA ' ' A' ' 133' ' ' GLU . 85.8 mt -37.76 -35.32 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.147 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -90.07 -59.22 2.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.937 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 25.2 mm-40 -63.64 -59.49 4.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.919 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.506 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 78.3 mmm -57.08 -40.09 76.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.897 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.436 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -52.15 118.65 7.7 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.519 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 97.83 -24.89 29.75 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.556 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . 0.411 ' NE2' ' HA ' ' A' ' 142' ' ' GLN . 8.7 mm-40 -56.64 -177.26 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.823 0.344 . . . . 0.0 110.901 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . 0.492 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 13.6 m95 -120.42 131.32 54.73 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.914 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.534 HD23 HD22 ' A' ' 85' ' ' LEU . 41.6 tp -128.97 129.17 45.08 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.942 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 0.863 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 71.66 -6.07 9.84 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.467 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 123.05 -10.54 8.81 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.504 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 17.1 mtt85 -125.84 147.76 49.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.741 0.305 . . . . 0.0 110.857 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.492 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 22.6 mt-30 -51.61 169.46 0.06 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.927 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 20.5 pt -140.62 151.19 20.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.14 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.473 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 16.9 ptp180 -113.74 118.79 35.28 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.862 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.436 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 72.2 p -112.08 125.28 53.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.153 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 11.2 m120 -152.76 179.13 8.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.868 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . 0.416 ' O ' ' C ' ' A' ' 154' ' ' ALA . 15.0 m95 -83.45 100.08 10.5 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.929 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.416 ' C ' ' O ' ' A' ' 153' ' ' TRP . . . -36.41 -50.96 0.79 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.097 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 54.4 p -116.44 121.46 41.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.114 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 4.7 tmm_? -146.48 109.15 4.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.839 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 85.0 mttt -121.57 133.78 24.35 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.548 0.69 . . . . 0.0 110.858 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 152.85 69.42 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.659 2.24 . . . . 0.0 112.367 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 161.22 46.76 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.68 2.253 . . . . 0.0 112.349 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -88.12 154.2 51.97 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.569 0.699 . . . . 0.0 111.1 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 -2.86 10.87 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.681 2.254 . . . . 0.0 112.359 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 27.3 ttpt -153.72 135.58 14.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.901 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 10.9 t -130.19 154.37 47.61 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.821 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 8.1 m -91.42 153.9 19.54 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.142 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 2.5 t80 -92.87 176.78 6.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.913 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -122.82 100.23 6.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.889 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 1.3 t -99.64 140.34 33.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.844 -179.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -59.27 170.61 0.91 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.914 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 8.8 t -117.01 144.05 45.03 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.109 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 13.3 tttp -121.34 157.01 31.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.927 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 10.2 pt20 -98.88 174.02 6.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.885 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 2.7 m -163.85 174.16 11.86 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.833 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -162.71 83.02 0.12 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.503 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 176.75 6.33 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.707 2.271 . . . . 0.0 112.345 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 61.5 m -154.1 176.73 11.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.893 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 1.4 t -142.83 161.77 37.22 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.89 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.477 -179.96 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.488 -0.245 . . . . 0.0 112.488 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.422 ' O ' ' C ' ' A' ' 65' ' ' SER . 73.5 m -153.06 129.21 10.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.854 0.359 . . . . 0.0 110.897 -179.723 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . 0.422 ' C ' ' O ' ' A' ' 64' ' ' SER . 6.5 t -36.71 115.89 0.4 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.856 -179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 105.1 -79.53 0.28 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.463 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 49.2 m -87.21 111.38 20.94 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.877 0.37 . . . . 0.0 110.884 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 37.5 t -85.02 -47.68 9.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.875 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.91 174.76 47.34 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.432 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 45.5 mt-30 -87.54 7.52 29.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.847 0.356 . . . . 0.0 110.893 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -108.81 121.65 45.53 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.884 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? 64.88 43.73 3.85 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.888 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -63.39 156.67 25.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.837 179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.1 p 49.82 53.59 12.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.141 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 83.3 p -84.58 -35.95 22.41 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.847 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -79.28 -25.28 42.51 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.887 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 27.2 m170 -75.82 145.72 40.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.898 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.574 ' CE1' ' HB2' ' A' ' 129' ' ' LYS . 46.9 m-85 -100.19 120.44 39.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.889 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.474 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.4 OUTLIER -87.21 144.24 26.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.84 179.984 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.407 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 69.4 t -120.22 144.16 29.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.141 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.469 ' HB2' ' HB2' ' A' ' 154' ' ' ALA . 19.7 t80 -95.63 134.66 38.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.877 -179.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.845 HG12 HD21 ' A' ' 85' ' ' LEU . 2.7 t -132.62 129.1 58.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.11 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.486 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -134.9 179.89 17.19 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.479 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 6.6 t0 57.75 45.05 19.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.82 0.343 . . . . 0.0 110.845 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.845 HD21 HG12 ' A' ' 82' ' ' VAL . 18.5 mt -100.2 131.72 45.98 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.902 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -52.92 154.1 5.39 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.671 0.748 . . . . 0.0 110.842 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.76 -16.0 37.37 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.654 2.236 . . . . 0.0 112.356 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -90.54 -6.53 54.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.853 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.96 HD11 ' HA3' ' A' ' 145' ' ' GLY . 42.6 mm -78.44 137.42 22.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.142 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.8 t -119.09 174.6 6.22 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.088 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.432 ' HA ' HG23 ' A' ' 109' ' ' VAL . 24.5 m -49.41 -47.31 48.03 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.158 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.413 ' O ' ' C ' ' A' ' 93' ' ' ASP . 37.3 mt-10 -56.27 -56.4 21.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.844 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.459 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.2 m-20 -36.51 -58.26 0.72 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.865 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.511 HD11 HG22 ' A' ' 109' ' ' VAL . 14.0 mt -47.43 -59.5 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.159 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.741 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 19.2 mtmt -46.64 -39.44 11.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.892 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.42 ' HB3' ' O ' ' A' ' 93' ' ' ASP . . . -61.26 -35.03 76.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.082 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.75 -54.92 9.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.109 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -87.35 5.37 38.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.896 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.794 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -56.63 -60.41 9.38 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.597 0.713 . . . . 0.0 111.129 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.794 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.7 Cg_endo -69.82 -1.01 7.79 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.677 2.251 . . . . 0.0 112.287 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -100.07 12.63 36.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.866 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 125.45 146.23 6.69 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.53 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 70.7 mtt180 -55.5 125.72 22.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.756 0.313 . . . . 0.0 110.901 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.43 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 11.9 mt -100.03 133.64 42.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.128 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.4 t -102.5 -61.98 1.33 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.852 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -100.34 103.42 14.82 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.846 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.455 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -133.66 124.96 27.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.105 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.401 ' HA ' HG23 ' A' ' 91' ' ' THR . 2.1 ptp180 -161.32 163.21 30.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.511 HG22 HD11 ' A' ' 94' ' ' ILE . 54.9 t -111.97 125.23 69.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.118 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.654 HG21 ' CE2' ' A' ' 121' ' ' TYR . 41.4 t -57.28 135.91 20.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.137 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 18.6 mttp -135.67 150.8 49.71 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.891 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.459 ' O ' ' N ' ' A' ' 116' ' ' GLY . 15.6 t0 -59.68 123.18 16.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.861 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 26.9 ptm -75.05 -2.27 26.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.89 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.0 -38.75 9.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.081 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.435 HG23 ' OD2' ' A' ' 112' ' ' ASP . 25.9 p -116.18 -33.01 5.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.165 -179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 91.27 25.6 23.48 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.471 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 68.3 mmtt -98.94 157.17 16.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.794 0.331 . . . . 0.0 110.866 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 2.7 t -57.27 121.83 11.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.876 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 35.3 mttt -75.48 -48.02 24.5 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.896 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 142.18 -43.67 1.04 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.482 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.654 ' CE2' HG21 ' A' ' 110' ' ' VAL . 14.8 p90 -98.74 146.45 25.88 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.886 0.374 . . . . 0.0 110.933 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -129.86 179.16 17.0 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.489 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 42.8 m-85 -127.11 140.1 52.51 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.898 0.38 . . . . 0.0 110.916 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.71 HG12 ' CE1' ' A' ' 126' ' ' PHE . 61.9 t -137.84 116.65 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.152 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 9.5 t -104.81 148.02 27.09 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.873 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.71 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.4 m-85 -128.37 156.38 43.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.892 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -65.16 -41.31 94.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.901 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -119.18 150.82 39.41 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.907 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.574 ' HB2' ' CE1' ' A' ' 78' ' ' PHE . 30.3 tttt -58.64 -65.68 0.62 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.927 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.45 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -33.17 -59.79 0.35 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.917 179.88 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 70.7 m-20 -37.78 -46.53 0.93 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.822 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.413 ' N ' ' O ' ' A' ' 129' ' ' LYS . . . -73.15 -59.19 2.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.076 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -40.63 -51.93 2.94 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 30.4 t-20 -46.31 -42.07 14.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.893 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -72.67 -54.31 9.37 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.109 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 96.0 mt -40.56 -31.95 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.109 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -84.84 -64.9 1.08 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.957 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -62.01 -62.55 1.7 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.912 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 68.8 mmm -49.76 -43.72 48.26 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.862 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.443 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -51.43 109.64 0.84 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.46 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 105.95 -28.23 14.67 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.482 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 54.1 mm-40 -55.01 179.88 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.819 0.343 . . . . 0.0 110.941 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . 0.506 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 13.3 m95 -116.2 127.18 54.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.912 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.416 ' HB3' HG21 ' A' ' 149' ' ' ILE . 32.8 tp -126.69 130.67 50.84 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.939 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 0.96 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.62 -3.61 11.61 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.474 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 120.86 -13.8 9.79 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.515 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 47.5 mtt180 -124.93 153.57 42.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 110.835 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.506 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 20.6 mt-30 -61.49 158.51 14.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.752 HG22 HD23 ' A' ' 85' ' ' LEU . 21.6 pt -130.86 153.07 38.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.145 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.486 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 2.8 ptp180 -111.68 115.95 29.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.887 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.443 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 58.5 p -110.21 128.12 55.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.142 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 19.8 m-20 -159.94 168.68 25.13 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 14.1 m95 -61.42 139.92 58.13 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.918 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.469 ' HB2' ' HB2' ' A' ' 81' ' ' PHE . . . -120.96 -46.97 2.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.104 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.419 HG23 ' N ' ' A' ' 156' ' ' ARG . 5.9 t -50.51 -43.49 55.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.118 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . 0.419 ' N ' HG23 ' A' ' 155' ' ' THR . 33.4 ttt180 -158.67 158.85 34.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.876 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.478 ' CD ' ' HD2' ' A' ' 158' ' ' PRO . 13.3 tptm -92.38 136.56 25.38 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.569 0.7 . . . . 0.0 110.919 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . 0.478 ' HD2' ' CD ' ' A' ' 157' ' ' LYS . 53.2 Cg_endo -69.82 146.71 60.67 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.693 2.262 . . . . 0.0 112.314 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 158.55 56.59 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.708 2.272 . . . . 0.0 112.307 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -66.05 145.79 99.01 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.589 0.709 . . . . 0.0 111.066 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 98.26 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.645 2.23 . . . . 0.0 112.391 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 2.8 ptpp? -76.2 132.61 40.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.861 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 1.8 t -122.41 88.45 2.93 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.841 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -145.01 129.51 17.94 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.15 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 1.7 t80 -70.75 104.24 2.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.918 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -174.15 154.83 2.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.863 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 59.8 p -92.81 159.53 15.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.872 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -162.07 147.44 13.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 4.4 t -144.03 132.73 22.41 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.098 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 20.9 tttp -165.47 144.59 6.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.894 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . 0.438 ' HG2' ' N ' ' A' ' 172' ' ' SER . 41.9 tt0 -174.96 151.82 1.41 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.899 179.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . 0.438 ' N ' ' HG2' ' A' ' 171' ' ' GLN . 4.2 t -127.4 168.05 15.38 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.845 -179.827 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -163.96 83.14 0.11 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.507 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.7 140.05 41.92 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.714 2.276 . . . . 0.0 112.36 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 15.5 m -122.54 167.78 12.95 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.896 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 5.9 m -69.01 160.79 30.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.85 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.548 -179.967 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 N-CA-C 112.526 -0.229 . . . . 0.0 112.526 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 85.5 p 44.15 42.69 5.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.882 0.372 . . . . 0.0 110.878 -179.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 80.2 p -126.75 147.01 50.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.84 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 160.8 118.35 0.48 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.483 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 8.0 m -106.89 175.4 5.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.817 0.342 . . . . 0.0 110.918 -179.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 33.0 t -134.34 42.83 2.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -104.67 -162.23 24.15 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.529 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 18.4 pt20 -117.59 -47.71 2.62 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.826 0.346 . . . . 0.0 110.93 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 11.0 mptt -108.86 -49.81 3.09 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 14.3 ptpt -166.06 156.01 12.31 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -125.84 85.0 2.33 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.837 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 53.5 p -90.93 39.72 1.0 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.135 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 66.3 m -79.76 -42.24 24.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.867 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 6.7 m-80 -113.59 43.07 1.85 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.877 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 59.6 m170 -123.53 152.95 41.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.853 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -102.23 116.42 32.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.91 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.484 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.7 OUTLIER -83.68 155.6 23.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.858 -179.971 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 36.8 t -134.27 135.34 54.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.112 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.406 ' CE2' ' HG2' ' A' ' 150' ' ' ARG . 15.4 t80 -87.44 128.15 35.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.84 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.978 HG12 HD21 ' A' ' 85' ' ' LEU . 4.0 t -127.96 109.86 20.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.103 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -115.31 -176.91 18.65 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.519 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 59.9 40.26 19.34 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.844 0.354 . . . . 0.0 110.883 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.978 HD21 HG12 ' A' ' 82' ' ' VAL . 11.5 mt -99.04 127.37 44.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.886 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.04 154.19 5.52 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.633 0.73 . . . . 0.0 110.867 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.88 -11.74 31.28 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.67 2.247 . . . . 0.0 112.294 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -92.32 -8.07 46.13 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.894 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.661 HD11 ' HA3' ' A' ' 145' ' ' GLY . 45.7 mm -78.27 138.06 20.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.147 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.5 t -119.55 163.73 16.88 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.118 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.489 ' HA ' HG23 ' A' ' 109' ' ' VAL . 27.7 m -38.85 -46.6 1.31 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.168 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.415 ' O ' ' C ' ' A' ' 93' ' ' ASP . 21.2 mt-10 -56.61 -58.95 5.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.853 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.59 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.9 m-20 -36.42 -57.94 0.73 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.852 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.539 HD11 HG22 ' A' ' 109' ' ' VAL . 8.1 mt -47.44 -58.59 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.103 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.58 ' HE2' ' HB3' ' A' ' 107' ' ' ALA . 26.1 mtmt -49.28 -42.14 40.16 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.893 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -59.09 -28.77 66.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.127 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.621 ' HB1' ' HE1' ' A' ' 139' ' ' MET . . . -74.75 -54.75 6.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.132 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -86.5 8.34 22.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.913 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.783 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -61.61 -60.31 10.77 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.621 0.724 . . . . 0.0 111.145 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.783 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.78 -0.95 7.68 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.681 2.254 . . . . 0.0 112.402 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -100.18 -4.48 29.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.83 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 146.46 156.87 7.09 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.517 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.415 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 31.9 mtm180 -64.84 123.79 20.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.818 0.342 . . . . 0.0 110.867 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 11.1 mt -100.42 139.12 22.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.18 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 8.3 t -110.03 -62.47 1.5 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.884 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -100.73 105.28 16.6 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.888 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.58 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -134.16 125.73 28.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.12 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 15.0 ptt180 -160.86 161.32 31.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.87 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.539 HG22 HD11 ' A' ' 94' ' ' ILE . 72.9 t -111.5 119.45 59.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.173 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.774 HG21 ' CE2' ' A' ' 121' ' ' TYR . 42.8 t -51.45 133.13 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.113 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -132.98 151.59 52.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.457 ' O ' ' N ' ' A' ' 116' ' ' GLY . 39.5 t0 -60.33 119.29 7.66 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.883 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 22.7 ptp -68.68 -2.28 8.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.913 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -97.55 -47.16 5.76 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.125 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 43.2 p -110.05 -34.5 6.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.162 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 92.66 31.98 8.4 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.468 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt -99.52 148.69 24.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.779 0.323 . . . . 0.0 110.88 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 19.5 t -54.92 102.09 0.06 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.832 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 42.2 mttt -52.02 -53.46 41.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.883 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 149.75 -39.82 0.88 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.488 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.774 ' CE2' HG21 ' A' ' 110' ' ' VAL . 5.8 p90 -100.07 161.27 13.71 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.931 0.396 . . . . 0.0 110.887 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -142.27 174.96 23.06 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.455 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -124.59 137.98 54.35 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.896 0.379 . . . . 0.0 110.932 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.591 HG12 ' CE1' ' A' ' 126' ' ' PHE . 71.0 t -138.11 120.38 18.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.105 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 21.1 m -103.06 150.88 23.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.828 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.591 ' CE1' HG12 ' A' ' 124' ' ' VAL . 15.3 m-85 -131.03 142.89 50.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.862 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.415 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 97.5 m-85 -60.9 -32.53 71.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.852 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 21.6 m-20 -117.66 169.58 9.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.849 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.519 ' HE3' ' CH2' ' A' ' 153' ' ' TRP . 20.6 tptm -78.99 -53.16 7.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.89 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.415 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.8 OUTLIER -48.07 -59.83 3.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.914 179.925 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 130' ' ' TRP . 79.4 m-20 -35.83 -40.63 0.19 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.908 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -77.75 -62.76 1.56 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.096 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -42.41 -58.88 2.05 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.877 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -39.97 -47.39 2.23 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.889 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.464 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -67.57 -54.45 19.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.079 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 54.9 mt -41.66 -35.37 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.163 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -88.62 -54.91 3.94 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.98 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 5.0 mm100 -68.11 -62.88 1.2 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.906 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.621 ' HE1' ' HB1' ' A' ' 97' ' ' ALA . 84.6 mmm -52.96 -35.64 59.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.874 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.442 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -52.97 110.6 1.34 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.514 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 100.97 -22.73 38.28 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.481 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 33.5 mm-40 -55.05 169.8 0.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.786 0.326 . . . . 0.0 110.925 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . 0.436 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 14.7 m95 -107.95 113.09 26.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.908 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.58 HD13 ' HB2' ' A' ' 97' ' ' ALA . 56.9 tp -103.98 129.74 51.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.899 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 0.661 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 68.83 -77.77 0.28 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.511 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -155.17 13.74 0.46 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.482 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 32.2 mtp85 -153.17 160.8 42.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.783 0.325 . . . . 0.0 110.902 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.436 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 24.0 mt-30 -62.03 168.7 3.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.933 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.542 HD11 ' HE3' ' A' ' 139' ' ' MET . 22.4 pt -140.2 144.47 27.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.13 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.406 ' HG2' ' CE2' ' A' ' 81' ' ' PHE . 3.7 ttm180 -105.5 124.21 49.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.907 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.442 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 61.9 p -117.52 132.54 56.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.132 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -157.2 169.17 25.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . 0.519 ' CH2' ' HE3' ' A' ' 129' ' ' LYS . 7.3 m95 -65.94 116.57 7.23 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.982 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -64.89 -47.27 78.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.106 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 66.6 p -58.02 149.13 24.01 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.138 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 37.9 mmt180 -119.84 165.35 14.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.882 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 14.0 ptmt -163.11 150.45 10.97 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.61 0.719 . . . . 0.0 110.884 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 148.33 64.59 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.711 2.274 . . . . 0.0 112.291 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 167.64 23.85 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.706 2.271 . . . . 0.0 112.368 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.517 ' HB1' ' HD2' ' A' ' 161' ' ' PRO . . . -80.02 158.45 72.46 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.543 0.687 . . . . 0.0 111.139 179.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . 0.517 ' HD2' ' HB1' ' A' ' 160' ' ' ALA . 54.5 Cg_endo -69.69 174.71 9.05 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.734 2.29 . . . . 0.0 112.363 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.443 ' HG2' ' N ' ' A' ' 163' ' ' SER . 40.9 tttm -174.1 156.36 2.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.904 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . 0.443 ' N ' ' HG2' ' A' ' 162' ' ' LYS . 5.0 t -171.45 176.62 3.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.862 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 4.8 t -149.23 122.45 8.95 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.181 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 9.1 p90 -95.65 118.25 31.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.955 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? -118.88 147.49 43.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.923 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 39.3 t -154.32 131.1 10.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.864 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 9.4 p-10 -165.88 118.82 1.12 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.918 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 29.5 m -150.09 135.04 17.77 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.12 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -147.5 129.89 15.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.854 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -128.71 142.51 50.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.92 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 2.7 t -166.72 123.23 1.23 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.804 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 154.66 66.0 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.435 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 178.17 4.84 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.665 2.243 . . . . 0.0 112.357 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 25.4 p -139.75 165.98 25.84 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.843 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . 0.401 ' O ' ' C ' ' A' ' 177' ' ' GLY . 16.2 m -73.53 121.68 20.99 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.881 -179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 176' ' ' SER . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.518 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.515 -0.234 . . . . 0.0 112.515 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 68.6 p -107.5 119.71 40.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.918 0.39 . . . . 0.0 110.844 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 34.3 t -126.58 89.17 2.95 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.876 -179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -56.66 126.95 42.99 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.538 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 46.9 m -123.45 -50.51 1.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.887 0.375 . . . . 0.0 110.844 -179.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 75.7 m 41.1 42.36 1.59 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.845 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -128.49 -45.81 0.19 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.493 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 20.6 mm-40 -95.04 167.58 11.3 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.857 0.361 . . . . 0.0 110.958 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -172.95 152.95 2.48 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.921 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 16.5 mmmt -80.19 49.4 1.11 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.907 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.405 ' O ' ' N ' ' A' ' 75' ' ' SER . 12.4 p-10 -94.91 33.99 1.42 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.868 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.596 HG22 ' HB2' ' A' ' 77' ' ' HIS . 0.6 OUTLIER -64.54 75.74 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.176 -179.891 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . 0.405 ' N ' ' O ' ' A' ' 73' ' ' ASP . 74.3 m -92.68 152.82 19.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.882 -179.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.6 m-20 55.93 30.92 16.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.909 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . 0.596 ' HB2' HG22 ' A' ' 74' ' ' THR . 9.0 m170 -118.67 159.84 22.91 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.873 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 -115.53 112.11 21.72 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.859 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.476 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.5 OUTLIER -82.51 142.15 32.08 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.867 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 56.0 t -120.94 148.94 23.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.159 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -100.69 136.97 39.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.887 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.884 HG12 HD21 ' A' ' 85' ' ' LEU . 3.5 t -136.77 109.66 8.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.134 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -120.97 179.57 16.3 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.484 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 4.0 t70 62.51 43.08 8.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.827 0.346 . . . . 0.0 110.838 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.884 HD21 HG12 ' A' ' 82' ' ' VAL . 9.1 mt -103.31 135.66 44.53 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.934 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.03 153.9 5.79 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.651 0.739 . . . . 0.0 110.901 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -16.56 37.67 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.678 2.252 . . . . 0.0 112.374 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -89.29 -7.01 56.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.907 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.909 HD11 ' HA3' ' A' ' 145' ' ' GLY . 40.3 mm -75.54 138.46 20.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.127 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.5 t -119.14 168.2 11.08 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.152 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.464 ' HA ' HG23 ' A' ' 109' ' ' VAL . 7.4 m -46.36 -44.12 16.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.112 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 29.6 mt-10 -58.24 -51.26 70.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.901 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.469 ' CB ' HG23 ' A' ' 89' ' ' ILE . 4.6 m-20 -44.04 -55.97 4.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.523 HD11 HG22 ' A' ' 109' ' ' VAL . 8.4 mt -49.53 -58.57 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.139 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.59 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 24.9 mtmt -48.99 -41.71 35.33 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.883 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -59.8 -31.89 70.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.108 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.429 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -72.52 -56.97 4.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.104 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.424 ' C ' HD11 ' A' ' 104' ' ' ILE . 33.5 m-85 -83.79 11.94 6.75 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.88 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.761 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -67.43 -59.95 6.41 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.583 0.706 . . . . 0.0 111.113 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.761 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.77 -0.83 7.48 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.7 2.266 . . . . 0.0 112.319 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.412 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 70.8 m-85 -99.77 -13.37 19.29 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.926 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 156.59 155.14 7.3 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.508 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.455 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 35.8 mtt-85 -63.31 123.21 18.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.795 0.331 . . . . 0.0 110.897 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.424 HD11 ' C ' ' A' ' 98' ' ' PHE . 12.6 mt -100.49 142.6 15.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.133 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.461 ' HB2' ' CZ ' ' A' ' 127' ' ' PHE . 38.6 t -114.94 -61.53 1.74 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.827 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -100.97 101.03 11.74 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.829 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.518 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -130.24 124.24 32.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.117 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 10.2 ptp180 -160.72 153.78 21.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.88 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.523 HG22 HD11 ' A' ' 94' ' ' ILE . 69.2 t -102.3 125.94 56.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.146 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.75 HG12 ' HG3' ' A' ' 119' ' ' LYS . 56.6 t -55.61 139.99 14.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.108 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 49.7 mttt -138.79 149.22 44.75 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.889 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 48.8 t0 -63.1 121.98 14.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.859 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 11.4 ptp -71.4 -1.45 13.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.901 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.97 -54.28 3.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.079 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 26.8 p -99.61 -24.99 14.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.186 -179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 81.35 27.17 49.42 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.457 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 73.6 mmtt -96.75 164.88 12.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.776 0.322 . . . . 0.0 110.914 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 24.6 t -66.33 115.04 5.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.86 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.75 ' HG3' HG12 ' A' ' 110' ' ' VAL . 7.0 mmtm -64.93 -40.92 95.78 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.894 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.549 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 130.44 -46.78 1.05 Allowed Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.481 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.612 ' CE2' HG21 ' A' ' 110' ' ' VAL . 29.6 p90 -100.02 141.18 33.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.905 0.383 . . . . 0.0 110.947 -179.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -125.28 178.64 16.49 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.513 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 62.5 m-85 -121.25 139.9 52.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.878 0.37 . . . . 0.0 110.874 -179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.703 HG12 ' CE1' ' A' ' 126' ' ' PHE . 63.9 t -136.56 115.68 15.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.118 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 43.9 t -101.63 151.43 22.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.833 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.703 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.8 m-85 -131.0 148.04 52.71 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.88 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.461 ' CZ ' ' HB2' ' A' ' 105' ' ' SER . 68.0 m-85 -64.91 -40.41 95.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.867 -179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -111.73 155.27 23.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.877 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.466 ' O ' ' C ' ' A' ' 130' ' ' TRP . 38.4 tttt -68.38 -63.4 1.07 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.893 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.466 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -33.19 -60.09 0.34 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.949 179.897 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.4 ' C ' ' O ' ' A' ' 130' ' ' TRP . 61.9 m-20 -37.77 -54.83 1.22 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.888 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -60.09 -64.95 0.77 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.085 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.2 mm-40 -39.37 -58.57 1.2 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.919 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -42.01 -50.29 4.63 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.878 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.468 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -66.79 -59.95 3.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.062 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 93.4 mt -37.67 -37.74 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.5 mt-30 -84.42 -61.66 1.75 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.935 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -61.24 -59.75 4.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.907 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.468 ' N ' ' O ' ' A' ' 135' ' ' ALA . 86.9 mmm -57.38 -36.33 71.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.855 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -52.39 104.31 0.17 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.495 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 111.86 -31.72 6.85 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.488 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 17.2 mm-40 -49.41 179.82 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.798 0.332 . . . . 0.0 110.923 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . 0.45 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 13.7 m95 -115.44 126.89 54.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.893 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.696 HD23 HD22 ' A' ' 85' ' ' LEU . 40.7 tp -123.29 126.78 47.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.906 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 0.909 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 71.66 -6.12 9.71 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.549 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 123.7 -11.11 8.42 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.485 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 17.8 mtt-85 -125.58 146.9 49.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.789 0.328 . . . . 0.0 110.866 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.45 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 22.4 mt-30 -56.18 158.64 3.93 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.921 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.699 HG22 HD23 ' A' ' 85' ' ' LEU . 21.0 pt -132.29 143.56 39.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.143 179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 11.2 ptt180 -107.07 109.32 21.16 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.876 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 62.4 p -101.0 131.98 46.63 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.188 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 17.1 t30 -155.35 172.88 17.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.881 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 82.8 m95 -72.93 119.67 17.49 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.912 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -52.93 -59.85 4.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.098 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 9.3 t -42.36 160.28 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.178 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 18.0 ptt180 -130.04 146.02 51.69 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.882 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.434 ' HD2' ' N ' ' A' ' 158' ' ' PRO . 0.0 OUTLIER -117.92 137.07 24.05 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-O 121.626 0.727 . . . . 0.0 110.909 179.972 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . 0.434 ' N ' ' HD2' ' A' ' 157' ' ' LYS . 53.6 Cg_endo -69.73 145.39 57.18 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.689 2.259 . . . . 0.0 112.291 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.81 167.04 25.67 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.695 2.263 . . . . 0.0 112.368 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -164.16 143.64 6.22 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.56 0.695 . . . . 0.0 111.097 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 137.71 36.01 Favored 'Trans proline' 0 N--CA 1.465 -0.179 0 C-N-CA 122.72 2.28 . . . . 0.0 112.356 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.438 ' HD2' ' N ' ' A' ' 162' ' ' LYS . 0.0 OUTLIER -154.6 142.31 19.91 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.894 179.955 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 26.9 t -173.75 122.05 0.33 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.871 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . 0.568 HG23 ' O ' ' A' ' 164' ' ' THR . 14.6 t -148.33 118.77 7.38 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.156 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . 0.498 ' O ' ' CG ' ' A' ' 165' ' ' TYR . 8.3 p90 -168.65 110.88 0.54 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.876 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -109.76 97.82 7.28 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.873 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 26.5 t -172.01 159.32 4.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.84 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -158.27 151.54 23.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.875 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 74.9 p -133.51 132.52 41.06 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.15 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 2.2 tmtp? -109.12 -45.4 3.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.926 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -157.96 121.82 4.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.913 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 88.2 p -112.62 133.95 54.39 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.825 -179.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 69.18 83.5 0.16 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.441 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 108.04 2.0 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.688 2.258 . . . . 0.0 112.349 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 44.9 t -128.09 125.06 38.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.9 -179.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 61.4 p -166.86 132.04 2.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.866 -179.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.527 179.986 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 74.4 m -132.14 135.28 46.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.916 0.388 . . . . 0.0 110.86 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 13.6 t -45.41 -51.67 11.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.855 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 141.74 135.65 3.15 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.451 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 5.1 m -95.24 104.14 16.02 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.831 0.348 . . . . 0.0 110.873 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.8 p -56.87 161.81 2.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.849 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 151.3 116.94 0.75 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.495 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 14.6 mm-40 -62.6 97.46 0.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.885 0.374 . . . . 0.0 110.892 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 27.6 mtmm -73.01 88.07 1.37 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.889 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.52 -23.5 56.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.909 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -88.4 160.64 17.48 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.88 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.5 HG21 ' CG ' ' A' ' 106' ' ' ASP . 5.4 p -120.33 33.94 5.4 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.153 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 90.8 p -63.63 -52.42 60.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.837 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 77.7 m-20 -99.2 41.56 1.14 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.907 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . 0.413 ' ND1' HG22 ' A' ' 74' ' ' THR . 8.9 m170 -113.48 158.04 21.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.86 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.55 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 5.1 m-85 -108.75 110.12 21.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.84 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.448 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.6 OUTLIER -83.99 149.09 26.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.836 -179.987 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.554 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 39.7 t -125.0 141.25 45.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.148 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.1 t80 -92.31 134.03 35.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.894 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.984 HG12 HD21 ' A' ' 85' ' ' LEU . 12.2 t -132.62 112.95 19.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.1 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.41 ' C ' ' HG2' ' A' ' 150' ' ' ARG . . . -120.52 -179.63 16.31 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.431 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.408 ' O ' ' O ' ' A' ' 148' ' ' GLN . 5.2 m-20 63.9 43.79 5.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.812 0.339 . . . . 0.0 110.878 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.984 HD21 HG12 ' A' ' 82' ' ' VAL . 9.6 mt -102.37 129.16 48.76 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.902 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.1 t -53.26 154.27 5.99 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.705 0.764 . . . . 0.0 110.849 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -7.65 21.6 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.719 2.28 . . . . 0.0 112.341 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -99.98 -8.67 23.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.864 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.826 HD11 ' HA3' ' A' ' 145' ' ' GLY . 38.6 mm -75.29 141.2 16.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.14 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 15.0 t -119.46 173.13 7.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.14 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.7 HG23 ' HA ' ' A' ' 108' ' ' ARG . 88.0 m -50.22 -47.28 54.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.099 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -54.74 -52.97 60.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.884 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.498 ' CB ' HG23 ' A' ' 89' ' ' ILE . 1.6 m-20 -42.72 -55.78 3.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.821 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.631 HD11 HG22 ' A' ' 109' ' ' VAL . 10.2 mt -49.5 -58.66 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.112 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.717 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 25.3 mtmt -47.87 -39.51 18.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.82 -32.72 72.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.095 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.629 ' HB1' ' HE1' ' A' ' 139' ' ' MET . . . -71.71 -51.85 20.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.094 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.488 ' C ' HD11 ' A' ' 104' ' ' ILE . 14.2 m-85 -93.51 13.2 22.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.882 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.767 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -66.76 -59.82 7.33 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.538 0.685 . . . . 0.0 111.081 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.767 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.3 Cg_endo -69.78 -0.61 7.18 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.685 2.257 . . . . 0.0 112.305 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -99.75 -1.33 38.0 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.846 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 142.54 143.24 4.15 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.451 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 68.4 mtm180 -53.47 123.38 11.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.795 0.331 . . . . 0.0 110.891 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.488 HD11 ' C ' ' A' ' 98' ' ' PHE . 20.1 mt -100.0 137.34 27.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.167 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.472 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 7.5 p -105.1 -62.3 1.36 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.884 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.5 ' CG ' HG21 ' A' ' 74' ' ' THR . 0.8 OUTLIER -100.74 105.14 16.44 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 179.948 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.501 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -135.18 125.29 26.02 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.13 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.7 ' HA ' HG23 ' A' ' 91' ' ' THR . 8.2 ptp180 -160.22 169.17 23.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.86 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.631 HG22 HD11 ' A' ' 94' ' ' ILE . 95.8 t -116.93 117.54 55.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.133 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.852 HG12 ' HG3' ' A' ' 119' ' ' LYS . 60.6 t -47.1 141.08 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.172 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 80.1 mttt -140.31 152.09 45.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.902 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -63.88 121.55 14.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.851 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 1.1 pmm? -74.89 -1.47 22.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.856 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -98.14 -44.37 6.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.097 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 52.1 p -111.12 -35.16 5.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.175 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 94.63 31.01 8.08 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.505 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 22.9 mmtm -99.53 164.39 12.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.822 0.344 . . . . 0.0 110.891 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 29.6 t -65.83 109.88 2.64 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.866 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.852 ' HG3' HG12 ' A' ' 110' ' ' VAL . 11.3 mmtp -59.78 -39.36 84.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.878 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.508 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 128.6 -47.16 1.04 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.549 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.577 ' CE2' HG21 ' A' ' 110' ' ' VAL . 12.8 p90 -99.94 146.56 26.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.969 0.414 . . . . 0.0 110.902 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -127.96 178.03 17.29 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.459 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 36.9 m-85 -121.73 140.12 52.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.912 0.386 . . . . 0.0 110.908 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.68 HG12 ' CE1' ' A' ' 126' ' ' PHE . 47.4 t -136.77 113.75 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.108 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . 0.436 ' O ' HG23 ' A' ' 104' ' ' ILE . 69.0 m -102.04 150.48 23.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.867 -179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.68 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.4 m-85 -130.77 143.33 50.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.846 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.472 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 22.7 m-85 -50.27 -48.89 54.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.904 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 12.8 m-20 -106.85 173.31 6.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.886 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.55 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 3.5 ttmt -79.36 -51.8 8.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.927 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.42 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.0 OUTLIER -48.03 -58.4 4.49 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.887 179.952 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 130' ' ' TRP . 81.9 m-20 -35.72 -42.74 0.26 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.86 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.554 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -78.7 -60.89 2.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.128 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.595 ' HA ' HD12 ' A' ' 136' ' ' ILE . 18.6 mt-10 -37.83 -55.56 1.18 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -43.15 -55.51 3.88 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.902 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.466 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -59.21 -54.66 44.35 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.075 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . 0.595 HD12 ' HA ' ' A' ' 133' ' ' GLU . 93.0 mt -38.62 -36.57 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.14 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -87.94 -60.8 1.87 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.908 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 20.1 mm-40 -61.32 -59.49 5.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.9 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.629 ' HE1' ' HB1' ' A' ' 97' ' ' ALA . 87.3 mmm -59.32 -35.57 74.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.429 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -53.31 111.03 1.56 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.466 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 102.11 -28.86 14.03 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.499 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -50.63 178.89 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.746 0.308 . . . . 0.0 110.898 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . 0.588 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 14.3 m95 -115.31 119.55 36.66 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.959 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.595 HD13 ' HB2' ' A' ' 97' ' ' ALA . 60.6 tp -109.5 129.5 55.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.918 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 0.826 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.24 -78.57 0.43 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.476 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -156.04 14.08 0.4 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.517 -179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 66.7 mtt180 -153.5 154.38 34.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.744 0.307 . . . . 0.0 110.883 -179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.588 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 15.8 mt-30 -55.91 167.8 0.54 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.914 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.499 HG21 ' HB3' ' A' ' 144' ' ' LEU . 28.8 pt -140.81 147.69 22.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.155 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.41 ' HG2' ' C ' ' A' ' 83' ' ' GLY . 15.8 ptt180 -111.83 120.47 42.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.805 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.429 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 82.5 p -111.02 133.12 53.66 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -155.06 165.52 36.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.886 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 12.9 m95 -62.04 102.78 0.31 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.945 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -39.92 -40.75 1.06 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.107 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.405 ' HB ' ' CD ' ' A' ' 157' ' ' LYS . 39.9 p -96.75 128.49 43.74 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.189 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 35.0 ttt180 -85.91 94.7 9.25 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.827 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.405 ' CD ' ' HB ' ' A' ' 155' ' ' THR . 0.8 OUTLIER -128.84 142.81 46.31 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.58 0.705 . . . . 0.0 110.86 179.967 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 148.7 65.57 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.706 2.271 . . . . 0.0 112.295 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 174.71 9.13 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.646 2.231 . . . . 0.0 112.327 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -166.0 145.97 5.34 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.584 0.706 . . . . 0.0 111.118 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.74 134.33 27.77 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.718 2.279 . . . . 0.0 112.335 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 21.8 ttpp -95.08 138.77 32.35 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.929 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 9.1 t -73.08 -60.66 2.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.84 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 9.3 t -166.47 130.04 2.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.118 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -49.97 -60.55 2.82 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.932 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -171.56 154.96 3.93 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.857 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 6.7 t -133.56 99.22 4.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.859 -179.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -171.88 168.16 6.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 44.0 p -98.81 156.7 16.73 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.149 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 8.4 tmtm? -55.74 131.49 46.83 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 22.7 tt0 -147.52 149.4 32.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 87.6 p -138.62 172.49 12.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.863 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -139.58 146.38 17.91 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.442 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -171.68 0.5 Allowed 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.753 2.302 . . . . 0.0 112.328 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 23.2 t -157.07 137.73 13.18 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.895 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 1.2 t -153.49 121.83 6.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.848 -179.757 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.451 179.955 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.272 0 N-CA-C 112.448 -0.261 . . . . 0.0 112.448 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 59.4 p -52.25 -56.81 12.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.927 0.394 . . . . 0.0 110.854 -179.737 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 28.5 m -58.0 135.43 56.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.891 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -177.81 79.91 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.451 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.0 m -50.84 -58.76 5.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.902 0.382 . . . . 0.0 110.858 -179.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 78.1 p 48.81 44.59 21.94 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.838 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -146.28 105.25 0.32 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.504 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 25.1 mt-30 -109.75 34.94 3.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.815 0.341 . . . . 0.0 110.889 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.46 ' HE3' ' N ' ' A' ' 71' ' ' LYS . 0.0 OUTLIER -51.05 170.59 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.921 179.945 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 13.2 tptt -124.08 -43.75 2.08 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.863 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 62.2 m-20 -75.21 178.7 5.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.902 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 37.2 p -119.17 78.7 1.32 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.127 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 91.8 p -93.84 143.48 26.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 72.4 m-80 43.73 35.43 1.04 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.86 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 8.8 m170 -106.49 159.87 15.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.888 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.498 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 75.9 m-85 -108.85 112.38 24.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.42 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.9 OUTLIER -88.49 163.81 15.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.895 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.407 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 49.0 t -138.32 143.66 32.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.112 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.2 t80 -98.11 132.08 43.95 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.854 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.983 HG12 HD21 ' A' ' 85' ' ' LEU . 2.7 t -132.63 109.79 15.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.136 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.446 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -116.3 -179.45 18.03 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.469 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.4 ' O ' ' O ' ' A' ' 148' ' ' GLN . 14.4 m-20 63.8 26.21 14.31 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.891 0.377 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.983 HD21 HG12 ' A' ' 82' ' ' VAL . 10.7 mt -83.79 135.59 34.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.951 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -52.93 147.61 15.68 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.717 0.77 . . . . 0.0 110.854 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -6.2 18.04 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.638 2.225 . . . . 0.0 112.344 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -100.61 -5.02 27.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.851 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.917 HD11 ' HA3' ' A' ' 145' ' ' GLY . 30.8 mm -74.8 145.29 11.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.124 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.411 HG22 ' OD1' ' A' ' 93' ' ' ASP . 9.1 t -121.03 165.0 15.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.133 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.631 ' HA ' HG23 ' A' ' 109' ' ' VAL . 22.5 m -43.63 -50.7 7.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.107 -179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 93' ' ' ASP . 34.3 mt-10 -54.55 -57.26 12.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.892 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.431 ' CB ' HG23 ' A' ' 89' ' ' ILE . 0.5 OUTLIER -35.78 -57.86 0.64 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.89 179.974 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.446 ' CD1' HG22 ' A' ' 109' ' ' VAL . 8.7 mt -47.36 -59.31 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.117 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.593 ' HE2' ' HB3' ' A' ' 107' ' ' ALA . 22.9 mtmt -47.93 -39.21 18.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.926 179.822 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 93' ' ' ASP . . . -60.82 -35.03 75.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.079 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -71.68 -51.81 21.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.09 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.529 ' C ' HD11 ' A' ' 104' ' ' ILE . 23.0 m-85 -89.43 16.82 6.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.865 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.8 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -68.05 -60.61 4.98 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.595 0.712 . . . . 0.0 111.102 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.8 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.5 Cg_endo -69.8 -1.43 8.5 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.647 2.232 . . . . 0.0 112.318 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -100.45 11.45 39.43 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.842 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 126.65 133.16 3.79 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.477 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 16.9 mtt180 -46.08 126.75 7.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.799 0.333 . . . . 0.0 110.87 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.621 ' CG2' HG13 ' A' ' 124' ' ' VAL . 11.0 mt -100.06 138.13 25.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.139 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.52 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 2.6 t -107.61 -62.72 1.39 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -100.56 104.27 15.62 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.842 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.593 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -134.46 125.92 28.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.076 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.441 ' NH1' ' HA ' ' A' ' 110' ' ' VAL . 0.1 OUTLIER -158.88 157.51 31.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.884 -179.911 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.631 HG23 ' HA ' ' A' ' 91' ' ' THR . 88.3 t -104.82 117.71 50.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.122 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.856 HG11 ' CZ ' ' A' ' 121' ' ' TYR . 85.8 t -50.33 143.04 2.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.103 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 33.8 mttm -142.68 157.1 45.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.865 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -71.37 128.03 34.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.858 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 24.8 ptp -76.96 1.06 18.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -99.59 -46.04 5.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.092 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 24.4 p -108.85 -26.28 10.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.169 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 81.5 24.62 56.09 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.479 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 66.8 mttt -97.88 164.59 12.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.814 0.34 . . . . 0.0 110.902 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 2.2 m -59.39 119.04 6.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.855 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.647 ' HG3' HG12 ' A' ' 110' ' ' VAL . 24.4 mmtt -71.25 -39.32 71.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.945 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 128.99 -40.5 1.69 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.459 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.856 ' CZ ' HG11 ' A' ' 110' ' ' VAL . 7.0 p90 -100.23 156.04 17.44 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.911 0.386 . . . . 0.0 110.956 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.17 174.8 21.53 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.56 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -130.55 139.24 50.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.888 0.375 . . . . 0.0 110.857 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.621 HG13 ' CG2' ' A' ' 104' ' ' ILE . 76.7 t -134.49 133.56 54.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.097 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 32.5 t -113.19 138.58 49.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.83 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.619 ' CD1' ' HB2' ' A' ' 132' ' ' ALA . 75.2 m-85 -118.65 147.38 43.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.878 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.52 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 23.3 m-85 -61.64 -36.21 80.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.912 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 4.7 m-20 -114.75 174.58 5.89 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.866 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.498 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 67.1 tttt -84.12 -39.34 19.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.93 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.42 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -61.15 -53.11 61.12 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.928 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 130' ' ' TRP . 75.6 m-20 -35.88 -52.39 0.73 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.891 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.619 ' HB2' ' CD1' ' A' ' 126' ' ' PHE . . . -64.97 -66.18 0.58 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.096 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.482 ' HA ' HD12 ' A' ' 136' ' ' ILE . 3.8 mm-40 -34.7 -56.5 0.54 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.866 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -42.26 -51.68 4.69 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.924 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -64.7 -55.79 17.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.086 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . 0.482 HD12 ' HA ' ' A' ' 133' ' ' GLU . 87.4 mt -39.2 -33.46 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.14 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 12.2 mt-30 -84.9 -67.38 0.8 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.889 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 20.7 mt-30 -57.73 -61.58 2.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.901 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . . . . . . . . . 64.8 mmm -53.47 -41.1 65.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.868 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.408 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -49.38 104.72 0.11 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.519 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 106.7 -31.16 8.51 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.454 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 50.7 mm-40 -49.33 173.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.823 0.344 . . . . 0.0 110.927 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . 0.485 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 12.9 m95 -108.89 127.41 54.02 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.899 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.537 ' HB3' HG21 ' A' ' 149' ' ' ILE . 36.6 tp -128.48 130.76 47.99 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.887 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 0.917 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.77 -2.09 13.48 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.488 179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 117.26 -14.27 13.58 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.48 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 20.1 mtt-85 -124.12 143.25 50.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.804 0.335 . . . . 0.0 110.829 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.485 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 28.4 mt-30 -52.5 160.04 0.92 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.951 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.56 HG22 HD23 ' A' ' 85' ' ' LEU . 21.3 pt -134.15 152.74 34.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.15 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.446 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 10.7 ptp180 -113.24 118.85 35.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.408 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 41.5 p -110.49 133.33 53.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.127 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 60.5 m-20 -163.06 164.43 25.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.887 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 14.3 m95 -58.05 126.61 28.21 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.922 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -75.57 -34.31 60.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.114 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 1.2 p -83.03 20.95 1.12 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.174 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 45.4 ttt180 -174.28 119.92 0.25 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.885 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 26.0 ttpt -126.14 127.35 24.7 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.585 0.707 . . . . 0.0 110.894 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 167.42 24.44 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.668 2.245 . . . . 0.0 112.387 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 157.99 58.55 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.697 2.265 . . . . 0.0 112.376 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -79.49 152.37 75.56 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.6 0.714 . . . . 0.0 111.104 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 136.86 34.06 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.725 2.283 . . . . 0.0 112.319 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.422 ' O ' HG23 ' A' ' 164' ' ' THR . 34.3 mtmt -122.52 148.63 44.95 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.905 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 29.3 t -63.97 116.42 5.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.903 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . 0.422 HG23 ' O ' ' A' ' 162' ' ' LYS . 38.4 p -118.51 100.65 7.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.099 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 3.4 p90 -69.29 -177.99 1.25 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.901 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -174.67 135.77 0.41 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.896 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 39.4 t -137.62 114.5 10.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.87 -179.789 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 2.7 p30 -165.08 122.43 1.56 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.855 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 79.8 m -125.43 144.3 50.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.13 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 28.2 tttp -163.45 120.18 1.79 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.932 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -107.92 93.95 4.81 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.899 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 60.1 p -92.0 164.6 13.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.818 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -129.2 70.92 0.51 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.524 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 -27.76 25.9 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.628 2.219 . . . . 0.0 112.319 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 72.8 p -93.51 141.58 28.3 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.872 -179.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 7.0 t -43.89 -59.7 2.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.882 -179.816 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.489 179.977 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 28.3 t -66.52 112.12 3.94 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.906 0.384 . . . . 0.0 110.879 -179.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 26.8 t -170.25 157.16 6.12 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.863 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -72.61 -147.92 0.81 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.467 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 60.9 m -85.09 141.33 30.32 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.914 0.388 . . . . 0.0 110.893 -179.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 60.9 p -159.05 141.1 13.7 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -165.91 133.26 2.89 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.501 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 46.1 mt-30 -125.49 -49.29 1.66 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.848 0.356 . . . . 0.0 110.892 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.23 156.35 18.36 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 11.0 pttm -87.16 44.86 1.21 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.906 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -112.81 158.3 20.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 179.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.769 HG21 ' HB2' ' A' ' 106' ' ' ASP . 39.1 p -119.13 90.84 3.41 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.173 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 31.1 p -119.17 -56.91 2.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.871 -179.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 2.7 m-80 -53.22 -38.86 63.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.891 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 53.2 m170 -65.16 174.05 2.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.822 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.564 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 17.5 m-85 -112.6 118.66 35.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.903 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.449 ' ND1' ' N ' ' A' ' 79' ' ' HIS . 1.1 m-70 -86.9 149.1 25.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.835 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.475 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 40.2 t -129.06 144.43 38.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.112 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.6 t80 -94.78 135.28 36.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.843 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.761 HG12 HD21 ' A' ' 85' ' ' LEU . 4.0 t -132.43 119.37 38.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.066 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.418 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -129.24 170.01 20.39 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.494 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 2.2 t70 72.43 38.92 0.78 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.847 0.356 . . . . 0.0 110.904 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.761 HD21 HG12 ' A' ' 82' ' ' VAL . 9.9 mt -100.39 133.82 44.24 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.965 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 t -54.34 153.74 9.42 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.654 0.74 . . . . 0.0 110.804 -179.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 -14.38 36.1 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.638 2.225 . . . . 0.0 112.406 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -90.4 -10.25 44.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.89 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.671 HD11 ' HA3' ' A' ' 145' ' ' GLY . 37.5 mm -76.64 135.7 26.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.16 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.409 ' O ' ' C ' ' A' ' 91' ' ' THR . 14.4 t -117.27 160.43 21.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.162 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.622 ' HA ' HG23 ' A' ' 109' ' ' VAL . 20.2 m -36.99 -47.14 0.69 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.13 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -52.92 -54.72 30.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.875 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.613 ' CB ' HG23 ' A' ' 89' ' ' ILE . 3.1 m-20 -42.26 -54.58 3.65 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.87 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.441 ' CD1' HG22 ' A' ' 109' ' ' VAL . 15.1 mt -51.04 -59.95 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.154 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.642 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 23.3 mtmt -48.27 -39.62 22.14 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.928 179.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.92 -32.17 73.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.043 179.859 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -73.15 -54.59 8.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.127 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.412 ' C ' HD11 ' A' ' 104' ' ' ILE . 28.9 m-85 -86.08 11.3 12.03 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.881 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.763 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -65.26 -59.5 9.67 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.593 0.711 . . . . 0.0 111.112 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.763 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.2 Cg_endo -69.76 -0.58 7.12 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.678 2.252 . . . . 0.0 112.354 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.581 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 78.6 m-85 -99.73 -8.59 24.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.885 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 147.52 133.66 2.41 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.507 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 34.4 mtp180 -45.42 123.63 4.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.775 0.322 . . . . 0.0 110.869 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.552 HG23 ' O ' ' A' ' 125' ' ' SER . 9.9 mt -99.39 137.96 25.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.139 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.436 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 89.5 p -104.02 -65.1 1.04 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.846 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.769 ' HB2' HG21 ' A' ' 74' ' ' THR . 35.2 t70 -100.65 106.41 17.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.868 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.587 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -135.05 127.9 31.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.118 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.427 ' HD3' ' N ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -161.06 158.94 28.6 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.886 -179.904 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.622 HG23 ' HA ' ' A' ' 91' ' ' THR . 88.6 t -107.64 116.9 52.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.129 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.668 HG21 ' CE2' ' A' ' 121' ' ' TYR . 59.6 t -48.3 137.97 3.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.135 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 53.6 mttt -134.48 156.46 48.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.874 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 116' ' ' GLY . 10.4 t0 -60.6 122.99 16.09 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.841 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 11.0 tpt -67.63 -4.26 11.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.896 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -106.34 -52.23 2.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.078 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 53.8 p -95.14 -28.59 14.99 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.131 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 79.53 26.67 56.41 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.491 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 54.0 mmtt -100.0 149.75 23.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.791 0.329 . . . . 0.0 110.869 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 8.2 t -50.38 108.3 0.22 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.878 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 40.3 mttt -61.47 -43.81 98.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.917 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 142.28 -42.44 1.13 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.502 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.668 ' CE2' HG21 ' A' ' 110' ' ' VAL . 15.5 p90 -100.04 146.13 27.11 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.927 0.394 . . . . 0.0 110.91 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -128.91 179.98 16.3 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.473 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -125.69 140.05 53.03 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.879 0.371 . . . . 0.0 110.899 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.539 HG12 ' CE1' ' A' ' 126' ' ' PHE . 50.7 t -135.17 121.34 32.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.161 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . 0.552 ' O ' HG23 ' A' ' 104' ' ' ILE . 5.2 m -106.01 148.33 27.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.854 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.539 ' CE1' HG12 ' A' ' 124' ' ' VAL . 21.2 m-85 -130.73 147.13 52.36 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.893 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.436 ' CE1' ' HB3' ' A' ' 105' ' ' SER . 23.4 m-85 -59.17 -43.18 92.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.846 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 23.9 m120 -118.9 157.33 27.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.888 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.564 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 8.3 ttmt -60.43 -63.47 1.29 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.89 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.443 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -34.66 -52.82 0.53 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 179.954 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -43.89 -45.6 7.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.892 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.475 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -76.53 -57.04 4.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.096 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.404 ' HG2' ' CZ2' ' A' ' 153' ' ' TRP . 11.2 mt-10 -44.33 -56.73 3.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.861 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 51.1 t30 -45.13 -42.88 9.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.837 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.485 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -71.83 -53.95 11.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.095 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 96.8 mt -40.63 -40.84 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.119 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -78.8 -59.61 2.71 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.917 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 15.2 mm-40 -63.7 -63.33 1.2 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.885 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.581 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 82.3 mmm -51.6 -39.06 57.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.865 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -54.08 112.34 2.51 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.519 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 91.58 21.51 34.14 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.531 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 62.8 mm-40 -101.25 168.44 9.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.792 0.33 . . . . 0.0 110.95 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . 0.426 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 14.8 m95 -105.0 109.15 21.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.892 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.497 HD23 HD22 ' A' ' 85' ' ' LEU . 63.1 tp -102.01 128.45 48.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.917 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 0.671 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 68.63 -72.51 0.36 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.484 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -160.88 17.56 0.19 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.499 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 33.3 mtt85 -155.78 156.72 35.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.782 0.325 . . . . 0.0 110.89 -179.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.426 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 46.7 mt-30 -59.68 173.37 0.57 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.908 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.4 HG21 ' HB3' ' A' ' 144' ' ' LEU . 20.2 pt -147.08 148.95 16.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.12 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.447 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 8.4 ptp180 -115.65 120.91 40.92 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.871 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 55.8 p -114.64 133.26 55.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.123 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -158.85 161.64 36.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.876 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . 0.404 ' CZ2' ' HG2' ' A' ' 133' ' ' GLU . 7.7 m95 -54.77 104.5 0.12 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.916 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.457 ' HB2' ' C ' ' A' ' 80' ' ' VAL . . . -49.04 -47.94 44.3 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.109 179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 77.7 p -70.18 161.74 29.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.107 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 9.1 ptm180 -161.9 166.04 26.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.896 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 16.5 mttm -128.16 151.49 76.24 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.613 0.721 . . . . 0.0 110.879 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 167.13 25.25 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.644 2.23 . . . . 0.0 112.4 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 174.41 9.6 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.649 2.233 . . . . 0.0 112.339 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -100.73 153.24 37.85 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.587 0.708 . . . . 0.0 111.089 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 174.22 9.78 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.701 2.267 . . . . 0.0 112.35 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 6.6 pttm -155.19 125.12 6.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.888 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 1.7 t -161.07 135.89 7.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.902 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 2.5 t -171.35 139.31 1.29 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.186 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . 0.412 ' CD1' ' N ' ' A' ' 165' ' ' TYR . 1.1 p90 -169.52 119.13 0.66 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.949 -179.885 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 7.2 tm-20 -143.19 120.27 11.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 89.3 p -158.62 108.97 2.06 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.91 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -152.84 138.71 18.03 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.905 -179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 45.1 m -151.32 118.04 5.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.145 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 5.3 mtpm? -120.78 144.24 48.41 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.863 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 27.0 mm-40 -146.64 138.87 24.88 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.895 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 18.8 m -78.24 -50.65 11.48 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.911 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 67.66 68.73 1.56 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.493 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 -0.08 6.41 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.668 2.245 . . . . 0.0 112.321 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 3.1 t 72.05 51.01 0.21 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.892 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 72.0 p -139.81 119.28 13.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.86 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.355 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.491 179.981 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.8 m 62.46 42.04 9.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.893 0.378 . . . . 0.0 110.861 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 64.6 m -97.37 -56.05 2.65 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.834 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -84.47 141.41 19.68 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.486 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.2 t -64.2 -48.61 75.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.887 0.375 . . . . 0.0 110.875 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 37.6 p -71.7 163.54 27.6 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.846 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -174.35 92.52 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.466 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 15.3 mt-30 -41.2 124.75 2.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.896 0.379 . . . . 0.0 110.914 -179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 52.3 mmtt -147.41 177.84 8.91 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.918 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.87 26.77 4.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.912 179.863 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -133.88 172.64 12.52 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 10.2 p -124.11 84.82 2.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.092 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 69.7 m -97.98 -60.53 1.54 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.847 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 42.2 t-20 -104.68 41.46 1.33 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.859 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . 0.455 ' CE1' ' HA ' ' A' ' 127' ' ' PHE . 14.2 m170 -110.72 159.76 17.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.834 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.582 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 76.5 m-85 -103.52 113.16 26.45 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.878 -179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.471 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.6 OUTLIER -83.92 156.73 22.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.827 -179.986 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.461 HG22 HD11 ' A' ' 136' ' ' ILE . 53.8 t -130.62 148.96 33.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.128 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 19.3 t80 -99.18 135.85 40.0 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.882 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.551 ' CG1' HD21 ' A' ' 85' ' ' LEU . 43.7 t -133.02 130.2 58.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.124 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.492 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -136.47 173.22 22.12 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.474 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 7.6 t0 64.4 52.1 1.92 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.846 0.355 . . . . 0.0 110.914 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.632 HD22 HD23 ' A' ' 144' ' ' LEU . 16.2 mt -108.26 131.64 54.49 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.24 154.07 6.14 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.659 0.742 . . . . 0.0 110.824 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -8.07 22.67 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.71 2.274 . . . . 0.0 112.336 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -100.06 -3.48 31.89 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.908 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.964 HD11 ' HA3' ' A' ' 145' ' ' GLY . 45.6 mm -78.96 137.11 22.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.102 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.3 t -119.0 168.41 10.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.135 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.547 HG22 ' CE ' ' A' ' 95' ' ' LYS . 36.8 m -47.47 -41.57 20.91 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.131 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 35.8 mt-10 -61.13 -53.21 59.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.902 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -42.87 -56.15 3.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.83 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.466 HD11 HG22 ' A' ' 109' ' ' VAL . 19.4 mt -50.09 -57.49 2.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.141 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.605 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 26.7 mtmt -46.93 -40.03 13.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.904 179.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.7 -32.58 73.7 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.106 179.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -68.87 -53.91 18.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.115 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 21.2 m-85 -89.43 10.44 22.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.847 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.758 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -64.51 -59.77 9.96 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.572 0.701 . . . . 0.0 111.131 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.758 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.8 -0.76 7.41 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.667 2.244 . . . . 0.0 112.345 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 -100.0 -11.76 20.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.881 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 155.7 157.01 8.05 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.494 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.529 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 27.1 mtp180 -64.52 123.46 19.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.825 0.345 . . . . 0.0 110.874 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 18.7 mt -100.43 144.56 12.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.112 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 65.8 p -119.91 -59.21 1.82 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.806 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.443 ' HB3' ' CB ' ' A' ' 125' ' ' SER . 8.7 t0 -100.82 100.52 11.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.857 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.479 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -130.59 127.11 38.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.916 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -162.23 156.54 21.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.845 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.466 HG22 HD11 ' A' ' 94' ' ' ILE . 72.9 t -106.16 119.98 56.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.134 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.611 HG21 ' CE2' ' A' ' 121' ' ' TYR . 95.1 t -53.47 134.43 15.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.113 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 38.7 mttt -134.7 146.37 49.4 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.848 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.426 ' O ' ' N ' ' A' ' 116' ' ' GLY . 29.6 t0 -57.4 120.53 8.37 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.9 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 7.7 ptp -68.61 -3.49 12.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.915 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -100.58 -50.1 3.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.111 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 44.0 p -97.69 -34.28 10.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.128 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 88.81 17.43 56.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 63.7 mttt -92.3 167.92 11.67 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.822 0.344 . . . . 0.0 110.888 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 8.2 t -69.34 113.24 6.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.849 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.442 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 37.1 mttt -62.87 -50.79 69.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.878 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 145.08 -41.4 1.07 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.447 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.611 ' CE2' HG21 ' A' ' 110' ' ' VAL . 10.2 p90 -98.99 149.7 22.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.937 0.398 . . . . 0.0 110.919 -179.791 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -129.77 175.54 19.02 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.458 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 47.8 m-85 -124.2 135.47 53.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.857 0.361 . . . . 0.0 110.882 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.546 HG12 ' CE1' ' A' ' 126' ' ' PHE . 56.5 t -134.53 122.0 37.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.127 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . 0.443 ' CB ' ' HB3' ' A' ' 106' ' ' ASP . 16.3 t -106.45 149.62 26.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.855 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.546 ' CE1' HG12 ' A' ' 124' ' ' VAL . 16.5 m-85 -130.96 138.23 49.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.9 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.529 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 84.1 m-85 -52.44 -35.24 51.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.901 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -118.12 167.0 11.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.876 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.582 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 9.3 tttp -77.19 -41.7 40.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.878 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.423 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -57.98 -59.44 5.25 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.88 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.423 ' C ' ' O ' ' A' ' 130' ' ' TRP . 45.3 m-20 -35.91 -39.91 0.18 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.879 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.423 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -77.79 -58.87 3.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.084 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -42.72 -54.78 3.9 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.859 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 56.3 t30 -43.34 -41.42 4.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.881 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.403 ' O ' ' N ' ' A' ' 137' ' ' GLN . . . -75.72 -58.15 3.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.102 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . 0.461 HD11 HG22 ' A' ' 80' ' ' VAL . 98.2 mt -38.92 -30.41 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.152 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . 0.403 ' N ' ' O ' ' A' ' 135' ' ' ALA . 7.0 mt-30 -87.49 -65.75 0.98 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.916 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 10.3 mm-40 -61.54 -61.03 2.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.955 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.652 ' HE3' HD11 ' A' ' 149' ' ' ILE . 79.0 mmm -49.18 -35.62 17.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -57.56 116.38 8.02 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.474 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 99.89 -19.09 54.69 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.45 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -66.38 177.18 1.56 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.788 0.328 . . . . 0.0 110.903 -179.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . 0.459 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 13.8 m95 -115.04 127.11 55.44 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.908 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.632 HD23 HD22 ' A' ' 85' ' ' LEU . 55.5 tp -121.28 123.88 43.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.926 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 0.964 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 73.65 -11.59 5.54 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.532 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 130.25 -7.18 6.0 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.485 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 67.9 mtt180 -130.35 144.93 51.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.767 0.318 . . . . 0.0 110.902 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.459 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 31.2 mt-30 -53.57 158.21 1.9 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.933 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.652 HD11 ' HE3' ' A' ' 139' ' ' MET . 21.2 pt -131.7 145.29 35.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.129 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.492 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 19.3 ptp180 -106.8 120.14 41.2 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.874 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 42.4 p -112.71 127.85 56.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.121 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -153.4 166.2 33.39 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.868 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 23.2 m95 -62.58 136.81 58.07 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.953 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -97.88 149.85 21.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.108 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 44.1 p -138.6 154.35 48.69 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.128 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -82.59 166.98 18.76 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.889 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 28.4 ttpt -59.6 137.07 89.61 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.588 0.708 . . . . 0.0 110.909 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 148.38 65.08 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.723 2.282 . . . . 0.0 112.317 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 156.69 62.79 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.689 2.259 . . . . 0.0 112.352 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -49.27 150.88 2.83 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.542 0.687 . . . . 0.0 111.139 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -50.2 0.49 Allowed 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.68 2.254 . . . . 0.0 112.323 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 21.3 tttm -169.43 152.7 4.91 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.879 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 68.5 m -79.42 166.06 22.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.863 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 60.1 p -64.45 136.81 57.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.103 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -119.78 20.53 12.25 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.865 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 5.4 mm-40 -57.56 99.87 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.914 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 8.9 t -157.13 118.15 3.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.842 -179.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -111.86 87.77 2.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.868 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 90.3 m -98.22 85.67 3.5 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.175 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 7.7 ptmm? -166.94 141.39 3.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.916 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 17.7 mm-40 -125.6 120.63 31.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.938 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 9.0 t -148.04 162.59 39.07 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.846 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 140.79 69.8 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.503 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . 0.431 ' O ' ' C ' ' A' ' 175' ' ' SER . 53.6 Cg_endo -69.75 -50.65 0.45 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.651 2.234 . . . . 0.0 112.354 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . 0.431 ' C ' ' O ' ' A' ' 174' ' ' PRO . 61.7 p 35.19 39.75 0.05 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.846 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 51.8 p -96.37 115.86 28.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.805 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.462 179.997 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 61.4 m -129.88 161.54 30.59 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.875 0.369 . . . . 0.0 110.886 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 56.6 p -84.19 153.51 23.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.852 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 115.58 142.86 7.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.536 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 51.6 p -82.19 172.6 12.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.842 0.353 . . . . 0.0 110.867 -179.701 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 70.8 m -104.81 -54.78 2.44 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.823 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 81.99 108.18 0.4 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.491 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 13.7 mp0 -71.36 84.29 0.79 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.897 0.38 . . . . 0.0 110.924 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 14.0 ptpt -106.42 174.01 6.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.868 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 74.0 tttt -59.15 -63.78 1.18 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.883 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -45.81 155.87 0.16 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.891 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.5 p -97.7 86.34 3.78 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.137 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 59.7 m -108.89 132.09 54.38 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.837 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 49.9 t30 55.8 31.51 17.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.865 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 20.5 m170 -100.03 168.65 9.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.894 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.577 ' CE1' ' HD3' ' A' ' 129' ' ' LYS . 90.9 m-85 -115.68 105.93 13.31 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.903 -179.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.544 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.1 OUTLIER -81.75 150.18 28.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 55.3 t -124.75 146.28 30.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.137 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 18.2 t80 -98.07 134.39 41.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.919 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.7 HG12 HD21 ' A' ' 85' ' ' LEU . 4.3 t -130.42 130.13 65.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.109 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.495 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -136.24 179.26 18.05 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.446 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.402 ' O ' ' O ' ' A' ' 148' ' ' GLN . 5.4 t70 56.39 53.63 8.51 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.852 0.358 . . . . 0.0 110.845 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.7 HD21 HG12 ' A' ' 82' ' ' VAL . 15.8 mt -109.94 131.14 55.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.904 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -53.01 154.91 4.74 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.646 0.736 . . . . 0.0 110.873 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -4.19 13.53 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.653 2.236 . . . . 0.0 112.348 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . 0.412 ' O ' ' HG3' ' A' ' 88' ' ' GLU . 1.4 tt0 -97.58 -28.81 13.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.857 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.838 HD11 ' HA3' ' A' ' 145' ' ' GLY . 47.9 mm -57.73 132.52 22.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.137 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 9.1 t -119.38 166.8 12.59 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.161 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.522 HG22 ' CE ' ' A' ' 95' ' ' LYS . 95.8 m -39.79 -49.02 2.32 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.169 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -56.04 -57.6 11.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.852 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -39.59 -56.8 1.6 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.483 ' CD1' HG22 ' A' ' 109' ' ' VAL . 16.5 mt -48.79 -59.44 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.132 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.717 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 20.8 mtmt -47.41 -38.93 14.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.914 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -62.97 -37.01 85.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.059 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -68.05 -52.9 30.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.112 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . . . . . . . . . 22.2 m-85 -89.27 6.91 38.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.93 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.778 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -59.48 -59.79 12.71 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.618 0.723 . . . . 0.0 111.082 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.778 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.6 Cg_endo -69.76 -0.92 7.62 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.72 2.28 . . . . 0.0 112.322 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -101.49 12.51 37.18 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.887 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.419 ' HA3' ' CG ' ' A' ' 131' ' ' ASP . . . 129.59 155.72 8.56 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.482 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.427 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 28.7 mtt180 -65.7 126.16 27.54 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.808 0.337 . . . . 0.0 110.841 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.436 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 13.8 mt -100.27 140.29 19.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.157 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 5.4 t -112.05 -62.09 1.62 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.883 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.9 t0 -100.81 102.91 14.09 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.867 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.529 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -130.32 125.5 34.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.083 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 15.2 ptt180 -160.81 154.98 22.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.886 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.483 HG22 ' CD1' ' A' ' 94' ' ' ILE . 60.1 t -105.2 119.14 53.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.11 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.611 HG21 ' CD2' ' A' ' 121' ' ' TYR . 61.1 t -53.12 133.06 15.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.126 179.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . 0.423 ' HG2' ' C ' ' A' ' 117' ' ' LYS . 37.0 mttm -134.14 149.25 51.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.94 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.548 ' OD2' ' HB3' ' A' ' 114' ' ' ALA . 1.7 t70 -62.02 132.0 51.46 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.863 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 26.0 ptm -80.47 1.36 29.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.883 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . 0.548 ' HB3' ' OD2' ' A' ' 112' ' ' ASP . . . -98.35 -29.11 13.34 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.084 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 21.2 p -131.14 -34.28 1.45 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.15 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 96.66 17.36 33.51 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.455 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . 0.423 ' C ' ' HG2' ' A' ' 111' ' ' LYS . 42.1 mttm -85.79 154.14 21.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.815 0.34 . . . . 0.0 110.875 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 1.9 m -60.09 111.1 1.38 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.82 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.415 ' HD2' ' CG1' ' A' ' 110' ' ' VAL . 31.6 mttt -59.25 -42.8 92.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.908 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 138.36 -41.72 1.34 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.532 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.611 ' CD2' HG21 ' A' ' 110' ' ' VAL . 7.4 p90 -99.99 151.12 21.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.923 0.392 . . . . 0.0 110.922 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -130.66 178.04 17.94 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.554 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -126.52 135.72 51.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.887 0.375 . . . . 0.0 110.876 -179.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.549 HG12 ' CE1' ' A' ' 126' ' ' PHE . 61.0 t -136.48 122.18 28.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.118 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 12.6 m -105.34 149.92 25.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.808 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.549 ' CE1' HG12 ' A' ' 124' ' ' VAL . 16.3 m-85 -131.06 137.85 49.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.906 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.427 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 78.3 m-85 -58.87 -36.67 75.0 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.841 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 13.6 m-20 -118.04 149.78 40.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.904 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.577 ' HD3' ' CE1' ' A' ' 78' ' ' PHE . 38.5 tptt -60.77 -63.39 1.31 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.932 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.463 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.9 OUTLIER -33.21 -57.92 0.39 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.917 179.921 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.419 ' CG ' ' HA3' ' A' ' 102' ' ' GLY . 80.7 m-20 -40.59 -49.26 2.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.867 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -67.1 -60.47 2.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.123 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -41.05 -61.62 0.96 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.916 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 44.1 t-20 -38.88 -52.91 1.75 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.877 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.485 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -63.55 -61.44 2.33 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.122 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 86.7 mt -37.01 -36.76 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.128 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.6 mt-30 -85.53 -60.1 2.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.876 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -64.85 -59.6 4.02 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.892 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.485 ' N ' ' O ' ' A' ' 135' ' ' ALA . 48.0 mmm -53.48 -39.92 64.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.939 179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -55.66 116.59 7.31 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.49 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 100.65 -12.66 59.6 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.494 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 48.6 mm-40 -73.28 172.57 10.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.75 0.31 . . . . 0.0 110.928 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . . . . . . . . . 15.7 m95 -109.43 126.41 53.44 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.877 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.536 HD23 HD22 ' A' ' 85' ' ' LEU . 57.3 tp -123.56 125.19 44.41 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.913 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 0.838 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 72.82 -9.25 6.58 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.48 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 127.47 -7.7 7.03 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.487 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 28.2 mtt-85 -130.34 145.89 51.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.789 0.328 . . . . 0.0 110.86 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.402 ' O ' ' O ' ' A' ' 84' ' ' ASP . 18.1 mt-30 -52.58 166.54 0.19 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.952 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.422 ' CG2' ' HB3' ' A' ' 144' ' ' LEU . 24.3 pt -137.42 146.28 28.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.066 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.495 ' HG2' ' CA ' ' A' ' 83' ' ' GLY . 16.4 ptp180 -108.07 114.86 29.08 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.89 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 80.9 p -110.19 122.57 47.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.134 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -150.58 168.48 24.14 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.904 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . 0.498 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 55.1 m95 -69.55 123.2 20.68 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.916 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -71.12 -53.6 14.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.095 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 62.7 p -50.75 154.89 1.26 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.162 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 18.1 ptt85 -134.69 144.0 47.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.9 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 13.5 pttp -79.4 148.71 70.88 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.552 0.691 . . . . 0.0 110.919 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.8 149.5 66.72 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.678 2.252 . . . . 0.0 112.344 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 175.57 7.89 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.721 2.28 . . . . 0.0 112.324 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.65 ' HB1' ' HD2' ' A' ' 161' ' ' PRO . . . -121.83 162.03 38.99 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.603 0.716 . . . . 0.0 111.112 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . 0.65 ' HD2' ' HB1' ' A' ' 160' ' ' ALA . 53.4 Cg_endo -69.79 123.48 10.13 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.69 2.26 . . . . 0.0 112.348 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 5.1 mtmp? -69.79 125.7 27.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.898 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 37.5 t -91.34 112.11 23.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.902 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 21.2 p -122.1 129.21 52.16 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.124 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . 0.426 ' CD1' ' C ' ' A' ' 165' ' ' TYR . 4.6 p90 -152.2 164.52 37.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.976 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -159.17 134.21 8.23 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.907 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 47.5 t -171.78 131.37 0.69 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.864 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 28.3 m120 -134.94 156.16 49.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.848 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.3 m -150.38 126.37 10.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.148 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.54 118.69 8.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.875 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -118.42 135.09 54.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.911 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 8.2 t -173.42 150.12 1.79 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.828 -179.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 147.09 65.88 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.466 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 156.65 62.82 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.713 2.275 . . . . 0.0 112.348 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 9.5 t -174.45 166.84 3.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.83 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 49.4 p -165.72 106.89 0.74 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.867 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.28 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.461 179.99 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.466 -0.254 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.7 m -40.72 120.17 1.24 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.883 0.373 . . . . 0.0 110.825 -179.746 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 74.0 m -142.99 169.44 17.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.858 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -160.58 -157.15 8.53 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.492 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 25.7 t -78.85 127.92 32.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.909 0.385 . . . . 0.0 110.857 -179.75 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 48.7 m -133.63 79.82 1.84 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.821 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 129.13 95.01 0.78 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.477 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 61.8 mm-40 -61.27 -45.83 92.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.845 0.355 . . . . 0.0 110.874 -179.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.0 53.68 2.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.874 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -113.18 176.69 4.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.941 179.825 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 23.3 t0 -53.05 137.8 32.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.84 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 61.8 p -78.07 53.43 1.19 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 22.5 t -89.09 -38.36 14.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.86 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 26.5 m-20 -80.53 -34.19 35.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.844 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 47.4 m170 -64.54 144.33 57.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.848 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.564 ' CE2' ' HB2' ' A' ' 129' ' ' LYS . 93.0 m-85 -96.88 124.52 40.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.875 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.51 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.2 OUTLIER -89.1 150.4 22.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 179.998 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.55 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 46.0 t -125.45 145.36 32.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.131 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.413 ' CE2' ' HG2' ' A' ' 150' ' ' ARG . 17.8 t80 -91.22 132.72 35.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.892 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.526 HG12 HD21 ' A' ' 85' ' ' LEU . 16.8 t -128.57 128.91 68.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.073 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -136.52 -177.96 15.42 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.54 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 55.11 54.25 9.1 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.809 0.338 . . . . 0.0 110.843 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.526 HD21 HG12 ' A' ' 82' ' ' VAL . 17.0 mt -110.89 130.11 55.68 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.937 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.2 t -53.18 154.22 5.84 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.664 0.745 . . . . 0.0 110.843 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -6.21 18.08 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.699 2.266 . . . . 0.0 112.29 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -100.29 -15.54 18.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.898 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.708 HD11 ' HA3' ' A' ' 145' ' ' GLY . 34.3 mm -69.57 134.25 30.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.141 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 7.0 t -119.67 168.0 11.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.123 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.648 HG22 ' CE ' ' A' ' 95' ' ' LYS . 98.8 m -38.82 -57.76 1.18 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.111 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 29.5 mt-10 -46.44 -59.36 3.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.942 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.437 ' CB ' HG23 ' A' ' 89' ' ' ILE . 0.5 OUTLIER -38.82 -56.19 1.4 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.899 179.932 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.626 ' CD1' HG22 ' A' ' 109' ' ' VAL . 10.7 mt -49.55 -60.77 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.167 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.648 ' CE ' HG22 ' A' ' 91' ' ' THR . 24.3 mtmt -45.67 -39.65 8.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.887 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . 0.435 ' HB3' ' O ' ' A' ' 93' ' ' ASP . . . -59.94 -37.84 80.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.106 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.636 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -66.35 -52.98 41.48 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.103 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.467 ' C ' HD11 ' A' ' 104' ' ' ILE . 11.8 m-85 -92.18 18.66 7.84 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.852 -179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.792 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -69.33 -60.44 4.08 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.581 0.705 . . . . 0.0 111.136 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.792 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.78 -0.83 7.49 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.662 2.241 . . . . 0.0 112.321 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -99.78 5.17 45.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.89 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 133.79 137.88 3.91 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.493 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.408 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 24.3 mtt-85 -49.89 125.1 11.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.741 0.305 . . . . 0.0 110.906 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.467 HD11 ' C ' ' A' ' 98' ' ' PHE . 11.1 mt -98.77 138.88 22.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.142 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 1.1 t -107.33 -62.94 1.35 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.858 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -100.51 109.66 21.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.905 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.508 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -138.25 129.13 26.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.13 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.1 ptm180 -162.57 154.72 18.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.873 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.626 HG22 ' CD1' ' A' ' 94' ' ' ILE . 41.3 t -105.33 117.38 50.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.133 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.531 HG21 ' CE2' ' A' ' 121' ' ' TYR . 48.8 t -49.84 138.04 5.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.125 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . 0.432 ' C ' ' HG3' ' A' ' 119' ' ' LYS . 52.6 mttt -138.16 154.63 49.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -69.16 138.55 54.24 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.836 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 13.5 ptp -85.75 3.45 41.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.862 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -102.64 -35.94 8.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.083 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 52.3 p -123.17 -35.17 3.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.098 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 90.86 26.61 21.74 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.481 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . 0.412 ' O ' ' C ' ' A' ' 118' ' ' SER . 86.1 mttt -97.73 136.39 38.14 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.769 0.318 . . . . 0.0 110.896 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 117' ' ' LYS . 2.2 m -37.7 111.76 0.18 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.853 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.491 ' HD2' HG12 ' A' ' 110' ' ' VAL . 9.3 mttm -61.82 -41.82 98.26 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.895 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.446 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 138.62 -46.75 0.96 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.531 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.531 ' CE2' HG21 ' A' ' 110' ' ' VAL . 10.1 p90 -100.04 148.65 24.3 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.996 0.427 . . . . 0.0 110.909 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -129.8 -177.31 14.81 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.503 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 50.1 m-85 -127.47 139.29 52.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.854 0.359 . . . . 0.0 110.925 -179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.647 HG12 ' CE1' ' A' ' 126' ' ' PHE . 58.3 t -138.83 120.65 16.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.146 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . 0.408 ' O ' HG23 ' A' ' 104' ' ' ILE . 42.3 m -106.65 149.81 26.86 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.853 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.647 ' CE1' HG12 ' A' ' 124' ' ' VAL . 2.1 m-85 -130.85 144.59 51.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.873 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.408 ' CE2' ' HB3' ' A' ' 103' ' ' ARG . 22.3 m-85 -56.38 -43.49 79.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.889 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 19.2 m120 -109.35 163.69 13.16 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.901 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.564 ' HB2' ' CE2' ' A' ' 78' ' ' PHE . 20.3 tptm -71.39 -59.55 2.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.902 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.417 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.8 OUTLIER -40.57 -57.39 1.86 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.9 179.922 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 130' ' ' TRP . 71.6 m-20 -35.86 -45.76 0.42 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.875 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.55 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -75.8 -58.27 3.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.065 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -44.16 -59.5 2.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.883 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -41.79 -44.49 3.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.891 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.47 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -69.23 -56.78 6.58 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.107 179.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 86.1 mt -38.73 -35.5 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.106 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 5.1 mt-30 -87.18 -57.07 3.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.892 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 37.3 mm-40 -68.3 -61.97 1.6 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.93 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.899 ' HE3' HD11 ' A' ' 149' ' ' ILE . 64.1 mmm -51.92 -38.93 58.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.858 180.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.44 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -57.55 93.51 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.492 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 119.44 13.17 6.39 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.508 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 87.4 mm-40 -94.27 169.66 10.07 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.753 0.311 . . . . 0.0 110.962 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . 0.42 ' NE1' ' HG3' ' A' ' 148' ' ' GLN . 17.2 m95 -106.3 109.47 21.41 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.899 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.636 HD13 ' HB2' ' A' ' 97' ' ' ALA . 60.9 tp -104.15 129.58 51.87 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.926 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 0.708 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.74 -77.0 0.4 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.475 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -156.33 15.93 0.41 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.464 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 43.2 mtp85 -157.99 161.01 38.09 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.758 0.313 . . . . 0.0 110.856 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.42 ' HG3' ' NE1' ' A' ' 143' ' ' TRP . 28.9 mt-30 -64.25 167.08 7.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.923 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.899 HD11 ' HE3' ' A' ' 139' ' ' MET . 21.1 pt -136.26 152.11 29.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.147 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.413 ' HG2' ' CE2' ' A' ' 81' ' ' PHE . 2.8 ttt180 -109.29 129.72 55.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.892 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.44 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 44.4 p -124.55 137.54 54.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.149 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 4.2 t30 -160.61 174.09 14.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.919 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . 0.546 ' CH2' ' CE ' ' A' ' 129' ' ' LYS . 4.6 m95 -69.15 128.27 36.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.898 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . 0.432 ' O ' ' C ' ' A' ' 155' ' ' THR . . . -96.66 123.59 40.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.066 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.432 ' C ' ' O ' ' A' ' 154' ' ' ALA . 16.3 p 34.95 41.42 0.06 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.115 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 4.8 tpt180 -139.5 150.95 45.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.879 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 15.7 mmmt -125.36 141.49 38.96 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.57 0.7 . . . . 0.0 110.884 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 157.74 59.32 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.651 2.234 . . . . 0.0 112.311 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 146.53 60.35 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.698 2.265 . . . . 0.0 112.329 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.626 ' HB1' ' HD2' ' A' ' 161' ' ' PRO . . . -46.07 161.65 0.26 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.575 0.702 . . . . 0.0 111.074 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . 0.626 ' HD2' ' HB1' ' A' ' 160' ' ' ALA . 53.6 Cg_endo -69.74 -19.6 36.02 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.7 2.267 . . . . 0.0 112.328 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 40.5 tttt -125.03 81.81 2.0 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.93 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 7.6 t -163.8 133.17 3.97 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.84 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 15.0 t -112.04 130.11 55.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.134 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 16.4 p90 -139.96 141.79 36.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.93 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 13.8 tt0 -172.05 147.05 2.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.911 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 7.0 t -132.32 164.2 26.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.892 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 37.7 t-20 -134.08 96.0 3.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.842 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 1.7 t -172.88 141.52 1.03 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.117 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 1.1 ttmp? -170.68 136.12 1.2 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.86 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 48.9 mt-30 -122.24 170.74 9.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.889 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 55.7 p -157.07 112.34 2.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.838 -179.828 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 165.11 146.18 4.68 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.506 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . 0.421 ' O ' ' C ' ' A' ' 175' ' ' SER . 53.9 Cg_endo -69.77 -20.66 34.51 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.724 2.283 . . . . 0.0 112.331 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 174' ' ' PRO . 8.0 t -36.71 137.37 0.31 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.841 -179.841 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 36.0 t -66.78 -49.87 64.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.863 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.489 -179.962 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 82.7 p -116.68 109.02 16.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.863 0.363 . . . . 0.0 110.844 -179.712 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 20.8 m -51.78 164.89 0.21 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.854 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 138.29 113.16 1.14 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.501 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 46.2 m -86.78 153.36 21.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.93 0.395 . . . . 0.0 110.793 -179.683 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 71.6 m -85.55 -44.77 12.38 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.884 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -171.12 108.49 0.29 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.488 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 15.1 tt0 -103.49 -45.12 4.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.893 0.378 . . . . 0.0 110.915 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.1 tppt? -66.04 122.41 17.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.94 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.23 -42.48 99.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.88 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -64.24 131.22 46.72 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.92 179.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.6 p -90.76 88.84 7.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.15 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 37.2 m -108.77 -58.83 1.96 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.829 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 72.4 m-20 -56.73 -36.4 69.69 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.896 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 15.8 m170 -67.6 137.84 55.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.879 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -87.65 121.63 30.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.862 -179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . 0.404 ' N ' ' ND1' ' A' ' 79' ' ' HIS . 0.9 OUTLIER -82.02 135.24 35.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.872 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 38.9 t -114.2 144.57 21.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.124 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.694 ' CD2' ' ND2' ' A' ' 152' ' ' ASN . 11.9 t80 -96.74 138.28 34.54 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.862 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.776 HG12 HD21 ' A' ' 85' ' ' LEU . 3.2 t -137.17 134.46 47.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.151 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -142.3 -173.1 14.04 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.456 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 56.93 29.3 16.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.816 0.341 . . . . 0.0 110.86 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.776 HD21 HG12 ' A' ' 82' ' ' VAL . 14.6 mt -86.31 132.25 34.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.956 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -53.87 155.3 6.2 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.639 0.733 . . . . 0.0 110.863 -179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.85 -15.96 36.98 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.688 2.259 . . . . 0.0 112.291 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 1.5 pt-20 -92.0 -7.14 49.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.873 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.825 HD11 ' HA3' ' A' ' 145' ' ' GLY . 33.2 mm -74.98 138.88 20.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.155 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.8 t -119.88 -176.71 3.24 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.133 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.6 ' HA ' HG23 ' A' ' 109' ' ' VAL . 84.9 m -53.77 -57.25 11.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.125 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.439 ' O ' ' C ' ' A' ' 93' ' ' ASP . 70.9 mt-10 -48.67 -58.48 4.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.914 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.439 ' C ' ' O ' ' A' ' 92' ' ' GLU . 2.9 m-20 -34.48 -55.28 0.54 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.841 -179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.605 HD11 HG22 ' A' ' 109' ' ' VAL . 4.5 mt -51.76 -60.34 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.152 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.638 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 25.6 mtmt -48.85 -41.93 34.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.899 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -60.68 -29.13 69.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.083 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.442 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -75.67 -53.74 8.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.131 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.423 ' C ' HD11 ' A' ' 104' ' ' ILE . 27.2 m-85 -86.82 3.49 45.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.915 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.776 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -56.5 -60.29 9.62 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.587 0.708 . . . . 0.0 111.154 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.776 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.3 Cg_endo -69.76 -0.81 7.45 Favored 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.708 2.272 . . . . 0.0 112.353 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.584 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 72.0 m-85 -99.77 -1.2 38.29 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 142.17 156.07 6.67 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.507 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.476 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 17.5 mtm105 -62.6 122.28 15.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.743 0.306 . . . . 0.0 110.871 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.452 ' CG2' HG13 ' A' ' 124' ' ' VAL . 13.9 mt -100.39 138.21 25.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.176 179.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.467 ' HB2' ' CZ ' ' A' ' 127' ' ' PHE . 47.8 t -112.92 -59.61 1.99 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.891 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.422 ' HB3' ' CB ' ' A' ' 125' ' ' SER . 25.9 t70 -100.63 99.78 10.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.449 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -132.08 124.94 30.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.081 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.446 ' HA ' HG23 ' A' ' 91' ' ' THR . 10.3 ptp180 -159.36 153.32 23.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 -179.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.605 HG22 HD11 ' A' ' 94' ' ' ILE . 90.0 t -100.93 124.12 54.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.111 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.955 HG12 ' HG3' ' A' ' 119' ' ' LYS . 53.4 t -59.64 143.96 13.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.118 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . 0.451 ' C ' ' HG2' ' A' ' 119' ' ' LYS . 74.5 mttt -140.7 153.87 46.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.492 ' N ' ' HG2' ' A' ' 119' ' ' LYS . 7.9 t0 -60.22 127.38 31.54 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.838 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 19.9 ptm -80.12 2.81 22.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.867 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -102.66 -38.38 7.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.074 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 42.1 p -119.9 -33.82 3.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.181 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 95.35 30.2 8.35 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.444 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 34.5 mttm -99.01 164.48 12.16 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.778 0.323 . . . . 0.0 110.903 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 36.4 t -56.62 115.05 2.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.907 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.955 ' HG3' HG12 ' A' ' 110' ' ' VAL . 0.5 OUTLIER -68.33 -38.56 81.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.909 179.962 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 126.39 -46.1 1.11 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.433 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.528 ' CE2' HG21 ' A' ' 110' ' ' VAL . 8.3 p90 -100.32 151.33 21.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.927 0.394 . . . . 0.0 110.934 -179.794 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -132.58 171.55 21.56 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.473 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -121.06 138.85 53.99 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.859 0.361 . . . . 0.0 110.907 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.661 HG12 ' CE1' ' A' ' 126' ' ' PHE . 93.9 t -138.91 112.26 6.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.103 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . 0.422 ' CB ' ' HB3' ' A' ' 106' ' ' ASP . 2.7 t -97.89 148.64 23.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.83 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.661 ' CE1' HG12 ' A' ' 124' ' ' VAL . 3.6 m-85 -127.06 148.38 50.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.882 -179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.476 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 77.9 m-85 -63.27 -34.66 78.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.916 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 25.4 m120 -115.93 168.88 9.68 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.87 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 66.8 tttt -81.0 -47.88 13.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.427 ' O ' ' C ' ' A' ' 131' ' ' ASP . 1.1 m95 -48.57 -62.47 1.48 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.935 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 130' ' ' TRP . 44.4 m-20 -35.87 -54.17 0.74 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.811 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -61.39 -67.08 0.44 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.107 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -37.26 -57.87 0.86 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.874 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 42.4 t-20 -41.01 -52.89 3.09 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.864 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . . . . . . . . . . . -63.96 -56.71 13.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.098 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 92.3 mt -38.17 -35.82 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.175 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -85.26 -63.53 1.31 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.899 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -59.56 -61.9 2.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.584 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 81.2 mmm -52.19 -35.23 48.44 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.913 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.401 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -54.94 99.43 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.522 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 111.59 -20.7 22.42 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.488 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 10.8 mm-40 -56.55 -179.92 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.791 0.329 . . . . 0.0 110.927 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . 0.486 ' CE2' ' HG3' ' A' ' 148' ' ' GLN . 13.4 m95 -116.86 124.72 50.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.927 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.592 HD23 HD22 ' A' ' 85' ' ' LEU . 47.2 tp -123.88 128.75 49.93 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.862 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 0.825 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 70.54 -3.69 11.15 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.516 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 120.91 -13.5 9.79 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.496 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 60.4 mtt180 -122.85 147.4 46.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.727 0.299 . . . . 0.0 110.88 -179.866 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.486 ' HG3' ' CE2' ' A' ' 143' ' ' TRP . 32.6 mt-30 -55.45 165.57 0.77 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.926 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.423 HG21 ' HB3' ' A' ' 144' ' ' LEU . 19.5 pt -138.15 151.34 25.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.117 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 27.0 ptt180 -113.99 109.1 17.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.906 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.401 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 69.3 p -106.54 141.43 37.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.167 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . 0.694 ' ND2' ' CD2' ' A' ' 81' ' ' PHE . 7.4 p30 -167.15 -178.95 4.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.876 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 31.2 m95 -74.73 135.37 41.79 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.916 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -80.34 -51.98 8.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.093 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.6 t -121.62 146.04 47.38 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.162 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -159.32 161.14 35.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.829 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.473 ' CG ' ' HD2' ' A' ' 158' ' ' PRO . 53.6 tttp -124.18 139.25 32.31 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.594 0.712 . . . . 0.0 110.853 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . 0.473 ' HD2' ' CG ' ' A' ' 157' ' ' LYS . 53.5 Cg_endo -69.8 145.23 56.28 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.722 2.282 . . . . 0.0 112.335 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -172.09 0.54 Allowed 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.686 2.257 . . . . 0.0 112.361 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -97.02 147.81 33.46 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.62 0.724 . . . . 0.0 111.069 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 -50.67 0.45 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.667 2.245 . . . . 0.0 112.367 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.449 ' HE3' ' CG2' ' A' ' 164' ' ' THR . 6.2 tmtm? -174.95 147.78 0.98 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.87 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . 0.408 ' N ' ' HD3' ' A' ' 162' ' ' LYS . 15.6 t -137.41 136.33 37.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.83 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . 0.449 ' CG2' ' HE3' ' A' ' 162' ' ' LYS . 33.4 p -142.48 177.68 8.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.15 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 3.9 t80 -112.98 146.1 39.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.933 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -161.53 143.3 11.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.902 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 64.8 p -108.98 81.5 1.45 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.891 -179.809 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 44.7 t30 -113.89 40.47 2.45 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 91.7 m -149.92 121.27 7.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.163 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 18.0 tptp -163.45 146.19 10.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.876 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -172.49 159.08 4.42 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.922 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 40.0 t -112.17 -58.06 2.18 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.873 -179.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . 67.4 82.86 0.13 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.513 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 115.76 4.25 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.726 2.284 . . . . 0.0 112.28 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 78.3 p -173.92 124.06 0.34 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.812 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 54.9 p -121.54 125.46 46.85 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.872 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.506 -179.929 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 31.3 t -64.84 98.66 0.29 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.837 0.351 . . . . 0.0 110.847 -179.72 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 1.8 m -169.81 139.55 1.97 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 161.66 97.03 0.11 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.468 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 13.8 t -94.43 84.43 4.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.915 0.388 . . . . 0.0 110.862 -179.788 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.7 p -166.47 115.54 0.91 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.886 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -147.77 139.97 8.13 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.469 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -125.82 168.99 13.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.846 0.355 . . . . 0.0 110.916 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.425 ' HG3' ' N ' ' A' ' 72' ' ' LYS . 0.1 OUTLIER -171.31 150.57 2.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.9 179.951 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.425 ' N ' ' HG3' ' A' ' 71' ' ' LYS . 29.2 mttm -79.51 -54.16 6.17 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.899 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 75.1 m-20 -67.97 149.01 50.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.863 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 26.2 p -79.44 95.28 5.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.138 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.3 t -87.54 -57.64 2.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.887 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -121.47 52.47 1.23 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.909 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 21.6 m170 -108.67 156.35 19.67 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.835 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.45 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 47.0 m-85 -98.05 115.78 28.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.874 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 87.4 m-70 -89.3 140.49 29.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.851 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.461 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 41.5 t -118.1 138.76 47.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.073 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 15.5 t80 -92.89 135.49 34.09 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.878 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.859 HG12 HD21 ' A' ' 85' ' ' LEU . 3.7 t -137.58 109.51 6.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.118 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -123.21 -177.48 15.15 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.472 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.403 ' O ' ' O ' ' A' ' 148' ' ' GLN . 4.5 t70 63.83 36.45 10.4 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.859 0.362 . . . . 0.0 110.91 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.859 HD21 HG12 ' A' ' 82' ' ' VAL . 15.6 mt -91.7 170.54 9.83 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.912 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -90.01 155.4 47.33 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.672 0.749 . . . . 0.0 110.786 -179.835 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 -10.79 29.39 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.668 2.245 . . . . 0.0 112.338 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -96.5 -6.11 37.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.841 HD11 ' HA3' ' A' ' 145' ' ' GLY . 45.8 mm -79.09 136.38 23.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.116 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 13.6 t -118.96 164.7 15.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.19 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.737 ' HA ' HG23 ' A' ' 109' ' ' VAL . 35.8 m -40.24 -48.77 2.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.149 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.441 ' O ' ' C ' ' A' ' 93' ' ' ASP . 32.7 mt-10 -55.64 -58.78 6.37 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.444 ' CB ' HG23 ' A' ' 89' ' ' ILE . 13.3 m-20 -34.78 -56.67 0.55 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.86 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.565 HD11 HG22 ' A' ' 109' ' ' VAL . 10.4 mt -49.26 -60.76 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.185 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.693 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 24.0 mtmt -46.69 -39.81 12.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.914 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -63.58 -30.77 71.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.103 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.656 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -73.92 -53.68 9.6 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.088 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.423 ' C ' HD11 ' A' ' 104' ' ' ILE . 22.3 m-85 -89.18 12.34 16.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.91 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.77 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -65.23 -60.07 8.56 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.661 0.743 . . . . 0.0 111.082 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.77 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.8 Cg_endo -69.76 -0.77 7.4 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.616 2.211 . . . . 0.0 112.376 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.497 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 77.6 m-85 -99.65 -3.14 33.78 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.892 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 143.03 131.95 2.6 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.485 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 46.2 mtt85 -44.09 124.93 4.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.803 0.335 . . . . 0.0 110.875 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.475 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 14.1 mt -100.11 145.18 11.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.136 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.448 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 3.8 t -116.01 -61.94 1.66 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.851 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -100.57 99.47 10.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.83 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.418 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -132.92 127.18 33.74 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.11 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.483 ' HA ' HG23 ' A' ' 91' ' ' THR . 6.7 ptm180 -160.15 155.29 24.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.871 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.737 HG23 ' HA ' ' A' ' 91' ' ' THR . 96.4 t -107.06 120.35 58.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.138 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.578 HG21 ' CE2' ' A' ' 121' ' ' TYR . 66.8 t -54.33 124.66 7.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.159 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -123.72 148.74 46.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.877 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.472 ' O ' ' N ' ' A' ' 116' ' ' GLY . 24.1 t0 -56.88 121.61 10.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.871 179.817 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 8.2 ptp -73.11 -1.54 17.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.938 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -97.86 -42.52 7.52 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.134 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 29.1 p -115.75 -29.43 6.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.137 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 89.51 30.3 14.07 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.499 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 51.7 mttm -98.9 152.5 19.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.829 0.347 . . . . 0.0 110.899 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 7.8 t -60.29 110.75 1.32 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.831 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 50.9 mttt -62.73 -47.82 81.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.93 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.678 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 139.75 -38.98 1.56 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.463 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.578 ' CE2' HG21 ' A' ' 110' ' ' VAL . 25.3 p90 -100.09 144.04 29.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.953 0.406 . . . . 0.0 110.92 -179.81 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -137.81 175.07 21.52 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.545 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -121.85 139.93 53.02 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.912 0.387 . . . . 0.0 110.866 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.682 HG12 ' CE1' ' A' ' 126' ' ' PHE . 59.4 t -135.62 111.46 12.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.122 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 1.8 t -100.49 145.64 28.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.856 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.682 ' CE1' HG12 ' A' ' 124' ' ' VAL . 1.3 m-85 -124.93 162.0 25.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.896 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.448 ' CE1' ' HB2' ' A' ' 105' ' ' SER . 22.1 m-85 -66.41 -48.17 70.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.875 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 78.6 m-20 -113.91 160.04 19.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.869 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.45 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 3.7 ttmt -63.22 -62.75 1.49 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.91 179.876 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.437 ' C ' ' O ' ' A' ' 129' ' ' LYS . 1.0 OUTLIER -35.16 -59.36 0.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.929 179.92 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.401 ' C ' ' O ' ' A' ' 130' ' ' TRP . 48.3 m-20 -37.58 -43.97 0.65 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.912 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.461 ' HB1' ' CG2' ' A' ' 80' ' ' VAL . . . -74.71 -59.16 2.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.099 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.7 mt-10 -40.53 -54.76 2.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.829 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -43.53 -45.37 6.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.845 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.423 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -71.95 -58.49 3.41 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.07 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 97.1 mt -38.44 -36.37 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.124 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -83.35 -63.63 1.32 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.891 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -62.92 -62.73 1.52 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.925 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.497 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 68.8 mmm -51.8 -41.32 61.62 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.913 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -55.13 103.75 0.23 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.486 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 100.5 21.15 13.28 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.498 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 9.5 mm100 -105.64 177.42 4.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.787 0.327 . . . . 0.0 110.905 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . . . . . . . . . 17.0 m95 -106.74 121.69 44.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.903 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.656 HD13 ' HB2' ' A' ' 97' ' ' ALA . 36.4 tp -121.53 127.78 51.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.924 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 0.841 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 73.54 -36.62 0.84 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.477 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . 0.425 ' H ' ' C ' ' A' ' 144' ' ' LEU . . . 160.2 -14.25 0.19 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.516 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 51.2 mtt180 -127.38 149.24 50.16 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.762 0.315 . . . . 0.0 110.838 -179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.403 ' O ' ' O ' ' A' ' 84' ' ' ASP . 38.8 mt-30 -53.89 169.35 0.16 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.915 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.509 HG22 HD23 ' A' ' 85' ' ' LEU . 33.8 pt -148.92 147.77 16.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.14 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . . . . . . . . . 9.6 ptt180 -110.58 123.26 49.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.909 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 29.4 p -118.26 141.92 48.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.138 -179.9 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . 0.459 ' CG ' ' N ' ' A' ' 153' ' ' TRP . 8.7 t-20 -165.08 166.91 18.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.904 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . 0.459 ' N ' ' CG ' ' A' ' 152' ' ' ASN . 11.2 m95 -56.51 112.25 1.22 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.934 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -51.23 -59.12 4.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.086 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 3.3 t -98.94 126.26 44.58 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.105 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 6.7 tpt85 -116.5 50.17 1.08 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.884 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . 0.423 ' CG ' ' HD2' ' A' ' 158' ' ' PRO . 44.2 tttm -63.97 140.26 97.83 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.581 0.705 . . . . 0.0 110.848 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . 0.423 ' HD2' ' CG ' ' A' ' 157' ' ' LYS . 54.0 Cg_endo -69.74 150.34 68.21 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.709 2.273 . . . . 0.0 112.336 179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.82 -174.45 0.92 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.649 2.233 . . . . 0.0 112.346 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -137.9 147.62 57.31 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.597 0.713 . . . . 0.0 111.088 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.84 -28.19 25.17 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.691 2.26 . . . . 0.0 112.313 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 4.9 tppt? -50.06 124.59 10.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.886 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 5.4 t -108.25 -48.82 3.29 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.869 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 3.0 m 61.69 28.29 17.44 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.14 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -39.15 157.91 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.906 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 2.8 pp20? -166.85 144.93 5.05 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.908 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 98.7 p -149.63 126.13 10.91 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.848 -179.74 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . 0.409 ' OD1' ' N ' ' A' ' 169' ' ' THR . 4.0 t-20 -135.44 153.74 51.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.937 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.409 ' N ' ' OD1' ' A' ' 168' ' ' ASN . 58.6 m -113.45 91.96 3.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.108 -179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 8.4 tptm -124.52 128.12 48.48 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.941 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -62.63 147.37 49.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.89 -179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 16.9 t -72.5 95.95 1.87 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.853 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -73.07 174.13 47.31 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.464 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 97.55 0.65 Allowed 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.669 2.246 . . . . 0.0 112.337 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 32.5 t -55.59 165.89 0.76 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.89 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 1.5 t -89.0 150.2 22.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.874 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.503 -179.992 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 N-CA-C 112.478 -0.249 . . . . 0.0 112.478 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 51.6 p -63.94 141.15 58.87 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.925 0.393 . . . . 0.0 110.824 -179.684 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 24.0 m -120.91 133.42 55.29 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.887 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 139.3 139.57 3.81 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.52 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 8.1 t -45.92 136.58 6.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.835 0.35 . . . . 0.0 110.873 -179.733 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 3.6 m -62.35 162.46 9.95 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.854 -179.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -141.06 -117.45 1.37 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.446 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 7.5 mm-40 -134.4 158.87 42.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.897 0.38 . . . . 0.0 110.91 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 33.7 ttmt -115.46 -47.34 2.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.924 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 2.5 ttmp? -53.56 -55.56 24.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.955 179.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -77.78 131.48 37.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.88 179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 37.8 p -106.37 43.06 1.18 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.138 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 38.9 m -65.99 -45.43 81.66 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.844 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 40.1 t30 -105.55 46.56 0.91 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.877 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . . . . . . . . . 6.7 m170 -121.07 157.54 29.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.855 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 -106.94 116.65 32.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.876 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 64.1 m-70 -90.55 161.51 15.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.913 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.423 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 49.5 t -137.64 135.83 46.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.159 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.439 ' CE2' ' HG3' ' A' ' 150' ' ' ARG . 17.9 t80 -87.63 132.41 34.09 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.899 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.846 HG12 HD21 ' A' ' 85' ' ' LEU . 6.5 t -132.38 110.0 15.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.116 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -117.74 -178.77 17.41 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.459 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.403 ' O ' ' O ' ' A' ' 148' ' ' GLN . 2.0 m-20 64.02 40.11 7.4 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.874 0.368 . . . . 0.0 110.859 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.846 HD21 HG12 ' A' ' 82' ' ' VAL . 9.4 mt -102.85 129.56 49.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.901 -179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.1 t -52.92 154.37 5.14 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.671 0.748 . . . . 0.0 110.832 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -4.23 13.6 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.636 2.224 . . . . 0.0 112.356 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . 0.401 ' O ' ' HG3' ' A' ' 88' ' ' GLU . 1.3 tt0 -95.71 -29.77 14.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.86 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 1.014 HD11 ' HA3' ' A' ' 145' ' ' GLY . 48.3 mm -57.9 136.64 20.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.139 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.3 t -117.18 164.05 15.36 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.145 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.549 ' HA ' HG23 ' A' ' 109' ' ' VAL . 16.7 m -40.78 -39.63 1.15 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.154 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 93' ' ' ASP . 29.5 mt-10 -61.92 -59.71 4.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.61 ' CB ' HG23 ' A' ' 89' ' ' ILE . 0.6 OUTLIER -36.78 -56.59 0.84 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.86 -179.988 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.557 HD11 HG22 ' A' ' 109' ' ' VAL . 6.3 mt -48.19 -58.06 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.131 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.634 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 23.9 mtmt -49.65 -38.95 34.48 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.908 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.17 -31.37 72.54 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.081 179.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.498 ' HB1' ' HE1' ' A' ' 139' ' ' MET . . . -72.78 -46.84 51.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.105 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.413 ' C ' HD11 ' A' ' 104' ' ' ILE . 20.1 m-85 -97.16 11.77 35.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.941 179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.77 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -63.8 -59.73 10.8 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.531 0.681 . . . . 0.0 111.109 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.77 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 53.4 Cg_endo -69.77 -0.7 7.3 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.717 2.278 . . . . 0.0 112.315 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . 0.598 ' CE1' ' SD ' ' A' ' 139' ' ' MET . 62.6 m-85 -99.64 -0.11 40.93 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.899 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 139.7 138.31 3.61 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.532 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.489 ' HB3' ' CE2' ' A' ' 127' ' ' PHE . 13.7 mtt85 -48.03 125.09 8.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.782 0.325 . . . . 0.0 110.862 -179.854 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.476 ' CD1' ' HA ' ' A' ' 95' ' ' LYS . 17.9 mt -100.02 138.73 23.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.102 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.453 ' HB2' ' CE1' ' A' ' 127' ' ' PHE . 1.3 t -111.9 -59.14 2.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.835 -179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.457 ' HB3' ' CB ' ' A' ' 125' ' ' SER . 23.2 t70 -100.33 100.32 11.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.888 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.546 ' HB3' ' HE2' ' A' ' 95' ' ' LYS . . . -133.6 124.93 27.72 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.117 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.475 ' HD3' ' N ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -161.67 155.59 21.92 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 -179.889 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.557 HG22 HD11 ' A' ' 94' ' ' ILE . 76.5 t -106.14 117.4 51.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.147 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.798 HG12 ' HG3' ' A' ' 119' ' ' LYS . 60.2 t -47.36 141.33 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.13 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 47.6 mttt -139.33 151.01 46.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.879 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.434 ' O ' ' N ' ' A' ' 116' ' ' GLY . 25.7 t0 -63.74 122.95 17.65 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.889 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 27.9 ptm -72.49 -6.61 44.95 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.878 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -96.74 -48.43 5.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.111 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 45.4 p -100.75 -32.19 10.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.116 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.434 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 86.71 24.13 39.89 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.452 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 44.8 mtmt -98.43 168.02 10.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.79 0.329 . . . . 0.0 110.917 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 15.8 t -64.37 114.26 4.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.826 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.798 ' HG3' HG12 ' A' ' 110' ' ' VAL . 27.3 mmtt -63.83 -47.25 81.54 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.887 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.473 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 139.38 -46.91 0.93 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.479 179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.664 ' CE2' HG21 ' A' ' 110' ' ' VAL . 12.7 p90 -100.14 146.28 27.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.948 0.404 . . . . 0.0 110.891 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -128.11 176.94 17.91 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.445 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -122.56 141.41 51.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.86 0.362 . . . . 0.0 110.907 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.686 HG12 ' CE1' ' A' ' 126' ' ' PHE . 56.8 t -137.63 122.3 23.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.112 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . 0.457 ' CB ' ' HB3' ' A' ' 106' ' ' ASP . 4.9 t -112.19 140.79 46.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.877 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.686 ' CE1' HG12 ' A' ' 124' ' ' VAL . 27.8 m-85 -121.53 147.97 45.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.843 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.489 ' CE2' ' HB3' ' A' ' 103' ' ' ARG . 21.6 m-85 -55.88 -49.8 72.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.89 -179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 48.9 m-20 -99.47 166.73 11.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.886 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.461 ' HE3' ' CZ2' ' A' ' 153' ' ' TRP . 45.5 tptt -75.61 -45.78 35.53 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.863 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.417 ' O ' ' C ' ' A' ' 131' ' ' ASP . 0.9 OUTLIER -55.78 -54.56 42.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.918 179.915 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 130' ' ' TRP . 60.5 m-20 -35.67 -43.24 0.27 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.883 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.504 ' HB2' ' CD1' ' A' ' 126' ' ' PHE . . . -77.81 -56.9 4.13 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.129 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.476 ' HA ' HD12 ' A' ' 136' ' ' ILE . 13.5 mt-10 -45.23 -56.96 4.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.857 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 29.6 t-20 -43.35 -49.71 6.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.931 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.547 ' HB1' ' HG3' ' A' ' 139' ' ' MET . . . -64.39 -53.32 50.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.087 179.856 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . 0.476 HD12 ' HA ' ' A' ' 133' ' ' GLU . 94.7 mt -41.49 -34.38 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.141 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 9.6 mt-30 -84.71 -69.55 0.64 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.905 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 28.2 mt-30 -55.99 -59.38 4.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.897 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.598 ' SD ' ' CE1' ' A' ' 101' ' ' PHE . 53.9 mmm -58.12 -43.1 87.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.871 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.449 ' CA ' ' OG1' ' A' ' 151' ' ' THR . . . -56.98 91.41 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.493 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 125.02 6.16 6.5 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.459 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . 0.492 ' HG2' ' CD1' ' A' ' 149' ' ' ILE . 0.5 OUTLIER -92.33 -178.57 4.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.728 0.299 . . . . 0.0 110.957 -179.915 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . 0.48 ' N ' ' HG3' ' A' ' 142' ' ' GLN . 16.6 m95 -114.47 115.16 26.81 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.923 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.59 HD23 HD22 ' A' ' 85' ' ' LEU . 62.4 tp -108.1 128.45 54.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.91 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 1.014 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 69.97 -75.57 0.46 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.481 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.24 15.9 0.28 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.479 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 39.1 mtt85 -155.48 157.18 36.53 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.722 0.296 . . . . 0.0 110.867 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.45 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 16.6 mt-30 -60.51 170.3 1.44 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.937 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.492 ' CD1' ' HG2' ' A' ' 142' ' ' GLN . 23.6 pt -135.17 152.98 33.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.179 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.439 ' HG3' ' CE2' ' A' ' 81' ' ' PHE . 12.5 ptm180 -120.38 104.23 9.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.86 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.449 ' OG1' ' CA ' ' A' ' 140' ' ' GLY . 44.9 p -99.45 127.91 45.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.174 -179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 6.8 m120 -150.85 173.79 13.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.878 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . 0.461 ' CZ2' ' HE3' ' A' ' 129' ' ' LYS . 7.3 m95 -68.99 138.23 54.37 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -99.83 77.05 2.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.117 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 77.7 p -153.71 138.52 17.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.171 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 33.6 ttp180 -73.1 104.04 4.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.839 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 79.5 tttt -139.44 133.95 16.16 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.601 0.715 . . . . 0.0 110.909 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 152.67 69.47 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.672 2.248 . . . . 0.0 112.352 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 176.53 6.67 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.679 2.253 . . . . 0.0 112.36 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -97.96 154.31 37.83 Favored Pre-proline 0 C--N 1.33 -0.283 0 CA-C-O 121.562 0.696 . . . . 0.0 111.097 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.77 165.07 32.2 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.718 2.278 . . . . 0.0 112.355 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 18.1 mmtp -139.63 156.41 46.86 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.906 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 94.0 p -135.16 110.75 9.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.837 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 12.2 t -95.18 133.71 38.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.138 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . . . . . . . . . 11.9 p90 -128.51 160.64 31.71 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.932 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 9.2 mm-40 -142.3 136.58 29.88 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 3.0 m -165.52 167.62 17.28 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.848 -179.761 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 35.8 t30 -137.25 173.58 11.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.847 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 13.8 t -156.17 163.4 39.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.134 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 15.4 ttpt -143.43 118.71 10.2 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.877 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.58 161.06 14.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.87 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 1.8 m -111.74 152.7 27.48 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.906 -179.834 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -106.33 86.62 0.48 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.469 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.73 95.66 0.56 Allowed 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.697 2.264 . . . . 0.0 112.328 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 16.7 m -43.09 166.6 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.884 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 45.1 t -121.22 -54.61 1.99 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.844 -179.823 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.535 -179.967 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.516 -0.234 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 9.0 t -72.4 117.58 14.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.927 0.394 . . . . 0.0 110.824 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' SER . . . . . . . . . . . . . 94.5 p -155.36 176.88 12.01 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.829 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 75.35 41.18 31.39 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.476 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 73.3 m -79.17 87.96 4.89 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.843 0.354 . . . . 0.0 110.803 -179.746 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 5.8 t 62.84 42.3 7.98 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.884 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -132.48 115.88 1.7 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.546 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 -82.87 139.79 33.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.876 0.369 . . . . 0.0 110.925 -179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -116.52 152.86 33.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.933 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 9.5 ptmm? -89.23 -43.19 11.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.892 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -79.83 98.23 6.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.865 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.407 HG22 ' ND1' ' A' ' 77' ' ' HIS . 1.7 p -53.56 115.01 1.73 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.187 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 19.8 m -119.5 -53.02 2.24 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.814 -179.811 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.5 m120 -108.33 42.02 1.46 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.902 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' HIS . . . . . 0.407 ' ND1' HG22 ' A' ' 74' ' ' THR . 36.8 m170 -115.44 160.07 20.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.85 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.561 ' CZ ' ' HB2' ' A' ' 129' ' ' LYS . 43.8 m-85 -108.16 116.49 32.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.864 -179.894 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' HIS . . . . . . . . . . . . . 58.2 m-70 -88.06 135.29 33.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.863 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 53.7 t -114.78 140.3 36.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.096 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 17.5 t80 -91.28 135.29 33.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.898 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.502 HG12 HD21 ' A' ' 85' ' ' LEU . 16.6 t -131.73 127.54 59.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.069 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.469 ' CA ' ' HG2' ' A' ' 150' ' ' ARG . . . -137.39 171.75 23.04 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.491 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ASP . . . . . 0.41 ' O ' ' O ' ' A' ' 148' ' ' GLN . 6.6 t70 64.37 53.07 1.75 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.839 0.352 . . . . 0.0 110.857 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.511 HD22 HD23 ' A' ' 144' ' ' LEU . 21.3 mt -106.34 133.39 51.11 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.941 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -54.07 155.1 6.85 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.651 0.739 . . . . 0.0 110.862 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 -10.08 27.67 Favored 'Trans proline' 0 N--CA 1.465 -0.159 0 C-N-CA 122.73 2.287 . . . . 0.0 112.352 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 22.6 pt-20 -97.78 0.49 46.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.896 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.944 HD11 ' HA3' ' A' ' 145' ' ' GLY . 49.0 mm -88.02 136.83 22.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.151 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 12.9 t -121.21 179.39 4.42 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.124 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.625 HG23 ' HA ' ' A' ' 108' ' ' ARG . 85.4 m -51.18 -45.44 61.78 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.102 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -59.34 -55.79 30.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.837 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' ASP . . . . . 0.55 ' CB ' HG23 ' A' ' 89' ' ' ILE . 6.8 m-20 -38.18 -57.78 1.05 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.887 179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.414 HD11 HG22 ' A' ' 109' ' ' VAL . 6.7 mt -48.37 -62.04 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.131 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.672 ' O ' ' HB2' ' A' ' 99' ' ' ALA . 26.0 mtmt -45.18 -39.88 6.62 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.948 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' ALA . . . . . . . . . . . . . . . -64.02 -32.45 74.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.097 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.536 ' HB2' HD13 ' A' ' 144' ' ' LEU . . . -69.84 -54.66 12.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.084 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' PHE . . . . . 0.407 ' C ' HD11 ' A' ' 104' ' ' ILE . 22.7 m-85 -88.23 8.55 26.67 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.894 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.76 ' HB3' ' HD3' ' A' ' 100' ' ' PRO . . . -62.06 -60.04 11.33 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.567 0.698 . . . . 0.0 111.096 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.76 ' HD3' ' HB3' ' A' ' 99' ' ' ALA . 54.0 Cg_endo -69.76 -0.76 7.38 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.721 2.28 . . . . 0.0 112.351 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -100.02 -10.91 21.05 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.905 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 154.69 156.43 7.71 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.47 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.449 ' HB3' ' CE1' ' A' ' 127' ' ' PHE . 29.8 mtm180 -64.61 121.7 15.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.742 0.306 . . . . 0.0 110.891 -179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.407 HD11 ' C ' ' A' ' 98' ' ' PHE . 15.3 mt -100.33 139.76 21.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.138 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 36.0 t -113.47 -59.59 2.0 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.832 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -100.82 100.97 11.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.842 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.48 ' CB ' ' HG3' ' A' ' 95' ' ' LYS . . . -131.67 128.34 38.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.067 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.625 ' HA ' HG23 ' A' ' 91' ' ' THR . 8.8 ptp180 -161.58 161.66 29.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.414 HG22 HD11 ' A' ' 94' ' ' ILE . 32.6 t -112.98 122.2 66.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.122 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.693 HG21 ' CE2' ' A' ' 121' ' ' TYR . 58.8 t -55.83 142.94 9.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.137 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 28.5 mttp -142.19 154.48 44.86 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.872 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.489 ' O ' ' N ' ' A' ' 116' ' ' GLY . 47.3 t0 -62.61 121.58 13.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.872 179.87 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 14.4 ptp -72.53 0.76 9.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.898 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -103.5 -34.62 8.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.099 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 6.9 p -123.39 -33.83 3.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.149 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.489 ' N ' ' O ' ' A' ' 112' ' ' ASP . . . 90.61 26.28 23.21 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.68 -0.772 . . . . 0.0 112.501 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -93.37 140.74 29.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.762 0.315 . . . . 0.0 110.9 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 2.8 t -46.24 113.06 0.56 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.866 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 34.5 mttt -67.23 -49.87 62.85 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.896 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.443 ' O ' HD12 ' A' ' 85' ' ' LEU . . . 140.51 -39.95 1.42 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.497 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' TYR . . . . . 0.693 ' CE2' HG21 ' A' ' 110' ' ' VAL . 24.5 p90 -100.13 144.43 29.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.927 0.394 . . . . 0.0 110.945 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -131.77 -179.79 16.48 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.507 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 65.4 m-85 -124.57 138.94 54.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.874 0.369 . . . . 0.0 110.884 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.681 HG12 ' CE1' ' A' ' 126' ' ' PHE . 48.4 t -138.84 113.3 7.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.113 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 20.6 t -100.97 151.49 21.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.82 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' PHE . . . . . 0.681 ' CE1' HG12 ' A' ' 124' ' ' VAL . 3.0 m-85 -131.0 149.57 52.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.885 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' PHE . . . . . 0.449 ' CE1' ' HB3' ' A' ' 103' ' ' ARG . 81.4 m-85 -64.27 -35.73 81.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.848 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -120.49 157.26 29.79 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.914 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.561 ' HB2' ' CZ ' ' A' ' 78' ' ' PHE . 40.4 tttt -65.89 -64.4 0.87 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.922 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' TRP . . . . . 0.453 ' C ' ' O ' ' A' ' 129' ' ' LYS . 0.8 OUTLIER -34.17 -62.04 0.34 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.93 179.903 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.415 ' C ' ' O ' ' A' ' 130' ' ' TRP . 5.7 m-20 -36.08 -43.41 0.34 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.841 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 129' ' ' LYS . . . -73.56 -60.69 2.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.084 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -42.99 -55.85 3.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.89 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -43.31 -44.65 5.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' ALA . . . . . 0.458 ' O ' ' N ' ' A' ' 139' ' ' MET . . . -74.06 -56.06 5.37 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.094 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' ILE . . . . . . . . . . . . . 76.9 mt -39.83 -37.35 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.125 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -83.04 -55.91 4.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.846 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' GLN . . . . . . . . . . . . . 4.3 mm-40 -66.26 -63.45 1.08 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.883 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' MET . . . . . 0.521 ' HE3' HD11 ' A' ' 149' ' ' ILE . 84.3 mmm -51.07 -36.21 38.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.843 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -56.15 107.75 0.94 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.531 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 104.1 -17.39 48.32 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.464 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' GLN . . . . . . . . . . . . . 15.1 mm-40 -67.69 -177.94 0.85 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.768 0.318 . . . . 0.0 110.945 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' TRP . . . . . 0.439 ' CD1' ' HG2' ' A' ' 148' ' ' GLN . 13.8 m95 -115.72 137.13 52.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.899 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.536 HD13 ' HB2' ' A' ' 97' ' ' ALA . 55.7 tp -130.27 121.56 26.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.937 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' GLY . . . . . 0.944 ' HA3' HD11 ' A' ' 89' ' ' ILE . . . 75.39 -24.19 1.44 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.473 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . 0.417 ' H ' ' C ' ' A' ' 144' ' ' LEU . . . 144.99 -6.88 1.61 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.477 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' ARG . . . . . . . . . . . . . 54.0 mtt85 -130.61 144.07 51.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.812 0.339 . . . . 0.0 110.843 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' GLN . . . . . 0.439 ' HG2' ' CD1' ' A' ' 143' ' ' TRP . 23.9 mt-30 -51.48 163.92 0.24 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.913 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.521 HD11 ' HE3' ' A' ' 139' ' ' MET . 25.3 pt -137.69 155.22 30.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.099 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.497 ' O ' ' CG ' ' A' ' 150' ' ' ARG . 7.6 ptm180 -118.12 118.23 31.33 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.874 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 34.3 p -117.64 132.35 56.51 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.136 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -158.55 173.35 16.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' TRP . . . . . . . . . . . . . 32.8 m95 -65.15 118.0 8.58 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.871 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' ALA . . . . . . . . . . . . . . . -49.12 -55.42 12.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.097 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 73.3 p -106.6 118.18 35.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.146 -179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' ARG . . . . . . . . . . . . . 5.1 ptm180 -140.82 156.38 46.15 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.872 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' LYS . . . . . . . . . . . . . 40.1 tttm -166.2 137.55 2.93 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.557 0.694 . . . . 0.0 110.906 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 148.46 65.34 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.661 2.241 . . . . 0.0 112.403 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 177.04 6.0 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.632 2.221 . . . . 0.0 112.366 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.758 ' HB1' ' HD2' ' A' ' 161' ' ' PRO . . . -145.34 165.67 20.77 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.581 0.705 . . . . 0.0 111.063 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' PRO . . . . . 0.758 ' HD2' ' HB1' ' A' ' 160' ' ' ALA . 54.2 Cg_endo -69.71 -10.29 28.24 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.695 2.263 . . . . 0.0 112.343 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 25.7 tptp -81.77 129.67 34.81 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.874 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 9.8 t -131.99 108.22 9.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.876 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 67.3 p -39.75 136.6 1.02 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.157 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' TYR . . . . . 0.463 ' O ' ' CG ' ' A' ' 165' ' ' TYR . 4.6 p90 -132.02 100.46 5.07 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.879 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -153.78 133.58 13.06 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.832 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' SER . . . . . . . . . . . . . 78.0 p -111.42 130.53 55.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.85 -179.795 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -139.95 167.99 20.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.89 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 14.0 t -67.64 152.21 46.0 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.157 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.12 159.31 34.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.908 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -123.61 -48.84 1.91 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.919 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' SER . . . . . . . . . . . . . 4.3 m -109.2 149.78 28.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.855 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' GLY . . . . . . . . . . . . . . . -173.5 76.99 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.488 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 97.35 0.63 Allowed 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.665 2.243 . . . . 0.0 112.348 -179.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' SER . . . . . . . . . . . . . 31.0 m -130.1 171.65 12.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.893 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 1.3 t -125.96 -61.02 1.26 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.914 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.526 179.988 . . . . . . . . 0 0 . 1 stop_ save_